0001437749-25-00266210-Q MESA LABORATORIES INC /CO/ 2025020420250204080050080052080052 0 0001437749-25-002662 10-Q 85 20241231 20250204 20250204 MESA LABORATORIES INC /CO/ 0000724004 3823 840872291 CO 0331 10-Q 34 000-11740 25585406 12100 W 6TH AVE LAKEWOOD CO 80228 3039878000 12100 W 6TH AVE LAKEWOOD CO 80228 MESA LABORATORIES INC /CO 19951117 MESA MEDICAL INC 19921123 10-Q 1 mlab20241231_10q.htm FORM 10-Q mlab20241231_10q.htm 0000724004 MESA LABORATORIES INC /CO false --03-31 Q3 2025 1,060 1,321 26,036 22,519 0 0 25,000,000 25,000,000 5,433,603 5,433,603 5,394,491 5,394,491 0.16 0.16 0.16 0.16 0.16 0.16 0 4 7.5 1 21 false false false false Intersegment revenues are not significant and are eliminated to arrive at consolidated totals. Unallocated corporate expenses are reported within corporate and other. Revenues of $12,117 from GKE are included in the Sterilization and Disinfection Control division during the six months ended September 30, 2024. Accumulated Other Comprehensive Income (Loss). Revenues of $5,863 from GKE are included in the Sterilization and Disinfection Control division during the three months ended September 30, 2024. Includes post-acquisition GKE results during the three and six months ended September 30, 2024. Balances for PSUs granted are reflected at target. 00007240042024-04-012024-12-31 xbrli:shares 00007240042025-01-28 thunderdome:item iso4217:USD 00007240042024-12-31 00007240042024-03-31 0000724004us-gaap:CustomerRelationshipsMember2024-12-31 0000724004us-gaap:CustomerRelationshipsMember2024-03-31 0000724004us-gaap:OtherIntangibleAssetsMember2024-12-31 0000724004us-gaap:OtherIntangibleAssetsMember2024-03-31 iso4217:USDxbrli:shares 0000724004us-gaap:ProductMember2024-10-012024-12-31 0000724004us-gaap:ProductMember2023-10-012023-12-31 0000724004us-gaap:ProductMember2024-04-012024-12-31 0000724004us-gaap:ProductMember2023-04-012023-12-31 00007240042024-10-012024-12-31 00007240042023-10-012023-12-31 00007240042023-04-012023-12-31 0000724004us-gaap:ServiceMember2024-10-012024-12-31 0000724004us-gaap:ServiceMember2023-10-012023-12-31 0000724004us-gaap:ServiceMember2024-04-012024-12-31 0000724004us-gaap:ServiceMember2023-04-012023-12-31 0000724004us-gaap:CommonStockMember2024-03-31 0000724004us-gaap:RetainedEarningsMember2024-03-31 0000724004us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-31 0000724004us-gaap:CommonStockMember2024-04-012024-06-30 00007240042024-04-012024-06-30 0000724004us-gaap:RetainedEarningsMember2024-04-012024-06-30 0000724004us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-30 0000724004us-gaap:CommonStockMember2024-06-30 0000724004us-gaap:RetainedEarningsMember2024-06-30 0000724004us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-30 00007240042024-06-30 0000724004us-gaap:CommonStockMember2024-07-012024-09-30 00007240042024-07-012024-09-30 0000724004us-gaap:RetainedEarningsMember2024-07-012024-09-30 0000724004us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-30 0000724004us-gaap:CommonStockMember2024-09-30 0000724004us-gaap:RetainedEarningsMember2024-09-30 0000724004us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-30 00007240042024-09-30 0000724004us-gaap:CommonStockMember2024-10-012024-12-31 0000724004us-gaap:RetainedEarningsMember2024-10-012024-12-31 0000724004us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-10-012024-12-31 0000724004us-gaap:CommonStockMember2024-12-31 0000724004us-gaap:RetainedEarningsMember2024-12-31 0000724004us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-31 0000724004us-gaap:CommonStockMember2023-03-31 0000724004us-gaap:RetainedEarningsMember2023-03-31 0000724004us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-31 00007240042023-03-31 0000724004us-gaap:CommonStockMember2023-04-012023-06-30 00007240042023-04-012023-06-30 0000724004us-gaap:RetainedEarningsMember2023-04-012023-06-30 0000724004us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-30 0000724004us-gaap:CommonStockMember2023-06-30 0000724004us-gaap:RetainedEarningsMember2023-06-30 0000724004us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-30 00007240042023-06-30 0000724004us-gaap:CommonStockMember2023-07-012023-09-30 00007240042023-07-012023-09-30 0000724004us-gaap:RetainedEarningsMember2023-07-012023-09-30 0000724004us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-30 0000724004us-gaap:CommonStockMember2023-09-30 0000724004us-gaap:RetainedEarningsMember2023-09-30 0000724004us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-30 00007240042023-09-30 0000724004us-gaap:CommonStockMember2023-10-012023-12-31 0000724004us-gaap:RetainedEarningsMember2023-10-012023-12-31 0000724004us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-10-012023-12-31 0000724004us-gaap:CommonStockMember2023-12-31 0000724004us-gaap:RetainedEarningsMember2023-12-31 0000724004us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-31 00007240042023-12-31 xbrli:pure 0000724004mlab:GkeAcquisitionMembermlab:GkeGmbhAndSalGmbhMember2023-10-16 0000724004mlab:GkeAcquisitionMembermlab:BeijingGkeScienceTechnologyCoLtdMember2023-10-16 0000724004mlab:GkeAcquisitionMember2023-10-162023-10-16 0000724004mlab:GkeAcquisitionMember2024-10-012024-12-31 0000724004mlab:GkeAcquisitionMember2024-04-012024-12-31 0000724004mlab:GkeAcquisitionMembermlab:InventoryStepupRelatedToCostOfRevenueMember2024-10-012024-12-31 0000724004mlab:GkeAcquisitionMembermlab:InventoryStepupRelatedToCostOfRevenueMember2024-04-012024-12-31 0000724004mlab:GkeAcquisitionMembermlab:CostOfRevenuesRelatedToIntangiblesAcquiredMember2024-10-012024-12-31 0000724004mlab:GkeAcquisitionMembermlab:CostOfRevenuesRelatedToIntangiblesAcquiredMember2024-04-012024-12-31 0000724004mlab:GkeAcquisitionMemberus-gaap:GeneralAndAdministrativeExpenseMember2024-10-012024-12-31 0000724004mlab:GkeAcquisitionMemberus-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:SterilizationAndDisinfectionControlMemberus-gaap:TransferredAtPointInTimeMember2024-10-012024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:ClinicalGenomicsMemberus-gaap:TransferredAtPointInTimeMember2024-10-012024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:BiopharmaceuticalDevelopmentMemberus-gaap:TransferredAtPointInTimeMember2024-10-012024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:CalibrationSolutionsMemberus-gaap:TransferredAtPointInTimeMember2024-10-012024-12-31 0000724004mlab:ConsumablesMemberus-gaap:TransferredAtPointInTimeMember2024-10-012024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:SterilizationAndDisinfectionControlMemberus-gaap:TransferredAtPointInTimeMember2024-10-012024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:ClinicalGenomicsMemberus-gaap:TransferredAtPointInTimeMember2024-10-012024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:BiopharmaceuticalDevelopmentMemberus-gaap:TransferredAtPointInTimeMember2024-10-012024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:CalibrationSolutionsMemberus-gaap:TransferredAtPointInTimeMember2024-10-012024-12-31 0000724004mlab:HardwareAndSoftwareMemberus-gaap:TransferredAtPointInTimeMember2024-10-012024-12-31 0000724004us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:SterilizationAndDisinfectionControlMemberus-gaap:TransferredAtPointInTimeMember2024-10-012024-12-31 0000724004us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:ClinicalGenomicsMemberus-gaap:TransferredAtPointInTimeMember2024-10-012024-12-31 0000724004us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:BiopharmaceuticalDevelopmentMemberus-gaap:TransferredAtPointInTimeMember2024-10-012024-12-31 0000724004us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:CalibrationSolutionsMemberus-gaap:TransferredAtPointInTimeMember2024-10-012024-12-31 0000724004us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember2024-10-012024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:SterilizationAndDisinfectionControlMember2024-10-012024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:ClinicalGenomicsMember2024-10-012024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:BiopharmaceuticalDevelopmentMember2024-10-012024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:CalibrationSolutionsMember2024-10-012024-12-31 0000724004mlab:GkeGmbhMembermlab:SterilizationAndDisinfectionControlMember2024-10-012024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:SterilizationAndDisinfectionControlMemberus-gaap:TransferredAtPointInTimeMember2023-10-012023-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:ClinicalGenomicsMemberus-gaap:TransferredAtPointInTimeMember2023-10-012023-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:BiopharmaceuticalDevelopmentMemberus-gaap:TransferredAtPointInTimeMember2023-10-012023-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:CalibrationSolutionsMemberus-gaap:TransferredAtPointInTimeMember2023-10-012023-12-31 0000724004mlab:ConsumablesMemberus-gaap:TransferredAtPointInTimeMember2023-10-012023-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:SterilizationAndDisinfectionControlMemberus-gaap:TransferredAtPointInTimeMember2023-10-012023-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:ClinicalGenomicsMemberus-gaap:TransferredAtPointInTimeMember2023-10-012023-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:BiopharmaceuticalDevelopmentMemberus-gaap:TransferredAtPointInTimeMember2023-10-012023-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:CalibrationSolutionsMemberus-gaap:TransferredAtPointInTimeMember2023-10-012023-12-31 0000724004mlab:HardwareAndSoftwareMemberus-gaap:TransferredAtPointInTimeMember2023-10-012023-12-31 0000724004us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:SterilizationAndDisinfectionControlMemberus-gaap:TransferredAtPointInTimeMember2023-10-012023-12-31 0000724004us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:ClinicalGenomicsMemberus-gaap:TransferredAtPointInTimeMember2023-10-012023-12-31 0000724004us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:BiopharmaceuticalDevelopmentMemberus-gaap:TransferredAtPointInTimeMember2023-10-012023-12-31 0000724004us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:CalibrationSolutionsMemberus-gaap:TransferredAtPointInTimeMember2023-10-012023-12-31 0000724004us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember2023-10-012023-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:SterilizationAndDisinfectionControlMember2023-10-012023-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:ClinicalGenomicsMember2023-10-012023-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:BiopharmaceuticalDevelopmentMember2023-10-012023-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:CalibrationSolutionsMember2023-10-012023-12-31 0000724004mlab:GkeGmbhMembermlab:SterilizationAndDisinfectionControlMember2023-10-012023-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:SterilizationAndDisinfectionControlMemberus-gaap:TransferredAtPointInTimeMember2024-04-012024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:ClinicalGenomicsMemberus-gaap:TransferredAtPointInTimeMember2024-04-012024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:BiopharmaceuticalDevelopmentMemberus-gaap:TransferredAtPointInTimeMember2024-04-012024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:CalibrationSolutionsMemberus-gaap:TransferredAtPointInTimeMember2024-04-012024-12-31 0000724004mlab:ConsumablesMemberus-gaap:TransferredAtPointInTimeMember2024-04-012024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:SterilizationAndDisinfectionControlMemberus-gaap:TransferredAtPointInTimeMember2024-04-012024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:ClinicalGenomicsMemberus-gaap:TransferredAtPointInTimeMember2024-04-012024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:BiopharmaceuticalDevelopmentMemberus-gaap:TransferredAtPointInTimeMember2024-04-012024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:CalibrationSolutionsMemberus-gaap:TransferredAtPointInTimeMember2024-04-012024-12-31 0000724004mlab:HardwareAndSoftwareMemberus-gaap:TransferredAtPointInTimeMember2024-04-012024-12-31 0000724004us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:SterilizationAndDisinfectionControlMemberus-gaap:TransferredAtPointInTimeMember2024-04-012024-12-31 0000724004us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:ClinicalGenomicsMemberus-gaap:TransferredAtPointInTimeMember2024-04-012024-12-31 0000724004us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:BiopharmaceuticalDevelopmentMemberus-gaap:TransferredAtPointInTimeMember2024-04-012024-12-31 0000724004us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:CalibrationSolutionsMemberus-gaap:TransferredAtPointInTimeMember2024-04-012024-12-31 0000724004us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember2024-04-012024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:SterilizationAndDisinfectionControlMember2024-04-012024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:ClinicalGenomicsMember2024-04-012024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:BiopharmaceuticalDevelopmentMember2024-04-012024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:CalibrationSolutionsMember2024-04-012024-12-31 0000724004mlab:GkeGmbhMembermlab:SterilizationAndDisinfectionControlMember2024-04-012024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:SterilizationAndDisinfectionControlMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:ClinicalGenomicsMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:BiopharmaceuticalDevelopmentMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:CalibrationSolutionsMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-12-31 0000724004mlab:ConsumablesMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:SterilizationAndDisinfectionControlMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:ClinicalGenomicsMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:BiopharmaceuticalDevelopmentMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:CalibrationSolutionsMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-12-31 0000724004mlab:HardwareAndSoftwareMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-12-31 0000724004us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:SterilizationAndDisinfectionControlMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-12-31 0000724004us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:ClinicalGenomicsMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-12-31 0000724004us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:BiopharmaceuticalDevelopmentMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-12-31 0000724004us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:CalibrationSolutionsMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-12-31 0000724004us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember2023-04-012023-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:SterilizationAndDisinfectionControlMember2023-04-012023-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:ClinicalGenomicsMember2023-04-012023-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:BiopharmaceuticalDevelopmentMember2023-04-012023-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:CalibrationSolutionsMember2023-04-012023-12-31 0000724004mlab:GkeGmbhMembermlab:SterilizationAndDisinfectionControlMember2023-04-012023-12-31 0000724004country:US2024-10-012024-12-31 0000724004country:US2023-10-012023-12-31 0000724004country:US2024-04-012024-12-31 0000724004country:US2023-04-012023-12-31 0000724004country:CN2024-10-012024-12-31 0000724004country:CN2023-10-012023-12-31 0000724004country:CN2024-04-012024-12-31 0000724004country:CN2023-04-012023-12-31 0000724004mlab:OtherMember2024-10-012024-12-31 0000724004mlab:OtherMember2023-10-012023-12-31 0000724004mlab:OtherMember2024-04-012024-12-31 0000724004mlab:OtherMember2023-04-012023-12-31 0000724004us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-10-012024-12-31 0000724004mlab:TheNotesMemberus-gaap:SeniorNotesMember2024-04-05 0000724004mlab:Outstanding2025NotesMember2024-04-05 0000724004mlab:Outstanding2025NotesMember2024-12-31 0000724004us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SeniorNotesMember2024-12-31 0000724004us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SeniorNotesMember2024-12-31 0000724004us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SeniorNotesMember2024-03-31 0000724004us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SeniorNotesMember2024-03-31

0000724004mlab:GkeAcquisitionMember2024-12-31 0000724004mlab:GkeAcquisitionMemberus-gaap:FairValueInputsLevel3Member2024-12-31 0000724004mlab:OtherLongtermLiabilitiesMembermlab:BelynticAcquisitionMember2022-11-17 0000724004mlab:BelynticAcquisitionMemberus-gaap:FairValueInputsLevel3Member2024-12-31 0000724004mlab:OtherAccruedExpensesMember2024-12-31 0000724004mlab:OtherAccruedExpensesMember2024-03-31 0000724004mlab:GkeAcquisitionMember2024-03-31 0000724004us-gaap:CostOfSalesMember2024-10-012024-12-31 0000724004us-gaap:CostOfSalesMember2023-10-012023-12-31 0000724004us-gaap:CostOfSalesMember2024-04-012024-12-31 0000724004us-gaap:CostOfSalesMember2023-04-012023-12-31 0000724004us-gaap:OperatingExpenseMember2024-10-012024-12-31 0000724004us-gaap:OperatingExpenseMember2023-10-012023-12-31 0000724004us-gaap:OperatingExpenseMember2024-04-012024-12-31 0000724004us-gaap:OperatingExpenseMember2023-04-012023-12-31 0000724004us-gaap:GeneralAndAdministrativeExpenseMember2024-10-012024-12-31 0000724004us-gaap:GeneralAndAdministrativeExpenseMember2023-10-012023-12-31 0000724004us-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-12-31 0000724004us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:SterilizationAndDisinfectionControlMember2024-03-31 0000724004us-gaap:OperatingSegmentsMembermlab:ClinicalGenomicsMember2024-03-31 0000724004us-gaap:OperatingSegmentsMembermlab:BiopharmaceuticalDevelopmentMember2024-03-31 0000724004us-gaap:OperatingSegmentsMembermlab:CalibrationSolutionsMember2024-03-31 0000724004us-gaap:OperatingSegmentsMembermlab:SterilizationAndDisinfectionControlMember2024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:ClinicalGenomicsMember2024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:BiopharmaceuticalDevelopmentMember2024-12-31 0000724004us-gaap:OperatingSegmentsMembermlab:CalibrationSolutionsMember2024-12-31 utr:Y 0000724004mlab:SeniorSecuredCreditAgreementMember2021-03-052021-03-05 0000724004us-gaap:RevolvingCreditFacilityMembermlab:SeniorSecuredCreditAgreementMember2021-03-05 0000724004mlab:SeniorSecuredCreditAgreementMembersrt:MaximumMembermlab:SwinglineLoanMember2021-03-05 0000724004us-gaap:LetterOfCreditMembermlab:SeniorSecuredCreditAgreementMembersrt:MaximumMember2021-03-05 0000724004mlab:SeniorSecuredCreditAgreementMembermlab:TheCreditFacilityTermLoanMembersrt:MinimumMember2021-03-05 0000724004mlab:SeniorSecuredCreditAgreementMembermlab:TheCreditFacilityTermLoanMembersrt:MaximumMember2021-03-05 0000724004mlab:SeniorSecuredCreditAgreementMembermlab:TheCreditFacilityTermLoanMembersrt:MaximumMember2023-10-05 0000724004mlab:TheCreditFacilityTermLoanMember2024-12-31 0000724004us-gaap:RevolvingCreditFacilityMembermlab:SeniorSecuredCreditAgreementMember2024-12-31 0000724004mlab:SeniorSecuredCreditAgreementMembermlab:TheCreditFacilityTermLoanMember2024-12-31 0000724004mlab:SeniorSecuredCreditAgreementMembersrt:MinimumMember2024-10-012024-12-31 0000724004mlab:SeniorSecuredCreditAgreementMembersrt:MaximumMember2024-10-012024-12-31 0000724004mlab:TheCreditFacilityTermLoanMember2024-12-31 0000724004mlab:TheCreditFacilityTermLoanMember2024-04-052024-04-05 0000724004mlab:SeniorSecuredCreditAgreementMembersrt:MinimumMember2024-04-052024-04-05 0000724004mlab:TermLoanMember2024-04-05 0000724004mlab:TermLoanMember2024-10-012024-12-31 0000724004mlab:TermLoanMember2024-04-012024-12-31 0000724004mlab:TermLoanMember2024-12-31 0000724004mlab:TermLoanMember2024-03-31 0000724004mlab:SeniorSecuredCreditAgreementMember2024-12-31 0000724004mlab:SeniorSecuredCreditAgreementMemberus-gaap:SubsequentEventMember2025-01-012025-01-01 0000724004mlab:SeniorSecuredCreditAgreementMembersrt:MinimumMember2024-07-012024-09-30 0000724004mlab:SeniorSecuredCreditAgreementMembersrt:MaximumMember2024-07-012024-09-30 0000724004mlab:PrepaidExpensesOtherAndOtherAssetsMembermlab:SeniorSecuredCreditAgreementMember2024-12-31 0000724004mlab:PrepaidExpensesOtherAndOtherAssetsMembermlab:SeniorSecuredCreditAgreementMember2024-03-31 0000724004mlab:TheNotesMemberus-gaap:SeniorNotesMember2019-08-12 0000724004mlab:TheNotesMemberus-gaap:SeniorNotesMember2019-08-122019-08-12 0000724004mlab:Outstanding2025NotesMember2024-04-052024-04-05 0000724004mlab:Outstanding2025NotesMember2024-04-012024-12-31 0000724004mlab:TheNotesMemberus-gaap:SeniorNotesMember2024-12-31 0000724004mlab:TheNotesMemberus-gaap:SeniorNotesMember2024-03-31 0000724004mlab:TheNotesMember2024-10-012024-12-31 0000724004mlab:TheNotesMember2023-10-012023-12-31 0000724004mlab:TheNotesMember2024-04-012024-12-31 0000724004mlab:TheNotesMember2023-04-012023-12-31 0000724004mlab:The2021EquityPlanMember2024-06-30 0000724004us-gaap:RestrictedStockUnitsRSUMember2024-03-31 0000724004mlab:PerformanceStockUnitsMember2024-03-31 0000724004us-gaap:RestrictedStockUnitsRSUMember2024-04-012024-12-31 0000724004mlab:PerformanceStockUnitsMember2024-04-012024-12-31 0000724004us-gaap:RestrictedStockUnitsRSUMember2024-12-31 0000724004mlab:PerformanceStockUnitsMember2024-12-31 0000724004us-gaap:RestrictedStockUnitsRSUMembermlab:NonemployeeDirectorsMember2024-04-012024-12-31 0000724004mlab:TheFy25PsusMembermlab:EligibleEmployeesMember2024-12-31 0000724004mlab:TheFy25PsusMembermlab:EligibleEmployeesMember2024-04-012024-12-31 0000724004mlab:TheFy25PsusMembersrt:MinimumMembermlab:EligibleEmployeesMember2024-04-012024-12-31 0000724004mlab:TheFy25PsusMembersrt:MaximumMembermlab:EligibleEmployeesMember2024-04-012024-12-31 00007240042023-04-012024-03-31 0000724004us-gaap:EmployeeStockOptionMember2024-10-012024-12-31 0000724004us-gaap:EmployeeStockOptionMember2023-10-012023-12-31 0000724004us-gaap:EmployeeStockOptionMember2024-04-012024-12-31 0000724004us-gaap:EmployeeStockOptionMember2023-04-012023-12-31 0000724004us-gaap:RestrictedStockUnitsRSUMember2024-10-012024-12-31 0000724004us-gaap:RestrictedStockUnitsRSUMember2023-10-012023-12-31 0000724004us-gaap:RestrictedStockUnitsRSUMember2023-04-012023-12-31 0000724004mlab:AssumedConversionOfConvertibleDebtMember2024-10-012024-12-31 0000724004mlab:AssumedConversionOfConvertibleDebtMember2023-10-012023-12-31 0000724004mlab:AssumedConversionOfConvertibleDebtMember2024-04-012024-12-31 0000724004mlab:AssumedConversionOfConvertibleDebtMember2023-04-012023-12-31 0000724004mlab:StockAwardsThatWereAntidilutiveMember2024-10-012024-12-31 0000724004mlab:StockAwardsThatWereAntidilutiveMember2023-10-012023-12-31 0000724004mlab:StockAwardsThatWereAntidilutiveMember2024-04-012024-12-31 0000724004mlab:StockAwardsThatWereAntidilutiveMember2023-04-012023-12-31 0000724004mlab:BelynticAcquisitionMember2024-12-31 0000724004mlab:BelynticAcquisitionMemberus-gaap:SubsequentEventMember2025-01-02 0000724004us-gaap:OperatingSegmentsMember2024-10-012024-12-31 0000724004us-gaap:OperatingSegmentsMember2023-10-012023-12-31 0000724004us-gaap:OperatingSegmentsMember2024-04-012024-12-31 0000724004us-gaap:OperatingSegmentsMember2023-04-012023-12-31 0000724004us-gaap:CorporateNonSegmentMember2024-10-012024-12-31 0000724004us-gaap:CorporateNonSegmentMember2023-10-012023-12-31 0000724004us-gaap:CorporateNonSegmentMember2024-04-012024-12-31 0000724004us-gaap:CorporateNonSegmentMember2023-04-012023-12-31 Â Â Table of Contents Â United States Securities and Exchange Commission Washington, D.C. 20549 Â Â FORM 10-Q Â Â â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedÂ December 31, 2024 or Â Â â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the transition period from ___ to ___ Â Commission File No: 0-11740 Â Â MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Â Colorado Â 84-0872291 Â Â (State or other jurisdiction of Â (I.R.S. Employer Â Â incorporation or organization) Â Identification number) Â Â Â Â Â Â Â 12100 West Sixth Avenue Â Â Â Â Lakewood, Colorado Â 80228 Â Â (Address of principal executive offices) Â (Zip Code) Â Â Registrantâ€™s telephone number, including area code: (303) 987-8000 Â Securities registered pursuant to SectionÂ 12(b) of the Act: Â Title of each classTrading SymbolName on each exchange on which registered Common Stock, no par valueMLABThe Nasdaq Stock Market LLC Â Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934, during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’Â Â Â No â˜ Â Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’Â Â Â Â No â˜ Â Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting companyâ€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filer â˜ Accelerated filer â˜’ Non-accelerated filer â˜ Smaller reporting company â˜ Emerging growth company â˜ Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act â˜ Â Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜Â Â Â Â No â˜’ Â Indicate the number of shares outstanding of each of the Issuerâ€™s classes of common stock, as of the latest practicable date: Â There were 5,433,607Â shares of the Issuerâ€™s common stock, no par value, outstanding as of January 28, 2025. Â Â Â Table of Contents Â Â Table of Contents Â Â Â Part I. Financial Information 1 Â Â Item 1. Financial Statements (unaudited)Â 1 Â Condensed Consolidated Balance Sheets 1 Â Condensed Consolidated Statements of Operations 2 Â Condensed Consolidated Statements of Comprehensive (Loss) Income 3 Â Condensed Consolidated Statements of Stockholdersâ€™ Equity 4 Â Condensed Consolidated Statements of Cash Flows 5 Â Notes to Condensed Consolidated Financial Statements 6 Â Item 2.Â Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 16 Â Item 3.Â Quantitative and Qualitative Disclosures about Market Risk 23 Â Item 4.Â Controls and Procedures 24 Â Â Â Part II. Other Information 25 Â Â Â Item 1.Â Legal Proceedings 25 Â Item 1A.Â Risk factors 25 Â Item 2.Â Unregistered Sales of Equity Securities and Use of Proceeds 25 Â Item 5. Other Information 25 Â Item 6.Â Exhibits 26 Â Signatures 27 Â Exhibit 31.1 Certifications Pursuant to Rule 13a-14(a) Â Â Exhibit 31.2 Certifications Pursuant to Rule 13a-14(a) Â Exhibit 32.1 Certifications Pursuant to Rule 13a-14(b) and 18 U.S.C Section 1350 Â Â Exhibit 32.2 Certifications Pursuant to Rule 13a-14(b) and 18 U.S.C Section 1350 Â Â Table of Contents Â Â Part I. Financial Information Â Item 1. Financial Statements Â Mesa Laboratories, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share amounts) Â Â Â December 31, Â Â March 31, Â Â 2024 Â Â 2024 Â ASSETS Â Â Â Â Â Â Â Â Current assets: Â Â Â Â Â Â Â Â Cash and cash equivalents Â $30,956Â Â $28,214Â Accounts receivable, less allowance for credit losses of $1,060 and $1,321, respectively Â Â 38,647Â Â Â 39,055Â Inventories Â Â 28,122Â Â Â 32,675Â Prepaid expenses and other current assets Â Â 13,120Â Â Â 9,408Â Total current assets Â Â 110,845Â Â Â 109,352Â Noncurrent assets: Â Â Â Â Â Â Â Â Property, plant and equipment, net of accumulated depreciation of $26,036 and $22,519 respectively Â Â 31,602Â Â Â 31,766Â Deferred tax asset Â Â 1,242Â Â Â 1,292Â Other assets Â Â 18,126Â Â Â 10,538Â Customer relationships, net Â Â 73,797Â Â Â 85,383Â Other intangibles, net Â Â 24,384Â Â Â 28,369Â Goodwill Â Â 177,152Â Â Â 180,096Â Total assets Â $437,148Â Â $446,796Â Â Â Â Â Â Â Â Â LIABILITIES AND STOCKHOLDERSâ€™ EQUITY Â Â Â Â Â Â Â Â Current liabilities: Â Â Â Â Â Â Â Â Accounts payable Â $4,087Â Â $6,041Â Accrued payroll and benefits Â Â 13,919Â Â Â 9,935Â Unearned revenues Â Â 14,608Â Â Â 15,478Â Other accrued expenses Â Â 22,351Â Â Â 12,858Â Term loan, current portion Â Â 3,750Â Â Â -Â Convertible senior notes, current portion, net of debt issuance costs Â Â 97,163Â Â Â -Â Total current liabilities Â Â 155,878Â Â Â 44,312Â Noncurrent liabilities: Â Â Â Â Â Â Â Â Deferred tax liability Â $18,800Â Â Â 19,780Â Other noncurrent liabilities Â Â 12,453Â Â Â 15,613Â Revolving line of credit Â Â 27,000Â Â Â 50,500Â Term loan, noncurrent portion, net of discounts and debt issuance costs Â Â 67,803Â Â Â -Â Convertible senior notes, noncurrent portion, net of debt issuance costs Â Â -Â Â Â 171,198Â Total liabilities Â Â 281,934Â Â Â 301,403Â Stockholdersâ€™ equity: Â Â Â Â Â Â Â Â Common stock, no par value; authorized 25,000,000 shares; issued and outstanding, 5,433,603 and 5,394,491 shares, respectively Â Â 352,788Â Â Â 343,642Â (Accumulated deficit) Â Â (180,952)Â Â (183,494) Accumulated other comprehensive (loss) Â Â (16,622)Â Â (14,755) Total stockholdersâ€™ equity Â Â 155,214Â Â Â 145,393Â Total liabilities and stockholdersâ€™ equity Â $437,148Â Â $446,796Â Â See accompanying notes to Condensed Consolidated Financial Statements. Â Â Page 1 Table of Contents Â Â Mesa Laboratories, Inc. Condensed Consolidated Statements of Operations (unaudited) (in thousands, except per share data) Â Â Â Â Three Months Ended December 31, Â Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenues Â $ 62,840 Â Â $ 53,473 Â Â $ 178,843 Â Â $ 157,283 Â Cost of revenues Â Â 23,086 Â Â Â 20,071 Â Â Â 66,385 Â Â Â 60,589 Â Gross profit Â Â 39,754 Â Â Â 33,402 Â Â Â 112,458 Â Â Â 96,694 Â Operating expense: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Selling Â Â 10,450 Â Â Â 9,737 Â Â Â 30,415 Â Â Â 28,363 Â General and administrative Â Â 18,472 Â Â Â 19,438 Â Â Â 52,754 Â Â Â 55,024 Â Research and development Â Â 5,053 Â Â Â 4,294 Â Â Â 14,422 Â Â Â 14,098 Â Total operating expense Â Â 33,975 Â Â Â 33,469 Â Â Â 97,591 Â Â Â 97,485 Â Operating income (loss) Â Â 5,779 Â Â Â (67) Â Â 14,867 Â Â Â (791) Non-operating expense: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Interest expense and amortization of debt issuance costs Â Â 2,842 Â Â Â 1,856 Â Â Â 9,340 Â Â Â 3,809 Â (Gain) on extinguishment of convertible senior notes Â Â - Â Â Â - Â Â Â (2,887) Â Â - Â Other expense (income), net Â Â 5,154 Â Â Â (3,869) Â Â 2,914 Â Â Â (4,284) Total non-operating expense (income), net Â Â 7,996 Â Â Â (2,013) Â Â 9,367 Â Â Â (475) (Loss) earnings before income taxes Â Â (2,217) Â Â 1,946 Â Â Â 5,500 Â Â Â (316) Income tax (benefit) expense Â Â (541) Â Â (170) Â Â 360 Â Â Â (653) Net (loss) income Â $ (1,676) Â $ 2,116 Â Â $ 5,140 Â Â $ 337 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (Loss) earnings per share: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Basic Â $ (0.31) Â $ 0.39 Â Â $ 0.95 Â Â $ 0.06 Â Diluted Â $ (0.31) Â $ 0.39 Â Â $ 0.94 Â Â $ 0.06 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted-average common shares outstanding: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Basic Â Â 5,429 Â Â Â 5,393 Â Â Â 5,413 Â Â Â 5,384 Â Diluted Â Â 5,429 Â Â Â 5,396 Â Â Â 5,464 Â Â Â 5,394 Â Â See accompanying notes to Condensed Consolidated Financial Statements. Â Page 2 Table of Contents Â Â Mesa Laboratories, Inc. Condensed Consolidated Statements of Comprehensive (Loss) Income (unaudited) (in thousands)Â Â Â Â Â Three Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net (loss) income Â $ (1,676) Â $ 2,116 Â Â $ 5,140 Â Â $ 337 Â Other comprehensive (loss) income: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Foreign currency translation adjustments Â Â (6,951) Â Â 10,965 Â Â Â (1,867) Â Â 2,951 Â Comprehensive (loss) income Â $ (8,627) Â $ 13,081 Â Â $ 3,273 Â Â $ 3,288 Â Â See accompanying notes to Condensed Consolidated Financial Statements. Â Page 3 Table of Contents Â Â Mesa Laboratories, Inc. Condensed Consolidated Statements of Stockholdersâ€™ Equity (unaudited) (dollars in thousands, except per share data) Â Â Â Â Â Common Stock Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of Shares Â Â Amount Â Â (Accumulated Deficit) Retained Earnings Â Â AOCI* Â Â Total Â March 31, 2024 Â Â 5,394,491Â Â $343,642Â Â $(183,494)Â Â $(14,755)Â $145,393Â Vesting of restricted stock units and exercise of stock options Â Â 20,858Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â Tax withholding on vesting of restricted stock units Â Â (6,194)Â Â (571)Â Â -Â Â Â -Â Â Â (571) Dividends paid, $0.16 per share Â Â -Â Â Â -Â Â Â (863)Â Â -Â Â Â (863) Stock-based compensation expense Â Â -Â Â Â 2,928Â Â Â -Â Â Â -Â Â Â 2,928Â Foreign currency translation Â Â -Â Â Â -Â Â Â -Â Â Â 452Â Â Â 452Â Net income Â Â -Â Â Â -Â Â Â 3,388Â Â Â -Â Â Â 3,388Â June 30, 2024 Â Â 5,409,155Â Â $345,999Â Â $(180,969)Â Â $(14,303)Â $150,727Â Vesting of restricted stock units and exercise of stock options Â Â 13,006Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â Tax withholding on vesting of restricted stock units Â Â (2,306)Â Â (307)Â Â -Â Â Â -Â Â Â (307) Dividends paid, $0.16 per share Â Â -Â Â Â -Â Â Â (866)Â Â -Â Â Â (866) Stock-based compensation expense Â Â -Â Â Â 3,837Â Â Â -Â Â Â -Â Â Â 3,837Â Foreign currency translation Â Â -Â Â Â -Â Â Â -Â Â Â 4,632Â Â Â 4,632Â Net income Â Â -Â Â Â -Â Â Â 3,428Â Â Â -Â Â Â 3,428Â September 30, 2024 Â Â 5,419,855Â Â $349,529Â Â $(178,407)Â $(9,671)Â $161,451Â Vesting of restricted stock units and exercise of stock options Â Â 13,780Â Â Â 23Â Â Â -Â Â Â -Â Â Â 23Â Tax withholding on vesting of restricted stock units Â Â (32)Â Â (3)Â Â -Â Â Â -Â Â Â (3) Dividends paid, $0.16 per share Â Â -Â Â Â -Â Â Â (869)Â Â -Â Â Â (869) Stock-based compensation expense Â Â -Â Â Â 3,239Â Â Â -Â Â Â -Â Â Â 3,239Â Foreign currency translation Â Â -Â Â Â -Â Â Â -Â Â Â (6,951)Â Â (6,951) Net (loss) Â Â -Â Â Â -Â Â Â (1,676)Â Â -Â Â Â (1,676) December 31, 2024 Â Â 5,433,603Â Â $352,788Â Â $(180,952)Â $(16,622)Â $155,214Â Â Â Â Â Common Stock Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of Shares Â Â Amount Â Â (Accumulated Deficit) Retained Earnings Â Â AOCI* Â Â Total Â March 31, 2023 Â Â 5,369,466Â Â $332,076Â Â $74,199Â Â $(12,795)Â $393,480Â Vesting of restricted stock units and exercise of stock options Â Â 20,074Â Â Â 52Â Â Â -Â Â Â -Â Â Â 52Â Tax withholding on vesting of restricted stock units Â Â (5,260)Â Â (712)Â Â -Â Â Â -Â Â Â (712) Dividends paid, $0.16 per share Â Â -Â Â Â -Â Â Â (859)Â Â -Â Â Â (859) Stock-based compensation expense Â Â -Â Â Â 2,968Â Â Â -Â Â Â -Â Â Â 2,968Â Foreign currency translation Â Â -Â Â Â -Â Â Â -Â Â Â (6,661)Â Â (6,661) Net (loss) Â Â -Â Â Â -Â Â Â (549)Â Â -Â Â Â (549) June 30, 2023 Â Â 5,384,280Â Â $334,384Â Â $72,791Â Â $(19,456)Â $387,719Â Vesting of restricted stock units and exercise of stock options Â Â 7,464Â Â Â 304Â Â Â -Â Â Â -Â Â Â 304Â Tax withholding on vesting of restricted stock units Â Â (18)Â Â (2)Â Â -Â Â Â -Â Â Â (2) Dividends paid, $0.16 per share Â Â -Â Â Â -Â Â Â (862)Â Â -

Â Â Â (862) Stock-based compensation expense Â Â -Â Â Â 3,183Â Â Â -Â Â Â -Â Â Â 3,183Â Foreign currency translation Â Â -Â Â Â -Â Â Â -Â Â Â (1,353)Â Â (1,353) Net (loss) Â Â -Â Â Â -Â Â Â (1,230)Â Â -Â Â Â (1,230) September 30, 2023 Â Â 5,391,726Â Â $337,869Â Â $70,699Â Â $(20,809)Â $387,759Â Vesting of restricted stock units and exercise of stock options Â Â 2,415Â Â Â 2Â Â Â -Â Â Â -Â Â Â 2Â Tax withholding on vesting of restricted stock units Â Â (98)Â Â (12)Â Â -Â Â Â -Â Â Â (12) Dividends paid, $0.16 per share Â Â -Â Â Â -Â Â Â (862)Â Â -Â Â Â (862) Stock-based compensation expense Â Â -Â Â Â 2,993Â Â Â -Â Â Â -Â Â Â 2,993Â Foreign currency translation Â Â -Â Â Â -Â Â Â -Â Â Â 10,965Â Â Â 10,965Â Net income Â Â -Â Â Â -Â Â Â 2,116Â Â Â -Â Â Â 2,116Â December 31, 2023 Â Â 5,394,043Â Â $340,852Â Â $71,953Â Â $(9,844)Â $402,961Â Â *Accumulated Other Comprehensive Income (Loss). Â See accompanying notes to Condensed Consolidated Financial Statements. Â Page 4 Table of Contents Â Â Mesa Laboratories, Inc. Condensed Consolidated Statements of Cash Flows (unaudited) (in thousands) Â Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Cash flows from operating activities: Â Â Â Â Â Â Â Â Net income Â $ 5,140 Â Â $ 337 Â Adjustments to reconcile net income to net cash from operating activities: Â Â Â Â Â Â Â Â Depreciation of property, plant and equipment Â Â 4,028 Â Â Â 2,899 Â Amortization of acquisition-related intangibles Â Â 13,002 Â Â Â 22,380 Â Stock-based compensation expense Â Â 10,004 Â Â Â 9,144 Â Gain on extinguishment of convertible notes Â Â (2,887) Â Â - Â Amortization of step-up in inventory basis Â Â 1,232 Â Â Â - Â Foreign currency adjustments Â Â 2,492 Â Â Â (3,128) Other Â Â 3,914 Â Â Â 2,206 Â Cash from changes in operating assets and liabilities: Â Â Â Â Â Â Â Â Accounts receivable, net Â Â 91 Â Â Â 8,294 Â Inventories Â Â (539) Â Â 217 Â Prepaid expenses and other assets Â Â (1,445) Â Â (7,841) Accounts payable Â Â (1,919) Â Â (1,656) Accrued liabilities and taxes payable Â Â 1,879 Â Â Â (124) Unearned revenues Â Â (849) Â Â (1,478) Net cash provided by operating activities Â Â 34,143 Â Â Â 31,250 Â Cash flows from investing activities: Â Â Â Â Â Â Â Â Acquisitions, net of cash acquired Â Â - Â Â Â (79,700) Purchases of property, plant and equipment Â Â (3,492) Â Â (2,032) Net cash (used in) investing activities Â Â (3,492) Â Â (81,732) Cash flows from financing activities: Â Â Â Â Â Â Â Â Proceeds from the issuance of debt, net Â Â 73,465 Â Â Â 71,000 Â Repayment of debt Â Â (26,313) Â Â (22,000) Repurchase of convertible debt Â Â (71,560) Â Â - Â Dividends paid Â Â (2,598) Â Â (2,583) Other financing, net Â Â (1,310) Â Â (648) Net cash (used in) provided by financing activities Â Â (28,316) Â Â 45,769 Â Effect of exchange rate changes on cash and cash equivalents Â Â 407 Â Â Â 27 Â Net increase (decrease) in cash and cash equivalents Â Â 2,742 Â Â Â (4,686) Cash and cash equivalents at beginning of period Â Â 28,214 Â Â Â 32,910 Â Cash and cash equivalents at end of period Â $ 30,956 Â Â $ 28,224 Â Â Supplemental non-cash activity: Â Â Â Â Â Â Â Â Right of use assets obtained in exchange for lease liabilities Â $ 9,596 Â Â $ 4,220 Â Â Â See accompanying notes to Condensed Consolidated Financial Statements. Â Page 5 Table of Contents Â Mesa Laboratories, Inc. Notes to Condensed Consolidated Financial Statements (unaudited) (dollar and share amounts in thousands, unless otherwise specified) Â Â Â Note 1. Description of Business and Summary of Significant Accounting Policies Â Description of Business Â In this quarterly report on Form 10-Q, Mesa Laboratories, Inc., a Colorado corporation, together with its subsidiaries, is collectively referred to as â€œwe,â€ â€œus,â€ â€œour,â€ the â€œCompany,â€ or â€œMesa.â€ Â We are a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare,Â and medical device industries. We offer products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. We have manufacturing operations in the United States and Europe, and our products are marketed by our sales personnel in North America, EuropeÂ and Asia Pacific, and by independentÂ distributors in these areas and throughout the rest of the world. We prefer marketsÂ in which we can establish a strong presence and achieve high gross profit margins. Â As of December 31, 2024, we managed our operations in four reportable segments, or divisions: Â Â â—Sterilization and Disinfection Control - manufactures and sells biological, chemical and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes in the medical device, pharmaceutical, and healthcare industries. The division also provides testing and laboratory services, mainly to the dental and pharmaceutical industries.Â Â â— Clinical Genomics -Â develops, manufactures and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables and services that enable clinical research labs and contract research organizations to performÂ genomic testing for a broad range of research applications in several therapeutic areas, such as screenings for hereditary diseases, pharmacogenetics, oncology related applications, and toxicology research. Â â— Biopharmaceutical DevelopmentÂ - develops, manufactures, sells and services automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Immunoassays and peptide synthesis solutions accelerate the discovery, development, and manufactureÂ of biotherapeutic therapies, among other applications.Â Â â— Calibration SolutionsÂ - develops, manufactures,Â sells and services quality control products using principles of advanced metrology to enable customers toÂ measure and calibrate critical parameters in applications such as environmental and process monitoring, dialysis, gas flow, air quality and torque testing. Â Basis of Presentation Â The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance withÂ the rules and regulations of the Securities and Exchange Commission and in accordance with accounting principles generally accepted in the United States (â€œU.S. GAAPâ€) for interim financial information. In the opinion of management, such unaudited information includes all adjustments, consisting of normal recurring adjustments necessary for theÂ fair statement of our financial position and results of operations. The results of operations for interim periods are not necessarily indicative of results that may be achieved for the entire year.Â The year-end Condensed Consolidated Balance Sheet data was derived from audited financial statementsÂ but does not include all disclosures required by accounting principles generally accepted in the United States of America. The Condensed Consolidated Financial Statements include the accounts of Mesa and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.Â We made no material changes to the application of our significant accounting policies disclosed in our annual report on Form 10-K. This quarterly report should be read in conjunction with the consolidated financial statements included in our annual report on Form 10-K for the year endedÂ March 31, 2024. Â Our fiscal year ends on MarchÂ 31. References in this quarterly report to a particular â€œyearâ€ or â€œquarterâ€Â refer to our fiscal year or fiscal quarters, respectively. Â Prior Period Reclassifications Â For the nine months ended December 31, 2024, certain prior period amounts in our unaudited Condensed Consolidated Statements of Operations related to cash interest payments on acquisition holdback liabilities and non-cash debt issuance cost amortizationÂ have been reclassified out of "Other expense (income), net" and into "Interest expense and amortization of debt issuance costs."Â Additionally, prior period third-party costs related to the repurchase of a portion of our convertible senior notes have been reclassified out of "Other expense (income), net"Â and are reflected within the "(Gain) on extinguishment of convertible senior notes."Â These reclassifications have not resulted in any change to "Non-operating expense (income), net" nor in any material change to other amounts presented in our unaudited condensed consolidated financial statements for the three and nine months ended December 31, 2024. Â Risks and Uncertainties Â The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the reporting date and revenues and expenses during the reporting periods. These estimates represent management's judgment about the outcome of future events. The global business environment continues to be impacted by cost pressures, the overall effects of economic uncertainty, and other factors. Changes in, and the resulting effects of, potential governmental stimulus or fiscal and monetary policies, interest rates, foreign currency values, supply chains, demand for goods and services, a global or regional recession, or other circumstances cannot be reliably predicted. Actual results could differ from our estimates. Â Page 6 Table of Contents Â Recently Issued Accounting Pronouncements Â InÂ November 2023,Â the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU")Â No.Â 2023-07,Â "Segment ReportingÂ (TopicÂ 280): Improvements to Reportable Segment Disclosures." ASUÂ No.Â 2023-07Â requires all annual disclosures currently required by TopicÂ 280Â to be included in interim financial statements and requires disclosure of significant segment expenses regularly provided to the chief operating decision maker ("CODM"), a description of other segment items by reportable segment, and applicable additional measures of segment profit or loss used by the CODM when allocatingÂ resources and assessing business performance. The ASU is effective for fiscal years beginning after December 15, 2023 (our fiscal year 2025 for annual periods)Â and interim periods within fiscal years beginning after December 15, 2024 (our fiscal year 2026 for interim periods) on a retrospective basis. Other than presentation changes to our segment footnote, we do not expect the adoption of ASU No. 2023-07 to have a material impact on our consolidated financial statements. Â InÂ December 2023,Â the FASB issued ASUÂ No.Â 2023-09,Â "Income Taxes (TopicÂ 740): Improvements to Income Tax Disclosures." ASUÂ No.Â 2023-09,Â which enhances the transparency, effectiveness and comparability of income tax disclosures by requiring consistent categories and greater disaggregation of information related to income tax rate reconciliations and the jurisdictions in which income taxes are paid.Â The guidance is effective for public business entities for fiscal years beginning afterÂ December 15, 2024 (our fiscal yearÂ 2026), with early adoption and prospective or retrospective application permitted.Â Other than presentation of additional disaggregated data in our income tax footnote disclosures for annual periods, we do not expect the adoption of ASU No. 2023-09 to have a material impact on our consolidated financial statement. Â In November 2024, the Financial Accounting Board ("FASB" issued Accounting Standards Update ("ASU") No. 2024-03, "Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses." ASU No. 2024-03Â requiresÂ that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The ASU is effective for fiscal years beginning after December 15, 2026Â (our fiscal year 2028Â for annual periods)Â and interim periods within fiscal years beginning after December 15, 2027 (our fiscal year 2029 for interim periods), with early adoption and prospective or retrospective applicationÂ permitted. We are currently assessing the effect the adoption of this standard will have on our consolidated financial statement disclosures. Â We have reviewed all recently issued accounting pronouncements and have concluded that, other than as described above,Â they are eitherÂ notÂ applicable to us or areÂ notÂ expected to have a significant impact onÂ our consolidated financial statements.Â Â Â Note 2. Significant Transactions Â GKE - Fiscal Year 2024 AcquisitionÂ We acquiredÂ 100% of the outstanding shares of GKE GmbH and SAL GmbH effectiveÂ October 16, 2023,Â and upon approval by applicable Chinese regulators, effective December 31, 2023, we acquiredÂ 100% of the outstanding shares of Beijing GKE Science & Technology Co. Ltd. (â€œGKE Chinaâ€ and together with GKE GmbH and SAL GmbH, â€œGKEâ€ or the "GKE acquisition"). Â GKE develops, manufactures and sells a portfolio of chemical sterilization indicators, biologics, and process challenge devices to protect patient safety across global healthcare markets. GKE is included in ourÂ Sterilization and Disinfection Control ("SDC") division, and GKE's strengths in chemical indictors are complementary to SDC's strengths in biological indicators as chemical and biological indicators are used in the same sterility validation workflows. Additionally, GKEâ€™s healthcare-focused commercial capabilities in Europe and Asia greatly expand our reach in the healthcare markets in those geographies. We are working to obtain regulatoryÂ 510(k) clearance on certain GKEÂ products for sale in the United States, which would further expand organic revenues growth opportunities from the GKE business. Â We finalized our purchase price accounting of GKE during fiscal year 2024. Total cash consideration for the GKE acquisition was $87,187, net of cash and financial liabilities acquired and inclusive of working capital adjustments. Of the total acquisition price, approximately $9,000 (at December 31, 2024 exchange rates) is being held backÂ until April 2025 in accordance with the purchase agreement as security againstÂ potential indemnification losses ("GKE holdback"). We funded the acquisition through a combination of cash on-hand and a total ofÂ $71,000 borrowed under our line of credit.Â Â During theÂ three and nine months ended December 31, 2024, GKE's operations contributed the following amounts to our consolidated results of operations:Â Â Â Â Â Three Months Ended Â Â Nine Months Ended Â Â Â December 31, 2024Â Revenues Â $6,854Â Â $18,971Â Gross profit Â Â 4,904Â Â Â 12,457Â Â Â Â Â Â Â Â Â Â Amortization of inventory step-up recorded in cost of revenues Â Â -Â Â Â 1,232Â Amortization of acquired intangibles recorded in cost of revenues Â Â 131Â Â Â 375Â Amortization of acquired intangibles recorded in general and administrative expense Â Â 935Â Â 2,423Â Â Â Note 3. Revenue Â We develop, manufacture, market, sellÂ and maintain life sciences tools and quality control instrumentsÂ and related consumables. Â Hardware sales include physical products such as instruments used for molecular and genetic analysis, protein synthesizers, medical meters, wireless sensor systems, data loggers, and process challenge devices. Hardware salesÂ mayÂ be offered with accompanying perpetual or annual software licenses, which in some cases are required for the hardware to function. Â Consumables are single-use products and require frequent replacement in our customers' operating cycles. Consumables sold by our Clinical Genomics and Biopharmaceutical Development divisions,Â such as reagents used for molecular and genetic analysisÂ or solutions used for protein synthesis, are critical to the ongoing use of our instruments. ConsumablesÂ such as biological and chemical indicator test strips sold by our Sterilization and Disinfection Control division are used on a standalone basis. Â Page 7 Table of Contents Â Revenues from hardware and consumables are recognized upon transfer to the customer, typically at the point of shipment.Â Â We also offer maintenance, calibrationÂ and testing services. Services result in revenues recognized over time, for example, when we are obligated toÂ perform labor and replace parts on an as-needed basis over a contractually specified period of time, or at a point in time, upon completion of a specific, discrete service. In many cases, our contracts contain both revenues recognized over time and revenues recognized at a point in time.Â Â We evaluate our revenues internally based on business division and the nature of goods and services provided. Table of Contents Â Â The following tables present disaggregated revenues for the three and nine months ended December 31, 2024Â andÂ 2023, respectively: Â Â Â Three Months Ended December 31, 2024 Â Â Â Sterilization and Disinfection Control (1) Â Â Clinical Genomics Â Â Biopharmaceutical Development Â Â Calibration Solutions Â Â Total Â Â Consumables Â $20,991Â Â $9,866Â Â $4,909Â Â $1,043Â Â $36,809Â Hardware and software Â Â 52Â Â Â 1,877Â Â Â 4,534Â Â Â 9,333Â Â Â 15,796Â Services Â Â 2,464Â Â Â 924Â Â Â 2,794Â Â Â 4,053Â Â Â 10,235Â Total revenues Â $23,507Â Â $12,667Â Â $12,237Â Â $14,429Â Â $62,840Â Â (1) Revenues of $6,854 from GKE are included in the Sterilization and Disinfection Control division during theÂ three months ended December 31, 2024.Â Â Â Â Three Months Ended December 31, 2023 Â Â Â Sterilization and Disinfection Control (1) Â Â Clinical Genomics Â Â Biopharmaceutical Development Â Â Calibration Solutions Â Â Total Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Consumables Â $16,832Â Â $9,758Â Â $4,080Â Â $539Â Â $31,209Â Hardware and software Â Â 180Â Â Â 1,639Â Â Â 2,672Â Â Â 8,254Â Â Â 12,745Â Services Â Â 2,326Â Â Â 1,149Â Â Â 2,678Â Â Â 3,366Â Â Â 9,519Â Total revenues Â $19,338Â Â $12,546Â Â $9,430Â Â $12,159Â Â $53,473Â Â (1) Revenues of $3,837 from GKE are included in the Sterilization and Disinfection Control division during the three months ended December 31, 2023, following the acquisition of GKE GmbH and SAL GmbH on October 16, 2023.Â Â Â Â Â Nine Months Ended December 31, 2024 Â Â Â Sterilization and Disinfection Control (1) Â Â Clinical Genomics Â Â Biopharmaceutical Development Â Â Calibration Solutions Â Â Total Â Â Consumables Â $60,860Â Â $26,156Â Â $12,657Â Â $2,067Â Â $101,740Â Hardware and software Â Â 365Â Â Â 6,511Â Â Â 14,539Â Â Â 24,067Â Â Â 45,482Â Services Â Â 7,444Â Â Â 2,903Â Â Â 8,916Â Â Â 12,358Â Â Â 31,621Â Total revenues Â $68,669Â Â $35,570Â Â $36,112Â Â $38,492Â Â $178,843Â Â (1) Revenues of $18,971 from GKE are included in the Sterilization and Disinfection Control division during the nine months ended December 31, 2024.Â Â Â Â Nine Months Ended December 31, 2023 Â Â Â Sterilization and Disinfection Control (1) Â Â Clinical Genomics Â Â Biopharmaceutical Development Â Â Calibration Solutions Â Â Total Â Â Consumables Â $45,288Â Â $28,490Â Â $12,753Â Â $1,834Â Â $88,365Â Hardware and software Â Â 381Â Â Â 9,540Â Â Â 7,838Â Â Â 22,216Â Â Â 39,975Â Services Â Â 6,676Â Â Â 3,434Â Â Â 7,935Â Â Â 10,898Â Â Â 28,943Â Total revenues Â $52,345Â Â $41,464Â Â $28,526Â Â $34,948Â Â $157,283Â Â (1) Revenues of $3,837 from GKE are included in the Sterilization and Disinfection Control division during theÂ nine months ended December 31, 2023, following the acquisition of GKE GmbH and SAL GmbH on October 16, 2023.Â Â Page 8 Table of Contents Â Revenues from external customers are attributed to individual countries based upon the locations to which the products areÂ shipped or exported, or locations where services are performed, as follows: Â Â Â Three Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â United States Â $30,476Â Â $25,595Â Â $85,415Â Â $79,205Â China Â Â 6,322Â Â Â 4,942Â Â Â 20,271Â Â Â 18,584Â Other Â Â 26,042Â Â Â 22,936Â Â Â 73,157Â Â Â 59,494Â Total revenues Â $62,840Â Â $53,473Â Â $178,843Â Â $157,283Â Â Other than China, noÂ foreign country exceededÂ 10% of total revenues for theÂ three and nine months ended December 31, 2024Â andÂ 2023. Â Contract Balances Our contracts have varying payment terms and conditions. Some customers prepay for products and servicesÂ resulting in unearned revenues or customer depositsÂ called contract liabilities. Short-term contract liabilities are included withinÂ unearned revenuesÂ in the accompanying unaudited Condensed Consolidated Balance Sheets, and long-term contract liabilities are included within other noncurrent liabilitiesÂ in the accompanying unaudited Condensed Consolidated Balance Sheets. The significant majority of our revenues and related receivables and contract liabilities are generated from contracts with customers with original durations of 12Â months or less. Contract liabilities will be recognized to revenue as we satisfy our obligations under the terms of the contracts.Â Â A summary of contract liabilities is as follows: Â Contract liabilities as of March 31, 2024 Â $15,686Â Prior year liabilities recognized in revenues during the nine months ended December 31, 2024 Â Â (9,069) Contract liabilities added during the nine months ended December 31, 2024, net of revenues recognized Â Â 8,083Â Contract liabilities as of December 31, 2024 Â $14,700Â Â Â Note 4. Fair Value Measurements Â Our financial instruments consist primarily of cash and cash equivalents, trade accounts receivable, obligations under trade accounts payable,Â and debt. Due to their short-term nature, the carrying values for cash and cash equivalents, trade accounts receivable, and trade accounts payable approximate fair value; they are classified within Level 1 of the fair value hierarchy.Â Â The financial instruments that subject us to the highest concentration of credit risk are cash andÂ accounts receivable. We maintain relationships and cash deposits at multiple banking institutions across the world in an effort to diversify and reduce risk of loss. Concentration of credit risk with respect to accounts receivable is limited to customers to whom we make significant sales. No customers accounted for more than 10% of total trade receivables as of December 31, 2024. Â On April 5, 2024, we entered into separate, privately negotiated purchase agreements with a limited number of holders of our 1.375% convertible senior notes dueÂ August 15, 2025 (the "Notes"), through which we repurchased $75,000 in aggregate principal amount of the Notes. See Note 7. "Indebtedness" for further information. As of December 31, 2024, we hadÂ remaining outstanding $97,500Â aggregate principal amount of the Notes. We estimate the fair value of the Notes using Level 2 inputs based on the last actively traded price or observable market input preceding the end of the reporting period. The fair value of the Notes is approximately correlated to our stock price. Â The estimated fair value and carrying value of the Notes were as follows: Â Â Â December 31, 2024 Â Â March 31, 2024 Â Â Â Carrying Value Â Â Fair Value (Level 2) Â Â Carrying Value Â Â Fair Value (Level 2) Â Notes Â $97,163Â Â $94,819Â Â $171,198Â Â $163,013Â Â The carrying amounts of our term loan and revolving line of credit (together, the "Credit Facility") on the unaudited Condensed Consolidated Balance Sheets approximateÂ fair value due to the variable interest rate pricing on the debt, with the balance bearing an interest rate approximating current market rates. Â We expect to pay approximately $9,000Â (atÂ December 31, 2024 exchange rates) for the GKE holdback in April 2025. We estimate the discounted fair value of consideration held back to be approximately $8,900 as of December 31, 2024Â based on Level 3 inputs from the acquisition, including discount rate estimates. We adjust the estimated fair value at each reporting period through earnings. Â During fiscal year 2023, weÂ acquired substantially all of the assets and certain liabilities of Belyntic GmbHâ€™s peptide purification business (â€œthe Belyntic acquisitionâ€). We are obligated to pay contingent consideration of up to $1,500 cash upon regulatory approval of certain patent applications. We estimate the fair value of the remaining contingent consideration is $675, using Level 3 inputs and a probability-weighted outcome analysis based on our expectations of patent approval, leveraging our historical experience and expert input.Â Â Amounts recognized or disclosed at fair value in the unaudited condensed consolidated financial statements on a nonrecurring basis include the initial recognition and disclosure of most assets and liabilities purchased inÂ business acquisitions and any related measurement period adjustments. Additionally, assets such as property and equipment, operating lease assets, goodwill and other intangible assets are adjusted to fair value if determined to be impaired.Â Fair values of such assets and liabilitiesÂ requireÂ measurement using Level 3 inputs. We recorded no impairments during the three and nine months ended December 31, 2024Â orÂ 2023.Â Â There were no transfers between the levels of the fair value hierarchy during the three and nine months ended December 31, 2024. Â Page 9 Table of Contents Â Â Note 5. SupplementalÂ Information Â Inventories consisted of the following: Â Â Â December 31, 2024 Â Â March 31, 2024 Â Raw materials Â $16,584Â Â $18,335Â Work in process Â Â 400Â Â Â 1,256Â Finished goods Â Â 11,138Â Â Â 13,084Â Total inventories Â $28,122Â Â $32,675Â Â Prepaid expenses and other current assets consisted of the following:Â Â Â Â December 31, 2024 Â Â March 31, 2024 Â Prepaid expenses Â $3,251Â Â $2,932Â Deposits Â Â 1,338Â Â Â 1,898Â Prepaid income taxes Â Â 5,682Â Â Â 1,237Â Other current assets Â Â 2,849Â Â Â 3,341Â Total prepaid expenses and other current assets Â $13,120Â Â $9,408Â Â Accrued payroll and benefits consisted of the following: Â Â Â December 31, 2024 Â Â March 31, 2024 Â Bonus payable Â $7,803Â Â $3,838Â Wages and paid-time-off payable Â Â 3,600Â Â Â 3,072Â Payroll related taxes Â Â 1,954Â Â Â 1,956Â Other benefits payable Â Â 562Â Â Â 1,069Â Total accrued payroll and benefits Â $13,919Â Â $9,935Â Â The increase in bonus payable is primarily due to our financial performance in fiscal year 2025 compared to fiscal year 2024.Â Â Other accrued expenses consisted of the following:Â Â Â Â December 31, 2024 Â Â March 31, 2024 Â Accrued business taxes Â $5,505Â Â $5,557Â Current operating lease liabilities Â Â 3,535Â Â Â 2,986Â Income taxes payable Â Â 1,364Â Â Â 1,615Â Current acquisition-related holdbacks Â Â 9,531Â Â Â 436Â Other Â Â 2,416Â Â Â 2,264Â Total other accrued expenses Â $22,351Â Â $12,858Â Â The increase in other accrued expenses is primarily due to the reclassification of held back Belyntic and GKE acquisition-related consideration from noncurrent liabilities. Â Other noncurrent liabilities consisted of the following:Â Â Â Â December 31, 2024 Â Â March 31, 2024 Â Noncurrent operating lease liabilities Â $12,361Â Â $6,613Â Noncurrent acquisition-related holdbacks Â Â -Â Â Â 8,792Â Other Â Â 92Â Â Â 208Â Total other noncurrent liabilities Â $12,453Â Â $15,613Â Â The increase in operating lease liabilities is primarily attributable to the right of use asset associated with an operating lease for a facility used by our Biopharmaceutical Development for manufacturing and administrative purposes. Â Â Â Three Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Depreciation expense in cost of revenues Â $610Â Â $788Â Â $2,376Â Â $2,117Â Depreciation expense in operating expense Â Â 496Â Â Â 286Â Â Â 1,652Â Â Â 782Â Total depreciation expense Â $1,106Â Â $1,074Â Â $4,028Â Â $2,899Â Â The increase in depreciation expense for the three and nine months ended December 31, 2024Â is primarily due to GKE's operations, which included $225Â and $850Â of depreciation expense, respectively.Â Â Page 10 Table of Contents Â Â Note 6. Goodwill and Intangible Assets, Net Â Finite-lived intangible assets consisted of the following: Â Â Â December 31, 2024 Â Â March 31, 2024 Â Â Â Gross Carrying Amount Â Â Accumulated Amortization Â Â Net Carrying Amount Â Â Gross Carrying Amount Â Â Accumulated Amortization Â Â Net Carrying Amount Â Customer relationships Â $186,272Â Â $(112,475)Â $73,797Â Â $189,911Â Â $(104,528)Â $85,383Â Other intangibles Â Â 60,356Â Â Â (35,972)Â Â 24,384Â Â Â 61,161Â Â Â (32,792)Â Â 28,369Â Total finite-lived intangible assets Â $246,628Â Â $(148,447)Â $98,181Â Â $251,072Â Â $(137,320)Â $113,752Â Â Amortization expense for finite-lived intangible assets was as follows: Â Â Â Three Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Amortization in cost of revenues Â $660Â Â $1,883Â Â $1,979Â Â $5,367Â Amortization in general and administrative Â Â 3,731Â Â Â 6,092Â Â Â 11,023Â Â Â 17,013Â Total amortization expense Â $4,391Â Â $7,975Â Â $13,002Â Â $22,380Â Â The decrease in amortization expense isÂ attributable to impairment losses recorded during the fourth quarter of fiscal year 2024 related toÂ intangible assets within our Clinical Genomics division.Â Â For the following fiscal years ending March 31, future amortization expense is estimated as follows, based on foreign currency exchange rates as of December 31, 2024: Â Fiscal Year Â Amortization ExpenseÂ Â Â Remainder of 2025 Â $4,278Â 2026 Â Â 16,566Â 2027 Â Â 15,921Â 2028 Â Â 15,349Â 2029 Â Â 14,815Â Â The change in the carrying amount of goodwill was as follows: Â Â Â Sterilization and Disinfection Control Â Â Clinical Genomics Â Â Biopharmaceutical Development Â Â Calibration Solutions Â Â Total Â March 31, 2024 Â $79,430Â Â $16,940Â Â $46,515Â Â $37,211Â Â Â 180,096Â Effect of foreign currency translation Â Â (1,994)Â Â (71)Â Â (849)Â Â (30)Â Â (2,944) December 31, 2024 Â $77,436Â Â $16,869Â Â $45,666Â Â $37,181Â Â $177,152Â Â Note 7.Â Indebtedness Â Credit Facility OnÂ March 5, 2021,Â we entered into aÂ four-year senior secured credit agreementÂ that includedÂ 1) a revolving credit facility with an aggregate principal amount of up to $75,000Â (the "Revolver"),Â 2) aÂ swingline loanÂ with an aggregate principal amountÂ notÂ exceeding $5,000, andÂ 3) letters of credit with an aggregate stated amountÂ notÂ exceeding $2,500Â at any time.Â The agreement also provided for an incremental term loan or an increase in revolving commitments with a minimum aggregate principal amount of $25,000Â and a maximum amount of $75,000, subject to the satisfaction of certain conditions and lender considerations.Â We refer to theÂ agreement in whole as the â€œCredit Facility.â€ Â OnÂ October 5, 2023,Â we amended the terms of the Credit Facility to increase the maximum principal amount available to us under the Revolver from $75,000Â to $125,000.Â Â OnÂ April 5, 2024,Â we further amended and restated the terms of the Credit Facility to: Â (i) Extend the maturity of the Credit Facility toÂ April 2029;Â (ii) Allow proceeds from the Credit Facility to be used to redeem some or all of the Companyâ€™sÂ 2025Â Notes; (iii) Include aÂ $75,000Â senior secured term loan facility (the â€œTerm Loanâ€), which is subject to principal amortization payments; and (iv) Make certain changes to the financial covenants. Â Page 11 Table of Contents Â In conjunction with the amendment and restatement of the Credit Facility during the nine months ended December 31, 2024, we incurred $1,987 of customary lender fees and debt issuance costs paid to third parties, of which $1,242 is related to the RevolverÂ and $745 is related to the Term Loan. The fees are being amortized to interest expense through maturity.Â Â Amounts borrowed under the Credit Facility bearÂ interest at either a base rate or a SOFR rate plus an applicable spread ranging fromÂ 1.5% toÂ 3.5%, depending on our total net leverage ratio. The weighted average interest rate on borrowings under the Credit Facility as ofÂ December 31, 2024Â wasÂ 7.5%. Â The financial covenants in the Credit Facility as amended include a maximum leverage ratio ofÂ 4.50Â toÂ 1.00Â on each of the quarterly testing dates through December 31, 2024;Â 4.0Â toÂ 1.0Â on each of the testing dates between March 31, 2025 and March 31, 2026; andÂ 3.5Â toÂ 1.0Â on each testing date thereafter. The Credit Facility also stipulates a minimum fixed charge coverage ratio ofÂ 1.25Â toÂ 1.0Â and a minimum senior net leverage ratio ofÂ 3.5Â toÂ 1.Â Other covenants include restrictions on ourÂ ability to incur debt, grant liens, make fundamental changes to our business as defined in the contract, engage in certain transactions with affiliates, or conduct asset sales. As ofÂ December 31, 2024, we were in compliance with all covenants underÂ the Credit Facility. Â Term Loan We borrowed $75,000Â under the Term Loan onÂ April 5, 2024, to fund the privately negotiated repurchases of a portion of theÂ Notes (see â€œConvertible Notesâ€ below). During the three and nine months ended December 31, 2024, we made required quarterly principal payments on the Term Loan of $938Â and $2,813, respectively.Â Â We are required to make quarterly principal payments on the Term Loan. For the following fiscal years ending March 31, future debt payments on the Term Loan are required as follows: Â Fiscal Year Â Amount Â Remainder of 2025 Â $937Â 2026 Â Â 3,750Â 2027 Â Â 5,625Â 2028 Â Â 5,625Â 2029 Â Â 7,500Â Thereafter Â Â 48,750Â Total Principal Remaining Â $72,187Â Â The net carrying amount of the Term Loan was as follows: Â Â Â December 31, 2024 Â Â March 31, 2024 Â Term Loan (7.5% as of December 31, 2024) Â $72,187Â Â $-Â Less: discount and debt issuance costs Â Â (634)Â Â -Â Less: current portion Â Â (3,750)Â Â -Â Noncurrent portion Â $67,803Â Â $-Â Â Revolver As ofÂ December 31, 2024,Â the outstanding balance under theÂ Revolver was $27,000, and $98,000Â was available for borrowing. Subsequent toÂ December 31, 2024,Â we repaid an additional $4,500 on theÂ Revolver. Â We are obligated to pay quarterly unused commitment fees ofÂ betweenÂ 0.20% andÂ 0.35% of the Revolverâ€™s aggregate principal amount, based on our leverage ratio. Â The balance of unamortized customary lender fees related to the Revolver, including fees from the original debt issuance and all subsequent amendments and restatements, was $1,278Â and $321Â as ofÂ December 31, 2024Â andÂ March 31, 2024,Â respectively. Â Convertible NotesÂ On August 12, 2019, we issued an aggregate principal amount of $172,500 of Notes. The net proceeds from the Notes, after deducting underwriting discounts and commissions and other related offering expenses payable by us, were approximately $167,056.Â The Notes mature on August 15, 2025, unless earlier repurchased or converted, and bear interest at a rate of 1.375% payable semi-annually in arrears on February 15 and August 15 each year.Â TheÂ NotesÂ are initially convertible, subject to certain conditions,Â at a conversion rate ofÂ 3.5273Â shares of common stock perÂ $1,000Â principal amount of Notes, which is equivalent to an initial conversion price of approximatelyÂ $283.50Â per share of common stock.Â Â On April 5, 2024, we entered into separate, privately negotiated transactions with certain holders of the Notes to repurchase $75,000 aggregate principal amount of the Notes for an aggregateÂ repurchase price of $71,250Â in cash, plus accrued and unpaid interest of $160. We accounted for the partial repurchase of the Notes as a debt extinguishment, which resulted in the recognition of a gainÂ on extinguishment of $2,887 in other income on the unaudited Condensed Consolidated Statements of Operations during the nine months ended December 31, 2024. As of December 31, 2024, $97,500 in aggregate principal amount of the Notes remained outstanding, which we intend to pay using a combination of cash on hand and a draw on our Revolver. Â Upon conversion, weÂ will pay or deliver, as the case may be, cash, shares of ourÂ common stock, or a combination of cash and shares of our common stock. The circumstances necessary for conversion were not met duringÂ the three or nine months endedÂ December 31, 2024. The Notes will become convertible at any time from and includingÂ AprilÂ 15,Â 2025Â until the close of business on theÂ secondÂ scheduled trading day immediately before the maturity date. As of December 31, 2024, the Notes were classified as a current liability on our unaudited Condensed Consolidated Balance Sheets.Â The if-converted value of the Notes did not exceed the principal balance as ofÂ December 31, 2024.Â Â Page 12 Table of Contents Â The net carrying amount of the Notes wasÂ as follows: Â Â Â December 31, 2024 Â Â March 31, 2024 Â Principal outstanding Â $97,500Â Â $172,500Â Unamortized debt issuance costs Â Â (337)Â Â (1,302) Net carrying value Â $97,163Â Â $171,198Â Â We recognized interest expense on the Notes as follows: Â Â Â Three Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Coupon interest expense at 1.375% Â $335Â Â $593Â Â $1,037Â Â $1,779Â Amortization of debt issuance costs Â Â 134Â Â Â 231Â Â Â 412Â Â Â 692Â Total interest and amortization of debt issuance costs Â $469Â Â $824Â Â $1,449Â Â $2,471Â Â The effective interest rate on the Notes is approximately 1.9%. Â Â Note 8. Stockholders' Equity Â Stock-Based Compensation During the nine months ended December 31, 2024, we issued time-based restricted stock units ("RSUs") and performance-based restricted stock units ("PSUs") pursuant toÂ the Mesa Laboratories, Inc. Amended and Restated 2021 Equity Incentive Plan, which authorizes the issuance of 660Â shares of common stock to eligible participants.Â Stock-based compensation expense is included in cost of revenues, selling, general and administrative, and research and development expense in the accompanying unaudited Condensed Consolidated Statements of Operations. Â The following is a summary of RSU and PSU award activity for the nineÂ months ended December 31, 2024: Â Â Â Time-Based Restricted Stock Units Â Â Performance-Based Restricted Stock Units Â Â Â Number of Shares Â Â Weighted- Average Grant Date Fair Value per Share Â Â Number of Shares Â Â Weighted- Average Grant Date Fair Value per Share Â Outstanding as of March 31, 2024 Â Â 76Â Â $157.83Â Â Â 56Â Â $240.96Â Awards granted(1) Â Â 117Â Â Â 93.46Â Â Â 41Â Â Â 102.57Â Awards forfeited Â Â (7)Â Â 123.42Â Â Â -Â Â Â -Â Awards distributed Â Â (36)Â Â 169.40Â Â Â (12)Â Â 302.06Â Outstanding as of December 31, 2024 Â Â 150Â Â $106.44Â Â Â 85Â Â $165.75Â Â (1) Balances for PSUs granted are reflected at target. Â Outstanding time-based RSUsÂ vest and settle in shares of our common stockÂ on aÂ one-for-one basis. The majority of RSUs granted to employees during the nine months ended December 31, 2024Â vest in equal installmentsÂ on the first, second, and third anniversariesÂ of the grant date. RSUs granted to non-employee directors during the nine months ended December 31, 2024 vest one year from the grant date. We generally recognize the expense relating to RSUs, net of estimated forfeitures, on a straight-line basis over the vesting period. Â We grantÂ PSUs to certain key employees. The number of shares earned is determined at the end of each performance period based on Mesa's achievement of certain pre-defined targets per the related award agreement. The outstanding PSUs vest upon completion of the service period described in the award agreement. We recognize the expense relating to the performance-based RSUs based on the probable outcome of achievement of the performance targetsÂ on a straight-line basis overÂ the service period.Â Â During the nine months ended DecemberÂ 31, 2024, the Compensation Committee of the Board of Directors created a plan to award 41Â PSUs at target (â€œthe FY25 PSUsâ€) to eligible employees. Of the 41 PSUs granted, 23 PSUs have a grant date fair value of $89.82 and are subject to service and company financial performance conditions. The financial performance measurement period is from April 1, 2024 through March 31, 2027. The remaining 18 PSUs have a grant date fair value of $119.54Â and are subject toÂ service and market conditions, with theÂ market performance period measured from June 18, 2024 through June 18, 2027. The service period for all of the FY25 PSUs is from JuneÂ 18, 2024 through June 18, 2027.Â The quantity of shares that will be earnedÂ based upon either company financial performanceÂ or market performance will range fromÂ 0% toÂ 200% of the targeted number of sharesÎ¾ if the defined minimum targets areÂ notÂ met, thenÂ noÂ shares will vest. Â Page 13 Table of Contents Â The following is a summary of stock option award activity for the nine months ended December 31, 2024: Â Â Â Stock Options Â Â Â Shares Subject to Options Â Â Weighted- Average Exercise Price per Share Â Â Weighted-Average Remaining Contractual Life (Years) Â Â Aggregate Intrinsic Value Â Outstanding as of March 31, 2024 Â Â 194Â Â $181.89Â Â Â 3.2Â Â $26Â Awards granted Â Â -Â Â Â -Â Â Â Â Â Â Â Â Â Â Awards forfeited or expired Â Â (15)Â Â 150.98Â Â Â Â Â Â Â Â Â Â Awards exercised Â Â (1)Â Â 131.67Â Â Â Â Â Â Â Â Â Â Outstanding as of December 31, 2024 Â Â 178Â Â $184.55Â Â Â 2.6Â Â $287Â Â Note 9.Â (Loss)Â EarningsÂ Per Share Â The following table presents a reconciliation of the denominators used in the computation of basic and diluted (loss) earnings per share: Â Â Â Three Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net (loss) income available for shareholders Â $(1,676)Â $2,116Â Â $5,140Â Â $337Â Weighted average outstanding shares of common stock Â Â 5,429Â Â Â 5,393Â Â Â 5,413Â Â Â 5,384Â Dilutive effect of stock options Â Â -Â Â Â -Â Â Â -Â Â Â 1Â Dilutive effect of RSUs Â Â -Â Â Â 3Â Â Â 51Â Â Â 9Â Fully diluted shares Â Â 5,429Â Â Â 5,396Â Â Â 5,464Â Â Â 5,394Â Â Basic (loss) earnings per share Â $(0.31)Â $0.39Â Â $0.95Â Â $0.06Â Diluted (loss) earnings per share Â $(0.31)Â $0.39Â Â $0.94Â Â $0.06Â Â Potentially dilutive securities include stock options and both time and performance based RSUs (collectively "stock awards"), as well as common shares underlying our Notes. Stock awards are excluded from the calculation of diluted EPS if they are subject to performance conditions that have not yet been achieved or if they are antidilutive. Diluted EPS does not consider the impact ofÂ potentially dilutive securities in periods in which there is a loss because the inclusion of the potential common shares would have an antidilutive effect in such cases. Â The following potentially dilutive awards were excluded from the calculation of diluted EPS: Â Â Â Three Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Assumed conversion of the Notes Â Â 344Â Â Â 608Â Â Â 354Â Â Â 608Â Stock awards that were anti-dilutive Â Â 406Â Â Â 277Â Â Â 202Â Â Â 223Â Total stock awards excluded from diluted EPS Â Â 750Â Â Â 885Â Â Â 556Â Â Â 831Â Â Shares underlying the Notes were excluded from the diluted EPS calculation for the three and nine months ended

DecemberÂ 31, 2024 and 2023 as the impact of the assumed conversion of the Notes calculated under the if-converted method was antidilutive. The decrease in assumed conversion of the Notes is related to the partial repayment of the Notes that occurred during the nineÂ months ended DecemberÂ 31, 2024 (see Note 7. "Indebtedness"). Â Table of Contents Â Â Â Note 10. Income Taxes Â We reported an income tax provision as follows: Â Â Â Three Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Income tax (benefit) expense Â $(541)Â $(170)Â $360Â Â $(653) Effective tax rateÂ Â 24.4%Â Â (8.7%)Â Â 6.5%Â Â 206.6% Â Page 14 Table of Contents Â For interim income tax reporting, we estimate our annual effective tax rate and apply this effective tax rate to our year-to-date pre-tax income. Each quarter, our estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. Additionally, the tax effects of significant unusual or infrequently occurring items are recognized as discrete items in the interim period in which the events occur. There is a potential for volatility in the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which they relate, changes in tax laws and foreign tax holidays, settlement with taxing authorities, and foreign currency fluctuations. Â The change in the effective tax rate for both the three and nine months ended December 31, 2024 compared to the prior year periods is primarily due to the valuation allowance established on the US deferred taxes during fiscal year 2024. The effective tax rate for both the three and the nine months ended December 31, 2024 differed from the statutory federal rate of 21% primarily due to the valuation allowance established on the US deferred taxes during fiscal year 2024. Â Â Note 11. Commitments and Contingencies Â We are party to various legal proceedings arising in the ordinary course of business. As ofÂ December 31, 2024, we areÂ notÂ party to any legal proceeding that management believes could have a material adverse effect on our unaudited consolidated financial position, results of operations, or cash flows.Â Â We expect to pay approximately $9,000Â (atÂ December 31, 2024 exchange rates) for the GKE holdback in April 2025, pending adjustments for potential indemnification losses thatÂ mayÂ arise. The liability is recorded at its discountedÂ fair value of $8,900 in other accrued expenses in our unaudited Condensed Consolidated Balance Sheets as of December 31, 2024.Â Â As part of the Belyntic acquisition, we agreed to pay the sellers a contingency based upon approval of contractually specified patents. The estimated fair value of the probableÂ remaining contingent consideration was $675Â as ofÂ December 31, 2024.Â On January 2, 2025, a notice of allowance was issued for one of the two remaining pending patents, and we expect to pay the Belyntic sellers $563 for the patentÂ within fiscal year 2025 or early in fiscal year 2026, depending upon the final approval date. We expect the other remaining pending patent will likely be approved within one year of December 31, 2024. Â Â Note 12. Segment Information Â The following tables set forth our segment information: Â Â Â Three Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenues (a): Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Sterilization and Disinfection Control (b) Â $23,507Â Â $19,338Â Â $68,669Â Â $52,345Â Clinical Genomics Â Â 12,667Â Â Â 12,546Â Â Â 35,570Â Â Â 41,464Â Biopharmaceutical Development Â Â 12,237Â Â Â 9,430Â Â Â 36,112Â Â Â 28,526Â Calibration Solutions Â Â 14,429Â Â Â 12,159Â Â Â 38,492Â Â Â 34,948Â Total revenues Â $62,840Â Â $53,473Â Â $178,843Â Â $157,283Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Gross profit: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Sterilization and Disinfection Control (b) Â $16,461Â Â $13,951Â Â $47,191Â Â $38,018Â Clinical Genomics Â Â 6,948Â Â Â 6,449Â Â Â 19,344Â Â Â 20,904Â Biopharmaceutical Development Â Â 7,539Â Â Â 5,841Â Â Â 22,665Â Â Â 17,783Â Calibration Solutions Â Â 8,806Â Â Â 7,212Â Â Â 23,258Â Â Â 20,050Â Reportable segment gross profit Â Â 39,754Â Â Â 33,453Â Â Â 112,458Â Â Â 96,755Â Corporate and other (c) Â Â -Â Â Â (51)Â Â -Â Â Â (61) Gross profit Â $39,754Â Â $33,402Â Â $112,458Â Â $96,694Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Reconciling items: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Operating expense Â Â 33,975Â Â Â 33,469Â Â Â 97,591Â Â Â 97,485Â Operating income (loss) Â Â 5,779Â Â Â (67)Â Â 14,867Â Â Â (791) Non-operating expense (income), net Â Â 7,996Â Â Â (2,013)Â Â 9,367Â Â Â (475) (Loss) earnings before income taxes Â $(2,217)Â $1,946Â Â $5,500Â Â $(316) Â Â (a) Intersegment revenues are not significant and are eliminated to arrive at consolidated totals. Â (b) Includes post-acquisition GKE results during the three and nine months ended December 31, 2024Â and 2023Â beginning on October 16, 2023 for GKE GmbH and SAL GmbH, and beginning on January 1, 2024 for GKE China.Â Â (c)Unallocated corporate expenses are reported within corporate and other.Â Â The following table sets forth inventoriesÂ by reportableÂ segment.Â Our chief operating decision maker isÂ notÂ provided with and does not regularly review any other segment asset information. Â Â Â December 31, Â Â March 31, Â Â Â 2024 Â Â 2024 Â Sterilization and Disinfection Control Â $5,728Â Â $7,014Â Clinical Genomics Â Â 10,709Â Â Â 11,813Â Biopharmaceutical Development Â Â 5,853Â Â Â 6,304Â Calibration Solutions Â Â 5,832Â Â Â 7,544Â Total Inventories Â $28,122Â Â $32,675Â Â Page 15 Table of Contents Â Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations (Dollars in thousands, except per share amounts) Â Forward-Looking Statements Â ThisÂ QuarterlyÂ Report on Form 10-QÂ contains forward-looking statements which are made pursuant to the safe harbor provisions of SectionÂ 27A of the Securities Act of 1933, as amended, and SectionÂ 21E of the Securities Exchange Act of 1934, as amended (theÂ â€œExchange Actâ€). The forward-looking statements in this Quarterly Report on Form 10-QÂ do not constitute guarantees of future performance. Investors are cautioned that statements in this Quarterly Report on Form 10-QÂ which are not strictly historical statements, including, without limitation, express or implied statements or guidance regarding current or future financial performance and position; results of acquisitions; managementâ€™s strategy, plans and objectives for future operations or acquisitions, product development and sales; and adequacy of capital resources and financing plans constitute forward-looking statements. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which the Company operates, and managementâ€™s beliefs and assumptions. In addition, other written and oral statements that constitute forward-looking statements may be made by the Company or on the Companyâ€™s behalf. Words such asÂ â€œseek,â€Â â€œbelieve,â€Â â€œmay,â€ â€œintend,â€Â â€œcould,â€ â€œtarget,â€ â€œexpect,â€ â€œanticipate,â€Â â€œplan,â€Â â€œestimate,â€ â€œproject,â€Â or variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks associated with:Â our ability to successfully grow our business, including as a result of acquisitions; the effectÂ that acquisitions have on our operations; our ability to consummate acquisitions at our historical rate and at appropriate prices, and our ability toÂ effectively integrate acquired businesses and achieve desired results; the market acceptance of our products; technological or market viability of our products; potential reduced demand for our products, including as a result of competitive factors; conditions in the global economy and the particular markets we serve;Â significant developments or uncertainties stemming from governmental actions, including changes inÂ trade policies and medical device regulations; the timely development and commercialization, and customer acceptance, of enhanced and new products and services; retirement of old products and customer migration to new products; the potential inaccuracy ofÂ projections of revenues, growth, operating results, profit margins, earnings, expenses,Â margins, tax rates, tax provisions, liquidity, cash flows,Â demand, and competition; the effects of actions taken to become more efficient or lower costsÍ¾Â supply chain challenges; cost pressures;Â laws regulating fraud and abuse in the health care industry, privacy and security of health and personal information; product liability; information security; outstanding claims, legal and regulatory proceedings; international business challenges including anti-corruption and sanctions laws and political developments; tax audits and assessments and other contingent liabilities;Â foreign currency exchange rates and fluctuations in those rates; general economic, industry, and capital markets conditionsÍ¾Â the timing of any of the foregoingÍ¾Â and assumptions underlying any of the foregoing.Â Such risks and uncertainties also include those listed in Item 1A.Â â€œRisk Factorsâ€Â in our Annual Report on Form 10-K for the year ended March 31, 2024Â and in this report.Â The foregoing list sets forth many, but not all, of the factors that could impact our ability to achieve results described in any forward-looking statements.Â We disclaim any obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise. Â Overview Â We are a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries. We offer products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. We haveÂ manufacturing operationsÂ in the United States and Europe, and our products are marketed by our sales personnel in North America, Europe and Asia Pacific, and by independent distributors in these areas as well asÂ throughout the rest of the world. We prefer markets in which we can establish a strong presence and achieve high gross profitÂ margins.Â Â As of December 31, 2024,Â we managed our operations in four reportable segments, or divisions: Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions.Â Each of our divisionsÂ is described further in "Results of Operations"Â below.Â Unallocated corporate expenses and other business activities are reported within Corporate and Other. Â Corporate Strategy We strive to create stakeholder value and further our purpose of Protecting the VulnerableÂ®Â by growing our business both organically and through acquisitions, by improving our operating efficiency, and by continuing to hire, develop and retain top talent.Â As a business, we commit to our purpose of Protecting the VulnerableÂ®Â every day by taking a customer-focused approach to developing, building, and delivering our products. We serve a broad set of industries, in particular the pharmaceutical, healthcare, and medical device verticals, in which the safety, quality, and efficacy of products is critical, by delivering the highest quality products possible.Â We are committed to protecting the communities we serve. Â Organic Revenues Growth Organic revenues growth isÂ driven by expansion of our customer base, increases in sales volumes, new product offerings, and price increases, and may be affected positively or negatively by changes in foreign currency rates. Our ability to increase organic revenues is affected by general economic conditions, both domestic and international, customer capital spending trends, competition,Â and the introduction of new products. Our policy is to price our products competitively and, where possible, we pass along cost increases to our customers in order to maintain our margins. We typically evaluate costs and pricing annually,Â withÂ price increases effective January 1. Â Inorganic Growth - Acquisitions Over the past decade, we have consummated a number of acquisitions as part of our growth strategy. We may pursue acquisitions of businesses, technologies, or intangibles such as customer lists, depending on available strategic opportunities.Â Our acquisitions have allowed us to expand our product offerings and the industries we serve, globalize our company, and increase the scale at which we operate. In turn, this growth affords us the ability to improve our operating efficiency, extend our customer base, and further the pursuit of our purpose:Â Protecting the VulnerableÂ®. Â Improving Our Operating Efficiency Our ongoing goal is toÂ maximize value in our existing businesses and those we acquire by implementingÂ efficiencies in our manufacturing, commercial, engineering,Â and administrative operations. We achieve efficienciesÂ using the four pillars that make up the Mesa Way, which is our customer-centric, lean-based system for continuously improving and operating the manufacturing and administrative aspects of our high-margin, niche businesses.Â The Mesa WayÂ is focused on: "Measuring What Matters" based on our customers' perspectives and setting high standards of performance; "Empowering Teams" to improve operationally and exceed customer expectations; "SustainablyÂ Improving" using lean-based tools designed to help us identify and prioritize the best opportunities; and "Always Learning" so that performance continuously improves.Â Â Page 16 Table of Contents Â Our gross profit isÂ affected by many factors, including product mix, foreign currency rates, manufacturing efficiencies, costs of products and labor, and price competition. Historically, as we have integrated our acquisitions and taken advantage of manufacturing efficiencies, our gross profitÂ percentages for some products have improved. There are, however, differences in gross profit percentages between product lines, and ultimately our mix of revenues will continue to impact our overall gross profit. Â Hire, Develop, and Retain Top Talent At the center of our organization are talented people who are capable of taking on new challenges using a team-based approach. Indeed, it is our exceptionally talented workforce that works together to find ways to continuously and sustainablyÂ improve our products, ourÂ services, and ourselves, resulting inÂ long-term value creation for our stakeholders.Â Â General Trends We are a global companyâ€¯with multinational operations. During theâ€¯nine months ended December 31, 2024, approximately 52%â€¯of our revenuesâ€¯were earned outside of the United States. We face both opportunities and challenges resulting from our geographic and industry diversity, such as operating in varied economic environments across served geographies, technology changes in served markets, expansion opportunities in high-growth markets, the impacts of foreign currency movements against the U.S. dollar ("USD"), changes in trends and costs of a global labor force, and increasing regulation. Our continued revenues growth will dependâ€¯onâ€¯our ability to (i) continue commercial efforts to expand business with new and existing customers, (ii) identify, consummateÂ and integrate acquisitions successfully, and (iii) develop or purchase differentiated products and services. We maintain our profitability by improving the effectiveness of our sales forces, by continuing to pursue cost reduction initiatives, and by improving our operating efficiency.â€¯Â Â During the first three quarters of fiscal year 2025, our revenues increased 13.7%Â versus the comparable prior year period. GKE, which we purchased during the third quarter of fiscal year 2024, contributed $18,971 of revenues in the first three quarters of fiscal year 2025 compared with $3,837 from the acquisition date in mid-October 2023 through December 31, 2023.Â Organic revenues increased 4.3% during the first three quarters of fiscal year 2025, primarily as a result of organic revenues growth of 26.6% from our Biopharmaceutical Development division,Â 10.1% from our Calibration Solutions division, and 2.9% from our Sterilization and Disinfection Control division, partially offset by aÂ 14.2% organic revenueÂ declineÂ in our Clinical Genomics division. Â Our Biopharmaceutical Development division has particularly benefited from anÂ improved environment for capital equipment purchases in the biopharmaceutical vertical in fiscal year 2025. Furthermore, consumables revenues in our Biopharmaceutical Development division increased by 20.3% in the third quarter of fiscal year 2025 versus the comparable prior year period, as customers who purchased equipment over the past 12 months areÂ adopting our technology into their businesses, resulting in escalating consumables purchases. Our Clinical Genomics business continued to experience challenges presented by changing global regulatory environments. However, Clinical Genomics' revenues increased 10.2% from the second quarter to the third quarter of fiscal year 2025, and increased 1.0% in the third quarter of fiscal year 2025 versus the comparable prior year period. Â Gross profit as a percentage of revenuesÂ increased 1.4Â percentage points in the first nine months of fiscal year 2025 versus the comparable prior year period, primarily due to $3,388 of lower intangible asset amortization expense flowing through cost of revenues as a result of the Clinical Genomics intangible asset impairment charge recorded in the fourth quarter of fiscal year 2024, partially offset by higher performance-based compensation costs related to our financial performance. Â Operating expenses were approximately flatÂ during the nine months ended December 31,Â 2025 versus the comparable prior year period. Increases in operating expense were primarily attributable to (i) higher performance-based compensation expensesÂ and higher professional services costs for compliance activities and integration activities related to the GKE acquisition and (ii) nine months of operating expenses from GKE, versus only about two and a half months in the comparable year to date period. These increases wereÂ largely offset by lower amortization expense in fiscal year 2025. The strengthening of the USD also decreased reported expenses incurred in Europe.Â Â Operating income was $14,867 for the nine months ended December 31, 2025, anÂ increase of $15,658 versus the comparable prior year period, primarily due to increased revenues and lower amortization expense.Â Â The weakening of foreign currencies against the USD decreases our reported revenues,Â gross profit margins, and operating expenses, and impacts the comparability of our results between periods.Â Â Results of Operations Â Our results of operations and period-over-period changes are discussed in the following section.Â The tables and discussion below should be read in conjunction with the accompanying unaudited Condensed Consolidated Financial Statements and the notes thereto appearing in Item 1.Â Financial Statements (in thousands, except percent data). Â Results by reportable segment are as follows:Â Â Â Â Revenues Â Â Organic Revenues Growth (non-GAAP) (a) Â Â Gross Profit as a % of Revenues Â Â Â Three Months Ended December 31, Â Â Three Months Ended December 31, Â Â Three Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Sterilization and Disinfection Control Â $ 23,507 Â Â $ 19,338 Â Â 7.8 % Â Â (4.8 %) Â Â 70.0 % Â Â 72.1 % Clinical Genomics Â Â 12,667 Â Â Â 12,546 Â Â Â 1.0 % Â Â (19.5 %) Â Â 54.9 % Â Â 51.4 % Biopharmaceutical Development Â Â 12,237 Â Â Â 9,430 Â Â Â 29.8 % Â Â (19.1 %) Â Â 61.6 % Â Â 61.9 % Calibration Solutions Â Â 14,429 Â Â Â 12,159 Â Â Â 18.7 % Â Â 12.9 % Â Â 61.0 % Â Â 59.3 % Mesa's reportable segments Â $ 62,840 Â Â $ 53,473 Â Â Â 12.6 % Â Â (8.6 %) Â Â 63.3 % Â Â 62.5 % Â Page 17 Table of Contents Â Â Â Revenues Â Â Organic Revenues Growth (non-GAAP) (a) Â Gross Profit as a % of Revenues Â Â Â Nine Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Sterilization and Disinfection Control Â $ 68,669 Â Â $ 52,345 Â Â Â 2.9 % Â Â 1.0 % Â Â 68.7 % Â Â 72.6 % Clinical Genomics Â Â 35,570 Â Â Â 41,464 Â Â Â (14.2 %) Â Â (14.6 %) Â Â 54.4 % Â Â 50.4 % Biopharmaceutical Development Â Â 36,112 Â Â Â 28,526 Â Â Â 26.6 % Â Â (18.2 %) Â Â 62.8 % Â Â 62.3 % Calibration Solutions Â Â 38,492 Â Â Â 34,948 Â Â Â 10.1 % Â Â 8.6 % Â Â 60.4 % Â Â 57.4 % Mesa's reportable segments Â $ 178,843 Â Â $ 157,283 Â Â Â 4.3 % Â Â (6.2 %) Â Â 62.9 % Â Â 61.5 % Â (a) Â Organic revenues growth is a non-GAAP measure of financial performance. See "Non-GAAP Measures" below for further information and for a reconciliation of organic revenues growth to total revenues growth.Â Â Our unaudited condensed consolidated results of operations are as follows: Â Â Â Three Months Ended December 31, Â Â Total Â Â Nine Months Ended December 31, Â Â Total Â Â Â 2024 Â Â 2023 Â Â Change Â Â 2024 Â Â 2023 Â Â Change Â Revenues Â $ 62,840 Â Â $ 53,473 Â Â 17.5 % Â $ 178,843 Â Â $ 157,283 Â Â 13.7 % Gross profit Â Â 39,754 Â Â Â 33,402 Â Â 19.0 % Â Â 112,458 Â Â Â 96,694 Â Â 16.3 % Operating expense Â Â 33,975 Â Â Â 33,469 Â Â 1.5 % Â Â 97,591 Â Â Â 97,485 Â Â Â 0.1 % Operating income (loss) Â Â 5,779 Â Â Â (67) Â Â 8,725.4 % Â Â 14,867 Â Â Â (791) Â Â 1,979.5 % Net (loss) income Â $ (1,676) Â $ 2,116 Â Â Â (179.2 %) Â $ 5,140 Â Â $ 337 Â Â Â 1,425.2 % Â Reportable Segments Â Sterilization and Disinfection Control Our Sterilization and Disinfection Control division manufactures and sellsÂ biological, chemical and cleaning indicatorsÂ used to assess the effectiveness of sterilization, decontamination, disinfection and cleaning processesÂ in the pharmaceutical, medical device, and healthcareÂ industries. The division also provides testing and laboratory services, mainly to the dental and pharmaceutical industries.Â Sterilization and Disinfection Control products are disposable and are used on a routine basis. Â Â Three Months Ended December 31, Â Â Total Â Â Nine Months Ended December 31, Â Â Total Â Â Â 2024 Â Â 2023 Â Â Change Â Â 2024 Â Â 2023 Â Â Change Â Revenues Â $ 23,507 Â Â $ 19,338 Â Â Â 21.6 % Â $ 68,669 Â Â $ 52,345 Â Â Â 31.2 % Gross profit Â Â 16,461 Â Â Â 13,951 Â Â Â 18.0 % Â Â 47,191 Â Â Â 38,018 Â Â Â 24.1 % Gross profit as a % of revenues Â Â 70.0 % Â Â 72.1 % Â Â (2.1 pt) Â Â Â 68.7 % Â Â 72.6 % Â Â (3.9 pt) Â Â The Sterilization and Disinfection Control division'sÂ revenues increased 21.6%Â and 31.2% for the three and nine months ended December 31, 2024, respectively, versus theÂ comparable prior year periods. The increase is primarily attributable toÂ the GKE acquisition, which contributed inorganic revenues of $2,857Â and $14,974 for the three and nine months ended December 31, 2024, respectively. The division's organic revenues increased 7.8%Â and 2.9% for the three and nine months ended December 31, 2024 compared to the corresponding prior year periods. Excluding GKE, orders increased 13.1% and 8.5% for the three and nine months ended December 31, 2024,Â driven by strong commercial execution. Increased orders, in turn, resulted in an increase in past due backlog as of December 31, 2024 versus both September 30, 2024 and March 31, 2024.Â We expect to increase order fulfillments during the fourth quarter which will enable us to lower our past due backlog, and drive increased organicÂ revenue growth for fiscal year 2025. Â For the three months ended December 31, 2024, gross profit percentage declined because the division made larger than normal sales to certain distributors at lower than typical margins, and experienced unfavorable changes in foreign currency. The division benefitted from $412 lower non-cash inventory step-up amortization in the three months ended December 31, 2024 versus the comparable prior year period.Â For the nine months ended December 31, 2024, gross profit declined because we incurred $820 more non-cash inventory step-up amortization costs versus the comparable prior year period, made larger than normal sales to certain distributors at lower than typical margins, and experienced unfavorable changes in foreign currency.Â Excluding the impact of non-cash inventory step up amortization, gross profit percentage would have been 70.0% and 74.3% and 70.5% and 73.4% for the three and nine months ended December 31, 2024 and 2023, respectively. Â Clinical Genomics The Clinical Genomics division develops, manufacturesÂ and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables and services that enable clinical research labs and contract research organizations to performÂ genomic testing for a broad range of research applications in several therapeutic areas, such as screenings for hereditary diseases, pharmacogenetics, oncology related applications, and toxicology research. Â Â Â Three Months Ended December 31, Â Â Total Â Â Nine Months Ended December 31, Â Â Total Â Â Â 2024 Â Â 2023 Â Â Change Â Â 2024 Â Â 2023 Â Â Change Â Revenues Â $ 12,667 Â Â $ 12,546 Â Â Â 1.0 % Â $ 35,570 Â Â $ 41,464 Â Â Â (14.2 %) Gross profit Â Â 6,948 Â Â Â 6,449 Â Â Â 7.7 % Â Â 19,344 Â Â Â 20,904 Â Â Â (7.5 %) Gross profit as a % of revenues Â Â 54.9 % Â Â 51.4 % Â Â 3.5 pt Â Â Â 54.4 % Â Â 50.4 % Â Â 4.0 pt Â Â The Clinical Genomics division'sÂ revenues increased 1.0% for the three months ended December 31, 2024Â versus the comparable prior year period, primarily due to strong consumables growth in North America, partiallyÂ offset by decreased revenues in China.Â Revenues in China have been impacted since the third quarter of fiscal year 2024 byÂ lower demand, driven by weakness in spending on capital equipment as Chinaâ€™s government continues to play a significant role in regulating industry development by imposing sector-specific policies and maintaining control over Chinaâ€™s economic growth through setting monetary policy and determining treatment of particular industries.Â Additionally, hardware sales in the United States continue to be impacted by increased regulations of new lab-developed tests.Â Clinical Genomics revenues decreased 14.2% for the nine months ended December 31, 2024 versus the comparable period primarily due to decreased revenues in China, and to a lesser extent, lower hardwareÂ sales in the United States as a result of regulatory challenges that affected results for the three months ended December 31, 2024. Â   Table of Contents Â Gross profit percentage for the Clinical Genomics division increased 3.5Â and 4.0Â percentage pointsÂ for the three and nine months ended December 31, 2024Â versus the comparable prior year periods, primarily due to lower intangibles amortization expense as a result of anÂ impairment charge recordedÂ in the fourth quarter of fiscal year 2024. Excluding amortization expense, gross profit as a percentage of revenues would have decreased 6.3% for the three months ended December 31, 2024 versus the comparable prior year period,Â primarily attributable to lower margin instrument sales into the APAC region.Â Excluding amortization expense, gross profit as a percentage of revenues would have decreased 4.7% for the nine months ended December 31, 2024 versus the comparable prior year period as a result ofÂ lower revenues on a partially fixed cost base and lower margin instrument sales into the APAC region. The lower margin sales into APAC reflect a change in our strategy for growth in this division that we expect will drive our future consumables sales.Â Â Biopharmaceutical Development Our Biopharmaceutical Development divisionÂ develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Immunoassays and peptide synthesis solutions accelerate the discovery, development, and manufactureÂ of biotherapeutic therapies, among other applications.Â Â Â Â Three Months Ended December 31, Â Â Total Â Â Nine Months Ended December 31, Â Â Total Â Â Â 2024 Â Â 2023 Â Â Change Â Â 2024 Â Â 2023 Â Â Change Â Revenues Â $ 12,237 Â Â $ 9,430 Â Â Â 29.8 % Â $ 36,112 Â Â $ 28,526 Â Â Â 26.6 % Gross profit Â Â 7,539 Â Â Â 5,841 Â Â Â 29.1 % Â Â 22,665 Â Â Â 17,783 Â Â Â 27.5 % Gross profit as a % of revenues Â Â 61.6 % Â Â 61.9 % Â Â (0.3 pt) Â Â Â 62.8 % Â Â 62.3 % Â Â 0.5 pt Â Â The Biopharmaceutical Development division's revenues increased 29.8% and 26.6%Â for the three and nineÂ months ended December 31, 2024Â versus the comparable prior year periods, primarily due to increased capital spending in the biopharmaceutical markets. Revenues from hardware and software sales increased 69.7% and 85.5% for the three and nine months ended December 31, 2024, respectively, versus the comparable prior year periods. Consumables revenues increased 20.3% for the three months ended December 31, 2024 versus the comparable prior year period as customers who purchased hardware over the past 12 months are adopting our technologyÂ into their business, increasing their demand for consumables. Â For the three months ended December 31, 2024, gross margin as a percentage of revenues for the Biopharmaceutical Development division decreased slightly as a result of unfavorable product mix. For the nine months ended December 31, 2024, gross margin as a percentage of revenues for the Biopharmaceutical Development division increased slightly, primarily as a result of higher revenues on a partially fixed cost baseÂ and aÂ favorable product mix, partially offset by foreign currency impacts. Â Calibration Solutions The Calibration Solutions division develops, manufacturesÂ and sells quality control products using principles of advanced metrology to measure or calibrate criticalÂ chemical or physical parameters in various dialysis, process monitoring,Â instrument monitoring, environmental monitoring,Â gas flow,Â environmental air quality,Â and torque applications, primarily inÂ medical device manufacturing, pharmaceutical manufacturing, laboratory, and hospitalÂ environments. Â Â Â Three Months Ended December 31, Â Â Total Â Â Nine Months Ended December 31, Â Â Total Â Â Â 2024 Â Â 2023 Â Â Change Â Â 2024 Â Â 2023 Â Â Change Â Revenues Â $ 14,429 Â Â $ 12,159 Â Â Â 18.7 % Â $ 38,492 Â Â $ 34,948 Â Â Â 10.1 % Gross profit Â Â 8,806 Â Â Â 7,212 Â Â Â 22.1 % Â Â 23,258 Â Â Â 20,050 Â Â Â 16.0 % Gross profit as a % of revenues Â Â 61.0 % Â Â 59.3 % Â Â 1.7 pt Â Â Â 60.4 % Â Â 57.4 % Â Â 3.0 pt Â Â The Calibration Solutions division's revenues increased 18.7% and 10.1%, respectively,Â for the three and nine months ended December 31, 2024Â versus the comparableÂ prior year periods, primarily dueÂ to commercial efforts and price increases, particularly in our Renal Care product lines.Â Â The Calibration Solutions division'sÂ gross profitÂ percentage increased 1.7Â and 3.0 percentage pointsÂ for the three and nine months ended December 31, 2024, respectively, versus the comparable prior year periods,Â primarily due to increased revenues on a partially fixed cost base and a favorable product mix. Â Operating Expense Operating expense increased 1.5% and 0.1%Â for the three and nine months ended December 31, 2024, respectively,Â versus the comparable prior year periods. Excluding decreased amortization expense resulting from prior year impairments of intangible assets, operating expense increased 10.5% and 7.6% for the three and nine months ended December 31, 2024. Â Selling Expense Selling expense is driven primarily by labor costs, including salaries and commissions; accordingly, it may vary with sales levels. Â Â Â Three Months Ended December 31, Â Â Total Â Â Nine Months Ended December 31, Â Â Total Â Â Â 2024 Â Â 2023 Â Â Change Â Â 2024 Â Â 2023 Â Â Change Â Selling expense Â $ 10,450 Â Â $ 9,737 Â Â Â 7.3 % Â $ 30,415 Â Â $ 28,363 Â Â Â 7.2 % As a percentage of revenues Â Â 16.6 % Â Â 18.2 % Â Â (1.6 pt) Â Â Â 17.0 % Â Â 18.0 % Â Â (1.0 pt) Â Â Selling expense forÂ the three and nine months ended December 31, 2024Â increased 7.3% and 7.2%, respectively, versusÂ the comparable prior year periods. The increases are primarily attributable toÂ increased performance-based compensation expense as our financial results improvedÂ and, for the nine months ended December 31, 2024, the addition of GKE's selling expenses. Â   Table of Contents Â General and Administrative Expense Labor costs, amortization of intangible assets, and non-cash stock-based compensation drive the substantial majority of our general and administrative expense. Â Â Â Three Months Ended December 31, Â Â Total Â Â Nine Months Ended December 31, Â Â Total Â Â Â 2024 Â Â 2023 Â Â Change Â Â 2024 Â Â 2023 Â Â Change Â General and administrative expense Â $ 18,472 Â Â $ 19,438 Â Â Â (5.0 %) Â $ 52,754 Â Â $ 55,024 Â Â Â (4.1 %) As a percentage of revenues Â Â 29.4 % Â Â 36.4 % Â Â (7.0 pt) Â Â Â 29.5 % Â Â 35.0 % Â Â (5.5 pt) Â Â Excluding decreased amortization expense related to prior year intangible asset impairments, general and administrative expense would have increased 10.5% for the three months ended December 31, 2024, primarily as a result of higher performance-based compensation expense. Excluding amortization expense, for the nine months ended December 31, 2024, generalÂ administrative costs would have increased 9.8%, primarily as a result of higher expense for performance-based personnel costs, the addition of GKE's administrative operatingÂ expenses, professional services costsÂ related to integrating GKE into our enterprise resource planning tool, and other compliance efforts. Â Research and Development Expense Research and development expense is predominantly comprised of labor costs and costs of third-party consultants. Â Â Â Three Months Ended December 31, Â Â Total Â Â Nine Months Ended December 31, Â Â Total Â Â Â 2024 Â Â 2023 Â Â Change Â Â 2024 Â Â 2023 Â Â Change Â Research and development expense Â $ 5,053 Â Â $ 4,294 Â Â Â 17.7 % Â $ 14,422 Â Â $ 14,098 Â Â Â 2.3 % As a percentage of revenues Â Â 8.0 % Â Â 8.0 % Â Â - pt Â Â Â 8.1 % Â Â 9.0 % Â Â (0.9 pt) Â Â Research and development expenses increased 17.7% and 2.3% for the three and nineÂ months ended December 31, 2024, respectively,Â versus the comparable prior year periods, primarily as a result of higher performance-based compensation expense, partially offset by lower salaries expense, which is expected to continue to future periods, and reduced project-specific research and development supplies purchases following our fiscal year 2024 cost containment efforts.Â Â Non-operating Expense (Income), NetÂ Â Â Three Months Ended December 31, Â Â Total Â Â Nine Months Ended December 31, Â Â Total Â Â Â 2024 Â Â 2023 Â Â Change Â Â 2024 Â Â 2023 Â Â Change Â Interest expense and amortization of debt issuance costs Â $ 2,842 Â Â $ 1,856 Â Â Â 53.1 % Â $ 9,340 Â Â $ 3,809 Â Â Â 145.2 % (Gain) on extinguishment of convertible senior notes Â Â - Â Â Â - Â Â Â N/A Â Â Â (2,887) Â Â - Â Â Â N/A Â Other expense (income), net Â Â 5,154 Â Â Â (3,869) Â Â (233.2 %) Â Â 2,914 Â Â Â (4,284) Â Â (168.0 %) Non-operating expense (income), net Â $ 7,996 Â Â $ (2,013) Â Â (497.2 %) Â $ 9,367 Â Â $ (475) Â Â (2,072.0 %) Â We incurred significantly more interest expense during the three and nine months ended December 31, 2024 versus the comparable prior year periods as we re-financed our Credit Facility during the first quarter of fiscal year 2025 in order to repurchase $75,000 in aggregate principal of our Notes. We had $98,553 outstanding under our Credit Facility as of December 31, 2024, net ofÂ discounts on the Term Loan, compared to $62,000Â outstanding under our Credit Facility as of December 31, 2023. Amounts outstanding under the Credit Facility bear interest at a significantly higher rate than amounts outstanding under the Notes.Â Â The $2,887 gain on extinguishment of ourÂ Notes represents the difference between the fair valueÂ and the carrying value of the Notes and unamortized debt issuance costs at the time of partial extinguishment in the first quarter of fiscal year 2025. Â During the third quarter of our prior fiscal year, we issued an intercompany loan denominated in USD to a wholly owned, euro-denominated subsidiaryÂ to fund the purchase of GKE. We recorded net unrealized foreign currency losses on the loan for the three and nine months ended December 31, 2024 due to the strengthening of the USD against the euro.Â Â Income Taxes Â Â Â Three Months Ended December 31, Â Â Total Â Â Nine Months Ended December 31, Â Â Total Â Â Â 2024 Â Â 2023 Â Â Change Â Â 2024 Â Â 2023 Â Â Change Â Income tax (benefit) expense Â $ (541) Â $ (170) Â Â 218.2 % Â $ 360 Â Â $ (653) Â Â (155.1 %) Effective tax rate Â Â 24.4 % Â Â (8.7 %) Â Â 33.1 pt Â Â Â 6.5 % Â Â 206.6 % Â Â (200.1 pt) Â Â Our effective income tax rate was 24.4% for the three months ended December 31, 2024Â compared to (8.7)% for the three months ended December 31, 2023.Â Our effective income tax rate was 6.5% for the nine months ended December 31, 2024 compared to 206.6% for the nine months ended December 31, 2023.Â Â The change in the effective tax rate for both the three and nine months ended December 31, 2024 compared to the prior year periods is primary due to the valuation allowance established on the US deferred taxes during fiscal year 2024. The effective tax rate for both the three and the nineÂ months ended December 31, 2024 differed from the statutory federal rate of 21% primarily due to the valuation allowance established on the US deferred taxes during fiscal year 2024. Â Our future effective income tax rate depends on various factors, such as changes in tax laws, regulations, accounting principles, or interpretations thereof, and the geographic composition of our pre-tax income. We carefully monitor these factors and adjust our effective income tax rate accordingly. Â Net (Loss) Income Net (loss) incomeÂ variesÂ withÂ changes in revenues, gross profit, operating expense, and currency exchange rate fluctuations. Net (loss) included $13,002,Â $10,004 and $4,028 of non-cashÂ amortization of intangible assets acquired in business combinations,Â stock-based compensation expense, and depreciation expense, respectively, for the nine months ended December 31, 2024.Â Â   Table of Contents Â Market-Based Awards Performance-based restricted stock awards granted during fiscal year 2025 and fiscal year 2024Â included a market-based component.Â Â Liquidity and Capital Resources Â Our sources of liquidity include cash generated from operations, cash and cash equivalents on hand, cash available from our Credit Facility and our Open Market Sale AgreementSM, working capital, and potential additionalÂ equity and debt offerings.Â We believe that cash flows from operating activities and potential cash provided byÂ borrowings under our Credit Facility orÂ funds from our Open Market Sale AgreementSM, when necessary, will be sufficient to meet our ongoing operating requirements, scheduled debt interest and principal payments, dividend payments, and anticipated capital expenditures.Â Â Our more significant uses of resources have historically included acquisitions, payments of debt and interest obligations, long-term capital expenditures, and quarterly dividends to shareholders. During fiscal year 2024, we acquired GKE for $87,187, net of cash and financial liabilities acquiredÂ and inclusive of working capital adjustments. We expect to pay a holdback of approximately $9,000 (at December 31, 2024 exchange rates) related to the acquisitionÂ in April 2025, pending adjustments for potential indemnification losses.Â Â Working capital is the amount by which current assets exceed current liabilities. We had working capital ofÂ $(45,033)Â and $65,040 as of December 31, 2024Â and March 31, 2024, respectively. Our working capital balance was negative as of December 31, 2024 because the balance on our Notes, due August 15, 2025, is due within twelve months of December 31, 2024 and is therefore classified as a current liability.Â As of December 31, 2024Â and March 31, 2024, we had $30,956Â and $28,214, respectively, of cash and cash equivalents. Â During the first quarter of fiscal year 2025, and in anticipation of settling the Notes, we amended and restated our Credit Facility to:Â Â Â â— Allow proceeds from the Credit Facility to be used to redeem some or all of the Notes. Â â— Add theÂ $75,000Â senior secured Term Loan. Â â— Extend the maturity of the Credit Facility to April 2029. Â â— Make certain changes to the financial covenants. Â Under the revised Credit Facility, weÂ maintainÂ access to our Revolver, allowing access to up to $125,000Â of borrowings. During fiscal year 2024, we borrowed a total of $71,000 under the Revolver to fund the majority of the GKE acquisition. As of December 31, 2024, $27,000 remained outstanding under the Revolver. In January 2025, we repaid an additional $4,500Â on the Revolver. Â We used proceeds of $75,000 from borrowings under the Term Loan to enter into separate, privately negotiated purchase agreements with a limited number of holders of our Notes. Pursuant to the purchase agreements, we purchased $75,000 aggregate principal amount of the Notes for an aggregate cash purchase price of approximately $71,250. Following these transactions,Â $97,500 aggregate principal amount of the Notes remainedÂ outstanding and is now classified as current in our unaudited Condensed Consolidated Balance Sheets.Â Â Using the interest rate and debt balance outstanding effective as ofÂ January 31, 2025, we expect to incur cash interest expense within the next twelve months of approximately $7,000Â (adjusted for required future principalÂ payments)Â on undiscounted borrowings of $94,688Â related to the Credit Facility as of the date of this filing. Â We have $97,500 due on the Notes in AugustÂ 2025. Together with the current portion of our Term Loan, the cash needed for principalÂ debt payments is $101,250 within the next twelveÂ months. We plan use cash on hand, draws against ourÂ Revolver, which hadÂ $102,500Â available as of the date of this filing, and cash generated from operating activities over the next two quarters to fund the amounts due. Â In April 2022, we entered into an Open Market SaleÂ AgreementSMÂ pursuant to which we may issue and sell, from time to time, shares of our common stock with an aggregate value of up to $150,000. We have not sold any shares under this agreement.Â Â We routinely evaluate opportunities for strategic acquisitions.Â Future material acquisitions may require us to obtain additional capital, assume additionalÂ third-party debt or incur other long-term obligations. We believe that we have the abilityÂ to issue more equity or debt in the future in order toÂ financeÂ our acquisition andÂ investment activities;Â however, additional equity or debt financing, or other transactions, may not be available on acceptable terms, if at all. Â We may from time to time repurchase or take other steps to reduce our debt. These actions may include retirements or refinancing of outstanding debt through tender offers, privately negotiated transactions, or otherwise. The amount of debt that may be retired, if any, could be material.

RetirementÂ would be decided at the sole discretion of our Board of Directors and would depend on market conditions, our cash position, and other considerations. Â Dividends We have paid regular quarterly dividends since 2003. We paid dividends of $0.16 per share during the three months ended December 31, 2024, as well as each quarter of fiscal years 2025 andÂ 2024. Â In January 2025, we announced that our Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, payable on March 17, 2025, to shareholders of record at the close of business on February 28, 2025. Â Goodwill and Intangible Assets We perform analyses at least quarterly to identify potential impairment indicators and assess whether it is more likely than not that any ofÂ our five goodwill reporting units (Sterilization and Disinfection Control, Clinical Genomics, Immunoassays (BPD), Peptides (BPD), and Calibration Solutions) is impaired. We determined our goodwill reporting units are not impaired as of December 31, 2024; however, changes in discount rates due to market volatility, failure to meet previously forecasted cash flows, and various other factors could result in future impairment losses in certain of our reporting units. Â Page 21 Table of Contents Â Impairment losses recorded in the prior fiscal year related to ourÂ Clinical Genomics and Immunoassays reporting units resulted in aÂ 0%Â cushion between their fair and carrying values as of our most recent annual impairment testing date, January 1, 2024. Our Biopharmaceutical Development division'sÂ Immunoassays reporting unit has exceeded the performance expectations used in our previous impairment models; however, the PeptidesÂ reporting unit within our Biopharmaceutical Development Division is sensitive to changes in inputs and assumptionsÂ due to the reporting unit's small size, and PeptidesÂ may become impaired in the future if it does not meet performance expectations, or if the estimated weighted average cost of capital increases. As of our prior year goodwill testing date, Peptides' fair value exceeded its carrying value by approximately 36%. Our qualitative analyses to date indicate that it is more likely than not that the Peptides reporting unit is unimpaired as of December 31, 2024. Goodwill and other intangible assets net of amortization related to the Peptides reporting unit totaled $13,709 and $918, respectively, as of December 31, 2024. Â As a result of cost saving measures deployed late in fiscal year 2024 and continuing throughout fiscal year 2025, weÂ do not believe our Clinical Genomics division is impaired as of December 31, 2024 despite lower than anticipated revenues;Â however, the Clinical Genomics reporting unitÂ remains susceptible to future impairment losses if actual results differ significantly from the assumptions used in our impairment models. Goodwill and other intangible assetsÂ net of amortizationÂ related to the Clinical Genomics reporting unit totaled $16,869Â and $9,617, respectively, as of December 31, 2024.Â Â When and if we determine it is more likely than not that a reporting unit is impaired based on robust qualitative assessments, or if we otherwise so choose, we perform quantitative goodwill testing with the aid of external valuation specialists to assess the fair values of our reporting units using weighted Gordon Growth and Exit Multiple discounted cash flow models and guideline public company models.Â Fair value estimates for goodwill testing require the use of unobservable Level 3Â inputs, includingÂ butÂ notÂ limited toÂ discount rates, the expected useful lives of assets, competitors, andÂ anticipated revenues growth and margins. We establish inputs and assumptions through discussions with external valuationÂ experts, and we consider market indicators, reputable valuation research resources, and internal expectations of future performance in developing our models. Fair value estimates are subject to uncertainty such that there is a reasonable possibility that further impairment losses, which could be material to our consolidated financial statements, may occur in the future. We performed quantitative impairment tests over our Clinical Genomics, Immunoassays, and Peptides reporting units in the prior fiscal year. We intend to perform quantitative impairment tests for all reporting units for our annual impairment testing in the fourth quarter of fiscal year 2025. Â Cash FlowsÂ Â Our cash flows from operating, investing, and financing activities were as follows (in thousands): Â Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Net cash provided by operating activities Â $ 34,143 Â Â $ 31,250 Â Net cash (used in) investing activities Â Â (3,492) Â Â (81,732) Net cash (used in) provided by financing activities Â Â (28,316) Â Â 45,769 Â Â Cash flows from operating activitiesÂ forÂ the nineÂ months ended December 31, 2024Â provided $34,143, an increase of $2,893Â versus the comparable prior year period. The increase in cash flows from operating activities for the nine months ended December 31, 2024 compared to December 31, 2023 was primarily a result of: Â â— improved performance, including an increase in revenues of $21,560 compared to the prior year period, partially offset by â— $5,600 more cash paid for interest on our Credit Facility as we had more debt outstanding for a loner portion of fiscal year 2025.Â Â Other than the GKE acquisition, cash used in investing activities for the nine months ended December 31, 2024Â increased compared to the nine months ended December 31, 2023 as we purchased equipment for our leased facility used by our Biopharmaceutical Development division. Â Cash used in financing activities resulted in a $28,316Â use of cash for the nineÂ months ended December 31, 2024. Net proceeds from borrowings under the Term Loan in the first quarter of fiscal year 2025 were almost fully offset by payments made to repurchase the Notes. We used $23,500 of cash to repay the Revolver and $2,813 to pay down the Term Loan in the nine months ended December 31, 2024, compared to $22,000 to pay down the Revolver in the comparable prior year period. Â Contractual Obligations and Other Commercial Commitments Â We are party to contractual obligations that involve commitments to remit payments to third parties in the ordinary course of business. For a description of our contractual obligations and other commercial commitments as ofÂ March 31, 2024, see our Annual Report on Form 10-K for the fiscal year ended March 31, 2024, filed with the Securities and Exchange Commission on June 28, 2024. Â On a consolidated basis, as ofÂ December 31, 2024, we had contractual obligations for open purchase orders of approximately $19,160 for routine purchases of supplies and inventory, the majority of which are payable in less than one year.Â Â As part of the GKE acquisition,Â we agreed to pay the GKE sellersÂ approximately $9,000 (at December 31, 2024Â exchange rates)Â of the acquisition price in April 2025, pending adjustments for potential indemnification losses that may arise.Â Â As part of the Belyntic acquisition, weÂ agreed to pay $1,500 to the sellers if specified patents are issued.Â The estimated fair value of the probableÂ remaining contingent consideration was $650 as ofÂ December 31, 2024.Â On January 2, 2025, a notice of allowance was issued for one of the two remaining pending patents, and we expect to pay the Belyntic sellers $563 for the patentÂ within fiscal year 2025 or early in fiscal year 2026, depending upon the final patent approval date. We expect the other remaining patent will likely be approved within one year of December 31, 2024.Â Â See "Liquidity and Capital Resources" for information related to future required debt and other payments. Â Page 22 Table of Contents Â Critical Accounting Policies and Estimates Â Critical accounting estimates are those that we believe are both significant and that require us to make difficult, subjective, or complex judgments, often because we need to estimate the effect of inherently uncertain matters. These estimates are based on historical experience and various other factors that we believe to be appropriate under the circumstances. Certain accounting policies that require significant management estimates and are deemed critical to our results of operations or financial position are discussed in our Annual Report on Form 10-K for the year ended March 31, 2024, in the Critical Accounting Policies and Estimates section of Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.Â Although we believe that our estimates, assumptions, and judgements are reasonable, they are based upon information presently available. ActualÂ results may differ significantly from these estimates under different assumptions, judgments, or conditions. Â Non-GAAP Measures Â In addition to the financial measures prepared in accordance with generally accepted accounting principles, we present organic revenues growth (reported revenues growth excluding revenues from recent acquisitions), as a supplemental non-GAAP financial measure. We believe that presenting supplemental organic revenues growth facilitates comparability between current period and prior period information, and provides insight into Mesaâ€™s short-term and long-term financial trends. We use organic revenues growth internally to forecast and evaluate Mesaâ€™s operating performance and to compare revenues of current periods to prior periods, for financial and operating decision-making, and for compensation purposes. Â A reconciliation of organic revenues growth to total revenues growth is as follows:Â Â Â Â Total Revenues Growth Â Â Impact of Acquisitions Â Â Organic Revenues Growth (non-GAAP) Â Â Â Three Months Ended December 31, Â Â Three Months Ended December 31, Â Â Three Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Sterilization and Disinfection Control Â Â 21.6 % Â Â 18.8 % Â Â (13.8 %) Â Â (23.6 %) Â Â 7.8 % Â Â (4.8 %) Clinical Genomics Â Â 1.0 % Â Â (19.5 %) Â Â - % Â Â - % Â Â 1.0 % Â Â (19.5 %) Biopharmaceutical Development Â Â 29.8 % Â Â (19.0 %) Â Â - % Â Â (0.1 %) Â Â 29.8 % Â Â (19.1 %) Calibration Solutions Â Â 18.7 % Â Â 12.9 % Â Â - % Â Â - % Â Â 18.7 % Â Â 12.9 % Total Company Â Â 17.5 % Â Â (1.5 %) Â Â (4.9 %) Â Â (7.1 %) Â Â 12.6 % Â Â (8.6 %) Â Â Â Total Revenues Growth Â Â Impact of Acquisitions Â Â Organic Revenues Growth (non-GAAP) Â Â Â Nine Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Sterilization and Disinfection Control Â Â 31.2 % Â Â 9.0 % Â Â (28.3 %) Â Â (8.0 %) Â Â 2.9 % Â Â 1.0 % Clinical Genomics Â Â (14.2 %) Â Â (14.6 %) Â Â - % Â Â - % Â Â (14.2 %) Â Â (14.6 %) Biopharmaceutical Development Â Â 26.6 % Â Â (17.9 %) Â Â - % Â Â (0.3 %) Â Â 26.6 % Â Â (18.2 %) Calibration Solutions Â Â 10.1 % Â Â 8.6 % Â Â - % Â Â - % Â Â 10.1 % Â Â 8.6 % Total Company Â Â 13.7 % Â Â (3.8 %) Â Â (9.4 %) Â Â (2.4 %) Â Â 4.3 % Â Â (6.2 %) Â Item 3. Quantitative and Qualitative Disclosures about Market Risk Â Foreign Currency Exchange Rates We faceÂ exchange rate risk from transactions with customers in countries outside the United States and from intercompany transactions between affiliates. Transactional exchange rate risk arises from the purchase and sale of goods and services in currencies other than the functional currency of theÂ applicable subsidiary. We also face translational exchange rate risk related to the translation of financial statements of our foreign operations into USD, our functional currency. Costs incurred and sales recorded by subsidiaries operating outside of the United States are translated into USD using average exchange rates effective during the respective period. As a result, we areÂ exposed to movements in the exchange rates of various currencies against the USD. Our Biopharmaceutical Development division is particularly susceptibleÂ to currency exposures since itÂ incurs a substantial portion of its expenses in Swedish Krona, while most of the division's revenue contracts are in USDÂ and euros. Generally, the USD strengthening against major currencies adversely impacts our reported revenues, but to a lesser extentÂ positively impacts our reported expenses.Â The ultimate impact to gross profit as a percentage of revenue depends on the magnitude of changes in foreign currencies.Â As we continue to consummate acquisitions of companies with foreign operations or with functional currencies other than the USD, our foreign currency exchange rate risk will increase. The effect of a change in currency exchange rates on our international subsidiaries' assets and liabilities is reflected in the accumulated other comprehensive income component of stockholdersâ€™ equity. Â Interest Rates Our Credit FacilityÂ bears interest at either a base rate or a SOFR rateÂ plus an applicable spread. Based on the balanceÂ outstanding as of December 31, 2024 and required future principal payments, we estimate that if interest rates increased 1Â percentage point, we would incurÂ approximately $930 of additional cash interest expense per year. Â Inflation Risk Inflation generally impacts us by increasing our costs of labor, materials, and freight. We have historically offset inflationary cost increases by our annual price increases, and inflation has not had a significantÂ impact on our financial statements. However, any price increases imposed may lead to declines in sales volume if competitors do not similarly adjust prices. We cannot reasonably estimate our ability to successfully recover any impact of inflation cost increases into the future. Â Other We have no derivative instruments. We haveÂ minimal exposure to commodity market risks. Â Page 23 Table of Contents Â Item 4. Controls and Procedures Â We maintain disclosure controls and procedures (as defined in RuleÂ 13a-15(e)Â promulgated under the Exchange Act) that are designed to ensure that information required to be disclosed in Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commissionâ€™s rulesÂ and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Â Evaluation of Disclosure Controls and Procedures Â As of December 31, 2024, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this report, due to a material weaknessÂ identified in the fourth quarter of fiscal year 2024 that hasÂ not yet been remediated. Two of the material weaknesses identified in the fourth quarter of fiscal year 2024 were remediated in the first quarter of fiscal year 2025. The material weaknesses are described further below. Â Prior Year Material Weaknesses Â A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Companyâ€™s annual or interim financial statements will not be prevented or detected on a timely basis. As disclosed in Part II Item 9A. "Controls and Procedures" in our annual report on Form 10-K for the year ended March 31, 2024, during fiscal year 2024Â we identified three material weaknesses in our internal controls:Â Â â— Controls over technical accounting for complex and non-routine transactions -Â We did not have adequate supervision and review controls over complex technical accounting related to non-routine goodwill impairment transactions and related analyses. â— Controls over determining the useful lives of our recently acquired intangibles - DuringÂ the GKE acquisition's measurement period, we selected a useful life over which to amortize acquired customer relationships, but there was evidence that a longer useful life may be appropriate. â— Certain controls related to change management and logical access controls related to our enterprise resource planning tool, part of our information technology general controls set, were not operating effectively for a portion of the year ended March 31, 2024. The failure of these information technology general controls extended to automated application controls across portions of financial reporting and business transaction cycles which rely upon the affected information technology application controls.Â Â Remediation Status for Material Weaknesses in Internal Control Over Financial Reporting Â Beginning during the three months ended June 30, 2024, and continuing into the three months ended December 31, 2024, we implemented our previously disclosed remediation plans:Â Â â— Technical accounting for complex and non-routine transactionsÂ - We executed two transactions during the first quarter of our fiscal year 2025, partial repurchases of the Notes and the amendment and modification of our Credit Facility, which met our definition of complex technical accounting matters for which we should obtain technical accounting support from an outside expert. We identified and selected qualified third-party advisors, including validation that that the advisors possessed adequate knowledge to address the complexities of the applicable technical accounting matters, and weÂ ensured analyses were appropriately reviewed, ensuring consensus on accounting conclusions. Following the execution of our remediation plan for these transactions, management hasÂ concluded that the material weakness has been remediated.Â â— Assessment of useful lives of recently acquired intangibles - We modified the useful life of our customer relationship intangible and recorded an immaterial cumulative effect true-up to release amortization expense during the three months ended June 30, 2024. Following the execution of our remediation plan related to the useful lives of recently acquired intangible assets, management has concluded that the material weakness has been remediated. â— Information technology general controls ("ITGCs") - We have not yet remediated the material weakness related to ITGCs. In fiscal year 2024, our risk assessment process was insufficient, and as a result, we did not design user access controls covering our ERP that operate at an adequate level of precision to appropriately identify the user groups tested in certain of our other logical access and change management controls. Therefore, we have designed aÂ new user access control regarding users of our ERP that will operate at a higher degree of precision compared with our existing user access control and will enhance our review of roles, particularly roles with the ability to add, edit or delete transactions. Management has modified the reports used as source data to test change management and logical access controls in our enterprise resource planning tool, which we expect will allow us to conclude that the related controls are operating effectively by the end of fiscal year 2025. We have engaged a third party specialist to assist inÂ the remediation of the material weakness associated with our ITGCs. Â Changes in Internal Control Over Financial Reporting Â We acquired GKE during the third quarter of our fiscal year ended March 31, 2024.Â As such, GKE's control environment and processesÂ are included in the scope of our assessment of our internal controls over financial reporting beginning in the third quarter of our fiscal year 2025.Â Â Other than asÂ discussed above, during theÂ three months ended December 31, 2024 there were no changes to our internal control over financial reporting (as defined in RuleÂ 13a-15(f)Â under the Exchange Act) that have materially affected or are reasonably likely to materially affect our internal control over financialÂ reporting.Â Â Page 24 Table of Contents Â Part II. Other Information Â Item 1. Legal Proceedings Â See Note 11. â€œCommitments and Contingenciesâ€ within Item 1. Financial StatementsÂ for information regarding any legal proceedings in which we may be involved. Â Item 1A. Risk factors Â During the three months ended December 31, 2024, there were noÂ material changes from the risk factors described in Part 1, Item 1A.Â Risk Factors of our Annual Report on Form 10-K for the year ended March 31, 2024.Â Â Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Â Issuer Purchases of Equity Securities Â The following table provides information about the Company's purchases of equity securitiesÂ for the periods indicated: Â Â Â Total Number of Shares Purchased(1) Â Â Average Price Paid Per Share Â Â Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(2) Â Â Maximum Number of Shares That May Yet be Purchased Under the Plans or Programs Â October 2024 Â Â 8 Â Â Â 92.74 Â Â Â - Â Â Â 162,486 Â November 2024 Â Â 14 Â Â Â 102.44 Â Â Â - Â Â Â 162,486 Â December 2024 Â Â 10 Â Â Â 92.74 Â Â Â - Â Â Â 162,486 Â Total Â Â 32 Â Â Â 96.98 Â Â Â - Â Â Â 162,486 Â Â Â (1) Shares purchased during the period were transferred to the Company from employees in satisfaction of minimum tax withholding obligations associated with the vesting of restricted stock awards during the period. Â (2) On November 7, 2005, our Board of Directors adopted a share repurchase plan which allows for the repurchase of up to 300,000 of our common shares; however, no shares have been purchased under the plan in any period presented. This plan will continue until the maximum is reached or the plan is terminated by further action of the Board of Directors. Â Item 5. Other Information Â During the three months ended December 31, 2024, none of our directors or officers entered into new or amended written plans for the purchase or sale of our securities intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c). Â Â Â Page 25 Table of Contents Â Item 6. Exhibits Â Exhibit No. Description of Exhibit 3.1 Amended and Restated Articles of Incorporation of Mesa Laboratories, Inc. (incorporated by reference from exhibit 3.1 to the Current Report on Form 8-K filed August 25, 2023 (Commission File Number: 000-11740)). 3.2 Amended and Restated Bylaws of Mesa Laboratories, Inc. (incorporated by reference from exhibit 3.1 to the Current Report on Form 8-K filed on May 10, 2019 (Commission File Number: 000-11740)). 31.1+ Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.2+ Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32.1* Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 32.2* Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101.INS+ XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. 101.SCH+ Inline XBRL Taxonomy Extension Schema Document. 101.CAL+ Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF+ Inline XBRL Taxonomy Extension Definitions Linkbase Document 101.LAB+ Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE+ Inline XBRL Taxonomy Extension Presentation Linkbase Document 104+ Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*). Â + Filed herewith * Furnished herewith Â Page 26 Table of Contents Â Signatures Â Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â Â MESA LABORATORIES, INC. (Registrant) Â Â DATED:Â February 4, 2025 BY: /s/ Gary M. Owens. Gary M. Owens Chief Executive Officer Â Â Â Â Â Â DATED:Â February 4, 2025 BY: /s/ John V. Sakys John V. Sakys Chief Financial Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Page 27 EX-31.1 2 ex_746128.htm EXHIBIT 31.1 ex_746128.htm Â Exhibit 31.1 Certifications Pursuant to Rule 13a-14(a) Â I, Gary M. Owens, certify that: Â Â 1. I have reviewed this quarterly report on Form 10-Q of Mesa Laboratories, Inc.; Â Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â Â 4. The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â Â (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â (c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â (d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â Â 5. The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â Â (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â Â (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Â Â Date:Â February 4, 2025 Â /s/ Gary M. Owens Gary M. Owens Chief Executive Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â EX-31.2 3 ex_746129.htm EXHIBIT 31.2 ex_746129.htm Â Exhibit 31.2 Certifications Pursuant to Rule 13a-14(a) Â I, John V. Sakys, certify that: Â Â 1. I have reviewed this quarterly report on Form 10-Q of Mesa Laboratories, Inc.; Â Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â Â 4. The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â Â (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â (c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â (d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â Â 5. The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â Â (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â Â (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Â Â Date:Â February 4, 2025 /s/ John V. Sakys John V. Sakys Chief Financial Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â EX-32.1 4 ex_746130.htm EXHIBIT 32.1 ex_746130.htm Â Exhibit 32.1 Certifications Pursuant to Rule 13a-14(b) and 18 U.S.C Section 1350 Â In connection with the Quarterly Report of Mesa Laboratories, Inc. (the â€œCompanyâ€) on Form 10-Q for the fiscal quarter endedÂ December 31, 2024Â as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Gary M. Owens, Chief Executive Officer of the Company, certify, pursuant to Rule 13a-14(b) and 18 U.S.C. Â§ 1350, that: Â Â (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and Â Â (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Â Date:Â February 4, 2025 /s/ Gary M. Owens Gary M. Owens Chief Executive Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â EX-32.2 5 ex_746131.htm EXHIBIT 32.2 ex_746131.htm Â Exhibit 32.2 Certifications Pursuant to Rule 13a-14(b) and 18 U.S.C Section 1350 Â In connection with the Quarterly Report of Mesa Laboratories, Inc. (the â€œCompanyâ€) on Form 10-Q for the fiscal quarter endedÂ December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, John V. Sakys, Chief Financial Officer of the Company, certify, pursuant to Rule 13a-14(b) and 18 U.S.C. Â§ 1350, that: Â Â (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and Â Â (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Â Date: February 4, 2025 /s/ John V. Sakys John V. Sakys Chief Financial Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â EX-101.SCH 6 mlab-20241231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 1 - Description of Business and Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 2 - Significant Transactions link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 3 - Revenue link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 4 - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 5 - Supplemental Information link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 6 - Goodwill and Intangible Assets, Net link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 7 - Indebtedness link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 8 - Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 9 - (Loss) Earnings Per Share link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 10 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 11 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 12 - Segment Information link:calculationLink link:definitionLink link:presentationLink 995466 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 995467 - Disclosure - Note 2 - Significant Transactions (Tables) link:calculationLink link:definitionLink link:presentationLink 995468 - Disclosure - Note 3 - Revenue (Tables) link:calculationLink link:definitionLink link:presentationLink 995469 - Disclosure - Note 4 - Fair Value Measurements (Tables) link:calculationLink link:definitionLink link:presentationLink 995470 - Disclosure - Note 5 - Supplemental Information (Tables) link:calculationLink link:definitionLink link:presentationLink 995471 - Disclosure - Note 6 - Goodwill and Intangible Assets, Net (Tables) link:calculationLink link:definitionLink link:presentationLink 995472 - Disclosure - Note 7 - Indebtedness (Tables) link:calculationLink link:definitionLink link:presentationLink 995473 - Disclosure - Note 8 - Stockholders' Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 995474 - Disclosure - Note 9 - (Loss) Earnings Per Share (Tables) link:calculationLink link:definitionLink link:presentationLink 995475 - Disclosure - Note 10 - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 995476 - Disclosure - Note 12 - Segment Information (Tables) link:calculationLink link:definitionLink link:presentationLink 995477 - Disclosure - Note 2 - Significant Transactions (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995478 - Disclosure - Note 2 - Significant Transactions - Schedule of Business Acquisitions (Details) link:calculationLink link:definitionLink link:presentationLink 995479 - Disclosure - Note 3 - Revenue (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995480 - Disclosure - Note 3 - Revenue - Disaggregation of Revenue (Details) link:calculationLink link:definitionLink link:presentationLink 995481 - Disclosure - Note 3 - Revenue - Revenues From External Customers (Details) link:calculationLink link:definitionLink link:presentationLink 995482 - Disclosure - Note 3 - Revenue - Contract Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995483 - Disclosure - Note 4 - Fair Value Measurements (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995484 - Disclosure - Note 4 - Fair Value Measurements - Fair Value and Carrying Value of the Notes (Details) link:calculationLink link:definitionLink link:presentationLink 995485 - Disclosure - Note 5 - Supplemental Information (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995486 - Disclosure - Note 5 - Supplemental Information - Inventories (Details) link:calculationLink link:definitionLink link:presentationLink 995487 - Disclosure - Note 5 - Supplemental Information - Prepaid and Other Current Assets (Details) link:calculationLink link:definitionLink link:presentationLink 995488 - Disclosure - Note 5 - Supplemental Information - Accrued Payroll and Benefits (Details) link:calculationLink link:definitionLink link:presentationLink 995489 - Disclosure - Note 5 - Supplemental Information - Other Accrued Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 995490 - Disclosure - Note 5 - Supplemental Information - Other Noncurrent Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995491 - Disclosure - Note 5 - Supplemental Information - Property, Plant and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 995492 - Disclosure - Note 6 - Goodwill and Intangible Assets, Net - Other Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 995493 - Disclosure - Note 6 - Goodwill and Intangible Assets, Net - Amortization Expense for Finite-lived Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 995494 - Disclosure - Note 6 - Goodwill and Intangible Assets, Net - Estimated Amortization Expense (Details) link:calculationLink link:definitionLink link:presentationLink 995495 - Disclosure - Note 6 - Goodwill and Intangible Assets, Net - Change in the Carrying Amount of Goodwill (Details) link:calculationLink link:definitionLink link:presentationLink 995496 - Disclosure - Note 7 - Indebtedness (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995497 - Disclosure - Note 7 - Indebtedness - Quarterly Periodic Payments (Details) link:calculationLink link:definitionLink link:presentationLink 995498 - Disclosure - Note 7 - Indebtedness - Carrying Amount of the Term Loan (Details) link:calculationLink link:definitionLink link:presentationLink 995499 - Disclosure - Note 7 - Indebtedness - Carrying Amount of the Term Loan (Details) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 995500 - Disclosure - Note 7 - Indebtedness - Carrying Amount of the Notes (Details) link:calculationLink link:definitionLink link:presentationLink 995501 - Disclosure - Note 7 - Indebtedness - Interest Expense on the Notes (Details) link:calculationLink link:definitionLink link:presentationLink 995502 - Disclosure - Note 8 - Stockholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995503 - Disclosure - Note 8 - Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995504 - Disclosure - Note 8 - Stockholders' Equity - Schedule of Stock Option Award Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995505 - Disclosure - Note 9 - Earnings (Loss) Per Share - Computation of Net Income Per Share, Basic & Diluted (Details) link:calculationLink link:definitionLink link:presentationLink 995506 - Disclosure - Note 9 - Earnings (Loss) Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) link:calculationLink link:definitionLink link:presentationLink 995507 - Disclosure - Note 10 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995508 - Disclosure - Note 10 - Income Taxes - Provisions for Income Taxes (Details) link:calculationLink link:definitionLink link:presentationLink 995509 - Disclosure - Note 11 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995510 - Disclosure - Note 12 - Segment Information - Operating Segment Information (Details) link:calculationLink link:definitionLink link:presentationLink 995511 - Disclosure - Note 12 - Segment Data - Segment Depreciation and Amortization (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 7 mlab-20241231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 mlab-20241231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 mlab-20241231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Note To Financial Statement Details Textual Convertible senior notes, noncurrent portion, net of debt issuance costs Significant Accounting Policies Note 2 - Significant Transactions Note 3 - Revenue Note 4 - Fair Value Measurements Note 5 - Supplemental Information Noncurrent portion Note 6 - Goodwill and Intangible Assets, Net Note 7 - Indebtedness Noncurrent liabilities: Note 8 - Stockholders' Equity Note 9 - (Loss) Earnings Per Share Income Tax Disclosure [Text Block] Note 10 - Income Taxes Note 12 - Segment Information Note 2 - Significant Transactions - Schedule of Business Acquisitions (Details) us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent Business Combination, Contingent Consideration, Liability, Current Note 3 - Revenue - Disaggregation of Revenue (Details) Note 3 - Revenue - Revenues From External Customers (Details) us-gaap_LiabilitiesCurrent Total current liabilities Schedule of Maturities of Long-Term Debt [Table Text Block] Note 3 - Revenue - Contract Liabilities (Details) Note 4 - Fair Value Measurements - Fair Value and Carrying Value of the Notes (Details) Convertible Debt [Table Text Block] Note 5 - Supplemental Information - Inventories (Details) Note 5 - Supplemental Information - Prepaid and Other Current Assets (Details) Note 5 - Supplemental Information - Accrued Payroll and Benefits (Details) Note 5 - Supplemental Information - Other Accrued Expenses (Details) Note 5 - Supplemental Information - Other Noncurrent Liabilities (Details) Note 5 - Supplemental Information - Property, Plant and Equipment (Details) The Notes [Member] Represents the Notes. Note 6 - Goodwill and Intangible Assets, Net - Other Intangible Assets (Details) Note 6 - Goodwill and Intangible Assets, Net - Amortization Expense for Finite-lived Intangible Assets (Details) Note 6 - Goodwill and Intangible Assets, Net - Estimated Amortization Expense (Details) us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred Business Combination, Consideration

Transferred, Liabilities Incurred Note 6 - Goodwill and Intangible Assets, Net - Change in the Carrying Amount of Goodwill (Details) Note 7 - Indebtedness - Quarterly Periodic Payments (Details) Note 7 - Indebtedness - Carrying Amount of the Term Loan (Details) Share-Based Payment Arrangement, Option, Activity [Table Text Block] Note 7 - Indebtedness - Carrying Amount of the Term Loan (Details) (Parentheticals) Share-Based Payment Arrangement, Activity [Table Text Block] Note 7 - Indebtedness - Carrying Amount of the Notes (Details) Note 7 - Indebtedness - Interest Expense on the Notes (Details) Awards granted, weighted average grant date fair value per share (1) (in dollars per share) us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired Business Acquisition, Percentage of Voting Interests Acquired Note 8 - Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details) Awards distributed, weighted average grant date fair value per share (in dollars per share) Awards forfeited, weighted average grant date fair value per share (in dollars per share) Note 8 - Stockholders' Equity - Schedule of Stock Option Award Activity (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Awards Outstanding, weighted average grant date fair value per share (in dollars per share) Awards Outstanding, weighted average grant date fair value per share (in dollars per share) Note 9 - Earnings (Loss) Per Share - Computation of Net Income Per Share, Basic & Diluted (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Awards forfeited (in shares) Note 9 - Earnings (Loss) Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) Assumed Conversion of Convertible Debt [Member] Represents the assumed conversion of convertible debt. Note 10 - Income Taxes - Provisions for Income Taxes (Details) Interest Expense on Convertible Debt [Table Text Block] Tabular disclosure of interest expense on borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Foreign currency translation Foreign currency translation us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Awards Outstanding (in shares) Awards Outstanding (in shares) Note 12 - Segment Information - Operating Segment Information (Details) Note 12 - Segment Data - Segment Depreciation and Amortization (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] Awards granted(1) (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Awards distributed (in shares) Other comprehensive (loss) income: Outstanding, Weighted- Average Remaining Contractual Life (Year) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Outstanding, Aggregate Intrinsic Value us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Term loan, current portion Less: current portion us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Options outstanding, weighted average exercise price (in dollars per share) Options outstanding, weighted average exercise price (in dollars per share) Convertible senior notes, current portion, net of debt issuance costs Unearned revenues Awards forfeited or expired, weighted average exercise price (in dollars per share) Goodwill and Intangible Assets Disclosure [Text Block] Schedule of Goodwill [Table Text Block] Income taxes payable Awards granted, weighted average exercise price (in dollars per share) Awards exercised, weighted average exercise price (in dollars per share) Other accrued expenses Total other accrued expenses Accrued payroll and benefits Total accrued payroll and benefits Accounts payable Revolving Credit Facility [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Options outstanding (in shares) Options outstanding (in shares) Other benefits payable Bonus payable Payroll related taxes us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Options forfeited or expired (in shares) Credit Facility [Axis] Credit Facility [Domain] Other us-gaap_OtherAccruedLiabilitiesCurrent Wages and paid-time-off payable us-gaap_PolicyTextBlockAbstract Accounting Policies Dilutive effect of shares (in shares) Other Intangible Assets [Member] us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchases of property, plant and equipment mlab_DebtInstrumentConvertibleConversionRatioPer1000Principal Debt Instrument, Convertible, Conversion Ratio Per 1,000 Principal Ratio applied to the conversion of debt instrument into equity with equity shares divided by $1,000 debt principal amount. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) LIABILITIES AND STOCKHOLDERSâ€™ EQUITY mlab_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesIssuedUponVestingPercentage Share-based Compensation Arrangement by Share-based Payment Award Number of Shares Issued Upon Vesting, Percentage The percentage of shares will be issued upon vesting. Supplemental Balance Sheet Disclosures [Text Block] Product [Member] Supplemental non-cash activity: us-gaap_Assets Total assets Plan Name [Axis] Plan Name [Domain] us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Net income Customer Relationships [Member] Deferred tax asset Share-Based Payment Arrangement [Text Block] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation Tax withholding on vesting of restricted stock units Award Type [Domain] (Loss) earnings before income taxes us-gaap_IncomeLossFromContinuingOperations Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Award Type [Axis] Net income (loss) Net (loss) income Net income (loss) us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Accumulated amortization Intangible assets Net carrying amount Biopharmaceutical Development [Member] Represents information related to biopharmaceutical development. Restricted Stock Units (RSUs) [Member] us-gaap_FiniteLivedIntangibleAssetsGross Gross carrying amount Coupon interest expense at 1.375% us-gaap_InterestExpenseDebtExcludingAmortization Share-Based Payment Arrangement, Option [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Effect of foreign currency translation Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Property, plant, and equipment accumulated depreciation Commitments and Contingencies Disclosure [Text Block] Schedule of Business Acquisitions, by Acquisition [Table Text Block] Property, plant and equipment, net of accumulated depreciation of $26,036 and $22,519 respectively Goodwill Goodwill Goodwill Performance Stock Units [Member] Represents information related to performance stock units. Long-Term Debt, Type [Axis] Long-Term Debt, Type [Domain] Cash flows from investing activities: Amortization of step-up in inventory basis Represents amortization of inventory step-up cost. Earnings Per Share [Text Block] Letter of Credit [Member] Accrued liabilities and taxes payable Income tax (benefit) expense Short-Term Debt, Type [Axis] Short-Term Debt, Type [Domain] CHINA us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable Significant Transactions [Text Block] The entire disclosure of significant transactions. mlab_BusinessCombinationHoldBackConsiderationliability Business Combination, Hold Back Consideration Liability Amount of hold back liability recognized arising from a business combination. Operating expense us-gaap_OperatingExpenses Total operating expense us-gaap_DebtInstrumentTerm Debt Instrument, Term (Year) General and administrative Eligible Employees [Member] Information pertaining to eligible employees. Cash and cash equivalents Interest expense and amortization of debt issuance costs us-gaap_DebtInstrumentConvertibleConversionPrice1 Debt Instrument, Convertible, Conversion Price (in dollars per share) Amendment Flag us-gaap_ComprehensiveIncomeNetOfTax Comprehensive (loss) income City Area Code New Accounting Pronouncements, Policy [Policy Text Block] Reclassification, Comparability Adjustment [Policy Text Block] us-gaap_DebtInstrumentPeriodicPaymentPrincipal Debt Instrument, Periodic Payment, Principal us-gaap_IncreaseDecreaseInContractWithCustomerLiability Unearned revenues us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Common stock, outstanding (in shares) Balance (in shares) The Credit Facility Term Loan [Member] Information pertaining to the credit facility term loan. Current interest rate Current Fiscal Year End Date us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Debt Instrument, Basis Spread on Variable Rate us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage Senior Secured Credit Agreement [Member] Information pertaining to the senior secured credit agreement Swingline Loan [Member] Information pertaining to the swingline loan. us-gaap_DebtInstrumentInterestRateEffectivePercentage Debt Instrument, Interest Rate, Effective Percentage Document Fiscal Period Focus Prepaid Expenses, Other and Other Assets [Member] Information pertaining to prepaid expenses, other and other assets. Document Fiscal Year Focus us-gaap_DebtInstrumentRepurchasedFaceAmount Debt Instrument, Repurchased Face Amount Document Period End Date Right of use assets obtained in exchange for lease liabilities mlab_FixedChargeCoverageRatio Fixed Charge Coverage Ratio Actual fixed charge coverage ratio under the debt agreement. us-gaap_IncreaseDecreaseInPrepaidExpense Prepaid expenses and other assets Entity File Number GKE GmbH [Member] Reprsents the group known as GKE GmbH. us-gaap_DebtInstrumentFeeAmount Debt Instrument, Fee Amount Entity Emerging Growth Company us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount Document Type us-gaap_DebtInstrumentRepurchaseAmount Debt Instrument, Repurchase Amount us-gaap_GainsLossesOnExtinguishmentOfDebt Gain (Loss) on Extinguishment of Debt Gain on extinguishment of convertible notes Entity Small Business Entity Shell Company us-gaap_DividendsCommonStockCash Dividends paid, $0.16 per share Inventory Step-up Related to Cost of Revenue [Member] Represents information pertaining to the inventory step-ups related to cost of revenue. Document Information [Line Items] Document Information [Table] Service [Member] Entity Filer Category Debt Instrument [Axis] Consumables [Member] Information pertaining to consumables. Entity Current Reporting Status Debt Instrument, Name [Domain] Non-employee Directors [Member] Represents information pertaining to non-employee directors. Schedule of Employee Related Liabilities [Table Text Block] The tabular disclosure for employee related liabilities. Contract liabilities added during the nine months ended December 31, 2024, net of revenues recognized Amount of revenue recognized arising from contract liabilities added during the period in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable, net Statement of Comprehensive Income [Abstract] Entity Tax Identification Number Entity Central Index Key mlab_SeniorLeverageRatio Senior Leverage Ratio Represents the senior leverage ratio. Stock Awards that were Antidilutive [Member] Information pertaining to stock awards that were antidilutive. Entity Registrant Name mlab_DebtInstrumentCovenantMaximumTotalLeverageRatioFollowingTheNinthTestingDate Debt Instrument, Covenant, Maximum Total Leverage Ratio Following the Ninth Testing date Requirement for maximum total leverage ratio under the debt agreement following the nine testing date. Entity [Domain] Legal Entity [Axis] Customer Concentration Risk [Member] mlab_DebtInstrumentCovenantMaximumTotalLeverageRatioForTheSixthSeventhAndEighthTestingDates Debt Instrument, Covenant, Maximum Total Leverage Ratio for the Sixth, Seventh, and Eighth Testing Dates Requirement for maximum total leverage ratio under the debt agreement for the sixth, seventh, and eighth testing dates. Entity Address, Address Line One mlab_DebtInstrumentCovenantMaximumTotalLeverageRatioForTheFirstFiveTestingDates Debt Instrument, Covenant, Maximum Total Leverage Ratio for the First Five Testing Dates Requirement for maximum total leverage ratio under the debt agreement for the first five testing dates. ecd_NonRule10b51ArrTrmntdFlag Non-Rule 10b5-1 Arrangement Terminated [Flag] Amortization of acquisition-related intangibles Entity Address, City or Town ecd_Rule10b51ArrTrmntdFlag Rule 10b5-1 Arrangement Terminated [Flag] mlab_NumberOfMajorCustomers Number of Major Customers Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc. ecd_Rule10b51ArrAdoptedFlag Rule 10b5-1 Arrangement Adopted [Flag] Entity Address, Postal Zip Code Entity Address, State or Province Concentration Risk Type [Axis] ecd_NonRule10b51ArrAdoptedFlag Non-Rule 10b5-1 Arrangement Adopted [Flag] Concentration Risk Type [Domain] Outstanding 2025 Notes [Member] Represents the outstanding 2025 note. Material Terms of Trading Arrangement [Text Block] Entity Common Stock, Shares Outstanding Cost of Revenues Related to Intangibles Acquired [Member] Represents the cost of revenues related to intangibles acquired Current acquisition-related holdbacks The current acquisition-related holdbacks. Accounts Receivable [Member] us-gaap_IncreaseDecreaseInInventories Inventories Trading Symbol The 2021 Equity Plan [Member] Related to the 2021 equity plan. Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Noncurrent acquisition-related holdbacks The noncurrent acquisition-related holdbacks. Local Phone Number us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity Line of Credit Facility, Remaining Borrowing Capacity Vesting of restricted stock units and exercise of stock options (in shares) Awards exercised (in shares) us-gaap_TableTextBlock Notes Tables Term Loan [Member] Represents the term loan amended into the credit facility. Prepaid expenses Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Line of Credit Facility, Maximum Borrowing Capacity Vesting of restricted stock units and exercise of stock options The FY25 PSUs [Member] Represents the psus for the full year 2025. mlab_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValueSharesSubjectToServiceAndC Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value, Shares Subject to Service and Company Performance (in dollars per share) The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan), for shares subject to service and company financial performance. us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage mlab_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAuthorizedForServiceAndCompanyFinancialPerformanceConditions Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized for Service and Company Financial Performance Conditions (in shares) Number of shares authorized for issuance under share-based payment arrangement for service and company financial performance conditions. Related and Nonrelated Parties [Axis] Related and Nonrelated Parties [Domain] mlab_SecuredDebtDiscountAndIssuanceCosts Less: discount and debt issuance costs The discounts and issuance costs related to the secured debt. Other Accrued Expenses [Member] Other accrued expenses not separately disclosed. Stock-based compensation expense mlab_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValueSubjectToServiceAndMarketC Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value, Subject to Service and Market Conditions (in dollars per share) The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan), subjected to service and market conditions. mlab_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAuthorizedSubjectToServiceAndMarketConditions Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized, Subject to Service and Market Conditions (in shares) Number of shares authorized for issuance under share-based payment arrangement subjected to service and market conditions. Options granted (in shares) mlab_BusinessCombinationContingentConsiderationLiabilityFairValue Business Combination, Contingent Consideration, Liability Fair Value Fair value of the amount of liability recognized arising from contingent consideration in a business combination. Selling us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholdersâ€™ equity Reported Value Measurement [Member] UNITED STATES Belyntic Acquisition [Member] Represents acquisition of Belyntic GmbH. mlab_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour Thereafter Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Research and development (Accumulated deficit) Accumulated other comprehensive (loss) Other Long-term Liabilities [Member] Represents other long-term liabilities. Debt Disclosure [Text Block] us-gaap_InterestExpenseDebt Total interest and amortization of debt issuance costs Cash from changes in operating assets and liabilities: Notes us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements us-gaap_OtherNoncashIncomeExpense Other Subsequent Event [Member] Noncurrent operating lease liabilities Schedule of Inventory, Current [Table Text Block] Subsequent Event Type [Axis] Current operating lease liabilities Subsequent Event Type [Domain] Remainder of 2025 2027 2028 2029 Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] 2026 us-gaap_ShareBasedCompensation Stock-based compensation expense Other assets Amortization of debt issuance costs us-gaap_AmortizationOfFinancingCostsAndDiscounts us-gaap_Revenues Revenues Amortization of inventory step-up recorded in cost of revenues Schedule of Finite-Lived Intangible Assets [Table Text Block] Depreciation, Total Depreciation of property, plant and equipment Depreciation us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation Tax withholding on vesting of restricted stock units (in shares) Accrued business taxes The value of the current portion of accrued business taxes. us-gaap_AssetsCurrent Total current assets Noncurrent assets: Deposits GKE Acquisition [Member] Relating to the GKE Acquisition. Beijing GKE Science & Technology Co. Ltd. [Member] Relating to Beijing GKE Science & Technology Co. Ltd. Common stock, no par value; authorized 25,000,000 shares; issued and outstanding, 5,433,603 and 5,394,491 shares, respectively GKE GmbH and SAL GmbH [Member] Relating to GKE GmbH and SAL GmbH. Senior Notes [Member] Adjustments to reconcile net income to net cash from operating activities: Common stock, authorized (in shares) Common stock, issued (in shares) Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Common stock, no par value (in dollars per share) Sterilization and Disinfection Control [Member] Reporting segment for Sterilization and Disinfection Control, formerly name Biological Indicators segment. Statistical Measurement [Domain] Maximum [Member] Minimum [Member] Other current assets Product and Service [Axis] Product and Service [Domain] Statistical Measurement [Axis] Prepaid income taxes Geographical [Axis] Property, Plant and Equipment [Table Text Block] Geographical [Domain] mlab_BusinessCombinationHoldBackConsiderationLiabilityFairValue Business Combination, Hold Back Consideration Liability, Fair Value Represents the fair value of hold back consideration liability from a business combination. Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Inventories Total inventories Portion at Fair Value Measurement [Member] Estimate of Fair Value Measurement [Member] Work in process Measurement Basis [Axis] Fair Value, Inputs, Level 3 [Member] us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Foreign currency adjustments Finished goods Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Axis] Raw materials Cash flows from operating activities: Schedule of Segment Reporting Information, by Segment [Table Text Block] Statement [Line Items] Allowance for doubtful accounts receivable Accounts receivable, less allowance for credit losses of $1,060 and $1,321, respectively AOCI Attributable to Parent [Member] Stockholdersâ€™ equity: us-gaap_OtherNonoperatingIncomeExpense Other expense (income), net us-gaap_NonoperatingIncomeExpense Non-operating expense (income), net Total non-operating expense (income), net Segment Reporting Disclosure [Text Block] Fair Value Disclosures [Text Block] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Effect of exchange rate changes on cash and cash equivalents us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net increase (decrease) in cash and cash equivalents us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash (used in) provided by financing activities us-gaap_Liabilities Total liabilities Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Operating income (loss) us-gaap_OperatingIncomeLoss Operating income (loss) Prior year liabilities recognized in revenues during the nine months ended December 31, 2024 us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash provided by operating activities Prepaid expenses and other current assets Total prepaid expenses and other current assets us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash (used in) investing activities Cost of revenues us-gaap_GrossProfit Gross profit Gross profit Consolidation Items [Domain] Deferred tax liability us-gaap_ContractWithCustomerLiability Contract liabilities, balance Contract liabilities, balance Consolidation Items [Axis] us-gaap_InterestPayableCurrentAndNoncurrent Interest Payable Other financing, net us-gaap_PaymentsOfDividends Dividends paid Retained Earnings [Member] Revenues Revenue from Contract with Customer, Excluding Assessed Tax Title and Position [Domain] Title and Position [Axis] Common Stock [Member] Equity Components [Axis] Equity Component [Domain] us-gaap_LongTermDebt Long-Term Debt Total Principal Remaining us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest (Loss) earnings before income taxes Revolving line of credit Timing of Transfer of Good or Service [Domain] us-gaap_DeferredFinanceCostsNet Debt Issuance Costs, Net Unamortized debt issuance costs Transferred at Point in Time [Member] Disaggregation of Revenue [Table Text Block] Timing of Transfer of Good or Service [Axis] Revenue from Contract with Customer [Text Block] us-gaap_RepaymentsOfConvertibleDebt Repurchase of convertible debt Statement of Financial Position Location, Balance [Axis] Statement of Financial Position Location, Balance [Domain] Document Quarterly Report Other [Member] Represents other. Entity Incorporation, State or Country Code Principal Outstanding Principal Outstanding General and Administrative Expense [Member] Accounting Policies [Abstract] Document Transition Report Basis of Accounting, Policy [Policy Text Block] Entity Interactive Data Current Dividends paid, per share (in dollars per share) Security Exchange Name Operating Expense [Member] Title of 12(b) Security Cost of Sales [Member] mlab_BusinessCombinationContingentConsiderationLiabilityAtAcquisitionDate Business Combination Contingent Consideration Liability, At Acquisition Date Amount of liability recognized arising from contingent consideration in a business combination, at the date of acquisition. us-gaap_ProceedsFromConvertibleDebt Proceeds from Convertible Debt Proceeds from the issuance of debt, net Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Description of Business [Policy Text Block] Represents significance related to the nature of business operations. Segments [Axis] Segments [Domain] Total stock awards excluded from diluted EPS (in shares) us-gaap_RepaymentsOfLinesOfCredit Repayments of Lines of Credit Diluted (in shares) Fully diluted shares (in shares) us-gaap_ProceedsFromLinesOfCredit Proceeds from Lines of Credit Statement [Table] Schedule of Depreciation and Amortization Expense [Table Text Block] Tabular display of the depreciation and amortization recorded during the periods for reportable segments. Statement of Financial Position [Abstract] Diluted (in dollars per share) Calibration Solutions [Member] Represents segment information for Calibration Solutions. Weighted average outstanding shares of common stock (in shares) Basic (in shares) Clinical Genomics [Member] Represents segment information for Clinical Genomics. Effective tax rate Business Acquisition [Axis] Basic (in dollars per share) Business Acquisition, Acquiree [Domain] Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Statement of Cash Flows [Abstract] us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Remainder of 2025 Statement of Stockholders' Equity [Abstract] Income Statement [Abstract] us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree 2028 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour 2029 Schedule of Accrued Liabilities [Table Text Block] Risk and Uncertainties, Policy [Policy Text Block] Disclosure of accounting policy for risk and uncertainties. us-gaap_RepaymentsOfDebt Repayments of Debt Repayment of debt us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths 2026 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo 2027 Other Noncurrent Liabilities [Table Text Block] Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Finite-Lived Intangible Assets Amortization Expense [Table Text Block] Hardware and Software [Member] Information pertaining to hardware and software. us-gaap_LiabilitiesNoncurrent Total other noncurrent liabilities Cash flows from financing activities: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Other Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] us-gaap_StockholdersEquity Total stockholdersâ€™ equity Balance Balance us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired Acquisitions, net of cash acquired Class of Stock [Axis] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] us-gaap_PaymentsToAcquireBusinessesGross Payments to Acquire Businesses, Gross Operating Segments [Member] EX-101.PRE 10 mlab-20241231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1 Document And Entity Information - shares 9 Months Ended Dec. 31, 2024 Jan. 28, 2025 Document Information [Line Items] Â Â Entity Central Index Key 0000724004 Â Entity Registrant Name MESA LABORATORIES INC /CO Â Amendment Flag false Â Current Fiscal Year End Date --03-31 Â Document Fiscal Period Focus Q3 Â Document Fiscal Year Focus 2025 Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Dec. 31, 2024 Â Document Transition Report false Â Entity File Number 0-11740 Â Entity Incorporation, State or Country Code CO Â Entity Tax Identification Number 84-0872291 Â Entity Address, Address Line One 12100 West Sixth Avenue Â Entity Address, City or Town Lakewood Â Entity Address, State or Province CO Â Entity Address, Postal Zip Code 80228 Â City Area Code 303 Â Local Phone Number 987-8000 Â Title of 12(b) Security Common Stock, no par value Â Trading Symbol MLAB Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Accelerated Filer Â Entity Small Business false Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 5,433,607 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 13 R2.htm IDEA: XBRL DOCUMENT v3.25.0.1 Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands Dec. 31, 2024 Mar. 31, 2024 Cash and cash equivalents $ 30,956 $ 28,214 Accounts receivable, less allowance for credit losses of $1,060 and $1,321, respectively 38,647 39,055 Inventories 28,122 32,675 Prepaid expenses and other current assets 13,120 9,408 Total current assets 110,845 109,352 Noncurrent assets: Â Â Property, plant and equipment, net of accumulated depreciation of $26,036 and $22,519 respectively 31,602 31,766 Deferred tax asset 1,242 1,292 Other assets 18,126 10,538 Intangible assets 98,181 113,752 Goodwill 177,152 180,096 Total assets 437,148 446,796 LIABILITIES AND STOCKHOLDERSâ€™ EQUITY Â Â Accounts payable 4,087 6,041 Accrued payroll and benefits 13,919 9,935 Unearned revenues 14,608 15,478 Other accrued expenses 22,351 12,858 Term loan, current portion 3,750 0 Convertible senior notes, current portion, net of debt issuance costs 97,163 0 Total current liabilities 155,878 44,312 Noncurrent liabilities: Â Â Deferred tax liability 18,800 19,780 Other 12,453 15,613 Revolving line of credit 27,000 50,500 Noncurrent portion 67,803 0 Convertible senior notes, noncurrent portion, net of debt issuance costs 0 171,198 Total liabilities 281,934 301,403 Stockholdersâ€™ equity: Â Â Common stock, no par value; authorized 25,000,000 shares; issued and outstanding, 5,433,603 and 5,394,491 shares, respectively 352,788 343,642 (Accumulated deficit) (180,952) (183,494) Accumulated other comprehensive (loss) (16,622) (14,755) Total stockholdersâ€™ equity 155,214 145,393 Total liabilities and stockholdersâ€™ equity 437,148 446,796 Customer Relationships [Member] Â Â Noncurrent assets: Â Â Intangible assets 73,797 85,383 Other Intangible Assets [Member] Â Â Noncurrent assets: Â Â Intangible assets $ 24,384 $ 28,369 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -

Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ConvertibleDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ConvertibleDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6 + Details Name: us-gaap_DeferredIncomeTaxAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6 + Details Name: us-gaap_DeferredIncomeTaxLiabilitiesNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesAndStockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -

SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_LineOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_SecuredDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_SecuredLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 14 R3.htm IDEA: XBRL DOCUMENT v3.25.0.1 Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ / shares in Thousands, $ in Thousands Dec. 31, 2024 Mar. 31, 2024 Allowance for doubtful accounts receivable $ 1,060 $ 1,321 Property, plant, and equipment accumulated depreciation $ 26,036 $ 22,519 Common stock, no par value (in dollars per share) $ 0 $ 0 Common stock, authorized (in shares) 25,000,000 25,000,000 Common stock, issued (in shares) 5,433,603 5,394,491 Common stock, outstanding (in shares) 5,433,603 5,394,491 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace amount per share of no-par value common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockNoParValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section

S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.0.1 Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Revenues [1] $ 62,840 $ 53,473 $ 178,843 $ 157,283 Cost of revenues 23,086 20,071 66,385 60,589 Gross profit 39,754 33,402 112,458 96,694 Selling 10,450 9,737 30,415 28,363 Research and development 5,053 4,294 14,422 14,098 Total operating expense 33,975 33,469 97,591 97,485 Operating income (loss) 5,779 (67) 14,867 (791) Interest expense and amortization of debt issuance costs 2,842 1,856 9,340 3,809 Gain on extinguishment of convertible notes 0 0 (2,887) 0 Other expense (income), net 5,154 (3,869) 2,914 (4,284) Total non-operating expense (income), net 7,996 (2,013) 9,367 (475) (Loss) earnings before income taxes (2,217) 1,946 5,500 (316) Income tax (benefit) expense (541) (170) 360 (653) Net (loss) income $ (1,676) $ 2,116 $ 5,140 $ 337 Basic (in dollars per share) $ (0.31) $ 0.39 $ 0.95 $ 0.06 Diluted (in dollars per share) $ (0.31) $ 0.39 $ 0.94 $ 0.06 Basic (in shares) 5,429 5,393 5,413 5,384 Diluted (in shares) 5,429 5,396 5,464 5,394 Product [Member] Â Â Â Â Revenues $ 62,840 $ 53,473 $ 178,843 $ 157,283 Service [Member] Â Â Â Â General and administrative $ 18,472 $ 19,438 $ 52,754 $ 55,024 [1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals. X - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B + Details Name: us-gaap_CostOfRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37:

http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionExpenses recognized in the period that are directly related to the selling and distribution of products or services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ServiceMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 16 R5.htm IDEA: XBRL DOCUMENT v3.25.0.1 Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Net income $ (1,676) $ 2,116 $ 5,140 $ 337 Other comprehensive (loss) income: Â Â Â Â Foreign currency translation (6,951) 10,965 (1,867) 2,951 Comprehensive (loss) income $ (8,627) $ 13,081 $ 3,273 $ 3,288 X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 17 R6.htm IDEA: XBRL DOCUMENT v3.25.0.1 Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands Common Stock [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Total Balance at Mar. 31, 2023 $ 332,076 $ 74,199 $ (12,795) [1] $ 393,480 Vesting of restricted stock units and exercise of stock options (in shares) 20,074 Â Â Â Vesting of restricted stock units and exercise of stock options $ 52 Â Â 52 Tax withholding on vesting of restricted stock units (in shares) (5,260) Â Â Â Tax withholding on vesting of restricted stock units $ (712) 0 0 (712) Dividends paid, $0.16 per share Â (859) Â (859) Stock-based compensation expense $ 2,968 Â Â 2,968 Foreign currency translation Â Â (6,661) [1] (6,661) Net income (loss) Â (549) Â (549) Balance (in shares) at Jun. 30, 2023 5,384,280 Â Â Â Balance at Jun. 30, 2023 $ 334,384 72,791 (19,456) [1] 387,719 Balance (in shares) at Mar. 31, 2023 5,369,466 Â Â Â Net income (loss) Â (549) Â (549) Foreign currency translation Â Â (6,661) [1] (6,661) Balance at Mar. 31, 2023 $ 332,076 74,199 (12,795) [1] 393,480 Foreign currency translation Â Â Â 2,951 Net income (loss) Â Â Â 337 Balance (in shares) at Dec. 31, 2023 5,394,043 Â Â Â Balance at Dec. 31, 2023 $ 340,852 71,953 (9,844) [1] 402,961 Balance (in shares) at Mar. 31, 2023 5,369,466 Â Â Â Net income (loss) Â Â Â 337 Foreign currency translation Â Â Â 2,951 Balance at Jun. 30, 2023 $ 334,384 72,791 (19,456) [1] 387,719 Vesting of restricted stock units and exercise of stock options (in shares) 7,464 Â Â Â Vesting of restricted stock units and exercise of stock options $ 304 Â Â 304 Tax withholding on vesting of restricted stock units (in shares) (18) Â Â Â Tax withholding on vesting of restricted stock units $ (2) Â Â (2) Dividends paid, $0.16 per share Â (862) Â (862) Stock-based compensation expense $ 3,183 Â Â 3,183 Foreign currency translation Â Â (1,353) (1,353) Net income (loss) Â (1,230) Â (1,230) Balance (in shares) at Sep. 30, 2023 5,391,726 Â Â Â Balance at Sep. 30, 2023 $ 337,869 70,699 (20,809) [1] 387,759 Balance (in shares) at Jun. 30, 2023 5,384,280 Â Â Â Net income (loss) Â (1,230) Â (1,230) Foreign currency translation Â Â (1,353) (1,353) Vesting of restricted stock units and exercise of stock options (in shares) 2,415 Â Â Â Vesting of restricted stock units and exercise of stock options $ 2 Â Â 2 Tax withholding on vesting of restricted stock units (in shares) (98) Â Â Â Tax withholding on vesting of restricted stock units $ (12) Â Â (12) Dividends paid, $0.16 per share Â (862) Â (862) Stock-based compensation expense $ 2,993 Â Â 2,993 Foreign currency translation Â Â 10,965 10,965 Net income (loss) Â 2,116 Â 2,116 Balance (in shares) at Dec. 31, 2023 5,394,043 Â Â Â Balance at Dec. 31, 2023 $ 340,852 71,953 (9,844) [1] 402,961 Balance (in shares) at Sep. 30, 2023 5,391,726 Â Â Â Net income (loss) Â 2,116 Â 2,116 Foreign currency translation Â Â 10,965 $ 10,965 Balance (in shares) at Mar. 31, 2024 5,394,491 Â Â 5,394,491 Balance at Mar. 31, 2024 $ 343,642 (183,494) (14,755) [1] $ 145,393 Vesting of restricted stock units and exercise of stock options (in shares) 20,858 Â Â Â Vesting of restricted stock units and exercise of stock options $ 0 Â Â 0 Tax withholding on vesting of restricted stock units (in shares) (6,194) Â Â Â Tax withholding on vesting of restricted stock units $ (571) 0 0 (571) Dividends paid, $0.16 per share Â (863) Â (863) Stock-based compensation expense 2,928 Â Â 2,928 Foreign currency translation Â Â 452 [1] 452 Net income (loss) $ 0 3,388 0 3,388 Balance (in shares) at Jun. 30, 2024 5,409,155 Â Â Â Balance at Jun. 30, 2024 $ 345,999 (180,969) (14,303) [1] 150,727 Net income (loss) $ 0 3,388 0 3,388 Foreign currency translation Â Â 452 [1] $ 452 Balance (in shares) at Mar. 31, 2024 5,394,491 Â Â 5,394,491 Balance at Mar. 31, 2024 $ 343,642 (183,494) (14,755) [1] $ 145,393 Vesting of restricted stock units and exercise of stock options (in shares) Â Â 1,000 Foreign currency translation Â Â Â $ (1,867) Net income (loss) Â Â Â 5,140 Balance (in shares) at Dec. 31, 2024 5,433,603 Â Â Â Balance at Dec. 31, 2024 $ 352,788 (180,952) (16,622) [1] 155,214 Net income (loss) Â Â Â 5,140 Foreign currency translation Â Â Â (1,867) Balance at Jun. 30, 2024 $ 345,999 (180,969) (14,303) [1] 150,727 Vesting of restricted stock units and exercise of stock options (in shares) 13,006 Â Â Â Vesting of restricted stock units and exercise of stock options $ 0 Â Â 0 Tax withholding on vesting of restricted stock units (in shares) (2,306) Â Â Â Tax withholding on vesting of restricted stock units $ (307) Â Â (307) Dividends paid, $0.16 per share Â (866) Â (866) Stock-based compensation expense 3,837 Â Â 3,837 Foreign currency translation Â Â 4,632 4,632 Net income (loss) $ 0 3,428 0 3,428 Balance (in shares) at Sep. 30, 2024 5,419,855 Â Â Â Balance at Sep. 30, 2024 $ 349,529 (178,407) (9,671) [1] 161,451 Balance (in shares) at Jun. 30, 2024 5,409,155 Â Â Â Net income (loss) $ 0 3,428 0 3,428 Foreign currency translation Â Â 4,632 4,632 Vesting of restricted stock units and exercise of stock options (in shares) 13,780 Â Â Â Vesting of restricted stock units and exercise of stock options $ 23 Â Â 23 Tax withholding on vesting of restricted stock units (in shares) (32) Â Â Â Tax withholding on vesting of restricted stock units $ (3) Â Â (3) Dividends paid, $0.16 per share Â (869) Â (869) Stock-based compensation expense 3,239 Â Â 3,239 Foreign currency translation Â Â (6,951) (6,951) Net income (loss) $ 0 (1,676) 0 (1,676) Balance (in shares) at Dec. 31, 2024 5,433,603 Â Â Â Balance at Dec. 31, 2024 $ 352,788 (180,952) (16,622) [1] 155,214 Balance (in shares) at Sep. 30, 2024 5,419,855 Â Â Â Net income (loss) $ 0 $ (1,676) 0 (1,676) Foreign currency translation Â Â $ (6,951) $ (6,951) [1] Accumulated Other Comprehensive Income (Loss). X - DefinitionAmount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of paid and unpaid common stock dividends declared with the form of settlement in cash. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_DividendsCommonStockCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification

Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 18 R7.htm IDEA: XBRL DOCUMENT v3.25.0.1 Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) - $ / shares 3 Months Ended Dec. 31, 2024 Sep. 30, 2024 Jun. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Jun. 30, 2023 Dividends paid, per share (in dollars per share) $ 0.16 $ 0.16 $ 0.16 $ 0.16 $ 0.16 $ 0.16 X - DefinitionAggregate dividends paid during the period for each share of common stock outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_CommonStockDividendsPerShareCashPaid Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration XML 19 R8.htm IDEA: XBRL DOCUMENT v3.25.0.1 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Cash flows from operating activities: Â Â Net income $ 5,140 $ 337 Adjustments to reconcile net income to net cash from operating activities: Â Â Depreciation of property, plant and equipment 4,028 2,899 Amortization of acquisition-related intangibles 13,002 22,380 Stock-based compensation expense 10,004 9,144 Gain on extinguishment of convertible notes (2,887) 0 Amortization of step-up in inventory basis 1,232 0 Foreign currency adjustments 2,492 (3,128) Other 3,914 2,206 Cash from changes in operating assets and liabilities: Â Â Accounts receivable, net 91 8,294 Inventories (539) 217 Prepaid expenses and other assets (1,445) (7,841) Accounts payable (1,919) (1,656) Accrued liabilities and taxes payable 1,879 (124) Unearned revenues (849) (1,478) Net cash provided by operating activities 34,143 31,250 Cash flows from investing activities: Â Â Acquisitions, net of cash acquired 0 (79,700) Purchases of property, plant and equipment (3,492) (2,032) Net cash (used in) investing activities (3,492) (81,732) Cash flows from financing activities: Â Â Proceeds from the issuance of debt, net 73,465 71,000 Repayment of debt (26,313) (22,000) Repurchase of convertible debt (71,560) 0 Dividends paid (2,598) (2,583) Other financing, net (1,310) (648) Net cash (used in) provided by financing activities (28,316) 45,769 Effect of exchange rate changes on cash and cash equivalents 407 27 Net increase (decrease) in cash and cash equivalents 2,742 (4,686) Cash and cash equivalents at beginning of period 28,214 32,910 Cash and cash equivalents at end of period 30,956 28,224 Supplemental non-cash activity: Â Â Right of use assets obtained in exchange for lease liabilities $ 9,596 $ 4,220 X - DefinitionRepresents amortization of inventory step-up cost. + ReferencesNo definition available. + Details Name: mlab_AmortizationOfInventoryStepupCost Namespace Prefix: mlab_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -

Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OtherNoncashIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDividends Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromLongTermLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_ProceedsFromPaymentsForOtherFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 1 - Description of Business and Summary of Significant Accounting Policies 9 Months Ended Dec. 31, 2024 Notes to Financial Statements Â Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Note 1. Description of Business and Summary of Significant Accounting Policies Â Description of Business Â In this quarterly report on Form 10-Q, Mesa Laboratories, Inc., a Colorado corporation, together with its subsidiaries, is collectively referred to as â€œwe,â€ â€œus,â€ â€œour,â€ the â€œCompany,â€ or â€œMesa.â€ Â We are a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare,Â and medical device industries. We offer products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. We have manufacturing operations in the United States and Europe, and our products are marketed by our sales personnel in North America, EuropeÂ and Asia Pacific, and by independentÂ distributors in these areas and throughout the rest of the world. We prefer marketsÂ in which we can establish a strong presence and achieve high gross profit margins. Â As of December 31, 2024, we managed our operations in four reportable segments, or divisions: Â Â â—Sterilization and Disinfection Control - manufactures and sells biological, chemical and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes in the medical device, pharmaceutical, and healthcare industries. The division also provides testing and laboratory services, mainly to the dental and pharmaceutical industries.Â Â â— Clinical Genomics -Â develops, manufactures and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables and services that enable clinical research labs and contract research organizations to performÂ genomic testing for a broad range of research applications in several therapeutic areas, such as screenings for hereditary diseases, pharmacogenetics, oncology related applications, and toxicology research. Â â— Biopharmaceutical DevelopmentÂ - develops, manufactures, sells and services automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Immunoassays and peptide synthesis solutions accelerate the discovery, development, and manufactureÂ of biotherapeutic therapies, among other applications.Â Â â— Calibration SolutionsÂ - develops, manufactures,Â sells and services quality control products using principles of advanced metrology to enable customers toÂ measure and calibrate critical parameters in applications such as environmental and process monitoring, dialysis, gas flow, air quality and torque testing. Â Basis of Presentation Â The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance withÂ the rules and regulations of the Securities and Exchange Commission and in accordance with accounting principles generally accepted in the United States (â€œU.S. GAAPâ€) for interim financial information. In the opinion of management, such unaudited information includes all adjustments, consisting of normal recurring adjustments necessary for theÂ fair statement of our financial position and results of operations. The results of operations for interim periods are not necessarily indicative of results that may be achieved for the entire year.Â The year-end Condensed Consolidated Balance Sheet data was derived from audited financial statementsÂ but does not include all disclosures required by accounting principles generally accepted in the United States of America. The Condensed Consolidated Financial Statements include the accounts of Mesa and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.Â We made no material changes to the application of our significant accounting policies disclosed in our annual report on Form 10-K. This quarterly report should be read in conjunction with the consolidated financial statements included in our annual report on Form 10-K for the year endedÂ March 31, 2024. Â Our fiscal year ends on MarchÂ 31. References in this quarterly report to a particular â€œyearâ€ or â€œquarterâ€Â refer to our fiscal year or fiscal quarters, respectively. Â Prior Period Reclassifications Â For the nine months ended December 31, 2024, certain prior period amounts in our unaudited Condensed Consolidated Statements of Operations related to cash interest payments on acquisition holdback liabilities and non-cash debt issuance cost amortizationÂ have been reclassified out of "Other expense (income), net" and into "Interest expense and amortization of debt issuance costs."Â Additionally, prior period third-party costs related to the repurchase of a portion of our convertible senior notes have been reclassified out of "Other expense (income), net"Â and are reflected within the "(Gain) on extinguishment of convertible senior notes."Â These reclassifications have not resulted in any change to "Non-operating expense (income), net" nor in any material change to other amounts presented in our unaudited condensed consolidated financial statements for the three and nine months ended December 31, 2024. Â Risks and Uncertainties Â The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the reporting date and revenues and expenses during the reporting periods. These estimates represent management's judgment about the outcome of future events. The global business environment continues to be impacted by cost pressures, the overall effects of economic uncertainty, and other factors. Changes in, and the resulting effects of, potential governmental stimulus or fiscal and monetary policies, interest rates, foreign currency values, supply chains, demand for goods and services, a global or regional recession, or other circumstances cannot be reliably predicted. Actual results could differ from our estimates. Â Recently Issued Accounting Pronouncements Â InÂ November 2023,Â the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU")Â No.Â 2023-07,Â "Segment ReportingÂ (TopicÂ 280): Improvements to Reportable Segment Disclosures." ASUÂ No.Â 2023-07Â requires all annual disclosures currently required by TopicÂ 280Â to be included in interim financial statements and requires disclosure of significant segment expenses regularly provided to the chief operating decision maker ("CODM"), a description of other segment items by reportable segment, and applicable additional measures of segment profit or loss used by the CODM when allocatingÂ resources and assessing business performance. The ASU is effective for fiscal years beginning after December 15, 2023 (our fiscal year 2025 for annual periods)Â and interim periods within fiscal years beginning after December 15, 2024 (our fiscal year 2026 for interim periods) on a retrospective basis. Other than presentation changes to our segment footnote, we do not expect the adoption of ASU No. 2023-07 to have a material impact on our consolidated financial statements. Â InÂ December 2023,Â the FASB issued ASUÂ No.Â 2023-09,Â "Income Taxes (TopicÂ 740): Improvements to Income Tax Disclosures." ASUÂ No.Â 2023-09,Â which enhances the transparency, effectiveness and comparability of income tax disclosures by requiring consistent categories and greater disaggregation of information related to income tax rate reconciliations and the jurisdictions in which income taxes are paid.Â The guidance is effective for public business entities for fiscal years beginning afterÂ December 15, 2024 (our fiscal yearÂ 2026), with early adoption and prospective or retrospective application permitted.Â Other than presentation of additional disaggregated data in our income tax footnote disclosures for annual periods, we do not expect the adoption of ASU No. 2023-09 to have a material impact on our consolidated financial statement. Â In November 2024, the Financial Accounting Board ("FASB") issued Accounting Standards Update ("ASU") No. 2024-03, "Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses." ASU No. 2024-03Â requiresÂ that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The ASU is effective for fiscal years beginning after December 15, 2026Â (our fiscal year 2028Â for annual periods)Â and interim periods within fiscal years beginning after December 15, 2027 (our fiscal year 2029 for interim periods), with early adoption and prospective or retrospective applicationÂ permitted. We are currently assessing the effect the adoption of this standard will have on our consolidated financial statement disclosures. Â We have reviewed all recently issued accounting pronouncements and have concluded that, other than as described above,Â they are eitherÂ notÂ applicable to us or areÂ notÂ expected to have a significant impact onÂ our consolidated financial statements.Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 250 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/250/tableOfContent + Details Name: us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 2 - Significant Transactions 9 Months Ended Dec. 31, 2024 Notes to Financial Statements Â Significant Transactions [Text Block] Note 2. Significant Transactions Â GKE - Fiscal Year 2024 AcquisitionÂ We acquiredÂ 100% of the outstanding shares of GKE GmbH and SAL GmbH effectiveÂ October 16, 2023,Â and upon approval by applicable Chinese regulators, effective December 31, 2023, we acquiredÂ 100% of the outstanding shares of Beijing GKE Science & Technology Co. Ltd. (â€œGKE Chinaâ€ and together with GKE GmbH and SAL GmbH, â€œGKEâ€ or the "GKE acquisition"). Â GKE develops, manufactures and sells a portfolio of chemical sterilization indicators, biologics, and process challenge devices to protect patient safety across global healthcare markets. GKE is included in ourÂ Sterilization and Disinfection Control ("SDC") division, and GKE's strengths in chemical indictors are complementary to SDC's strengths in biological indicators as chemical and biological indicators are used in the same sterility validation workflows. Additionally, GKEâ€™s healthcare-focused commercial capabilities in Europe and Asia greatly expand our reach in the healthcare markets in those geographies. We are working to obtain regulatoryÂ 510(k) clearance on certain GKEÂ products for sale in the United States, which would further expand organic revenues growth opportunities from the GKE business. Â We finalized our purchase price accounting of GKE during fiscal year 2024. Total cash consideration for the GKE acquisition was $87,187, net of cash and financial liabilities acquired and inclusive of working capital adjustments. Of the total acquisition price, approximately $9,000 (at December 31, 2024 exchange rates) is being held backÂ until April 2025 in accordance with the purchase agreement as security againstÂ potential indemnification losses ("GKE holdback"). We funded the acquisition through a combination of cash on-hand and a total ofÂ $71,000 borrowed under our line of credit.Â Â During theÂ three and nine months ended December 31, 2024, GKE's operations contributed the following amounts to our consolidated results of operations:Â Â Â Â Three Months Ended Â Â Nine Months Ended Â Â Â December 31, 2024Â Revenues Â $6,854Â Â $18,971Â Gross profit Â Â 4,904Â Â Â 12,457Â Â Â Â Â Â Â Â Â Â Amortization of inventory step-up recorded in cost of revenues Â Â -Â Â Â 1,232Â Amortization of acquired intangibles recorded in cost of revenues Â Â 131Â Â Â 375Â Amortization of acquired intangibles recorded in general and administrative expense Â Â 935Â Â Â 2,423Â Â X - DefinitionThe entire disclosure of significant transactions. + ReferencesNo definition available. + Details Name: mlab_SignificantTransactionsTextBlock Namespace Prefix: mlab_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 22 R11.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 3 - Revenue 9 Months Ended Dec. 31, 2024 Notes to Financial Statements Â Revenue from Contract with Customer [Text Block] Note 3. Revenue Â We develop, manufacture, market, sellÂ and maintain life sciences tools and quality control instrumentsÂ and related consumables. Â Hardware sales include physical products such as instruments used for molecular and genetic analysis, protein synthesizers, medical meters, wireless sensor systems, data loggers, and process challenge devices. Hardware salesÂ mayÂ be offered with accompanying perpetual or annual software licenses, which in some cases are required for the hardware to function. Â Consumables are single-use products and require frequent replacement in our customers' operating cycles. Consumables sold by our Clinical Genomics and Biopharmaceutical Development divisions,Â such as reagents used for molecular and genetic analysisÂ or solutions used for protein synthesis, are critical to the ongoing use of our instruments. ConsumablesÂ such as biological and chemical indicator test strips sold by our Sterilization and Disinfection Control division are used on a standalone basis. Â Revenues from hardware and consumables are recognized upon transfer to the customer, typically at the point of shipment.Â Â We also offer maintenance, calibrationÂ and testing services. Services result in revenues recognized over time, for example, when we are obligated toÂ perform labor and replace parts on an as-needed basis over a contractually specified period of time, or at a point in time, upon completion of a specific, discrete service. In many cases, our contracts contain both revenues recognized over time and revenues recognized at a point in time.Â Â We evaluate our revenues internally based on business division and the nature of goods and services provided. Â The following tables present disaggregated revenues for the three and nine months ended December 31, 2024Â andÂ 2023, respectively: Â Â Â Three Months Ended December 31, 2024 Â Â Â Sterilization and Disinfection Control (1) Â Â Clinical Genomics Â Â Biopharmaceutical Development Â Â Calibration Solutions Â Â Total Â Consumables Â $20,991Â Â $9,866Â Â $4,909Â Â $1,043Â Â $36,809Â Hardware and software Â Â 52Â Â Â 1,877Â Â Â 4,534Â Â Â 9,333Â Â Â 15,796Â Services Â Â 2,464Â Â Â 924Â Â Â 2,794Â Â Â 4,053Â Â Â 10,235Â Total revenues Â $23,507Â Â $12,667Â Â $12,237Â Â $14,429Â Â $62,840Â Â (1) Revenues of $6,854Â from GKE are included in the Sterilization and Disinfection Control division during theÂ three months ended December 31, 2024.Â Â Â Â Three Months Ended December 31, 2023 Â Â Â Sterilization and Disinfection Control (1) Â Â Clinical Genomics Â Â Biopharmaceutical Development Â Â Calibration Solutions Â Â Total Â Consumables Â $16,832Â Â $9,758Â Â $4,080Â Â $539Â Â $31,209Â Hardware and software Â Â 180Â Â Â 1,639Â Â Â 2,672Â Â Â 8,254Â Â Â 12,745Â Services Â Â 2,326Â Â Â 1,149Â Â Â 2,678Â Â Â 3,366Â Â Â 9,519Â Total revenues Â $19,338Â Â $12,546Â Â $9,430Â Â $12,159Â Â $53,473Â Â (1) Revenues of $3,837 from GKE are included in the Sterilization and Disinfection Control division during the three months ended December 31, 2023, following the acquisition of GKE GmbH and SAL GmbH on October 16, 2023.Â Â Â Â Â Nine Months Ended December 31, 2024 Â Â Â Sterilization and Disinfection Control (1) Â Â Clinical Genomics Â Â Biopharmaceutical Development Â Â Calibration Solutions Â Â Total Â Consumables Â $60,860Â Â $26,156Â Â $12,657Â Â $2,067Â Â $101,740Â Hardware and software Â Â 365Â Â Â 6,511Â Â Â 14,539Â Â Â 24,067Â Â Â 45,482Â Services Â Â 7,444Â Â Â 2,903Â Â Â 8,916Â Â Â 12,358Â Â Â 31,621Â Total revenues Â $68,669Â Â $35,570Â Â $36,112Â Â $38,492Â Â $178,843Â Â (1) Revenues of $18,971 from GKE are included in the Sterilization and Disinfection Control division during the nine months ended December 31, 2024.Â Â Â Â Nine Months Ended December 31, 2023 Â Â Â Sterilization and Disinfection Control (1) Â Â Clinical Genomics Â Â Biopharmaceutical Development Â Â Calibration Solutions Â Â Total Â Consumables Â $45,288Â Â $28,490Â Â $12,753Â Â $1,834Â Â $88,365Â Hardware and software Â Â 381Â Â Â 9,540Â Â Â 7,838Â Â Â 22,216Â Â Â 39,975Â Services Â Â 6,676Â Â Â 3,434Â Â Â 7,935Â Â Â 10,898Â Â Â 28,943Â Total revenues Â $52,345Â Â $41,464Â Â $28,526Â Â $34,948Â Â $157,283Â Â (1) Revenues of $3,837 from GKE are included in the Sterilization and Disinfection Control division during theÂ nine months ended December 31, 2023, following the acquisition of GKE GmbH and SAL GmbH on October 16, 2023.Â Â Revenues from external customers are attributed to individual countries based upon the locations to which the products areÂ shipped or exported, or locations where services are performed, as follows: Â Â Â Three Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â United States Â $30,476Â Â $25,595Â Â $85,415Â Â $79,205Â China Â Â 6,322Â Â Â 4,942Â Â Â 20,271Â Â Â 18,584Â Other Â Â 26,042Â Â Â 22,936Â Â Â 73,157Â Â Â 59,494Â Total revenues Â $62,840Â Â $53,473Â Â $178,843Â Â $157,283Â Â Other than China, noÂ foreign country exceededÂ 10% of total revenues for theÂ three and nine months ended December 31, 2024Â andÂ 2023. Â Contract Balances Our contracts have varying payment terms and conditions. Some customers prepay for products and servicesÂ resulting in unearned revenues or customer depositsÂ called contract liabilities. Short-term contract liabilities are included withinÂ unearned revenuesÂ in the accompanying unaudited Condensed Consolidated Balance Sheets, and long-term contract liabilities are included within other noncurrent liabilitiesÂ in the accompanying unaudited Condensed Consolidated Balance Sheets. The significant majority of our revenues and related receivables and contract liabilities are generated from contracts with customers with original durations of 12Â months or less. Contract liabilities will be recognized to revenue as we satisfy our obligations under the terms of the contracts.Â Â A summary of contract liabilities is as follows: Â Contract liabilities as of March 31, 2024 Â $15,686Â Prior year liabilities recognized in revenues during the nine months ended December 31, 2024 Â Â (9,069) Contract liabilities added during the nine months ended December 31, 2024, net of revenues recognized Â Â 8,083Â Contract liabilities as of December 31, 2024 Â $14,700Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 4 - Fair Value Measurements 9 Months Ended Dec. 31, 2024 Notes to Financial Statements Â Fair Value Disclosures [Text Block] Note 4. Fair Value Measurements Â Our financial instruments consist primarily of cash and cash equivalents, trade accounts receivable, obligations under trade accounts payable,Â and debt. Due to their short-term nature, the carrying values for cash and cash equivalents, trade accounts receivable, and trade accounts payable approximate fair value; they are classified within Level 1 of the fair value hierarchy.Â Â The financial instruments that subject us to the highest concentration of credit risk are cash andÂ accounts receivable. We maintain relationships and cash deposits at multiple banking institutions across the world in an effort to diversify and reduce risk of loss. Concentration of credit risk with respect to accounts receivable is limited to customers to whom we make significant sales. No customers accounted for more than 10% of total trade receivables as of December 31, 2024. Â On April 5, 2024, we entered into separate, privately negotiated purchase agreements with a limited number of holders of our 1.375% convertible senior notes dueÂ August 15, 2025 (the "Notes"), through which we repurchased $75,000 in aggregate principal amount of the Notes. See Note 7. "Indebtedness" for further information. As of December 31, 2024, we hadÂ remaining outstanding $97,500Â aggregate principal amount of the Notes. We estimate the fair value of the Notes using Level 2 inputs based on the last actively traded price or observable market input preceding the end of the reporting period. The fair value of the Notes is approximately correlated to our stock price. Â The estimated fair value and carrying value of the Notes were as follows: Â Â Â December 31, 2024 Â Â March 31, 2024 Â Â Â Carrying Value Â Â Fair Value (Level 2) Â Â Carrying Value Â Â Fair Value (Level 2) Â Notes Â $97,163Â Â $94,819Â Â $171,198Â Â $163,013Â Â The carrying amounts of our term loan and revolving line of credit (together, the "Credit Facility") on the unaudited Condensed Consolidated Balance Sheets approximateÂ fair value due to the variable interest rate pricing on the debt, with the balance bearing an interest rate approximating current market rates. Â We expect to pay approximately $9,000Â (atÂ December 31, 2024 exchange rates) for the GKE holdback in April 2025. We estimate the discounted fair value of consideration held back to be approximately $8,900 as of December 31, 2024Â based on Level 3 inputs from the acquisition, including discount rate estimates. We adjust the estimated fair value at each reporting period through earnings. Â During fiscal year 2023, weÂ acquired substantially all of the assets and certain liabilities of Belyntic GmbHâ€™s peptide purification business (â€œthe Belyntic acquisitionâ€). We are obligated to pay contingent consideration of up to $1,500 cash upon regulatory approval of certain patent applications. We estimate the fair value of the remaining contingent consideration is $675, using Level 3 inputs and a probability-weighted outcome analysis based on our expectations of patent approval, leveraging our historical experience and expert input.Â Â Amounts recognized or disclosed at fair value in the unaudited condensed consolidated financial statements on a nonrecurring basis include the initial recognition and disclosure of most assets and liabilities purchased inÂ business acquisitions and any related measurement period adjustments. Additionally, assets such as property and equipment, operating lease assets, goodwill and other intangible assets are adjusted to fair value if determined to be impaired.Â Fair values of such assets and liabilitiesÂ requireÂ measurement using Level 3 inputs. We recorded no impairments during the three and nine months ended December 31, 2024Â orÂ 2023.Â Â There were no transfers between the levels of the fair value hierarchy during the three and nine months ended December 31, 2024. Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R13.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 5 - Supplemental Information 9 Months Ended Dec. 31, 2024 Notes to Financial Statements Â Supplemental Balance Sheet Disclosures [Text Block] Note 5. SupplementalÂ Information Â Inventories consisted of the following: Â Â Â December 31, 2024 Â Â March 31, 2024 Â Raw materials Â $16,584Â Â $18,335Â Work in process Â Â 400Â Â Â 1,256Â Finished goods Â Â 11,138Â Â Â 13,084Â Total inventories Â $28,122Â Â $32,675Â Â Prepaid expenses and other current assets consisted of the following:Â Â Â Â

December 31, 2024 Â Â March 31, 2024 Â Prepaid expenses Â $3,251Â Â $2,932Â Deposits Â Â 1,338Â Â Â 1,898Â Prepaid income taxes Â Â 5,682Â Â Â 1,237Â Other current assets Â Â 2,849Â Â Â 3,341Â Total prepaid expenses and other current assets Â $13,120Â Â $9,408Â Â Accrued payroll and benefits consisted of the following: Â Â Â December 31, 2024 Â Â March 31, 2024 Â Bonus payable Â $7,803Â Â $3,838Â Wages and paid-time-off payable Â Â 3,600Â Â Â 3,072Â Payroll related taxes Â Â 1,954Â Â Â 1,956Â Other benefits payable Â Â 562Â Â Â 1,069Â Total accrued payroll and benefits Â $13,919Â Â $9,935Â Â The increase in bonus payable is primarily due to our financial performance in fiscal year 2025 compared to fiscal year 2024.Â Â Other accrued expenses consisted of the following:Â Â Â Â December 31, 2024 Â Â March 31, 2024 Â Accrued business taxes Â $5,505Â Â $5,557Â Current operating lease liabilities Â Â 3,535Â Â Â 2,986Â Income taxes payable Â Â 1,364Â Â Â 1,615Â Current acquisition-related holdbacks Â Â 9,531Â Â Â 436Â Other Â Â 2,416Â Â Â 2,264Â Total other accrued expenses Â $22,351Â Â $12,858Â Â The increase in other accrued expenses is primarily due to the reclassification of held back Belyntic and GKE acquisition-related consideration from noncurrent liabilities. Â Other noncurrent liabilities consisted of the following:Â Â Â Â December 31, 2024 Â Â March 31, 2024 Â Noncurrent operating lease liabilities Â $12,361Â Â $6,613Â Noncurrent acquisition-related holdbacks Â Â -Â Â Â 8,792Â Other Â Â 92Â Â Â 208Â Total other noncurrent liabilities Â $12,453Â Â $15,613Â Â The increase in operating lease liabilities is primarily attributable to the right of use asset associated with an operating lease for a facility used by our Biopharmaceutical Development for manufacturing and administrative purposes. Â Â Â Three Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Depreciation expense in cost of revenues Â $610Â Â $788Â Â $2,376Â Â $2,117Â Depreciation expense in operating expense Â Â 496Â Â Â 286Â Â Â 1,652Â Â Â 782Â Total depreciation expense Â $1,106Â Â $1,074Â Â $4,028Â Â $2,899Â Â The increase in depreciation expense for the three and nine months ended December 31, 2024Â is primarily due to GKE's operations, which included $225Â and $850Â of depreciation expense, respectively.Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R14.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 6 - Goodwill and Intangible Assets, Net 9 Months Ended Dec. 31, 2024 Notes to Financial Statements Â Goodwill and Intangible Assets Disclosure [Text Block] Note 6. Goodwill and Intangible Assets, Net Â Finite-lived intangible assets consisted of the following: Â Â Â December 31, 2024 Â Â March 31, 2024 Â Â Â Gross Carrying Amount Â Â Accumulated Amortization Â Â Net Carrying Amount Â Â Gross Carrying Amount Â Â Accumulated Amortization Â Â Net Carrying Amount Â Customer relationships Â $186,272Â Â $(112,475)Â $73,797Â Â $189,911Â Â $(104,528)Â $85,383Â Other intangibles Â Â 60,356Â Â Â (35,972)Â Â 24,384Â Â Â 61,161Â Â Â (32,792)Â Â 28,369Â Total finite-lived intangible assets Â $246,628Â Â $(148,447)Â $98,181Â Â $251,072Â Â $(137,320)Â $113,752Â Â Amortization expense for finite-lived intangible assets was as follows: Â Â Â Three Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Amortization in cost of revenues Â $660Â Â $1,883Â Â $1,979Â Â $5,367Â Amortization in general and administrative Â Â 3,731Â Â Â 6,092Â Â Â 11,023Â Â Â 17,013Â Total amortization expense Â $4,391Â Â $7,975Â Â $13,002Â Â $22,380Â Â The decrease in amortization expense isÂ attributable to impairment losses recorded during the fourth quarter of fiscal year 2024 related toÂ intangible assets within our Clinical Genomics division.Â Â For the following fiscal years ending March 31, future amortization expense is estimated as follows, based on foreign currency exchange rates as of December 31, 2024: Â Fiscal Year Â Amortization ExpenseÂ Â Â Remainder of 2025 Â $4,278Â 2026 Â Â 16,566Â 2027 Â Â 15,921Â 2028 Â Â 15,349Â 2029 Â Â 14,815Â Â The change in the carrying amount of goodwill was as follows: Â Â Â Sterilization and Disinfection Control Â Â Clinical Genomics Â Â Biopharmaceutical Development Â Â Calibration Solutions Â Â Total Â March 31, 2024 Â $79,430Â Â $16,940Â Â $46,515Â Â $37,211Â Â Â 180,096Â Effect of foreign currency translation Â Â (1,994)Â Â (71)Â Â (849)Â Â (30)Â Â (2,944) December 31, 2024 Â $77,436Â Â $16,869Â Â $45,666Â Â $37,181Â Â $177,152Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for goodwill and intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R15.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 7 - Indebtedness 9 Months Ended Dec. 31, 2024 Notes to Financial Statements Â Debt Disclosure [Text Block] Note 7.Â Indebtedness Â Credit Facility OnÂ March 5, 2021,Â we entered into aÂ four-year senior secured credit agreementÂ that includedÂ 1) a revolving credit facility with an aggregate principal amount of up to $75,000Â (the "Revolver"),Â 2) aÂ swingline loanÂ with an aggregate principal amountÂ notÂ exceeding $5,000, andÂ 3) letters of credit with an aggregate stated amountÂ notÂ exceeding $2,500Â at any time.Â The agreement also provided for an incremental term loan or an increase in revolving commitments with a minimum aggregate principal amount of $25,000Â and a maximum amount of $75,000, subject to the satisfaction of certain conditions and lender considerations.Â We refer to theÂ agreement in whole as the â€œCredit Facility.â€ Â OnÂ October 5, 2023,Â we amended the terms of the Credit Facility to increase the maximum principal amount available to us under the Revolver from $75,000Â to $125,000.Â Â OnÂ April 5, 2024,Â we further amended and restated the terms of the Credit Facility to: Â (i) Extend the maturity of the Credit Facility toÂ April 2029;Â (ii) Allow proceeds from the Credit Facility to be used to redeem some or all of the Companyâ€™sÂ 2025Â Notes; (iii) Include aÂ $75,000Â senior secured term loan facility (the â€œTerm Loanâ€), which is subject to principal amortization payments; and (iv) Make certain changes to the financial covenants. Â In conjunction with the amendment and restatement of the Credit Facility during the nine months ended December 31, 2024, we incurred $1,987 of customary lender fees and debt issuance costs paid to third parties, of which $1,242 is related to the RevolverÂ and $745 is related to the Term Loan. The fees are being amortized to interest expense through maturity.Â Â Amounts borrowed under the Credit Facility bearÂ interest at either a base rate or a SOFR rate plus an applicable spread ranging fromÂ 1.5% toÂ 3.5%, depending on our total net leverage ratio. The weighted average interest rate on borrowings under the Credit Facility as ofÂ December 31, 2024Â wasÂ 7.5%. Â The financial covenants in the Credit Facility as amended include a maximum leverage ratio ofÂ 4.50Â toÂ 1.00Â on each of the quarterly testing dates through December 31, 2024;Â 4.0Â toÂ 1.0Â on each of the testing dates between March 31, 2025 and March 31, 2026; andÂ 3.5Â toÂ 1.0Â on each testing date thereafter. The Credit Facility also stipulates a minimum fixed charge coverage ratio ofÂ 1.25Â toÂ 1.0Â and a minimum senior net leverage ratio ofÂ 3.5Â toÂ 1.Â Other covenants include restrictions on ourÂ ability to incur debt, grant liens, make fundamental changes to our business as defined in the contract, engage in certain transactions with affiliates, or conduct asset sales. As ofÂ December 31, 2024, we were in compliance with all covenants underÂ the Credit Facility. Â Term Loan We borrowed $75,000Â under the Term Loan onÂ April 5, 2024, to fund the privately negotiated repurchases of a portion of theÂ Notes (see â€œConvertible Notesâ€ below). During the three and nine months ended December 31, 2024, we made required quarterly principal payments on the Term Loan of $938Â and $2,813, respectively.Â Â We are required to make quarterly principal payments on the Term Loan. For the following fiscal years ending March 31, future debt payments on the Term Loan are required as follows: Â Fiscal Year Â Amount Â Remainder of 2025 Â $937Â 2026 Â Â 3,750Â 2027 Â Â 5,625Â 2028 Â Â 5,625Â 2029 Â Â 7,500Â Thereafter Â Â 48,750Â Total Principal Remaining Â $72,187Â Â The net carrying amount of the Term Loan was as follows: Â Â Â December 31, 2024 Â Â March 31, 2024 Â Term Loan (7.5% as of December 31, 2024) Â $72,187Â Â $-Â Less: discount and debt issuance costs Â Â (634)Â Â -Â Less: current portion Â Â (3,750)Â Â -Â Noncurrent portion Â $67,803Â Â $-Â Â Revolver As ofÂ December 31, 2024,Â the outstanding balance under theÂ Revolver was $27,000, and $98,000Â was available for borrowing. Subsequent toÂ December 31, 2024,Â we repaid an additional $4,500 on theÂ Revolver. Â We are obligated to pay quarterly unused commitment fees ofÂ betweenÂ 0.20% andÂ 0.35% of the Revolverâ€™s aggregate principal amount, based on our leverage ratio. Â The balance of unamortized customary lender fees related to the Revolver, including fees from the original debt issuance and all subsequent amendments and restatements, was $1,278Â and $321Â as ofÂ December 31, 2024Â andÂ March 31, 2024,Â respectively. Â Convertible NotesÂ On August 12, 2019, we issued an aggregate principal amount of $172,500 of Notes. The net proceeds from the Notes, after deducting underwriting discounts and commissions and other related offering expenses payable by us, were approximately $167,056.Â The Notes mature on August 15, 2025, unless earlier repurchased or converted, and bear interest at a rate of 1.375% payable semi-annually in arrears on February 15 and August 15 each year.Â TheÂ NotesÂ are initially convertible, subject to certain conditions,Â at a conversion rate ofÂ 3.5273Â shares of common stock perÂ $1,000Â principal amount of Notes, which is equivalent to an initial conversion price of approximatelyÂ $283.50Â per share of common stock.Â Â On April 5, 2024, we entered into separate, privately negotiated transactions with certain holders of the Notes to repurchase $75,000 aggregate principal amount of the Notes for an aggregateÂ repurchase price of $71,250Â in cash, plus accrued and unpaid interest of $160. We accounted for the partial repurchase of the Notes as a debt extinguishment, which resulted in the recognition of a gainÂ on extinguishment of $2,887 in other income on the unaudited Condensed Consolidated Statements of Operations during the nine months ended December 31, 2024. As of December 31, 2024, $97,500 in aggregate principal amount of the Notes remained outstanding, which we intend to pay using a combination of cash on hand and a draw on our Revolver. Â Upon conversion, weÂ will pay or deliver, as the case may be, cash, shares of ourÂ common stock, or a combination of cash and shares of our common stock. The circumstances necessary for conversion were not met duringÂ the three or nine months endedÂ December 31, 2024. The Notes will become convertible at any time from and includingÂ AprilÂ 15,Â 2025Â until the close of business on theÂ secondÂ scheduled trading day immediately before the maturity date. As of December 31, 2024, the Notes were classified as a current liability on our unaudited Condensed Consolidated Balance Sheets.Â The if-converted value of the Notes did not exceed the principal balance as ofÂ December 31, 2024.Â Â The net carrying amount of the Notes wasÂ as follows: Â Â Â December 31, 2024 Â Â March 31, 2024 Â Principal outstanding Â $97,500Â Â $172,500Â Unamortized debt issuance costs Â Â (337)Â Â (1,302) Net carrying value Â $97,163Â Â $171,198Â Â We recognized interest expense on the Notes as follows: Â Â Â Three Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Coupon interest expense at 1.375% Â $335Â Â $593Â Â $1,037Â Â $1,779Â Amortization of debt issuance costs Â Â 134Â Â Â 231Â Â Â 412Â Â Â 692Â Total interest and amortization of debt issuance costs Â $469Â Â $824Â Â $1,449Â Â $2,471Â Â The effective interest rate on the Notes is approximately 1.9%. Â X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 27 R16.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 8 - Stockholders' Equity 9 Months Ended Dec. 31, 2024 Notes to Financial Statements Â Share-Based Payment Arrangement [Text Block] Note 8. Stockholders' Equity Â Stock-Based Compensation During the nine months ended December 31, 2024, we issued time-based restricted stock units ("RSUs") and performance-based restricted stock units ("PSUs") pursuant toÂ the Mesa Laboratories, Inc. Amended and Restated 2021 Equity Incentive Plan, which authorizes the issuance of 660Â shares of common stock to eligible participants.Â Stock-based compensation expense is included in cost of revenues, selling, general and administrative, and research and development expense in the accompanying unaudited Condensed Consolidated Statements of Operations. Â The following is a summary of RSU and PSU award activity for the nineÂ months ended December 31, 2024: Â Â Â Time-Based Restricted Stock Units Â Â Performance-Based Restricted Stock Units Â Â Â Number of Shares Â Â Weighted-Average Grant Date Fair Value per Share Â Â Number of Shares Â Â Weighted- Average Grant Date Fair Value per Share Â Outstanding as of March 31, 2024 Â Â 76Â Â $157.83Â Â 56Â Â $240.96Â Awards granted(1) Â Â 117Â Â 93.46Â Â 41Â Â 102.57Â Awards forfeited Â Â (7)Â Â 123.42Â Â -Â Â -Â Awards distributed Â Â (36)Â Â 169.40Â Â (12)Â Â 302.06Â Outstanding as of December 31, 2024 Â Â 150Â Â $106.44Â Â 85Â Â $165.75Â Â (1) Balances for PSUs granted are reflected at target. Â Outstanding time-based RSUsÂ vest and settle in shares of our common stockÂ on aÂ one-for-one basis. The majority of RSUs granted to employees during the nine months ended December 31, 2024Â vest in equal installmentsÂ on the first, second, and third anniversariesÂ of the grant date. RSUs granted to non-employee directors during the nine months ended December 31, 2024 vest one year from the grant date. We generally recognize the expense relating to RSUs, net of estimated forfeitures, on a straight-line basis over the vesting period. Â We grantÂ PSUs to certain key employees. The number of shares earned is determined at the end of each performance period based on Mesa's achievement of certain pre-defined targets per the related award agreement. The outstanding PSUs vest upon completion of the service period described in the award agreement. We recognize the expense relating to the performance-based RSUs based on the probable outcome of achievement of the performance targetsÂ on a straight-line basis overÂ the service period.Â Â During the nine months ended DecemberÂ 31, 2024, the Compensation Committee of the Board of Directors created a plan to award 41Â PSUs at target (â€œthe FY25 PSUsâ€) to eligible employees. Of the 41 PSUs granted, 23 PSUs have a grant date fair value of $89.82 and are subject to service and company financial performance conditions. The financial performance measurement period is from April 1, 2024 through March 31, 2027. The remaining 18 PSUs have a grant date fair value of $119.54Â and are subject toÂ service and market conditions, with theÂ market performance period measured from June 18, 2024 through June 18, 2027. The service period for all of the FY25 PSUs is from JuneÂ 18, 2024 through June 18, 2027.Â The quantity of shares that will be earnedÂ based upon either company financial performanceÂ or market performance will range fromÂ 0% toÂ 200% of the targeted number of sharesÍ¾ if the defined minimum targets areÂ notÂ met, thenÂ noÂ shares will vest. Â The following is a summary of stock option award activity for the nine months ended December 31, 2024: Â Â Â Stock Options Â Â Â Shares Subject to Options Â Â Weighted- Average Exercise Price per Share Â Â Weighted-Average Remaining Contractual Life (Years) Â Â Aggregate Intrinsic Value Â Outstanding as of March 31, 2024 Â Â 194Â Â $181.89Â Â 3.2Â Â $26Â Awards granted Â Â -Â Â Â -Â Â Â Â Â Â Â Â Â Â Â Awards forfeited or expired Â Â (15)Â Â 150.98Â Â Â Â Â Â Â Â Â Awards exercised Â Â (1)Â Â 131.67Â Â Â Â Â Â Â Â Â Outstanding as of December 31, 2024 Â Â 178Â Â $184.55Â Â Â 2.6Â Â $287Â Â X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 28 R17.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 9 - (Loss) Earnings Per Share 9 Months Ended Dec. 31, 2024 Notes to Financial Statements Â Earnings Per Share [Text Block] Note 9.Â (Loss)Â EarningsÂ Per Share Â The following table presents a reconciliation of the denominators used in the computation of basic and diluted (loss) earnings per share: Â Â Â Three Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net (loss) income available for shareholders Â $(1,676)Â $2,116Â Â $5,140Â Â $337Â Weighted average outstanding shares of common stock Â Â 5,429Â Â Â 5,393Â Â Â 5,413Â Â Â 5,384Â Dilutive effect of stock options Â Â -Â Â Â -Â Â Â -Â Â Â 1Â Dilutive effect of RSUs Â Â -Â Â Â 3Â Â Â 51Â Â Â 9Â Fully diluted shares Â Â 5,429Â Â Â 5,396Â Â Â 5,464Â Â Â 5,394Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Basic (loss) earnings per share Â $(0.31)Â $0.39Â Â $0.95Â Â $0.06Â Diluted (loss) earnings per share Â $(0.31)Â $0.39Â Â $0.94Â Â $0.06Â Â Potentially dilutive securities include stock options and both time and performance based RSUs (collectively "stock awards"), as well as common shares underlying our Notes. Stock awards are excluded from the calculation of diluted EPS if they are subject to performance conditions that have not yet been achieved or if they are antidilutive. Diluted EPS does not consider the impact ofÂ potentially dilutive securities in periods in which there is a loss because the inclusion of the potential common shares would have an antidilutive effect in such cases. Â The following potentially dilutive awards were excluded from the calculation of diluted EPS: Â Â Â Three Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Assumed conversion of the Notes Â Â 344Â Â Â 608Â Â Â 354Â Â Â 608Â Stock awards that were anti-dilutive Â Â 406Â Â Â 277Â Â Â 202Â Â Â 223Â Total stock awards excluded from diluted EPS Â Â 750Â Â Â 885Â Â Â 556Â Â Â 831Â Â Shares underlying the Notes were excluded from the diluted EPS calculation for the three and nine months ended DecemberÂ 31, 2024 and 2023 as the impact of the assumed conversion of the Notes calculated under the if-converted method was antidilutive. The decrease in assumed conversion of the Notes is related to the partial repayment of the Notes that occurred during the nineÂ months ended DecemberÂ 31, 2024 (see Note 7. "Indebtedness"). Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R18.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 10 - Income Taxes 9 Months Ended Dec. 31, 2024 Notes to Financial Statements Â Income Tax Disclosure [Text Block] Note 10. Income Taxes Â We reported an income tax provision as follows: Â Â Â Three Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Income tax (benefit) expense Â $(541)Â $(170)Â $360Â Â $(653) Effective tax rateÂ Â 24.4%Â Â (8.7%)Â Â 6.5%Â Â 206.6% Â For interim income tax reporting, we estimate our annual effective tax rate and apply this effective tax rate to our year-to-date pre-tax income. Each quarter, our estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. Additionally, the tax effects of significant unusual or infrequently occurring items are recognized as discrete items in the interim period in which the events occur. There is a potential for volatility in the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which they relate, changes in tax laws and foreign tax holidays, settlement with taxing authorities, and foreign currency fluctuations. Â The change in the effective tax rate for both the three and nine months ended December 31, 2024 compared to the prior year periods is primarily due to the valuation allowance established on the US deferred taxes during fiscal year 2024. The effective tax rate for both the three and the nine months ended December 31, 2024 differed from the statutory federal rate of 21% primarily due to the valuation allowance established on the US deferred taxes during fiscal year 2024. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R19.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 11 - Commitments and Contingencies 9 Months Ended Dec. 31, 2024 Notes to Financial Statements Â Commitments and Contingencies Disclosure [Text Block] Note 11. Commitments and Contingencies Â We are party to various legal proceedings arising in the ordinary course of business. As ofÂ December 31, 2024, we areÂ notÂ party to any legal proceeding that management believes could have a material adverse effect on our unaudited consolidated financial position, results of operations, or cash flows.Â Â We expect to pay approximately $9,000Â (atÂ December 31, 2024 exchange rates) for the GKE holdback in April 2025, pending adjustments for potential indemnification losses thatÂ mayÂ arise. The liability is recorded at its discountedÂ fair value of $8,900 in other accrued expenses in our unaudited Condensed Consolidated Balance Sheets as of December 31, 2024.Â Â As part of the Belyntic acquisition, we agreed to pay the sellers a contingency based upon approval of contractually specified patents. The estimated fair value of the probableÂ remaining contingent consideration was $675Â as ofÂ December 31, 2024.Â On January 2, 2025, a notice of allowance was issued for one of the two remaining pending patents, and we expect to pay the Belyntic sellers $563 for the patentÂ within fiscal year 2025 or early in fiscal year 2026, depending upon the final approval date. We expect the other remaining pending patent will likely be approved within one year of December 31, 2024. Â X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 12 - Segment Information 9 Months Ended Dec. 31, 2024 Notes to Financial Statements Â Segment Reporting Disclosure [Text Block] Note 12. Segment Information Â The following tables set forth our segment information: Â Â Â Three Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenues (a): Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Sterilization and Disinfection Control (b) Â $23,507Â Â $19,338Â Â $68,669Â Â $52,345Â Clinical Genomics Â Â 12,667Â Â Â 12,546Â Â Â 35,570Â Â Â 41,464Â Biopharmaceutical Development Â Â 12,237Â Â Â 9,430Â Â Â 36,112Â Â Â 28,526Â Calibration Solutions Â Â 14,429Â Â Â 12,159Â Â Â 38,492Â Â Â 34,948Â Total revenues Â $62,840Â Â $53,473Â Â $178,843Â Â $157,283Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Gross profit: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Sterilization and Disinfection Control (b) Â $16,461Â Â $13,951Â Â $47,191Â Â $38,018Â Clinical Genomics Â Â 6,948Â Â Â 6,449Â Â Â 19,344Â Â Â 20,904Â Biopharmaceutical Development Â Â 7,539Â Â Â 5,841Â Â Â 22,665Â Â Â 17,783Â Calibration Solutions Â Â 8,806Â Â Â 7,212Â Â Â 23,258Â Â Â 20,050Â Reportable segment gross profit Â Â 39,754Â Â Â 33,453Â Â Â 112,458Â Â Â 96,755Â Corporate and other (c) Â Â -Â Â Â (51)Â Â -Â Â Â (61) Gross profit Â $39,754Â Â $33,402Â Â $112,458Â Â $96,694Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Reconciling items: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Operating expense Â Â 33,975Â Â Â 33,469Â Â Â 97,591Â Â Â 97,485Â Operating income (loss) Â Â 5,779Â Â Â (67)Â Â 14,867Â Â Â (791) Non-operating expense (income), net Â Â 7,996Â Â Â (2,013)Â Â 9,367Â Â Â (475) (Loss) earnings before income taxes Â $(2,217)Â $1,946Â Â $5,500Â Â $(316) Â Â (a) Intersegment revenues are not significant and are eliminated to arrive at consolidated totals. Â (b) Includes post-acquisition GKE results during the three and nine months ended December 31, 2024Â and 2023Â beginning on October 16, 2023 for GKE GmbH and SAL GmbH, and beginning on January 1, 2024 for GKE China.Â Â (c)Unallocated corporate expenses are reported within corporate and other.Â Â The following table sets forth inventoriesÂ by reportableÂ segment.Â Our chief operating decision maker isÂ notÂ provided with and does not regularly review any other segment asset information. Â Â Â December 31, Â Â March 31, Â Â Â 2024 Â 2024 Â Sterilization and Disinfection Control Â $5,728Â Â $7,014Â Clinical Genomics Â Â 10,709Â Â Â 11,813Â Biopharmaceutical Development Â Â 5,853Â Â Â 6,304Â Calibration Solutions Â Â 5,832Â Â Â 7,544Â Total Inventories Â $28,122Â Â $32,675Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContentReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_SegmentReportingDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.25.0.1 Insider Trading Arrangements 3 Months Ended Dec. 31, 2024 Insider Trading Arr Line Items Â Rule 10b5-1 Arrangement Adopted [Flag] false Non-Rule 10b5-1 Arrangement Adopted [Flag] false Rule 10b5-1 Arrangement Terminated [Flag] false Non-Rule 10b5-1 Arrangement Terminated [Flag] false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a + Details Name: ecd_InsiderTradingArrLineItems Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration XML 33 R22.htm IDEA: XBRL DOCUMENT v3.25.0.1 Significant Accounting Policies (Policies) 9 Months Ended Dec. 31, 2024 Accounting Policies [Abstract] Â Description of Business [Policy Text Block] Description of Business Â In this quarterly report on Form 10-Q, Mesa Laboratories, Inc., a Colorado corporation, together with its subsidiaries, is collectively referred to as â€œwe,â€ â€œus,â€ â€œour,â€ the â€œCompany,â€ or â€œMesa.â€ Â We are a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare,Â and medical device industries. We offer products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. We have manufacturing operations in the United States and Europe, and our products are marketed by our sales personnel in North America, EuropeÂ and Asia Pacific, and by independentÂ distributors in these areas and throughout the rest of the world. We prefer marketsÂ in which we can establish a strong presence and achieve high gross profit margins. Â As of December 31, 2024, we managed our operations in four reportable segments, or divisions: Â Â â—Sterilization and Disinfection Control - manufactures and sells biological, chemical and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes in the medical device, pharmaceutical, and healthcare industries. The division also provides testing and laboratory services, mainly to the dental and pharmaceutical industries.Â Â â— Clinical Genomics -Â develops, manufactures and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables and services that enable clinical research labs and contract research organizations to performÂ genomic testing for a broad range of research applications in several therapeutic areas, such as screenings for hereditary diseases, pharmacogenetics, oncology related applications, and toxicology research. Â â— Biopharmaceutical DevelopmentÂ - develops, manufactures, sells and services automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Immunoassays and peptide synthesis solutions accelerate the discovery, development, and manufactureÂ of biotherapeutic therapies, among other applications.Â Â â— Calibration SolutionsÂ - develops, manufactures,Â sells and services quality control products using principles of advanced metrology to enable customers toÂ measure and calibrate critical parameters in applications such as environmental and process monitoring, dialysis, gas flow, air quality and torque testing. Â Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Â The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance withÂ the rules and regulations of the Securities and Exchange Commission and in accordance with accounting principles generally accepted in the United States (â€œU.S. GAAPâ€) for interim financial information. In the opinion of management, such unaudited information includes all adjustments, consisting of normal recurring adjustments necessary for theÂ fair statement of our financial position and results of operations. The results of operations for interim periods are not necessarily indicative of results that may be achieved for the entire year.Â The year-end Condensed Consolidated Balance Sheet data was derived from audited financial statementsÂ but does not include all disclosures required by accounting principles generally accepted in the United States of America. The Condensed Consolidated Financial Statements include the accounts of Mesa and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.Â We made no material changes to the application of our significant accounting policies disclosed in our annual report on Form 10-K. This quarterly report should be read in conjunction with the consolidated financial statements included in our annual report on Form 10-K for the year endedÂ March 31, 2024. Â Our fiscal year ends on MarchÂ 31. References in this quarterly report to a particular â€œyearâ€ or â€œquarterâ€Â refer to our fiscal year or fiscal quarters, respectively. Â Reclassification, Comparability Adjustment [Policy Text Block] Prior Period Reclassifications Â For the nine months ended December 31, 2024, certain prior period amounts in our unaudited Condensed Consolidated Statements of Operations related to cash interest payments on acquisition holdback liabilities and non-cash debt issuance cost amortizationÂ have been reclassified out of "Other expense (income), net" and into "Interest expense and amortization of debt issuance costs."Â Additionally, prior period third-party costs related to the repurchase of a portion of our convertible senior notes have been reclassified out of "Other expense (income), net"Â and are reflected within the "(Gain) on extinguishment of convertible senior notes."Â These reclassifications have not resulted in any change to "Non-operating expense (income), net" nor in any material change to other amounts presented in our unaudited condensed consolidated financial statements for the three and nine months ended December 31, 2024. Â Risk and Uncertainties, Policy [Policy Text Block] Risks and Uncertainties Â The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the reporting date and revenues and expenses during the reporting periods. These estimates represent management's judgment about the outcome of future events. The global business environment continues to be impacted by cost pressures, the overall effects of economic uncertainty, and other factors. Changes in, and the resulting effects of, potential governmental stimulus or fiscal and monetary policies, interest rates, foreign currency values, supply chains, demand for goods and services, a global or regional recession, or other circumstances cannot be reliably predicted. Actual results could differ from our estimates. Â New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Pronouncements Â InÂ November 2023,Â the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU")Â No.Â 2023-07,Â "Segment ReportingÂ (TopicÂ 280): Improvements to Reportable Segment Disclosures." ASUÂ No.Â 2023-07Â requires all annual disclosures currently required by TopicÂ 280Â to be included in interim financial statements and requires disclosure of significant segment expenses regularly provided to the chief operating decision maker ("CODM"), a description of other segment items by reportable segment, and applicable additional measures of segment profit or loss used by the CODM when allocatingÂ resources and assessing business performance. The ASU is effective for fiscal years beginning after December 15, 2023 (our fiscal year 2025 for annual periods)Â and interim periods within fiscal years beginning after December 15, 2024 (our fiscal year 2026 for interim periods) on a retrospective basis. Other than presentation changes to our segment footnote, we do not expect the adoption of ASU No. 2023-07 to have a material impact on our consolidated financial statements. Â InÂ December 2023,Â the FASB issued ASUÂ No.Â 2023-09,Â "Income Taxes (TopicÂ 740): Improvements to Income Tax Disclosures." ASUÂ No.Â 2023-09,Â which enhances the transparency, effectiveness and comparability of income tax disclosures by requiring consistent categories and greater disaggregation of information related to income tax rate reconciliations and the jurisdictions in which income taxes are paid.Â The guidance is effective for public business entities for fiscal years beginning afterÂ December 15, 2024 (our fiscal yearÂ 2026), with early adoption and prospective or retrospective application permitted.Â Other than presentation of additional disaggregated data in our income tax footnote disclosures for annual periods, we do not expect the adoption of ASU No. 2023-09 to have a material impact on our consolidated financial statement. Â In November 2024, the Financial Accounting Board ("FASB" issued Accounting Standards Update ("ASU") No. 2024-03, "Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses." ASU No. 2024-03Â requiresÂ that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The ASU is effective for fiscal years beginning after December 15, 2026Â (our fiscal year 2028Â for annual periods)Â and interim periods within fiscal years beginning after December 15, 2027 (our fiscal year 2029 for interim periods), with early adoption and prospective or retrospective applicationÂ permitted. We are currently assessing the effect the adoption of this standard will have on our consolidated financial statement disclosures. Â We have reviewed all recently issued accounting pronouncements and have concluded that, other than as described above,Â they are eitherÂ notÂ applicable to us or areÂ notÂ expected to have a significant impact onÂ our consolidated financial statements.Â Â X - DefinitionRepresents significance related to the nature of business operations. + ReferencesNo definition available. + Details Name: mlab_DescriptionOfBusinessPolicyTextBlock Namespace Prefix: mlab_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for risk and uncertainties. + ReferencesNo definition available. + Details Name: mlab_RiskAndUncertaintiesPolicyPolicyTextBlock Namespace Prefix: mlab_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 205 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1 + Details Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 2 - Significant Transactions (Tables) 9 Months Ended Dec. 31, 2024 Notes Tables Â Schedule of Business Acquisitions, by Acquisition [Table Text Block] Â Â Three Months Ended Â Â Nine Months Ended Â Â Â December 31, 2024Â Revenues Â $6,854Â Â $18,971Â Gross profit Â Â 4,904Â Â Â 12,457Â Â Â Â Â Â Â Â Â Â Amortization of inventory step-up recorded in cost of revenues Â Â -Â Â Â 1,232Â Amortization of acquired intangibles recorded in cost of revenues Â Â 131Â Â Â 375Â Amortization of acquired intangibles recorded in general and administrative expense Â Â 935Â Â Â 2,423Â X - DefinitionTabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 3 - Revenue (Tables) 9 Months Ended Dec. 31, 2024 Notes Tables Â Disaggregation of Revenue [Table Text Block] Â Â Three Months Ended December 31, 2024 Â Â Â Sterilization and Disinfection Control (1) Â Â Clinical Genomics Â Â Biopharmaceutical Development Â Â Calibration Solutions Â Â Total Â Â Consumables Â $20,991Â Â $9,866Â Â $4,909Â Â $1,043Â Â $36,809Â Hardware and software Â Â 52Â Â Â 1,877Â Â Â 4,534Â Â Â 9,333Â Â Â 15,796Â Services Â Â 2,464Â Â Â 924Â Â Â 2,794Â Â Â 4,053Â Â Â 10,235Â Total revenues Â $23,507Â Â $12,667Â Â $12,237Â Â $14,429Â Â $62,840Â Â Â Three Months Ended December 31, 2023 Â Â Â Sterilization and Disinfection Control (1) Â Â Clinical Genomics Â Â Biopharmaceutical Development Â Â Calibration Solutions Â Â Total Â Â Consumables Â $16,832Â Â $9,758Â Â $4,080Â Â $539Â Â $31,209Â Hardware and software Â Â 180Â Â Â 1,639Â Â Â 2,672Â Â Â 8,254Â Â Â 12,745Â Services Â Â 2,326Â Â Â 1,149Â Â Â 2,678Â Â Â 3,366Â Â Â 9,519Â Total revenues Â $19,338Â Â $12,546Â Â $9,430Â Â $12,159Â Â $53,473Â Â Â Nine Months Ended December 31, 2024 Â Â Â Sterilization and Disinfection Control (1) Â Â Clinical Genomics Â Â Biopharmaceutical Development Â Â Calibration Solutions Â Â Total Â Â Consumables Â $60,860Â Â $26,156Â Â $12,657Â Â $2,067Â Â $101,740Â Hardware and software Â Â 365Â Â Â 6,511Â Â Â 14,539Â Â Â 24,067Â Â Â 45,482Â Services Â Â 7,444Â Â Â 2,903Â Â Â 8,916Â Â Â 12,358Â Â Â 31,621Â Total revenues Â $68,669Â Â $35,570Â Â $36,112Â Â $38,492Â Â $178,843Â Â Â Nine Months Ended December 31, 2023 Â Â Â Sterilization and Disinfection Control (1) Â Â Clinical Genomics Â Â Biopharmaceutical Development Â Â Calibration Solutions Â Â Total Â Â Consumables Â $45,288Â Â $28,490Â Â $12,753Â Â $1,834Â Â $88,365Â Hardware and software Â Â 381Â Â Â 9,540Â Â Â 7,838Â Â Â 22,216Â Â Â 39,975Â Services Â Â 6,676Â Â Â 3,434Â Â Â 7,935Â Â Â 10,898Â Â Â 28,943Â Total revenues Â $52,345Â Â $41,464Â Â $28,526Â Â $34,948Â Â $157,283Â Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Â Â Three Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â

United States Â $30,476Â Â $25,595Â Â $85,415Â Â $79,205Â China Â Â 6,322Â Â Â 4,942Â Â Â 20,271Â Â Â 18,584Â Other Â Â 26,042Â Â Â 22,936Â Â Â 73,157Â Â Â 59,494Â Total revenues Â $62,840Â Â $53,473Â Â $178,843Â Â $157,283Â Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Contract liabilities as of March 31, 2024 Â $15,686Â Prior year liabilities recognized in revenues during the nine months ended December 31, 2024 Â Â (9,069) Contract liabilities added during the nine months ended December 31, 2024, net of revenues recognized Â Â 8,083Â Contract liabilities as of December 31, 2024 Â $14,700Â X - DefinitionTabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details Name: us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details Name: us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 36 R25.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 4 - Fair Value Measurements (Tables) 9 Months Ended Dec. 31, 2024 Notes Tables Â Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Â Â December 31, 2024 Â Â March 31, 2024 Â Â Â Carrying Value Â Â Fair Value (Level 2) Â Â Carrying Value Â Â Fair Value (Level 2) Â Notes Â $97,163Â Â $94,819Â Â $171,198Â Â $163,013Â X - DefinitionTabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 37 R26.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 5 - Supplemental Information (Tables) 9 Months Ended Dec. 31, 2024 Notes Tables Â Schedule of Inventory, Current [Table Text Block] Â Â December 31, 2024 Â Â March 31, 2024 Â Raw materials Â $16,584Â Â $18,335Â Work in process Â Â 400Â Â Â 1,256Â Finished goods Â Â 11,138Â Â Â 13,084Â Total inventories Â $28,122Â Â $32,675Â Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Â Â December 31, 2024 Â Â March 31, 2024 Â Prepaid expenses Â $3,251Â Â $2,932Â Deposits Â Â 1,338Â Â Â 1,898Â Prepaid income taxes Â Â 5,682Â Â Â 1,237Â Other current assets Â Â 2,849Â Â Â 3,341Â Total prepaid expenses and other current assets Â $13,120Â Â $9,408Â Schedule of Employee Related Liabilities [Table Text Block] Â Â December 31, 2024 Â Â March 31, 2024 Â Bonus payable Â $7,803Â Â $3,838Â Wages and paid-time-off payable Â Â 3,600Â Â Â 3,072Â Payroll related taxes Â Â 1,954Â Â Â 1,956Â Other benefits payable Â Â 562Â Â Â 1,069Â Total accrued payroll and benefits Â $13,919Â Â $9,935Â Schedule of Accrued Liabilities [Table Text Block] Â Â December 31, 2024 Â Â March 31, 2024 Â Accrued business taxes Â $5,505Â Â $5,557Â Current operating lease liabilities Â Â 3,535Â Â Â 2,986Â Income taxes payable Â Â 1,364Â Â Â 1,615Â Current acquisition-related holdbacks Â Â 9,531Â Â Â 436Â Other Â Â 2,416Â Â Â 2,264Â Total other accrued expenses Â $22,351Â Â $12,858Â Other Noncurrent Liabilities [Table Text Block] Â Â December 31, 2024 Â Â March 31, 2024 Â Noncurrent operating lease liabilities Â $12,361Â Â $6,613Â Noncurrent acquisition-related holdbacks Â Â -Â Â Â 8,792Â Other Â Â 92Â Â Â 208Â Total other noncurrent liabilities Â $12,453Â Â $15,613Â Property, Plant and Equipment [Table Text Block] Â Â Three Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Depreciation expense in cost of revenues Â $610Â Â $788Â Â $2,376Â Â $2,117Â Depreciation expense in operating expense Â Â 496Â Â Â 286Â Â Â 1,652Â Â Â 782Â Total depreciation expense Â $1,106Â Â $1,074Â Â $4,028Â Â $2,899Â X - DefinitionThe tabular disclosure for employee related liabilities. + ReferencesNo definition available. + Details Name: mlab_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock Namespace Prefix: mlab_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs. + ReferencesNo definition available. + Details Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of other noncurrent liabilities. + ReferencesNo definition available. + Details Name: us-gaap_OtherNoncurrentLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1 + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 38 R27.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 6 - Goodwill and Intangible Assets, Net (Tables) 9 Months Ended Dec. 31, 2024 Notes Tables Â Schedule of Finite-Lived Intangible Assets [Table Text Block] Â Â December 31, 2024 Â Â March 31, 2024 Â Â Â Gross Carrying Amount Â Â Accumulated Amortization Â Â Net Carrying Amount Â Â Gross Carrying Amount Â Â Accumulated Amortization Â Â Net Carrying Amount Â Customer relationships Â $186,272Â Â $(112,475)Â $73,797Â Â $189,911Â Â $(104,528)Â $85,383Â Other intangibles Â Â 60,356Â Â Â (35,972)Â Â 24,384Â Â Â 61,161Â Â Â (32,792)Â Â 28,369Â Total finite-lived intangible assets Â $246,628Â Â $(148,447)Â $98,181Â Â $251,072Â Â $(137,320)Â $113,752Â Finite-Lived Intangible Assets Amortization Expense [Table Text Block] Â Â Three Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Amortization in cost of revenues Â $660Â Â $1,883Â Â $1,979Â Â $5,367Â Amortization in general and administrative Â Â 3,731Â Â Â 6,092Â Â Â 11,023Â Â Â 17,013Â Total amortization expense Â $4,391Â Â $7,975Â Â $13,002Â Â $22,380Â Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Fiscal Year Â Amortization ExpenseÂ Â Â Remainder of 2025 Â $4,278Â 2026 Â Â 16,566Â 2027 Â Â 15,921Â 2028 Â Â 15,349Â 2029 Â Â 14,815Â Schedule of Goodwill [Table Text Block] Â Â Sterilization and Disinfection Control Â Â Clinical Genomics Â Â Biopharmaceutical Development Â Â Calibration Solutions Â Â Total Â March 31, 2024 Â $79,430Â Â $16,940Â Â $46,515Â Â $37,211Â Â Â 180,096Â Effect of foreign currency translation Â Â (1,994)Â Â (71)Â Â (849)Â Â (30)Â Â (2,944) December 31, 2024 Â $77,436Â Â $16,869Â Â $45,666Â Â $37,181Â Â $177,152Â X - DefinitionTabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1AReference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2 + Details Name: us-gaap_ScheduleOfGoodwillTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 39 R28.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 7 - Indebtedness (Tables) 9 Months Ended Dec. 31, 2024 Notes Tables Â Schedule of Maturities of Long-Term Debt [Table Text Block] Fiscal Year Â Amount Â Remainder of 2025 Â $937Â 2026 Â Â 3,750Â 2027 Â Â 5,625Â 2028 Â Â 5,625Â 2029 Â Â 7,500Â Thereafter Â Â 48,750Â Total Principal Remaining Â $72,187Â Convertible Debt [Table Text Block] Â Â December 31, 2024 Â Â March 31, 2024 Â Principal outstanding Â $97,500Â Â $172,500Â Unamortized debt issuance costs Â Â (337)Â Â (1,302) Net carrying value Â $97,163Â Â $171,198Â Interest Expense on Convertible Debt [Table Text Block] Â Â Three Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Coupon interest expense at 1.375% Â $335Â Â $593Â Â $1,037Â Â $1,779Â Amortization of debt issuance costs Â Â 134Â Â Â 231Â Â Â 412Â Â Â 692Â Total interest and amortization of debt issuance costs Â $469Â Â $824Â Â $1,449Â Â $2,471Â Term Loan [Member] Â Notes Tables Â Convertible Debt [Table Text Block] Â Â December 31, 2024 Â Â March 31, 2024 Â Term Loan (7.5% as of December 31, 2024) Â $72,187Â Â $-Â Less: discount and debt issuance costs Â Â (634)Â Â -Â Less: current portion Â Â (3,750)Â Â -Â Noncurrent portion Â $67,803Â Â $-Â X - DefinitionTabular disclosure of interest expense on borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. + ReferencesNo definition available. + Details Name: mlab_InterestExpenseOnConvertibleDebtTableTextBlock Namespace Prefix: mlab_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount. + ReferencesNo definition available. + Details Name: us-gaap_ConvertibleDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of maturity and sinking fund requirement for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=mlab_TermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R29.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 8 - Stockholders' Equity (Tables) 9 Months Ended Dec. 31, 2024 Notes Tables Â Share-Based Payment Arrangement, Activity [Table Text Block] Â Â Time-Based Restricted Stock Units Â Â Performance-Based Restricted Stock Units Â Â Â Number of Shares Â Â Weighted- Average Grant Date Fair Value per Share Â Â Number of Shares Â Â Weighted- Average Grant Date Fair Value per Share Â Outstanding as of March 31, 2024 Â Â 76Â Â $157.83Â Â Â 56Â Â $240.96Â Awards granted(1)

Â Â 117Â Â Â 93.46Â Â Â 41Â Â Â 102.57Â Awards forfeited Â Â (7)Â Â 123.42Â Â Â - Â Â Â -Â Awards distributed Â Â (36)Â Â 169.40Â Â Â (12)Â Â 302.06Â Outstanding as of December 31, 2024 Â Â 150Â Â $106.44Â Â Â 85Â Â $165.75Â Share-Based Payment Arrangement, Option, Activity [Table Text Block] Â Â Stock Options Â Â Â Shares Subject to Options Â Â Weighted-Average Exercise Price per Share Â Â Weighted-Average Remaining Contractual Life (Years) Â Â Aggregate Intrinsic Value Â Outstanding as of March 31, 2024 Â Â 194Â Â $181.89Â Â Â 3.2Â Â $26Â Awards granted Â Â -Â Â Â -Â Â Â Â Â Â Â Â Â Awards forfeited or expired Â Â (15)Â Â 150.98Â Â Â Â Â Â Â Â Â Awards exercised Â Â (1)Â Â 131.67Â Â Â Â Â Â Â Â Â Outstanding as of December 31, 2024 Â Â 178Â Â $184.55Â Â Â 2.6Â Â $287Â X - DefinitionTabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 41 R30.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 9 - (Loss) Earnings Per Share (Tables) 9 Months Ended Dec. 31, 2024 Notes Tables Â Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Â Â Three Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net (loss) income available for shareholders Â $(1,676)Â $2,116Â Â $5,140Â $337Â Weighted average outstanding shares of common stock Â Â 5,429Â Â Â 5,393Â Â Â 5,413Â Â Â 5,384Â Dilutive effect of stock options Â Â -Â Â Â -Â Â Â -Â Â Â 1Â Dilutive effect of RSUs Â Â -Â Â Â 3Â Â Â 51Â Â Â 9Â Fully diluted shares Â Â 5,429Â Â Â 5,396Â Â Â 5,464Â Â Â 5,394Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Basic (loss) earnings per share Â $(0.31)Â $0.39Â Â $0.95Â Â $0.06Â Diluted (loss) earnings per share Â $(0.31)Â $0.39Â Â $0.94Â Â $0.06Â Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Â Â Three Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Assumed conversion of the Notes Â Â 344Â Â Â 608Â Â Â 354Â Â Â 608Â Stock awards that were anti-dilutive Â Â 406Â Â Â 277Â Â Â 202Â Â Â 223Â Total stock awards excluded from diluted EPS Â Â 750Â Â Â 885Â Â Â 556Â Â Â 831Â X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 42 R31.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 10 - Income Taxes (Tables) 9 Months Ended Dec. 31, 2024 Notes Tables Â Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Â Â Three Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Income tax (benefit) expense Â $(541)Â $(170)Â $360Â Â $(653) Effective tax rateÂ Â 24.4%Â Â (8.7%)Â Â 6.5%Â Â 206.6% X - DefinitionTabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9 + Details Name: us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 43 R32.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 12 - Segment Information (Tables) 9 Months Ended Dec. 31, 2024 Notes Tables Â Schedule of Segment Reporting Information, by Segment [Table Text Block] Â Â Three Months Ended December 31, Â Â Nine Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenues (a): Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Sterilization and Disinfection Control (b) Â $23,507Â Â $19,338Â Â $68,669Â Â $52,345Â Clinical Genomics Â Â 12,667Â Â Â 12,546Â Â Â 35,570Â Â Â 41,464Â Biopharmaceutical Development Â Â 12,237Â Â Â 9,430Â Â Â 36,112Â Â Â 28,526Â Calibration Solutions Â Â 14,429Â Â Â 12,159Â Â Â 38,492Â Â Â 34,948Â Total revenues Â $62,840Â Â $53,473Â Â $178,843Â Â $157,283Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Gross profit: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Sterilization and Disinfection Control (b) Â $16,461Â Â $13,951Â Â $47,191Â Â $38,018Â Clinical Genomics Â Â 6,948Â Â Â 6,449Â Â Â 19,344Â Â Â 20,904Â Biopharmaceutical Development Â Â 7,539Â Â Â 5,841Â Â Â 22,665Â Â Â 17,783Â Calibration Solutions Â Â 8,806Â Â Â 7,212Â Â Â 23,258Â Â Â 20,050Â Reportable segment gross profit Â Â 39,754Â Â Â 33,453Â Â Â 112,458Â Â Â 96,755Â Corporate and other (c) Â Â -Â Â Â (51)Â Â -Â Â Â (61) Gross profit Â $39,754Â Â $33,402Â Â $112,458Â Â $96,694Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Reconciling items: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Operating expense Â Â 33,975Â Â Â 33,469Â Â Â 97,591Â Â Â 97,485Â Operating income (loss) Â Â 5,779Â Â Â (67)Â Â 14,867Â Â Â (791) Non-operating expense (income), net Â Â 7,996Â Â Â (2,013)Â Â 9,367Â Â Â (475) (Loss) earnings before income taxes Â $(2,217)Â $1,946Â Â $5,500Â Â $(316) Schedule of Depreciation and Amortization Expense [Table Text Block] Â Â December 31, Â Â March 31, Â Â Â 2024 Â Â 2024 Â Sterilization and Disinfection Control Â $5,728Â Â $7,014Â Clinical Genomics Â Â 10,709Â Â Â 11,813Â Biopharmaceutical Development Â Â 5,853Â Â Â 6,304Â Calibration Solutions Â Â 5,832Â Â Â 7,544Â Total Inventories Â $28,122Â Â $32,675Â X - DefinitionTabular display of the depreciation and amortization recorded during the periods for reportable segments. + ReferencesNo definition available. + Details Name: mlab_ScheduleOfDepreciationAndAmortizationExpenseTableTextBlock Namespace Prefix: mlab_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 44 R33.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 2 - Significant Transactions (Details Textual) - GKE Acquisition [Member] $ in Thousands Oct. 16, 2023 USD ($) Payments to Acquire Businesses, Gross $ 87,187 Business Combination, Consideration Transferred, Liabilities Incurred 9,000 Proceeds from Lines of Credit $ 71,000 GKE GmbH and SAL GmbH [Member] Â Business Acquisition, Percentage of Voting Interests Acquired 100.00% Beijing GKE Science & Technology Co. Ltd. [Member] Â Business Acquisition, Percentage of Voting Interests Acquired 100.00% X - DefinitionPercentage of voting equity interests acquired at the acquisition date in the business combination. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of liabilities incurred by the acquirer as part of consideration transferred in a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-5Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7 + Details Name: us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireBusinessesGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=mlab_GkeAcquisitionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=mlab_GkeGmbhAndSalGmbhMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=mlab_BeijingGkeScienceTechnologyCoLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R34.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 2 - Significant Transactions - Schedule of Business Acquisitions (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Gross profit $ 39,754 $ 33,402 $ 112,458 $ 96,694 GKE Acquisition [Member] Â Â Â Â Revenues 6,854 Â 18,971 Â Gross profit 4,904 Â 12,457 Â GKE Acquisition [Member] | Inventory Step-up Related to Cost of Revenue [Member] Â Â Â Â Amortization of inventory step-up recorded in cost of revenues 0 Â 1,232 Â GKE Acquisition [Member] | Cost of Revenues Related to Intangibles Acquired [Member] Â Â Â Â Amortization of inventory step-up recorded in cost of revenues 131 Â 375 Â GKE Acquisition [Member] | General and Administrative Expense [Member] Â Â Â Â Amortization of inventory step-up recorded in cost of revenues $ 935 Â $ 2,423 Â X - DefinitionThe aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AdjustmentForAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=mlab_GkeAcquisitionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=mlab_InventoryStepupRelatedToCostOfRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=mlab_CostOfRevenuesRelatedToIntangiblesAcquiredMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R35.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 3 - Revenue (Details Textual) - USD ($) 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Revenue from Contract with Customer, Excluding Assessed Tax [1] $ 62,840,000 $ 53,473,000 $ 178,843,000 $ 157,283,000 Sterilization and Disinfection Control [Member] | GKE GmbH [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax $ 6,854,000 $ 3,837,000 $ 18,971,000 $ 3,837 [1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals. X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mlab_SterilizationAndDisinfectionControlMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mlab_GkeGmbhMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R36.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 3 - Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Revenue from Contract with Customer, Excluding Assessed Tax [1] $ 62,840 $ 53,473 $ 178,843 $ 157,283 Consumables [Member] | Transferred at Point in Time [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 36,809 31,209 101,740 88,365 Hardware and Software [Member] | Transferred at Point in Time [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 15,796 12,745 45,482 39,975 Service [Member] | Transferred at Point in Time [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 10,235 9,519 31,621 28,943 Operating Segments [Member] | Sterilization and Disinfection Control [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax [1],[2] 23,507 [3] 19,338 68,669 [4] 52,345 Operating Segments [Member] | Clinical Genomics [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax [1] 12,667 12,546 35,570 41,464 Operating Segments [Member] | Biopharmaceutical Development [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax [1] 12,237 9,430 36,112 28,526 Operating Segments [Member] | Calibration Solutions [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax [1] 14,429 12,159 38,492 34,948 Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 20,991 [3] 16,832 60,860 [4] 45,288 Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 9,866 9,758 26,156 28,490 Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 4,909 4,080 12,657 12,753 Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 1,043 539 2,067 1,834 Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 52 [3] 180 365 [4] 381 Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 1,877 1,639 6,511 9,540 Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 4,534 2,672 14,539 7,838 Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 9,333 8,254 24,067 22,216 Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 2,464 [3] 2,326 7,444 [4] 6,676 Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 924 1,149 2,903 3,434 Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 2,794 2,678 8,916 7,935 Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax $ 4,053 $ 3,366 $ 12,358 $ 10,898 [1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals. [2] Includes post-acquisition GKE results during the three and six months ended September 30, 2024. [3] Revenues of $5,863 from GKE are included in the Sterilization and Disinfection Control division during the three months ended September 30, 2024. [4] Revenues of $12,117 from GKE are included in the Sterilization and Disinfection Control division during the six months ended September 30, 2024. X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards

Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=mlab_ConsumablesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mlab_HardwareAndSoftwareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ServiceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mlab_SterilizationAndDisinfectionControlMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mlab_ClinicalGenomicsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mlab_BiopharmaceuticalDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mlab_CalibrationSolutionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R37.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 3 - Revenue - Revenues From External Customers (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Revenue from Contract with Customer, Excluding Assessed Tax [1] $ 62,840 $ 53,473 $ 178,843 $ 157,283 UNITED STATES Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 30,476 25,595 85,415 79,205 CHINA Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 6,322 4,942 20,271 18,584 Other [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax $ 26,042 $ 22,936 $ 73,157 $ 59,494 [1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals. X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_CN Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=mlab_OtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R38.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 3 - Revenue - Contract Liabilities (Details) $ in Thousands 9 Months Ended Dec. 31, 2024 USD ($) Contract liabilities, balance $ 15,686 Prior year liabilities recognized in revenues during the nine months ended December 31, 2024 (9,069) Contract liabilities added during the nine months ended December 31, 2024, net of revenues recognized 8,083 Contract liabilities, balance $ 14,700 X - DefinitionAmount of revenue recognized arising from contract liabilities added during the period in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + ReferencesNo definition available. + Details Name: mlab_ContractWithCustomerLiabilityIncreaseDuringPeriodNetOfRevenueRecognized Namespace Prefix: mlab_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 50 R39.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 4 - Fair Value Measurements (Details Textual) $ in Thousands 3 Months Ended Dec. 31, 2024 USD ($) Apr. 05, 2024 USD ($) Mar. 31, 2024 USD ($) Nov. 17, 2022 USD ($) Aug. 12, 2019 GKE Acquisition [Member] Â Â Â Â Â Business Combination, Hold Back Consideration Liability $ 9,000 Â Â Â Â Business Combination, Hold Back Consideration Liability, Fair Value 8,900 Â Â Â Â GKE Acquisition [Member] | Fair Value, Inputs, Level 3 [Member] Â Â Â Â Â Business Combination, Hold Back Consideration Liability, Fair Value 8,900 Â Â Â Â Belyntic Acquisition [Member] Â Â Â Â Â Business Combination, Contingent Consideration, Liability Fair Value 675 Â Â Â Â Belyntic Acquisition [Member] | Other Long-term Liabilities [Member] Â Â Â Â Â Business Combination Contingent Consideration Liability, At Acquisition Date Â Â Â $ 1,500 Â Belyntic Acquisition [Member] | Fair Value, Inputs, Level 3 [Member] Â Â Â Â Â Business Combination, Contingent Consideration, Liability Fair Value 675 Â Â Â Â Outstanding 2025 Notes [Member] Â Â Â Â Â Debt Instrument, Repurchase Amount Â $ 75,000 Â Â Â Principal Outstanding 97,500 Â Â Â Â Senior Notes [Member] | The Notes [Member] Â Â Â Â Â Debt Instrument, Interest Rate, Stated Percentage Â 1.375% Â 1.375% Principal Outstanding $ 97,500 Â $ 172,500 Â Accounts Receivable [Member] | Customer Concentration Risk [Member] Â Â Â Â Â Number of Major Customers 0 Â Â Â Â X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination, at the date of acquisition. + ReferencesNo definition available. + Details Name: mlab_BusinessCombinationContingentConsiderationLiabilityAtAcquisitionDate Namespace Prefix: mlab_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value of the amount of liability recognized arising from contingent consideration in a business combination. + ReferencesNo definition available. + Details Name: mlab_BusinessCombinationContingentConsiderationLiabilityFairValue Namespace Prefix: mlab_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents the fair value of hold back consideration liability from a business combination. + ReferencesNo definition available. + Details Name: mlab_BusinessCombinationHoldBackConsiderationLiabilityFairValue Namespace Prefix: mlab_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of hold back liability recognized arising from a business combination. + ReferencesNo definition available. + Details Name: mlab_BusinessCombinationHoldBackConsiderationliability Namespace Prefix: mlab_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc. + ReferencesNo definition available. + Details Name: mlab_NumberOfMajorCustomers Namespace Prefix: mlab_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionFair value amount of debt instrument that was repurchased. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentRepurchaseAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_BusinessAcquisitionAxis=mlab_GkeAcquisitionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=mlab_BelynticAcquisitionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=mlab_OtherLongtermLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mlab_Outstanding2025NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mlab_TheNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R40.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 4 - Fair Value Measurements - Fair Value and Carrying Value of the Notes (Details) - Senior Notes [Member] - USD ($) $ in Thousands Dec. 31, 2024 Mar. 31, 2024 Reported Value Measurement [Member] Â Â Notes $ 97,163 $ 171,198 Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member] Â Â Notes $ 94,819 $ 163,013 X - DefinitionFair value portion of notes payable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_NotesPayableFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R41.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 5 - Supplemental Information (Details Textual) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Depreciation $ 1,106 $ 1,074 $ 4,028 $ 2,899 GKE Acquisition [Member] Â Â Â Â Depreciation $ 225 Â $ 850 Â X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=mlab_GkeAcquisitionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R42.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 5 - Supplemental Information - Inventories (Details) - USD ($) $ in Thousands Dec. 31, 2024 Mar. 31, 2024 Raw materials $ 16,584 $ 18,335 Work in process 400 1,256 Finished goods 11,138 13,084 Total inventories $ 28,122 $ 32,675 X - DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoods Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterials Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryWorkInProcess Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 54 R43.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 5 - Supplemental Information - Prepaid and Other Current Assets (Details) - USD ($) $ in Thousands Dec. 31, 2024 Mar. 31, 2024 Prepaid expenses $ 3,251 $ 2,932 Deposits 1,338 1,898 Prepaid income taxes 5,682 1,237 Other current assets 2,849 3,341 Total prepaid expenses and other current assets $ 13,120 $ 9,408 X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: mlab_PrepaidExpensesCurrent Namespace Prefix: mlab_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DepositsAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5 + Details Name: us-gaap_PrepaidTaxes Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 55 R44.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 5 - Supplemental Information - Accrued Payroll and Benefits (Details) - USD ($) $ in Thousands Dec. 31, 2024 Mar. 31, 2024 Bonus payable $ 7,803 $ 3,838 Wages and paid-time-off payable 3,600 3,072 Payroll related taxes 1,954 1,956 Other benefits payable 562 1,069 Total accrued payroll and benefits $ 13,919 $ 9,935 X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedBonusesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedPayrollTaxesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8 + Details Name: us-gaap_AccruedSalariesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligations incurred for employer-related costs classified as other, payable within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherEmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 56 R45.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 5 - Supplemental Information - Other Accrued Expenses (Details) - USD ($) $ in Thousands Dec. 31, 2024 Mar. 31, 2024 Current operating lease liabilities $ 3,535 $ 2,986 Income taxes payable 1,364 1,615 Current acquisition-related holdbacks 9,531 436 Other 2,416 2,264 Total other accrued expenses 22,351 12,858 Other Accrued Expenses [Member] Â Â Accrued business taxes $ 5,505 $ 5,557 X - DefinitionThe value of the current portion of accrued business taxes. + ReferencesNo definition available. + Details Name: mlab_AccruedBusinessTaxes Namespace Prefix: mlab_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe current acquisition-related holdbacks. + ReferencesNo definition available. + Details Name: mlab_AcquisitionrelatedHoldbacksCurrent Namespace Prefix: mlab_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_TaxesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_BalanceSheetLocationAxis=mlab_OtherAccruedExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R46.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 5 - Supplemental Information - Other Noncurrent Liabilities (Details) - USD ($) $ in Thousands Dec. 31, 2024 Mar. 31, 2024 Other $ 12,453 $ 15,613 GKE Acquisition [Member] Â Â Noncurrent operating lease liabilities 12,361 6,613 Noncurrent acquisition-related holdbacks 0 8,792 Other 92 208 Total other noncurrent liabilities $ 12,453 $ 15,613 X - DefinitionThe noncurrent acquisition-related holdbacks. + ReferencesNo definition available. + Details Name: mlab_AcquisitionrelatedHoldbacksNoncurrent Namespace Prefix: mlab_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1:

http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_BusinessAcquisitionAxis=mlab_GkeAcquisitionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R47.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 5 - Supplemental Information - Property, Plant and Equipment (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Depreciation, Total $ 1,106 $ 1,074 $ 4,028 $ 2,899 Cost of Sales [Member] Â Â Â Â Depreciation, Total 610 788 2,376 2,117 Operating Expense [Member] Â Â Â Â Depreciation, Total $ 496 $ 286 $ 1,652 $ 782 X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R48.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 6 - Goodwill and Intangible Assets, Net - Other Intangible Assets (Details) - USD ($) $ in Thousands Dec. 31, 2024 Mar. 31, 2024 Gross carrying amount $ 246,628 $ 251,072 Accumulated amortization (148,447) (137,320) Net carrying amount 98,181 113,752 Customer Relationships [Member] Â Â Gross carrying amount 186,272 189,911 Accumulated amortization (112,475) (104,528) Net carrying amount 73,797 85,383 Other Intangible Assets [Member] Â Â Gross carrying amount 60,356 61,161 Accumulated amortization (35,972) (32,792) Net carrying amount $ 24,384 $ 28,369 X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R49.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 6 - Goodwill and Intangible Assets, Net - Amortization Expense for Finite-lived Intangible Assets (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Amortization of acquisition-related intangibles $ 4,391 $ 7,975 $ 13,002 $ 22,380 Cost of Sales [Member] Â Â Â Â Amortization of acquisition-related intangibles 660 1,883 1,979 5,367 General and Administrative Expense [Member] Â Â Â Â Amortization of acquisition-related intangibles $ 3,731 $ 6,092 $ 11,023 $ 17,013 X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R50.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 6 - Goodwill and Intangible Assets, Net - Estimated Amortization Expense (Details) $ in Thousands Dec. 31, 2024 USD ($) Remainder of 2025 $ 4,278 2026 16,566 2027 15,921 2028 15,349 2029 $ 14,815 X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 62 R51.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 6 - Goodwill and Intangible Assets, Net - Change in the Carrying Amount of Goodwill (Details) $ in Thousands 9 Months Ended Dec. 31, 2024 USD ($) Goodwill $ 180,096 Effect of foreign currency translation (2,944) Goodwill 177,152 Operating Segments [Member] | Sterilization and Disinfection Control [Member] Â Goodwill 79,430 Effect of foreign currency translation (1,994) Goodwill 77,436 Operating Segments [Member] | Clinical Genomics [Member] Â Goodwill 16,940 Effect of foreign currency translation (71) Goodwill 16,869 Operating Segments [Member] | Biopharmaceutical Development [Member] Â Goodwill 46,515 Effect of foreign currency translation (849) Goodwill 45,666 Operating Segments [Member] | Calibration Solutions [Member] Â Goodwill 37,211 Effect of foreign currency translation (30) Goodwill $ 37,181 X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillForeignCurrencyTranslationGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mlab_SterilizationAndDisinfectionControlMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mlab_ClinicalGenomicsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mlab_BiopharmaceuticalDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mlab_CalibrationSolutionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R52.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 7 - Indebtedness (Details Textual) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Jan. 01, 2025 USD ($) Apr. 05, 2024 USD ($) Mar. 05, 2021 USD ($) Aug. 12, 2019 USD ($) $ / shares Dec. 31, 2024 USD ($) Sep. 30, 2024 Dec. 31, 2023 USD ($) Dec. 31, 2024 USD ($) Dec. 31, 2023 USD ($) Mar. 31, 2024 USD ($) Oct. 05, 2023 USD ($) Long-Term Debt Â Â Â Â $ 72,187 Â Â $ 72,187 Â Â Â Repayments of Debt Â Â Â Â Â Â Â 26,313 $ 22,000 Â Â Gain (Loss) on Extinguishment of Debt Â Â Â Â (0) Â $ (0) 2,887 $ (0) Â Â The Credit Facility Term Loan [Member] Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Fee Amount Â Â Â Â 1,987 Â Â 1,987 Â Â Â Senior Secured Credit Agreement [Member] Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Term (Year) Â Â 4 years Â Â Â Â Â Â Â Â Long-Term Debt Â Â Â Â 27,000 Â Â 27,000 Â Â Â Line of Credit Facility, Remaining Borrowing Capacity Â Â Â Â 98,000 Â Â 98,000 Â Â Â Senior Secured Credit Agreement [Member] | Prepaid Expenses, Other and Other Assets [Member] Â Â Â Â Â Â Â Â Â Â Â Debt Issuance Costs, Net Â Â Â Â 1,278 Â Â 1,278 Â $ 321 Â Senior Secured Credit Agreement [Member] | Subsequent Event [Member] Â Â Â Â Â Â Â Â Â Â Â Repayments of Lines of Credit $ 4,500 Â Â Â Â Â Â Â Â Â Â Senior Secured Credit Agreement [Member] | The Credit Facility Term Loan [Member] Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Fee Amount Â Â Â Â $ 745 Â Â 745 Â Â Â Senior Secured Credit Agreement [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Basis Spread on Variable Rate Â Â Â Â 3.50% Â Â Â Â Â Line of

Credit Facility, Unused Capacity, Commitment Fee Percentage Â Â Â Â Â 0.35% Â Â Â Â Â Senior Secured Credit Agreement [Member] | Maximum [Member] | The Credit Facility Term Loan [Member] Â Â Â Â Â Â Â Â Â Â Â Line of Credit Facility, Maximum Borrowing Capacity Â Â $ 75,000 Â Â Â Â Â Â Â $ 125,000 Senior Secured Credit Agreement [Member] | Minimum [Member] Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Basis Spread on Variable Rate Â Â Â Â 1.50% Â Â Â Â Â Â Fixed Charge Coverage Ratio Â 1.25 Â Â Â Â Â Â Â Â Â Â Senior Leverage Ratio Â 3.5 Â Â Â Â Â Â Â Â Â Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Â Â Â Â Â 0.20% Â Â Â Â Â Senior Secured Credit Agreement [Member] | Minimum [Member] | The Credit Facility Term Loan [Member] Â Â Â Â Â Â Â Â Â Â Line of Credit Facility, Maximum Borrowing Capacity Â Â 25,000 Â Â Â Â Â Â Â Senior Secured Credit Agreement [Member] | Swingline Loan [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Â Â Line of Credit Facility, Maximum Borrowing Capacity Â Â 5,000 Â Â Â Â Â Â Â Â Senior Secured Credit Agreement [Member] | Revolving Credit Facility [Member] Â Â Â Â Â Â Â Â Â Â Line of Credit Facility, Maximum Borrowing Capacity Â Â 75,000 Â Â Â Â Â Â Â Â Debt Instrument, Fee Amount Â Â Â Â $ 1,242 Â Â $ 1,242 Â Â Â Senior Secured Credit Agreement [Member] | Letter of Credit [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Â Â Â Line of Credit Facility, Maximum Borrowing Capacity Â Â $ 2,500 Â Â Â Â Â Â Â Â The Credit Facility Term Loan [Member] Â Â Â Â Â Â Â Â Â Â Debt Instrument, Interest Rate, Effective Percentage Â Â Â Â 7.50% Â Â 7.50% Â Â Â Debt Instrument, Covenant, Maximum Total Leverage Ratio for the First Five Testing Dates Â 4.5 Â Â Â Â Â Â Â Â Â Debt Instrument, Covenant, Maximum Total Leverage Ratio for the Sixth, Seventh, and Eighth Testing Dates Â 4 Â Â Â Â Â Â Â Â Â Debt Instrument, Covenant, Maximum Total Leverage Ratio Following the Ninth Testing date Â 3.5 Â Â Â Â Â Â Â Â Â Term Loan [Member] Â Â Â Â Â Â Â Â Â Â Principal Outstanding Â $ 75,000 Â Â $ 72,187 Â Â $ 72,187 Â 0 Â Debt Instrument, Periodic Payment, Principal Â Â Â Â $ 938 Â Â $ 2,813 Â Â Â The Notes [Member] | Senior Notes [Member] Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Interest Rate, Effective Percentage Â Â Â Â 1.90% Â Â 1.90% Â Â Â Principal Outstanding Â Â Â Â $ 97,500 Â Â $ 97,500 Â 172,500 Â Long-Term Debt Â Â Â Â 97,163 Â Â 97,163 Â 171,198 Â Debt Issuance Costs, Net Â Â Â Â 337 Â Â 337 Â $ 1,302 Â Debt Instrument, Face Amount Â Â Â $ 172,500 Â Â Â Â Â Â Â Proceeds from Convertible Debt Â Â Â $ 167,056 Â Â Â Â Â Â Â Debt Instrument, Interest Rate, Stated Percentage Â 1.375% Â 1.375% Â Â Â Â Â Â Â Debt Instrument, Convertible, Conversion Ratio Per 1,000 Principal Â Â Â 3.5273 Â Â Â Â Â Â Â Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares Â Â Â $ 283.5 Â Â Â Â Â Â Â Outstanding 2025 Notes [Member] Â Â Â Â Â Â Â Â Â Â Â Principal Outstanding Â Â Â Â $ 97,500 Â Â 97,500 Â Â Â Debt Instrument, Repurchased Face Amount Â $ 75,000 Â Â Â Â Â Â Â Â Â Repayments of Debt Â 71,250 Â Â Â Â Â Â Â Â Â Interest Payable Â $ 160 Â Â Â Â Â Â Â Â Â Gain (Loss) on Extinguishment of Debt Â Â Â Â Â Â Â $ 2,887 Â Â Â X - DefinitionRatio applied to the conversion of debt instrument into equity with equity shares divided by $1,000 debt principal amount. + ReferencesNo definition available. + Details Name: mlab_DebtInstrumentConvertibleConversionRatioPer1000Principal Namespace Prefix: mlab_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionRequirement for maximum total leverage ratio under the debt agreement following the nine testing date. + ReferencesNo definition available. + Details Name: mlab_DebtInstrumentCovenantMaximumTotalLeverageRatioFollowingTheNinthTestingDate Namespace Prefix: mlab_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionRequirement for maximum total leverage ratio under the debt agreement for the first five testing dates. + ReferencesNo definition available. + Details Name: mlab_DebtInstrumentCovenantMaximumTotalLeverageRatioForTheFirstFiveTestingDates Namespace Prefix: mlab_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionRequirement for maximum total leverage ratio under the debt agreement for the sixth, seventh, and eighth testing dates. + ReferencesNo definition available. + Details Name: mlab_DebtInstrumentCovenantMaximumTotalLeverageRatioForTheSixthSeventhAndEighthTestingDates Namespace Prefix: mlab_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionActual fixed charge coverage ratio under the debt agreement. + ReferencesNo definition available. + Details Name: mlab_FixedChargeCoverageRatio Namespace Prefix: mlab_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionRepresents the senior leverage ratio. + ReferencesNo definition available. + Details Name: mlab_SeniorLeverageRatio Namespace Prefix: mlab_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5 + Details Name: us-gaap_DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of the fee that accompanies borrowing money under the debt instrument. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentFeeAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of the required periodic payments applied to principal. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentPeriodicPaymentPrincipal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFace (par) amount of the original debt instrument that was repurchased. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentRepurchasedFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPeriod of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DeferredFinanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest payable on debt, including, but not limited to, trade payables. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_InterestPayableCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility. + ReferencesNo definition available. + Details Name: us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:

debit Period Type: duration X - DefinitionAmount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_RepaymentsOfLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_LongtermDebtTypeAxis=mlab_TheCreditFacilityTermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mlab_SeniorSecuredCreditAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=mlab_PrepaidExpensesOtherAndOtherAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShortTermDebtTypeAxis=mlab_SwinglineLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mlab_TheCreditFacilityTermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mlab_TermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mlab_TheNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mlab_Outstanding2025NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R53.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 7 - Indebtedness - Quarterly Periodic Payments (Details) $ in Thousands Dec. 31, 2024 USD ($) Remainder of 2025 $ 937 2026 3,750 2027 5,625 2028 5,625 2029 7,500 Thereafter 48,750 Total Principal Remaining $ 72,187 X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: mlab_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour Namespace Prefix: mlab_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 65 R54.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 7 - Indebtedness - Carrying Amount of the Term Loan (Details) - USD ($) $ in Thousands Dec. 31, 2024 Apr. 05, 2024 Mar. 31, 2024 Less: current portion $ (3,750) Â $ 0 Noncurrent portion 67,803 Â 0 Term Loan [Member] Â Â Â Principal Outstanding 72,187 $ 75,000 0 Less: discount and debt issuance costs (634) Â 0 Less: current portion (3,750) Â 0 Noncurrent portion $ 67,803 Â $ 0 X - DefinitionThe discounts and issuance costs related to the secured debt. + ReferencesNo definition available. + Details Name: mlab_SecuredDebtDiscountAndIssuanceCosts Namespace Prefix: mlab_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_SecuredDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_SecuredLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=mlab_TermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R55.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 7 - Indebtedness - Carrying Amount of the Term Loan (Details) (Parentheticals) 9 Months Ended Dec. 31, 2024 Term Loan [Member] Â Current interest rate 7.50% X - DefinitionThe average effective interest rate during the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentInterestRateDuringPeriod Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=mlab_TermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R56.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 7 - Indebtedness - Carrying Amount of the Notes (Details) - USD ($) $ in Thousands Dec. 31, 2024 Mar. 31, 2024 Total Principal Remaining $ 72,187 Â The Notes [Member] | Senior Notes [Member] Â Â Principal Outstanding 97,500 $ 172,500 Unamortized debt issuance costs (337) (1,302) Total Principal Remaining $ 97,163 $ 171,198 X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DeferredFinanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name

Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=mlab_TheNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R57.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 7 - Indebtedness - Interest Expense on the Notes (Details) - The Notes [Member] - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Coupon interest expense at 1.375% $ 335 $ 593 $ 1,037 $ 1,779 Amortization of debt issuance costs 134 231 412 692 Total interest and amortization of debt issuance costs $ 469 $ 824 $ 1,449 $ 2,471 X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F + Details Name: us-gaap_InterestExpenseDebtExcludingAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=mlab_TheNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R58.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 8 - Stockholders' Equity (Details Textual) - $ / shares shares in Thousands 9 Months Ended Dec. 31, 2024 Jun. 30, 2024 Restricted Stock Units (RSUs) [Member] | Non-employee Directors [Member] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) 1 year Â The FY25 PSUs [Member] | Eligible Employees [Member] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) 41 Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized for Service and Company Financial Performance Conditions (in shares) 23 Â Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value, Shares Subject to Service and Company Performance (in dollars per share) $ 89.82 Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized, Subject to Service and Market Conditions (in shares) 18 Â Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value, Subject to Service and Market Conditions (in dollars per share) $ 119.54 Â The FY25 PSUs [Member] | Eligible Employees [Member] | Minimum [Member] Â Â Share-based Compensation Arrangement by Share-based Payment Award Number of Shares Issued Upon Vesting, Percentage 0.00% Â The FY25 PSUs [Member] | Eligible Employees [Member] | Maximum [Member] Â Â Share-based Compensation Arrangement by Share-based Payment Award Number of Shares Issued Upon Vesting, Percentage 200.00% Â The 2021 Equity Plan [Member] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) Â 660 X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan), for shares subject to service and company financial performance. + ReferencesNo definition available. + Details Name: mlab_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValueSharesSubjectToServiceAndC Namespace Prefix: mlab_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan), subjected to service and market conditions. + ReferencesNo definition available. + Details Name: mlab_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValueSubjectToServiceAndMarketC Namespace Prefix: mlab_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement for service and company financial performance conditions. + ReferencesNo definition available. + Details Name: mlab_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAuthorizedForServiceAndCompanyFinancialPerformanceConditions Namespace Prefix: mlab_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement subjected to service and market conditions. + ReferencesNo definition available. + Details Name: mlab_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAuthorizedSubjectToServiceAndMarketConditions Namespace Prefix: mlab_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe percentage of shares will be issued upon vesting. + ReferencesNo definition available. + Details Name: mlab_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesIssuedUponVestingPercentage Namespace Prefix: mlab_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=mlab_NonemployeeDirectorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=mlab_TheFy25PsusMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=mlab_EligibleEmployeesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=mlab_The2021EquityPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R59.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 8 - Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details) 9 Months Ended Dec. 31, 2024 $ / shares shares Restricted Stock Units (RSUs) [Member] Â Awards Outstanding (in shares) | shares 76 Awards Outstanding, weighted average grant date fair value per share (in dollars per share) | $ / shares $ 157.83 Awards granted(1) (in shares) | shares 117 [1] Awards granted, weighted average grant date fair value per share (1) (in dollars per share) | $ / shares $ 93.46 [1] Awards forfeited (in shares) | shares (7) Awards forfeited, weighted average grant date fair value per share (in dollars per share) | $ / shares $ 123.42 Awards distributed (in shares) | shares (36) Awards distributed, weighted average grant date fair value per share (in dollars per share) | $ / shares $ 169.4 Awards Outstanding (in shares) | shares 150 Awards Outstanding, weighted average grant date fair value per share (in dollars per share) | $ / shares $ 106.44 Performance Stock Units [Member] Â Awards Outstanding (in shares) | shares 56 Awards Outstanding, weighted average grant date fair value per share (in dollars per share) | $ / shares $ 240.96 Awards granted(1) (in shares) | shares 41 [1] Awards granted, weighted average grant date fair value per share (1) (in dollars per share) | $ / shares $ 102.57 [1] Awards forfeited (in shares) | shares Awards forfeited, weighted average grant date fair value per share (in dollars per share) | $ / shares $ 0 Awards distributed (in shares) | shares (12) Awards distributed, weighted average grant date fair value per share (in dollars per share) | $ / shares $ 302.06 Awards Outstanding (in shares) | shares 85 Awards Outstanding, weighted average grant date fair value per share (in dollars per share) | $ / shares $ 165.75 [1] Balances for PSUs granted are reflected at target. X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix:

Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=mlab_PerformanceStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R60.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 8 - Stockholders' Equity - Schedule of Stock Option Award Activity (Details) $ / shares in Units, shares in Thousands, $ in Thousands 9 Months Ended 12 Months Ended Dec. 31, 2024 USD ($) $ / shares shares Mar. 31, 2024 USD ($) $ / shares shares Options outstanding (in shares) | shares 194 Â Options outstanding, weighted average exercise price (in dollars per share) | $ / shares $ 181.89 Â Outstanding, Weighted- Average Remaining Contractual Life (Year) 2 years 7 months 6 days 3 years 2 months 12 days Outstanding, Aggregate Intrinsic Value | $ $ 287 $ 26 Options granted (in shares) | shares 0 Â Awards granted, weighted average exercise price (in dollars per share) | $ / shares $ 0 Â Options forfeited or expired (in shares) | shares (15) Â Awards forfeited or expired, weighted average exercise price (in dollars per share) | $ / shares $ 150.98 Â Awards exercised (in shares) | shares (1) Â Awards exercised, weighted average exercise price (in dollars per share) | $ / shares $ 131.67 Â Options outstanding (in shares) | shares 178 194 Options outstanding, weighted average exercise price (in dollars per share) | $ / shares $ 184.55 $ 181.89 X - DefinitionFor presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price of options that were either forfeited or expired. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 72 R61.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 9 - Earnings (Loss) Per Share - Computation of Net Income Per Share, Basic & Diluted (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Net income $ (1,676) $ 2,116 $ 5,140 $ 337 Weighted average outstanding shares of common stock (in shares) 5,429 5,393 5,413 5,384 Fully diluted shares (in shares) 5,429 5,396 5,464 5,394 Basic (in dollars per share) $ (0.31) $ 0.39 $ 0.95 $ 0.06 Diluted (in dollars per share) $ (0.31) $ 0.39 $ 0.94 $ 0.06 Share-Based Payment Arrangement, Option [Member] Â Â Â Â Dilutive effect of shares (in shares) 0 0 0 1 Restricted Stock Units (RSUs) [Member] Â Â Â Â Dilutive effect of shares (in shares) 0 3 51 9 X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of additional shares included in diluted EPS for potentially dilutive effect of nonvested equity-based payment award containing forfeitable rights to dividends or dividend equivalents, whether paid or unpaid. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -

Paragraph 68B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-68B + Details Name: us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R62.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 9 - Earnings (Loss) Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares shares in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Total stock awards excluded from diluted EPS (in shares) 750 885 556 831 Assumed Conversion of Convertible Debt [Member] Â Â Â Â Total stock awards excluded from diluted EPS (in shares) 344 608 354 608 Stock Awards that were Antidilutive [Member] Â Â Â Â Total stock awards excluded from diluted EPS (in shares) 406 277 202 223 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mlab_AssumedConversionOfConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mlab_StockAwardsThatWereAntidilutiveMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 74 R63.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 10 - Income Taxes (Details Textual) 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2024 Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 21.00% 21.00% X - DefinitionPercentage of domestic federal statutory tax rate applicable to pretax income (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.1.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration XML 75 R64.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 10 - Income Taxes - Provisions for Income Taxes (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Income tax (benefit) expense $ (541) $ (170) $ 360 $ (653) Effective tax rate 24.40% (8.70%) 6.50% 206.60% X - DefinitionPercentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 76 R65.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 11 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands Jan. 02, 2025 Dec. 31, 2024 GKE Acquisition [Member] Â Business Combination, Hold Back Consideration Liability Â $ 9,000 Business Combination, Hold Back Consideration Liability, Fair Value Â 8,900 Belyntic Acquisition [Member] Â Â Business Combination, Contingent Consideration, Liability Fair Value Â $ 675 Belyntic Acquisition [Member] | Subsequent Event [Member] Â Â Business Combination, Contingent Consideration, Liability, Current $ 563 Â X - DefinitionFair value of the amount of liability recognized arising from contingent consideration in a business combination. + ReferencesNo definition available. + Details Name: mlab_BusinessCombinationContingentConsiderationLiabilityFairValue Namespace Prefix: mlab_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents the fair value of hold back consideration liability from a business combination. + ReferencesNo definition available. + Details Name: mlab_BusinessCombinationHoldBackConsiderationLiabilityFairValue Namespace Prefix: mlab_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of hold back liability recognized arising from a business combination. + ReferencesNo definition available. + Details Name: mlab_BusinessCombinationHoldBackConsiderationliability Namespace Prefix: mlab_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_BusinessAcquisitionAxis=mlab_GkeAcquisitionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=mlab_BelynticAcquisitionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 77 R66.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 12 - Segment Information - Operating Segment Information (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Revenue from Contract with Customer, Excluding Assessed Tax [1] $ 62,840 $ 53,473 $ 178,843 $ 157,283 Gross profit 39,754 33,402 112,458 96,694 Operating expense 33,975 33,469 97,591 97,485 Operating income (loss) 5,779 (67) 14,867 (791) Non-operating expense (income), net (7,996) 2,013 (9,367) 475 Operating Segments [Member] Â Â Â Â Gross profit 39,754 33,453 112,458 96,755 Operating expense 33,975 33,469 97,591 97,485 Operating income (loss) 5,779 (67) 14,867 (791) Non-operating expense (income), net 7,996 (2,013) 9,367 (475) (Loss) earnings before income taxes (2,217) 1,946 5,500 (316) Operating Segments [Member] | Sterilization and Disinfection Control [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax [1],[2] 23,507 [3] 19,338 68,669 [4] 52,345 Gross profit [2] 16,461 13,951 47,191 38,018 Operating Segments [Member] | Clinical Genomics [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax [1] 12,667 12,546 35,570 41,464 Gross profit 6,948 6,449 19,344 20,904 Operating Segments [Member] | Biopharmaceutical Development [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax [1] 12,237 9,430 36,112 28,526 Gross profit 7,539 5,841 22,665 17,783 Operating Segments [Member] | Calibration Solutions [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax [1] 14,429 12,159 38,492 34,948 Gross profit 8,806 7,212 23,258 20,050 Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Â Â Â Â Gross profit [5] $ 0 $ (51) $ 0 $ (61) [1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals. [2] Includes post-acquisition GKE results during the three and six months ended September 30, 2024. [3] Revenues of $5,863 from GKE are included in the Sterilization and Disinfection Control division during the three months ended September 30, 2024. [4] Revenues of $12,117 from GKE are included in the Sterilization and Disinfection Control division during the six months ended September 30, 2024. [5] Unallocated corporate expenses are reported within corporate and other. X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting

Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from continuing operations attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-18 + Details Name: us-gaap_IncomeLossFromContinuingOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mlab_SterilizationAndDisinfectionControlMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mlab_ClinicalGenomicsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mlab_BiopharmaceuticalDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mlab_CalibrationSolutionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 78 R67.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 12 - Segment Data - Segment Depreciation and Amortization (Details) - USD ($) $ in Thousands Dec. 31, 2024 Mar. 31, 2024 Total inventories $ 28,122 $ 32,675 Operating Segments [Member] | Sterilization and Disinfection Control [Member] Â Â Total inventories 5,728 7,014 Operating Segments [Member] | Clinical Genomics [Member] Â Â Total inventories 10,709 11,813 Operating Segments [Member] | Biopharmaceutical Development [Member] Â Â Total inventories 5,853 6,304 Operating Segments [Member] | Calibration Solutions [Member] Â Â Total inventories $ 5,832 $ 7,544 X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mlab_SterilizationAndDisinfectionControlMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mlab_ClinicalGenomicsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mlab_BiopharmaceuticalDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mlab_CalibrationSolutionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 79 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

%8Z@LO"FC3#V1"M*98!MSK0]MR*O5PVO:LYDS7 E1QZJY6]L>IT[$$,X\ (M?XM8%":N M<3(O8S8E=_.[\^MUA6H"9!$4(CH\J98IBDD0MH3V38SV2W7"Z@ MN6;U>-M3+85L:-
D*UF0KJ+3#ML\B%=AQDI[0B)_08,Q;0XO14H;B=0F302TT M5P;L;;M1\'N-2J56[2B1"^48@4R*RQ(:(F? M:/=:O6?+K?
TH,:D4IT#VPPVRB&5)ZHJFGG")?]}L2XX5ESD^0A\:&1%N$8MB M3!VX>O8C?O:[YFM1K:G?69&:E/P>IL#,F!;M M@C3,7&>M/7M3_RR["[4[XQ,+")1Y\V9CS=';YGS5#MZ<8-
C.#;.**UR8>(Z M/Z4[Y\2'3+K*F7M6T!:.C:+=,^L.M$4.F#%SE K:DS'UD[%1T-H@?Z41)B%; M1WB;G&>$ISUS4$]SG[?O<2!6KGG5GM2I>;E4Z'?^.*>R_];,7LUOK;F'4O;
MOOU].T#C(YSB4F]/\6J3CZ1MW^2^P:#^!N.@@SEJM@$)33+C?8HIED8T=>56 MWRS00V;K':1G+5)_7'I5OGJ3CJ1MWP%]'T+]?)RLO-VNOG7@&],/I2U0A6?P;K@0P*!+3=O
MVS&PO=V]R:W-H965T&ULE ME951;]HP$,>_RBG: TBL"4F M0*DEFK:'B:ALF(/)CF(5<=.;0?:??J=DS2B M--"6!^*+[RZ___EL3_=*/Y@,T\<3+J29>9FUQ97OFR3#G)D+5:"DF8W2.;-D
MZJUO"HTLK8)RX8=!,/9SQJ4WGU;OEGH^5:457.)2@RGSG.GG&Q1J/_.&WLN+ M.[[-K'OASZ<%V^(*[7VQU&3Y;9:4YR@-5Q(T;F;>]?!J,7'^E<,?CGMS, :G M9*W4@S-^IC,O<$
H,+$N Z/'#AVFSF??,@Q0TKA;U3^Q_8Z!FY?(D2IOJ'?>,;>)"4QJ\"2:"G,OZR9Z: M.AP$#.,3 6$3$'XT(&H"HDIH35;)NF66S:=:[4$[;\KF!E5MJFA2PZ5;Q975 M-
,LISLX72J:T)I@"C8P2/&66C!LFF$P05BZQ@=ZBU!JEA25JKE*XEZQ,.3GV MH;=D;B9#RQ,F3!^^POWJ%GI?^O %?# 931O@$GYGJC1,IF9 $X?VU+]:T%ZH
MRD6["E)5KNVF%-2AB2HE54]C@GS'U@*[I-:YQU5NM^=V\V$P#J;^[E!0AU,4 M#ENG5]A1BQV=Q5YJ.@NT?1Y 08MM!T"+ ?A8\B)W2TWX95Z*JAU2I",BX1B 5% P#3LF2H0>
M=5FJ&A&#: "FM>[`?Q1^_(3M>@',>K[A'+??H$]RLM)G2_!_5VE'7NZ83M0Z2XSEGJ=R^U[W),/UNR3I)-IR:4#@AB*#BPFET/7%4QM6 M%=79O5:6;H)JF-%=C=HYT/Q&*?
MBN.N@O?WG_P%02P,$% @ %D!$6DBQ MT2BR!@ #AT !@ !X;"]W;W)KRCZ(%NT+502/9%VLOWZD;(LV>01FV[) M0ZS+=X[X'1X>?B1O'EGUC6\H%>BIR$M*.]@(L;T>C?
AR0XN$7[$M+>6;%:N* M1,C;:CWBVXHF:6U4Y"/B.,&H2+)R,+ZIG]U7XQNV$WE6TOL*\5U1)-7?=S1G MC[<#/#@^^)BM-T(]&(UOMLF:/E#Q>7M?R;M1ZR7-
"EKRC)6HHJO;P1M\/2>! M,J@1?V3TD9]<(T5EP=@W=?,NO1TXJD4TITNA7"3R9T\G-,^5)]F.OQJG@_:; MRO#T^NA]7I.79!8)IQ.6_YFE8G,[B 8HI:MDEXN/[/%7VA#RE;\ERWG]'STV
M6> ECLN6-$8RQ8467GX39Z:0)P88+?'@#0&1#?P>PS Z\Q\)[[M!;\Q\)_[A: QJ#MS= A6'>EI(I+Q3<4>4:70TINZJ+NKMI8!SDJ560^BDF\S M:2?&$U:F,D]HBN059WF6)D+>/
CY(Q-(<,16Z,.65HE*!(XN/I?)+LTDYA(- MT>>'*;IX=8GX)JDH1UF)/FW8CB=ERE^C5V?W-R,AFZL^.EHV39L]I- &4ZSE$HVFB,":>'VD\35@2(M'2:V,XY9Q;&7\ MH>6:E4M64'21R\%
["3&.S1X.0XW*U 0- SVC30SV(ATU!SR%)S$Y8XN=3M@X M5K[O2D&E*!"KJU3.RE8);)_:C&C:G1*%P)EG.^204E4S TU;C_;15>J7[/F0&0(8DBO2TL'HZYT\Z_L0^",2&5FU&7!Q&
MPN5K5%*PU#7>SD8"-N8O #5T(V/L S 28T]G#3CS9++U,._D&K:KKD/!*UDY M-(K>,^+@&HT*XUB7*P!J2!RLBS, %KM&48"<>6%/#<2=-L-V<7;QFRIZ$YV MI8P 1PLJ5^?
T6!)%\M23^*9\&A*"0ST")@S'GE$!3)3O.T8% #[IXJ G)UB MPW;)]JYEBBX6M*12N5W:9C]L"JJA[V&=.(#"H3'P :47&+P!5X'?HV]PI^"P M7<+]3D4SXS6=#9(-C!7!$
>AD>@FC&!L=+.)\K%9Z$V4>Z(,S]EV<@[;]=Q= MPK.E&M5%*DR[I7+]/!&;]Q%YX2=ZY MT'I2J>O< 90;&X4=\J67_SGHJV]^(YW<(W:Y=]KO%K[$U%4 7PCEZO/=#/05
MZ!,Z[*N/;Z?DB%W)W5%@M:@5LJ=A=JT_J:;Y,EO1UL9;QHM:># M\<_X<#Y!=S=>DEOLQ?U-G\I;^>=T5ELVP26/ZO8TM ;M; $P<&L+
MPEGVMDBG(XE=1S[(X&5RK63-.ZN+'\Z[E_0V>U%O\Y?R=MX9G9HE=C7[5@JX M2LKZ>FF;%EF9<:&T_1Y4-XVSLYR(O%!?QD*PV',C/1--F$^,S;TY!//K'6PP M#Y6./7_2*3QB5WA?
\-=ZS<_INE[4'O=?D9P,U)(6\6Q=9JMLFCDZ*6@U;H^)./2?%>*PSYJ^[0] MB+NKCY^TYQ-\/<7 \QF^GD//WQ#_>D9\\$T@WQR.A[HF'4X*WR?5.BLYRNE* M-
L^Y"N6T5!T.WPXW@FWKPZ(%$X(5]>6&)BFM%$"^7S$FCC?J ^T1Z/A?4$L# M!!0 (!9 1%IU@TF)"@, ,8) 8 >&PO=V]R:W-H965T&ULK59M;]HP$/XK5E9-
G;0V[X$RB%0(TRJM6U76[;:;&!(UL9EMH/WW M.SLA"TE U=8OQ"_W/'/^;!OO&/\2:2$2/18$)QI4Y*9C68*%9X(P:X5BOW?%PS#8RSRBYXTALB@+SERG)
MV6YBV,9^X3Y;I5(MF.%XC5=D0>3#^H[#S*Q9DJP@5&2,(DZ6$^/:'LT#9:\- M?F9D)QICI)0\,O:D)C?)Q+!40"0GL50,&#Y;,B-YKH@@C-\5IU&[5,#F>,_^ M66L'+8]8D!G+?V6)3"?
&T$)6>)-+N_9[@NI]/B*+V:YT+]H5]E:!HHW0K*B M D,$14;++WZN\M $_P*D 3AO@'0&X%O GBO]>!7 "W=++7KQ$58
MXG#,V0YQ90UL:J"SK]&0KXRJ.EE(#KL9X&0X8S2!4R<)@I%@>99@"9.%A ^4 M@Q2(+6&K@"),575L";JA,2L(.O_*A/B +M##(D+G9Q_0&?'0:?W4";T):ZMPX^]Q,G9.$$8DO
MD6M_1([E>#WQS%X/=_OD_)_W^3]/TB&6Q>*J_F\(WS?X,[*],GWG6R)#316 M74W;\,(.!L'8W#;SU;5R;+ME%'6-?-NS#HWF72/7'=0V!P*]6J"G0>X1@=]E M2CB*#TK]/-]0GW3B5-
7?(CL<8QF1C *@C?$B-\_\X.K$]]]?269-%; MDLW?B.S@8/SZ8/R3E0F[TA*-K]9B\&5;[=J ML6ME6U>!WRK&'BY[& Q:U=BUK@I.K9\4+L$QUT_X##P&D%.NM:
MV:XU;*4FZEJYSL!M:>XS&@Y;FLW&PU00OM(=@8 _V8;*\NJI5^NFXUJ_M:WU MJ3V:V3WK$30I94_QE[[L<&XQ7V54H)PLP95U.8#CX6774$XD6^MG\9%)>&3U M,(5&BW!E
/M+QN1^HAS4K5OX!U!+ P04 " 60$1:U:U'G>H. #=B@ M& 'AL+W=O225SVIOK-=.TO1>=>\%(C*V))+HD;:??_D!9$01@N1" !P/7Y?=-^[*[KNH\^;=;;
[O7DNN]O7DVGW>*ZWE3=R^:FWJK??&C: M3=6K;]NK:7?3UM5R]]!F/>5Q+*>;:K6=7)SO?O:VO3AO;OOU:EN_;:/N=K.I MVK^^K]?-_>L)FWS^P2^KJ^M^^,'TXORFNJK?U?UO-
V];]=WTH+)<;>IMMVJV M45M_>#UYPUZ5+.;#$[LBOZ_J^^[HZVAHR_NF^3A\\^/R]20>JE2OZT4_:%3J MO[MZ5J_7@Y2JR)][U?UL/ MU>VZ_Z6Y_Z'>MR@=]!;-
NMO]&]WOR\:3:";]NNW=/*P:OM$%KO^E;]=J6>ZR]FS7:I J5>1NJK MKEFOEE6OOGG7J_]4!/5=U'Q0WS6+C]?->EFWW3^BRS]O5_U?T8O?MM7M_6Q4@VYK-KM:GO585IS7.O-
S[,?HS=]WZ[> MW_;5^W4=]4WTMFJ5=S#5$E?]M>FKM?G85/7=H0/YH0/Y3D>,Z'Q?K:OMHHZJ M/OJI:E]&"?LNXC%/(-<_*,F=TC#FW%TD"8\S>3Z].W:M6RP3K"C,4G.WU!GC
M69&:Q2[QVO_!0-BCW\KKD9!L$N>J%"N[M6'=]]"WGWP7AZ5&DUOF?" M=7=5(OZ]43-%%W=WM63B[__CU%Q4,#(!9 MYK8I3^V)CM)BZ;%H>#$_>#%'O;A;+)T-
Z^MEM&@VBCJZ:K=LKS\-7X-NS)VP MX87,K;!!S89^W6 M.U="+D350B.14FQ>N$$$FI636R@SWQLC*S"=M>)[%FD)BU-I_%$2OMBIXZ^C% MNNG@Z0;7"/7X7LVU6?
ILFMX[8CAV$@,<3=<##_SK=JMX(![G@;VL MLPK'[8>&)ZE:2:5F^E[C%SN9O_S^A@!,*(_;[N9.OV0*K9@=FVZQ M,U:(U.*Y2T\+1C[I@'J29QD;BU9-80S'L)%H]=(K-
LY0H,V,NRT#C+"D^^6R:WM,(Q7"&"ETAX'+!CB0%*0; M&[!(\'AD;.SPB9L=H)F)X= 4LMG%7#("=[N8"S;0=A=0#-SO\K1@S&&N.K;C MQ31@,9RP@D.6E*]
(U>:D:B5S48P7Z5B(:A9C.(R=-L)2PM",5&U.JE8RE]22 M)!MQLB8UAL/)R!)B7B\\8X*++VE2B%@D]]! RF.D:B65FGG?.1BQWN4@M-%.K5^9 L;,B%];R^=+3@+$S!U=8;FPT
MYAKH. YTH6L,7"[8WZ2T1ZI69H#T' MH!BXY^!IP=@8[*IC>PY6)CWZYRSN9D(Z+20&.5*VD4C/[1X,=Q['H M"0 $QXUP/2T!D*. ^%3G -SX%2+V8=)>+V"74W*
M@E1J9I]H9N0X,U*=!7/W5._66J3PB*I6LE=6#P;.6'FFA4YSHJ/.&/&%8,7 M*,"962ZY/;&2,J+/IGE_2K-?@J/38TZ:$X !66X#-VXX^%X4Z:E=XI*AT0+3 MF9H+$YP+0Y?-
N%QH5)*JS1.75<]88@-\Z2UFNE)C7D* >;A&L/^@PS>>V/=J M2(V67J.F_XXN1C[J2.Y=?8/#10(=R14LX_86!6X_.-IH[ST^Q9%8&[OME&B82W"8>^QU MA\2E-/BZ VX_.%I)08U*S?
2]!K4$![731EI*#IHEX,F;.]*2PI?7J.D_C5\) M[7D<+A?L2E(&2R#L R9]7S'3E9J:$IR:GOHZ/W#'4+#4'BI(<8I4K:2;.Q],' M@U>"@]<3[.GL+1K75NT.(3VY(U4K$Y?*1!,:"03.)[Q7Z.
_9[)('1U<,70: M%0"&N3LZI#9+GTW3EYK\!$Y^C]G1V4N:+P\4]HX.;C@X+DF13T#G\DS@#UPCVGXN'G#%I M?ZI):IC1QVCW)T/M1PJ4>^'X4;C\XUDC1C4K-]+TF/($37LC]J+V4
M]WZ4#M-)%+8DU$*'4+EB2BL>68.%A19:K\RX6G#R'P$5)<)Y;:157RJD2C] MJFE"4BA/2)[:VRMX)8/CE12?J-3,#M*8E>*8]00;BZE[L.:DL2#%*U*U,G4I M;.2D(CW*%_(5$H9
[X4Q>^"8X34+=C5MSI"G.']+-=FESY,V) 7RAJ29,VGZ M$X?XBY1 $<.6Z0H-6BEV\A!<,7@!!B7SD#:4D=HL!?39-7VH&2^E3B*10$@[N MS&.D\$6J5OI:8#I30U5*FT@$EPN.2M.(#L-
0E)V%O3UQZ_#&V@,.ES:Q*FLDD M0281Z5*,/=U+X-)?DEO1/0=*.7F3/$)F.S4PR2_.^0&N\B7 &B(NF+TJG^'V M0^.(5*VD4C-
]KZE*/BKG!^QOB*K2PKZ+-9,@52FTMB]M@05%$EOSSJ6G#2,? M2D"=I7'&1UX2DYJJ)$Y5IWTNW9,EYW/IXA/TN71+.9]+CY#93@TGDO8,")<+ M'?Q)U>;2Q0IW\/X8RS.7.
:'_PUL\A'W0ST;GU(Z&8@M(N$VP_V+RF9G- (MTZU'J0H?E78#=B7PVA6TBRR2A(W;0+A)8$-A%\K1A+ [=ZF*[2%+3B<3IY(EW MD7#KP<,&Z;U 4K52NL3#XGAD>T-
JXI$X\02/TZ0I.TC5YJ1JI03>(F.Y'%L! M:"R2!&=-N$:PFTE9B%2ME$ N$B9&XCK3_).=EIX#.?H'Q^W,Q914)(FTUY4S MW'ZH3TG52BHUT_>:R;+3F.PD?
[MW^Y*49_9*=I9!5^@4%]CKL#E84$INK]<\ M;1B9)P%UA8RW<(U@K/^DF;H(%4K,Y>_D%%!TU=&FZ(#EPMV M..E9%JE:F;D8B,QVF>;
#.>>D#V"S(4A<(\@=&/'%CGQ0$2=5**C6S5S0P9L^3I",#\"J) M,[LC2 &15*W,@#0=QRTP':SY,"-/U($K!B]3P*09]LU$4INESZ;Y!R$T!>;T MB3IRX* J3^S Q V'!B:I6NEK@>E,C74Y;:
(.7"XT*DG5YKG+<4(F%B.6OE*F M(S7KY02LE[L'9O:"(?2& K[YL$<*&6? ?F$%'9JVLJ_:)T&R YDY#L")W MSF9Q^\$Q00I45&JF[S5WY2=SE]_?
$'<5*;>Y*X=P*LN%/6O/H8*%M*]577J: M,()=@#B33(RED\PU=N5?G$\#=A]PX 1>)<#M!XR6"'TOYML*=XI2K7&),_>]J+'$A[81_+X+4*[A%2R,F!UZ]& M#M@+C3C%\R>^*
(#$%_8'>X;7*]33I&HEE9K9)YJ4BN=)?%$ B2_L@,>K$MP- MI/<3"^ L;BS@-3T5Y&DO<,706;0 4U#89P^D-DN?3=.7FM *^K07!7!AD"PT,!PK@12LF[;]]-0>*V3S@53);JL&G^.
(4%2!T%D"*"O">"FX_."Y(3XVH MU$S?:Q@K'I6B O8WD*"(NJ=2@#G@@7LJ8$'@GHJG#6_GQ:X+8C<4RDT=Q5? MG*4"]A^0I0+96 MN54M
'_NK]4B>J:6@6U]K59_J[LZ^G$?;O\>PNTE%,73[KJN^WG55Q?GF[J] MJF?U>MVIU>3M5AD=5J*'GRKR^3 XX]4EFTR=GZOJLE?ET"3P=WSX'1]^-]5F
M+LYOJJOZIZJ]6FV[:%U_4";CE\/MD'9U=7WXIF]NE&&PO=V]R:W-H965T&ULC95M;]HP$,>_BA5-6BMU M)"04IBH@E8=VFU0)%75[[<8'L>K8J>U
^^UW=D+**F!Y0WR7^_U]%Q_G=*?T MB\D!+'DKA#3C(+>VO E#D^504--3)4A\LU:ZH!9-O0E-J8$R#Q4BC*-H&!:4
MRV"2>M]23U)56<$E+#4Q55%0_3X%H7;CH!_L'8]\DUOG""=I23>P OM4+C5: M8:O"> '2<"6)AO4XN.W?W"_<[7CK4\4P,S)?YP9O-Q\#T@#-:T$O91[7Y
M4\^UT\N4,/Z7[)K8*"!99:PJ&A@S*+BLG_2M^0X' .H* MVW=R\21IQ3A&7Y*+)=48G(/E&17FDGPC7TA(3(YNDX86$W7;A5F3U+1.*CZ1 M5$(>%*H9LL#DV+]\B 6V5<;[*J?
Q6<$Y9#V2]*](',6#(_G,SN,K*!&/3N+S M_BO2I[%%]V33X[@=]V3/X;?=T\^.7,42=MPB=<;G*J&;SEV'#.DI)Q=D1)T MW2?D@DO"E!!4FP_OY;'NJ7<8^1WC^ M/T'U!PT/_LT%Z(T?
U(9DJI*V;OG6V]X%MWX$?O)/\8ZH1/3!W!/%"]X=(0 M 6N4C'HC'%NZ'MJU857I9\SLCB!_#+'>PZT"\#W:Z7LWG ;M#?GY"]02P,$ M% @ %D!$6J^KI@\D!P LQX !@
!X;"]W;W)K(N'7^Q)7E9/[O+[K,K+I^$_*PVE&KPO*VYNIILM-Y=S&:JW- M M4>_%CG+SRUK(+='F5C[\$UY24KE%VWJ&DF0QVQ+&)\M+]^Q.+B_%7M>,TSL) MU'Z[)?+E
ZW%T]4$3@X//K*'C;8/9LO+'7F@]U1_VMU)3:WAQ@S.[P$G\R>B3.KH&UI25$)_MS2_5U22QB&A-2VU5$//U2&]H75M- M!L<_K=))]YVX?'U0?N/SGACS(HH>B/JOUBE-U>3? (JNB;
[6G\43S_3UJ"Y MU5>*6E>\-3*)A-0[I46VW:Q0;!EO/DFSZTCCA88/>$%J%V A@O2D06X78"= MH0TR9]8MT61Y*<43D%;::+,7SC=NM;&&<1O&>RW-
K\RLT\L;P2L3%%H!WX,VW;\&W@"P MQT;L%>&5NIQI@\SJGY4MB@\-"C2"H@"_"JXW"OQ@T%2GZV?&HLXL=##K XHJ MO*7E>X#A.X 2E ;PW'S]=Q.8=I EJRG@'5S[W-
Z5+H2O"M[\G,$[D[(3-RTZ-RVBP;NE1FG)B"N\ MIA[LI/6!?GD'=C7A@IBD!_2?/=M93X8\T:B?'X4N35 ^B*\OA/*B" 376R$U^[=#3DH#4S%[.Y6T=K6.<4WX UO5-
%BY,@\6Q$F"!N!]*81PGH31 MYQWZ/(K^7HOR\]2R5 7,7C34K1I+Z+.]#J92[L--DB0=P/6E"IBF8;1%A[:(MHOW)- W @;/)8=R\L=O!>MUDU:/9+];%@ L=]G/A09JB/,\&P'VI$1_#I&?
MY%5[1&FZF^YWEM*8P$A]J2F&1\EZBA;U:%$4[>]Z0V40%O+^$)O-.(3E M2R&4+$90];P,OX:8;54O-Z8(4&6C?E3@E:*&&FQ]JQE9L7J\V,.S4O6YM)VZ MI2=K&&?
KZ[(4>TN*INQ3]DA,XKZS+!@T/ W4DF'T?)D<%2/U!O;L#:.LM_RE M34\6KBCMZI.M/,?%$)LOA>!(7P%[QH1QRKR3=$=8=:C4S1X2-@?:314$[%/@ MU)3E^1!Q0"S+4SB"N>=*^
6R/$1]1UYLR(,0?:*;P@)Z3@V)+>9C^=H3(HPS MHH$H]_0D&YUG-7FF<=P!7LPS#[8O-85H;)_VQ CCS/B)4R*Y@2VIV;#[D=T: M(, \]1
&I&":C91GU),@BI/@;X<6U_1VC\P,86#U$NQT0]"1SVXXA2D>8 ^) M030?(4+4$R&"KYJN+&NKKVG0491@7UNSSZ7MU L]P:(XP5[WK:URQ=IU7M8U MKNF5P[FZ=8'/J\.Y*R
RS8HL&8M;3[XHRF++N[TTK&N+X_^9*5KEIXV*W\^$ MQ%!RU*"=@N\I$GUYH'?>?;-7;HAX&]QW0>0^&P:1\1RF(U"[VD3Q:?>8;ZL M&2=F[/V*?#GK1'LN;:=>Z!D:?8FA14EIU?K
,#-@2NV-(ZC=CA5=Z=&6!_D$ MG.%T,>3ID)@=QD;BU_,TBO/T1]-:O!QF*PLTB#' P&B!H5>40W)H'&5/U2A. MU09EF]_#$7 4 7)EQM#VU,TBE/T+;.LQRO;1+!PI0P-J/-B^!8C
M+)?;C,$#<$S2.$[2-P3\4X/I,&JN)Q0Q&J M-$$C D,HRC%<#*WPY=)YMAAY:81[+L5Q+OUAO::E2R_ZW R&P#1"M!L2!6^9
MU9"4N[!,]4CJL=$;^Q2:)L-7&P$A-#*'X*,7SW&.;=^[2FKS\$U%FRO+5:^T MP*=1E*5#R(I(3=-%/M+VXYYL<9QL;:@ J+!BCXPSNVFLFT$E4P$\Q?[=(IR MY+UH"(AA5,"1 H-
[TL7Q635J K7#812\/Z3BI)A[^1"897,T-L#@GBOQ(MHQ MW.]WN]J=!Y$:<,&G;5_IWP M4DBL-&'<%;F^2JR%!+7+M:,)->B>S#O-*.:%%T]?*C7D/ CG[.CX;TOE@SL5 M5< -\\V16?
>T.WF]=N>-@^OD?4$L#!!0 (!9 M1%K7]$>AB < %P1 8 >&PO=V]R:W-H965T&ULK5A= M<]LV%OTK&&&4F;6>XDBPK=IS8GK&&=IIN'M)ZXV3YT^@"1((D&!!@ E*S]]7ON
M!4E)L+IP\XT%0G@?I]][+NC+C+?-?0JU%T%^<\)Z'4KH$N:7'F[\>?34+K5>R8*'&S!S+^S>FLD=I.KB]Y[=Y?Y7[7N[&FN&FW5O1+D!TPN%
MN,W5Y&0R+*S251UI879)N-6@K=*!NTL*K\FIR<_+F=DGG M^? M!^WO.7;$LI)!W3GSARYB?35Y/1&%*F5GXB>W^;?]XWE%^G)G O]?;/JS\XG(MNQ!=TPO#@T;;]"L?
^SS\$X%%+[!@OY,A]O*=C/+ZTKN-\'0:VNB!0V5I.*4A>NQJR,7K7UU4XD3\2[Q3(?>ZY52Y4MQV 2=#$-(6XB%5C-8?=&5UJ7-I MH[C)<]?9]&TE[IW1N5;AY;T#M\F!Q7<Q-
:F:NK";HH*+]6D^N7+T[.YF^?<78K]WM\3OOU;[Z2 M5O]74ADS<>=L0&&*_O56!AVHB/=DV,9A>2CU/@2H]$?]*_[\73U&<6M<_N6O M8\$_Z]QX'L(3O]/$/RNF@]6Q!H)^-
I)'Y4W6Y!*ZWP4.$<=+D[FX@\EI,<_ M41FW0J4->$YYH4E4H=L#;+,_C;1="4KIW0YZM*1AT& 6.%(U1E@JA"R;1&&3%N]V;:6X)]<=:PJ$[62)M8Y
M',V2+ZI@&X5:ZUQ!J@!O>*1B2O&XLD0$K7=%E\?D%25>)T>AS+3"=;XG&^6# M .526+T(]$55(8YMAL<I)'7PC M@=66-
X,T$(/6X*Q5AK3^"@C4X@:1(XE9KR[A/V@I[F5.8$OZH07959B(!45? M:,KSJHO.#PX&!I!,KGT3*A ?*0V'8:,1J$#)4U:SJ75>BXT2@+B C%P9'6J M$M8NI@S>\T&J?
LI^==C]OA^!U:FT'WB[*NT7D8=VZU.P0L M+*\Q_%LBS)T\0+%*M14/8R\<92CQ._(ET>A-*^V68-%9V16, [B%2H3TU',= M7HY1=<+72BE+"6Q1I8*238I
(2F=&PT@<*$ZTX.K;TQVKJ_<@\H[ZNH!?H]Y M+6VEX$#3Z!"&[!U1+7=DU0+>N6[)3*4L0&Y 1]A7;4QN/<7ZCR]?O%XLYF_ M3Q^FXI>;FWM^/WG[$S,(-:G7C2C'R%$[OK;
H6GB/G!!BZHE6D2CX=)%F=DG=DZ2.-UU!L1HC9/$W2(*SF1&3H5@<#=19DC#(%Y+#K;MW5EA +P2B M;W*5'"FE1C,.M2$%A,6=\ZT+>@0BL(
[%A=@1PA3AL71K8.$8%6[(K&!==05 M6_ZUCO@>_WV4'M&/3?*;^Q$(MULE/<@0PG!D.#8%-C7TW[->\4GE1J+JY4C: M[_L0+:;.TZ;+: ;Y@ET /:COG9N*3SI\21#[# 3YB
LV@X["3@"6PXC;Y2WL MX.[5UTY[(GD(=("%,A$-R-SPN^N:9/7L99@\Y+:O>* MQA=&4)H:N0-IDPLT$T.6+*VY8X7B?"%N%'00#Z*-AF+UL]!! I""0DR)J;AC
MMB">S_H9,:"8TK#3F*$'(IRCJE9DD%WE$NNF,QW.C$#E2X"S*E*+M?T]*$LM M0#/'4R8S:@M%]Q=J4\^:*0NJASWSMZ=(=M= MCM+%!?!)C:^8_#):3C'GVN== TCRI0C#C$"_HG
)/C"(M.+F@D1C1F'DLYK4 MSR!*4V"^YA?AA1,:6^0SJ@XP,*HP]OJBBKHS*D/OA (WZ=N@N==9KA M=-'^GGU9&.9-LZXG?>UP.AX]ENC%YDX7\X/
M%_ZAXHMOHUF.BI=B#BL8$&*GF]:>J#Y+JE_V3A/&Q?C70SMBX]@X@"3"LP) MURGA!\/L(.&$%I9'2_#P*)A=LAX5> :M![I,XW:\|(E4K1,2=M66:5IH/]I:. MXMAGT6SOBQ&UL
ME59M;]LV$/XK!W7K-L")+=E=G.2YL8)<)*^#%N[(LE6#,,^T-))(D*1*DGE9;]^ M#RG9=9?$P+[8%,E[[KGC>W!E[XVIF3-TNXTJ;UO7XW'+J^Y$6[?M*RQ M4AK;"
(]/6XU=tAT:A1XVPR.1@W0NID<1+G/MG%B>F\DIH_67)=TPC[<,;* MW)TF:;*>N)15[''2BHJOV/_>?K+X&F]0"MFP=M)HLER>)LOTU=DL[(\; M_I!\Y[;&%"9&7,3/GXN3I-)(,2*
(W^ M-L:.6%;"\;E1GV7AZ]/D**&"2]$I?VGNWO,0SSS@Y4:Y^$MW_=XI-N>=\Z89 MC,&@D;K_%_=#'K8,CB;/&&2#019Y]XXBRPOAQ>+$FCNR83?0PB"&&J!U!3NIP M*%?
>8E7"SB\^&L^4T1Y=R4K+4N9">[JV0CL1T^9.QAYNPN9Q/D">]9#9,Y#' M],%H7SMZHPLNOK4?@\]Z&8[;F>);M!+S@?)^FZ8BR23;;@3?=Q#R->-,=,3OR MAMY*+70NA:
(K+SQ#:_[)>'NXV=-PH6Q>N5;D?)]@+AS;6TX6+U^D!Y/7.\C. M-F1GN] 7SYT+_77-]Y[.E,EO_GZ*]$[8ITD/8MA_5@ST[I1=LWI/6*&KY:_] M!YFOW%3/X?&87?2'2N
M#RN(P(F&UQE'>FZ%DD4?8FC8):X%I&19%#+,(Z7) M(S B:-C&PLU%*U8!6'D:J:SN+ BNZ63@BK<5%X]$-^W82ZD&3-YO2;W^'CZ M%>.8*C:5%6T-Z/TH<6P*E(.:D3:S\KCT
%=U*D3^0/-T$O:5:"LX1N[=M9V% M@#76@@'ZLA-IWW &$JAZ&SX*ONB>E@7U?XCU<]H"0P5AG.ZZ*U"#+ZVS*11 MX4^87,?%
[8Y,'\/.;V8>FUVBM'2'G'Y'!Z.C^0S_Z='H^#"E=U'=T'XI/B91.4YH>SO_4L6:[2!N4>"ZE:@*$9L2!(2G"-/Q=$X(M-YO24\U]O'430Z)5?&^@:L*1]Y?R9G;SI%GV-_G7[?
U[Z(.PE43+55S"=+)_M.$_(JF^,_L,;-M[K*^/Q2HA#]+E@&S9@O31H3\-'<+!YZ"W^!5!+ P04 M^ M"@N\(!9%P B@O 'AL+W=O0ZW5,J++ZNF==>3I??=J\M+
M5RW52KH+TZD67^;&KJ3'HUUM7*VFWMZHQF^M)--F]^* 72T\O+F^N.KE0]\K_VKVW>K<:ZGU2K5. MFU98-;^>O(Y>W:8DSP+_T&KCCL:"+)D9\XD>?
]JO)R$!4HVJ/&F0^%FK.J4T MI @P/H\Z)_LE:>+Q>*?]1[8=MLRD4W>F^4W7?GD]*2:B5G/9-_Z#V;Q5HST9 MZ:M,X_B_V RR:3D15>^]68V3@6"EV^%7?AG]
'#2A")^8$(\]38L8]+,0HWT@O M;ZZLV0A+TM!& S:9P.<;BDH]]BJ\8\]?_.+]4HDXJ7XH-J;]=75I8=6^G99 MC6IN!PWQ$QI*%;-I_=*)')I:U0_G7P+>
<#E]@W0;GU7X1E47(HD"$8=Q>D9? MLC M&-.&7XH[9H*$SXYT?UQ8O; MQE2?_G4*_]D53N,?:' A?E.@!:]IV@5@6=O/L7IO%3W83\H' OG4"-G6@A+>
MXT\T>JZ$J[1]*W8S",D"GWO9:+\5%1D!7.NO6>=NST_F[50V"4--W5 0Y:Y2[M$&^EK3?20]'$,^9435\KT2VW3E<(7&=-W5?0X/IJ*:1[H+5W4(V"O:BK$Q:MY);"NK-8\!?=+AKU$O /
M]@T>^MP# [B 2S$BZY!X,A:&"Y,;\<2 2!_%2C45GKH$M6V8F\]>+^1,4XO9 MEB?=@1-LZM]5:U:Z&I:[U:9;2E2Z2O6>/[\9],#KU7JMJ1+#XIWOL0DLOL7Q M@IQHFI[*|=&DKZ-
!/H75E=#"F0NW@O3+@P91VXR<[;C*/A?3LBG&F#.+$6 B D0[&C_HED+ML3A*@Q?0HKN'+KH'!W2C?Y?#WH');V!^.Q\WD[N1U#NO,&*V
MB,90B!FR,:VB+4,#W9C7;DCLY8X4C.HK.EA5F44+M:B[Z .):!U<^3]Z(A= MR /AMQV9TVR%]/RI@X<]><-,UHVSN EJ>"L550&D=.8JF?V8"'Y@CQ, M-6$@[_TX
B:';8Y(9W>&',$T:T*'O3K@@*HO-@L52LVBJTRLT8O..%A M!IA*_81HY,S8D>M,;=%)"T(Q(3P9:L4-I7!B<,RI2L\UA*!4 MFYJL'Z"09@_YP2F /KQFGU:&$++ED)<[+1626[O*H@+LO'

A?FJI%**08?,' M-SGK1@B.1U0%9P85^]QO1C,?2SP&R5%3:]GTW>=._!-I)XKA)."'YS'Q[$7U_HG]= MKUQW1S2_WY>?C\9#[KAH? ?X38,R+/$;!6&:X#?)@P(OWZG MKS-
SSP]9#+EB.L6L+$FA(TD2$67!M,P/B10':8YOY!M\2"$;9I *@SC)1DQ[M%P-0$F3AE #$09Z/@SCA01JD,6'+XZ!(0_%"1&,L'COWXCDQ2/X8,8C@XB3F
M&$RS@F,0%B%^LX2L!=CXR0A$$(R"()PUS0611!G*;ELFF;'(4CB'')1.L@5 M(@D2A+L,LJA|'(.(ED,KL_2G)&E23B\B+*2H07I-#D3@B00[RIOZ WLXS<7 MXA?*F?^'M,A#I
,9'.L!E<4%LC,F^D873+.$B5:#L?">*(B"'/Q&* M(B*B(U13B!_PZ-+W<7TJ.%F_5C>T'M M';:VGL1,C[!H3!^$VRZ&CPKZ%TY,RSU-)VQ
M4,]MQ6$N.ARK#EIJ31I[&Q*5;MQ6W:O_6H&?4PV8AH?1KZTF@_DP2S%(0I0A M\GB,;"@I& 42+*+!M$39S,3=$D=@!#>)8]K;TIBVO'B*O$2PBE2\@PLLI7E(MGY"
(22ZF"9)^*C)4/>Q7CU-PV'[V1?"0<(> #VK]$CT=(PA$:T"H/S^C>=@? M@6]E(_F$^>Y!_[64:R76TFZI<^GDEM,)%%FY76]=:PX5FEG0Y8@VZ&\@OSN! M'$Y=
[F'/2WK1EO6MDK8];H#,X?"%TUYGG*9VD,Y_]1X?#L=RAIKA-7?32U#H M)8$[*<#L&4^|-1_Y3ZZK!_[*BGI8]*5|)FIE7S,9X*|:Q]5AA .-KKEM&[T'
M"$KY|="*X|GB&]$8#F1KVJJWECQ]/.%_ &QH19U&9XQF7&*!E?RWL72-,![Y M]FXXOD) ,ZWT>CQ!M:?=S_;0B=3R%"XF!QKQ!:2DW=VS'= 0*; MR^O=%28]GUP+AY7CW+|[B8?
5_2PM*L^>|Y0S05[DXCW.,E9L$?P'DXZ.#<=G M,2#DSGTY)M-JJ"/JB3KRHL3V6XKOGP!6TZQO4XF,5GSP/'7 *=#!)>><|!@A M][?3,!2GKM0NCZX[$:X%7^JZH=0/-Y_[M_M[X]?
#=>E!?+ATAOL18R<:-&PO=V]R:W-H965T2&Y%I6 MO[YGR)6LIK);]"$QE^0,SYR9.:3.EL[?A8HYTD-M;#CO53$VI-A*"JN51BX
MABU6YL[7*N+3+X:A\:S*9%2;X60T.AS62MO>Q5F:^^ OSEP;C;;\P5-HZUKY MU14;MSSOC7OKB8]Z4469&%Z<-6K!MQQ_;3YX? TW7DI=LPW:6?(\/^]=CD^O
M]F5_VO!9\S)LC4DBF3EW)Q_E^>]D0!BPT44#PI_[OF:C1%'@/&U\]G;'"F& MV^.U]YL4.V*9]<#7SGS19:S.>\<]*GFN6A,_NN5/W,5S(/X*9T+ZGY9Y[_2P
M1T4;HJL[8R"HM@)@TEG,$FX\T$)Y1L5U<69=TORLAO>9)!" M3=8 IZTDY39ZK&K8Q8MW+C+MTRNZ4=K39V5:IK>L0NL9U,=P-HPX1?8.B\[C M5?8X><+C";UU-E:!?
K0EEW^W'P+=!N)D#?%J\JS#-UP,:#KNTV0TV7_&WW03 M\C3YFSX3OGP&[OP&[_YSWBZVTO-&A,XR^BW3_P0Z% M:\7<<\%8G!GNDYL9O5#2EX%:U(G_=G.C5GFGN"YY%@?
T!AP@:[%B4!(JY^.K MR+XFJR(XZ/=A[M\YCK*'=$3/\R;S'REF_!(3,F-"QIVP%%#TW2# M4&?*W@F=@E3'-B=,%=Z%D.!!/D :ST @7|+FMMH?>6+E"0UV&$Y2
M8I&G5!3E5E5T_&Y7I40KW&4=6C*2IZ12#2[(<+K#^UOEB^KQ\WKM+_+Y+^CDJ#|^G,I@OW\|/L%@?#3NCT^.970X[8_&TQ3>)@I5YVP@
M#@>Q2$UHG+)=MN^=N9=MHCI;F=V+;L&(V^=.[5WGZ1M5:*/CJO>24 BRTEK5 MEBFQ*)(2]W\>!6=TF=B]4@8-Q'0KMUYXHAVIW,@%)KS.16,!5MK)RV:DNA"@
MW;FB,OU<>_(YZTZ9,:PE:ON-^>.YLERTWJ.@473^CO..D/J.']9E#/W8!@O] M?"2'XU&M/(>6^V?:TJN2GT,.&:XUJ EJP 4U:F?2Q=UIM^<2C_/T$: MA+#,%P@^<-X64_I;WHL-
[\4V[X_"%3;WI9"GR#J+H\" ,(C"O@Y.>8Z/KF1I,ZJ1V8A7"FG&+5(&=2&AI5VK1H 26(';6!I16$"&" MF ?=J9)HGUUE> M?Q9 _!:X?<#W'*:CP=%!#Y=$>FKGC^B:]+R=N8@K(
TK_#IA+QNP/G?0N>Y# M#MC\WKGX"U!+ P04 " 60$1:,^WHEE\% !T#0 &0 'AL+W=O>NLKNR[6[FZ M$KVN>?.?;2IL7B]551[?LCND_NUN)I\7LI> - M:Q47+9&LO'8^^)?
KR,RW$_[B;*<.QL14LA'BP3Q*:X=SR3$:I9KXX'B]L@^ MLKHVCI#&OZ-/9PYI# _'D_?/MG;4LJ&*?13U#U[HZMI)'5*PDO:U_BYVO[&Q
MGMCXRT6M[)7LAKEQX)"\5UHTHS$R:'@[W.G3B,.!0>]J81",!H'->PADL[RA MFJZNI-@1:6;#FQG84JTUDN.M(>5.2WSEL-.K;T(S$I-S\K&F-A!FYLWJ]X2JOA>H1E/Q]
MSYXT6=2=907A#UA-5.80EN4@ (D1"8E+ E5BNEW5O@J#!) ;[)R,W" !XZH3C" M^*@8%;AIELY6O,U%PXBF3[",W20-3/GADOQQ+-' 3:,[L/('R'H_G>19P8[M/_ PR-S(2\F'/)
<]:N[H7J)>:[EA+2OY>R%9B[97QB_=U SQEF[JA1:7% #\ MP,(_Y&DR/]=8[\]%6<[S0S=!$X#G94!NQ]PDJZE)9L#)=[,XLM=DQ&G.>W(2
M)P9(+\E&G.BI8BTTF9]9:#)TY3T*!C/8\909D,V+@CB&DF,_X_6>%#TSRXKH M)2GGI:5CTBZF1K@6]OU #8F?H MK=B+AWN\)!_'WL!&+
['DMUM2VUIK3C>\YMHH*G1C0($>3A.L!P=M.N& ?DX, M#8D?SPYI_F_/T>W81&AWFK)S MDKK++!A+P^# TG'(U1M5V8A1;&3OQS;D*\9.Y/N"-JJUY)M>VZ:;^#,G+P-8
M#TN[PIFK@/I,^CNN*W#W*@1$22@I:6[B[(TM"-];\:ZYZ"H*S>:L!_,H[X8] MXOS:F6W8&D+./4QU+XU#TQFT:,PFI4V,1T:Z7F*E-WS?5Y*Q%T>BETQ^@S9/ M?+;,XA(>C+"+H&?
YT&QC>QL4"AR@Q@<38/[16OT'4$L# M!!0 (!9 1%K&&PO=V]R:W-H965TO&%*+ C46]4%*6&&BW&S,[UX%K5XXT! M.W2=-]7V.K-Q81/'A=NU:IQ?
F$Z.U_+%=ZA^W5]8V@VW6FI58>]5;H'@\N+ MR24_NTK]^7#@-X4;^VP,WI.%UE_|Y$-].8D\(&RQD4$X^^M
MSLG.I!=\/G[4_B[X3KXLI,6Y;G]7M6LN)L4$:ES*H76W>0,S;OW)O+Y*MS9\ M83.>S;()5(-UNML$X).]>-?WF]Y>"901-\1B+<"<<]&@HHKZ63LW.C-V#\ M:=+F!\'5($W@5.^#
/OM:XWJFU!]C5\ZWL5VK1(EQ: MB\XR^(3N?.K(HI>;5EOM5Z/V^#O:2_BH>]=8>-O76._+3PGI#F[\"/5NP=7 MK:Z^_'7(BZ-V#GLQ)LJI)THY?--2+=6@GD#($42EJ5ZMHSV]!-
<@+'5+A:_Z MU1E0\+!;H-D%$#Y*4S5/T_=&6PMS:P655#=W02J^4EHQ3_\A0 MT922+P[_#RKFH>H(IL$VG+*-6EMX!;P0+,YC&IUP'K,TS^ U3?*$Y64>]DM6
M$_=W_HHFO\RO)&6AMMXVS/XW!C$O?K?3X!/E'5'MD-"T"=Y-MJ# MIGI*-NM\GAG\BOV WGDA(N\+*XAQ_R_SDOX4 9&_$%]ACT:.Y21K:JZ4N$;Z M6P*
(BH2#8!'QSXDN,LYS%O%D&P1YB*170/$K/<4YVV7'X7/5H3\ :6Q@'WMUY[J[P7W9U3I0> /$MBG[NT6Z"WZ6[\F M(8H!R62!@3@O_$0 %RP3PH]SX)3B,??
CPH^3M/3C$GC*"IX%7]J&$BJPXG%7 MCT4IQZ(D"ZO']O=MIMTY-*I]1.>C2:U0]R50LS*KW3[1!:P3;^WS0NBGC)TB2DGF!E MZ@=4A1GWE%"-Q=05>!%1.@EXN_3
O$-45/1HH#0>C,&^>@#*OMZ./8=JDY5E M2I5YDG/_+8@R^B6^6$]BLN'W7E8,(KN578Y/D:>CH]/.F)II8BS%I:;IWMQ!O8O55G_P)02P,$% @ M%D!$6N9+7-R9!@ ! !D
!X;"]W;W)K&UL ME5=M;]M&$OXK U4I'(GB:0D2D2HYMP$YJ-$";!$YRQ>%P%'U;D2.*%Y"J[2\ON MK^\S2XJ28\EH\XC/XC:UYEGWI[=O=AJ]\VNF1T]E$S5E+WMKYS;GPZ%%--UUPJ.] ;
MKC"SU*94#EVS&MJ-897Y364QC$:CZ;!4>=6[NO!CG\S5A:Y=D5?R9"MRU*9 MQQLN]/:R%_9V W?Y:NUD8'AUL5$K_LSNZ^:306_82RNSUZF4 MC8?MG?
1;;SML62C+;W7Q1YZY]65OUJ.,EZHNW)W>_LJM/1.1E^K"^B]MF[7Q MJ]$=I;9TNV\U 4.95\Z\>6C\<;J)B=VA"U&R*/NU'D4;Y33EU=&+TE(ZLA31K> M5+\;X/)*@O+9&N/FC'E-
"_Z'V5\<)Q5K&U%T,'T;)@F+9B;AHQT0DQ M<_I=5VYMZ1>(R9[N'P)2ARO:X;J)7A3XCM,!Q6% T2@:OR O[NR,O;SX!3LM M.4VW>:6J-%<%?7;*,?
++';6W$3<^+DY*Y=QN5,J7/=2"97//O:N?PJGHSQMG$?/(D[O36< MY8YN59H7N7NDCQ7]KDRZIHD/!,*QU+6AD"*JM*/8?['H8^KT@DV[+ YD['IC M\J(=&0=TEK^F7QX<5QFY-
2.%76U$A5[Z_H^:$:E& ';/WV WME\7H!#:&)TR M9Y:61I>G]BZ8:LN9-#')7)+5)9,VI(JBTZG+C:H>?_YI%H7)&RNJ)J()JMY7
M:5%G3(KZR208C488OW\-9WQC2MDXL!VE:U6MFJ02:K_ M==5PT#9W:[]8(>\RR3U2< BBLLO%4_[(X*UJY:3$9B>3A SCQ3_D;&VY)JQR9/N]-F2?,[AIY-2;]I MA.
/WL=XEZ1[;^S7Z6>EZ-:&3Z61B%6@',/?Z]PT]%51*UG^OE4$8BD<4(!R1 M;^"\C7KT_"DZGB@=$(],IBJT%*U/#/ 9]CPBZ2RU^; W_;:9_8^D9)/"=,=R MJ1"#X%?OJ3[-X\1[B>
(@@:/13%'-HSO;-.27!! Y!L)&O=2P"G\)S M[U-G0Z-%P/0IB8)PEO@,D>1,E3&/,],.0&UI[EV[E>2PK8WV_(@WG\3Y,'IG ME PF>Y5]G,"_@8'/*8,CO#8A!]%FRJVMD:T@'FWAZ[-I/*;7W?JT-
D9X8Z.- MIYBSQC.RX(.N?ISMTS0)9]/8*[SC>UT@@>GZ1*FSE+]AMF2L:#:+1*V->.!"#)"UJW[M!T=*Q6*\,KSSI=M)I(M!)Z@LAV=""-1A2J\SR"\KK +YO\IL/R-"K=/;/*IY<$9+G;&:"
()VHKWV2OK MNA-'FQQD!SQ/ R0VR?EBZX5%_7AZWQ&]_9'I;>#SIQ\&43+SD_TX"D_2UM-, M"G!X58 (Y<+!S>U&#MUZ!0LIC&19.^Z@:;X\;WEA:G%>%D/RDHA#^>"]O' M6>
(8,WW=:'_8 97-*WA,(7CJ(:<-G(*B&=_H4HK*E]?4@^XZ6TUG81"/(C0^'$*]5T7-C=1P&GNI81#.9U*'!FY855YN=T#R TY:RSL^:FP[MM.N+]_/A7?VIJ1\D
J>GO>ERPSMHO=6U1/X9!MPGPD&=7MES=O8R0?^;:"M);8.AHDDQZ9YKW9=)S>^#?> M0COPFV^N<2MC(PLPO]1 WW9$0??HO_H+4$L#!!0 (!9 1%K3)C*.%04 M "P_9
>&PO=V]R:W-H965T=ZH6DWZ*UDLL3*2%6!QM6Q-PO?S&.6=P)?)&[,SAK8DZ52 M5[QYEQU[_0/" E/+%@@3]7..)%@4,(AC?.IM>?R4K[JZWUL^<[^3+4A@\4<6E MS&Q^[$T\R'
EFL*>J\VOV/F3L+U4%<9]PZ:5C1,/TL9857;*A*"45?LK;KHX M["A,@B<4HDXAG7Y0 M%F$"!W!A57]5]R)#;5[_Z;=&VMNC@:4K6'"0=N;FK;GH"7.'\%Y5-C=P6F68 MW=7[3%-
X_V&G&R+J0_#\#5$0I3OL1L_1TZ>\,]_AJP"UV1D]:I4BH(\ M%Q:ISJQYS-_67/RX.6Z9-Z86*7E9:J[U[,&]35ZTY["$?!SWO QCW8>)_UZ44N M-!
[,]>@R6(A;Q@@SK46U=GCACT]X8V%>4.,^? S[7NN/8V_KP6_+H;OZ1?% M 4.X-GK.;%FMP>8(%1D$2A"62]1]DO@KA$]TOE(%]3Q+2P-BV_>@5G!^|1E$
M14[Q[T;HK.U.*CE2TON,?R)&Z&"=H[%:H:6#BU\KJ0UL$#MN*I*GQ'\T#C3 M!,?%V<"E:V',#F!VC9HH"7ZA6%N@QD(X$U+#%U$T"#5I.97_P\3'QAI+L> P M"<.FW@N=YG<>CT?
P(X3)V)\,(>%U% ?^X0AF"#<#:[9/GKT,7T$8CN%PZ,HW6OW>GY?0OOERR\C6EUE6206L+!%F!:3-!T%2C(55E255K7-[Y+4!?Z#Y/ M%)C-
)97C$X>L=XDMY!8],4F*VM+;#Z[P%K"L"W6+:'S7 55?'QTJ%+HB[-0/ M&5K41.B=KR2,Y 9)HJ#LUW=%S&N!,FB]}A?>HQ$OJ*'27.)U2P2DMD5!K7Q M,R5GN(V@=<7&-V@LA
MNVW)KC4Z]Q:IVPKSH8]O4=",%L2[0M3_=Q):8+>0= MM@Q-2L7#GE7N_,$-EWQ[JM:5_!M;,V^84SI,+K7*/=_Q?#?1O?=.1]NE6!8. M,V%#1O5=.+XSU8?"E0!5NN
^/6!*9-.4#W7=!>F?-_[SA/<:SKY&" M?J7&,*]@MJ:*63-7OB,)2-?VA'FLS09'[;-,)/0GQS"T(^8*!^0Y [?W1$N M18:*46I"RUUu*$%?[W?*(Z)(VL^15 B6N5&/HBVO?XU[/1/*9T])- M0MO%3L8)%$T@5^V3F4&E;?
=6VWT?B2\RAY)R/<)>>3=%8HLKQ6I^=2[%KQ$ M,YH,HM28S*2TE4VY)<]?->?1_+,CA-$(7L"5]RI-W&*H&S):'Y@N\I. UU@,X6PT@#S+ MQR?PSGKE9Q'O[(3R

M'JR2I90/]O EGW]!30A+S(QE8+0\XA66I26B-'[M.+TNI 4>[O?L'YUVTK)D M&J]D^9WG9CWU1A[D6+"F-/=R\QEW>OJ6+Y.E=K^P.7T'8P^R1AM9[<"40<5% MN[+M[AT. */@!4"T
T0N[S:0R_*:&99.E-R LM[$9C=.JD-32H,0P1G,^4KP@F=,&%@H)C1SSZ;A[8(M2]3O)KZA>!;E9SON6SJG]\J9$D 7, M&DVW6L-E]JOAFKO"]&#Y=&B 'TX(+'!K8%;*
[.'G,4TGHQ[7M%@KQ&>UA%O" M/;=0;;!:HNKJ_?XB**A!WX-@]ZHG] :CGKC80B?E"0QM9(%-Y#TQD$"8=1+ M^D.XK*0R_#=S@D@Y%\1AI'H";;^:VH.!)E4-B 7D$EMK)?:1SJ#L!?
%T3\T MS#Z374L5P;Q>SH =S2*-4(X[@/ M)#>*X=C_Q#]HY@K5RHTL31DVPK1]W5F[J7C9#H._[NU(O6%JQ.F%2RP(&IP/ M^QZH=DRU!R-K-
QJ6TM"@<=LU3794UH'N"TD=LCO8 -VW(OT#4$L#!!0 (M !9 1%]>M@9Y004 &X. 9 ->&PO=V]R:W-H965TNA>;DNZ]O/><<_EQLC/VLJB2$Z;0K>3V4EX=V5G)V;K:MVJ*TNZ
M;=,4]NY0L?GTNO7TP^%VK7;3YQV)1J^[%R=0AO#>: MED.H\SX4>R)43MZ;UE4=>=,NU?);_RG2&G-C7W,[9P<#?JKR%>$Q)2QBXD | M/M,*0SQ^H-
:.]/4]5E[O+1[W]MWQNML4I3J=0/Z=LC=J,OOQAUA&/QW(38RY MB4/19Y>Z*]9KJ]9%$*M9C83\&1(F']6M(^>U*3__]5CN!Z,_GOO'RBKU#6<$
MB*MFH>R(.ID[976MO_1I%2UL=*?;U=!4%_"V$.WS^ 6YP*RZ+&KRBVI-H\N. MG&NSJ0KT3JFV+GRZ1%&UV:"K';DH:KVP?>"YJ;=^ 'J,@QWB8ID(3)%GR(3F
M>8Q!3C,I\2]H'N7XCVDD./ZYI!E>O"WL"5<(;G MG,0)37-)YH!"EYB$42'Q#14S?!"PC1)8193Q9,C)]H2$A#A-HM0GP*B4PX#Q M,!!4,)^;9#03$3D"9?
Y]H!P#1,X"RFF2!92C+,)_PGT]2)8]B7$,PYA*& *0 ME)&,LD1X4%*1[(/,F81=+'][C'#*06A.DSA_B'+LJ2!BHL\PIBOH1!.6G"P]*183%X1K*,>DR?0#N+O3C!1@KS MC#!T.:#D.@!V
B[0&$@P#NM.2#!A M7@\<:YL(HD]2)_)@7Y.#F,L=1,KG%)K*WK:RL:MC"24/9 M+M3_SK3KE^]P6EJ2LZY3KJ-D<0=VS-H6FRKP<8838'DWG0PN?^V-QW3\$&& M]Z-
/K7:PF[O"!0YXA*7#(\X@^-R3D:&'8C]|X)"E'7Z1AE_6_PKAPW??4483+D7!Y MD/#073CPXC#I]I%<2L;W@=:]YW>Z6*!;W1T- K@&F/HF<'L9SB<>YZ MF%L#(6@*&GU?
V+*Z])#0V4FR975QI([5=AOG*PJS;K57\"N;N_17FZM;M<$ M))'6RZ7IY:*>D,OS' MI3EZ0QQ-;>J]_%Y*2%K(>_/^)@;XUQHK:JU6 M<(U>I6A@V]]N^@=G-N%&L3
.P@K#"A="9;T!OJ\,3MK#@Y]@O&+._@%02P,$ M% @ %D!$6J7Z3+Y? @ &ULC51K3]LP%/TK5]DT]@=0U3_I@;20*0TP:"!7&/DS[X":WC85C9[9# MX=_/CQ
ZJ53[DMQKWW/N.;:N9ULA'U6%J.&Y9ES-@TKKYC0,55%A3=10-,C- MSEK(FFB3RDVH&HFD=*":A4D4C<*:4!{D,[=V*_.9:#6C'&\EJ+!:NB7Q9(!/;> M>1 'KPM+NJFT70CS64,V>(?
Z1W,K31,V+"6MD2LJ.$A4VY M_Y/G[AQV)/H'4#2 1*GVS=R*B^()OE,BBU(6VW8;."L.K011[F]E#LMS2XU M.)W?"(V0P6>X)%3" V$MPC42U4HT1Z\5'-V3%4-U/
NU:6=!8=%1+SQU\@[U M%*X%UY6"K[S$\E]\.&3V6I-7K8OD(.$%%D-(XP$D49(=X$M[[ZGC2P]X5^#] M[,/GT=E^M)V64]60 N>!&0>%\@F#_.-'>!1].: MZ[5EA]CS=ZYC $LL6BDI
MWP#A)=P(+ON%7\X*W..SA@43Q>/O?.X.]MWORAP\UBN4_>*#%@%]9:>$RE? MK 2O>$?\T7=\0@;)\7_5^!OY"-/Q(!ZE-L@&DWAJ@G@<#^+IQ$:C=!#%*>P[MY'!G$&J4&S?
N"@K1) M%HT;JY709DA=6)E7$:4M,/MK8^[N>7A\.=LI?6^V)8\UK(QY[.MM>W;^=R46ZBY>-::/#/6NF:6^SJ MS=RT&GCEC6HY9V&8SFLNFMGBS'];ZL69ZJP4#2PU,5U=
<_UT"5+MSF=TMO]P M(S9;ZS[,%V?$2I1 V-$:HA&M;GLPOZ]K)PX_V /P7LS$&; MN$Q62MV[SH?]?!Z@$!":1T"Q]<#7(&4#@C#^#)@SD:7SO"PO4=_[W/'7%;< MP)62GT5EM^>S?
$8J6/-.VANU^Q6&?!0*5RI_)/LAK'AC)2=E.H>C#&"6C3] MFS\./+S$@ T&S,?=-_)17G/+%V=:[8AVHQ'--7RJWAJ#$XT3Y=9J_"O0SBX^ M*0LD(:?DMFM;"4BWY9)\:'JY'6_W?
&5!//SV=RB/V&O&LJJ+ZVGV.<8[!L'^PEFP2\AO(-B6A 6,CB";QH3#[R>-%$\H;T^1U+ MK[>.CUN[?_WL00F71Q/ #F&>@5ZY)E\Y+KDTO)#YR2A> MR?
P0'H%'7)*-9RA"8JEC*B@B1JZA549@N!250&:#O,A'*]&4J@9B^2-:)D&: M,R=+E V)EL/$XGW"+,CC N&CF [2M/_U[DA2QVQ/G*:4A=@H@CC,IW1+1]W2 M%Y?#N[J5Z@F
W(#$B5B1WP1?"2FLFS4ODV?2V2OEN51-9TC+GWP)R0+\C#R M&N4HQF?V4[5>C^.C(,5"P5K(&%GR)ZVDQ$VOSZ_7C 9%$OMG M.FBV@@;63N\]2)(Z4<.TC9.D[<"Y[0.=^-
/(R%;3P,A719'EEHTS9BV6Z M&)Q_OSJ3/EZISCZ:56<0#]>EGM03+(4D3/IWDHWK*YYZ-.Y_S89(P$V?R(,D MHB!!MK#D\A27YH.JVLN Y9N
MV&GB74Z(4(PB%),B++5+TN*>OY3'MS(M5\)0I")WUXH?$0'+=R6-)2B/TX.,]>=$$K<@MU"H0$W-_<[SF%*W:V1Y[O>T
M*$O]F]+LFR#/,V'_,2ZPOX[WEHC^N/P_O+STXPS>B,3B+UV@:OLGP MW*#[BT3?L:KUA_>5LG@5\,TMWKU NP'X?ZWP##MTG(/Q-K?X%U!+ P04 M" 60$1:Q)??'I4$ "E"P &0
'AL+W=OE!2EQC(H\D*K%G19!N&81\8^6P3E427I.IT M?_V.E*(FK:L%6+]{Q\?]{GV\HYTV[^T&T<%=4[?V>+9Q;OMR/K?5!AMI7^@M
MMG2RTJ.1CI9F/;=;@W(9F)IZ'D>1F#=2M;/%4=A[:Q9'NG.U:O&M =LUC32? M3K'6N^,9GJUOO%/KC?,;\|715]Q&MUOV[>&5O,19.D:;*W2+1A<'<].^,O3 MW-
\/%WY7N+,/:/"6W&K]WB]>+X]GD5<(:ZR<1Y#T^XAG6-<>B-3X,&#.1I&> M\2%]CWX1,"=;;]7%,UW_H99NQ]]T]O?L;!GLSC5;]VX0N[X6XT M@ZJS3C<#,VG0J+;_R[O!#T]AB
>&..C="PI:GDLG%T=&I[#XVX3FB6!]X";E M5.N#\;W>I_$DX#E6 M+R#A#:(H3B?PDM$/2M@Y.JZIJNEHZT MI2WCU#\R5*-/Q(!ZE-VG216;4DAEUDGG#*7^H-
'Q\I5^"HBKE\$Z" M.PV=)GB^EHAOF@N\X?R>0#JV;0[H$1Y]5Z+>4 S%/B[T2]><=Q:JZ'R1*S/Q>Z&J=RY8=D*O1AZ <0I<&NZEN#5 3_@5, M#X912L^$/#?FAT.S"OK#V.]*;-PF-
NY,K.TKMX)Q^')G&3N9LTZ,=S;&I/4P M^5]-_D.OJ6M;^GWZ#&=H._L,8=GD\&!U:8]^|+?T8[^ G!]\;>NF]DZV MEXAJ]KP]G]52(AW?F"JE"CUK.KXY<"_X/W=[$,7]Q
NMP5/32H5R9>"&PO=V]R:W-H965T3S$DNQFSF!HWS..W74!I/)6HA'TWF=SQS? M",(2,VT8&/T]X0V6I2$B&9]Z3F=8T@0>MP_LKVSNE,N:*;P1Y4>>Z^W,&3N0
MXX:UI;X3NU^PS\<*S$2I["_L.FPZ<2!KE195'TP**EYW_VS?[\-1P-C_2D#8 M!X16=[>05?F2:3:?2K$=:=#$9AHV51M-XGAM#N5>2YKE%"?G;X5&&,;5W&N1
M/6Y%F:-4/\+MIY,K9[AX8.L2U>74T[26B?"RGG?9\89?X9W &U'KK8+;.L?\ M[_$>:1R$A@>AR_LX4O,7(B"%Q#Z87R&+QH2CRQ?="9Q!5U^I]+KHN/3T>:J
M7*N&93ASZ"XHE$_HS'_X+DC]G\YHBP=M\3GV^?V62;Q:DMER6+%GN@,:%E*R MND#3?@$+XV5S0+_;!.
!]QJ6)9W@'Z=R.;O:Z5P>Z.;U"NY0:#;MEJC!+$!FY>"C_J8'X%BR>4=/7A9\I- QD8X17C$CZP MLD5H*.J&_!\4[UJM-*MS7A? E*%ZPV2V'2P%HQ2^AR 9N>,($M,.8]^=I+#8 M,9DK*
P_97817$(0C& 2N7$*<0"!'[K)Z "C+=D@M\ 1$#(D6$C7Z^H R+G9 MI'5K(5%J,.G$C7TB#JD3$9N?GE!+_D>["8/@(/&-8C]UXQC&B6FGB3M*X(P#
MD\&!R7]SX+O&/*K_VHEG5SWMQ,Y*W7KJM=!BV'F2TO<[E%F7"&L MR)7'7AB@!^0=FOIE-ON&7BU)I.)E)?S*-P@7OR&3ZA(612&Q,/9Z30A.52GK M/?9-
9P63V!S..'#'$XC2SAX0$W#=<6M\EQBL)>7)\ &*?H)DU MDU^@IJ-_YIW1V$J*W22!T+5V'X]..L<[*BX5RL*64 69:&O=U9EA=*C2BZXX M?
89W)9[VI:"=@Q(W%.]35QV07=GL.EHTME2MA:;"9YM;^M) :0 TOQ'T:O<= ML\#P[3+_"U!+ P04 " 60$1:Y5-=4H$# "G" &0 'AL+W=OH2TU\W2ADA1.JA!\%0>97C-?>8N:^K=1B
M)ELC>(TK!,JM*J:^+U'(_=P+O<.'>[XKC?W@+V8-V^$:S==FI>CD#UH*7F&M MN:Q!X7;N7867R]3R.X._>[U"QHLDHV4C_;PN9A[@74(!>;&:F"T/>$U"F$5 MD1O_]3]]P:05?$D?
M']TV G+AFF\EN(;+TPY]R8>%+AEK3#WSS.P5P* M[5;8]R!!WFKC:QZ8?*@XG6WL^<^#F\1B'J!R/G=&7)>WC##%C,E]Z L-VFS MA(/JI,DY7MNDK(VB6TYR9G$G#
<(4WL/97U+K<[AEJN;U3L,*%:Q+IA#.'MA& MH#Z?^88,6C$_[Y4O.^71+Y1/X8NL3:GAMBZP>"WODZ.#M]'!VV5T4N$-YA<0 MAR.(@B@YH2\>T,=.7WP"O88.WS%XG71R7-
J^ETO=L!SG'CT(C>H)O<6[/\(L_M^#"MV3P+3FE?;&F]U>T D%NCV1E!$NF>0ZL+N"&B]9@ ?\X(/" SP:60N:/ M_Q[#=-+J<4P/I4)\E4N@3&"U(6]L-
NY(R8EKFRR[Q"^H.^HW9*5'*]S62&P M)\:% T"M!K0%64I1H-+P)YR%HVRBOV%QQCOUU_M/:D*Z5%];(7X#D6?G=Z-GV8S2V>)HY,^G7U(
M\)#O!OM0V!@$%W'H0D#$U&W3U&U!-M3 [RI(#@I.5&PZ5&SZYHJ]J@TO#@%: M8]XJ;CC!OWW.16LK9*MD!=>R:EK#7'\^6N9OK.FX7?OUO-7VE:;018RYK*D/=
M@S(E0M=GXB2!+)A G';[VI45VS-5:&)C!O9(D!F%[OT0NX1R$XW'U@)9.1! M&B;ZBNQ%\55,#_5VNUK*. U@,DDA33.84.Z/)=E_3PJ5#LW(C6!:&O3S9'A MZS"%K[KA\Y.]&^%?F-
IQ>B$"MR0:7(PI+ZH;B]W!R,:-HHTT--@<6=(_"526 M@>ZWD@+5'ZR!X;_)X@=02P,$% @ %D!$6J+22CA_@ @@4 !D !X M;"]W)K&UL?53+;MLP$/R5A=H4-AM#95E.4UM
MG*9H#@F"Q&T&8#J*$Q@ *&2=$*24&D\I8! ^,J_L#C3^)E7R(X3X6)K(&V#N 'F.S2:$5X*$5V4*-PNGJZ$QZTY$JKNOB!!$R U$ME*N"5SX=#XG71R7- M%$F*,!F=Y4&'L(%%Z&T&PB41(%J)+9*5JE4PE9U:"TA*Z4DNK7 V-]
:TYWDM06\:(_+=$*G8++_(.$P_UIM)V(LCF#=G@(^H?S;TT6="S%#5# MKFK!06*Y\"ZCBV5BZUW!SQIWZB@&V\E:B">;W!0++[2"D&*N+0,QPS->(:66 MR,CXVW%Z_986>!P?
V+^YWDTO:Z+P2M!?=:&KA7?N08$EV5+]('?L>MG:OER M097[PJZMG24>Y%NE!>O 1@&K>3N2?7<.1X#S\ U W %BI[O=R*G\2C3)YE+L M0-IJPV8#UZI#&W$UMY?
RJ*59K0U.9W="(T0A?((G@N&L")[5#!:D35%-9X' MVFQB2X.\(URVA/$;A)_A5G!=*;CF!1.O\8$1URN,#PJ7\2#A5\Q]F$0?(0[C M9(!OTG<\<7R3@8X5M/V=:J]%)Z?1UB,7JB$Y+CQC
H7R&;WLP[LH#;\:$MZ_9H/%=L*8(HX4JP1G#D6MGLY7;@>F\B"21K:-)U.3'I=EN@LZP@D,?]G/@G;'HW)_!V1A2?>MP. M%,Y.G7YPY N&&PO=V]R:W-H965TO&&R
K262>LL2 TW2=076KDBR[<.P#[)\MH5*HD712;I?OX>4 MXSJ8ZW5?S"/%NWONN1?S_;'83_V:V=%CVW3Q6CMW.9L.NVK-;=E_\ILN,.7
MI;%MZ;"UJVF_L5PN@E+;3&44I=.VK+O1[#R:'_H#F7PD[[BIO&&..OGAKN9 M&E&U[9UI=\I T-;=L):/.QX.%/+H*PIRIR #[L%10'E=NG)V;LT#67\;UKP0 M0@W:
%=W/BFWSN)K#3TW^V <4RSI)=WR"F0[>M<-J?;_*>F\ZM>WK3+7CQ7'*C'N@\@GHI3QI\)JK5Z1B03*2^H0] MM0]U?.N<]9NRXHL1>J%G>\^CV???Q6GTPPEL>H]-
MG[(^NT7K+;8-DUGNTW+#&V-=W:T.$R1H_GE_XX\0#-W0HZ/+QE2?_CP6UVG/ M=VO+_"QU!.*YG;-Y'__1.??6[\CS]0;OB>NRVX'I>3,[IU;.NF_GNHK[*#
M@;]ON^6N2:]@VJ()QO,)O2"I!!)E$.)"%)5#2'.1I@6$1 JE$[I" '55-O26 M.]/658]:QHW,+XE.224BR2+2L="IILO:;-8EN*MXZX+:-< U9A/X@XI4&15" MJXA4*F*TA@&NM-
"R\'IQ4I#*A2XD*2T*G=.=<3!O MGV('E[VEBSK-W_I'I.$6'L!26*Q LZ M$W'A!0*+XOP(56E "D5=!(:USY@HHO\B*A.)*B@!*)BDISM!+")# ,=Y0IA1 M"BWI"55")KGW$R71KJA#V?:
[*EX=<$"J$%FB28&R1!$2@C6G(L4ILNKI&&R^"%8CZ2G;V7WA+:>%!JS*=!6X1[?5 MCMO^C'[9L(\+!_R(/\2>O7J1)<$**K(*6 ;B\Z3@]MU5YF6:=P PP2<95D! M6!E@H7IR"..L\'
F.ZE^9>/\: ^$=2QY[TH4AI+I%-!!1GS^AH@)C3^.3C@ MTG8PT-.<,23XR;TK'T,10E?&WCF"1O)37XYH,5^68Q6G-#DQO)+]\$J^>?7A= M,Z9C57^IX->M'V*[DGZSB+;!M=@)K\
<'\K/9]+ZTU?K9E-+?VF*>I4SZ LG MO3XV=2*11>BB6.3(S>GV0>.@F%.AT&C'&P8WE/1MAHX!.T,%?AY=-39;:=&YX'^]/]X^KU*,X""R]1?P?6GP9[O;> ?[)^?L'U!+ M P04 " 60$1:
<)NR)/0" ';!P &0 'AL+W=OYKR_GP4]J)SU'-/"29T(/H\1XTIO/(.M9"KEDS6NDZ$76"#,#8V J_)9YCEME A/%GT/$DQ9D9D[N;K"]IZ.C1?+3+M?6%5[P_B
M0AN95\Y$D'-1_K.72H<-AS#!>,;&9DTW#T04:QC,-]_AB"I:] MI$:!/Y<84S^6""3A? M8M.$5KP\/D HX.WOX:QJ<*ZS+#NLS0Q6WOB#MFK]1)1H.1),A"&!6: M=FF-
N@&72NJMN&78K@MK&WP9]7NM?F_@+[?0'-ZCJ).8H8X9#E MBU/ZS..YD)F]1WJKP*2L(A1N_4VEHF+O'.=V>J.P&>I]*&L&582=Z?1]'/P%0 M2P,$% @ %D!$6J^!R6X4! UQ_!D
!X;"]W)K&UL9BJ*,V]$.LV$/XKA%8A,#,+;!KW[+.VI7?:!D"W[#W^U&W'L^V#&)T- M2J1"4'V^6T#2,^O&5%L?&&[UT].)U^@ST'&+Z] SGJKCAJ]]0NF^"'*'#ZH=
^QK^(/8!S^H.K)EO$$2W7+=Z9(.> H-TIBT[&LH9E@0HWY-!^[X_IRV1, M*-QO)+(DP?S;&>F)VG!FV\3AP3W9]J0?,^33%.UB#_J)S><75G5)B@128 *PBCB
ML)T9"_LZL!UMD,_XD\!1G%PC'O@ME@ 2L6_T4BN9\98P-%L,59+._9\3,@5L:N"]E\$H# M[Z4,@]{@#]TL8L^%\|'$\REG1\3U;(6F+W+U4Q8#8%BTSH1"$0(OP:T8$*>:\]4%B
M$HMW:O;GM8_>OGF'WB"!T:<]RP2FD9B:KFG..8\XYF+,AF5>X$" M&PO=V]R:W-H965T67VG\]G!7A^-B?5D(>4W.WE?C+R> MW1!PR(UEH/C:P0XMT2XC3]J3]\Q:8"XWOVN?,=?
5E0#1/)?V>%6#8"\OD<* M6-(M-[=R_PY]Q++ETNNW9_9U[H[/1;;619@W$')1/5FQ[].P!@N@$(*P! MX6- <@(0U#H,2 ^ 8AK0/Q4"TD-2D)Y](:T!J8M]%2P7Z2DU=#Q4O>W3
MW92\^/GET##=HT>+\O&:?5.SA"?:(7$MAUIK,1 %%!WYV'O_F#-Y'3QMWPWMW M^%9PBGD%R0*T&P%8=^YD'1YUN?.?X,__M?4'P8B.W$>.+S[!^Y_RI9(E
MF6"@%9YSK#^S)A-7>:!>D=DAY]N"B16YU!KP*NC8_5Y8U^"KUWU4X%2 M![(?P=TX#?MQ@W]#?W>,5H4#OPQK_\%*2]7[L*_3G)9L])-G\FL@>92YK,)?_C MD9@D[>KN)W&[N-
MZ43_*VK7=U@OZ,[*@7=K=A-U5G7J^J]P%+7 M)6PV"?X8"G"55 A#>L^2#L1Y5$2Y337+2GP,J,[S&J,&@&8D2A8T%H8;D4FC) M65&O,KU15=:
[#K.Q1899456G4TV,W+B;>2$-EI8; MKK$Y!&45<'TI\7:N)]9 TVZ_P902P,$% @ %D!$6J;,8B 1"0 4$4 M !D !X;"]W)K&UL05kZ-(%OTK)6]K-2-E
M8NK!*YM$ZM@AC%:]V^KTS'QHS0=BEVTT#Q03C*K_?%;@&.,<<&AJ47]!X93 MIRYU[Z7]7!I7+TGZ1!;A7*#7;11G-Y.-$+NKZ31;;/@VR"Z3'8_ED562;@,A M?Z;K:;9+>;
L&FVC*3$,:]H-PGAR>UWL^YS>7B=[$84Q_YRB;+_=!NE?=SQ* M7FXF>/*VXTNXVNA@Q_3V>A>L^2,70^P+_+7],B#+<\SL(D1BE?W4P^XBN? MT;Q!@?@UY"_9R3;*3^4I2?[(?
_R\O)D8N4N\X@N14P3ROV<^XU&4,TD[_CR0 M3HY]Y@U/M)8O->DY!N*X9B[-YSN34/LV"]3ODZ M**(K61V/_3#G(@BC[$S)^N5QCG[Z/Z@,(8?
=TD^RR(E]GU5$BC]WMW8[V4SD8QQ$A,R,R(YV$<[ZX1!1?(&(0 M!MAS__[F%#}=8;W[W]U[;3#H,3QHP<=:^-X\OT]3+9K)@4[EQ4:&J-B@61&< M/+Y@
]Z^+:+\,XS7ZF&5<_EFBK\$K8/Q==V??\.J0_)2-K*)1?BE^OK6(PXSK MZ?.I5YHHHDS*UE%>$X5MQV$*S =@IDV<"E8;3'8<3-9Y?G+\Y!01/$4\0]\^ M\>T33W]'_T5?TR#.5CQ-Y;@%
GU.PE@4227GB".&IC.WO))]RK;!0M^,X&S M6L;39SZY_?O?L\T!]ZX-+&IQ6Z>3C)?$UG-9-,19>:>1]\K.S-/XHI:CN$]H0R@M_M,%%17A.%#6RK>>$W8Y#+1..9.LX+%%;GL/A@NGP)4H[D-
1\])BM1_-1TYW] MJHUIG62>3C)?$UG->?;1>?:8,6TWX]"T4N):0!%;&8J,=U$,9,Y1-GD)HJZ MKMT2TLYQ5)S.47F4HQPN] 1Q9T]]@UF@F:>3S-=$5G.7>W27.V80N\#%E% E
M/.^;*-?$ZG6Y":+8(EB)X2:*."YK66!@HUK-&YW#\N\=3^6R79[Q[U]+B2EJ M*XU'P=,P"O]3+NSS:[=J>=3C9/*YNO MBZWNM$KOXE$%[YG>6A3OH55]M6192LK=@S"366KR-&'4-
&U5*PAIG%6M*@M$KVX6_5V\\%]5M'V+(A_FT@-1LLN1W2FA5?YJ9?.TLOFZV.H:K"0P M'E\(.VD1/,F5U6&A0#L=8U1D
C#@FL5HRHA+/N%L]GYD8 M@BA\2LLEVE,2[?.,Y.#5M&LE$SE?'>FM[9,*0T8T0M M(D$P@DU5K0 PZC"WD0H C+G,:4F%2G3C,M5]]A4&%$PUR1VM4EXKFZ>5S=?%
M5@^$2L[C4?4\O2UX,I8%2W=1K6)J!:8#F4]*G5A%F&8QFJ.#EC0XMH:9(S MDS@M"4FJ @(94D 8F)#]-$^WI7US3RN;IY7-U\]6]WE5:B!CEAIFI*FG72G6 ME?
D)0MFF*OP!%+&PJ9#Y$$S.8D9+-E02G@R2\..RX?NE3[?5O3-#:S5 *YNO MBZWN_ZH:0.:L!LP((+'=QNT_ZH!!)J8]#ZH!
YNOBZWN]ZH80$:]{4Z@N]CJXQCW_.JDJH(!0,10:V8^ MU*%#6XITH:K>4$ MK6R>5C9?%UO=^U4Y@8Q:3B" XG=LM?@,H:SF/ 64!4RL/A\ H%R3M0@:6LE[M.D3>:\N
[Y?/G922ILS-K5(&XB;$O4!&0!E,Z98\'#. M EC< -R69;Z,:R=\|YI+29H9?-UL=7]7143Z*C%!-J4 MW"YI+-: N@!FJIP!4,0U&B]40<\/M)7=:"7RZ1"1/R -!@@8K1)?
YNGE>5F&>CBOE#;Z?OOS+#5!4+@)4O<_O 2A, MJ'JCWX=@AN.VJ'F6]_GZGDK=L;//7\<2[F1E=F!TG+I0+^3@1* O7<;B2 M%WUY,%A=LP#H0<,Y'(/6GXS/
D6<@42*P>3@B@BB[_$9D!_E02\Y= MDHF?@L6?>ZEFBL1Y^.>]@!#';1S(ME_LT\]X;80?0%%C+\#CDW/DO1L.VL3:QN$R87&>J&J*+S^-/Z/>,TQ0:DU;/!!4@LV)=?#8CDW[N7J
]G]D\@"#CU!YI/CFQ;0ZA?); M(Y^"=!W*]W+$5_)TC$M,SBYI^?F.\H=(=L7^()X2(2\+Q>:&!TN>Y@!Y?)4D MXNU'WL'Q(RJW_P-02P,$% @ %D!$6MJK!^G> P CP\ !D !X;"]W
M,W)K&UL05=K;^(X%/TK5G:TFF_<#I!H$T@ MM%L5.OMAM!_0]<_!0U[]&0][!S-E]@UU5 ?=6-%&&H4OW$Z,?OQ^=\#?M6=?M/EFL:? +#$?]^P-G4P(\#+)3RKU^R<*!X>H*2V+!W&1QWBGDQR$+C_%7D2K8]:^-AXA6P:34XHJ@J(/%/]=-G2D
+@9T(6*:GJ+'*!B,3D]$]VS+!ZJ8'#H:SY^Z,A)5N+%M&9SF)E=?\$52:E(VV1VUQUY+[DFZ?WR9YVXAH*H1C'BX]2[]&G9+E$MT9S_>HJ9JXA#F4V..DS3K,2)#BL>-%GDXGUXP'8L&-I1%9-
1]@A7[6\1-A70>)4HE\D;.1@(<%@$A0.:>,;9_RIMJY^YJY/0B50'3D4E%N7E\X"#:A%:HN!?1^(!X[4$TOO!K4\UCUAT@BKL6M@M3+8[4T+$+P*G\D%G\UU97*B8*"$01R9&%E5-$HAH8B#=!1@F1
!@QJ6@U*QJ91+!P6F4\Q;%QG7:6!Z_M2Y\M)@HX/L\"*UZ/^\U%;'L\F!3DAA'^@!O!V6]TTHU/E\EQH=^NI^HN4(JIE@K=8N#KOPGB8%([PB4%WI;B8&X5X#%_>N%%X5P)&S[G
6\SDD(@&TE[[X2*OUWQ^5A/VVEQBD2SO)(@DC#*ZZSOBLU^Q86OW!HR0!OOA:T4%8DFM.!HJ^NKW=]Z/[WH@G%9XG1MG=1H@J@F/QK*Z*G&8GM/;D+8BJDL0^&E=@J!D!X!DG8ROL3]W=@D[0BQJ@H;$6K
@`\*Y\0J%FY\ *C2]Q$8%H\C!0=-J_)^3\/ZX*;H&!=_+^;HU%_7%8P_<*JL02/!OFUG5K0JIY3Q\%]R!`Y]%I%8/8=MZ-E%3DG0Z+J:-D0J1/FB$&F]5L&F$2DIX5U+*@3/EI%E^/%8F
+I6TFIR M"[YRMN2"6XX&CN9H&1?F&#X E_"J4HUALC!I.(F%PPKSKN*LK1B_4O$"JA M9>"K<+#X.S\D]KV^G+'X3<([Y&0P)Q'!0CN[^9P]. X#=@A\|W0XXY>MP>U]$#L?
3N@*""9S/*2[A4L\G'L,FVPP3B9)&FX.L!CU+$9OLEAHKC0<=/[M/.@]Y*J4_#<6[CAT>W@&BD9S68*M$"0!0=U:CA$E%X=%C'L1XW=;":QPI-[^ 0D-2JUVBG>&7%(S?
B%FDDT&1X6D_1BDO]{ M+Y*7]V)T'D7_L CW'G&-NO2MRD"N&FG;J]RO]MWPJFT"N_"VE=XP77)I0."* M4].SX]QE,BSSEJIS1O+ MDN$:8BI/^ 82?>>&BY@J?2I6EMP(H,O<*

(XLU[:'5DQ9TIE.\FN78CKAJ8I8 M I>"R#2.J?AQ#A&_.^LXG?L+5VRU5MD%:SK9T!5<@_JRN13ZS"HI2Q9#(AE/ MB(";L\[,>1.XN4'^Q%<&=
[)V3+*N+#B_S4[>+\|Z=M8BB"!4&8+JGRW,(8HR MDF['MP+:*7UFAO7C>WJ0=UYW9D$ES'GT!UN]]5GGM$.6<$/32%WQNW=0=&B0 M\4(>R?PON=L].QIU2)A*Q>/"6+
<@9LGNEWXO7D3-P'4?,7 + _=8@UYAT#O6 MH%\8](\U&!0&@P<&3O\1@V%A,,S?_>YEY6_:HXI.)X+?9]K6G902Y7;JU? M,$NRD76MA+[+M)V:?N0*2)^\)@%E@GRE40KD
JA,!>CQHR1YZ8&B+)+D,WQ7 M*8U>D1>$)>3SFJ>2)DLYL91N1@:SPL+E^^3EBU<'VC4W8V8;<4+LP9,8SXRYH.*H MUOAFS$>^/2'.*,>X!DSP1*?2E<:X&<89&]YUKQPOO9S7?
X3W]G>?S,)O*9,L MSPQ_7D"\ /"7H6%@)&4I\XWT;M3U/I,XB)9GS>,$2F@G<)>]XM"3G-+S5E_6$L@21WR ?&%VP MB*D?AZ3?.1KFCK+);3L=V[8]L;9U28VM:2LD)LS'A
5(L(:D@U+2P<^0M%N; M#@()NW,ZJ,E[.MZ3U]BRMO)BPGQ,6($:\@[+.4=/BL;DW]] G;)^V23*MDE M'V +$>D9D[;18=NDC0GS,&$^)BQ @C6&P*@< J/_()'QT2XL65MY<6$^9BP
M G6D/>TE/?4+"]$/Q+%PJ,7749CP8/X-;:LK;R8,!\3%B#!&O(Z=O6!;3\_@O5$ M_4FM09 //%F]5B#B4F &TACH9K=M(QV5YJ'2?%1:@$5K#H=:O<5I'>^/AGM]
MOIZIQ@CRJ#H8]V;WK8<%)LU#I?D%K?Z1ZOP>KE$"+)]-N=U*;O<_1?]SE^EF MMZUEQ]1YJ#O?E19@T9K#H:J>.>;RV<^;[0NWYNG>W+;6*J,6T5!I 1:MJ7)5
M1W/,A;1/.HP5399:TZQ\.R!9E?V)V1RSY#1'I7FH-!^5%F#1FDI?Y37'7%_S M8*%TWI9*I-F_2[KD"C:I"=4 IG%/$W40;$Q"U#S@E:?!T>#O6]KA^K41Z4%
M6+2FBE45S3&7T2X%2T*VH1&I1>Y!X89[:78\VEMSS,WN6HI5U>E41<\PEL,V< M^S[1'\X@%;G2WT1=0(B^Q])H]@H1UPQ>6M,J6:O;<,*E>:A MTGQ46H!%:XZ&JBCEFHM2']-
,4<)OR 7]6T^H[(?W-U3L,J+H(GJQ:;NN;Y9O9K.KQW9["RI6+)$D M@AMM:I^,M%YBM\UN=Z+X)M\6MN!*:YT?KH$N060Z/LW7"^@BI(,0;G9&PO=V]R:W-
H965T30MA:611CLTI#$A.MB':1_=>^SI92/6@"P!#'DLN],_KC*G.?5]G M!914G\@*!.Y,I2JIP:F:^;I20','*KD?!4'/+RD37IJXM1N5)K(VG FX4437 M94G5TP5PN1AXH?>\<,MFA;$+?
H4= 9C,'?5C<*9W[+DK 2AF11$P73@?0C/ MAUT;[P+N&2STRIA8)Q,I^SD*A]X@14$'#)C&2A^YC $SBT1ROC9<'KM7UK@ MZOB9_=)Y1R\3JF$H^3>6FV+@]3V2PY36W-
S*Q2=H_#B!F>3:_9)%$QMX)*NU MD64#1@4E$\LO?6SRL ((XQV J %$?POH-(".,[I4YFR-J*%IHN2"*!N-,';@ M4UT"N@>I: =;*Z/4=*G(RI$H] M,3%KEN24F *(Y='D<
2&,JZ/$#8&P:1J+KQ'G5=;!0/7[\8C^W.7XE MLC7_G=9_9Z]_5^=M#I>PGH/9GC)/ST[#7B?QYZO2-Z/"TS \Z[=A:Z+B5E2\ M5]1';1A>=7=*MQ_P/R?SUTK$;,D256WT,?D,<^
DVEO#O1K^M8:O1+:6KFZ; MKN[_U;"[6<.X'YZ]].%F%-8Y"#LO:NBO="O[4N!-G#&A"8EO4$L#!!0 (!9 1%KF M!2$&PO=V]R:W-H965TI6 MOA"_W/,\=^?#Y^&:\7N1
DCTF&=4C*Q4RF)@VR).(5+ M6Q0<<&) >69[CM.U:T&DD-W!P_L7\RL:M8YEC A&4_ M2"+3D=6W4
(+7&,RAJV_0!V/<3!FF3"_:%W9]GH6BDLA65Z#E0O(.G2!"T6W*2H%I(H:V5!YI7CNNU<>5NO>,>@==,2I3 M@:8T@:0%'QW&GQ_VRH333J\IW2,O8.$$<1G]..^1Y[C^2W^3%X.
[[2%\SKU MZ7^K,R6CT]1&Q_#YS_*IJRKT'6=[M!>;2:LQ$> M9-+W^4 4.(:1I,(F@*_"M^^<;O.Q[8Z.B99=$RRZ9'(MHXC:(XC>%7%!?LE MX
4[!7=0X5\SNR_8#YR=NCR28)4P>^,]SX$O30\5*&8EE=4_MUEMVO2%Z4X[MZV-W,'%;UB/5UJLN_)>^>A-<8;XD5*,%DK*.>NIP'C59ZN)9(5I)',F55LR MPU0]38!K
[6_8*J9U!,MT#QVPC]02P,$% @ %D!$6NLUG<%7 @ \P4 M !D !X;"]W;W)K&ULC93?3]LP$,?_%2OB :1! M^C*M9%&*S0>-B$*X]DDU\;"L3/;;=A_O[,30FC3:B^>S[[O^7-GGV>-5&^Z
M!##DO>)"S[W2F/K&]W5>0D7UE:Q!X,I:JHH:-^7&U[4"6CA1Q?TH""9^19GP MLIF;>U#93&X-9P(>%-';JJ+J[RUPV&2;TM@)/YO5= ,K,,_U@T++ M[Z,4K *AF11$P7KN?
0]O%JGU=PZ_&31Z,"8VDU3:?4G3^08>R;?:R*H3(T"%1/NG[UT=!H(P.2*(.D'TOX*X$\0NT9;_MI;6DAF8S)1NBK#=&LP-7&Z?&;)BPI[@R"E<9ZDSV2QH@*;DDJVU=<\#S,923
M>]'>#UOH2[1V."T5 TW.EV HX_H"YY]72W)^=D'."!/DJ91;346A9[Y!+AO= MSSN&VY8A.L*PA/R*Q.W@51,B)?G);_I.J8W,=]J"]6)^I)$+EYR)-XC;;#" M!A2C?
#2;5CYQC>$'O&:QG'>WUABWNV^"3;"_:$K7:M9 YZ ME*X-D [V38)@C^W0)XS2R3A:TJ,E)]'NF&!X#PNRD7+\%B2'NX9A/-UC&_&* M@T%U@\"E/5QZ$NY)VFO-/B_R&%]Z<&+1-
(RB/;Y#KSB:7.^?]S]H2?L&ULC95=;YLP%(;_BH5ZT4K 7/11"(;:)=IO=@6->UV[*$8K6 HDF](DXN\3 M,+Z,:,[S^>"%;@ME'KAI4I,MK$"JU4NA9VX?):&[T5
M_**PDP=C9#)9<_YN)L_YS/$,$##(E(E].T#YL"8":0Q_G0QG7Y)8SPA12E 272] $"-U+;9.(J#6N6=+,. M[*D%PR? %I#=H<#_@K"'PQ'[_+S].Q&G[*XN45\GW-<)VWCAB7B?-8"]/C\2
M1A-J(\0V@CD]'VF (S]Q/PZQAR(\#7 O^@\NZ.&"LW +]+FD.A2J=48'Z_E! M,#F"&A%-H-Q] +"'"B^J&*TR7@29#]>M7"P=A1/\!'@4.3CX'X<,.H!H[. M[5;:NJU,[%8> XP&:^>.#T"'(J"
(/3'>,>,#X+^,K-6:R/=IX]AOQ"]GBP MV_S Q]X1_% U#;WCS^]>-!G3X/4)V])*(@8;;?/N[G7RHFV:[43QVO:=-5>Z MB]EAH?\S((Q O]]PW7NZB6EE_9\K_0=02P,$% @ %D!$6LB$?#V1
@ MR@8 !D !X;"]W;W)K&ULC97;;J,P$(9?Q4*] M:*5-.06:5 2I2;3:7NQNU+3;:P>&8-5@UC9-^_:U#4%L0M#>@ _SC[\9/$-T M8/Q-Y 2?12T% LKE[*ZMVVIY%!@<B+@K,/Y=
V6%AN=9QX8GLP8>].3QW1A.1H(*"12 M>\#]]0XKH%0[4AA_6Y]6=Z06]L=']]-["J6'1:P8O25I#)?6#,+I9#AFLHG M=O@!;3R!]I>P)U>$'BMP/M?@=* M?!-H0V;"6F.)XXBS
^+:6GG3 Y,;HU;1D%)_Q:WD:I0H@W^Y(Q2A,I4+:&C$B!KM<@,:'B1AF^;-?H M^NH&72HN>KH<>5V./.-O>L'?DI6U0!7^Q@#L*0]TM#(==F\QW=T3]D?D?
FCY*I]D(3YGM4F*03J>IKPK)LC+5Q&/0Q0L'@X42W6;)/Z P,LQ/3OV[A..!\F##O"<)3PF>GJQ&T]5KUZ/%(/T89G-_UY^[\A/?< M:C[W@Q->N]=I=)=7I;8GI4
4,B5S;N]4O+SIG,U$LLHTGQV3]I698:Y^-L"U M@=K/F&I [43WL^[W%7\!4$L#!!0 (!9 1%I^:S/I]P(&@(9 M>&PO=V]R:W-H965T/9;02\DEE M)]L/]RQ1:;-!WLR*ND"[D$_EK<2
M>W87)64Y%(J)@DB8CZU+YV(:&?O:X">#=IH$Z,D%N+)=*[3L34P0, AT28" MQ=<2IL"Y"808SVU,JYO2.&ZV7Z-_K,6CEI@JF K^BZ4Z&UN115*8TXKK.['Z M!JV>P,1+!%?
UDZQ:VX%%DDHD;?.2)"SHGG3=9N'#0?'W^/@M@[N>QV\UL&K MA39DM.P9U70RDF)%I+'&:*91YZ;V1C6L,*MXKR6.,O33D^]" PG(*;FORI(# MKH^FG%P7S?
XPB3XE/W0&DEPFB:P@)5_6N(,4*'(\ TT95R=H\G@_(\=')^2(ML((\9*)2M$C5R-:(:":RDQ;GJL%Q]^#,(#DCGO.)N /7[W&?'G:_H7*?NXV) MZ;+C=MEQZWC^GGC32DK,",%#
(S$;Q8)PP#U#.*,QXTPSZ-78! WKH.88+2=> MX 4C>[FI9-?(/8_"SN@-K]?Q>@=YKXMY T7>/ZE/2%QASZ)LHP<;)= M(]_;D]&@ PX. M=[OP\HV)G+]9UP"ZC'R-
W(\QNBL",*#Q(]"'-"17TF:7LF MH3V3?:!A#X,7;*=NU\IQHR#]1QUVJ,_)V_WXOA] WD,\D\?[<& IJ1=])(F M,+:P9BF02[F'S\XX>!SWV7QGX*]T1YUVJ.#VE]5QY7"$:6:0]DG.=JY"()@
ML'U,]!D%PZWEL3?]@*G!>!TN6*'PTIJCV^!LB.LKF[K6=+0HZ](0"XV%IFYF M^"L TAC@^%Q@>6@[IMIT/Q>3OU!+ P4 " 60$1:PDL"S;H" "_!P M&0 'AL+W=O%[D
M%I@P)XGMMNV1Q+Q2E#"X%DA618"%[S.@?#ET?.?IPPV9YI\!<).XQ'.8@+HK MKX6>N6V4C'6.!?).$,"9@-G5/_9#0P> OX3F IU\,(.)ER?F\F%]G0\8P@H) J M$P'KUP)&0*D)I&4\-
#&==DE#7!_13^WWK67*98PXO0'R50^=(X=E,$,5U3= M\.5G:/R$)E[*J;1/M&RPGH/22BI>-&2MH"'L?N'/)@]K!+^_A1 TA."UA%Y#
MZ%FCM3)K.XP53F+!ET@8M(YF!C8WEJW=$&.J.%%"_R6:IY(KK@"%Z!!-JK*D MH.NC,$47K-X?)M&'Z)O*0: KSM)*" U 7PF>$DH4 8GVQZ PH?) ^\F8[2_M=X#V$&'H-
N>5Q"R3L:NT4+.YB76P'*HS\%>J9IEZK MJ;=3TZO.IH=J(ZCZ:ZU M5W.UZ?XR)TSJG3?3/.]HH/V*^KJH)XJ7MN-.N=+]VPYS?<.",#]?\9UUVTF MIHFW=W;R!U!+ P4 "
60$1:\L'QD1X# !$"P &0 'AL+W=O4/?((0*#G-"%\HD5" M9"-=YV$$*>:7- ,BOZPH2[&02[;6>>&8 +W-2FNB68?3U%,=$|\;YWHQY8[H1 M24Q@QOA?#!"EF+]>0T-U$,
[77C,MX'0FUH7OC#*]A#N(AFS&YTBN599P"X3$E MB,%JHEV9H\!5^!SP/88=WWM']I(%I8]J<,:<:(9*"!((A5+ \K&%*22)$I)I M/)6:6A52$????]4_Y[7+6A:8PY0F/^*EB";:0$-+6.%-
(N[H[@N4]?247D@3 MGO^B78DU-!1NN*!I29891#$IGOBY[,,>0>)T$ZR28-4)SAL$NR38[XW@E 3G MO1%Z)2$O72]]SQOG8X&],;,[Q!1:]JF7O/LY6_8K)LHG<\'DUUCRA/>5"D] M=
('FFRQ+0#I X 3=D,*!ZB@OT(Q)6S+Q5\W_1@W^.?M , MN_*,G>LY\K)*RF_L\YO\K*519(U"I[E.,"ATWB= M6G]KO&.*^<<4"XXD=G @;G4@[C&,YS9OJ6']NFMBK$$-XS2!15RQ,E?
(SGF E_^7U%Y6!2+E2 M:G#V?@-02P,$% @ %D!$6J)Q5)L] P <@L !D !X;"]W;W)K&ULK99;;]HP%%>_BI55TR:U39@?M/9AP(-:]&&[$&$,7,3Z!MBMM*@T@4*4*2]5!
[@22][(DXL];8'PS=+#S^.*>+@IE7KBCP9(LX '4E^6=T".W59G1$BI M>84$S(?.-X8J\OU\]I\$/U9D/ ,C-!=*1,7B>?>(:;4/TM&I?^IP+)ZN=GD2]:[8(<><<.#%-Y4Y@>
U=_5P>M@ID3"F+-O+*:*H9,Z: 9SLF+JGF\^0!-09/1R MSF3]BS:-K>>@?"45+QMG35#2:OM/?>)Z#C@\(B#WSCXSW4(&H>@#G1+5H>S#64,D6]&]&.M/E:*5
LZ98"NI00ES]&M+JD+]$D5(ZGT:L)*$*9?*UMOCQ,T*NSU^@,T0I] M+OA*;DDY<)7&-8NZ>8/V=HOF'T&;0'Z) GR.?,\/+>[C?O<;(HZYNSI):;:\ M-E-
^K1<>T7LON)0H)T+\H=4"D9*O*F6+:BL3US)F%ZU'?AC'?CIPUUUZBUF$ MO<1OS78H@Y8RZ*6\SO-5N6)$PI3V._4\C;6&QF68:Q_0LE+65RLGI/+'6,_3")]DAM=EX8=7;P#FK:
MHJ:GJ/?T8/4D2++]/7EHE49!&M@)LY8PZR4\=KKWU7NOXO_6^XG$=H+'WM-5 MZ)VFXAN=;O9C+XCBO6]D,\,X/E+QN'-EXY/5?".U4\Q!E!WL3]N=GV1'#E#\
M=&OB_FOSF56(;:=FD(;[F!:S-(BS/4JWTQ"9;E3W @M:2<1@KOV\RT3*8-MWG:@^++ND:9G]FTON7B44P"%GG/%>,9*C4[=N1;?-YXH2!K<"R7F>8_'S'"A?=AS? M>9FX(Y.LA-
NMSW#$[@'13"]%7KD5BH9R8%)PAD2,.XX/?]LD!B\!7PEL)0K MF[\AD,N3\T0RNLHJCF04!A9$R"E@_%M '2HV07L93]>E4(0UQ]?U%_<+FKG,9
M8@E]3K^13$T[SJF#,ACC.55W?/D9RGR:I:2_:%EB/0>-YE+QO"3K%>2$ M%4_\7-9AA:!UZ@E!20@V"=$KA+ DA&^-$)6$Z*T1FB7!INX6N=O"I5CA;EOP
M)1(&K=7,BZV^9>MZ$69\+A/T>'!$3I A*$O4SZ7.J1NTJG8Q;ECLJEGQ=+#UY9>HBN.5-3B08L@ZR& MG^[FMW;P75W&]L!2RW/@YV"*8Q.4.@?H\ +HIKU]-
I.#^O2^;_H@W^.OE:,_ML#)6:/6B5_36G,+'^D1XFA-)S+ A@&*E?4[JG]1N?Q$@M@',>:?H1F'+;[N+ MU9IN@Y6TEP'I=L@/_2\8!TUV$8%07C]5:BU.D15'.*==>ASJ4S^]UAGB;Y?
M0SX$\;,NW9TZYKXXDS,\@HZC+P0)8@%.]^,/_8^U5EMGV+I/L&>Q);VXQF MM1G-]S9E$;"Y8I(X]C8\N8WQ3T_##4_6@%)\.2VZ!F&"?UCHRK(L0[BW) M# 0N#OI>IN\4(I7
YKZN3O1=-MTI_K6^;)EMG M69B$FV?G-BCV6ANG8KH-\GU[1;P9M0:5>'ZXX51WI5')04QLARC1B,^9*]Z6 M:K9]0GNV]I]8/_?/^G[-?*],U]+'_"-?=+S76$P(DXC"6(?
R3A+]IQ)%%UD, M/%)_9-FG(E6ZZ[.M4-]X@#$'_W/=*I4#$Z!JY,N_5!+ P4 " 60$1: M$U$R)C\" !8!0 &0 'AL+W=OQP?IY60KZI U' L&5<3K]!Z?^_].E-
@251/J)&;E:V0)=%F*'>^VDLD MN0LJF1_V^XE?3+L]]+'5S"YFEX] 9Y;B0H YE2>2O&3)13;S >Y]8TEVA[82? MI7NRPQ?E_U"FI']N2T1*ZHX"!O._&FP?TLL?
O=AN\4*W72!YO)6HA7.WC* M)U[?&D*&&VT5B&G>\ $9LT+&QL]&TVN1-O"T_Z[^R>5N MR(,PQ/7A._HFB%,E4*M,N'97) [>%2:FJ/ '*:ED)K^)NYL'X_FDBB$
MZSEJ0IFZ@2N@+X5XJ";GDI];,Q:HKI]!.UJ7^39/W\<]& 0W$+8#R-X6#@ &0 'AL+W=O^K[,,>) MA[WCPD>VR8Q;!*C+=W LRG]9.R,[_VLF(V,_VD0 K6$^!>WSV0PJ#8\0>#
M@SX9(Y?*4LK/;O)N-?$"%Q%P2(US0>UC#S/@W'FR",/K6!-=]Q\E(??HI#HZ/REDNOB%QVJO8&'TITV,J^, M;00Y$^63?]D*<6) 2(L!J0Q($7<)5$0YIX9.QTH>D"*[K3NQ;VS8#MQ/
MJQ ?RA!)2X@)>I3"9!]]$2M8G=O[-MTZ9W+,^8%T.IQ#>HL&^#4B 0G1I\4< MO7SQ]L/OH*[EH/;MO@]YGXMQ=(R*BS=2=E/\2@(DFCL[Z]@AC5BV(GX9KVV M['9UM^?
3$E!8RB@%(GU&1E&A.774OQ9/Z7=X$\[\-2<+P>CC#.IQA]P(,+P!Q M',AN8X8U8A1) ^+^%*3!R9+Z7@ C96+(Q&?SU"O@3U-_H/+0PHQMF.M0 2^PY MTTRL*T6865HI>^*.%M?"
[H1WDGFGMS2%B6C5'->#H!]%I=$DGG"0M=$K]<)+>^2>?^K^W?0*;]DTRAL^V\;0<;]%1E? M2G(XC*(V26HT&?T+\CGT>5XS,>M7UE22/-
I+\T5Z;160WPZ\U\$^N_#FH3='8:)2Z M>WAY^Z]7Z^;IOFP9FNUEY_5(U899TG!86]/@-K;9]K*9*2=&;HL&8BF-;4>* M868;0%!N@WV_EK:)]"8.H&XHU\!4$L#!!0 (!9 1%K2!LM*!0\
)?: M 9 >&PO=V]R:W-H965TH=U1TWU&H]%\H/9*C+8-.8#35#H_?L A(,GO#W ^8\L_ZM82EF*^_4]+=X?+,OR]MWQ<3%?RG5<'&6W,JW^Y3K+ MUW%9?9G?'!>WN8P7VXG6]V-
S-#HY7L=)>G!QOGWO.K\XSS;E*DGE92Z*S7H= MYS_RE7VX_V(-P7,UJ.<_$OFC>)5N)=[BR9]1(LE3D M\OK]P?C770RJB?8[I[LE3D M\OK]P?C770RJB?8[1<_$OFC>)5N)=[BR9]1(LE3D M\OK]P?C770RJB?8[1<
@LTK;UYMBJV?XH?S?>.#L1\4Y39NIFXFH-UDC[\'=\W_Q'/)C#- M%R8PFPG,?2<8-Q_]YU@TDPPV9E@^'YA@FDSP73?3A$:"4YV)C F+TPP-R:8 M[3O":3/!Z?X3G#43G.T[@%3#F-
]]DZ8>]]T_;>/QO&\N?]_'#'VO]J;3B M,KXXS[.,5H:6O&+O:8I^$%ZE'&,$ZNfO...
KQOD)EG*P*\4W>EYMX[5;\)HY%%L8Q$68@D%7*F25D<5F]6K]MLTT1 MIXOB_#BL9]AFC^>P:X/X@X%RPMEX6P[\$7/=/[^NG/--?5_\13_\;
MYN/_QD=3"P9Q>B1&Q]$P1^94_'EEB3>_O>V9KT]ZYL-M7C'3+3/1,):>^1RW MC*%A[%%9F9G-S) RS9HRS1^;9#[3OYZ87+3D_$F/CU>5S]\U_0 X9DE@$84JB)D^)FF@3
M]57>QC^KS=]RS-GUBZG2&D-316(6B=DDYI"82V(>B?D/V19^,R3L3'>"=^D M$U&SVE$;J=\5DC,609B2]NE3]];:5+G5_]=X$V5%\594^WKV?9FD-YND6-9) MTP5-RPX-
&HE9)&:3F#/M?)W/ES9LM;C=EGWS/S+.^PZ5?M1]0]-*8!9^.2?B9[5(M?F!H'%'-0C4;U9Q& M4XY]S#]\%QT4_5_/T6(4'#5$MM8C0U7L_UAOZ>%5?
UX,,3B&I6:AFHYK3.:_PF>G/2DD'_50S=]O M$0)TT!#5(DI34VBV*32174?Q+W&9R]LX60C[_E:FA2P.Q1_E4N8B3A?-JP]% M(X]%NW#H]U(U_UQ($Z)BA
MT6WAC$U#'3*BAE33TW9=#'W99<"*\VKSO9#_W-3OVG>O'8_5#SLX:6A!!M5L M5'-0S44U#]5]5 M0+42UB-+4B+?%&T/?O%'[;/7^:M'NL/9FMUOFQW]T8^ MZ4<=G$FT3(-
J#]JY]..AFH]J :J%]!91FIK)MOYCZ/L_ U:I?[\]I)^P>M@ MM"R$:C:J.:CFHIJ':CZJ!:@6HEI$6:6K>V]J0@?:&]-K@Y*+-(52S4=)_'TEQ=>XE+UA1EM']&:AFHUJ3]/5]F?
5D]CH]&XLUY%BT:HYJ-@&HA MJD64IEZMWJ-S%?1:B_5(?Y,-T6]1FX:$?B4M)$[Z]PE 3\'%@%4W8EZ'C]'Z M.PLA;?:%QZ=$/YYPFZE]?MHAX. M)6PA]-&:
[91C+)>C.)WJ.HT0SC^7;%D;GS0;7006U4 MFHTPWP6QO%1)XMHFPG5'%1S49_ETG>=#6$ZI9]&:CFH-J,J-U3O*8 MN^=XT.(3]@6H%]):1&EJ=MN&E,DUI':.+?
W:.1ZT2H5J%]K9].:@FHMJ"JKY MJ!:@6HAJ$:6IOP+:*I6IKU)1YWC0/A6]68VFW->D[QP/6I1"-1?5/%3S42U
MM1#5(DI3G^W0UJG&^CK5D,MSZ\#6TZOKXCV;SF\!F5+-0S48U!]5<5/-0 MS4>U -5"5(LH3M^&9QHM%0U[M[P]&?MC(]HH)]+:AZJ
M^:@6H%J(:A&EJEMRU)C[*Y37^5=MKK;9G9G]UF[5D9K5*AFH9J-:@ZJN:CF MH9J/:@&A]A:@649]:]6>/67OE.6O06IE]&AO[.+;N/9+ZBI'HH ZJN:CFH9J/ M:@&JA:@649H:U;9D-
1Y8LM)?;*_?!D<2;52AFHU]3].I=>)N?N,1+1/A6K^ M7DL0H&.&J'!91FIJTMBD!FP 1[(L9?YL#3KT !7:L4(U"]5L5'-0S44U M#]5\5 M0+42UB-+4U=+5=K+&^BD5M"]-
%+52S&DUY.F?G%G@V.J:#:BZJ>:CF MHU] :B&J192F)K4M:HWU1.V-P?X(/%PX#B?:Q4.U:9Q&M4XY]S#]U'M0#50E2+ M*$T-
<=O8&NL;6YW=63^MM]1E46ZO$3H4]O6UG))W6OU2OTP@R.--K!0S48U MI]%V"Y&SW2N"T$%]5/W7(8 '35$M8C2U!BVK:GQP!M0U=<%I7']ZG&[]UM6
MQ]N=2Q3$=:6#7%;K82?)]\@Z=4Z_5>&MMXZM*K]]#Y/(]^5P5%M;N#T_!]& M2><:!G1,&]4<5'-1S4,U'J4"5 M1+:(T)K?C7.5\E]N3P45]^
M%$+UHGY\D)W<+,OEZ_'6S]K0>$^Z"SW";[&0;'=!&-0?57%3S4,U'M0#50E2+ M*$W-=MN@FN@;5'\WVTZV6CT:CFHU] :B&J192FQKFM64WT-:O]CECID<%!1+M2]&:CFH-J+]IY
MJ.:C6H']J(:I%E&8+&MNU*3?1=;_6"_6-3%UA%5U9WMG2,.IV9JO,UB^]S$[.9 ...

MJ.:C6H']J(:I%E&8+&MNU*3?1=;_6"_6-3%UA%5U9WMG2,.IV9JO,UB^]S$[.9
M60#SU!COQ@DM*:%:1&EJ]MJ2TD1?4]H/@G]2EDH5\]-)?4]WMSA_:.4,U" M-1O5'%1S4]HHN\=4?="]<,,CC1;/$(U&]6<1NO<
M0O%L=VV*5H]0S=]S&0)TU!#5(DI38]B6BB;Z4M'^>W=HAPC5+%2S4X*!-'52S4,U&-:?1ILJGSC@9[P8'+>J@FK_?(@3HH&'/H,;,,Y.=X/S M[VC@3-
H&SF2?!DY1,.)T7M^6MRB+0_%%]D<(;=^@?FH5J-JHYD^Z-D\,CSN%'_MM$#:OX^"Q"@0X:-IEQ&-MZ]7V)$C:F$9]KV7:8\$D]-I-S1]&:A MFMUH)Z]L-CCH]"Z]>:CFHU]
:B&J192FAK(MJDSU197+/)M+N2C$=9ZM]S5: M>B?S,JD?__#2I]$>'!Q+]*X^]&8WFA++D]EH>K(;2]1P@FH>JOFH%]!:B&H1 MI-FQ; LG4WWAY+4#C5=E]=?
BE:,,^C$&)_5!.]LY;#7>;?!;Z+#VOL,ZZ+ N MJGFHYJ-:@&HAJD64]J:P;9%,]2V2GA;GT_KQ\8LBR=*FO%FE41B'H]%(?QY= M/^C@6*(WX$$UN]&,\?-=H:.I.1OO9A>]!0^]>:CFHU]
:B&J192F9K=MNTP'MMEU>RFZ5U6HW]$V2BD6V6L5Y(6ZK'!?+.)=OQ;_$;^+XX8O>ZRCT,S&XRV@G M!M7L1C,F2@NDTPQWT%%=5/-0S4>U -5"5(LH38UR6Y^9ZNLSST]R"7-
D3O?H MS.C%P;E$.S.H9]..@VHNJGFHYJ-:@&HAJD64IJ:W!TF MGR_C^FEHKYUH05LRTV[QHN\:"'10&]4<5'-1S4,U']4"5 M1+:(T-9]MY6;]
MKJQ4<7RXR**H[UOWXKD5M'8S[98]9H8Y[201]=.@FH-J+]IY]..C6H']J(:I% ME*8FL>WP3/4-G]BBP5]GU]BXM-4BRW=VW6K"+U[M!H
MHI]%:C:J.:CFHIJ':OY)MTUEGG:N_D7'#%$MHK2';!X72RE+*R[CB_.US&_D M)[E:%6)>[PZ^/ZA/ACZ]XF)*W)Y7677>/?!/#CNO.\8[SRCYWW?>!=LWS]N^8OS MV_A&?
H]SFR0M@S]I>5T.-CF;5MFA>WZ+J\8LRNWU_8(UE99NOMRZ6,%S*O MOZ'Z)^LL*Q^J ?Q>5_;1?GXO\!4$L#!!0 (!9 1%]],0&7 70("X& M 9 >&PO=V]R:W-H965T9"S[W*F.,&]W5>04WU2#8@<*64]8&3;7Q@=,.%LZIYGXP'D=^ M39GPLM3-K526RJWA3,!*$;VM:ZH."!R/6I6 MBV_5RE8#4(S#8*8-+_8T_9
=.7[AR.'(+@C$/0.00N[A;D MHEQ20[-4R3U1=C>]V8%+U7EC<$S82WDP"E<9^IGLAS1 8O*9W(D"U@8* 5]C M^7-
+E0%#V0%BLF"Y61%#W@;1I/+)1C*N+XB%X0)EC)K::BT*EO,"*KZ^<= M?=2@S/T)>0C,IU\(L$XF)&GAR6YO+CZ6\;'A/]L@CZKP.G.SNC>@ZW' A21
MI=4.AT)K)2(G86MWEUU/X]3?#7"G/7?Z+A=1T1"]]0]4-,X'^S9CUK]A$K M'T+-3EAA9]@B!7VK/ C5C+$"O^#%6Z6LZ"/6]1 K.F'A$9XYP[AGQ>^R'BO
M3E9BH0\1XQ/B+#E[;4F/3-Y'2D,Y62DF&PO=V]R:W-H M965TU0'|N' M:1],<@&KB9W9!MI_/SND*24/@<078B_"2/22]52,C:64 M^=-ET;R$$
(L>RX&]+W&,RS5E"]D7/ 20'*4M.V+_J),<;_--N,-8/XLU@"2/22]52,C:64 M^=- T1;R$#
(L>RX&]+W&,RS5E"]D7/ 20'*4M.V+_,_*%%&."K>37DX8BN9 M$@I3CL0]RS*\%@Z?.P+6&+Q4IR?)MS[?K%]M-GGPLYF&K/Y;[Q4$FFRM(%/P1Q\ H-
&6LF,L6<\N4[&A]43@A1BJ1FP)QA FFJB50: M_TI.HPH@;QC-_.A7:E988%3%3CZFR1R.38&!D\I@CCE)>IO&>;'U#]I3!?S%)1 M-N=R&P2DF4E6D@60$;,HM7JEE[PJLK!!%"2AQU WVTIV"7
/A3@E #G4(!;_MS"F:V4 MPH<(2QR-.L@KEML?)%=?B<+)(Y)0 &Z0-LKQ6>-0- MO\6\+;]I7*VLM2MK[8+/>&[44X.U1YR#LK G%|T)M,V=+X!8V^INOPP@D\ M:V2N=
[5W!M/582AR',/84-=? %^#$7[^U/>M;TU.U$.^A_L@UJG$.IUB[Q@] M0.F6P[L)ZP<#R]E3VAGI6*7UD"U*W4JJIVZGT_0K\N85L!OQOD]).CB,U3$Y) M%IV([(-
W7N6=U^G=E!,.DQRGZ.=*"[FJA"HQ3?9YM5T+[/X@V#LH7NT4JVMC M[5V^X>ZHZ M@Q^]V_6(+>*#2QPFJH6U+4V5+7.K8=L$3NHQ Y.4-&M6/85-4Z(QVK
MM!YR7ZFYTQ/H!D]INRT(%2B%N<)8O4#9Q+=-T78B5ZT"3,F5=-1#)>]CP2N MZCOAI=#2]G8U\]%5'GY*W+N#-7@G*V/N?7!33]/$"\(;" (,@E\IG&-= M>R*6\:?
CC/HC/?!P_<3^.7AG+ROA<&\]7]*D:AJ]CZ#$M=C6=&OV7[#S<^[Y M"E.[\(1]5YM$4&P=&=6!68&2NGV+A^XI'"8YS@@[0!IT-T>%%1>"Q)Y9LT> MK*]F-K\(5@.:Q4GM?

|H=6=Z5C*/\FR&$";R#&UWBBK#4Z!R'^2+ 0GLIA8F*>/BT[$K!61OB#B M RP,$SCXQ"+*_$Q&^I=I4^N9NE)PFLL!C :OH4T2<?KDO7B *G$8^/0[O#*'_]:GB1?#RA<-PK'[4.-];_Q-
M;D)F)["")C(EF:8!!X_LKL\&223\RS>'1X?'[240KL)@^.@\,W0=E>?[6?S MJFW)Y_)VL!?";J1V4...H&ULK55=;YLP%/TK5ZR:.FDM7PFT'4%]$TWK0[>H M;;>':0\.W
2K8#/;).VT'S*$OS@?K0%[#-/0I+Y'I+PLN"J+T5"QM60HD:0TJ9,@MV')5DB3-4]^54Z)G=L:2T0"8I M9R!P,;(NW8MQ8.+K@.\4UW)C#,;)G/,',[E.1Y9C!&&.B3(,1+]6.,8\-T1:
MON^6T^JV-,#-\3/[YJ[]C(G$L<_T%3E8VL,PM27) J5[=_05;/T/#E_!< MUD]8M[&.!4DE%2]:L%904-:\R6.;APV .S@ \%J]UJ WP+\VFBCK+8U(8K$
MD>!K$"9:LYE!G9L:K=U09JHX4T)_11]GXJ\<(81P MCHF0CQ1 MMH3+@E=, 5^ RA!,N(3C"2I"<_E!!][/)G!\] &.@#*XRW@E"4ME9"LMSFQA M]ZV0JT:(=T#(!)-3\-V/X#G>8]\W
^_(>(0W-8IZ?+B=7GQ:K[! ;X[KD@._M4T%90DL]ND73CHA^YPU5%-9=IF%8>>>Q9&]FK30.^&IELO9$D2"%FZ'26* M%5KQ^W=NX'SJL>-W=OQ^.UWM?MY@,4?
Q"_["#!GE8FM]G[]>[MGZKE%3Z3SU0T89FN%'1\W#H.%L5'>S4W0V]S; 7(H>=R&&O MR'M&"BX4_8,IF)X$*F5%6(*0<*GVMM9P1^Z)[V_?WN"7-_Q]HL-.K'!V_5) ML).O\] -
_"V=NU%NZ+KG9UM"[8U#SUPX^@184B8AQX4&.J>A=BJ:0[R9*%[6 MY^"<*WVJUL-,WWLH3(#^ON"Z$=]).5J[FS3^!U!+ P04 " 60$1:'IO, MNN "!M" &0 'AL+W=OP
M+\]S=_YXLMX)^2#R@ T>2IRKB9.IO7FW'55DD%!54]L@..3E9 %U;B5:U=M M)-#4DHK<]?O]@5M0QIWIV-]NY70LMCIG'*XE4=NBH/+/#'*QFSB>LS?@[S?7$G=N[25E!7#%!"
<25A/GPCM?1 9O =\9[-3!FA@E2R$> MS.8RG3A]DQ#DD&CC@>+?(\PASXTC3.-WY=.I0QKBX7KQ_8O5CEJ65,%& M@'ZZ"7Y%))N$\!5"4!&"MT8(*T+XU@A11;#2W5*
[+5Q,-9V.I=@1:=#HS2QL M]2T;Z\6XZ9-:+?$!0YZ>?A.:R)!\)<\A:6&E(-2=JM!@M)D\80MJ8#@H>H, MB,$K:K&KL:436 W MJ=*:E>GYKZ07D"O!=:;(M-
+._CQ8N(VQNL'PY>@10=H.!S5H!>JPUIU M>%3U12&D9G^IO>C$BICWAC"EMI0G0!*A=&>CETZCPU2"L*&[C?$#KZ&[C0D] MOR&[C1F_&
[54;TZ,]KZ3FB;/Q\UOLZ$O]\04>M,PL&H48@VYLQO%"MN8[PP M;#A;M$%^./0:I7 /[L\"Y-H.+H4*MER7;T-MK6?CA1T)#?O,.Y][']?889VDY
M^I[=EX/XBLHUXXKDL,)0_=X0$Y;E<"LW6FSL[;T4&F>!76;X/0#2 /#Y2N#= M6VU,@/H+8_H/4$L#!!0 (!9 1%H#9>3OG@0 "P5 9 >&PO=V]R M:W-
H965T,#>:L[W_WN9_O.K:F0CR]@ M,5,-S%'+5M@W*)D@$9#0T/LJQK2:2$C]1BD+;+9?K=D08 MMSJMY%U?=EHBUB'CM"]!Q5%$Y.R,AF+:MAQK\>*6C0-
M7MB=UH2,Z8#]^TE? MXI.=6?%91+EB@H.DH[:5=4Y[3MTH)!(/C$Y5[AY,*$,A'LW#E=^VRL8C&E)/ M&Q,$+T^T1\/06$(_OL^-6MF81C%_F0!^F02/P0R)HCT1?F6^#MI6PP*?
CD@< MZELQ_8W. ZH9>YX(5?(/T[ELV0(O5EI$W,/SE(/W!<!;,*UX#I0<,%]Z]_JVQA-%I*[".G,+31X M3KUCJ#@E<,MN=8L_O6+UWV-.ZN5MZBON5#*$*XF]Z@OV;JG2DGF:^BG&
<,^9 M5G!P.[A7A_#'-8V&5/X)_\"-X$D'IU[^91LL>S*V E(U ZE:"-+ ..GH#.>C#ST1X2*E2#+- MNU(2/J:X<&0#8SB OUR>SY'5W2J1?2B_P@&@S/H8*E4SX(VE
KU=D2IE]%4*_3]+]!P^?"0Z6$#! EYE' 5?^9 C"9W#)..$>(Z&9@TF=P5&B M)[C/S.CJ-51/-E!U*VNH%L:](ZJ-#-7&1Z,ZWURO.&X,L?F@X(L.$&<=$ Y? M)@E,)?
@5[>ED=TT7LQ)\38H2--A]HA*+K%0$<,/'=8$P"0\DC&EID:O!//P+ M-Q'08FNB\NDQ.?%%&!+<<";H29*?K>E)T3G)I:?1/&XXS=QO+5N%>.Z8K6:6 MK>8GSH'22Q!?$_F()?
C;2=_<(+W36(.Q.- =873*RS*Q_/^G_7N2\3:VSU') MTJUQFL>UZEIRBM'-3NY(M[9>V& 7Z\99U$<%=8*Q2._MUC8E[55G-PE3NX; M6#@\(XN'FRS>7
VNE(I1ZGZ"5N;%9\DPUT,=Y.I62%,G&SE2E=?Y5!C'KC@M M6Q:GN&?9E4_D^74^[;5GV9>U59R678OSEK;ET_E4W>"3N\ZGCVA;G&7?XKS> MN&
I]2SV@'Z(*WXA2_;:HNS+VFKTRR;%^2]W*<7.O1O*S;:G7E^N7BE"=NX\ M*]RG!S3*?!$S'5Z-)6]S8X"N\D!F+T43]\1,]RR0SI"U?+Q"8XLTZ.Y M]$&+27*Z-
11:BRBY#2CQJ30"^"TDA%X\F &R]+.OU!+ P04 " 60$1: MI.2(#G@$ 5%0 &0 'AL+W=OKNPV@>7/B2H +.V$XR(^V/7QL(MD 8H5-
JF#PTV_CZ?,QE:K(5Z;8<*!!&A1')K&LSXQIF!CS:5IWQ^=3MI51F,=1V(;QY3,N(;(M[6<&-@X5]^%|+76%.9]NZ H>0#YN[K@JF466((PA$2%+$(?ES+C"DP7Q=$#:
MXN\0]J+RC#25)\:>=>&/8&98&A%XN=@]J?'2P@BG0FA>-;GM0H^M2!U>=# M]L\I>47FB0I8L.B?,)#KF3$R4 !+NHWD/=Q_#CDA5^?S6232_VB?M[4,Y&^%
M9'$>K!#$89+]TN^Y$)4 FS0$D#R O C =D. G0?8*=$,64KKADHZGW*V1URW M5MGT0ZI-&JW8A(D>Q@?)U=M0Q9-L(T L26Z!R%YZ$L(LM;H,0DENM(#H1M?
W("D820NIZ94R'1^T/]17&MA.QH3[,#+4N!? = M&/-??L*]>]5L+;J= [;2BOMI3'@CTUU8*29,@3%;H(DQR52]1O[7Z9+"SQ&Z; M6&\.N_G0FYJ[&C!N <;M">8#VJ?
K3HE*=\#5/H)6G"82!51-TR4-.=K1: MH M SR#FL(/6!11+LI:S:0<]#HV&;)AA0UVAX.17<_(*QAY71BEF"&XP)>=U?5. MU,5X6(!)VRS:^_Z"O[9,D&'!8-B#P5O&
(R?]AC$9GHS)V!XX[KCR]T*1=B[M MBHP*149=%%&.N810*I%U2$//.1OG;#CH0K=HA[GH_D7-HV*G*[(T'3@,I4I[B_]>N MGV<^VIA!C I0'CO@[)9S00[M>,62@?
OR?/0*A5>D*$T8IW/A MI[/9FK=^L:.VCZ'29DDGFSW#P2$'YE7&KL$]2.G1I*]'=QZ"///1H0$WG&&) MZ:^DD[^>Y="00ZLN#ELM#JMAVR*E1Y.^'MU=9?
M$Y9';@*>T5]+WT_4=179. M=R#//'0R;2&D#/JXI+9"\^AEW32-]B$C7*[I[>"RV7:0I<%CJ.S!=DDA2O@(Y MJ-LDS;JE4 RJF;XK$\AGVT1FW^A%;7$?=Y7>0KVHO\.3!:ZK)Y-%7?
LKXJH7 M;NT;[W#E9Y:0L@O#6\4D3 2*8*G@64L;_'L#BXK2+9)K[&>F)0L3A_70 /@ MNH%ZOV1,'@JZ@^(F=/X?4$L#!!0 (!9 1%]YW3.O\0, -D/ 9 M>&PO=V]R:W-
H965T7I&19MA7!,1"@+Y9(SPS/.4-2,Y,U MX\]B0I3PDL2IF%]1E-FU;0L_PH2(#LLP5?\L&4^(5$,>VB+C2 +CE,2VYS@# M.R$TM683,W?'9Q.6RYBF>,=!Y$E"^.L-
QFPJM5QK,W%/PTCJ"7LVR4B(#R@? MLSNN1G85):]H*R%#@NJ];U@++Y37(O:.V@]3XP]Z\'G8&HY&A'&& MZ$L=@E]C"+<AQ3SJ2PO&S#&I5:VK'^OLF^A^&O"+S1
0N6/R#!C*:6B,+ ER2 M/);W;/TGEH3Z.H/8F%^85W:.A;XN9 L*9T5@H2FQ9.\E$+4"IO.7BE@W>L M0[=TZ!]B!3)#ZY9(.MPM@:NK54T_6*T,=Z*#4UU&A\D5_]2Y2=GWYA$&,$5
M/$CF/T&)+Q4>CLOT2^TV!W7L#^QB^ MLE1& CZE 08-_HMV?]=K"6 K(2LUO8V:-UYKQ%OT.]!U+\%SO!X\]/MS"^=F.
M(L6C"6IX*^$OS_P#H5NM2&Z9J?>&RL5Z16@CKR0*B\T#>%]B;VJ\VQ=75]:UR(C/DXM=2L)Y"NT9K^XQ@ZD8 %DA5S<7X MRGPJ$C%,?#?F Q3'A C+D!7VMPU;]D]BT*)..Z
M%B.W,QKOR=$*^$0Y^I4<_78YZC+*&6X@GFIPSWJSX#._T*=$JXNW)S$\(4N ME2;_(.$73;3;5_3@%;6.0TB*@S> @+PVGH?V0-TRD+<)I,[R8:0=50:5*H/C M59F'(<>0]#ORLY*
]]^7#]]G*/.?O/_(O:@EG9O--S+>8/-H#+9P3RL_^/ MVM@A)ZG>RL<>V.'!@?7VL+;N>^+^"%6L1]VLS">F(O5A)W5TD(Y]$5IAGBC" MN!)A?%1]5<6V1*K9,ZZ(9Y2_(_C@SQ?N?
T]D]TP3B3I.MLRQ#DFUTTL/RSQ M);2=.[KO=,:C/67:H9\]3:U"U3N7E;;MZ]N'U< MKKW#7'?=SF#_;F['>ZH/>V^++_;C]RVTHOX8'>[F]1MN%O:VKW/]/8>4V55:] M3G_/FNTVZG
"K)VK7E*D(>FIQ3@LSR511]5S59]Z]QT;_;6O&AZ594>]AH! M8EPJ5Z&ULM5==<^(V%/TK&C>S0V:2^!.(L!,P-[ISC1;)C3=ATX?%%N M)
[;E2C)L_GVO9,+.D+,,"FFQE\H(1'*N@+#4=RQJ8&4YR8S)2?7,V&=%2I$E, MY@SQ,LLP>YV2E&['AFV\=3PF]J60'>9D5. 561#Q5,P9M,R&)4XRDO.$YHB1 MY=BXM^]"6P4HQ.\)V?
*=9R2E/%/Z(AM?X[%AR1F1E$1"4F#XV9 925/)\//X MJR8UFC%EX.[S&_L7)1[$/&-.9C3]GL1B/39N#123)2Y3\4BW/Y-:4%_R133E MZC_;UEC+0%')!)A G)M^H(,A'
MURC$+$_R%4>]7RCGEVA.&%]L.2/P;D:SHA18?5FZ1-\@?[_F$@$1.$F!]AH]+0+4N[A$%\A$7(9PE.3H*4\$O]KI^&U- M2X]S&#HO]MHC4X!>.6LSJK5-*VW.$6TN>]"Y6',4YC&)-?
%!=[S?$6^"SXW9 MSIO94Z>3,"#1#7+M*^18C]>9S^ST<%VA-8$#&:PK6.G1"^I!QE>O+G6N M5 /V=Z5XCM\R10-R?:=EBH]);H%"'=.MIW>EWFC2[W3E2YFFKRBN-XC.A@]D
M]T^1K0&Y?CL7=$P#KR5;RW1$]J"1/>B47>V.4F=.TQ0SC@K8.I5FK>2*;;B; M_]:-:[9AI^;F%#A9]? DU81-\HX7.")C ZZ*G+_,2:??K('UF?=$7-.LN"<9.&9R/8^D]]\
M)O_C5(4;*R++)5QAY;Y\VM;D'^P5K9-E]B$B^ 1'B)L?5K:UON]S^I4_$BX M8$DDU^="3WJ)H9ZCXLGN*YUI6,W\3_-Q[.R!6=E"_%MO^)=J[FIO^3E#5O
M5U9](.TK@@;2;VW%H0;CMS+3W"E,,L)6]BKD<.THO*\5_56]WJ] MW\UL37\@*U55#+W35V7N V.K).)CV8)(+L9K8S':@^_>SG9 22*-N0WLAL7/N;['!_N. M=HS?BQ1
HH<\HV)LI5)NKFU;Q"GD6%RQ#5#U9<5XCJ4:\K4M-AQP8D]Y9KN. MT[=S3*@U&9FY.9^,6"$S0F'.D2CR'/-?-Y"QW=C[6?N).I9ZP)Z,-7L," MY)?-G*N17;,D) O!AV1L.7I! MD$$L-
0-6CRW,(,LTD5K&SXK3]E-JX.'[GOV=J5W5LL0"9BS[1A*9C]VAA1) 8 MX2*3=VSW']IZ LT7LTR87[2K8AT+Q860+*_ ;@4YH>43/U0Z' 43SO K0#N M,5H+6]E[5 M&[>3,
(3X"GF]U\AU7+]E/;GP[VV_3?V1MB>+7%/,/G/\'WF4F<(>7D M^![A'>;)0+ WSDH;QUA+#:+Y ETH)Y2>>-7F@S)38#+1(W [&03.R-X>;GL: M,QP&S9CP-
"8(^LV8](7'Z]4Q#2G\6@J_4XJI4.>QJG3&Z!:XJ/XIY4B2908H MA*5$WV\A7P+_T:9 9P)]JUR+#8YA;*EK0P*@C5Y^:+7=]ZVV?"<9.$YR:(S MD35V*:AW*?
AOA@U.3.3Y_I%A3V/ZSO#(L"T\P1%/U,W3D*)?2]'OE&)A1)B6 M(L@42[0#=9 W+H0NMW:R_ZE;STD6GI,L.A-98XL&]18-_IM;!R<.\IVC8W%V
M&N,.!D=N;8EQW".WML3HZZ;A5ON@LK9O6]>G5CN9O M>M>S7LM)]BA$&UGL511;]HP$/XKISQM$L,A M=%M7A4@%DA5$/[TG!TV[-)+L2]8S/[O3?SW9"QB;*IKTDOO-]G^\
[WSG=:_-L M*T2"0RV5G405T?:&,9M76',[U%M4,]?4IN;D3+-A=FN0%P%42Y,$\0=6K])!I%1\=2;"KR#I:E6[!%=+7[<(XB_4L
MA:A16:$5&"PGT>WH9C,V\2'@F\"]/5F#5[+6^MD;#\4DBGU"*#$GS\#=;X2%K]_6?L]+SW M?+F6-GOAW\7&$>2-)5UW8)=!+53[YX>N#B< OW,>D'2 Y%\!XPX0*L?:S(*L
M.2>>I4;OP?AHQ^87H38![=0(Y6]O1<;M"H>C[(LFA%&.[^!!Y:]&>.('M/!F MCL2%M/"$!V]X?]LR[G>$/Z%^*["=02P,$% M @ M@ 50< !D
!X;"]W;W)K$ULI579;MLP$/P5D@&\VBLTTX:R +BHV@>4A@YVF=:6EE$)-(EZ2-_WR6E_M]+:K&$'[8G')G=F=-3&,=T*^J) DWU5M)=#,@JK2#3QOY%:4<2>)[=Y"K'8Z))Q6$BB-
E5%Y>L$2K$;.[[S MMO' 5H4V&VX2K^D*'D$_KQ<2([=ER5@%7#"!B81\[-SZ-/(Y-N$'PQVZF!- MC)*E$"\FN,O&CF<;@A)2;1@H?K8PA;(T1-C&KX;3:4L:X.'ZC?VKU8Y.EE3!
M5)0_6::+L7/MD QRNBGU@]A]@T;/T/"EHE3VE^R:7,\AZ49I435@[*!BO/[2 M?3.' P#R= ."!A"<]]W &$#"#]:(6H T4[6VNW@9E33))9B1Z3) M1C:SL-.W:)P7X^>:/&])IPQO.ODN-!#?
(Y?DC]>B O)$]Z P7$BQ9>8V*(*W M\?BT-P--6:GZF/?\.".IBSZY((R3IT)L%.69BEV-S9D2;MHT,]D;"=YD"3W M@NM"D3G/\=+.[S\]COYS!NSB4=C+!VV0FP5G"&:0#$Q]?2>
%44<_TX_#PRXY M_U=]_L_5CX81MMO!E?>IWW5).OF]T?!D !UI ::-3D;@'OA$!?)E M#$5]15&RXKN]"N]N^.?6^D[V)_[-U._8G^&:45O\'_KZP;FGBHL[.0=0Z"&A3/:=N5*+
(]>5T1P2+.M\ 4SO M3+E(L-)3,7/E0@".+2BAKN]Y@9M@PIRP9]P1C4S>)2Z)E;L,0D 28)9TC M.\<-XZ&76-O#6X) MK.3.&!DE$\
[OS.1+W'<\XQ!0B)1AP/JUA"%0:HBT&.LY3Z7&R9ZKM%^&W8UR'P:9#_X6'[YB5D>>?T.^ MY[=+X.-J^ BB.FHV++RU"7=U-(J0^$5(?,Q7VL)W]NT$'4?W*9'$5MJO"T@F
M('Z7":MD,C?P2"YP!'U'7$S)8@E.^/%#(_^E\E\[](-TD5* M4P83PK!17D/GG,9H@*,[4PV2Q"#!OI.)(10HA[+8E)YT*XQR<@"2V:^2,OP MT/.\GKLLT=HJM+;>0VL-
G6(BT"VF*93IKCQT5]T967M-=_=PF^YVH;M=K1OH MH[[3T8NKNY]N5T5O1+:A/"B4!Z_(>/&%4YLIK_W+^7]27GG]K@$*GI5ZT&F7 M9]Q3Z.Z\/N/H#Q]G$PGW]8G R=
(\]ZJA\]A=Q;X1V494ND54NN33=HH%4); ME(6G^RQH:!9I"]37>G7K]K=M;^^Z;G;R@L\:@NL)@1)&%J.;WZAU)XT36Q603Q1)V M$9APL=L*YSKQ@^$,=#4ZZ;@7QB>HNBE0S_E!+
P04 " 60$1:]Q3] MJK@' #")P &0 'AL+W=OEWE17@P64]I.AL-RNF#+M#SE*U:H MD3D7RU2JC^)I6*X$2V<5T3(?$L+\A\LT*P:7Y]6[;^+RG*]EGA7LFT#E>KE,
MQ1]7+.'MQESTMI'XQO#Q?I4_LGLGOJV]"?1INN,RR)2O*C!=(L/G% MX!,^FY!$$U2(?V?LI=QZ1M]41\Y_TQ\^SRX&GM:[Y6PJ-8M4_7MF(Y;GFI/2 MX_>&Z6 C4Q-N/[JO'U?
&*V.>TY*->/Z?:"87%X-X@&9LGJYS><=?)]PQ*-#\ MICPOJ[_HI<%Z S1=EY(O&V*EP3(KZO_I:S,16P38[R @#0$Q"8(. K\A\ ^5 M0!L":A+0#H*@(0@.52EL",)#58H:@NA0E>*&
(*Z\6]NC\N5U*M/+\<]%?D-!H MQ4T_5 NBHE8NS]]=N^E4*.9HI.77D]ED"!-T@N]QDU]3$GTNZHC0*^L$_;]B M0CT73^#XT363:9:7'Q7R^_TU.OKP$7U
68%^7?!UF1:S\GPHE99:UG#::#2] M-2(=@OGH"R_DHD0WQ8S-/]QFSYQT_5[&RFB+O-T8@X&5ZSZ2GR\3$B'J& M/C>'D_N0.3\G??)_2]^9#;!^S7OR*'^W@=\>>6;%:"[X$HW41
N5?=2:E0LT MJE8K$\?HYG6:KV=ZT7PJ2Z9^9NC7]!50_LHM[_' _@-9/31161#HW/U^&)*;> M^?!YVRLV*O!IY.^BQC8*1W%,#=@$@
41B5O8SF32S612IWVW@,I0RU41@3&L2&H38L"<.$PG8&&SL#IYUM$F&O;M,M M&61L)BAK#6,A5 T3 QC;93BE&##$%A%XP"V-=S8&AYH:U9,53B@HUPY^2-D M<6C)#Z+
(..7&!IV$D6&NC<$T-E$3@%.T-2<[UD8;:R.GM5]Y<<)-[Z*CVO2/ MQZA@X.*.(%62T##=1A$/FP$,L$I\RW8;!;..1<;T;*,#'=WLC"5Z^,*6CTR
M2H9^4]G;*+@2I!2R:>V>#R[W_#H?"39>"3Y MJ72:')1. 91/ W/9V2@PG=JP)(R"CI6'O;9H\WX^H38\]F54$&:G5 &Y500 MUIE4\5:9BOM*JPVG/7D50-F)%0!!F17BU9E:,6EM)G]%
(66>"Q6VMB=WUW]&_M(\12T6A9]!$CTRU'NQM!>8$ ")]"9,0%L?8G>!Z-ACT/_0O60BR(_UKV8ZK;0 M=59FQ;PY%JB]<]50NG8EM_SW;DN]K?N('GA$/HNY-]GF^U@_N+=\M[MU!
MWR>W<:_<)GUQVW5^_NC+;M'7'W(GNCWFY*XM@SSV0 5$3,S#4&4,0GUM$>C[/.]P.LPM>V# MB+N1>?L>^(ZMN-#1?ZP>I[R89KE>+)\E6QZK1274:"H9^]]BOJ%POKY3Z+MC
MOT]NXUZY3?KBMNN^MDB!.@^E/TNGOZZS,_MJAWS]]\W2F*YSM6F.EL+'5ERP=2O8*R25F.O:%E?=&#ZHH/;@U>RBB_D>_5M M@=,'_]?=F]9\CCX$QW"HUUE?\T_KLU2MP4Q?
VM "#CO3G&7/675]R=)MKTYT M5R=,CC&._C*E#]]FX,?W(LUS/]W<,]WDKN;(O7:Y]/*=&M?]I%*LA6F%N!(F M3]$('6Y=SE$;ZU-U4:M4Y,M"UE^T;MYN+H-
=55>@<F,E78Y6RNS/%.([?AB/K" M6/U!\E5U_>B12U595(\+3SM92O2GO^+B428 BCQE:2X'1]4<6F:,DX@H_*<%Y*CDQD7 M&54X%7-3%@+HM
1EJ>E8EF]FE.5&U"_7;D74YPN5LAQN!9&++*/BUS6D?#4P M;&.]<.?FB=(+9M0OZ!S&H!Z*6X$SLV&9L@QRR7A.,P&OI5].0M#2@COC)8
MR8TQT:E,.'_4DT_3@6%I19!"K#0%Q;\E#"%--1/J^%F3&LV>&K@Y7K._+Y/' M9"94PI"GW]A4)0(C-,@49G21]CN^^@AU0I[FBWDJRU^RJF,M@\0+J7A6@U%! MQO+JGS[5A=@
V+T#_*<&.A+<&N 6R9:*2O3&@&%%H[[@+P)T+++I05F;$HW9 ML%S;,%8"GS+$]>@S5T!LA[PE8YBC/8IHFLTIX.L1,UH5/9^2]XP+Q7Y7"Z$Y>?0^X0N)X;)O*I2I-
S/C6M)U)"WS8#;^AXA#$[6ESVWTN9WZOA0@T(Q\OK9,DN\WD$U _"!_R%B! M8.G:+NW?B$F6S^I3-.2Y$OC2K1%MN75NKS\SE[*@,0P,?%$DB"48T>M7MF^]
M;_/NAXZ=WNN;2]$ME48V_K7%UC'&U=S M^%O.N;O77DM4X/5VK3,WFAC=0>(]/F=8[Q1F"+/.]1>5$U9-5&*/N:"5?8 M)97#!!M9$#H G||X]C;U1+=*36L<_0502P,$% @
%D!\6IKB_S]2 P MD!4 T !X;"]S=EL97,N>&ULW5%B0BMPL/V5*(P)I(DTS9HVHZTVT54*: MM$U(+ EQ,L=E+5^/KYVF:?%%P,-HEPIBW^-S[K%]TOB&E5IS>K.@
M5'FKG(MJY"^4*K\$035;T)Q4%T5)A4:R0N9$Z:Z?N_'(_?F: ('K1P74UADG'N])F^*D6LL13C-9WT'26%M7T M,/K
3=]AH^3$26Y1$6*_@YCN]A&Z>&+=N&933#"05U"XV%6B&TY1;X-Z,PD MI]X]X2-_0CB;2@:LC.2,KVVX"X%9P0OI*5W'VDH(D>K!P]'M08G7.CD3A32Y M;0;]>UH/WP,V/3#
(.&\,=GT;&]+HA25XDIWS& 3?)Y=?MV76]'M&RLB\$,1XV##JAI:= M4UHK[+6GI]"$$U3&ZJ;5L9V0+^M9K7;LKTWZ7HENR_4MZ6>CC!]
M]!5Z+6G&5J;_RAH#F"J[JY.RY.NOG,U%3NWD7YQP/"0;GK_=4ZG8K!WY*TEY7U=J4TZK(#@NLG<,)N-C,'D4-3DX?)-1Z^/D@9OLO]LW^VM,A@=I
M,JB/:ZTSX^;_@C,^W2;WIDG'01-U,I#2EXLG!4,LK,M5_;N]H MZ_]IS-*N82'J4=OV#YA>&#?'?IV+B92N;]INW(^ M-4U/-W36^@+^/G)E+C>"<2SF1@##\F.,
(YE87G^I_D,T/E8#/,V<"(#E#- M.9;E0B;F@^5Q:)%$4Q]B*3B9.!Q-LW>(8?MQ]F#=@8'D@T^O6&M]M MO$*>KP-L3Y^K$&RF>"5B,]77&A#WN@$C2=R[C>4!!K8+6.U ?
G<>J"DW)XI@ M5S%MOV!.,(TF"(5"+[AJ-8X1*U8OBXJP=[2(H2=P(8&X'480A\#3B".8 /&(-(M%)GWX-[[*-B\IX+M_V#'U!+ P04 " 60$1:EXJ]' 3 @ "P M
%]R96QS+RYR96QSQG9*Y;L,P#'!5]L[Q)2(,B]Q^?/BD6=?$7)!?!!Z@ZU:'$!U1(@+?X]@&,S:+#9 ?%O/\;AXZ!%9*\E. QF%E@^[!O:2@.PCH:M)@KPSR]#PF)A:;#\[E.OAR(Q9+U&X5-
G@LAC ^:3YCTH6(XCYQPHCCY-DC&O(\AE+-B&Y8?0*&5N^4']M#TCH<Z!M^K8PA_A[.C8M!KP+M7Z+O6MA+QSLH6^V8NAOC]%"-X%.0>[3:?"A)F7TM,A+4JKBP!@ ^ ZE`4C?3+MJPB*YZV-B
(Z[FJI[X$AA'D]=%M@(NR$8@7:%]$=#(HS#^#L(MO^:G@OGA'0E]I=,1N@CFGH>V($[G:[OPTGN%^G,P7D_5&!9LRS]'K7W0@FKL0$D*:2+\T[C7G!MJA!]QHA#5@N=&Q[YFRU5'Q=G!$L]JK5-JAIG=
&X&[UQ_G@#%KJMQ0AH{ T$C\\S<F8,#3\V<;GDGJ&S]DN^\T!L\I'`]M+0*J+7-AQ0[Y#F]^H"SJ7*5)$=H#*H.C'9XEIU*HHH<(![T'.D@P$H8&<8@;]FS.F'H^_^9#A=U]&#K2$JI*/KN&\S[YK
:[MRG&^_PLD?K8U]"Y7#J)(W$V!#X^C#_GD]5T'W^A\S['R4Y<*IC=DEKD/U?7!8UZ?R*M>F[HTJG(\SLJT%U]+[3RJ(U=-FE=L+Q(&YSN:]IYD=!9:(2V$?"A)/!DC!/JX<6W^\F
MS5U9](.TK@@;2;VW%H0

=+GAM;,W:RT[#,! %T%^ILD6-ZR7M+2;-DVNMOGGV+A^7@1]8S&YV&T< MLN:%];YM*IOR.GOLZT\IT]>$,I\<]\15X^-1WE"P+Q.&E>\#7L_=/%((34V3 M6QO2M>WR+K9M64S/+
<5R?XDO>G3+95-1[:I-EX^4T0>R=5P1I:XM=T6/]B>G M?,.T^^0'YX]E]@7FG;?!^9@G%NCW<6\C&4Y/?2Y$(37[7_$],9<^^/UHF'9- M]0^S_4^N;
>YQ'9^#C\CC_.^+W^+_L0('U(D#X42!\:I \#TL&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 (!9 1%KY/<5ET@4 .4> M 8 " @0T(!X;"]W;W)KW@' #_(& @($5#@ M>&PO=V]R:W-
H965T&UL4$L! A0#% @ %D!$6M9WEP7M M @ "0@ !@ ("!PQ4 'AL+W=O88 !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ %D!$6M6M1YWJ#@ W8H !@ M ("!#B,
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0# M% @ %D!$6M?T1Z&(!P 7!$!@ ("!/SP 'AL+W=O M&UL M4$L! A0#% @ %D!$6C+?F(+O" 61< !D ("!OD@ M 'AL+W=O&PO=V]R:W-
H965TB67P4 '0- 9 M " @;Y7 !X;"]W;W)K&UL4$L! A0#% @ M%D!$6L9S$[_;! MPH !D ("!5%T 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ %D!$6C+BJ>\H!0 7 L !D M ("!E'H
'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ %D!$6LTZ6>?$ @ -P8 !D ("!?8H 'AL M+W=O4$% M !N#@ &0 @(%XC0 >&PO=V]R:W-H965T&UL4$L! A0#% @ %D!$
M6AG5_VKK! V0T !D ("!AI4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ %D!$6F:=E4J9 P QP@ M !D ("!CZ, 'AL+W=O&PO=V]R:W-H965TK !X;"]W;W)K&UL4$L! A0#% @
%D!$6N6MFE22! ?@H !D M ("!S:T 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ %D!$6N[E^DM/ P >@H !D ("!#+H 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @
%D!$6@RC MM[5_@ +P8 !D ("![\H 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ %D!$6N8%(1R\ @ ^ @ !D M ("!.-8 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @
%D!$6LB$?#V1 @ R@8 !D ("! M=-X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ %D!$6O+!\9$> P 1 L !D ("!6^< 'AL+W=O#@ &0 M@($;] >&PO=V]R:W-H965T&UL4$L!
A0#% @ %D!$6HQ 9?]= @ +@8 !D M ("!2 @! 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ %D!$6G?QDANM @ 50< !D ("!?A ! M 'AL+W=O&PO=V]R:W-H965T3OG@0
"P5 9 M " @7D6 0!X;"]W;W)K&UL4$L! A0#% @ M%D!$6J3DB YX! %14 !D ("!3AL! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ %D!$6A@VL_%. P M!@P !D ("!<2@!
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ %D!$6O1JV&'K @ 5@H !D M ("!'S$! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ %D!$6IKB_S]2 P D!4 T (!?#\! 'AL
M+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0# M% @ %D!$6LA XML 80 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 81 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 83 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.0.1 html 283 274 1 true 60 0 false 6 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.mesalabs.com/20241231/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) Sheet http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-comprehensive-income-loss- Condensed Consolidated Statements of Comprehensive Income (Loss) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) Sheet http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) Statements 7 false false R8.htm 007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 8 false false R9.htm 008 - Disclosure - Note 1 - Description of Business and Summary of Significant Accounting Policies Sheet http://www.mesalabs.com/20241231/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies Note 1 - Description of Business and Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Note 2 - Significant Transactions Sheet http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions Note 2 - Significant Transactions Notes 10 false false R11.htm 010 - Disclosure - Note 3 - Revenue Sheet http://www.mesalabs.com/20241231/role/statement-note-3-revenue Note 3 - Revenue Notes 11 false false R12.htm 011 - Disclosure - Note 4 - Fair Value Measurements Sheet http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements Note 4 - Fair Value Measurements Notes 12 false false R13.htm 012 - Disclosure - Note 5 - Supplemental Information Sheet http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information- Note 5 - Supplemental Information Notes 13 false false R14.htm 013 - Disclosure - Note 6 - Goodwill and Intangible Assets, Net Sheet http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net Note 6 - Goodwill and Intangible Assets, Net Notes 14 false false R15.htm 014 - Disclosure - Note 7 - Indebtedness Sheet http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness Note 7 - Indebtedness Notes 15 false false R16.htm 015 - Disclosure - Note 8 - Stockholders' Equity Sheet http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity- Note 8 - Stockholders' Equity Notes 16 false false R17.htm 016 - Disclosure - Note 9 - (Loss) Earnings Per Share Sheet http://www.mesalabs.com/20241231/role/statement-note-9-loss-earnings-per-share Note 9 - (Loss) Earnings Per Share Notes 17 false false R18.htm 017 - Disclosure - Note 10 - Income Taxes Sheet http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes Note 10 - Income Taxes Notes 18 false false R19.htm 018 - Disclosure - Note 11 - Commitments and Contingencies Sheet http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies Note 11 - Commitments and Contingencies Notes 19 false false R20.htm 019 - Disclosure - Note 12 - Segment Information Sheet http://www.mesalabs.com/20241231/role/statement-note-12-segment-information Note 12 - Segment Information Notes 20 false false R21.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 21 false false R22.htm 995466 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.mesalabs.com/20241231/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.mesalabs.com/20241231/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies 22 false false R23.htm 995467 - Disclosure - Note 2 - Significant Transactions (Tables) Sheet http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-tables Note 2 - Significant Transactions (Tables) Tables http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions 23 false false R24.htm 995468 - Disclosure - Note 3 - Revenue (Tables) Sheet http://www.mesalabs.com/20241231/role/statement-note-3-revenue-tables Note 3 - Revenue (Tables) Tables http://www.mesalabs.com/20241231/role/statement-note-3-revenue 24 false false R25.htm 995469 - Disclosure - Note 4 - Fair Value Measurements (Tables) Sheet http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-tables Note 4 - Fair Value Measurements (Tables) Tables http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements 25 false false R26.htm 995470 - Disclosure - Note 5 - Supplemental Information (Tables) Sheet http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-tables Note 5 - Supplemental Information (Tables) Tables http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information- 26 false false R27.htm 995471 - Disclosure - Note 6 - Goodwill and Intangible Assets, Net (Tables) Sheet http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-tables Note 6 - Goodwill and Intangible Assets, Net (Tables) Tables http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net 27 false false R28.htm 995472 - Disclosure - Note 7 - Indebtedness (Tables) Sheet http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-tables Note 7 - Indebtedness (Tables) Tables http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness 28 false false R29.htm 995473 - Disclosure - Note 8 - Stockholders' Equity (Tables) Sheet http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-tables Note 8 - Stockholders' Equity (Tables) Tables http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity- 29 false false R30.htm 995474 - Disclosure - Note 9 - (Loss) Earnings Per Share (Tables) Sheet http://www.mesalabs.com/20241231/role/statement-note-9-loss-earnings-per-share-tables Note 9 - (Loss) Earnings Per Share (Tables) Tables http://www.mesalabs.com/20241231/role/statement-note-9-loss-earnings-per-share 30 false false R31.htm 995475 - Disclosure - Note 10 - Income Taxes (Tables) Sheet http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes-tables Note 10 - Income Taxes (Tables) Tables http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes 31 false false R32.htm 995476 - Disclosure - Note 12 - Segment Information (Tables) Sheet http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-tables Note 12 - Segment Information (Tables) Tables http://www.mesalabs.com/20241231/role/statement-note-12-segment-information 32 false false R33.htm 995477 - Disclosure - Note 2 - Significant Transactions (Details Textual) Sheet http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-details-textual Note 2 - Significant Transactions (Details Textual) Details http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-tables 33 false false R34.htm 995478 - Disclosure - Note 2 - Significant Transactions - Schedule of Business Acquisitions (Details) Sheet http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-schedule-of-business-acquisitions-details Note 2 - Significant Transactions - Schedule of Business Acquisitions (Details) Details 34 false false R35.htm 995479 - Disclosure - Note 3 - Revenue (Details Textual) Sheet http://www.mesalabs.com/20241231/role/statement-note-3-revenue-details-textual Note 3 - Revenue (Details Textual) Details http://www.mesalabs.com/20241231/role/statement-note-3-revenue-tables 35 false false R36.htm 995480 - Disclosure - Note 3 - Revenue - Disaggregation of Revenue (Details) Sheet http://www.mesalabs.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details Note 3 - Revenue - Disaggregation of Revenue (Details) Details 36 false false R37.htm 995481 - Disclosure - Note 3 - Revenue - Revenues From External Customers (Details) Sheet http://www.mesalabs.com/20241231/role/statement-note-3-revenue-revenues-from-external-customers-details Note 3 - Revenue - Revenues From External Customers (Details) Details 37 false false R38.htm 995482 - Disclosure - Note 3 - Revenue - Contract Liabilities (Details) Sheet http://www.mesalabs.com/20241231/role/statement-note-3-revenue-contract-liabilities-details Note 3 - Revenue - Contract Liabilities (Details) Details 38 false false R39.htm 995483 - Disclosure - Note 4 - Fair Value Measurements (Details Textual) Sheet http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual Note 4 - Fair Value Measurements (Details Textual) Details http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-tables 39 false false R40.htm 995484 - Disclosure - Note 4 - Fair Value Measurements - Fair Value and Carrying Value of the Notes (Details) Notes http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-fair-value-and-carrying-value-of-the-notes-details Note 4 - Fair Value Measurements - Fair Value and Carrying Value of the Notes (Details) Details 40 false false R41.htm 995485 - Disclosure - Note 5 - Supplemental Information (Details Textual) Sheet http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-details-textual Note 5 - Supplemental Information (Details Textual) Details http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-tables 41 false false R42.htm 995486 - Disclosure - Note 5 - Supplemental Information - Inventories (Details) Sheet http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-inventories-details Note 5 - Supplemental Information - Inventories (Details) Details 42 false false R43.htm 995487 - Disclosure - Note 5 - Supplemental Information - Prepaid and Other Current Assets (Details) Sheet http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-prepaid-and-other-current-assets-details Note 5 - Supplemental Information - Prepaid and Other Current Assets (Details) Details 43 false false R44.htm 995488 - Disclosure - Note 5 - Supplemental Information - Accrued Payroll and Benefits (Details) Sheet http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-accrued-payroll-and-benefits-details Note 5 - Supplemental Information - Accrued Payroll and Benefits (Details) Details 44 false false R45.htm 995489 - Disclosure - Note 5 - Supplemental Information - Other Accrued Expenses (Details) Sheet http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-accrued-expenses-details Note 5 - Supplemental Information - Other Accrued Expenses (Details) Details 45 false false R46.htm 995490 - Disclosure - Note 5 - Supplemental Information - Other Noncurrent Liabilities (Details) Sheet

http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-noncurrent-liabilities-details Note 5 - Supplemental Information - Other Noncurrent Liabilities (Details) Details 46 false false R47.htm 995491 - Disclosure - Note 5 - Supplemental Information - Property, Plant and Equipment (Details) Sheet http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-property-plant-and-equipment-details Note 5 - Supplemental Information - Property, Plant and Equipment (Details) Details 47 false false R48.htm 995492 - Disclosure - Note 6 - Goodwill and Intangible Assets, Net - Other Intangible Assets (Details) Sheet http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-other-intangible-assets-details Note 6 - Goodwill and Intangible Assets, Net - Other Intangible Assets (Details) Details 48 false false R49.htm 995493 - Disclosure - Note 6 - Goodwill and Intangible Assets, Net - Amortization Expense for Finite-lived Intangible Assets (Details) Sheet http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-amortization-expense-for-finitelived-intangible-assets-details Note 6 - Goodwill and Intangible Assets, Net - Amortization Expense for Finite-lived Intangible Assets (Details) Details 49 false false R50.htm 995494 - Disclosure - Note 6 - Goodwill and Intangible Assets, Net - Estimated Amortization Expense (Details) Sheet http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-estimated-amortization-expense-details Note 6 - Goodwill and Intangible Assets, Net - Estimated Amortization Expense (Details) Details 50 false false R51.htm 995495 - Disclosure - Note 6 - Goodwill and Intangible Assets, Net - Change in the Carrying Amount of Goodwill (Details) Sheet http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-change-in-the-carrying-amount-of-goodwill-details Note 6 - Goodwill and Intangible Assets, Net - Change in the Carrying Amount of Goodwill (Details) Details 51 false false R52.htm 995496 - Disclosure - Note 7 - Indebtedness (Details Textual) Sheet http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual Note 7 - Indebtedness (Details Textual) Details http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-tables 52 false false R53.htm 995497 - Disclosure - Note 7 - Indebtedness - Quarterly Periodic Payments (Details) Sheet http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-quarterly-periodic-payments-details Note 7 - Indebtedness - Quarterly Periodic Payments (Details) Details 53 false false R54.htm 995498 - Disclosure - Note 7 - Indebtedness - Carrying Amount of the Term Loan (Details) Sheet http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-term-loan-details Note 7 - Indebtedness - Carrying Amount of the Term Loan (Details) Details 54 false false R55.htm 995499 - Disclosure - Note 7 - Indebtedness - Carrying Amount of the Term Loan (Details) (Parentheticals) Sheet http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-term-loan-details-parentheticals Note 7 - Indebtedness - Carrying Amount of the Term Loan (Details) (Parentheticals) Details 55 false false R56.htm 995500 - Disclosure - Note 7 - Indebtedness - Carrying Amount of the Notes (Details) Notes http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-notes-details Note 7 - Indebtedness - Carrying Amount of the Notes (Details) Details 56 false false R57.htm 995501 - Disclosure - Note 7 - Indebtedness - Interest Expense on the Notes (Details) Notes http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-interest-expense-on-the-notes-details Note 7 - Indebtedness - Interest Expense on the Notes (Details) Details 57 false false R58.htm 995502 - Disclosure - Note 8 - Stockholders' Equity (Details Textual) Sheet http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-textual Note 8 - Stockholders' Equity (Details Textual) Details http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-tables 58 false false R59.htm 995503 - Disclosure - Note 8 - Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details) Sheet http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-restricted-stock-unit-activity-details Note 8 - Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details) Details 59 false false R60.htm 995504 - Disclosure - Note 8 - Stockholders' Equity - Schedule of Stock Option Award Activity (Details) Sheet http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-stock-option-award-activity-details Note 8 - Stockholders' Equity - Schedule of Stock Option Award Activity (Details) Details 60 false false R61.htm 995505 - Disclosure - Note 9 - Earnings (Loss) Per Share - Computation of Net Income Per Share, Basic & Diluted (Details) Sheet http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-computation-of-net-income-per-share-basic-diluted-details Note 9 - Earnings (Loss) Per Share - Computation of Net Income Per Share, Basic & Diluted (Details) Details 61 false false R62.htm 995506 - Disclosure - Note 9 - Earnings (Loss) Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) Sheet http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details Note 9 - Earnings (Loss) Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) Details 62 false false R63.htm 995507 - Disclosure - Note 10 - Income Taxes (Details Textual) Sheet http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes-details-textual Note 10 - Income Taxes (Details Textual) Details http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes-tables 63 false false R64.htm 995508 - Disclosure - Note 10 - Income Taxes - Provisions for Income Taxes (Details) Sheet http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes-provisions-for-income-taxes-details Note 10 - Income Taxes - Provisions for Income Taxes (Details) Details 64 false false R65.htm 995509 - Disclosure - Note 11 - Commitments and Contingencies (Details Textual) Sheet http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies-details-textual Note 11 - Commitments and Contingencies (Details Textual) Details http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies 65 false false R66.htm 995510 - Disclosure - Note 12 - Segment Information - Operating Segment Information (Details) Sheet http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-operating-segment-information-details Note 12 - Segment Information - Operating Segment Information (Details) Details 66 false false R67.htm 995511 - Disclosure - Note 12 - Segment Data - Segment Depreciation and Amortization (Details) Sheet http://www.mesalabs.com/20241231/role/statement-note-12-segment-data-segment-depreciation-and-amortization-details Note 12 - Segment Data - Segment Depreciation and Amortization (Details) Details 67 false false All Reports Book All Reports mlab-20241231.xsd mlab-20241231_cal.xml mlab-20241231_def.xml mlab-20241231_lab.xml mlab-20241231_pre.xml mlab20241231_10q.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 86 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "mlab20241231_10q.htm": { "nsprefix": "mlab", "nsuri": "http://www.mesalabs.com/20241231", "dts": { "schema": { "local": ["mlab-20241231.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["mlab-20241231_cal.xml"] }, "definitionLink": { "local": ["mlab-20241231_def.xml"] }, "labelLink": { "local": ["mlab-20241231_lab.xml"] }, "presentationLink": { "local": ["mlab-20241231_pre.xml"] }, "inline": { "local": ["mlab20241231_10q.htm"] } }, "keyStandard": 244, "keyCustom": 30, "axisStandard": 26, "axisCustom": 0, "memberStandard": 29, "memberCustom": 30, "hidden": { "total": 33, "http://www.mesalabs.com/20241231": 1, "http://fasb.org/us-gaap/2024": 22, "http://xbrl.sec.gov/ecd/2024": 4, "http://xbrl.sec.gov/dei/2024": 6 }, "contextCount": 283, "entityCount": 1, "segmentCount": 60, "elementCount": 451, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 850, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.mesalabs.com/20241231/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": null, "uniqueAnchor": null }, "R4": { "role": "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "longName": "003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "d_2024-10-01_2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-10-01_2024-12-31", "name": "us-gaap:CostOfRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "unique": true } }, "R5": { "role": "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-comprehensive-income-loss-", "longName": "004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "d_2024-10-01_2024-12-31", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-10-01_2024-12-31", "name": "us-gaap:ComprehensiveIncomeNetOfTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "unique": true } }, "R6": { "role": "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "longName": "005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "unique": true } }, "R7": { "role": "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "longName": "006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": null, "uniqueAnchor": null }, "R8": { "role": "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "longName": "007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "unique": true } }, "R9": { "role": "http://www.mesalabs.com/20241231/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "longName": "008 - Disclosure - Note 1 - Description of Business and Summary of Significant Accounting Policies", "shortName": "Note 1 - Description of Business and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R10": { "role":

"http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions", "longName": "009 - Disclosure - Note 2 - Significant Transactions", "shortName": "Note 2 - Significant Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "mlab:SignificantTransactionsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "mlab:SignificantTransactionsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.mesalabs.com/20241231/role/statement-note-3-revenue", "longName": "010 - Disclosure - Note 3 - Revenue", "shortName": "Note 3 - Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements", "longName": "011 - Disclosure - Note 4 - Fair Value Measurements", "shortName": "Note 4 - Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-", "longName": "012 - Disclosure - Note 5 - Supplemental Information", "shortName": "Note 5 - Supplemental Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net", "longName": "013 - Disclosure - Note 6 - Goodwill and Intangible Assets, Net", "shortName": "Note 6 - Goodwill and Intangible Assets, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "longName": "014 - Disclosure - Note 7 - Indebtedness", "shortName": "Note 7 - Indebtedness", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-", "longName": "015 - Disclosure - Note 8 - Stockholders' Equity", "shortName": "Note 8 - Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.mesalabs.com/20241231/role/statement-note-9-loss-earnings-per-share", "longName": "016 - Disclosure - Note 9 - (Loss) Earnings Per Share", "shortName": "Note 9 - (Loss) Earnings Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes", "longName": "017 - Disclosure - Note 10 - Income Taxes", "shortName": "Note 10 - Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies", "longName": "018 - Disclosure - Note 11 - Commitments and Contingencies", "shortName": "Note 11 - Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information", "longName": "019 - Disclosure - Note 12 - Segment Information", "shortName": "Note 12 - Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": null, "uniqueAnchor": null }, "R22": { "role": "http://www.mesalabs.com/20241231/role/statement-significant-accounting-policies-policies", "longName": "995466 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "22", "firstAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "mlab:DescriptionOfBusinessPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "mlab:DescriptionOfBusinessPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-tables", "longName": "995467 - Disclosure - Note 2 - Significant Transactions (Tables)", "shortName": "Note 2 - Significant Transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["mlab:SignificantTransactionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["mlab:SignificantTransactionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-tables", "longName": "995468 - Disclosure - Note 3 - Revenue (Tables)", "shortName": "Note 3 - Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-tables", "longName": "995469 - Disclosure - Note 4 - Fair Value Measurements (Tables)", "shortName": "Note 4 - Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-tables", "longName": "995470 - Disclosure - Note 5 - Supplemental Information (Tables)", "shortName": "Note 5 - Supplemental Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-tables", "longName": "995471 - Disclosure - Note 6 - Goodwill and Intangible Assets, Net (Tables)", "shortName": "Note 6 - Goodwill and Intangible Assets, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-tables", "longName": "995472 - Disclosure - Note 7 - Indebtedness (Tables)", "shortName": "Note 7 - Indebtedness (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-tables", "longName": "995473 - Disclosure - Note 8 - Stockholders' Equity (Tables)", "shortName": "Note 8 - Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.mesalabs.com/20241231/role/statement-note-9-loss-earnings-per-share-tables", "longName": "995474 - Disclosure - Note 9 - (Loss) Earnings Per Share (Tables)", "shortName": "Note 9 - (Loss) Earnings Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes-tables", "longName": "995475 - Disclosure - Note 10 - Income Taxes (Tables)", "shortName": "Note 10 - Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:IncomeTaxDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:IncomeTaxDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-tables", "longName": "995476 - Disclosure - Note 12 - Segment Information (Tables)", "shortName": "Note 12 - Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SegmentReportingDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SegmentReportingDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-details-textual", "longName": "995477 - Disclosure - Note 2 - Significant Transactions (Details Textual)", "shortName": "Note 2 - Significant Transactions (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "d_2023-10-16_2023-10-16_BusinessAcquisitionAxis-GkeAcquisitionMember", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "mlab:SignificantTransactionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-10-16_2023-10-16_BusinessAcquisitionAxis-GkeAcquisitionMember", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "mlab:SignificantTransactionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-schedule-of-business-acquisitions-details", "longName": "995478 - Disclosure - Note 2 - Significant Transactions - Schedule of Business Acquisitions (Details)", "shortName": "Note 2 - Significant Transactions - Schedule of Business Acquisitions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "d_2024-10-01_2024-12-31", "name": "us-gaap:GrossProfit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-10-01_2024-12-31_BusinessAcquisitionAxis-GkeAcquisitionMember", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "mlab:SignificantTransactionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "unique": true } }, "R35": { "role": "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-details-textual", "longName": "995479 - Disclosure - Note 3 - Revenue (Details Textual)", "shortName": "Note 3 - Revenue (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "d_2024-10-01_2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-10-01_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-GkeGmbhMember_StatementBusinessSegmentsAxis-SterilizationAndDisinfectionControlMember", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "tbody", "table", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "unique": true } }, "R36": { "role": "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details", "longName": "995480 - Disclosure - Note 3 - Revenue - Disaggregation of Revenue (Details)", "shortName": "Note 3 - Revenue - Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "d_2024-10-01_2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-10-01_2024-12-31_ProductOrServiceAxis-ConsumablesMember_TimingOfTransferOfGoodOrServiceAxis-TransferredAtPointInTimeMember", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "unique": true } }, "R37": { "role": "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-revenues-from-external-customers-details", "longName": "995481 - Disclosure - Note 3 - Revenue - Revenues From External Customers (Details)", "shortName": "Note 3 - Revenue - Revenues From External Customers (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "d_2024-10-01_2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-10-01_2024-12-31_StatementGeographicalAxis-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "unique": true } }, "R38": { "role": "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-contract-liabilities-details", "longName": "995482 - Disclosure - Note 3 - Revenue - Contract Liabilities (Details)", "shortName": "Note 3 - Revenue - Contract Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "i_2024-03-31", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-03-31", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual", "longName": "995483 - Disclosure - Note 4 - Fair Value Measurements (Details Textual)", "shortName": "Note 4 - Fair Value Measurements (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "i_2024-12-31_BusinessAcquisitionAxis-GkeAcquisitionMember", "name": "mlab:BusinessCombinationHoldBackConsiderationliability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31_BusinessAcquisitionAxis-GkeAcquisitionMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member", "name": "mlab:BusinessCombinationHoldBackConsiderationLiabilityFairValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "unique": true } }, "R40": { "role": "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-fair-value-and-carrying-value-of-the-notes-details", "longName": "995484 - Disclosure - Note 4 - Fair Value Measurements - Fair Value and Carrying Value of the Notes (Details)", "shortName": "Note 4 - Fair Value Measurements - Fair Value and Carrying Value of the Notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "i_2024-12-31_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember_LongtermDebtTypeAxis-SeniorNotesMember", "name": "us-gaap:NotesPayableFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember_LongtermDebtTypeAxis-SeniorNotesMember", "name": "us-gaap:NotesPayableFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-details-textual", "longName": "995485 - Disclosure - Note 5 - Supplemental Information (Details Textual)", "shortName": "Note 5 - Supplemental Information (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "d_2024-10-01_2024-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-10-01_2024-12-31_BusinessAcquisitionAxis-GkeAcquisitionMember", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "unique": true } }, "R42": { "role": "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-inventories-details", "longName": "995486 - Disclosure - Note 5 - Supplemental Information - Inventories (Details)", "shortName": "Note 5 - Supplemental Information - Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:InventoryRawMaterials", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:InventoryRawMaterials", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-prepaid-and-other-current-assets-details", "longName": "995487 - Disclosure - Note 5 - Supplemental Information - Prepaid and Other Current Assets (Details)", "shortName": "Note 5 - Supplemental Information - Prepaid and Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "mlab:PrepaidExpensesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31", "name": "mlab:PrepaidExpensesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-accrued-payroll-and-benefits-details", "longName": "995488 - Disclosure - Note 5 - Supplemental Information - Accrued Payroll and Benefits (Details)", "shortName": "Note 5 - Supplemental Information - Accrued Payroll and Benefits (Details)", "isDefault":

"false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:AccruedBonusesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "mlab:ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:AccruedBonusesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "mlab:ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-accrued-expenses-details", "longName": "995489 - Disclosure - Note 5 - Supplemental Information - Other Accrued Expenses (Details)", "shortName": "Note 5 - Supplemental Information - Other Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-noncurrent-liabilities-details", "longName": "995490 - Disclosure - Note 5 - Supplemental Information - Other Noncurrent Liabilities (Details)", "shortName": "Note 5 - Supplemental Information - Other Noncurrent Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:OtherLiabilitiesNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31_BusinessAcquisitionAxis-GkeAcquisitionMember", "name": "us-gaap:OperatingLeaseLiabilityNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "unique": true } }, "R47": { "role": "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-property-plant-and-equipment-details", "longName": "995491 - Disclosure - Note 5 - Supplemental Information - Property, Plant and Equipment (Details)", "shortName": "Note 5 - Supplemental Information - Property, Plant and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "d_2024-10-01_2024-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-10-01_2024-12-31_IncomeStatementLocationAxis-CostOfSalesMember", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "unique": true } }, "R48": { "role": "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-other-intangible-assets-details", "longName": "995492 - Disclosure - Note 6 - Goodwill and Intangible Assets, Net - Other Intangible Assets (Details)", "shortName": "Note 6 - Goodwill and Intangible Assets, Net - Other Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-amortization-expense-for-finitelived-intangible-assets-details", "longName": "995493 - Disclosure - Note 6 - Goodwill and Intangible Assets, Net - Amortization Expense for Finite-lived Intangible Assets (Details)", "shortName": "Note 6 - Goodwill and Intangible Assets, Net - Amortization Expense for Finite-lived Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "d_2024-10-01_2024-12-31", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-10-01_2024-12-31_IncomeStatementLocationAxis-CostOfSalesMember", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "unique": true } }, "R50": { "role": "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-estimated-amortization-expense-details", "longName": "995494 - Disclosure - Note 6 - Goodwill and Intangible Assets, Net - Estimated Amortization Expense (Details)", "shortName": "Note 6 - Goodwill and Intangible Assets, Net - Estimated Amortization Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-change-in-the-carrying-amount-of-goodwill-details", "longName": "995495 - Disclosure - Note 6 - Goodwill and Intangible Assets, Net - Change in the Carrying Amount of Goodwill (Details)", "shortName": "Note 6 - Goodwill and Intangible Assets, Net - Change in the Carrying Amount of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "i_2024-03-31", "name": "us-gaap:Goodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "unique": true } }, "R52": { "role": "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual", "longName": "995496 - Disclosure - Note 7 - Indebtedness (Details Textual)", "shortName": "Note 7 - Indebtedness (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:LongTermDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-03-31_BalanceSheetLocationAxis-PrepaidExpensesOtherAndOtherAssetsMember_DebtInstrumentAxis-SeniorSecuredCreditAgreementMember", "name": "us-gaap:DeferredFinanceCostsNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "unique": true } }, "R53": { "role": "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-quarterly-periodic-payments-details", "longName": "995497 - Disclosure - Note 7 - Indebtedness - Quarterly Periodic Payments (Details)", "shortName": "Note 7 - Indebtedness - Quarterly Periodic Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-term-loan-details", "longName": "995498 - Disclosure - Note 7 - Indebtedness - Carrying Amount of the Term Loan (Details)", "shortName": "Note 7 - Indebtedness - Carrying Amount of the Term Loan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:SecuredDebtCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31_DebtInstrumentAxis-TermLoanMember", "name": "mlab:SecuredDebtDiscountAndIssuanceCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "unique": true } }, "R55": { "role": "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-term-loan-details-parentheticals", "longName": "995499 - Disclosure - Note 7 - Indebtedness - Carrying Amount of the Term Loan (Details) (Parentheticals)", "shortName": "Note 7 - Indebtedness - Carrying Amount of the Term Loan (Details) (Parentheticals)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "55", "firstAnchor": null, "uniqueAnchor": null }, "R56": { "role": "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-notes-details", "longName": "995500 - Disclosure - Note 7 - Indebtedness - Carrying Amount of the Notes (Details)", "shortName": "Note 7 - Indebtedness - Carrying Amount of the Notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:LongTermDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true }, "uniqueAnchor": null }, "R57": { "role": "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-interest-expense-on-the-notes-details", "longName": "995501 - Disclosure - Note 7 - Indebtedness - Interest Expense on the Notes (Details)", "shortName": "Note 7 - Indebtedness - Interest Expense on the Notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "d_2024-10-01_2024-12-31_DebtInstrumentAxis-TheNotesMember", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "mlab:InterestExpenseOnConvertibleDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-10-01_2024-12-31_DebtInstrumentAxis-TheNotesMember", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "mlab:InterestExpenseOnConvertibleDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-textual", "longName": "995502 - Disclosure - Note 8 - Stockholders' Equity (Details Textual)", "shortName": "Note 8 - Stockholders' Equity (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "i_2024-12-31_AwardTypeAxis-TheFy25PsusMember_TitleOfIndividualAxis-EligibleEmployeesMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31_AwardTypeAxis-TheFy25PsusMember_TitleOfIndividualAxis-EligibleEmployeesMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-restricted-stock-unit-activity-details", "longName": "995503 - Disclosure - Note 8 - Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details)", "shortName": "Note 8 - Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "i_2024-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-stock-option-award-activity-details", "longName": "995504 - Disclosure - Note 8 - Stockholders' Equity - Schedule of Stock Option Award Activity (Details)", "shortName": "Note 8 - Stockholders' Equity - Schedule of Stock Option Award Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "i_2024-03-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-12-31", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "unique": true } }, "R61": { "role": "http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-computation-of-net-income-per-share-basic-diluted-details", "longName": "995505 - Disclosure - Note 9 - Earnings (Loss) Per Share - Computation of Net Income Per Share, Basic & Diluted (Details)", "shortName": "Note 9 - Earnings (Loss) Per Share - Computation of Net Income Per Share, Basic & Diluted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "d_2024-10-01_2024-12-31", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-10-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember", "name": "us-gaap:IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "unique": true } }, "R62": { "role": "http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details", "longName": "995506 - Disclosure - Note 9 - Earnings (Loss) Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details)", "shortName": "Note 9 - Earnings (Loss) Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "d_2024-10-01_2024-12-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-10-01_2024-12-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes-details-textual", "longName": "995507 - Disclosure - Note 10 - Income Taxes (Details Textual)", "shortName": "Note 10 - Income Taxes (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "d_2024-10-01_2024-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-10-01_2024-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes-provisions-for-income-taxes-details", "longName": "995508 - Disclosure - Note 10 - Income Taxes - Provisions for Income Taxes (Details)", "shortName": "Note 10 - Income Taxes - Provisions for Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "d_2024-10-01_2024-12-31", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-10-01_2024-12-31", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "unique": true } }, "R65": { "role": "http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies-details-textual", "longName": "995509 - Disclosure - Note 11 - Commitments and Contingencies (Details Textual)", "shortName": "Note 11 - Commitments and Contingencies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "i_2024-12-31_BusinessAcquisitionAxis-GkeAcquisitionMember", "name": "mlab:BusinessCombinationHoldBackConsiderationliability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2025-01-02_BusinessAcquisitionAxis-BelynticAcquisitionMember_SubsequentEventTypeAxis-SubsequentEventMember", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "unique": true } }, "R66": { "role": "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-operating-segment-information-details", "longName": "995510 - Disclosure - Note 12 - Segment Information - Operating Segment Information (Details)", "shortName": "Note 12 - Segment Information - Operating Segment Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "d_2024-10-01_2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-10-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember", "name": "us-gaap:GrossProfit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "unique": true } }, "R67": { "role": "http://www.mesalabs.com/20241231/role/statement-note-12-segment-data-segment-depreciation-and-amortization-details", "longName": "995511 - Disclosure - Note 12 - Segment Data - Segment Depreciation and Amortization (Details)", "shortName": "Note 12 - Segment Data - Segment Depreciation and Amortization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:InventoryNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-SterilizationAndDisinfectionControlMember", "name": "us-gaap:InventoryNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "mlab:ScheduleOfDepreciationAndAmortizationExpenseTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlab20241231_10q.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "presentation": ["http://www.mesalabs.com/20241231/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r51", "r671"] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual"], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": ["r608"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Accounts receivable, less allowance for credit losses of $1,060 and $1,321, respectively", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r740"] }, "us-gaap_AccruedBonusesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedBonusesCurrent", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-accrued-payroll-and-benefits-details": { "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-accrued-payroll-and-benefits-details"], "lang": { "en-us": { "role": { "label": "Bonus payable", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r54"] }, "mlab_AccruedBusinessTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "AccruedBusinessTaxes", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-accrued-expenses-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-accrued-expenses-details"], "lang": { "en-us": { "role": { "label": "Accrued business taxes", "documentation": "The value of the current portion of accrued business taxes." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 }, "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-accrued-expenses-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-accrued-expenses-details"], "lang": { "en-us": { "role": { "label": "Other accrued expenses", "totalLabel": "Total other accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r54"] }, "us-gaap_AccruedPayrollTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedPayrollTaxesCurrent", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-accrued-payroll-and-benefits-details": { "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-accrued-payroll-and-benefits-details"], "lang": { "en-us": { "role": { "label": "Payroll related taxes", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r54"] }, "us-gaap_AccruedSalariesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedSalariesCurrent", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-accrued-payroll-and-benefits-details": { "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-accrued-payroll-and-benefits-details"], "lang": { "en-us": { "role": { "label": "Wages and paid-time-off payable", "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r54", "r627"] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Property, plant, and equipment accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r32", "r121", "r499"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive (loss)", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r17", "r18", "r71", "r126", "r495", "r534", "r535"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r3", "r9", "r18", "r394", "r397", "r441", "r530", "r531", "r714", "r715", "r716", "r725", "r726", "r727", "r728"] }, "mlab_AcquisitionrelatedHoldbacksCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "AcquisitionrelatedHoldbacksCurrent", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-accrued-expenses-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-accrued-expenses-details"], "lang": { "en-us": { "role": { "label": "Current acquisition-related holdbacks", "documentation": "The current acquisition-related holdbacks." } } }, "auth_ref": [] }, "mlab_AcquisitionrelatedHoldbacksNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "AcquisitionrelatedHoldbacksNoncurrent", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-noncurrent-liabilities-details": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-noncurrent-liabilities-details"], "lang": { "en-us": { "role": { "label": "Noncurrent acquisition-related holdbacks", "documentation": "The noncurrent acquisition-related holdbacks." } } }, "auth_ref": [] }, "us-gaap_AdjustmentForAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentForAmortization", "crdr": "debit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-schedule-of-business-acquisitions-details"], "lang": { "en-us": { "role": { "label": "Amortization of inventory step-up recorded in cost of revenues", "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives." } } }, "auth_ref": ["r6"] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to net cash from operating activities:" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "negatedLabel": "Tax withholding on vesting of restricted stock units", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Allowance for doubtful accounts receivable", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": ["r127", "r213", "r217"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-interest-expense-on-the-notes-details": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-interest-expense-on-the-notes-details"], "lang": { "en-us": { "role": { "verboseLabel": "Amortization of debt issuance costs", "label": "us-gaap_AmortizationOfFinancingCostsAndDiscounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": ["r295", "r647", "r648", "r721", "r821"] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-amortization-expense-for-finitelived-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Amortization of acquisition-related intangibles", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r6", "r230", "r237", "r643"] }, "mlab_AmortizationOfInventoryStepupCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "AmortizationOfInventoryStepupCost", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Amortization of step-up in inventory basis", "documentation": "Represents amortization of inventory step-up cost." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details"], "lang": { "en-us": { "role": { "label": "Total stock awards excluded from diluted EPS (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r172"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r24"] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r24"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r101", "r111", "r125", "r145", "r176", "r182", "r200", "r204", "r214", "r262", "r263", "r265", "r266", "r267", "r268", "r269", "r271", "r272", "r389", "r391", "r422", "r491", "r567", "r635", "r636", "r671", "r696", "r778", "r779", "r825"] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r118", "r130", "r145", "r214", "r262", "r263", "r265", "r266", "r267", "r268", "r269", "r271", "r272", "r389", "r391", "r422", "r671", "r778", "r779", "r825"] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Noncurrent assets:" } } }, "auth_ref": [] }, "mlab_AssumedConversionOfConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "AssumedConversionOfConvertibleDebtMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details"], "lang": { "en-us": { "role": { "label": "Assumed Conversion of Convertible Debt [Member]", "documentation": "Represents the assumed conversion of convertible debt." } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-restricted-stock-unit-activity-details", "http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-computation-of-net-income-per-share-basic-diluted-details"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355"] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-accrued-expenses-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r250", "r837", "r838"] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-accrued-expenses-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r45", "r46", "r250", "r837", "r838"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "mlab_BeijingGkeScienceTechnologyCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "BeijingGkeScienceTechnologyCoLtdMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Beijing GKE Science & Technology Co. Ltd. [Member]", "documentation": "Relating to Beijing GKE Science & Technology Co. Ltd." } } }, "auth_ref": [] }, "mlab_BelynticAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "BelynticAcquisitionMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies", "http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual"], "lang": { "en-us": { "role": { "label": "Belyntic Acquisition [Member]", "documentation": "Represents acquisition of Belyntic GmbH." } } }, "auth_ref": [] }, "mlab_BiopharmaceuticalDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "BiopharmaceuticalDevelopmentMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-12-segment-data-segment-depreciation-and-amortization-details", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-operating-segment-information-details", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-change-in-the-carrying-amount-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "Biopharmaceutical Development [Member]", "documentation": "Represents information related to biopharmaceutical development." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies", "http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-schedule-of-business-acquisitions-details", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-noncurrent-liabilities-details"], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": ["r231", "r232", "r233", "r234", "r235", "r384", "r656", "r657"] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies", "http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-schedule-of-business-acquisitions-details", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-noncurrent-liabilities-details"], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": ["r38", "r40", "r231", "r232", "r233", "r234", "r235", "r384", "r656", "r657"] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired", "terseLabel": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": ["r39"] }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "crdr": "credit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "terseLabel": "Business Combination, Consideration Transferred, Liabilities Incurred", "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination." } } }, "auth_ref": ["r0", "r1", "r42", "r386"] }, "mlab_BusinessCombinationContingentConsiderationLiabilityAtAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "BusinessCombinationContingentConsiderationLiabilityAtAcquisitionDate", "crdr": "credit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual"], "lang": { "en-us": { "role": { "label": "mlab_BusinessCombinationContingentConsiderationLiabilityAtAcquisitionDate", "terseLabel": "Business Combination Contingent Consideration Liability, At Acquisition Date", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, at the date of acquisition." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent", "terseLabel": "Business Combination, Contingent Consideration, Liability, Current", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r43", "r99"] }, "mlab_BusinessCombinationContingentConsiderationLiabilityFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "BusinessCombinationContingentConsiderationLiabilityFairValue", "crdr": "credit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual"], "lang": { "en-us": { "role": { "label": "mlab_BusinessCombinationContingentConsiderationLiabilityFairValue", "terseLabel": "Business Combination, Contingent Consideration, Liability Fair Value", "documentation": "Fair value of the amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [] }, "mlab_BusinessCombinationHoldBackConsiderationLiabilityFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "BusinessCombinationHoldBackConsiderationLiabilityFairValue", "crdr": "credit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual"], "lang": { "en-us": { "role": { "label": "mlab_BusinessCombinationHoldBackConsiderationLiabilityFairValue", "terseLabel": "Business Combination, Hold Back Consideration Liability, Fair Value", "documentation": "Represents the fair value of hold back consideration liability from a business combination." } } }, "auth_ref": [] }, "mlab_BusinessCombinationHoldBackConsiderationliability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "BusinessCombinationHoldBackConsiderationliability", "crdr": "credit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual"], "lang": { "en-us": { "role": { "label": "mlab_BusinessCombinationHoldBackConsiderationliability", "terseLabel": "Business Combination, Hold Back Consideration Liability", "documentation": "Amount of hold back liability recognized arising from a business combination." } } }, "auth_ref": [] }, "country_CN": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "CN", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-3-revenue-revenues-from-external-customers-details"], "lang": { "en-us": { "role": { "label": "CHINA" } } }, "auth_ref": [] }, "mlab_CalibrationSolutionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "CalibrationSolutionsMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-12-segment-data-segment-depreciation-and-amortization-details", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-operating-segment-information-details", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-change-in-the-carrying-amount-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "Calibration Solutions [Member]", "documentation": "Represents segment information for Calibration Solutions." } } }, "auth_ref": [] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-fair-value-and-carrying-value-of-the-notes-details"], "lang": { "en-us": { "role": { "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": ["r47", "r48"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r22", "r120", "r624"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r22", "r84", "r143"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net increase (decrease) in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r2", "r84"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "mlab_ClinicalGenomicsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "ClinicalGenomicsMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-12-segment-data-segment-depreciation-and-amortization-details", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-operating-segment-information-details", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-change-in-the-carrying-amount-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "Clinical Genomics [Member]", "documentation": "Represents segment information for Clinical Genomics." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r92", "r254", "r255", "r609", "r768", "r773"] }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareCashPaid", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Dividends paid, per share (in dollars per share)", "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding." } } }, "auth_ref": ["r95"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r687", "r688", "r689", "r691", "r692", "r693", "r694", "r725", "r726", "r728", "r811", "r868", "r869"] }, "us-gaap_CommonStockNoParValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockNoParValue", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, no par value (in dollars per share)", "documentation": "Face amount per share of no-par value common stock." } } }, "auth_ref": ["r63"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r63", "r555"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r63"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Common stock, outstanding (in shares)", "periodStartLabel": "Balance (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r10", "r63", "r555", "r573", "r869", "r870"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Common stock, no par value; authorized 25,000,000 shares; issued and outstanding, 5,433,603 and 5,394,491 shares, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r63", "r494", "r671"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-comprehensive-income-loss-": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-comprehensive-income-loss-"], "lang": { "en-us": { "role": { "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive (loss) income", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r19", "r132", "r134", "r139", "r487", "r504", "r505"] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": ["r25", "r26", "r49", "r50", "r211", "r608"] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": ["r25", "r26", "r49", "r50", "r211", "r537", "r608"] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": ["r25", "r26", "r49", "r50", "r211", "r608", "r706"] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": ["r25", "r26", "r49", "r50", "r211", "r608"] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-12-segment-data-segment-depreciation-and-amortization-details", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-operating-segment-information-details", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-change-in-the-carrying-amount-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]" } } }, "auth_ref": ["r109", "r147", "r176", "r184", "r198", "r199", "r200", "r201", "r202", "r204", "r205", "r206", "r262", "r263", "r264", "r265", "r267", "r268", "r269", "r270", "r271", "r635", "r636", "r778", "r779"] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-12-segment-data-segment-depreciation-and-amortization-details", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-operating-segment-information-details", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-change-in-the-carrying-amount-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]" } } }, "auth_ref": ["r109", "r147", "r176", "r184", "r198", "r199", "r200", "r201", "r202", "r204", "r205", "r206", "r262", "r263", "r264", "r265", "r267", "r268", "r269", "r270", "r271", "r635", "r636", "r778", "r779"] }, "mlab_ConsumablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "ConsumablesMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details"], "lang": { "en-us": { "role": { "label": "Consumables [Member]", "documentation": "Information pertaining to consumables." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-3-revenue-tables"], "lang": { "en-us": { "role": { "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": ["r782"] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-3-revenue-contract-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ContractWithCustomerLiability", "periodStartLabel": "Contract liabilities, balance", "periodEndLabel": "Contract liabilities, balance", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r304", "r305", "r316"] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Unearned revenues", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": ["r304", "r305", "r316"] }, "mlab_ContractWithCustomerLiabilityIncreaseDuringPeriodNetOfRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "ContractWithCustomerLiabilityIncreaseDuringPeriodNetOfRevenueRecognized", "crdr": "credit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-3-revenue-contract-liabilities-details"], "lang": { "en-us": { "role": { "label": "Contract liabilities added during the nine months ended December 31, 2024, net of revenues recognized", "documentation": "Amount of revenue recognized arising from contract liabilities added during the period in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-3-revenue-contract-liabilities-details"], "lang": { "en-us": { "role": { "label": "Prior year liabilities recognized in revenues during the nine months ended December 31, 2024", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": ["r317"] }, "us-gaap_ConvertibleDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtCurrent", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Convertible senior notes, current portion, net of debt issuance costs", "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": ["r53"] }, "us-gaap_ConvertibleDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Convertible senior notes, noncurrent portion, net of debt issuance costs", "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": ["r15"] }, "us-gaap_ConvertibleDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtTableTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-tables"], "lang": { "en-us": { "role": { "label": "Convertible Debt [Table Text Block]", "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount." } } }, "auth_ref": [] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateNonSegmentMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-operating-segment-information-details"], "lang": { "en-us": { "role": { "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": ["r13", "r199", "r200", "r201", "r202", "r205", "r735"] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Cost of revenues", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": ["r75", "r145", "r214", "r262", "r263", "r265", "r266", "r267", "r268", "r269", "r271", "r272", "r422", "r635", "r778"] }, "mlab_CostOfRevenuesRelatedToIntangiblesAcquiredMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "CostOfRevenuesRelatedToIntangiblesAcquiredMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-schedule-of-business-acquisitions-details"], "lang": { "en-us": { "role": { "label": "Cost of Revenues Related to Intangibles Acquired [Member]", "documentation": "Represents the cost of revenues related to intangibles acquired" } } }, "auth_ref": [] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-property-plant-and-equipment-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-amortization-expense-for-finitelived-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r261", "r776"] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r261", "r776", "r777"] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual"], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": ["r90", "r211"] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-other-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": ["r41", "r756", "r757", "r758", "r759", "r761", "r763", "r766", "r767"] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness"], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r93", "r144", "r245", "r246", "r247", "r248", "r249", "r260", "r261", "r273", "r279", "r280", "r281", "r282", "r283", "r284", "r289", "r296", "r297", "r298", "r434"] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-notes-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-term-loan-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-term-loan-details-parentheticals", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-interest-expense-on-the-notes-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-tables"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r15", "r53", "r54", "r102", "r104", "r147", "r274", "r275", "r276", "r277", "r278", "r280", "r285", "r286", "r287", "r288", "r290", "r291", "r292", "r293", "r294", "r295", "r644", "r645", "r646", "r647", "r648", "r669", "r722", "r769", "r770", "r771", "r820", "r822"] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-notes-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-notes-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-term-loan-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "Principal Outstanding", "terseLabel": "Principal Outstanding", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": ["r15", "r104", "r299"] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentConvertibleConversionPrice1", "terseLabel": "Debt Instrument, Convertible, Conversion Price (in dollars per share)", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": ["r94", "r276"] }, "mlab_DebtInstrumentConvertibleConversionRatioPer1000Principal": { "xbrltype": "pureItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "DebtInstrumentConvertibleConversionRatioPer1000Principal", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "mlab_DebtInstrumentConvertibleConversionRatioPer1000Principal", "terseLabel": "Debt Instrument, Convertible, Conversion Ratio Per 1,000 Principal", "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by $1,000 debt principal amount." } } }, "auth_ref": [] }, "mlab_DebtInstrumentCovenantMaximumTotalLeverageRatioFollowingTheNinthTestingDate": { "xbrltype": "pureItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "DebtInstrumentCovenantMaximumTotalLeverageRatioFollowingTheNinthTestingDate", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "mlab_DebtInstrumentCovenantMaximumTotalLeverageRatioFollowingTheNinthTestingDate", "terseLabel": "Debt Instrument, Covenant, Maximum Total Leverage Ratio Following the Ninth Testing date", "documentation": "Requirement for maximum total leverage ratio under the debt agreement following the nine testing date." } } }, "auth_ref": [] }, "mlab_DebtInstrumentCovenantMaximumTotalLeverageRatioForTheFirstFiveTestingDates": { "xbrltype": "pureItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "DebtInstrumentCovenantMaximumTotalLeverageRatioForTheFirstFiveTestingDates", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "mlab_DebtInstrumentCovenantMaximumTotalLeverageRatioForTheFirstFiveTestingDates", "terseLabel": "Debt Instrument, Covenant, Maximum Total Leverage Ratio for the First Five Testing Dates", "documentation": "Requirement for maximum total leverage ratio under the debt agreement for the first five testing dates." } } }, "auth_ref": [] }, "mlab_DebtInstrumentCovenantMaximumTotalLeverageRatioForTheSixthSeventhAndEighthTestingDates": { "xbrltype": "pureItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "DebtInstrumentCovenantMaximumTotalLeverageRatioForTheSixthSeventhAndEighthTestingDates", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "mlab_DebtInstrumentCovenantMaximumTotalLeverageRatioForTheSixthSeventhAndEighthTestingDates", "terseLabel": "Debt Instrument, Covenant, Maximum Total Leverage Ratio for the Sixth, Seventh, and Eighth Testing Dates", "documentation": "Requirement for maximum total leverage ratio under the debt agreement for the sixth, seventh, and eighth testing dates." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r274", "r434", "r435", "r645", "r646", "r669"] }, "us-gaap_DebtInstrumentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFeeAmount", "crdr": "debit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentFeeAmount", "terseLabel": "Debt Instrument, Fee Amount", "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument." } } }, "auth_ref": ["r57"] }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateDuringPeriod", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-term-loan-details-parentheticals"], "lang": { "en-us": { "role": { "label": "Current interest rate", "documentation": "The average effective interest rate during the reporting period." } } }, "auth_ref": ["r56", "r292", "r820"] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentInterestRateEffectivePercentage", "terseLabel": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": ["r56", "r301", "r434", "r435", "r669"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r56", "r275"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-notes-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-term-loan-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-term-loan-details-parentheticals", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-interest-expense-on-the-notes-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-tables"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r15", "r147", "r274", "r275", "r276", "r277", "r278", "r280", "r285", "r286", "r287", "r288", "r290", "r291", "r292", "r293", "r294", "r295", "r644", "r645", "r646", "r647", "r648", "r669", "r722", "r769", "r770", "r771", "r820", "r822"] }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPaymentPrincipal", "crdr": "debit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentPeriodicPaymentPrincipal", "terseLabel": "Debt Instrument, Periodic Payment, Principal", "documentation": "Amount of the required periodic payments applied to principal." } } }, "auth_ref": ["r15"] }, "us-gaap_DebtInstrumentRepurchaseAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRepurchaseAmount", "crdr": "debit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentRepurchaseAmount", "terseLabel": "Debt Instrument, Repurchase Amount", "documentation": "Fair value amount of debt instrument that was repurchased." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRepurchasedFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",

"localname": "DebtInstrumentRepurchasedFaceAmount", "crdr": "debit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-
textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentRepurchasedFaceAmount", "terseLabel": "Debt Instrument, Repurchased Face Amount",
"documentation": "Face (par) amount of the original debt instrument that was repurchased." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTerm": { "xbrltype":
"durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-
7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentTerm", "terseLabel": "Debt Instrument, Term (Year)", "documentation":
"Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five
months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": [
"http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-tables"], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and
Other Assets Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage
of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount
of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": {
"http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-notes-details": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0,
"order": 0.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-notes-details",
"http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredFinanceCostsNet",
"terseLabel": "Debt Issuance Costs, Net", "negatedLabel": "Unamortized debt issuance costs", "documentation": "Amount, after accumulated amortization, of debt issuance
costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": ["r781", "r819", "r820", "r822"] }, "us-
gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit",
"calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets",
"weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"],
"lang": { "en-us": { "role": { "label": "Deferred tax asset", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset
attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": ["r362", "r363"] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": {
"http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0,
"order": 0.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": {
"role": { "label": "Deferred tax liability", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional
netting." } } }, "auth_ref": ["r362", "r363", "r492"] }, "us-gaap_DepositsAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DepositsAssetsCurrent", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-prepaid-and-
other-current-assets-details": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-prepaid-and-other-current-assets-details"], "lang": { "en-us": { "role": { "label":
"Deposits", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within
one year or during the operating cycle, if shorter." } } }, "auth_ref": ["r712"] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-
flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.mesalabs.com/20241231/role/statement-note-5-
supplemental-information-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-property-plant-and-equipment-details"],
"lang": { "en-us": { "role": { "verboseLabel": "Depreciation, Total", "label": "Depreciation of property, plant and equipment", "terseLabel": "Depreciation", "documentation":
"The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-
production related depreciation." } } }, "auth_ref": ["r6", "r31"] }, "mlab_DescriptionOfBusinessPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://www.mesalabs.com/20241231", "localname": "DescriptionOfBusinessPolicyTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-
significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Description of Business [Policy Text Block]", "documentation": "Represents significance
related to the nature of business operations." } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-3-revenue-
tables"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into
categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r783"] }, "us-
gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-"],
"lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } },
"auth_ref": ["r328", "r329", "r356", "r357", "r358", "r659"] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DisclosureTextBlockAbstract", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-1-description-of-business-and-summary-of-significant-
accounting-policies", "http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes", "http://www.mesalabs.com/20241231/role/statement-note-11-commitments-
and-contingencies", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information", "http://www.mesalabs.com/20241231/role/statement-note-2-
significant-transactions", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-
measurements", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-
and-intangible-assets-net", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-8-
stockholders-equity-", "http://www.mesalabs.com/20241231/role/statement-note-9-loss-earnings-per-share"], "lang": { "en-us": { "role": { "label": "us-
gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "us-gaap_DividendsCommonStockCash": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": [
"http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "us-
gaap_DividendsCommonStockCash", "negatedLabel": "Dividends paid, $0.16 per share", "documentation": "Amount of paid and unpaid common stock dividends declared with
the form of settlement in cash." } } }, "auth_ref": ["r95"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": {
"role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have
value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype":
"gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.mesalabs.com/20241231/role/statement-
document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in
YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." }
} }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"DocumentInformationLineItems", "presentation": ["http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": {
"label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable
information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]",
"documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": []
}, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [
"http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation":
"For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date;
for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [
"http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation":
"Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r700"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.mesalabs.com/20241231/role/statement-document-and-entity-
information"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } }
}, "auth_ref": ["r701"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation":
["http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type
of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
} } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic",
"presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited",
"http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-computation-of-net-income-per-share-basic-diluted-details"], "lang": { "en-us": { "role": {
"label": "Basic (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the
reporting period." } } }, "auth_ref": ["r140", "r153", "r154", "r155", "r156", "r157", "r158", "r163", "r166", "r169", "r170", "r171", "r175", "r382", "r388", "r400", "r401",
"r488", "r506", "r628"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EarningsPerShareDiluted", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited",
"http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-computation-of-net-income-per-share-basic-diluted-details"], "lang": { "en-us": { "role": {
"label": "Diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit
outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive
potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r140", "r153", "r154", "r155", "r156", "r157", "r158", "r166", "r169", "r170",
"r171", "r175", "r382", "r388", "r400", "r401", "r488", "r506", "r628"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-9-loss-earnings-per-share"], "lang": { "en-
us": { "role": { "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r162", "r172", "r173", "r174"]
}, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit",
"calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation":
["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Effect of exchange
rate changes on cash and cash equivalents", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash
and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes,
but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash
equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that
they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r818"] }, "us-
gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EffectiveIncomeTaxRateContinuingOperations", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes-provisions-for-income-taxes-
details"], "lang": { "en-us": { "role": { "label": "Effective tax rate", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense

(benefit) pertaining to continuing operations." } } }, "auth_ref": ["r365", "r661"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "terseLabel": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": ["r146", "r365", "r373", "r661"] }, "mlab_EligibleEmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "EligibleEmployeesMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Eligible Employees [Member]", "documentation": "Information pertaining to eligible employees." } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-accrued-payroll-and-benefits-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-accrued-payroll-and-benefits-details"], "lang": { "en-us": { "role": { "label": "Accrued payroll and benefits", "totalLabel": "Total accrued payroll and benefits", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r54"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-computation-of-net-income-per-share-basic-diluted-details"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r698"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-comprehensive-income-loss-", "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.mesalabs.com/20241231/role/statement-document-and-entity-information", "http://www.mesalabs.com/20241231/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes", "http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes-provisions-for-income-taxes-details", "http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes-tables", "http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies", "http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-data-segment-depreciation-and-amortization-details", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-operating-segment-information-details", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-tables", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-schedule-of-business-acquisitions-details", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-tables", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-contract-liabilities-details", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-revenues-from-external-customers-details", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-tables", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-fair-value-and-carrying-value-of-the-notes-details", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-tables", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-accrued-payroll-and-benefits-details", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-inventories-details", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-accrued-expenses-details", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-noncurrent-liabilities-details", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-prepaid-and-other-current-assets-details", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-property-plant-and-equipment-details", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-tables", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-amortization-expense-for-finitelived-intangible-assets-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-change-in-the-carrying-amount-of-goodwill-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-estimated-amortization-expense-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-other-intangible-assets-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-tables", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-notes-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-term-loan-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-term-loan-details-parentheticals", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-interest-expense-on-the-notes-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-quarterly-periodic-payments-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-tables", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-restricted-stock-unit-activity-details", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-stock-option-award-activity-details", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-tables", "http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details", "http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-computation-of-net-income-per-share-basic-diluted-details", "http://www.mesalabs.com/20241231/role/statement-note-9-loss-earnings-per-share", "http://www.mesalabs.com/20241231/role/statement-note-9-loss-earnings-per-share-tables", "http://www.mesalabs.com/20241231/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r698"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r698"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r704"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r698"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r698"] }, "dei_EntitySmallBusiness": {

"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r698"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r698"] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r10", "r115", "r135", "r136", "r137", "r148", "r149", "r150", "r152", "r157", "r159", "r161", "r177", "r215", "r216", "r242", "r303", "r371", "r372", "r379", "r380", "r381", "r383", "r387", "r388", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r427", "r428", "r429", "r430", "r431", "r432", "r436", "r437", "r441", "r503", "r530", "r531", "r532", "r541", "r594"] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-fair-value-and-carrying-value-of-the-notes-details"], "lang": { "en-us": { "role": { "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": ["r287", "r421", "r645", "r646"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-tables"], "lang": { "en-us": { "role": { "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity." } } }, "auth_ref": ["r662", "r812", "r813", "r816"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-fair-value-and-carrying-value-of-the-notes-details"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r287", "r320", "r321", "r322", "r323", "r324", "r325", "r402", "r403", "r404", "r405", "r406", "r412", "r413", "r415", "r445", "r446", "r447", "r645", "r646", "r653", "r654", "r655", "r662", "r665"] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementBasisAxis", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-fair-value-and-carrying-value-of-the-notes-details"], "lang": { "en-us": { "role": { "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": ["r287", "r645", "r646"] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements"], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r408", "r410", "r411", "r412", "r415", "r416", "r417", "r418", "r419", "r485", "r662", "r666"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-fair-value-and-carrying-value-of-the-notes-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r287", "r320", "r325", "r403", "r404", "r413", "r446", "r645", "r646", "r653", "r654", "r655", "r662"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r287", "r320", "r321", "r322", "r323", "r324", "r325", "r403", "r404", "r405", "r406", "r413", "r447", "r645", "r646", "r653", "r654", "r655", "r662", "r665"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-fair-value-and-carrying-value-of-the-notes-details"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r287", "r320", "r321", "r322", "r323", "r324", "r325", "r402", "r403", "r404", "r405", "r406", "r412", "r413", "r415", "r445", "r446", "r447", "r645", "r646", "r653", "r654", "r655", "r662", "r665"] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-other-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization", "negatedLabel": "Accumulated amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r123", "r218", "r236", "r643"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-estimated-amortization-expense-details"], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r238", "r621", "r643"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-estimated-amortization-expense-details"], "lang": { "en-us": { "role": { "label": "Remainder of 2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": ["r871"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-tables"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-estimated-amortization-expense-details"], "lang": { "en-us": { "role": { "label": "2029", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r238", "r621", "r643"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-estimated-amortization-expense-details"], "lang": { "en-us": { "role": { "label": "2028", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r238", "r621", "r643"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-estimated-amortization-expense-details"], "lang": { "en-us": { "role": { "label": "2027", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r238", "r621", "r643"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-other-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r229", "r231", "r232", "r233", "r235", "r236", "r239", "r240", "r453", "r454", "r621"] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-other-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsGross", "terseLabel": "Gross carrying amount", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r218", "r236", "r454", "r643"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-other-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r229", "r231", "r232", "r233", "r235", "r236", "r239", "r240", "r621"] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-other-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Intangible assets", "terseLabel": "Net carrying amount", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r453", "r763"] }, "mlab_FixedChargeCoverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "FixedChargeCoverageRatio", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "mlab_FixedChargeCoverageRatio", "terseLabel": "Fixed Charge Coverage Ratio", "documentation": "Actual fixed charge coverage ratio under the debt agreement." } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": {

"http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax", "negatedLabel": "Foreign currency adjustments", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": ["r423", "r424", "r425", "r426", "r591"] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 }, "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_GainsLossesOnExtinguishmentOfDebt", "terseLabel": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Gain on extinguishment of convertible notes", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": ["r6", "r34", "r35"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r77", "r577"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-schedule-of-business-acquisitions-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-amortization-expense-for-finitelived-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r77"] }, "mlab_GkeAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "GkeAcquisitionMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies", "http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-schedule-of-business-acquisitions-details", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-noncurrent-liabilities-details"], "lang": { "en-us": { "role": { "label": "GKE Acquisition [Member]", "documentation": "Relating to the GKE Acquisition." } } }, "auth_ref": [] }, "mlab_GkeGmbhAndSalGmbhMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "GkeGmbhAndSalGmbhMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "GKE GmbH and SAL GmbH [Member]", "documentation": "Relating to GKE GmbH and SAL GmbH." } } }, "auth_ref": [] }, "mlab_GkeGmbhMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "GkeGmbhMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-3-revenue", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "GKE GmbH [Member]", "documentation": "Reprsents the group known as GKE GmbH." } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-change-in-the-carrying-amount-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "Goodwill", "periodStartLabel": "Goodwill", "periodEndLabel": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r122", "r219", "r486", "r636", "r642", "r663", "r671", "r745", "r752"] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net"], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": ["r743", "r755"] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-change-in-the-carrying-amount-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "Effect of foreign currency translation", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r226"] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-operating-segment-information-details", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-schedule-of-business-acquisitions-details"], "lang": { "en-us": { "role": { "label": "us-gaap_GrossProfit", "totalLabel": "Gross profit", "terseLabel": "Gross profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": ["r72", "r75", "r110", "r145", "r214", "r262", "r263", "r265", "r266", "r267", "r268", "r269", "r271", "r272", "r422", "r630", "r635", "r733", "r734", "r736", "r737", "r738", "r778"] }, "mlab_HardwareAndSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "HardwareAndSoftwareMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details"], "lang": { "en-us": { "role": { "label": "Hardware and Software [Member]", "documentation": "Information pertaining to hardware and software." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperations", "crdr": "credit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-operating-segment-information-details"], "lang": { "en-us": { "role": { "verboseLabel": "(Loss) earnings before income taxes", "label": "us-gaap_IncomeLossFromContinuingOperations", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": ["r44", "r74", "r86", "r153", "r154", "r155", "r156", "r157", "r167", "r171", "r388"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "(Loss) earnings before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r73", "r106", "r110", "r489", "r501", "r630", "r635", "r733", "r734", "r736", "r737", "r738"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-schedule-of-business-acquisitions-details", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-property-plant-and-equipment-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-amortization-expense-for-finitelived-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r243", "r250", "r251", "r407", "r409", "r414", "r527", "r529", "r578", "r621", "r664", "r839"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-schedule-of-business-acquisitions-details", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-property-plant-and-equipment-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-amortization-expense-for-finitelived-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r250", "r251", "r407", "r409", "r414", "r527", "r529", "r578", "r621", "r664", "r839"] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes"], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r146", "r361", "r365", "r366", "r367", "r368", "r369", "r370", "r374", "r376", "r377", "r378", "r540", "r661"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes-provisions-for-income-taxes-details"], "lang": { "en-us": { "role": { "label": "Income tax (benefit) expense", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r112", "r113", "r160", "r161", "r176", "r190", "r204", "r364", "r365", "r375", "r507", "r661"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable, net", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Accrued liabilities and taxes payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability", "terseLabel": "Unearned revenues", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r451", "r720"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Cash from changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidExpense", "negatedLabel": "Prepaid expenses and other assets", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": ["r5"] }, "us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-computation-of-net-income-per-share-basic-diluted-details": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-computation-of-net-income-per-share-basic-diluted-details"], "lang": { "en-us": { "role": { "label": "Dilutive effect of shares (in shares)", "documentation": "Number of additional shares included in diluted EPS for potentially dilutive effect of nonvested equity-based payment award containing forfeitable rights to dividends or dividend equivalents, whether paid or unpaid." } } }, "auth_ref": ["r23", "r729", "r730", "r731", "r732"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "auth_ref": ["r702"] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-interest-expense-on-the-notes-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-interest-expense-on-the-notes-details"], "lang": { "en-us": { "role": { "label": "us-gaap_InterestExpenseDebt", "totalLabel": "Total interest and amortization of debt issuance costs", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": ["r79", "r293", "r302", "r647", "r648"] }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebtExcludingAmortization", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-interest-expense-on-the-notes-details": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-interest-expense-on-the-notes-details"], "lang": { "en-us": { "role": { "verboseLabel": "Coupon interest expense at 1.375%", "label": "us-gaap_InterestExpenseDebtExcludingAmortization", "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs." } } }, "auth_ref": ["r79", "r294", "r647", "r648"] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Interest expense and amortization of debt issuance costs", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": ["r186", "r717"] }, "mlab_InterestExpenseOnConvertibleDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "InterestExpenseOnConvertibleDebtTableTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-tables"], "lang": { "en-us": { "role": { "label": "Interest Expense on Convertible Debt [Table Text Block]", "documentation": "Tabular disclosure of interest expense on borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder." } } }, "auth_ref": [] }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_InterestPayableCurrentAndNoncurrent", "terseLabel": "Interest Payable", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": ["r103", "r834"] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-inventories-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-inventories-details"], "lang": { "en-us": { "role": { "label": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": ["r709"] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-inventories-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-data-segment-depreciation-and-amortization-details", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-inventories-details"], "lang": { "en-us": { "role": { "label": "Inventories", "totalLabel": "Total inventories", "terseLabel": "Total inventories", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r128", "r625", "r671"] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-inventories-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-inventories-details"], "lang": { "en-us": { "role": { "label": "Raw materials", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r711"] }, "mlab_InventoryStepupRelatedToCostOfRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "InventoryStepupRelatedToCostOfRevenueMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-schedule-of-business-acquisitions-details"], "lang": { "en-us": { "role": { "label": "Inventory Step-up Related to Cost of Revenue [Member]", "documentation": "Represents information pertaining to the inventory step-ups related to cost of revenue." } } }, "auth_ref": [] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-inventories-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-inventories-details"], "lang": { "en-us": { "role": { "label": "Work in process", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": ["r710"] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-comprehensive-income-loss-", "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.mesalabs.com/20241231/role/statement-document-and-entity-information", "http://www.mesalabs.com/20241231/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes", "http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes-provisions-for-income-taxes-details", "http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes-tables", "http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies", "http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-data-segment-depreciation-and-amortization-details", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-operating-segment-information-details", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-tables", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-schedule-of-business-acquisitions-details", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-tables", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-contract-liabilities-details", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-revenues-from-external-customers-details", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-tables", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-fair-value-and-carrying-value-of-the-notes-details", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-tables", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-accrued-payroll-and-benefits-details", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-inventories-details", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-accrued-expenses-details", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-noncurrent-liabilities-details", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-prepaid-and-other-current-assets-details", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-property-plant-and-equipment-details", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-tables", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-amortization-expense-for-finitelived-intangible-assets-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-change-in-the-carrying-amount-of-goodwill-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-estimated-amortization-expense-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-other-intangible-assets-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-tables", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-notes-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-term-loan-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-term-loan-details-parentheticals", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-interest-expense-on-the-notes-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-quarterly-periodic-payments-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-tables", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-restricted-stock-unit-activity-details", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-stock-option-award-activity-details", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-tables", "http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details", "http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-computation-of-net-income-per-share-basic-diluted-details", "http://www.mesalabs.com/20241231/role/statement-note-9-loss-earnings-per-share", "http://www.mesalabs.com/20241231/role/statement-note-9-loss-earnings-per-share-tables", "http://www.mesalabs.com/20241231/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LetterOfCreditMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r15", "r53", "r54", "r55", "r58", "r59", "r60", "r61", "r145", "r214", "r262", "r263", "r265", "r266", "r267", "r268", "r269", "r271", "r272", "r390", "r391", "r392", "r422", "r554", "r629", "r696", "r778", "r825", "r826"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and stockholders\u2019 equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r67", "r105", "r497", "r671", "r723", "r741", "r817"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r55", "r119", "r145", "r214", "r262", "r263", "r265", "r266", "r267", "r268", "r269", "r271", "r272", "r390", "r391", "r392", "r422", "r671", "r778", "r825", "r826"] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-noncurrent-liabilities-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-noncurrent-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesNoncurrent", "totalLabel": "Total other noncurrent liabilities", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r15", "r58", "r59", "r60", "r61", "r145", "r214", "r262", "r263", "r265", "r266", "r267", "r268", "r269", "r271", "r272", "r390", "r391", "r392", "r422", "r778", "r825", "r826"] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Noncurrent liabilities:" } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Revolving line of credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": ["r15", "r104", "r835"] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": ["r52", "r57"] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity", "terseLabel": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": ["r52", "r57", "r261"] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "terseLabel": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-quarterly-periodic-payments-details": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-notes-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-notes-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-quarterly-periodic-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebt", "terseLabel": "Long-Term Debt", "totalLabel": "Total Principal Remaining", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r15", "r104", "r286", "r300", "r645", "r646", "r669", "r835"] }, "mlab_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-quarterly-periodic-payments-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-quarterly-periodic-payments-details"], "lang": { "en-us": { "role": { "label": "mlab_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour", "terseLabel": "Thereafter", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-quarterly-periodic-payments-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-quarterly-periodic-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "terseLabel": "2026", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r8", "r147", "r291"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-quarterly-periodic-payments-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-quarterly-periodic-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "terseLabel": "2029", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r8", "r147", "r291"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-quarterly-periodic-payments-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-quarterly-periodic-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "terseLabel": "2028", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r8", "r147", "r291"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-quarterly-periodic-payments-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-quarterly-periodic-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "terseLabel": "2027", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r8", "r147", "r291"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-quarterly-periodic-payments-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-quarterly-periodic-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "terseLabel": "Remainder of 2025", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": ["r724"] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-fair-value-and-carrying-value-of-the-notes-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-notes-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": ["r15", "r769", "r770", "r771"] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-fair-value-and-carrying-value-of-the-notes-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-notes-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r15", "r33", "r769", "r770", "r771"] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": ["r256", "r257", "r258", "r259", "r327", "r359", "r406", "r450", "r526", "r528", "r536", "r546", "r547", "r598", "r600", "r602", "r603", "r605", "r619", "r620", "r640", "r649", "r658", "r665", "r666", "r667", "r668", "r681", "r780", "r827", "r828", "r829", "r830", "r831", "r832"] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": ["r256", "r257", "r258", "r259", "r327", "r359", "r406", "r450", "r526", "r528", "r536", "r546", "r547", "r598", "r600", "r602", "r603", "r605", "r619", "r620", "r640", "r649", "r658", "r665", "r666", "r667", "r681", "r780", "r827", "r828", "r829", "r830", "r831", "r832"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": ["r703"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash (used in) provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r142"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash (used in) investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r142"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash provided by operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r84", "r85", "r86"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Net income (loss)", "totalLabel": "Net (loss) income", "terseLabel": "Net income (loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r76", "r86", "r107", "r117", "r131", "r133", "r137", "r145", "r151", "r153", "r154", "r155", "r156", "r157", "r160", "r161", "r167", "r214", "r262", "r263", "r265", "r266", "r267", "r268", "r269", "r271", "r272", "r382", "r388", "r401", "r422", "r502", "r575", "r592", "r593", "r695", "r778"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 }, "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-comprehensive-income-loss-": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-comprehensive-income-loss-", "http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-computation-of-net-income-per-share-basic-diluted-details"], "lang": { "en-us": { "role": { "label": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "terseLabel": "Net income", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": ["r141", "r153", "r154", "r155", "r156", "r163", "r164", "r168", "r171", "r388"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrAdoptedFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r703"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrTrmntdFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r703"] }, "mlab_NonemployeeDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "NonemployeeDirectorsMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Non-employee Directors [Member]", "documentation": "Represents information pertaining to non-employee directors." } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-operating-segment-information-details"], "lang": { "en-us": { "role": { "label": "us-gaap_NonoperatingIncomeExpense", "terseLabel": "Non-operating expense (income), net", "negatedTotalLabel": "Total non-operating expense (income), net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r78"] }, "mlab_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": [] }, "us-gaap_NotesPayableFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableFairValueDisclosure", "crdr": "credit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-fair-value-and-carrying-value-of-the-notes-details"], "lang": { "en-us": { "role": { "label": "Notes", "documentation": "Fair value portion of notes payable." } } }, "auth_ref": ["r15", "r53", "r54", "r813", "r815"] }, "mlab_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "mlab_NumberOfMajorCustomers": { "xbrltype": "integerItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "NumberOfMajorCustomers", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual"], "lang": { "en-us": { "role": { "label": "mlab_NumberOfMajorCustomers", "terseLabel": "Number of Major Customers", "documentation": "Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenseMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-property-plant-and-equipment-details"], "lang": { "en-us": { "role": { "label": "Operating Expense [Member]", "documentation": "Primary financial statement caption encompassing expenses associated with normal operations." } } }, "auth_ref": ["r14"] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-operating-segment-information-details"], "lang": { "en-us": { "role": { "verboseLabel": "Operating expense", "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expense", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-operating-segment-information-details"], "lang": { "en-us": { "role": { "verboseLabel": "Operating income (loss)", "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Operating income (loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r110", "r630", "r733", "r734", "r736", "r737", "r738"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-5-

supplemental-information-other-accrued-expenses-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-accrued-expenses-details"], "lang": { "en-us": { "role": { "label": "Current
operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref":
["r438"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-
noncurrent-liabilities-details": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-noncurrent-liabilities-details"], "lang": { "en-us": { "role": { "label": "Noncurrent
operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } },
"auth_ref": ["r438"] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingSegmentsMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-12-segment-data-segment-depreciation-and-amortization-details",
"http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-operating-segment-information-details",
"http://www.mesalabs.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-
and-intangible-assets-net-change-in-the-carrying-amount-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "Operating Segments [Member]", "documentation":
"Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of
the same entity." } } }, "auth_ref": ["r198", "r199", "r200", "r201", "r202", "r205", "r635", "r636"] }, "us-
gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [
"http://www.mesalabs.com/20241231/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies"], "lang": { "en-us": { "role": { "label":
"Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the general note
to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies,
consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": ["r87", "r88", "r89", "r100"] },
"mlab_OtherAccruedExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "OtherAccruedExpensesMember",
"presentation": ["http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-accrued-expenses-details"], "lang": { "en-us": { "role": { "label":
"Other Accrued Expenses [Member]", "documentation": "Other accrued expenses not separately disclosed." } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": {
"http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-accrued-expenses-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-accrued-expenses-details"],
"lang": { "en-us": { "role": { "verboseLabel": "Other", "label": "us-gaap_OtherAccruedLiabilitiesCurrent", "documentation": "Amount of expenses incurred but not yet paid
classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r54"] }, "us-gaap_OtherAssetsCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": {
"http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-prepaid-and-other-current-assets-details": { "parentTag": "us-
gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-
information-prepaid-and-other-current-assets-details"], "lang": { "en-us": { "role": { "label": "Other current assets", "documentation": "Amount of current assets classified as
other." } } }, "auth_ref": ["r129", "r671"] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-
unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-
balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } },
"auth_ref": ["r124"] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit",
"calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-comprehensive-income-loss-": { "parentTag": "us-
gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-
statements-of-comprehensive-income-loss-", "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"],
"lang": { "en-us": { "role": { "verboseLabel": "Foreign currency translation", "label": "Foreign currency translation", "documentation": "Amount after tax and reclassification
adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a
foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": ["r4", "r503"] }, "us-
gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-
consolidated-statements-of-comprehensive-income-loss-"], "lang": { "en-us": { "role": { "label": "Other comprehensive (loss) income:" } } }, "auth_ref": [] }, "us-
gaap_OtherEmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherEmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-accrued-
payroll-and-benefits-details": { "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-accrued-payroll-and-benefits-details"], "lang": { "en-us": { "role": { "label": "Other
benefits payable", "documentation": "Amount of obligations incurred for employer-related costs classified as other, payable within one year or the normal operating cycle, if
longer." } } }, "auth_ref": ["r54"] }, "us-gaap_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherIntangibleAssetsMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
"http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-other-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Other
Intangible Assets [Member]", "documentation": "Intangible assets classified as other." } } }, "auth_ref": ["r643", "r756", "r757", "r758", "r759", "r760", "r761", "r763", "r765",
"r766", "r767"] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-noncurrent-
liabilities-details": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 }, "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-
balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.mesalabs.com/20241231/role/statement-
note-5-supplemental-information-other-noncurrent-liabilities-details"], "lang": { "en-us": { "role": { "label": "Other", "documentation": "Amount of liabilities classified as
other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r59"] }, "mlab_OtherLongtermLiabilitiesMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.mesalabs.com/20241231", "localname": "OtherLongtermLiabilitiesMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-
fair-value-measurements", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual"], "lang": { "en-us": { "role": { "label": "Other
Long-term Liabilities [Member]", "documentation": "Represents other long-term liabilities." } } }, "auth_ref": [] }, "mlab_OtherMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.mesalabs.com/20241231", "localname": "OtherMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-3-revenue-revenues-
from-external-customers-details"], "lang": { "en-us": { "role": { "label": "Other [Member]", "documentation": "Represents other." } } }, "auth_ref": [] }, "us-
gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit",
"calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-
consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_OtherNoncashIncomeExpense", "negatedLabel": "Other", "documentation":
"Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": ["r86"] }, "us-
gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherNoncurrentLiabilitiesTableTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-tables"], "lang": { "en-
us": { "role": { "label": "Other Noncurrent Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other noncurrent liabilities." } } }, "auth_ref": [] }, "us-
gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense",
"crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-
gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-
of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_OtherNonoperatingIncomeExpense", "negatedLabel": "Other expense (income), net",
"documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r80"] }, "mlab_Outstanding2025NotesMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "Outstanding2025NotesMember", "presentation": [
"http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-
details-textual", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-
textual"], "lang": { "en-us": { "role": { "label": "Outstanding 2025 Notes [Member]", "documentation": "Represents the outstanding 2025 note." } } }, "auth_ref": [] }, "us-
gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividends", "crdr": "credit", "calculation": {
"http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-
gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-
consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfDividends", "negatedLabel": "Dividends paid", "documentation":
"Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": ["r82"] },
"us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesGross",
"crdr": "credit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-details-textual"], "lang": { "en-us": { "role": { "label":
"us-gaap_PaymentsToAcquireBusinessesGross", "terseLabel": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of
business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": ["r20", "r385"] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": {
"http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-
gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-
consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired", "negatedLabel":
"Acquisitions, net of cash acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } },
"auth_ref": ["r20"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-
of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [
"http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-
gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchases of property, plant and equipment", "documentation": "The cash outflow associated with
the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows
to pay for construction of self-constructed assets." } } }, "auth_ref": ["r81"] }, "mlab_PerformanceStockUnitsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.mesalabs.com/20241231", "localname": "PerformanceStockUnitsMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-
stockholders-equity-schedule-of-restricted-stock-unit-activity-details"], "lang": { "en-us": { "role": { "label": "Performance Stock Units [Member]", "documentation":
"Represents information related to performance stock units." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-",
"http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation":
"Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794",
"r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809"] }, "us-gaap_PlanNameDomain": { "xbrltype":

"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809"] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyTextBlockAbstract", "presentation": ["http://www.mesalabs.com/20241231/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-fair-value-and-carrying-value-of-the-notes-details"], "lang": { "en-us": { "role": { "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": ["r420"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-prepaid-and-other-current-assets-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-prepaid-and-other-current-assets-details"], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r713"] }, "mlab_PrepaidExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "PrepaidExpensesCurrent", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-prepaid-and-other-current-assets-details": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-prepaid-and-other-current-assets-details"], "lang": { "en-us": { "role": { "label": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "mlab_PrepaidExpensesOtherAndOtherAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "PrepaidExpensesOtherAndOtherAssetsMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "Prepaid Expenses, Other and Other Assets [Member]", "documentation": "Information pertaining to prepaid expenses, other and other assets." } } }, "auth_ref": [] }, "us-gaap_PrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidTaxes", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-prepaid-and-other-current-assets-details": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-prepaid-and-other-current-assets-details"], "lang": { "en-us": { "role": { "label": "Prepaid income taxes", "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r626", "r641", "r742"] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": ["http://www.mesalabs.com/20241231/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": ["r707"] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromConvertibleDebt", "terseLabel": "Proceeds from Convertible Debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": ["r21"] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromLinesOfCredit", "terseLabel": "Proceeds from Lines of Credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": ["r21", "r722"] }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLongTermLinesOfCredit", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Proceeds from the issuance of debt, net", "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": ["r21"] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Other financing, net", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": ["r705", "r718"] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": ["r650"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": ["r207", "r452", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r622", "r650", "r680", "r681", "r682", "r685", "r686", "r774", "r775", "r783", "r836", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details"], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": ["r207", "r452", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r622", "r650", "r680", "r681", "r682", "r685", "r686", "r774", "r775", "r783", "r836", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Property, plant and equipment, net of accumulated depreciation of $26,036 and $22,519 respectively", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r7", "r440", "r490", "r500", "r671"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-tables"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r7"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r256", "r257", "r258", "r259", "r319", "r327", "r352", "r353", "r354", "r359", "r406", "r448", "r449", "r450", "r526", "r528", "r536", "r546", "r547", "r598", "r600", "r602", "r603", "r605", "r619", "r620", "r640", "r649", "r658", "r665", "r666", "r667", "r668", "r681", "r689", "r772", "r780", "r814", "r828", "r829", "r830", "r831", "r832"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r256", "r257", "r258", "r259", "r319", "r327", "r352", "r353", "r354", "r359", "r406", "r448", "r449", "r450", "r526", "r528", "r536", "r546", "r547", "r598", "r600", "r602", "r603", "r605", "r619", "r620", "r640", "r649", "r658", "r665", "r666", "r667", "r668", "r681", "r689", "r772", "r780", "r814", "r828", "r829", "r830", "r831", "r832"] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-3-revenue", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r212", "r326", "r442", "r443", "r493", "r498", "r549", "r550", "r551", "r552", "r553", "r572", "r574", "r597"] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-3-revenue", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r212", "r326", "r442", "r443", "r493", "r498", "r549", "r550", "r551", "r552", "r553", "r572", "r574", "r597", "r824"] }, "us-gaap_RepaymentsOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfConvertibleDebt", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfConvertibleDebt", "negatedLabel": "Repurchase of convertible debt", "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": ["r83"] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebt", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfDebt", "terseLabel": "Repayments of Debt", "negatedLabel": "Repayment of debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": ["r719"] }, "us-gaap_RepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLinesOfCredit", "crdr": "credit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfLinesOfCredit", "terseLabel": "Repayments of Lines of Credit", "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." }

} }, "auth_ref": ["r83", "r722"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r360", "r621", "r635", "r833"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-restricted-stock-unit-activity-details", "http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-computation-of-net-income-per-share-basic-diluted-details"], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "(Accumulated deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r64", "r95", "r496", "r533", "r535", "r539", "r556", "r671"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r115", "r148", "r149", "r150", "r152", "r157", "r159", "r161", "r215", "r216", "r242", "r371", "r372", "r379", "r380", "r381", "r383", "r387", "r388", "r393", "r395", "r396", "r398", "r399", "r436", "r437", "r530", "r532", "r541", "r869"] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-operating-segment-information-details", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-revenues-from-external-customers-details"], "lang": { "en-us": { "role": { "label": "Revenues", "terseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r108", "r109", "r176", "r183", "r184", "r198", "r204", "r207", "r209", "r211", "r314", "r315", "r452"] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-3-revenue"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r114", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r318"] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-schedule-of-business-acquisitions-details"], "lang": { "en-us": { "role": { "label": "us-gaap_Revenues", "terseLabel": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r108", "r109", "r138", "r145", "r176", "r183", "r184", "r198", "r204", "r207", "r209", "r211", "r214", "r262", "r263", "r265", "r266", "r267", "r268", "r269", "r271", "r272", "r422", "r489", "r635", "r778"] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Right of use assets obtained in exchange for lease liabilities", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r439", "r670"] }, "mlab_RiskAndUncertaintiesPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "RiskAndUncertaintiesPolicyPolicyTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Risk and Uncertainties, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for risk and uncertainties." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrAdoptedFlag", "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r703"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrTrmntdFlag", "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r703"] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-9-loss-earnings-per-share-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r24"] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts." } } }, "auth_ref": ["r38", "r40"] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": ["r810"] }, "mlab_ScheduleOfDepreciationAndAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "ScheduleOfDepreciationAndAmortizationExpenseTableTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Depreciation and Amortization Expense [Table Text Block]", "documentation": "Tabular display of the depreciation and amortization recorded during the periods for reportable segments." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-9-loss-earnings-per-share-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r732"] }, "mlab_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Employee Related Liabilities [Table Text Block]", "documentation": "The tabular disclosure for employee related liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": ["r643", "r762"] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": ["r642", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754"] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r16", "r68", "r69", "r70"] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": ["r8"] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-3-revenue-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": ["r30", "r72"] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": ["r27", "r28", "r29"] }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-tables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Activity [Table Text Block]", "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value." } } }, "auth_ref": ["r11", "r12", "r97"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-tables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r11", "r12", "r96"] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": ["r643", "r764"] }, "us-gaap_SecuredDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredDebtCurrent", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-term-loan-details"], "lang": { "en-us": { "role": { "label": "Term loan, current portion", "negatedLabel": "Less: current portion", "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower." } } }, "auth_ref": ["r53", "r102"] }, "mlab_SecuredDebtDiscountAndIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "SecuredDebtDiscountAndIssuanceCosts", "crdr": "credit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-term-loan-details"], "lang": { "en-us": { "role": { "label": "mlab_SecuredDebtDiscountAndIssuanceCosts", "negatedLabel": "Less: discount and debt issuance costs", "documentation": "The discounts and issuance costs related to the secured debt." } } }, "auth_ref": [] }, "us-gaap_SecuredLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredLongTermDebt", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-term-loan-details"], "lang": { "en-us": { "role": { "label": "Noncurrent portion", "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets." } } }, "auth_ref": ["r15"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r697"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r699"] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-12-segment-data-segment-depreciation-and-amortization-details", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-operating-segment-information-details", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-change-in-the-carrying-amount-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r108", "r109", "r110", "r111", "r176", "r179", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r204", "r205", "r206", "r211", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r241", "r252", "r253", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r632", "r635", "r636", "r642", "r684", "r836", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-3-revenue-revenues-from-external-customers-details"], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": ["r209", "r210", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r543", "r544", "r545", "r599", "r601", "r604", "r606", "r607", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r623", "r651", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r683", "r689", "r783", "r836", "r840", "r841", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867"] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-12-segment-information"], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": ["r111", "r176", "r178", "r179", "r180", "r181", "r182", "r194", "r196", "r197", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r211", "r631", "r633", "r634", "r635", "r637", "r638", "r639"] }, "us-gaap_SellingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingExpense", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Selling", "documentation": "Expenses recognized in the period that are directly related to the selling and distribution of products or services." } } }, "auth_ref": ["r77"] }, "mlab_SeniorLeverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "SeniorLeverageRatio", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "mlab_SeniorLeverageRatio", "terseLabel": "Senior Leverage Ratio", "documentation": "Represents the senior leverage ratio." } } }, "auth_ref": [] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorNotesMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-fair-value-and-carrying-value-of-the-notes-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-notes-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "mlab_SeniorSecuredCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "SeniorSecuredCreditAgreementMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "Senior Secured Credit Agreement [Member]", "documentation": "Information pertaining to the senior secured credit agreement" } } }, "auth_ref": [] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ServiceMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details"], "lang": { "en-us": { "role": { "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": ["r650"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensation", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r5"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r659"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-restricted-stock-unit-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "negatedLabel": "Awards forfeited (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r346"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-restricted-stock-unit-activity-details"], "lang": { "en-us": { "role": { "label": "Awards forfeited, weighted average grant date fair value per share (in dollars per share)", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r346"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-restricted-stock-unit-activity-details"], "lang": { "en-us": { "role": { "label": "Awards granted(1) (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r344"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
"presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-restricted-stock-unit-activity-details"], "lang": { "en-us": {
"role": { "label": "Awards granted, weighted average grant date fair value per share (1) (in dollars per share)", "documentation": "The weighted average fair value at grant date
for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation
rights plan, performance target plan)." } } }, "auth_ref": ["r344"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
"presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-restricted-stock-unit-activity-details"], "lang": { "en-us": {
"role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "periodStartLabel":
"Awards Outstanding (in shares)", "periodEndLabel": "Awards Outstanding (in shares)", "documentation": "The number of non-vested equity-based payment instruments,
excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r341", "r342"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [
"http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-restricted-stock-unit-activity-details"], "lang": { "en-us": { "role": { "label": "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
"periodStartLabel": "Awards Outstanding, weighted average grant date fair value per share (in dollars per share)", "periodEndLabel": "Awards Outstanding, weighted average
grant date fair value per share (in dollars per share)", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment
arrangement. Excludes share and unit options." } } }, "auth_ref": ["r341", "r342"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
"presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-restricted-stock-unit-activity-details"], "lang": { "en-us": {
"role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedLabel": "Awards
distributed (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } }
}, "auth_ref": ["r345"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
"presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-restricted-stock-unit-activity-details"], "lang": { "en-us": {
"role": { "label": "Awards distributed, weighted average grant date fair value per share (in dollars per share)", "documentation": "The weighted average fair value as of grant
date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service
and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r345"]
}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [
"http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-
Based Payment Award, Number of Shares Authorized (in shares)", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } }
}, "auth_ref": ["r660"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [
"http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-stock-option-award-activity-details"], "lang": { "en-us": { "role": { "label": "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "negatedLabel": "Options forfeited or expired (in
shares)", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of
occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": ["r790"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [
"http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-stock-option-award-activity-details"], "lang": { "en-us": { "role": { "label":
"Awards forfeited or expired, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price of options that were either forfeited or
expired." } } }, "auth_ref": ["r790"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
"presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-stock-option-award-activity-details"], "lang": { "en-us": { "role":
{ "label": "Options granted (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r337"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [
"http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-stock-option-award-activity-details"], "lang": { "en-us": { "role": { "verboseLabel":
"Outstanding, Aggregate Intrinsic Value", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
"documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r36"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [
"http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-stock-option-award-activity-details"], "lang": { "en-us": { "role": { "label": "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodStartLabel": "Options outstanding (in shares)",
"periodEndLabel": "Options outstanding (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [
"r333", "r334"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [
"http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-stock-option-award-activity-details"], "lang": { "en-us": { "role": { "label": "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodStartLabel": "Options outstanding,
weighted average exercise price (in dollars per share)", "periodEndLabel": "Options outstanding, weighted average exercise price (in dollars per share)", "documentation":
"Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r333", "r334"] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-
textual", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-restricted-stock-unit-activity-details",
"http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-computation-of-net-income-per-share-basic-diluted-details"], "lang": { "en-us": { "role": {
"label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r330", "r331", "r332", "r333", "r334", "r335", "r336",
"r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355"] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [
"http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-stock-option-award-activity-details"], "lang": { "en-us": { "role": { "label":
"Awards exercised, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when
converting their stock options into shares." } } }, "auth_ref": ["r338"] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
"presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-stock-option-award-activity-details"], "lang": { "en-us": { "role":
{ "label": "Awards granted, weighted average exercise price (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire
shares of common stock by exercise of options." } } }, "auth_ref": ["r337"] },
"mlab_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValueSharesSubj
{ "xbrltype": "perShareItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValueSharesSubjectTo:
"presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label":
"mlab_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValueSharesSubj
"terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant
Date Fair Value, Shares Subject to Service and Company Performance (in dollars per share)", "documentation": "The weighted average fair value at grant date for nonvested
equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan,
performance target plan), for shares subject to service and company financial performance." } } }, "auth_ref": [] },
"mlab_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValueSubjectToS
{ "xbrltype": "perShareItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValueSubjectToService
"presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label":
"mlab_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValueSubjectToS
"terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant
Date Fair Value, Subject to Service and Market Conditions (in dollars per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based
awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance
target plan), subjected to service and market conditions." } } }, "auth_ref": [] },
"mlab_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAuthorizedForServiceAndCompanyFinancialPerformanceConditions": { "xbrltype":
"sharesItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAuthorizedForServiceAndCompanyFinancialPerformanceConditions", "presentation": [
"http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label":
"mlab_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAuthorizedForServiceAndCompanyFinancialPerformanceConditions", "terseLabel":
"Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized for Service and Company Financial Performance Conditions (in
shares)", "documentation": "Number of shares authorized for issuance under share-based payment arrangement for service and company financial performance conditions." }
} }, "auth_ref": [] }, "mlab_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAuthorizedSubjectToServiceAndMarketConditions": {

"xbrltype": "sharesItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAuthorizedSubjectToServiceAndMarketConditions", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "mlab_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAuthorizedSubjectToServiceAndMarketConditions", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized, Subject to Service and Market Conditions (in shares)", "documentation": "Number of shares authorized for issuance under share-based payment arrangement subjected to service and market conditions." } } }, "auth_ref": [] }, "mlab_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesIssuedUponVestingPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesIssuedUponVestingPercentage", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "mlab_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesIssuedUponVestingPercentage", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award Number of Shares Issued Upon Vesting, Percentage", "documentation": "The percentage of shares will be issued upon vesting." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-stock-option-award-activity-details"], "lang": { "en-us": { "role": { "verboseLabel": "Outstanding, Weighted- Average Remaining Contractual Life (Year)", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r98"] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_SharesOutstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation", "negatedLabel": "Tax withholding on vesting of restricted stock units (in shares)", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": ["r53", "r769", "r770", "r771"] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": ["r51", "r769", "r770", "r771"] }, "mlab_SignificantTransactionsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "SignificantTransactionsTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions"], "lang": { "en-us": { "role": { "label": "Significant Transactions [Text Block]", "documentation": "The entire disclosure of significant transactions." } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-12-segment-data-segment-depreciation-and-amortization-details", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-operating-segment-information-details", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-change-in-the-carrying-amount-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": ["r108", "r109", "r110", "r111", "r116", "r176", "r179", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r204", "r205", "r206", "r211", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r241", "r244", "r252", "r253", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r632", "r635", "r636", "r642", "r684", "r836", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r10", "r63", "r65", "r66", "r115", "r135", "r136", "r137", "r148", "r149", "r150", "r152", "r157", "r159", "r161", "r177", "r215", "r216", "r242", "r303", "r371", "r372", "r379", "r380", "r381", "r383", "r387", "r388", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r427", "r428", "r429", "r430", "r431", "r432", "r436", "r437", "r441", "r503", "r530", "r531", "r532", "r541", "r594"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-3-revenue-revenues-from-external-customers-details"], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": ["r209", "r210", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r543", "r544", "r545", "r599", "r601", "r604", "r606", "r607", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r623", "r651", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r683", "r689", "r783", "r836", "r840", "r841", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-comprehensive-income-loss-", "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "http://www.mesalabs.com/20241231/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes", "http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes-provisions-for-income-taxes-details", "http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes-tables", "http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies", "http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-data-segment-depreciation-and-amortization-details", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-operating-segment-information-details", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-tables", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-schedule-of-business-acquisitions-details", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-tables", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-contract-liabilities-details", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-revenues-from-external-customers-details", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-tables", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-fair-value-and-carrying-value-of-the-notes-details", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-tables", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-accrued-payroll-and-benefits-details", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-inventories-details", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-accrued-expenses-details", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-noncurrent-liabilities-details", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-prepaid-and-other-current-assets-details", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-property-plant-and-equipment-details", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-tables", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-amortization-expense-for-finitelived-intangible-assets-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-change-in-the-carrying-amount-of-goodwill-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-estimated-amortization-expense-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-other-intangible-assets-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-tables", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-notes-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-term-loan-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-term-loan-details-parentheticals", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-interest-expense-on-the-notes-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-quarterly-periodic-payments-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-tables", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-restricted-stock-unit-activity-details", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-stock-option-award-activity-details", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-tables", "http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details", "http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-computation-of-net-income-per-share-basic-diluted-details", "http://www.mesalabs.com/20241231/role/statement-note-9-loss-earnings-per-share", "http://www.mesalabs.com/20241231/role/statement-note-9-loss-earnings-per-share-tables", "http://www.mesalabs.com/20241231/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r148", "r149", "r150", "r177", "r437", "r452", "r538", "r542", "r548", "r549", "r550", "r551", "r552", "r553", "r555", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r568", "r569", "r570", "r571", "r572", "r574", "r576", "r577", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r594", "r690"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-comprehensive-income-loss-", "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "http://www.mesalabs.com/20241231/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes", "http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes-provisions-for-income-taxes-details", "http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes-tables", "http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies", "http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-data-segment-depreciation-and-amortization-details", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-operating-segment-information-details", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-tables", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-schedule-of-business-acquisitions-details", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-tables", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-contract-liabilities-details", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-revenues-from-external-customers-details", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-tables", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-fair-value-and-carrying-value-of-the-notes-details", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-tables", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-accrued-payroll-and-benefits-details", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-inventories-details", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-accrued-expenses-details", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-noncurrent-liabilities-details", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-prepaid-and-other-current-assets-details", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-property-plant-and-equipment-details", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-tables", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-amortization-expense-for-finitelived-intangible-assets-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-change-in-the-carrying-amount-of-goodwill-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-estimated-amortization-expense-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-other-intangible-assets-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-tables", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-notes-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-term-loan-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-term-loan-details-parentheticals", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-interest-expense-on-the-notes-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-quarterly-periodic-payments-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-tables", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-restricted-stock-unit-activity-details", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-stock-option-award-activity-details", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-tables", "http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details", "http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-computation-of-net-income-per-share-basic-diluted-details", "http://www.mesalabs.com/20241231/role/statement-note-9-loss-earnings-per-share", "http://www.mesalabs.com/20241231/role/statement-note-9-loss-earnings-per-share-tables", "http://www.mesalabs.com/20241231/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r148", "r149", "r150", "r177", "r212", "r437", "r452", "r538", "r542", "r548", "r549", "r550", "r551", "r552", "r553", "r555", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r568", "r569", "r570", "r571", "r572", "r574", "r576", "r577", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r594", "r690"] }, "mlab_SterilizationAndDisinfectionControlMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "SterilizationAndDisinfectionControlMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-12-segment-data-segment-depreciation-and-amortization-details", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-operating-segment-information-details", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-change-in-the-carrying-amount-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "Sterilization and Disinfection Control [Member]", "documentation": "Reporting segment for Sterilization and Disinfection Control, formerly name Biological Indicators segment." } } }, "auth_ref": [] }, "mlab_StockAwardsThatWereAntidilutiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "StockAwardsThatWereAntidilutiveMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details"], "lang": { "en-us": { "role": { "label": "Stock Awards that were Antidilutive [Member]", "documentation": "Information pertaining to stock awards that were antidilutive." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-schedule-of-stock-option-award-activity-details"], "lang": { "en-us": { "role": { "label": "Vesting of restricted stock units and exercise of stock options (in shares)", "negatedLabel": "Awards exercised (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r10", "r62", "r63", "r95", "r338"] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Stock-based compensation expense", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r37", "r62", "r63", "r95"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Vesting of restricted stock units and exercise of stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r10", "r63", "r65", "r66", "r95"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquity", "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r63", "r65", "r66", "r91", "r557", "r573", "r595", "r596", "r671", "r696", "r723", "r741", "r817", "r869"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies", "http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r433", "r444"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies", "http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r433", "r444"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies", "http://www.mesalabs.com/20241231/role/statement-note-11-commitments-and-contingencies-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r433", "r444"] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-"], "lang": { "en-us": { "role": { "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": ["r708"] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Supplemental non-cash activity:" } } }, "auth_ref": [] }, "mlab_SwinglineLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "SwinglineLoanMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "Swingline Loan [Member]", "documentation": "Information pertaining to the swingline loan." } } }, "auth_ref": [] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TableTextBlock", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-10-income-taxes-tables", "http://www.mesalabs.com/20241231/role/statement-note-12-segment-information-tables", "http://www.mesalabs.com/20241231/role/statement-note-2-significant-transactions-tables", "http://www.mesalabs.com/20241231/role/statement-note-3-revenue-tables", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-tables", "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-tables", "http://www.mesalabs.com/20241231/role/statement-note-6-goodwill-and-intangible-assets-net-tables", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-tables", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-tables", "http://www.mesalabs.com/20241231/role/statement-note-9-loss-earnings-per-share-tables"], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "us-gaap_TaxesPayableCurrent": { "xbrltype":

"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-accrued-expenses-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-5-supplemental-information-other-accrued-expenses-details"], "lang": { "en-us": { "role": { "label": "Income taxes payable", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r53", "r54"] }, "mlab_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "TermLoanMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-term-loan-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-term-loan-details-parentheticals", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-tables"], "lang": { "en-us": { "role": { "label": "Term Loan [Member]", "documentation": "Represents the term loan amended into the credit facility." } } }, "auth_ref": [] }, "mlab_The2021EquityPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "The2021EquityPlanMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "The 2021 Equity Plan [Member]", "documentation": "Related to the 2021 equity plan." } } }, "auth_ref": [] }, "mlab_TheCreditFacilityTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "TheCreditFacilityTermLoanMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual"], "lang": { "en-us": { "role": { "label": "The Credit Facility Term Loan [Member]", "documentation": "Information pertaining to the credit facility term loan." } } }, "auth_ref": [] }, "mlab_TheFy25PsusMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "TheFy25PsusMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "The FY25 PSUs [Member]", "documentation": "Represents the psus for the full year 2025." } } }, "auth_ref": [] }, "mlab_TheNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "TheNotesMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements", "http://www.mesalabs.com/20241231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-carrying-amount-of-the-notes-details", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-details-textual", "http://www.mesalabs.com/20241231/role/statement-note-7-indebtedness-interest-expense-on-the-notes-details"], "lang": { "en-us": { "role": { "label": "The Notes [Member]", "documentation": "Represents the Notes." } } }, "auth_ref": [] }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TimingOfTransferOfGoodOrServiceAxis", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details"], "lang": { "en-us": { "role": { "label": "Timing of Transfer of Good or Service [Axis]", "documentation": "Information by timing of transfer of good or service to customer." } } }, "auth_ref": ["r652", "r783"] }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TimingOfTransferOfGoodOrServiceDomain", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details"], "lang": { "en-us": { "role": { "label": "Timing of Transfer of Good or Service [Domain]", "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time." } } }, "auth_ref": ["r652", "r783"] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": ["r739", "r823"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-", "http://www.mesalabs.com/20241231/role/statement-note-8-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.mesalabs.com/20241231/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransferredAtPointInTimeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransferredAtPointInTimeMember", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details"], "lang": { "en-us": { "role": { "label": "Transferred at Point in Time [Member]", "documentation": "Contract with customer in which good or service is transferred at point in time." } } }, "auth_ref": ["r652"] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": ["http://www.mesalabs.com/20241231/role/statement-note-3-revenue-revenues-from-external-customers-details"], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-computation-of-net-income-per-share-basic-diluted-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-computation-of-net-income-per-share-basic-diluted-details"], "lang": { "en-us": { "role": { "label": "Diluted (in shares)", "totalLabel": "Fully diluted shares (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r165", "r171"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-computation-of-net-income-per-share-basic-diluted-details": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.mesalabs.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.mesalabs.com/20241231/role/statement-note-9-earnings-loss-per-share-computation-of-net-income-per-share-basic-diluted-details"], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average outstanding shares of common stock (in shares)", "label": "Basic (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r163", "r171"] }, "mlab_statement-statement-note-10-income-taxes-provisions-for-income-taxes-details": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-10-income-taxes-provisions-for-income-taxes-details", "lang": { "en-us": { "role": { "label": "Note 10 - Income Taxes - Provisions for Income Taxes (Details)" } } }, "auth_ref": [] }, "mlab_statement-statement-note-10-income-taxes-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-10-income-taxes-tables", "lang": { "en-us": { "role": { "label": "Note 10 - Income Taxes" } } }, "auth_ref": [] }, "mlab_statement-statement-note-12-segment-data-segment-depreciation-and-amortization-details": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-12-segment-data-segment-depreciation-and-amortization-details", "lang": { "en-us": { "role": { "label": "Note 12 - Segment Data - Segment Depreciation and Amortization (Details)" } } }, "auth_ref": [] }, "mlab_statement-statement-note-12-segment-information-operating-segment-information-details": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-12-segment-information-operating-segment-information-details", "lang": { "en-us": { "role": { "label": "Note 12 - Segment Information - Operating Segment Information (Details)" } } }, "auth_ref": [] }, "mlab_statement-statement-note-12-segment-information-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-12-segment-information-tables", "lang": { "en-us": { "role": { "label": "Note 12 - Segment Information" } } }, "auth_ref": [] }, "mlab_statement-statement-note-2-significant-transactions-schedule-of-business-acquisitions-details": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-2-significant-transactions-schedule-of-business-acquisitions-details", "lang": { "en-us": { "role": { "label": "Note 2 - Significant Transactions - Schedule of Business Acquisitions (Details)" } } }, "auth_ref": [] }, "mlab_statement-statement-note-2-significant-transactions-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-2-significant-transactions-tables", "lang": { "en-us": { "role": { "label": "Note 2 - Significant Transactions" } } }, "auth_ref": [] }, "mlab_statement-statement-note-3-revenue-contract-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-3-revenue-contract-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 3 - Revenue - Contract Liabilities (Details)" } } }, "auth_ref": [] }, "mlab_statement-statement-note-3-revenue-disaggregation-of-revenue-details": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-3-revenue-disaggregation-of-revenue-details", "lang": { "en-us": { "role": { "label": "Note 3 - Revenue - Disaggregation of Revenue (Details)" } } }, "auth_ref": [] }, "mlab_statement-statement-note-3-revenue-revenues-from-external-customers-details": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-3-revenue-revenues-from-external-customers-details", "lang": { "en-us": { "role": { "label": "Note 3 - Revenue - Revenues From External Customers (Details)" } } }, "auth_ref": [] }, "mlab_statement-statement-note-3-revenue-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-3-revenue-tables", "lang": { "en-us": { "role": { "label": "Note 3 - Revenue" } } }, "auth_ref": [] }, "mlab_statement-statement-note-4-fair-value-measurements-fair-value-and-carrying-value-of-the-notes-details": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-4-fair-value-measurements-fair-value-and-carrying-value-of-the-notes-details", "lang": { "en-us": { "role": { "label": "Note 4 - Fair Value Measurements - Fair Value and Carrying Value of the Notes (Details)" } } }, "auth_ref": [] }, "mlab_statement-statement-note-4-fair-value-measurements-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-4-fair-value-measurements-tables", "lang": { "en-us": { "role": { "label": "Note 4 - Fair Value Measurements" } } }, "auth_ref": [] }, "mlab_statement-statement-note-5-supplemental-information-accrued-payroll-and-benefits-details": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-5-supplemental-information-accrued-payroll-and-benefits-details", "lang": { "en-us": { "role": { "label": "Note 5 - Supplemental Information - Accrued Payroll and Benefits (Details)" } } }, "auth_ref": [] }, "mlab_statement-statement-note-5-supplemental-information-inventories-details": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-5-supplemental-information-inventories-details", "lang": { "en-us": { "role": { "label": "Note 5 - Supplemental Information - Inventories (Details)" } } }, "auth_ref": [] }, "mlab_statement-statement-note-5-supplemental-information-other-accrued-expenses-details": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-5-supplemental-information-other-accrued-expenses-details", "lang": { "en-us": { "role": { "label": "Note 5 - Supplemental Information - Other Accrued Expenses (Details)" } } }, "auth_ref": [] }, "mlab_statement-statement-note-5-supplemental-information-other-noncurrent-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-5-supplemental-information-other-noncurrent-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 5 - Supplemental Information - Other Noncurrent Liabilities (Details)" } } }, "auth_ref": [] }, "mlab_statement-statement-note-5-supplemental-information-prepaid-and-other-current-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-5-supplemental-information-prepaid-and-other-current-assets-details", "lang": { "en-us": { "role": { "label": "Note 5 - Supplemental Information - Prepaid and Other Current Assets (Details)" } } }, "auth_ref": [] }, "mlab_statement-statement-note-5-supplemental-information-property-plant-and-equipment-details": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-5-supplemental-information-property-plant-and-equipment-details", "lang": { "en-us": { "role": { "label": "Note 5 - Supplemental Information - Property, Plant and Equipment (Details)" } } }, "auth_ref": [] }, "mlab_statement-statement-note-5-supplemental-information-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-5-supplemental-information-tables", "lang": { "en-us": { "role": { "label": "Note 5 - Supplemental Information" } } }, "auth_ref": [] }, "mlab_statement-statement-note-6-goodwill-and-intangible-assets-net-amortization-expense-for-finitelived-intangible-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-6-goodwill-and-intangible-assets-net-amortization-expense-for-finitelived-intangible-assets-details", "lang": { "en-us": { "role": { "label": "Note 6 - Goodwill and Intangible Assets, Net - Amortization Expense for Finite-lived Intangible Assets (Details)" } } }, "auth_ref": [] }, "mlab_statement-statement-note-6-goodwill-and-intangible-assets-net-change-in-the-carrying-amount-of-goodwill-details": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-6-goodwill-and-intangible-assets-net-change-in-the-carrying-amount-of-goodwill-details", "lang": { "en-us": { "role": { "label": "Note 6 - Goodwill and Intangible Assets, Net - Change in the Carrying Amount of Goodwill (Details)" } } }, "auth_ref": [] }, "mlab_statement-statement-note-6-goodwill-and-intangible-assets-net-estimated-amortization-expense-details": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-6-goodwill-and-intangible-assets-net-estimated-amortization-expense-details", "lang": { "en-us": { "role": { "label": "Note 6 - Goodwill and Intangible Assets, Net - Estimated Amortization Expense (Details)" } } }, "auth_ref": [] }, "mlab_statement-statement-note-6-goodwill-and-intangible-assets-net-other-intangible-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-6-goodwill-and-intangible-assets-net-other-intangible-assets-details", "lang": { "en-us": { "role": { "label": "Note 6 - Goodwill and Intangible Assets, Net - Other Intangible Assets (Details)" } } }, "auth_ref": [] }, "mlab_statement-

statement-note-6-goodwill-and-intangible-assets-net-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-6-goodwill-and-intangible-assets-net-tables", "lang": { "en-us": { "role": { "label": "Note 6 - Goodwill and Intangible Assets, Net" } } }, "auth_ref": [] }, "mlab_statement-statement-note-7-indebtedness-carrying-amount-of-the-notes-details": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-7-indebtedness-carrying-amount-of-the-notes-details", "lang": { "en-us": { "role": { "label": "Note 7 - Indebtedness - Carrying Amount of the Notes (Details)" } } }, "auth_ref": [] }, "mlab_statement-statement-note-7-indebtedness-carrying-amount-of-the-term-loan-details": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-7-indebtedness-carrying-amount-of-the-term-loan-details", "lang": { "en-us": { "role": { "label": "Note 7 - Indebtedness - Carrying Amount of the Term Loan (Details)" } } }, "auth_ref": [] }, "mlab_statement-statement-note-7-indebtedness-carrying-amount-of-the-term-loan-details-parentheticals": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-7-indebtedness-carrying-amount-of-the-term-loan-details-parentheticals", "lang": { "en-us": { "role": { "label": "Note 7 - Indebtedness - Carrying Amount of the Term Loan (Details) (Parentheticals)" } } }, "auth_ref": [] }, "mlab_statement-statement-note-7-indebtedness-interest-expense-on-the-notes-details": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-7-indebtedness-interest-expense-on-the-notes-details", "lang": { "en-us": { "role": { "label": "Note 7 - Indebtedness - Interest Expense on the Notes (Details)" } } }, "auth_ref": [] }, "mlab_statement-statement-note-7-indebtedness-quarterly-periodic-payments-details": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-7-indebtedness-quarterly-periodic-payments-details", "lang": { "en-us": { "role": { "label": "Note 7 - Indebtedness - Quarterly Periodic Payments (Details)" } } }, "auth_ref": [] }, "mlab_statement-statement-note-7-indebtedness-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-7-indebtedness-tables", "lang": { "en-us": { "role": { "label": "Note 7 - Indebtedness" } } }, "auth_ref": [] }, "mlab_statement-statement-note-8-stockholders-equity-schedule-of-restricted-stock-unit-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-8-stockholders-equity-schedule-of-restricted-stock-unit-activity-details", "lang": { "en-us": { "role": { "label": "Note 8 - Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details)" } } }, "auth_ref": [] }, "mlab_statement-statement-note-8-stockholders-equity-schedule-of-stock-option-award-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-8-stockholders-equity-schedule-of-stock-option-award-activity-details", "lang": { "en-us": { "role": { "label": "Note 8 - Stockholders' Equity - Schedule of Stock Option Award Activity (Details)" } } }, "auth_ref": [] }, "mlab_statement-statement-note-8-stockholders-equity-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-8-stockholders-equity-tables", "lang": { "en-us": { "role": { "label": "Note 8 - Stockholders' Equity" } } }, "auth_ref": [] }, "mlab_statement-statement-note-9-earnings-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-9-earnings-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details", "lang": { "en-us": { "role": { "label": "Note 9 - Earnings (Loss) Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details)" } } }, "auth_ref": [] }, "mlab_statement-statement-note-9-earnings-loss-per-share-computation-of-net-income-per-share-basic-diluted-details": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-9-earnings-loss-per-share-computation-of-net-income-per-share-basic-diluted-details", "lang": { "en-us": { "role": { "label": "Note 9 - Earnings (Loss) Per Share - Computation of Net Income Per Share, Basic & Diluted (Details)" } } }, "auth_ref": [] }, "mlab_statement-statement-note-9-loss-earnings-per-share-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-note-9-loss-earnings-per-share-tables", "lang": { "en-us": { "role": { "label": "Note 9 - (Loss) Earnings Per Share" } } }, "auth_ref": [] }, "mlab_statement-statement-significant-accounting-policies-policies": { "xbrltype": "stringItemType", "nsuri": "http://www.mesalabs.com/20241231", "localname": "statement-statement-significant-accounting-policies-policies", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "68B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-68B" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-5" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-18" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",

"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r119": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-
45-1A" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r133": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r136": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r138":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r139": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r140": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r141": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5",
"Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r142": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r144":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r145": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r146": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r147": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r148": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-
45-5" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r152": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r153": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r156": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r158":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r161": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting
Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r165": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-
10-45-2" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r168": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r169": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r170": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-
50-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r176": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards
Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-21" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r372": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher":

"FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

"Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r559": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r560": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r561": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r562": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r563": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r564": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r565": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r566": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r567": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r568": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r569": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r570": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r571": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r572": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r573": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r574": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-
45-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r599":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r600": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r601": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r602": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4(a)))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r603": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4(b)))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r604": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r605": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r606": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r607": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r608": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name":

"Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/210/tableOfContent" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r751": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r752": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r753": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r756": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-
30-50-1" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r760": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r761": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r762": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r763": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r764": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r765": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r766": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r767": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r768": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/405-30/tableOfContent" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" },
"r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r771": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r772": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r773": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/450/tableOfContent" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" },
"r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r776": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r777": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r778": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r779": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r780": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r781": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r782": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-
10-50-5" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r785": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r786": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r787": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r788": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r789": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r790": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r791": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r792": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r793": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r794": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r795": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r796": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r797": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r798": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r799": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r800": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r801": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r802": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r803": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r804": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r805": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r806": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r807": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r808": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r809": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r810": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",

"Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 87 0001437749-25-002662-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-25-002662-xbrl.zip M4$L#!!0 (!9 1%JS_J"<% @ !0T - 97A?-S0V,3(X+FAT;>U; M:W/;MA+]W/R*O;IS4V=&LIY^5)(UXS:.)W.;UC?7_=R!R*6)"0@P "A9_?7=
M!:F')3FQ6]>-4LUX+!%< L0Y^Q9@!]F/E.C88HB'KWX9NBE5SC"VU]/>L?M MSNDAW1TVR\(7W]#]?S4:<(D:K? 8PW@&UVFA8[2O389P9:P7"AK0;C?IK]/J
M]."TWSWN=T_@ZATT&J-AAEY E KKT)_5"I\T3FM5J189GM428S/A&S%ZC+PT MN@:1T1XU67M4F*=&XYDVM=&+8;-T>C@V\0R.L;0LD;*K3R)O5;NOB#OM9&+_78 MY8-A,Q^]6/%AM;EOUQKZ=JV-I2_!E$2SCI;Z&XY'0ZYQIZ>)L%)H MWW>94*H1B=R1Y<5M*L?20[=]V(8?T']9R$CP:1(5)IYZ>UN'2V%G\.X0?IZBIC:B,#LS*GP_>=R
MX\Z@O1@KA+&QA-^S6HN0ADI5ZWYQ[7(1S:\KYZ8R]BEUUOK/X$_X60N$0HQC MZ0M_QFOMG^:K'OOX$V83GLM(J&JPWN2A>3+?.J./(88ELM=0'69T]2U4?LP
M3"]WOL7I+\G3MY"*"8+%B<0IL;E/I8./A; $$#6C\ISX'(R&-\3)5*GQ/S) MO$,GX$=!RT9X8R4[\%9'AX/U4=,G/UFBZ;#.GG9Y-\;&>Y/U5TIXE!1KE@6! M=E! 0LAE\T&:J,+[!>HF7
M"B6QH7ZU\4&M")(,0L^@T-X62.Z26,IH=3%\!'5/^)*DDQ(149$%D\D0%(/= MAH'&")WCV$$FF?B U.]*FX[*8G*&NE2\X+D/-HBDC8J,S#15AZ#18)K** 57 M\+]E_2E:K!KA

R0OBGN1ZF[R9:=@A!_XLQ\Y!>#(L1;)+^2#;X@"N M9E -LTSR$< HCN9^$46"%HO+'W6$\DS(,>/%[ZX;*':1A%=U_VNA85@\O =? M]HY]R:082DL;F[;
MS'NHB!)_WM6U$Z1%^+RB^XMPD_&<(CC=Q:>%PHS_DZM,2Z-CF'?;&$U#AQ'M M_|+9=)V<6G3E'?F-9/'SM16(B[Y'OS)70[ZZ:7TST_=[;:F2[5B_O%,W.! M,OE??Y0>#Z*ZE-
_78\"1%7,&+GQA.]$^!+] H>\ 68_/CE99;F8<<$5 M\GM*3HCX@2>)@>.7/WO>=UY<0F3NT2H2OX\2.A\&Z?K]C[7VP3%9CU9H!\7X MX ->V6%=8[$[#B):]3ES7!9>1>
(_VKA00B[;.]7US_6Z54.Q;BW@^3;V]7LC M88:M=:U=M&N4]'V_?/6%86;MC2GB^01:%L)\C$\7R0YK:WUP]7ADG,7X@I[/ MEX&,:Q9*$U2" 0^E\ MAQ.?
V6.F=*^1]$T9M*TCI>,&+"*QH8A'I32KC%]+=8:0W>Z] 8,-"]"91%9HZ M@0@L(A^O-9@1M3#S?;RZ8 90'6FAI+4L:^H*M\"VXTI>=^%0U=[5H*362LH0A]">!41)0-'[E-43D*XH-
@'F"C(CL]T7/^@_1]%B\,W_%!+ P04 M " 60$1:D-E^:ZI_ " \P8 %0 &UL86(M,C R-#$R,S%?9&5F+GAM M:.U]]7/C-M+I]GZNZ_V$N]YF:S&0G+UN[SU-
^G76=Q_;92O(\]R4%DY"$#$4H M .FQ\M\1QE"4HAO_U34:_^<__^)__XY__ M*XH^X0PSE./DW?WFW6Q99 EFIW2%W_W7\>WEN^C==S_|X_OO;CZ_^V5V\N[#
M=Q\^1M^?C[I[_+HK*XV\IR;[\0_[G'G'3A"1\?+KO[Y9YOGZ'|]'^ 7KU[\] MWK/T;Y0MOOWPW7???[MK_3F-C2R\4[:0 MWZ>=LTC^*7K_(?K^_=\>>?*-F/5W[Z]H0RQF-
,6W>/YN^_&7VXO7IN B4%'^6S__=!SWRS%F+ R6]=XF^^[4Y40E>(M9-$*K^XQ:TE>[1C6"24KG,F5$E6/:TNK8AC;Y"[%>"PN[G'T],26%&M&ZG&.
M\1P5:=Y]DI^/HR1X1^U+4N6S5IBC%-WSO\5T)9[WX>_O/WS__MN28*$(
ME4<9S;%*#/R88Z'VM\H1TE*XU>OC>]>.|?QWQ;TX=L$D_+Y\D,Y'=6+P^3WLRPG M^>;TV>H0)./T7]^H?]ZH2:4.1FP]*^Z]]1>V7]BZQ N45L\^>B2\AC!%B]8T
MS1&_+Q=7/87;/_Q^2GB<4EXP/!.2KKE:+?*A9; %^+C2^%I;C@,O3-TG^(F M6I\UTM&YUY9'+'Y'F;!=__6-L'^KG>0?\E7AY%_?Y*QX&FZ[2;4T:>:,KD"3
M2UNL!O%DE_PI3)B*19WRH4T]W"TC&LM&\;]>RQ<%]%H@1^^MOYKG>U&K=U.__MH77E:/M'FN5"]_2^$QD7Y09]BN!2_=FD< MP(%<6-E&I/1B6Q^)QR>2A/,4+6]LQMK?>
[1C3Z2^81B=T.3E+][ZN4]]"L8D M[V(9H/2_,6)G67(]7EX=90U->Z3R="M%U;.%KTQH<(QB5 MKUHZH/%BOPI5%C"TN5MJZ^Q?2%,'5%;2IEY"VG8.Z/N_!6(Y9NFFBLE]*%2T
M=$#CC"%AN,FWUTBD]]D*L4C=)0=_-P[4G.4) QSOOU'KL[W2MA&T]85G7*' MNV8S^E4-+BE;N]+QA@H3)OU_9*W8I9L;NZ*TM-NOV0VC#Z0Z$Z"E5=&\=VI/
MQ*)@*+T0YMWC_\$;)9F*=OW31U3EN1.2U1F-\$[]4UZ9 M94]9-O(-UYH,0XZX>>[;";"%>S2=&O^9+(61KE*E7C+9U[[2> MDQ1?
%8>>^BL"7S=Q0A4[$9IN09EZYFI;]4[;1193)A9?::"6ZOB$%D+I;;1; M#:B7][%38CBG#Q@8;FBK2[1$*UKWCNUMWA!)"B4Y5=HI9[:^F:]4W>WQ&G:
MM+CK&O5/V0]EZ7'\A7'(U1M);:O>:9NAQXM$XDAS4AUX;%_^#>TG%:\$T$0E M)+*DF5IG7YKT2-4=C@LF)N^]A_L9R6M]>U43!U2=/<9+E"VP0H?HF05(G7!]
MI95YMUG=T[2&K-K?!XL#OIDX&0B'"M&R-F^]YV@%&.ND)FBCX]>HCIR9L@?P MQH&\??"4-YW9!V3M>^]8TP2S@#S]W3N>8'$G('L?O6,/&*\"\O>#Y_PI(EU
M[G[TEKO7@#^0I9^\94D; @)R]L.WW&E"<-!-N_]\E];2J V,0?GSU2I1 8I0 MOGRU2 PP/BBK_EDH!K ,E$G_3!9@K!7*H']&"RA,"V7//YL%'C*%\NB?Y0(- M84,Y],^04:?
207GRSWS1P[-0E]P_RT4\$+Y\LIBT>"P4*;\,U>:,6\H;[[-M)Y L"2B/OIHGD.@LE$=?+11-B!_*F]_6B2;^"F7-5Z,$D-("9=$_IZ0IL__E
MS#_;Q#0I;L]I[T=K8IH)=U/,DOS$:4H263@ZNA<]A4D?\266A[WC2@7*]DF$ M)E&1H2(ALMT:R:\O<2Z\U?2)[^:#.+T\UL6QG1X)#P?
H!THN',)VBM<,QZ14.N)SBDL5F"5"*VF4_57^77CE0OKRS8T0S%S\=O9G0=:'$>$7 M!Z1M#^]V;M*4?I4+)RR4UKH/8KRC=[VLON-&V'8KJ:ML[*O(E9>0OH>D::5?
U&):#"\X+,/7/6P]+N3IY MWZ1+*$=UOXX%EN2U>K%:(;4]E1A99 MF6LG*W%5-K78P**UT($QP0;ZOY?'.BOWVP_A(:(1(A]3+@E\S18HVSJA)T^6
MD_ARC#CAU_,81>+-5,],;NB3O<+3;]Q3VOH9KN$FBH(.WEFL"%\MW$&VOI# MP>& 8+=^-4,CV*'@L'6M85APV.'FY=KE^/#,-I;GI[G,(15,&CH1S0,YYLGG9VIC2U*+
MGA9(%4\ZBO\L2'7T4TV8KIT=,CZM[I="B]VA5'[24]\K:H&8N_W*GATL;)7[M8=3'[3F^VR<.WESYD6%NY>4!N'-F"6GF.6+3Q>UYCC]Q'##SC;3Q,08GS5SQFBJ'AR !#?(("XW=8:
M03#[T%>.&4FW80BQ]PJ%0+(YCK=1B5P(KIHHX\X!KC#BX!:7>?\WB"E62W/# ML= [*"1W2,[AUG:\.?Q%@]*9#^"8OW*?.1=;?
[DL!76_D7QY4O"X6(]NL/*VXU;;QF\I!U\.3^;MSD+>D<P/8ZQTC9FN8@A2K MC_RUV*8IW,@>+:!MH+]] S#]}9!V.XRP$ *0DA 3>8$C@&*<;,6X,RM9M;#R=S.'K?(G9)/5V*)Z\A];&V!I-
D2-Y!1W\)U/<\7%9Q]R84V M=YO.6Y6[O9/5;B]I=5&-+I^WH?G@M.LSJQL[C)5^[U+"0]I^2-NW50M(B+PT MZB45MX1_.<99O%PA]D7[.]#=IL#+H)+UFKC-$WD:$8-
V&Y]7F7B^&1LO>PS+ M@:3&3+A>]Q@O!\.NC"W^\(H^K7D(].4V%PG?YQ<9SUEY489F.:@;#DBOO+M) M*T!-S<=(^Z"2/_[7^ &GFE5@UGD8OO83WEBG
M"-]G&"XNLG61\W)*O]=]54"/83CX? ";OA86[=)O-<:TN1Q4Z^TP.JF2&\Q& M7=-!:=:^"GWCL=$];(XBS@AE:FRSL5W(10RYB"$7T3M&P$ Y-8>E?>03@G_0
M%F##2'BMAZQT#&MA2!^Y-G1FJ!7[U,>)F$HM"1BW&B2'FB(G/O*GM<"IFNS0QL")]?B$1(/KN53)CG_O/Q!*KP>$8_V6Y1MD<,FH2)1B+-+>T M'"">280W'AKP3WH9-
\MFI#BV>X:6D=C,5.DFGI1OL+$IG4X3/.]EL-%$I()/0 M2[GL9]+[L//;?'W0?%0@AY9N6 R%^T+A/G-XH-/:M'1WID7);1,/]TZ0VZ%9 M=;/0%(+V4KP=P8 CV97,M1KPB N04TMWR-
KO89L6-^% WAM-[@_IC#W1>;")'CH0 M!F<-V@P14C9#RF;(]PHAAQ!R&"KDX$\B4(!U]SC*ZS3WK9QC?+\&)$LP?W=X5BH].1$_)_D1PMA.!]S+!HE?Q0L3S? E11](3M/,
M1K4Z&1C4/K>^A9U">=44GZ-8QB4W \I@749=Q8^S-_"X$-_V:DE\^?TS>B2K M8E5+E_+W_]D2^Z&6]KK>Z?]%F6+NB/MM,^YH48Y0S6_^D/1L+!S]/<8ZCW-MK6OU;-?
0%4=3-AR07GTL4W3,=$\;/4GX7W5N.;]X\"^=:AS%N]7.,\ONYY72D1;BD;7--19"G66O*RS=(L?:/H@G/[GNZ16T$%]0K4H-;5+ MRO(9;(%]VPY+M5;4&U]/CW(_;FR]#
DY5NDL[CG^LQ TG#VHL%I0VR&I;M(@ M^M9#4ZY?BTWMQTF]B2X)"5HA0:N!D7]$F39 O3YQ (93)U(54&_544,SRD<. MIUX>30/=4A.XU$?>QEOZ#;CZ&BPB:FR
C#:!=;K5:DRS*[S*>[2C12>2L@]-MEGDG]UKM__QZ7BB>Y]64MM\+)U:9#@#6>2>D318FA6>&2F:70WMB12GT^0 M>2.0*F>5-].:>25Y4&?752-:$@
MG_N"?.U.0GDIOQZ4YK/DS4VT(K=_-? M6>$>E^ .Q2)#58%05:"Z*>"Z(6-)43!Z/A+TEQ,VT0]1^$&<%!2!DA,(";["PP%E*%D3HDS,A M@G2#=>>;&YI:
(.:*9G@[^"EA.!8#:>AI;FWGV+?XX_NS7P@7X8$D!4H5;U';SCV5OY%\ M>8O3TM/F2[*>4)P"L[[TRO3.057;W-3ESN# MC]-2:QE2FWFS_-#CRUX"6[Y=AB7H;:?
N$]60.&H"VGH5&6VWU'S(0;0H M@!K(PSL)['4GH*T<,2\%>1 M=2*GFX" LS=KH\O620WC?UX)>U^&A0_ZW0-= M"(F >C,I-A0!*"CO-GLRG(6S4SD8"?I:B?#]Q[G1O#
[2+19D;RTS".4)9&4!R)GO]R\OBP+?>3X*;86]1K%%.@CM^%F S.CTCNH!RZ#%.R7>05%]K$N M/4\?:?]N@?[_;#.M0\%0;]?GX 5#_8XY"K,=1K*<+TN0P^L/)(B-S M$B/Q&
<4Q+4HZHS5-B23UZ0,\ &0ZHHL84#N:0ACH#8.!3C&/&5E+L;N>]PS# M&RD?&Q6X;-S/ IFWA'\1>N67+,8L%V\G%]);/0U]W%GM\6/GA;HS799-N#? MS1W4Y#@P V
MM'9+.2.4W6#QW^06QRGBO-SX2K,I^:/@I4ERH*Q4++4<)@2:0NID_<%TR!KQ M";D=$>->7.G@2H_)E6[2!=3PK(MO+N+<-RDNZ6S"639W5TR9N^[FY?
C.OW[PS.$3#"5<<&7K$40Y7(_SGE7=G1G+>@*";1QL M8^TYK:STBF5)NY."YW2UO=/X*$LN";JO[HZ'&#T=1G]8@LM%DS,?07AW5:+ M!\2C4=^!?)PM3?Q<*.XSL?
A9AM+=^Y#)3?+^X$OR@)/]ZNKCS2=,%PRME\+9 M3H\81APT%?:T_/A+P5*_E+PEX*_%/REZ?I++4P*[^*))EYAOI:"=W"YJGI M;#>[1I?
_'LT18=$#2H7+N1(OI&!5]*R=_PP=SID_;490*^#?ZVQ?\^%*/T] M):E29P=KFL@Z*5P)=?9+8X+QDBV$ VN:,9V7\O<"Y -W=^#@A\6_+#@AP4_
M+/AAP0^;KA_6]_[IVDK_&/%BO:YD!*41R>:4KA4H?LYV9#A/F9UN2%$PU*=L.7NYQA]WE2]M;+@X6M]8TZCB*V\@6GF/&MC=XG* U$B)$DH:*F>RYT,]KK;=G=\:)
ZZNZ"E6B1/)BU'6Y M$S=P!>\X4.SR(Z% 0!>G.T'&(B_BTQ6=J%LO#7@[\> M_/7@KT_77V^W*XXP=&K7_!Y1@-2*Z^7=64P3R3:S9KT]@]G,:CLW"\CH1X\8 M-?
6\7*.%/T0+2I.O)$W+VW;$'*"LO+,Z0]5>B3*, M)78/^DLIQ646T\633&WC"BO*+$>%>_9M*HP;%&DQEU\C)CQ')$GR?XT36.FB'D6C'<(;& *@(N,>4
M<0]%#I50.9AAGF\5RW5V0K,'+/2-D(]3(2_-^5/M1K! ^@RSU25%FNN8ZUNX M+L$ GDZC/HZ3S^[SBXR+'4]]%,V=H>]&])[A5;Z^S:,FH^1]D&OMMYOZ)^1 M,&'*H,_U7)
[^E$L2O!#:#A,PHX 9!X2N- M[X,"#$*O #\[\NC#G:\JPU8[52QVC96Z0B!6@-_=$1(;&?PPC48^5/$7UW5YEPVW.@?P@0,B$Q"9@,@$I"9XAL$S? N>87N;883^ MH6TSP;5C]7,DIE
X'HAE)%OP2*BEB$M.VCE7T.&<.5AF! 4G*SA9L'H>@I"$ MI(58T/A.ELHJD;"SQS@MA/C($L!2"13YMO;QV5;\;C KU81!W0_+#OIHOE[2 M):N*Q4=9_]=1#+12OHIC[AE^KU^$&<^&
(2,X'D%SPOD2,7@4P:,('D7P*()'$3R*M^!1=-PHG9O0'Z*M!'2_) TECN# M&DY-L*NG;%T#+N8>%PO@3&=&H/L,;6TLC Z*,MIZO<,VX&^' M@DUIK]"W/B0VE%9R+*U*!4E-O"JOY-
(+3-C="VJ##'05OZDAWNZ07QA+-GPR M(.ON:D;!6#=S4H!,NJO*,_9^;?BV+]'5_MH%-&+I?-<;S5A+D09#51 MQIV=0BS;NY9O$%/(6G/#L= [*'Q_2.
[L(.QZO#G\18/HFP_@F+]2:U>G"H50 M"^I^(_GRI. Y76%6G3H49]"\TTC\+YFA1R6CK4=R"TY6_H-6"&O;^$WEL%=& M[(R!GV-
@&0;41/1FF%1+\++:W"^AMCO(#@D[%4]BEW>*XP[!Y M+A;UKW)-6V+OU7C]L/5OFB;'*/YBARG#T1RRE.Z(Z,+)]T&F-D@K+[V-(:PZ[(8WRTQ
MSB_E(QL.T#0T'YQV_5&FQ@YCI=^[,UCAG%PX)V>'TV!5X&E:S7Q&V>R-.(&+3;T+S,Q//-V'C98U@.)#5FPO6ZQW@Y M&'9E;-V'5_1IS4-@+Z>@]08QM)"R\DG8WB/+Z+@/RL#LG
M<(MR7(+ER?XL 8@CR #\G>%5OI%WM1\C+0/JIV>$W6+UP6+EXAC@U6BZN24 MCR?<[7@/P?V;8(8$99M+_(!3C;XRZSP,7Q?9NLAY2 M3[-VZ;0:8]I<#]HU=CBD5 0-IK&NZ:
T:U^%OO'8Z!XV;1EGA#(U?MO8+]0G MA_3DBN!1IBMM(QK(4B?>3:T$RF5NPW'R=B M*H5]8-QJT!Q]ZIG]R)_60]5F-N%H3U.8 ?'>):2#E>L!R[(O%?YS7WN/Q,[M:P$.R?
@ORS7*YI!1DTC!6*2YI>4XD4,7<.S$.^%MV"0IV- W4E*[F0]=I--2 MM2.+TMD4Y?-.AM-5 K()O12+KN9Z#[L_#9?'S0G%#= M]@;$7FB+LSA>+F$[,:E.*_1';^0VE#@P7GRAQ$$_)0[
AP_=0EK62C>T349U MBY'TQ*X^3]*M,]H8B]]$;;<^BYVEV/'0M%L3SBW+32?>W9H!O?'>I4(#K->5.8+2B.RO%>Y8:<=\8&>E=MJ2%FKMO,%:.ZX+06]P4@"M M
V@I'=ZV51RC0/*-S@!-_G.)&]H*/O#QO,F.]OOD[P\=^@C_\"D:?9 V8Y M$4]F^BB5]*U8O?_NN^]N&,EBLMZ+SB$.T'6L"MAYP!G*\L_HD:R*U8SF
M*)4I)PPM<$G).4U3^I5D"YG#*53=R'GPNK[4^(XOELU=BCWWPDRQ,Q3EYQ,G)K%EM0] M45+'3%-;"^1X6!#VAN$U(LG9XUI8G9B7^3CBK53_"95 M=91IFEDCX@['!1,24]]/>
[00;I%5_N M*Y0'UDSAB=S^7L*G@]W/*S4[EBV4I#=F30DRS,-6SY(IF MRS-RE=NDK2NL:^J69I+A'1D[1V^+31Y3QLJPX@E:BU]>W>#898C!>;S%2L5031/G-(82 M]:.A>U
+^(;1&..$;Z^4WR$+&O$&]'#*@;!1*Y.;:\T35;/!.)5ZC^\4'X#H MVO:.]7^@Z8/5'E#H+9#4MVD0?2MAZ9A-=$DX*=F:D M/AN(-]3E^,3!3]+>RN4[>]N'&IH9/G(X]5M(-&DV5-5]++R-
]X85X.IKL!BH M\08]VI/4TRT*;YH)[4!7#M:=")GIP$]UT]9U6]_V@IO\E)*V^^%$[L !@!F M>2>D318FA9[B\5(TNQK:$[D#1G->Q!N!5#FKM/%8D%>2!W7&?=B<+>YAS6D;
MWK#6>&CJDUY %OR[@6:2-Y.9'ZCT2E'8;9HD9,[O*R_C[=E56'L]F=*_]N M"P)%8KQ3-,T0CYK%T2@9&Y?7)U43]KUQ?^]-N[97]LJO!S?OS@N+NM8HP77_IW
MU:R]]S>&NNDRW,D4REN&\I:@FVY>GZGRSG>L779^DB)=]MH.,#LW9;0 MAC=H%0.W_]&#R\0:3VZ]3'L7,O35]5&M[;!@'-A6,(1."]>7=W46S53X&3\ M[--DP$IC0]T1A_A1,VN-
E2*A7/EM9%FX3O"];_96FX()4%Y],[74AT"A'/EF M8-59R]"CR5">?:.S@.?OH.SY8E3I7FF+H]=0]GVQH_;Z"%'U \J<+\:0PM=3 M5&^!+=;-K!3Z$#(4F?+%QFCT*]=%?
#%^K%XUP*4=;-(G!Y/RB[OEE& MQA6FH(SZ9C#I*PY N?+-)#(NBP1EU#?CR+">U9[-02YZBK?^8H3*%131>90O M<22#A%%*T?Y&Y#62KVB) M,.7B@HPW7K[ZT-0]+82EMZB
(A-/39T'Y"L4=W7-0RB$HK:V0E&(MW40/QQS M=I-('HXT.Y?+D"]GO,1"OMQ0X%W:*6-'_P4\9S&7D%A\S,AD72#==<]-
C2U0,P5S?!V\%/"<"P&TM#3 MW-H"27=+Q/"]1.I/Z$H>@ZE.CC FS_^629>:?9-M5L?15]22LW+%[15B=7IF MMD39]5H.P3^)(7)^D55Z\3;# MQQM>Z*^XKF_4'20-
MUQ;HRK<2+V]Q6NI:OB3K&=5XEAU&F!YG@P;'RHWO9>F*%[&FVC9.J92]G02L-436 M-1F$1FV M+Z1[W0.*]&WPOIB)!8>V)V$[W]2,YO[WYIN&T&T,=M4%?:E,?-
M1NGQ2Z.T_,_> A4.]>IZZ#X>,8XY4GD[MB>]Z3E^S1;7ON]2GV<)2!OT^:@P M9_!'A32:D$8S@3Z=RM4F\94Y>:T\=I];7%*,6O!E1YL!IG:Y MO,O]4D@<=&%6OO M6?>EZ(TGR;C
6?.E@HYGLMK3;/M2S7"0W&?7O??Q>13+3"48X>,>]X3A$X MFK,3BD;TA+.)4SZ;V#G]X>D"@(M2HF;H49X[OL7"_9$%?BN]D]CH<-0*C5+ M(8C;/&O\@K,>1@X)+"&!10D"#
(GX!8 F #33 VBL:V[GYM_[*Z]1,XCE"61 ME!9AH&+!07=[L.7P[@S$3@0&BW'*%]/B3.&[8<-P/VFP>S-2V'9+]AC/0 M#:V'IEQ_%*VI_3BI-]D%
NAE]7!/TXY&6YLE/G+;M.ZI\3(;'9!I9,IXDYAI M+H,4[UXA=SVL2X]3_-L_VZ! (=;3BVN49"9XMT;;=<:A:'(WW]6EC]YG(M.:40&C->,=@V;NMN0%0*\;S# >[(5#WED]*3@.5UA]K1L+
[*8 M8<2?W3=RA?/K^6TE7#+W8Y'5U$KK8VBG,*.6=@74".KC#Q=-[]#;("TW(S ME4[.R"'-X(&!]0SF]Q@[QF9OVEC&QICF]F+]>3:Y?H8]6*]KI8[2B.2E>/$9PE.4M;>]6HWN#,7K
MYP16;LBO6V7Z\V.J//*I.^!(GGRA-5#:OOO$P M= M=U43M09-A.+Q%7S^+!&V2;&9E9F)3C32ZIS; /'(>UPRO$4G*(XQ4%G;) MXBK"&"':
<=Z#1VGZ1!_L7]37.DOG"3O0)DRYP@GE_L3!WH6 MP/W< S5M63+K'*"% "T$:"% "P%:<.(2R5D8(+$&-@I.@"U$8;,]9@:#", M%'|HS>7@Z$,51=]YV7B+3MK"6#/\0%Q,*$T8
U3QAH4F06[O79;-* NZ-K8 MS@H93R6;6*5V9,+>Q1_T24[P'M9+%*8:MIV 4^U%6'FUL/ 5F_>/&]FYK MVPI%7;FX;HEQ?BD?V5"6MZ'YX+3K"R0W=A@K_8-
6=KY>EU5/LL6E/D'K($,_MZS1 ?I+AZ&&-]%7B*M=&?6A]FP S0-H/AW0'.B=CQ0P-S' 1PJ<-YIA(T/_M6R$S(X7*3?P](]N^W.]NB 1Y%P7(:+8]3M>]C*BEI_D3$3"A-\0%WF1<0*G
MKYYDQQ"3?]W1 J'A&L!P#: 3KL9Q#>#!/]U1'.' M_,V"#%0E8#,"H'LBU\]%"]?"A6OF$AM [P!Z!]#;(3RLLI]&!H*W]:='"H1#
MK>"1X>$&WI9K$/6';$\I5LCR(+UE&V($(Y]"]093B/X]7X(Q8_1N+11#%B M;",67(16M!#CT/E^C';8:K]$.(-<-T_1D-@WB,0>$]I>(K9"2YR$]/T%#_@
ME*ZEZ*GA3G@O"R2>H)3<5W?*W=&TD/I]4].:6]L@2321;'_"&5V16$>.M]4% M4NYDU=B4_%6ES&3)]=C.LSF.=S?S"6VBILZXBLU2]0IF.@=5"_--VVU)@;R]_'H2V<\HP6615]#K>
MS!C*>%K.XB1[?PZ(5B(?T$4 M+4NF0)A_P1/]&P.";6[?6H@VAVCSI*+-]3"6?_K0B!E35,MUC/+'B&0)OL]Q M(K?DZ,\",6%SI)MH75ZK3&)93;GQIH";\%8!;+N6Z48"^X)D'-?"LA8! Z
MG/_H">?-*./ (&K-P0-Y'D',_RI**%H?C@N%& M+NA3895)<3G*D@O."UGO\H3RO+9XOD$W"T1*E7,IY%9]]*"^A5/G6L[%1<:% M@I;K4I.84/VY%'W]Y4 [0?H/WI0?
MP8W]DL'T[!W:DR'R3X3U2W+W1//<3CY1-+65UFCS!,QQ2 M0V/ (-\@!CE;XBLI$AIXK[9%@/<"O!?@O5YYF&-A,R3G)'NRBJZP6GRTK4/& M- V-^9: F7BP1]?HF@Y*LU:F]8W'1O?
0'M&*%/ODHWM F@=0&LE0!-ZZ'Y MTRIX.J92 RCO'RBO\5^\0G8#*]8=".0S 8]0<$6@Y?2V4U:=I+.4$XBA(Q" MR.BMA8R,((Z11H]\B*6(M9G(6^03^6E;2$U\>6K
90PA1GP9S5/ZE4=%AH]$ MB";P8$KG1[B(IE@B,H13WF X1>A;EF\+V%W/+[('(2^4;>YRO"[64F7515C MG9P",T?)'P7/2X&7-XP(>2_5UXS>8K$N8I)BH7TO,K&2L*SK,Z,GHLD-
HP]$ M"/WQYA>Q@"ZRIW*31W%.'LKC.D?W8I-"L0H:=O58MW/YX@WO;O,X*B_S4,T$ M]J-3/N1U0?%C>[AC/19L9>E1,7(L1G'(H]>"2#,ROL[-'N8<6A"_E?GP]UT1T MP"
V<3@@CL3GA1= M!^:I+%XMEOEO)%">"/-6&*[=Q-NP.R!1AF8TYWW8O+::OH,S,63_W""UB1' M:8//8C P/S=,+Q&)E[7%N \Q5?3>GO CGK\[A]T#!9PZ?@BOS 3SEKT$F
MVP_D []2)?"\P_O4#. I?^W>)V @'_BM 63,^-0,X"E_[=ZG;\C5,[#MZ &1 M5)]*,WI"5RN:W>4T_K*D:8(9/T:&]L]I?[F MJ032*9$"E26]!:9I.0C%,UI>2L[P[](4+,-ZU_,2+ZA^21I8,1EB6!
[%UBF)?R#8BY%W-.E&O!^PW& MS6[BSRDK%SCF*CY'0M;%9K]#3Z5X[/;]2^EJ-6$#%D9TF^2]1$(Y"S(2L]>/+35*NNL, MAV1Z]\GT]NDLUNL]!0RE56I%=ZIDR&FQR3WR[M%-
|2$ M09P&[Y+#AY@HPT0-[VH4N9RS-MFYP ES=Z/ $$+6.LL).'ON;B488O: D07O MU!G,V&]+.&=V=2"$>TT-&5D>6<8V9X 91Z0=Q:;+?.^Y+XVM=(]M^Z'[K4YB]
[9$[8GP"'KT3OKH-M M&00]30@PY\$[*'.=+1-%6<;,6%2#X2SHTSG& MH@ Z,*U-O?'.4[D^DT)B][90_;?O'$BF7?:W\ZKVIGF(4_# Z?TI[+CSLEO7EG#)MR<6@&V4IZ?
U+8=E.I3DA:Y\H>0^M0V:8]-S@3NV4]%MY1LA+;M+2;A-W= M<&85V,LM)TS,K5 D<^5IP9H6KNMG;--[)!1S4CD80@SV'D:5S52UFZ%'S(6<
M,"2L:^$4L4UIT]M\'AGH*D@;7&]1Y9CA5^4@'3YQ@!D4=&X%[5C(H?]]-[1V M3'DU;5M2Q)S2G8^AI+ZQQW G^!4TU]9Q2^7!-$%.WS>V=UL]8$?*E@C5/"Q; M#4-
MHUQH6@Y2F\%(1&"=7)PE_:R]AJIVC..SU9SC%@L(;A382"GM RVZR<; MU,J.C1U&*R.-@"(UPO+@L MAS[<%6?
SQ6F,!K=,A8H9H6+&]"IF=/:#O$O0A/&MB15YEW()XTB]]'N72@E< M;![GUKM,2. K,@G5C#2GR0 T\BZS$,9A ^#K77*?(5\04.W4 W
M<(>)=3"ETDOQC_>^&2HFR#"41]^,$LOL^6:A.(N 0R?(-Y,'%"2';\:.) M1T-9/LW6 :1P05GSS<@!97E!F?/-UND P$-9]LT,ZA1;\2V[GA]4K(SPGP7) M-
[VEV8.>Y4V^O0&U+1+O6UV3&\?%]D@EK:4))TOY,;R4P-/#=]??!HV-^SL- M!QZ4$KO%)9$S*O9O":')MR!6TCEE1I72+8SH.#'[]8:L]CT[VPU%+30]#>GB
ME(>G$],'E,ES5PKZFY]I334O59(46IH)$:\[A ![.RZ]!STZ,8YD495R+]U% M9>G)HRPIOZ754<,GW5E6V5%G?_7[,,8&3TX()X.U]E32 M7?YXO2XQO;-'S&+"E>?)V@_D [^_HK3
9NN_]4#^\-O]]3:/X](\K=]Y.)"/,6*-@1'2PIM2X%R^S%T%9>B'>)2^ W";%FO4M/ M G/7$M@C571T G][^4G20O*1;P:6/SD;
M&+S$29%BF:!PO[T((4+R'@!.JA:)].32)S:; M4S>L/1)%!D=/1(<*BE.NH/AZ%90W&#X[O[2W8?:WBO+=_2*U <%.8U@@_],7 M?
+07;#6)NG86R'AQ\^/3%#R;&35U+;H/E)TD]Q_#.R\$5X'9C>Z?4'V]5X($ M,.41:S,PP/VFP!M&(KXZ5@92/C]PV60VT MM>GGEEN+B1H@0\]I%
WXVZ%@]V^P<+1#".R#*51O*W]US8LV_X!SH*P74G1'*-:9'E M;%,!,=LO>POF^X?23ZY>X"ZO?^Z@**YI;@P; M;A)X8<0*!AA^
&VF]F1:AT:=!&^@TKR!,&'O@ZIM.Z^0#3MBZ#D,:?S*7CH& MWH 8$[T%N/H(AX!+@QPH6>(E,7+'MQ@57^/YHBPZ$&>W!'\[UZP::W#@[^C M+(EBQ-A&4+[]$YU'0H^48[1%L?
IXM#-\]S_BPV&#*%.\W>LK;N7!%]\ID^5F M5]((.1="5YZ^.R5<:D(AC?I:D>U&<5L3D.=D)1;=]?R)+E,VVPSAE,K%E4N]:#TJQ]%?K& M8Z-[V.]TTM:\01OI9-7L?
@I&@+V<5_4$ACC58S#CKOM2#Y(9_|Z MJSVR.KI3*5W@5N]6;COCL6X6FM!-+Y>V(ZN[DPZP=,HB)%B$!(OI)5@8P9*N MDRD^1KQ8KZN7CM*(9'/*5N6!I&C-
Y+W3+29:I[(]H0BE/B]^A#=5K9S2NTI7C,<$UWAP+HF/E2S"E7%OL[% MH%&@Z$V!2W9 E(44-\XQ(-"/$AI[/L?]A*Q;%0R:A=9<&.\0K/[L/B1T)
M:&K\7B%;UN@"P$6"K"09[]"0VCURC0']$"TH3;Z2-"UA#/)4GRQ"G..<1QG. M(RK/X-7\U@X(LOE(9VB0?:(#)!0@(1TDM#V#5Y8.%&+,EV3=-XU]W";XBX7 M(+XD#SC9EST*E?
$P56F@%LHV@_D"[_'F_H#\I.4]$0= =*S$?PA<.R5ILY M6\^Z^<++?].OT$?/]RE.ES.BA,IZ'U"]ONP8!U<@LW2GOBU6QK,81NDW!=L$D"+9PFW_K@NU7?I27:#",1K@)AT9RRJ"0-

~~IY(S MMV"X'8K\PLIM\A2@] "EZVX]/A"UZ_E+I:1P\F&=0I:HDMIHWJ<;\DI#7FF M20-,ZCM,&O(SH3R. /0,^9F&$CL2V-*C6Q4#7!G@R@!7JB[N,_%O82T\+;\~~
~~M15(/N_0(79D]V2^(J@WM 8H*4%3+G,@#&=ONYU="FF9?5@GO,]$T]680X= M1_.=\Z_4'M_[L0+4%: N+Z&NX$T&;W)ZWJ1U"V6"^3&F9NOTX:9OHQDDKH/L=)ACF7@~~
~~EFF.=/8(C8T;I>L-?E$R)EU'W7! >AM/9S8U'R/M@V;D7&P5^W83EC0JR->T M')KB_?V]S8?L3;L'T"B 1EZ"1K#*(V:IZ9J=72@&'2O\RX1JO%]4(UY17B M9T<>?'FC~~
~~M0+Z)>+S$29'BB,XC22XCLFT;IU3>/JW&_:3=WOVB M/0@(ZN/6M5\BAH^1V,!.Z$KN'-4I!<90MJBNC=SLF]R@36G.R[D_*_73WGKG M9<61V1)EU^NR#,TY97-,2]E~~
~~SRP<2^_O&3G%O_Q+XE?1-Y.UQ!;'$ZN M"LTNZ/SY4YM=_\3>G+2)O)-?2ZX'T_7UCY_DW/HG]"WI\^OMP\K2VY2 ME#4&OOM\5)@S^*-"Z8\0VIY0:+L>Z:$N]D693#(/.C_3PFZ=H~~
~~M^DB/TPT6#P7.UP]O;;Y:A#"!4_GCFYE*'4X-G*R?WNADM18]7]+\JEPU6O(6 M(3D#_>?X&3S3HP0_8ZI#=M^4L_N&"\V]W@"/LN3L<4U8=<587_%.T^=.:S9? M:/JS1\QBPO$-~~
~~(['UX*9-FD;U%IZ[%+I[?GM\TJAF[+K(Q4Z6R2,B%UG.2,9) MW$O '?J\L/TE13<\9ZVP-H T-G^[7S"I#&UOF=BSTNMWT0L2XYEF+63F9 M9',*W,_P??,JO3=>I55QN?*~~
~~(G]@XA.M4H'2&V>J#;J:'H20DY;A/RNF!3N&O M7W!>X.2T$(;*HEIQI*"0AA;!Y")N'L+DM6G ;BJE--8C=E_WUB+5[2(,;RU$;3\Z)S!GWV; MP8Z.&=1\=)AF[T8?~~
~~=0#Z7&)%=1JVPY*]6FU3H%TOVCMEG*A]^@&XX.M6EN@J;&]XQK8,2M5+$K%-KRB M665W'.7"+[P7*O4^Q3/ZE)E?_?@;R9=;NTW^?DH>2"+TIFI)]/$(IW-TA?/J~~
~~MWNE+L>LVN'Z\.!KR!GA4;[; !-"'\"HI8-"U M$(I+C*- 24B5":DRTTN5Z>3ZCS01IH,Y.M)TEOYPKI'FJ73RO$::?0) U$>: M/P+"W/T)K"*Q:Y;!/O* (X[C@@DJ,(]P>1<13B(Y!R\#AT^#~~
~~[<>Q'6[MB2X/ M@K"]V7Q-J6HTZN@UY'Y!Q][2DS[8K^EPLZ)/]>KZ>O]PCCE;R M]C-5J-SFV&.:E>--_0"ZM(+^G^C!##:&CJ#=IL!+"&D-'](*(1![(1 '&HRV MU13C#8ZXVA>\"[6~~
~~7S#M9!!Z!19[NI9&$EPQEI@69GF(EH1HB1G'(5IB>4^K M\PM=PY+OO]N=/\C1(^;1FM$'(L6:1W/*GO_6#F#L\ 1G4&%G&@/H-V70KWOF M_7R.9>U27 579^CQ5LB?//)-~~
~~LD*HA&NQ.U:'"14.H?D KG/S*ZK.'F4N"#[& MF5BA*CBMH76 #P)\X"5\$(S88,1.SX@%:>.1IO:TW3:=6^$?HJU 1PG*T?X+ M7C,6]KB-9[FSS.U1&VST*=OHBDCW,:%KX6NO4(R%~~
~~MFQZC]!0_X)2NI1"IP]SP7A9(/$$IN:_4T!V58()01VK2FEO;($DTD6Q_PAE= MD5A'CK:EE50%S$BZ7=A'67(J_/*LU.HT*VMFT527KF#8N;LMSUE^8,>+;_NU M(+~~
~~[\+I[*:4J2DJ)RWZI9$LT-!Z"S5JM FHZ!UD%#V!?9@] KE&VNL-IE?MW$ M*8U;2RE;W%4;<+U* +9VZS%7).@/^M:U\9M*/Y(NC@NA4#'GN_>L20P"]0G8 M3\!^O,1^](P -~~
~~FQJLEGZQ)O9^J4@I3HZW YJD7F3? *2-6JX8WL%3G9?C.D,])X=B5 6OA3JXGL_0HP+W ?0(I4A[MX;2\L;YF^B7)YY1ALLA."L9P%F]F#&4@"F S"M-+1'#FX&)R@X09XY~~
[illegible]

&RF>I?*BU4F4(N%% ;2 &=;?1 =\B![M00VQ>)3DC^]SW*GN?"&CMX@ZW5_7L].M^>QWYTGQV1'E=^V!U)X>3E)9 M]AANM_QW]I T-F-D?HY>R&]S>]:EE.YM]9FY
MWAE*U_=G[7/<3ZA<=7X'B8WK91D=XX.CZ;W&3U$J]'8*!AHH3')!SVYGF=. M#M6S[?_]P!#S] 1'O%W;U+>Z9S 6<)#!(7!'BE\''YY)?]5Y+3/2N_/HCO]. M?X\^
@!A'ZS)O)3+>P@8*)?S++F FC/M<^YP5_) R8N5 M((5HF@:#%'3W*K C#GHT(T!M!K67CV*&]G'.>,4+,93&JGC=/ UK88A?%X+)
M19O)6#"Y;7&BIUO)UI6Q\:TN#4$)DG"1.7HOK/-3,6W_5:)0-MM4V4CCX] MV2L5R5G] P+BZ"8+Y7D.2Y$5Y29ZQ$SUCL'=OND4GBNG]$YUP M_9QWEC@50&_@R!%
#Z$G6.+;%'2#!6?D ACY*G6!X2W'Z/R7F&6C,Q '2>6F MB)/=F<_^ 0_A[C8!?O?\?MW\SQ_R%=9F5RFT=/!3BW55G'?'>S3]2XZ2%QE M;5L>A<8.!^].@3P"^B?O$$, A6-
%#0.CF)T.!8%_GM0/ M#TF#"4Q:;TGV4SV>^K"[SMB/-_D#_=Q%]3;TM3FVO?HV^("RO"V"VB'M;8Z MN-IE;_6QRM$Q+7U&6S^@PYW.=H[F@.?R=,]DN0/9YFGS=I]00AED:@HW-
RT] &<.(H_""L!'IGS;!6?%CU M2^2":3O\"2!_+LW^\.[M_X#SBBD/_4T]WVO<4P6!.K5[UUIYG"E^8BS>+F* M\E]GU;-GDL7I)L'L['O6DT HL'9H5C"]=EEYAT M')>]G/-
A0MS2HHS2_Y>LSVC2'R$+U-C4D-CKU+Z 6[J/3L/;CN.:0/2(7,LR_"9:C#/S[W$L!XWWMC\ M9L*S-M=/W?!NPK=.-W0Y$5BODQ";[JL)N]J=E7T6%N=@-EZ)+VSML[N>@^VS
M(;/RRG!Z:*?M8Y^A]^UF4S(%,TM(]L3^^/U'*+W:_UA[O+6.RZV_5]>2T](, M.0&_1YRV_DMLFR.QXKFBAP.$VKH!_$,2@D,5>>A(Q?BYS%-
PQ1N<8:*D9_IZZ7P_,6,@)LY(Y>?!@/N01EYWV^?R+="9=!Z>S!.>I&AO= MYB3:U;>\A\J<14NZ>XUIF8_TLQ4-=.[)L!80$,? K&N. K5@A,ID),-VJL=+ MX\S#K1J,15.:
<1>74,QC'I27#!6IT>M#+Y>P&BWW&N%>\=*B7=BT!0K5[$S] MX+@>N16]X*!4Z5TYU:TCHCFR<<2(KM]ZLIKM3*3!@NV/DN"JKB[)IFCQ& M\:]%5;RE:XG*?Z6S*=
[=_^Z4Y3-N^SIUGG$97WMOR,<]FWT*'^I*M,"IBFORV"3HV=) M2M]82TS>ZMNU8$F!L).*7&]4)CG(I8?@+>UXE]0,YAOO9HC$[8R_N^W]T>: M'BR&WK]K&*9[_;@6\MJC(:AY-
S6[>49'&6&HCS+-A/WRW04[T,OM+6-(OYTX MTE1'\^SITOE4,W4,Z")!& %E?#% 9X&5#P:E!]-[0]GUD3
MO/WNPPK>I"YL^Q@_*I#W'3G8_K(<&BYF8X_M.QIVA%P+5D[2O[\32:CTWNEPBGASC!4)5F M>KE'95CB[?"^)AF^69SE."'E913S&GQW>"62VY_2/.>Y8L^B-?M;>5AZQ]P3 MS8-
=C9@OUY(:*AU?D^MQ:P0[B1>5HR#0C6]&6IPH088DAN[(YU'4T*I'?9[M6\W\QQZJ*#8X:1?0%'?X_(\W:SA\BHL7G,>D.*K9:]Z1YJ16)^AZ9?^E2MK# M+Y.+,B M>"
(_4$=KVT!6]3U^>UOCW:7$#Z2GI[ZXWMHT+0"O=Z+N4]590].XM<+_()ROKNF@#[ZSA9,K?:\GYQYW1@T!.0,WNR%@*^%1)8PC MA7%$*U$^GF25XST62MRBTFU"^-V[A8-*,-
!0<&]SO(Y(%HN2%S5CO)C4E:0!%>.5SY(I]!$ MR7/$I(\GLX 8P:I0VQK>CR888?8579$8$E?@!2AWGTFYA._08E-N<@PEWY@Z M !3!],#%48ZJ1(\9E(5+F=[':3*-,=[&D+""+-
A*RYYP'F IC8@I59C$H*Z(M*I&DB2-BK N+;H@^4B&=$'V8;+D@[(W9I@.B3G4[8??#]%R..!_D&!_;]?"7 M*-U@"YZ'\7]L.A[ZZ4W<[S E$UQBTL8M<-F9, \DNMR^__ZVV P\$^UMI!D\
MM-^9C["AR[^]_Q[=WG\R> MJ_;<56V;-..RR;6_25&AE\+8R3-!0CVA0.;X9 MRB]W5#U&;%F>-I]M=D]MH"[_BKCP1OK3+X5W<,'[F#\LHJ];
M!RCT6EQE8CG^E=,_<%P^T'N2/DXZ\ZK'X?.+O :Q^MZHWJUC%&O*;5Q#]QB'6ISC5R4)3=,H+\"A(*Y-E*Z'_AM)C7]N+3"<4XN/]0T>R9*=JLN0@[/N%L0Y&XYR)<(44)UTB%
MWE%Y@C)$=^(D=/ WK#O0T;^NM'$>P5R@-T &OT2K-?B%W]Q]25>UVBZ*X"UG M![^+UDSAB4F=5Y6-]:C:K5M"54;Y$Q8=?#WC(Q*W<:C8"6;1$LRX$LP%R=CW MD!6AU5L
S>DU2O.1%_9 M#]$^[\$2X]P5I0]YH\I66E>S&+4FFALBLF8'W-I7PWU-%HB#O=_8H' E>-[L M@^I!\&V4E]L'-MPBBCF0 M]S/<0U>-R:#F' XBK((/7?L;6A_^/T]:QX0LY*/6
?;VB).#AZOW.-XPZPI] MXIZ3@N<#8GOM575N0MZV;M-#_C,MTV"\>S^]^S@.=?7,ZMA,GD5&'H1FN*)S! 8\JZ/3X1A+(_MG80)B\0)]!S-H10ZA16%=7EMFF2ZY8LHI4QM#Y&O?
%R&]"(IIQ%B"-;.Z:&YI!-C.-B1BR##3H*N MUQY'5%GO<=M74PGM],((A^=%-HY0@ME?3"#6\1W@SU'^*RX=.<(#XG_=@5?C MXYRV:ST 0UYQR(R+V?Y2 ZRZ(ZL$OPX]_%]47)4+
(?D_\50Z\515$)4P:]OW M&2LAA;_SXB+D63V]D"G5U3:U" C?FIX%').(<7CUFI?!P,+?A'!FM! V(*B M%C.9.(4)]2"6 O.^S!/=QI[L+/;.V0EK]E/L= @=#_7T<*B=JL:'G!9]40D.
M*>EZ)>TC>-QHWUV:]8W^=#1,$[I>-$43@,HZA5]N:&AN-4#40@@1_#5& MM =RAA]8+2_3Q+FBIS%=[OPS3&L"\TO4)$Q*&R;D.*9/&5>CHIP4X(^!W0T4
MH]J!^\F4>#ZDQYKI\8X! 10E*UL$M3ZG_A07G++NG]J+V3Z=H[.1KK]PUYGS M"TI!+H9#]3/M9W'#W_EZ_ M#>/0>^1F>VPE+:-4[=1[@$^:;1PB+\%X+5I@?O>;/[Y_]X<_5?[W0
_7)(6,_MZG+77WV;*,^W;+'Y37-P8_C]JF_S\7T3R;?+A6IV8ONM5OU*BYCQP6,(3* MA7[&$=#FWIB@!3YU)X5;XK11<0\>GIAOA0A7_]A);_6+OS/V]XQ(\1\496S7 M@6NQ^?
3QZN'B'-T_S!\N]KT*2 >3:/_(3:UGG&Z9LAFWJL/T!X&.-M:R>_LZ M=3W#-6'4HJP? &IQ&,89REH%B\#].@;Z8?XYQ#FT]C84#4F&LK\-(*$S
MA%K_')6;G!_[C'_">57<+&YSDL5D':?S18GSO^$HOV1L[UH2IGWIK!A=FEZ\ M1+K@E!>(<>ECC'$9"=\+A,TU]#AND3GM6=OS9A "&[_PP5K!_NT-DP MVR '0T#H6S-N+(A & Y
0U@0550.SXD=Y]A]6D"\XA78'I=(..$0ZK,@+ZP9 MS1DU($HRWF2=UU=H$ 0T0RO.,D:=8A+$]X=D#?E CRMEN$RU6.=1O,J(9#BYB'(H MV57,8[;S;OB+M7.\
(#$YK/>@_]&VH(T1<"UM;UHDF;1QFF$N5!683?4YZ$WH M6D!XD")<9764Q?^)H6Q4=HI<>"=3L15,<%:FYELVV:]] M)6X#0F]2!B:,L.K."[7$;!NO3T%)
%6NY7P=>8$Z^H7V*]3>GOV\1+UN=.D6 M_,/G]!:'9.R2$*MG9S&TKA!"O40=ER6JP4UOVWO]4%QX>,>*\HVTUMRN>WIU MO62 +-K11;\ 9<1)A_'ECW&7*K+,FQ!=@0V+BUH]!G
] C304E-X.GKT=3_; M05KG2M;*"+1O84E%73@H5C0OR;^BVN>KG/_#T5F=1L:P\7DN("N4/+G0W86^&([;@'[A%9R:\TY72D=]?"RZK- M4'\;5[S$R2;%-XNK#%8#S;=5E?
('T,_'7*Z]G^MN;Y)DG.]X%0[P/C5(9]C" M@G[A:%!H3ZWRI%!33H3UL@'#+S_!AW^X_<:I:%ML/G3;=$[<,Y?'[9F?L_;L=1VTARP?/V4[^1ARSQ]L9##:WMZ^Y:>N0<.%;*<
MP3B/AWYDZY1%F%'N<[@;]N9/C(&]!T'^XVL1Y+U9 M.!/E8]9.6)@[WA_:Z,KD>3#5U,V&>O=0TH7 [O-^4FQQW@ ME;RH-DD8>EIM0/'IC15H3SASS$MOIU,L9(
MD\I:0:IG#5/7B:NQ-0Z=_.>3+ 4F7^[+8DDO.T%G8M6.QT@,M34)-COLT_K M.1%A'BXT]Y>3AV%9P^SQ]S2XM:N#>Y+'?69/O,@HO)NO*ZWV2(_JY[J/@27) MJ,O8,\X?
J>I>M:TQ1\0SSC:X;\T=_ED[MWX/HQ!GW].L\!<;#MDSKV"Q4E7I]LUCR7>9XP#99D_]B 5GE(<1]? ZK,V !1 MEP-FJ6(IG)/QK&8TA2GXPB4>Y]HIVS8=>5
M)\VY37*&^.MUK8=R1LC5EDV;%BR==0X1@.5VQFMSBC?WD-E0(C&:B\%H*#AM M@H&29'3(,)7AB%^?8G$;D82=A0_1RU])N80$E,Q,8+]0]SAJ=F7BCU0DZ=5; MJ8A-VY?
IC@*#D.M8OXC*(Q%F1->&E 4#H:]P0IU&5WZ0G7% M^-!3:C0OA@G'YG&<;W!R6E7;81".3.W1=CK)Q;KZ\Y"V#FCNRB650%4YB9@= MZ/JEO_>*2-
4OWB";G4FY1W##)!.;%!F]#0W_=GT7/<=?M/1V4;7=F_WYZ MY@^O![0IBY+]P.9RAKZ?_?Z]]V8_O/V,_^G[V7<_^G[V^Q_?5=-P$NVQG%)
MGG$:IK9H]XQ1V6DP5UP^K!ZANLE]E,)/@[K+4%--]:6K2Q\:#!2OXU)Q/[\6 M_S#18^R,PGQO[AQ9&&5F4%:H"NO\W=?@C-"<)[<3BO7UT[WIN6P/^>W^)P@
M$JDZPZ:2ZV4EE>9/@."EHDZ(6.)5\4#O, R5I/@C+G>53AXH9+*^S>DS27!R MNOU40,1 DSAE#@>/*!$]XFKR1-8XE,H-/.?7&SO\L(7F-6]4X1(1CAM^#_^* MF\SDK73D#>! +C-?
TM$9Y.5CRD.HV>*"<=YHG>,:=]\7YLKW8<]^]?"6YAWZ M]EB&V]V*\S +PPG8%3=<9(5KO[4MP1*]^A6]RF";G$ =<'A(F+K8YN]U;IW,
MOWI6F25[=:0BR%Z>W&1W4!87RM>R!FRCSNM_GD8%D0MZ=4=(]Q6O=4"N1)1\0 M(PX95?CXP3E##49NK;513B5VUN'L4W]3&F)[_TAOHUS25W?$IFF4%U#66FSUP7?
Z#G9W[_]/#1TN=U#G>^T>A4A7HJ1;_%N2)]=T:QD M0^IWPBE_K..6DR;BW$_1!L)WR3845&'1]]PY*AVB4L(2&,G0(&?>(GW!ORHNQ(->W*\TQMRBY-+2TE+"I([MXR =88O3"?\Y
M>B&KS:IWRCO_KC'I>_VXGO:*6!@?<#_7Z"@KW$XUR8:GNNOO.E/=[L?Y5 MB M :>ZDVMTE!4A,IZ,)*CO;6B>Z\13X)Y(=#*!V. !7G9G.W$0)3RR'=SF--G$ MY4U^C_-
G$G>5P1AKIK$Y="7G6BHJFN+V6) -4?9BE)M4ED4^Y (<%A6 HK/: M@%!;?0DY[C.(F(12%,4<'&>)- MI[C-\3HB2=?IP*$FFGI$NROWFP"GU=R0C[\)=*1!=/*/RC#%Z5)OBMY^P/0I
MCJ9+6"L]2W^TK<96T-NG\^BZ%KU0^\$X0ZD2ESSN%R(QQ"VDA6 GU46=%&+L MHD[^0^V]98R ![6C2IQVR3-:%!,Y$;UZ[6A;G9VK MKT^_.U6]:+X>T];H6.4-XZL^*/)"
(ZM0#0^U\,T0($0 $>UA1 W(&=H% M64R:)=JW@NRO(D!UB=$"QMIDLX"T)^@1F!/O,:>(HYX?0\W>]HISFS
MN!5S%KHB:)S:T#8PYYZ/5@;$"KM8835XU*#G&BK@KW(DUA52'K=H3]7@HYB* M NM!9#K3*K]5 V]+O*GE_1'W71]U-=%<1NVN7 M^36NT1K$+]-KI;TA0U.H: MD")]1YM
IXA2&;;X\Y2(S%WSLCG4FQ\@IWI*P2<]^(Q/HP==WXD\)>=.E"KA M652BJL#DL.\!=>:$6F"F-[&]*$]RBDK((ZPKMSI=:_JN"BG7DEMCX:FG)RBZ M6M-";?
#:OW+S5YK_>I?=YC1FYM>8FM/9V%3AV>O4M>@!,4C'OQ,DPAJ)W>SL M.IP'>.3_I=+IMK52^9N-CLLPQ:],WQ!U]^X\$]^U8W&B(6[)5#G=]5Y'AGW^
M!>TJ6V_*XIJ9D^EW@^>HQ!>F G;947$WR!\B$@&[]Q/\8*U>8A>^@1.O0==-92GY%H@-2#I M&.IN1FR2H+U"5-79QEL4[;(FA%F!&N)'+7#8OWH*)5J*)4X^4)J,]J>=C4W5
MT[U.G>_Y%3'T!-3";]=W.S23@=8Y%]I:+_;G[Y9X)S!F*R]W*Y^$]-]_2Y%!_]?Y1]JJ+Y75GC?.U-XWS+e6>-]/3^$]Y/;(MPMO)PA"F^['HI?
R[N+/O\YI3>3G6%9!M/C;T'4CWBN289Y)M(^6>]M MJ"O&1QWZ>'A9778#3<2)!I*W?FY2>1;YR]Z895/%+&3]SMS^\Y<8Y^_&[]^F4 -$:HZH#N-
]2N9FM4GACHQG:H&RNSE>XJQ@;!5Y MP <=D\K?Z\NL'!WG GQS=H7F99F3QTW)E<>2HMLH#Q[$ICX3U)B]'O5$I]/" M>RF<%_#"MMR.6/WC'VCKC7T=N]8W
M9]A'FC7.$'"F%R]0=KPO]Z_<1R:YQ'H[]Q7M,8Q")\##VKA,8CI$VC0L:$)^ M8X#P]0R*@X3+GC8N28>9U"39Z,]-J[B 7*V=X,Q&ZH]O.!J-ATR,^LG.1:RQ M9-P-:G\'>-
!]6I:9CM"5.UQE/YC:5G#H:]R]?!AU9,M_J;NUC5-PKKX=.:5W M(- OP3W0"E-#?CJ/P1B!ZF0+IDR](UIP$-7WQ[C'%KDPTN=',.[PAO&N>BO
M=DA4+.'_P:IYCE+,'3S,M"$Q.Z+@#_,LV?]%]R7;N---(E;.FA91^B&GF[7(ME,\8R-;4AIGDZRH=1M_M2 @(NI5./$+UI?OY')..YC5MGK-/"4WNRR@OU70Y M'M8 #F%>W!'O(,;3Z4?\1+
(,CEFZ0(+$E\]ZBTS1%AYD'(92W'(LP>OE[,)G&33 ;;[[C]X)R_YNE(PI1<%0_(X_I)@E.G>UFNKOG+/@NQHH;GB6CWY
M6EI(MDCIKQ@BQ=J+*5!:T(Y'OFG$JP11O0GN.%SC/V1E)B[(XB]:$<8W\"R=5 M?1=VCK:JO,E?&[K]5G-YF])WO:9]?(@#G*$6O!FJ0,ZXPB=B8P30_5O)2;R. ML3;/U-
7D^0M:V[_PA]0M?9%[_2UUP]..>U07X6>&Y N*D"]_SYO*#6.=._TK*99T:O:EM4.5/ MO\,Q?U4Z,I3,"6GPI 4:]4G"]607RB]5?CHONX[M_$I1X4QMXH6C%-P?/J)>:A4G+(K#4.4R[!
['I^W*6-L9]J-EJ")MQV5DY5D< M^GB$/#R%R?$XT('=X[.#CL0.1Q>/1RGCM>-])#66BA^.0#(X?CJ..]FBZ M%653XZK7,NMHHVUXM?IRGAF*$8-
(GMIT"F0+=7&/2K'$FQA]R&E1,"E=D#Y= MJ*.%]@BT>O*UF]9(ZFR71H@U]D-.#VR%('C5G]3)XW6TQK]$DTKPPVQ]C92K MAE*?-"4)#T?C"89ZJU6/-55<:4-
=NM]S6W1%%]AP):M'^4I5F.7]1E$X=A^B ME]8E9W_Y1LFO#.\#>WKW=MU71B^[$L)!+^S&^-QQ'R?>O&FX[76\]"Z=\M[B M-H=-:(59VAV5_GNB"D?
[BF&&'],4LE)-9F#]KWWTAQ7B\D/YKB.HPM*11WV\ MH15EQ4=^]$Y5Q7]:= F.]]HI0=.=,TL!%^5MM&VE()QGR490>?M<#VWF7[7?Q4KVC@TM\ M]G])?
^56@YZTY4Z9HGNAE+G>"S@<#(ZVPB4]VC0^CL\,&]JQS5"##M7PT&B5 M6F2 EE!ZYRA(X?C91"MCN<"H2#BS)^H%>9"4IN^MR&O2@ MX5)1I.1ZC7(X/-
(]EA:$.UR"W0KI3@*UP%F_\MGCOQML9T/6?'CONB0]C/-N MF)U]4A/0=7=&5RN:\9SE@XIK;SOM"YZ#_MQ[>($@XA3#:]K]K*32_/%?MT]D MLH=R"30#PVN@K]K4-
Z;5K+KZ=IX0BM-$.Z(A2Z?*<;FKRM4XZ_RE9]N',EC$ M?+"M;A*SKCY]BU'80N3#;*5*O/*7'8)F3P\X7YWCQ[ZKI:XFNODA6EUY2Q#1 MHJF5(<((LX:9"@1/@"(*!%GW*
M^GEQ;9:3,;/XM4NU=XH7-,=-R /2O$:[]X8\<;9U%H 2\@>[$ MW:\A&F :/>:BRIB]?L8K-?9I&QU-M+-1[;KRX"^GZ3.XC5/('T 753W*0.F= M.GA(91CC31(>R HD>?&01UFQP/G-
X@.ER4U^C_-G$N-!^T7I6TW9D:+AWAVW MJM+1US#@9P"":(XJ*&&-'K6YH$8,]OY60,2!8]Q:?R-0$]KP]35J]]WO:R-!P_AYM M#P2H.G7$QE322BK-!#5B[U0T\8'K*84OW6CA?
J]$I73P<-=7*K,@KW\'O,H: MB5<:VRY5/W<3L^=MTY0(:@M?M5%Y3N3#UT]OGW=XW410,WS/F.GH:%S[JL^*$'W;CYYFOG-O/-M*D MFC"^F%64-
/97'DC*4\]^XU4>>Z>9CG'$TQAFB*, 7TZ%! $4[_N9"O.I)D<\WI\^EE=9 M4>9*9]%>;Z%]V4K -9[B3K^B?9-;G_7[A.!UR&1-YNR**,L&0V*]#$(C9M4
MC9$XNW64$!6]PSI_J6%QAO,HG6?)/%F1C#!P;/T^XRKA^. UI-*WNNED96BX M7CL5"/X<;1\&]G"$O9I4FPAJQ%UODCF/8U@?;(':-MGVH*#\FJ]X\"_/G+8Q&
/J;ORDQ&)Z=KOWK]Y M_!K5Y(-M($]MIJRX'_;G/@B3*H'&2H=,@]?R MJ"!:+X,.K\[/-P7)<%$P!>>19/P]2CQ7?@*/!*T!NN(&ZJF!L.\G,?_W!#A M=F":^>&^8;U?
G4MW&_1=2Z(UH,H7_6&XHW%W50-%+:1H!Q7M844-V!F:EZB% M%[TB+NG%48A+,=C7FG)0*&\JP],H9YB8,=_^(]_C$[+4*/-VD+&VSYS6MUMNW#PXEIU
X99GZ/]$EPU'>L2;*6^(QA<071GF\.GOV&N8N M<$SK&84,UX\R/TFP.K2@#;ZGD/K&KK %>%71+VXA7U+(\7Y4_0X"\YQ M$>=D+5["U_KR\"6_\G5;%+RH6].
MDY)W]>W^]E#0FD0N\D'F=N4B'^>8/ZD2$ 9U@\XVNE+3]LN?E(0\WKO91Z5X MXB^6."M)0M(-Q-Y4]U,$4I1"O2&<"#-^M=Z455*K2/Z'.7,*,<50F&=\Q%],G;>QYCP^-
]BC"!-79GE3]=JB 9 M1F2\2Z/M+607\>I-&@5@FEG$<#1:I>A]Z]#<=KK!12[P.CGBZE(DQ/'5"\#T.M'_\;5_MOS.%XVM<:OIN?@^HR)N-#)DKG(ZLW_607O#F8%MM2;CH-CK?
0]>*Z%3,*!V:'GI>=4=VD4L1PI+6FY/7TZM-RGL@# MQ3'^4D6F&2H_9U%*'JL,512>GOU?E3D1UEU)#63Z]G/:Y0VV<_*'>@:Q-($W*>2]=& @6,43[Z ME-"5::#.>6K.3G\YQ*HPN-
:3NJ"'$L.M=;.$=??]_*ROOV3;3UJ9#EHX882Y5 MY%@P7\:0@CW8UI(?P[.F.%$:?]]R*,&NH-L/_)CCX9+6TM]9W)+V^@^Q.M+.X*%-TG^$?EJ+> M;%=IC^-
K_;N5/0*NUNYPC,DSORV;2!%3DVFE%NWU6@RH(TY^0M=A_=SNO@8;8:$W&:O?A$,R@I_AT1]/+V^'R3;U$^XP MG X)^*\N2<$L^K_A]"]-EJUN-
675E+ROR#I3G#IN7O^\T0HSKRC#@F="^WV0 M]6U-BJDK]HT-E>!@1QI'6=K(Z^!*X*H5#*TPUK'R-,;<_;9D5S2 \]*@];B@MYY_?!WK>4\839;S,6_]62!-M/L\CO,-;IQU M#+&46UB]
UU;1)J0S^?B,TV"\,\W*95]$G)4^?1A] MA[0G;;=@G1NN)ES1<^_^V'Z:EROL.H:A6U>5J>1V M,RI3]NEWW(%K1U@^)],-F\]B%]/1?YM3&FG?])PGKRMDDN2D1)?DV><7&4E
MFU@H5\1C9 O5K$\VN]1<)R:D72\4@>V$@T,[="(XN["3 L_H[8X#CTG_%7K MV?1:.*AY9C"*ENV1%A6X_)[WV,0B.YL,BO3]D]DNWLD70'*(P%/2@]5(ESWM;"1US"@X[;G#Z3!">G
MVT\%G&)5KK/L:0Y/SSG4D>A4_8XT5Y$Z0?=9IXHE6O#G/3Q)]Z*&@](&RT]! M1--@=@"L(A#5?O+CM)R]4 U-$^5E[#NX*+&KR"\W0+69TQLYRKRE.]-;%
M..X3@ZGTZUM6433'/S@V^P=1.3GE<'Y@:7U,ED,>$PKD:PKIBAB2]]I8IQTO MW5X!.4!/O\ZJL%7RL#N>^)]I%K/=GLC4]:L2K^#!?X4.+B7]=&-R%K*S=_YC
M\T"5F>OQG>3AZ]B^>X/>AMHO(\]]*6A'%/643ALX-&I8)]!:1FS&;Q*BVLCT5,Y1A']L- M@ZLEDA]HHZ6G)8C4!]?]9TXX2Z.BJ-LF/RY2I[FMOFB'AL%_W>7FCHF@R(DRB M2'4O:
[M2'@SS*T#H2F?>P'F65!40%,-6M'HS#EE1HNHS7*4&!HX@Q*'-D$@Q M"3>%=U#7[B?VR_A7]G\>HP.PW_S]02P.$% M @ %D!$6]'F$KXN40)'4' !4
!M;&%B+3(P,C0Q,C,Q7W'R92YX;6SM M?5MSY+:2YOM&['_H]3[SN"*V9?77*H*A91S8M:ˆMY5^_%DW2220((D+48B8.6Y)"3"12
"97R82_K/IV7RYA%E.2;]K]^]^\]?;_M?[G@=-"(Q3N>_?O?;?3"Y/]V_,Y-7H1I"8D1;^EY+O.O__N?.^-?_*H/) M*$596*#XSOGG_]OW" MX.VIX,/;(/B/?
R4X_?)/]CV88]>4":2O/KQ^\61;'ZY_???_OV[1]/#UGR M+-OW__VVWV5_C8M?@D/CC]_4?=Z2ONO[VH:)]\LOOWQ?_75' MFN,F0MKIN^__Z_/5?:1 RS# *9-
(Q'C)\3_SZI=7)]+2HS"(;QH16_!5NR M@/T]>/<^^/#N'T]Y_!V5^ILWM>@RD] [-'O#_OO;W>6S;RY1'B;A0_Z/B"QI MK^]_>/?^P[OO&>7WE.L"+5%:!"DI$.LZ1_/]9YS.2+:L!D
'57UCD:'9K]\M M:S?!MA?&QO^6ZJ8KR5SZ.Y'BY2M!WWQ^,8)64G+:IB*_H+S;TC$TEHZD904\% MHEJZD>66EX1<SE$\;/]IO=2I'T3_FY/'|&.']^^P?E4 J8= ?_CQ/"URL]>*'
M>/\R,*H>,&.9*O.8IN%^4.URLH\F(?AJI8=2HI\ M^YN]$#>_^/,.YU%"\C)#4ZHV)[3_+RVCD@QWA$$[XV,X;Y>TG=H1;*"'DL-
M'+;.1:*EWA%MU9MN>^B2_O/E&A43FN%W&CXD2,3K,R(>GX<'P"2+WI",6@^_ M?DE) 7KPSY9TI[TR-R9DZWZSH6Y3=L_4L M'#K=Y=^#.:$Q-]PD@1A&@>8?BN=
M8SJY09CGJ,B%.T&!/2<9+K4Z$3]L^7]*>]/>7]3/[4I]T^G3ZKE M#8]3=>O$>U]>!_*]?\?E2/2_Q.?E/?>GC>?4Y$;6Z8S&>RNH?S#M!E3IWRP($ M=]3']9)B1HG#-:&?
CQD+%TDX;W!P&O^NT.4Z9?M4AL)3$K^TA-K^K)*;,F,+ M[H(NA3#Y;Q1FYVE\1B>OB3,!]4(NSS9:5'_]%F68Q!?T=TT.JY!6&Y]1C N M7U%JX/%ROPK;O
@HN5YNFWP("*D&+FMM:U]"7#H-_/W?.LRH59^LZPP.#HT(FVTAU<$#_D_P>/LX,*N=E8O7%,C^Q\\Q^V.M^U(HL<6EU\
MLA/N)IN2;^WX9RNE+AYO"35ADO^'5RVGM)A8%Z&>5V7^3W6;D$=?T?]"ZE62I/<%]0&] $U^4Q;5+2N<-AF-\$;] M.: _LEU.'IOA1I,#0]Z<6UL"'_7GSI?
_M,HU(1M6\,@6KC>^4E'I[67,W M=5 K#;Q3ZRN,"OR(](T8;E8MAVD>N7)N[] <,P@F+:[#9;MHF\F4_0$DB M6MQ-1.HY6X9)2(_M?%B0M'W/;B-1R-4]BL],"N'=^X@0+#2,82A9
0!1PP=58_7HR5@%]=111&(MA&<8@B7RW@V)<.)18%%!<$,4L(@36"H_N"$58(++):/+HJE):(&%L]/@GE M=3P"+(F?W)($-[%%LK/;@F%$X\$B^07MT3"CRW"S32G3-
/P>+AI'S%MH&@9<,(Y8 MN^U9I'!1.&+C\L,L<'$X8M_RXSMPL,T1NY83O8'+PA&C5AQ@@XO$*2L6DC,% M%XU31BPD\00N&]?
L6$[2$UPB3MFPG$06N$2<,ET!*6B3RABNYX+\K'@ G'$ M@CV73#;&5>FTQ(FF,4BHG]^<)#AF#U\$#[0E4^#?(%8;96H/A=A9Y4!,X]!;
MPS+&C*Z6T@(5F%KINY&&+SD]^:R>*Y$*6?<5:Q0D^W4I>&&)Z/(N$S:Q9XA] M3X0KW:_3E"U2Z7Q9,F,R;^KW]]FA,YSL;ZE*E#0OYU_+?%JB5XE_*KJ7]JL MDH1\8ZI^0;
(S4CX4LS*A V+(>7Z'(H0?6591<\9SKSZTCO)@N]XFMV'V>YCL M3Y$7H^2FN*Z/F0F9;$@&?X;Q6+>VUJ8'<%EGI=P[]]3F^6_0]23!-?F C"
M[\UL5Y+GEM1Q7T'U*YFFOMB2\;HID%DR7G')IW3K5XSC2^;V-86ZE1WK870Z MIS)02EQ3^"XCPLR!/@$8(%8&G^H+!"^HP$6BZ71AIYB:?)@P"*Q--S04R16
M(Z4[@CP@,_H3Y71$CH;>8#H1EBLU:&E_3]M%#$=BOT.]&E/_X,/V(ZHGA7 M#_XTS!>W(0;.%,*FWM^!^?OW!_IR7]D+W.$7M_4>O.$S C1-1^+R>Y>OMRD!
MW'BUFA3U.^M!C/(HPROV!782/FPR+*]:]WFY7(;9NCHA!3RM$O%9.=;;Z46 M4;"B!V]$D80YH>2S&I"4<.Z#[X.$WSUSX4T"=^N9#AQW"3S<-T T*=[CP+ M^L-)F,\9G9[L/-
LT[;.]CL'@[%VF\+M9D]0O2ZBY9O>!_#6,M\,\H^1^,=(-M?.#0!PZ]%ZGS,1*-A]]^/_3],W>)57(*V<40.DQ)SU+G\G M"/_%[DE\0?^4Z=.(KK=HD9*$S->GY*](/Z.&*IL=6@[
*OW2)/I:XCK)]TQ M'MTP;'Q;/BSHGG$*?)NQ?7$YXI(XY]RTLWN^7^?1;YXQTNVT(+UY@.D*B'],OX1&,)X/#HQOO/:HQ,>G?#H!1>M$!V I-Y MJX]$Q. %R(AP!+1X [(L = MX
+]".Z'($./*-T+"@C8OFJG$9]H^3'::8Y7"L9M#0 @I'B602)U@G&RB//28 MI#L$3F0&C\(S $:=VAZFK=;9BU;$9B0F^IY]).^O# MOW!07?D.-(^O.H NJ%U0+5'*W1^X6)R6>4&6*!-
EA,DVUPM'HCG;)EJUDAC M!C3=>K,;EG*.4H':>*C:0]4>]OJ0M8>]%6H%=P,FH'/&%9ETL'0(W-YS14H2 MZ)/XK9((X2 MM1,:Y)<]))-

$QC\"0VDN%]13KZH>GZQW__PW1EF818OU%7I$"6<5 MR#4V,ZZ]R(55@T!MS(SB,EU15ZH2Z0?NK@IH868$GP]PH-?*PMVV.O6A=91; MSYMML +S@T=JE&?
N%/")-2=+I9AD[1Z_D,ZG&_ET(Y]NY-.-?+K1\%HAQ/Z(M/-+FBFP@P /IX.4[+)}F?(DG)"Z^YH]D)/TN,H@I[8KP_.5]8:I%.[A%9,$D M5V3"==N(G*/DBDS$R4ER(0-
7LO]Z'&2P@*\K$N]D.$ MPM$U5_0%>B)8+#C2905A>Q<40R^]2;,AW)EKP"(9J=!A,)6-ZZ]$6Y@([@ MT$6YQO+R9ZN"=(GXN](O Z NH]"L*YLO=&D!T\[!8OG1;K$ -F!0[JPK*PH2
M+9!.;P<+YR>[A:/C]MO/8Q4!-&KN"M0F>?M-(1-) Y6WCT%>KE9)]9LP"7 Z M(]FR^ERP90UXZ0W0D\9K;V!N_,4WU67S_#TS?PW%R6LH/FG:AJ1IG]2GB,^# M_/0-Y#(X>[2A4]<]
(F+KZ(%/G'QP-L\@L1%GQ7DHP>61P\LEX@.P,IRW-L# M5AT!]^YFFW[\ZJ< IS%Z*%#,UK\D9-7<6"-*Q6/ U-*@2F;$@YE>YS=] MQ/YTP]E.O_YCD]. S*MAV W3K?
ZAY%=.^*3^G_XV(RIZ8AFS'. MBQ3@5D.P^(U.&"5#5R3DX*.58<@#3TI_W.27_X\W/XA)?ELI&OUK^KYP]G?*Z;_JZ[6F\HDFMA ;YY1=)XI!]K]'3X VU!3OXU+X: MD]^&Y -[ZF]BH*)
VJ5OT_'3A*@JHC:^@ MT\[M@F3%%*;@7%]S7/,?=^-3^^0&)Y(;'G+TM:0\G#^V84$@6I-2E.'R:R%8B;]>)- -W1("@C7W48,SMB*MZ\4U.(FGCN2(5 M7T+HM4PX&"]1P2U=D8O:^6
MN('D1610_0U>-KKN'/]088PXN\B*[V+ M?]@.:9;PSF=;K)&O/N&:M)!+D:G:-/Y&]9=7[;F*N?HBHL$WM2=Z3;V$6"Y+2&VD,78V[F9V2 M)4,OZO>:F#!1?$KR(K]?
4%/V)*2V\&VXKHX,X57187H=[R7!]8_T#5'9@&P M;$O.HFDB,<(C]\Y&,Y'F*X%T*G%$%]P]\VE^2W&1W]W_)K@2"&BC^;K:=I\X MW$DF6<;.UVK?.%F_VDN]C76_NZ8Q:,Y4?LI?E--
_46Y/2]W3UQ)2FB;;7 \5Q7 M)"'6!@I"XXH0A.>0A$_I2B8(/UT? +^.73E IXI4S,P5U6A=+I XU-B% %<+ M4&C7E11E?[OGY9B'N-5A\1I0>]O)\F11'3EPEF=&^ARXKCEP0P86]>?
*O7L;_MX)12H: (GY#L QTMK35FQW$Y\&EQ1_-$AUVAZO&/P%"P_:)-RJ/P"5X$'-+$ MASI]]-.'.GVHTX.>-]$/[L->$;O D]SQ$5U 1A&M.?]2*G MM>$@3HD=L MFD=+?
_CSU]H3CNGGXLL866T\YO9-(OIQ]L 71BQ0DZO27I7)NC= MVX>/[^BG)S%9%2B^2,)Y Z?MQ / F]*\3K-E6@!9W=-JX10N4I/R! NSCR3' M=>@
=PXBMW+56:L:L30YT0#U6IW%:]UDX)NH.EO66N' =AIUEW^L%0SX/-.: MK93C>8IG. KIO\,H(F5E,0I&U<^;4EIVM(9-MR[,.K]@$W\RV<-LMFXEUF[DMW6X -N]P_H5ZHK^E$I1L/
MP/'!VG=> (=C&*(_O<5*=PS=;M@0Y'V(&^A-C@IS3$W2%UP)U*U;8ZWCND;? M#MC*2$K_&=7H@\P(NW:CMZSFDL<=7?]0OT'F M(XW/2OD)K"@B;_&[(AK
>$EG]]J5E0034AI'RY4$#SE)]3.G7G(6-7AH& GN.SM8'_&J\'2_+D@7:E0'N3 MORDW32(XN,NDZX(=#@6*2U:CLR&C-S]9'_PD A[[=.6A(0=N#59?%FE),Y'M M?
+]8##34=N6AMC:HC:]#8W>>/<+F$3;/L!U*HN5L(T/:2/H]L@]!AAY16]}N M#EA;4:5I0; [^I) (U1]]TA)WC#4WY!]_5SNB]D:9AL MYX-=N+HBZ?P*/Z*XFARZ87]"9)Z%]P4UDY-
)AL(<) KU'_0.M7>H;>;S^!S] MUA/+^_>?_;^L_>?O?\L]H\[V)"NJ(D,N*#6]G0E34,LT=YNF7ZTYH=@%N(L M> P3:FDLZ4R661WM[X;>0+O3B.;
(L>31'3/H#G260&B/W)1K\GHN*$N_X[] M3?1@2\#L!*8;GDWQ6*#;DD\U3-4MUIE4;%$=WBVOU?G(TR# MNS;77..!K%!6K&^3,&4PY?
G7$]\].T$P*GA#0[D9DRBB%@1XO^G>@:'Q7::L M\#?]U]>U7DF.#M;<(SX>\;&9S^-#?.#F@H=\/.3C(1\/^7C(1R870L8N$#()>N%*K0V;YR3E=KM3H$$NH&X@
EL_'LQ&FVC99CZ/#UKN!F"= MO3%\1<+T,UH^H*R)M68*E9@I5Z%!Z"A@26CRE64T0:]-Y@3FA^(RS>E1PF3< ML+[$A ;YO0Z7]'&;@I(;PE_A]2\],*2-S-6-8*M1+ 2=>W&
(XD>2;29S^-# M$OF'F<,/69XM)@AQ]P@LL>[*S(1@X@B(\T59(RO'4+GQA4QZ #6+ M!;7KXCBXLFA]>F@7KHKRTB0HMT'Q-(/ ?],[6S*QH(D5/1Y@+Z6= OLA@1#
MNM((",/9\;BPF:Q0R R!@$[X5&M*K^X7=#\Y"7-VSV7)-H1ZLXL*_A]F:%? M9U:-^YY-TTWUAFP^] S@'7MDSR-[-O-Y?,@>;/?V)\'^(X6X/-)@1Z[Z(1= M=#<87=&;_M*2-
2WU^_"_!%2(].,LO2G\SQ8H2S(V5BZ^?'0[C3Z\G(L>7_> MC#\/G2603R\WY=K]VPF5;(R3DNX'Z)Z5::T0XO.G*"FIYK%73]@>4A:;5V+. M-
|.X15FURTB4C!OX0X;D]9(O5M$VF]3Q&1L:BB5!@$Z]><_?>_XV\WE\GC]X MC_?>O_?^O??OO7_O__M$XVN/X01[_";NE?5NZK>5?6NJHSOU=,^,N!DO0]R-*]^[OWT
M':@OG2X7G!_O>6EZ\NX,T7F.<+T%I+%LUE/]3$*T2*N93PO57?UYTS=@= M6C&1[_/+/8,GZ\T?)9*AN_3F74KO4MK,YQ&ZE* -RWN6WK/TG]7W++UG*974 MV]U$6AW(+]#OA]-
C$\O3/]Z5.>^K*_753Q*#^B^XOG[Z@^PBC-*++)%]D)"'S]2FY*N+VVI)R M+0=@E7YI$GTM<8Z9VK0SQ],AHU/RX<%W6GNPX3]B\L)CW0 9]ITI]2"YR&
M*=T!D]U1>E8O]>GS%77(FUO+K=[729EC5B[M8!:K?V:(7PH2W,[X:-]+< JH M37-^B[*(G0MS>N[^3FK+I"X9!(FZ,K.O)) M9PO'%0F),220V>0*,@)0&* CY(I$CAAG%6RA<#\4+
A+"QU"!-$%LQB[7,8 MQ%L;HQO&:U6WQU@K.%D'L.]YU$9^(!8 %*/TUFK0#!WKG^&,^($,/*"U1 MSY"-L!^-
$1P@+SY@HS1@L['EA$&'HP@UM"6@TBV+;I=_;T/"9_3H3FX/7"Q.R[P@2Y35]["IC<@>'-7_%T_#I].!2O=D"H6N\T^XZM=(8P9[MWMI9&Y9RCK*!VGC$WR/^'O'WB/\
[@UWFR&@W=05F70XYPG^F?K2_6]$>3ORYF%?Q7GZR9KV&X$RX(7$ M0S#4&+UBX5"]*_B6-O@U7I2'#!T1I6ND?@ >]Z M4SVP?
Y,D/@FC+\,,"]B;D4$E6S;ZC&77R:!#L.2>RXCB/=R"R77>Y6%FGUIA.X7"!57[)." M^T<"VBQEKSZT[W#^Y02ET6(99E^XTP!M9G@L MZQU;G.F -
C,]EBG]OMPP7K8P.P+&C9Q2O6ZA=P0;(^@57]PC#MA*ZTC8,_67 M:5YD)3,V.4K43FB0W],PR]8,_UHRVP'$^?,FAI)!GK.T386^HR9_9??'^W1I MT)AX'5@QPNMPR5_@(G*#O-
^A59E%BS!'$EKVLI&A6=C!!2=[Y.#?F#KBE+?U M%7I$"6?%RS4V,Z[+=$4=KH]9#]R]%]#"S @^'X#%K\]7,732=?M ZR]U_SA:' MP$CAD1KEF3L%?&+-
"88I)ED[+B"D\REZ/D7/I^CY%+T>=ZQ%.!B11YUKQLBDA 'Z"&R#KLK,N$Z)T3. M'7!%)N*$/CGXW)5,V"X'&2SXZ8]$.FE.,R;@BDADK4.92(+[2=1P#,D5?8$> M2
*PYWB2RT7A*U<4@V^]"7.#7-DK &* 9FJ!1?*#W2+Q]0!-UP/\:+=$Q K2 M)2+HBKX,@+](0H^N,+[0I06\<0$6RX]VBP6P 8/R2%U949!H@72]-U@X/]DM
M'!TW1G\>JPB@L>CNCJ<5%#W?YAG53ZI\NI.Y-'(BQ1)ILZ"&$D N(GE*KS M'JT3SS"W -5Y4^,6F/@*J#H]>322ZWWI69WYZ(P ?]G]]+$QR O5ZND^DV8 M/"M0N5^I"?F.-
=:.Z,]<+S:ANL:POX'N[X0Z?2?T\-7@%G8/2?R#;SZWW.>6 M^]QRG[AI!U[] [S^P3?%,07+0Y,^IM)[VPWZ?0[_3]1CS=&#P6*V>KNZ>C# M.M/HW,LPY!UZI0[]"YB?I(\H*S#=-
NI_YBSEELW\+O7W][C;#U&A=-?O6 M7?L:M,C:2R8>$;6SB^A$UZ6RRDIPH3EIF3A"%6\7) D(=]P.F<)@S@M%E.4 M,V2PK0CE@-V;'79&.;K 65YC<_Z'O\5"SN6H[G MBV?3,IP
A%\:5!@7^ G%IXLPFR/&WXZ7IN&TT0[*D(T@W7C*]YF:!7B^/QI MA=(+4M6PD-\LNO9A#G.[U<9 M"N.;]/W M@WLDQ3RRB??#%.[S6?
40W2/]436UH0_KQNE+PS:2&^2=BA*3&$>WX;KZL04! MEFMLQ:SLL_YCR4VNL:458V*>,6@(C- 8QW7 L ;XZ*F7%_DU:I=\[[4AWC_1 M19E?$?
84W4UZ,L2@W!+G"R;1FQF3<.LHA.T,C6>[==(%RHS#TS)CX=1)&E^3 M-*L:D1H*6A,5VAHF WQ&HGA%LGED>]EV>(7;04=[ZC+.]$XM&^EM:T@-CR]@I62YQL;$ZA09/Y_Y,
MC9^D\^FF=D_;D Y(#'+I2W?KX?LV(Q%"<;YYYW7K\W(4A-/"D+Y0NZ\V9'/N M8?^2S)NV?Z1;S<0 -O/Z(WQ_TB21[;7/S_3> 3A_;(O]@VA-
'?,&C8301FI&VRIR1C*^H#=I;.R5)NR(:P$,.@O0\5R0!.VPD$+@C MNG KALIYPAG]WP[^|6H'Z797WA4#Q;^D)@4;#_72H.4GCHF'Y?Q3-?ZI&B?+RHDN
MW:@[<:T5RE6/FPK]CAQKQ06\HZK.[1N)9.#7W=69;R,1E>2U8'6&C77R4ESO M3IV_Z9 DI0OG];,R'9$]O]E.FO53E%"2R&"Y?*+&W(!5.]#6ZZNVO,#/8OW MSAW3OEOY!
[BDW+']>==?X?)PQY9O<@KAU[KA$G/'I ??UX0+9_SV.T^=.EV8 MAPMQ_";[?A<'U5R!BV;|=G<+&--;_0]ZP<7DCG$N]F@"EXD]YG>' FAP,;ECB$M7
MOML+R=!K6]\$&U0G">OV365 L4,_21(*$A/L7]&L1+5"!HS#9#;[;]UP]/U]+ MSL3K78,P[E_Y4OK*E\'G/O;*HU2-#L>BZ9.^CGVG"L]G)376YS4R#!]#]+&O MZ^QK3;TD^/!ZA%
(!X3_"<123.Z>R3 M->*]MRD@'8"9:Y*B3>=G.$,1[8C#CYAZ$)9&\W3R_8+NFP\L8G)*ENP.Y693 MSUC9ARHK?
[TGV>2!3;Z%67Q>+#_USF'U!+)09XZI'NR=0S+\=$W==LFWK9E9KW*0L M%B3#?Z/X@I5Y>Z%UNQWE0/T4S<=P;-DM9MUZWH,/&P5YF>FVX3P>OH/-)AF+E8O_]XFY?\A]&;B?
ICQOYM],&X M.OJWT04<37&1H)O9)=WY'G%,3>4667'I]'/Y!RX6=RBI]K1\@5=3PG$V>_2@ M-?Y3;;"-S ::;1RR79>7<.:_VR#0&[00]/^4S'GS& R#CP;^7Y!,7_'M)2Y&A2W1NVJZ(
MLM$<)S!#>.PR$/NN9 '<>Q2@N<^M+MVKJ3 M*T6./;HBB3$VL!!(UP1@O < MDO#'W4^1 D*%8U<.T*DBE3[ABF]T+A=(S&3L0H"K!2C+!RP.R]\U\$\"O1SS
M$$_!6+P&E#Z%9'F%>1T9U):74[4 M"@5%^(3RGK?.@+UIO&\FQ9&_:::THF--ZEZIXGL7NRXK-1L&CZQZZ5W*"(I M*W1;;QG%!:(;8\UX29E;/R-^,>(!>S:5'N53?
8;$!7RJCT_UL1DY&PX\M!0O M]^!A#Z!+P3%FP$Q^%T2[$O5Y$*8Q_3EEQCRBH^AO-W?L7]@[$R9X]@Y-1Q?]#&![O&Z59;&,*08[,<:^T, M'ZH'(7;(1"]//?H;]"YH R/_)DE\$D9?
AAD6L#[1=F8/!%?],T/]RO@=L9'TWY=4$!MA'.)37!3"%TP./D./;!@ M$E@8GL_R(4=?2\K#.7OHDWO'DTMKDFO![60!M6G.^9<-1?0>AO(PU'' 4*(# MF72V/UR1D&BC(]+
[BC.2$>)W('//%3@3L)2 /M/8$X-E)0*$4%Q1% #N#3&N MG!%'YPW6Y;6C(SXTVLLD/C[4G&+5&S0\HLSQ@1'C8TL2'S*$<$39W<-CA?]C MMQ^"#-
'CE\XC"UEF850$VPWE('(&;.5ZU1C1+8+8SX^]S0^>[J9"%:WX[3, M"[)$V6Z97*91AL+\V9,4UZBXF=W5T\A2)>9I0U4U%5T/-C6!]+D%/-PD -U MJ17CY4Y,"\
[+;1/\X,@X/MHW#M%2Z]>)CY'YY%M U&.H7)^](-7ZO5XGL;C6XT?VV2D M"T7Y&.3E:I54OPF3 *?5/7KV.?IO%MT@67: M,Q#PT$<=-
#E6EQL^6.42G"]0_(F0N,T9Y!.,X9L>%2)N*4GPP2R7=^&WSU0U M,AR^4B$0K1FN_R#9E\OT-B,1RH5L-Q)[4.,#&GU C8X[] (6/]*DSP(/2TLQ%]X-G45H$-]-NK$,?5%73"B] %
MT2;1),QS5"A (&2_: ?#\30&D(-I'5];Y8 M2C<=UN3DG:$5R7&13RI6^%=MN;1:N:[]1D)8;B?4RN,S=3!)8_"T-@4<, MSJ:L)"&?^6[<8G"=:X#Y=UP@
M3+MYX]QE0*X<1$8V6!KR;Q+8"D1U,-NMP]?"**+RBX-5N*8MD\]D>D IFF$5 MV)3,U^S I>0Y]IB4=?DS,I/%P225QA-+N>D9NR$I&4KE@>B-<'U;2W-Z@0&
ML[H3L0P!$.\MQ'I?"MB\IUD]W$T/Z?T-#OX0A.T;@5C5L=QU4'*-M/?#E@2]%P)?4X>)!+P]Z>=#+@UXMGBO QG-.2 "X5I?QX5[06WI(T3!)*W! M(T3&I#T!]W"Q.]RXM;?0)C@P/"
(&^XX=6)@,KQX%4X]";0_O39VKIMP,(=T@ M;.Q*BF;U,F?UW1["Z LO60S>:@ 6:SR^%L,VQM?^XH:8VA"$"5M[?<%+F16N M%T #8S6M](:
IQ.Z[Z81NE\@5%RQ3P]>\!"0&^>=_XB*L(%>T&]55?E+YU?L M8C_PG1%8(P-9D)(+@=\H>.?A2H?>?1D=N]G,0;X:L&A] K] #TT.KQ0*O" M$YG(GW^NR ;P1@7(GG$%:(3HBI2?
X8I@=,0GQ@*Y^OB$."E7C%LXMS+XF+.$ M4^+<@N%*1FC/'D=PHA.PIBX]\8BR!V+GVP!R?C%81!^=''=R $30+ S8I2;=7 MP?
H_FC#0UVP*WLAP[$,XBD,XK9OU]6Z6),,GKQL.P*@EKY5WAW-@2C],[$1F M@>E"\?V+Z%:\B'YPH+8N<"ZMJ=3I9M]#. 9P._VQ%)FI$#?P$12?*TT'@$\ M5'Q4XHBB$OYE\?
ZQ"?]^]FL,:<#WLRV7B(])^)C$,#!\FTGHW$KI!#WWELY8 M%I$8=@:X$>K"%=8"SB!G5S_8_&,P)R3^AC?W+#']5CK'=)_<5AE+$1L_26B M?PSH_ 91F&5KNCT$X9*4M!\RV_?1#8-
6RX1&:%K'0#QBK12Q/L%DM0BI:QJA MLL!1F)RA1Y20%9OD=E@8WFH %D_#!#_4+WO?DZ1D_^5D^XNIAV")DK!A?T(I M6>*
(QPZ7<@!6[EF)^03_71\E:7Q&3^QTAB+V8_6>%TG:N9-NK!+S5[N;@$(! M.C:T/AA=GA4'^!S].;^1T!_8^VTY27!<36=U-#?L)V)" WPV;L404]VXYZ?-
MQ+8@GML_&WHG&\]=F=>OMY^_(!G"\[1./XC6TRQ,\Z2:W4]T6]](ZV-0\AV8 MB:C6\EQ(H6@-C[2XR,]?2(]BFT& M'P'R/P $,,F(C#DT=GG([=\$=$PY)Y-7\#[4L!\
[@@U;+5*6UMA%TB'V(S:) MG!.*.!?I XDX%_@ "0N";CEW5P,D&5F$5-VU#9NE! 5KG5M="M,3QK*,+$Q/ MH*8")C']?E;8&%-MPQ>=.ZA!4I#% =7M(;7:G*>QU4KSL4T YF*,6>/N0Q-
!U'0E-NDROZ18Q_8:21_29^]N+M@A#KSZ[J:A> M.;0LS5Y]C67<4_KAMG!-M\Y&,_)O9+!Q?R/VC_H.L5.9.&]XWLPN<1V'"..\O M@<9N#4G#!TU'&*]09AWX@*C[5&=>-
E80!$+\3*Z9.VL!S3T0:=.F5P0H=@] M4(>]N2&_%FM3X;TA=\36Y)RHBZ:Y([@F=Q8L-_G*:+;);5"$#BRW']VYX,=! MQ8S'%AH2+%G>)9W!99"0,!TFP"#[%7-
1AFZ<^E"#TE##/8I*N@VP!71&+4\V M,9,TOLSSDM6;/B5YT8BX YH%Z<\#\LE6^155DO9K9,T4&H,7LOK=)8+1;0UI M@IR8-ERF.3T2&/^<*Q'MA ;Y/=V(=E))%L1YR)RS7=^=IL(
M_VF1UX0=-Y>A6 8$[#B4'K?VN/6 N+7TF>#!Z^,!KSE'+9$]%ER1B1C-%ADH MKN#Z?.T0FM6NB,$7;+,ZPF-C C#<$5"P2'ZIY9)2Q2R050F_G<$!!>O(7BE) M^#7.W;B "*3=:;
(5U&6D V6,RWS!.C"7PZ4'[#\F,%R[NE'Y,X;5V3B M P@R 02.V^F*&,0*(38B79$%=,,06'ON!U9\M1T?6_*QI2[B@>$="N_[^'QX
M0<@@(M3A2]E$V+\V13+I#SN"G#E=49@O@EE"ON5!F89EC"D)/';2^Q-Z@B<# ML>FC)VK?3%^2K-C4V[R97::/=&9(MKXOT*I_2*:E:U74S)':
(:&.$$TB*%41NF]^NS>F7Y8H:W5=4G55'U-DF &FD=!Y,U^__SKR5^ M#!,V27>(RA5'=*-A?YBD\?-?'%#224OHEI3.SW"^(G3+^Y21K
M1/%FYN@6UR(5G2P8>OODV*1LY@V77D.\K2I[T(%F[)W-,U3_=S?P\Z?ZC80[M>CB?SUC!915REF;"4(SL#%%+*,+5;+?&'E^3:.6Q%M#-[%!H-ZD%*]$>QK3. M1U-!U# Z+
(AZ@F:49AH^M0A.H@=3(6[&2,XX0?E->O[$#)82YPMF_-S,.'%O M83M3 WJ]%TVB*F\SOPW7G+"BL)VA8EWM?%%K%-'UU&5(^Z9635-&%_W!0[P>]]X#1X>MQ=KU'+K-
,I,W$$;>Q1QY[F= MABM=LU@/K,VVX9&+P# M0Z8]G$&!8G;OR(;QL]TA+WK,:$,'=LUH X/=9A30D0WC;4#$Y,;9T(%=,RH/ M-7;O2/=X]WCGY#'$";,=I^24+)#-"C
MWI3_14@W:LI&3*T =FSR(/IF8E]%7X[?^B2\8"D: NL4TL2%"R+#\UFN5DG% M0YAL)7>9SDBVK!.V!&*7:^W.U1:$#;, M,59P"P(+7?KI%'?WD"Y7$L!RAC^U"#1N0O%7$NZ:X*5
IO8IIV -7B(!<4,?NY XM05[VHF-%8(<6G2"94%VY M ,.@:J%VY*7[HK!J4!LW"1Q!0:D.SHGE8*NP!8T5ZV@GR2[9S(Z5S&E"UH/ MSFQUS-;K(8X#H?9*B'/,]E,D47CVG5,E7(:19O?$?
5=LG%Z;(_@BARO!H1YR M.%S#<*/6)K M3!9)>7:_/:K.*1ZC7MI64@0\.S\=C:J;K0L$GI"?92=D5;%&+>^L.+HZ5E\ M##PIOW2;E/-TE&:)R4IEZLYH&SWA3CIO-M\/RS/BH.[8?2G/6?
T!^:*Q26U>;-[E#WB].F9 M+A&9+AYS>OQL/I\W3BR(5F\I39+3#>X./:)TO_N^K'391*.WQ&.8I72'9>;Q M-F6WM5H&E]8HUV 4$HW^82NN4F\Q"EF1SXU404E2H"M M]
(XDH^*E>\BLM2#$ 86A,C_[!$^&GYW6UCC5A;TY7B?$UG33\ GE5%FRD-]3 MU(/(UI4=RS(Z6?8$22AK\|NT0-0RX!234_5%HS+4;5]@^D*UQW\]]L(6Y@E,M/#^C,54([$!0D&)1K?
1!^NZM MD1'LW+X-(VW2?D5G2.(WS\7'T8\&2E,\;S+[I52%W\A@=2=F]7,?OVVDT5P& M*$=A%C'@[8R:^PFI_2D M^7GERF3A3U0SD68^*X=7\ 1T XVO4.1
=9_$(-343QYI#OS'%V7;(993D+E MZ%9.;WY3%GD1IG&[R=6Q%QM&^HHY'H[1]0_W:A])/!M?SLC]0HFF=6@!LZ['?"I81 \>X&KLVB%?%<#7/+-4$L0B@E]MS6^3K
M<9(!W3SGU@Y77)QXH%.W=6#2X(1;CNLN(@]?<"6['*@2,G'#X\I$DT +U65^ M6[N7"(,%3N5;2\]D/1RA+NG9QB4$CCD]2#LV>1<*N/>]JS3W;AR7X('+2BY,
M!A=2U_N<4ULW((G8,UQ*[MB_&E-OX.)UPJ &I<; 92)M6ENKFN<(E8?H>RFT0:$VGA,I&VI&V428]@(EQ23EC7O<++]EWSR0]>%PC0UY*5 M'5-UWP?
T+8LN_DCPV^$&4)>\@4D4EGV M6K,B#HH#WZ&DMOFI=<.@=C8+=#5=D$S]8;,>/9I*!#QX](,[E:UTIKB%YN?P MFKR\&*UI%+NJ)P>\L9N@+2-H(S>E,N?
5UL24EZ14U1MOEH%H[4Y%'P>7)E]7 M;MC.*[^[M?[\)(VKGY+:5MOMEE49P_:T5[4?\W*3^UCPSHCD[E!]V7WK3G%/ M*SZQ_I=1 >>4+8=3=WX_&N3W-
L0Q5>E^YEN7KDP=PCOO\<4)FS?<1Y=]XU/; M88_O'KZ35\L3_@]ON*U/V&_DDXKM,L]+%)^5&5V5=7F]>ME6?[Q950C_^1/* M(IRWWFWOWI$-X_T]3$HDM[%U[LB>\?:?
7G$_^D?[;!/@#><9H2G3H ?'(.-@ MY$F=H(W]2"Z(",;8) 6Q5>*<4+A#)F#TS;E\7ZA<('Z> FBL6*R,EJ4''7Q.Q3 #*G)2=XJ>)^R2@$(T1N%=XIL=VI&<[= M&\-[UUWN/G1]05C^,HB-
&ZV./"6M*=TI*5#P/L@IXWB&HY#^JM@SG@=YM$!Q MF2"6O?RP>90V"-F3]CFN*6(&T"8[:8DSNP?_I)X$;T5L^Y<>AGGIX;7&L=\|
MKQRR]_XN]5:D<_:F8[Y]5[DQVZQ7'P.P_^D+FNQ5])U%'MT ;+"'?E/:>GU? MH%6YVHG@F63:N>O0? "F]TM7X2(^'*:6#Q]Z/T$/M\F29 7^&W8[HH5>*_K(S-0D7%_4
M%C:,@+M^06U,U =O$_KVSX:T9+0INL,FLXXKT4BCQ7$D^6Q'7?!89O]_53 $ MM-6Z(B&1944Z&Y*N2$B<>@2R3EW)Q (H#-"'=T4B8@4!FZ&NB 2X[_:#4US) MR)
(15C_PSI6L+,ECO8/7[8INZ2CF;KFRV)PZ;&V4M,V'5W= 62L*#N[EW"[! M%000#M?I]0MPZ_4?>H=M89S\=M_"R?X/"@/(/IR]C6E6^2?M M@=:&/ZL,I'9?0*"P:=_UV0>.SK/B
(JF/^UU@+U^=(_FC,]/B,RS<+7 49@T MJB>(5CVW6[D>\M"@NR#:XWE8U8=C?#AFF'!,CYW,!U_<#[[ ]ETB=9R,729B M,$+BM!H[2@Q6D#:S?.Q^M[0 7GI(8\?FP
+@^P%C7P@Z45I+EX)':?NCM'V\ M /UHW0_!+,19\,BNE09+%.9EMBDI?_#[,(V#*,RR-;NU5/^*S *Z#U1]=,7Q M5'Q:(*GCGU_;4,ISM7]2:F841 8I4Z5=!76W_!UAU8D8\^-
+)FI=$&9K^ZK MG^&<;=%T5/Q' KKUHK=Z?5[@)9V\F]F.+]EA=NE"ZQAWW)RL=__|-T89/9T6 MZROVSBDGR5NNL:EQ?=XO,O9($*_L,;"5F9%7;*7.]?TPQPUXY$:Y9D[!7QBO6]?
L%/P-EPSCZ5A M/VT9 +"5UI'6\N1+ Z*!*O: 7 M5^0F5B>QD^:*+*!;M,!"=R4@UF%)=8?Y7!&:U/8,!@M=66$#6) B+&_LB0DZ M(_)C*2%H843>QNLQ4KB>_K#[QR
O5ZND^DV8!#B=D6Q9%P5?962%LF(=K!)6 M7X.!$.PU]U75N%ND?:"O:0RN#\]QCZ>;B:\:7*?)TEU4HC,.M<00$EI0*Q!5Q1&'_3Q&IEGXT MZ\=@3DC\#2=)94+A7?VS(,QS5.1!BH]
L'MC#7_K!FD-^4F-N-;P;'MPRPRX M->1,@A"NX55'%\RUN0!7U4=D1: 7>"4 O,0M]":KXQ07Z H_HGA?VW%22?;@ ME73 &Q;R';UZ!=/\D$_6G\._2'::4-WBW9N0[\&6$59%YN2'534S5-
B%P]9> MUM?ADI_.W[$76T9ZC=]>R^ W,C1GU4WZ5W+F J7B%AXM]6AI'[1T4#/#0Z;' M YEV.>_)0$>/*S($9,QUM:I4S6:DS6VNH_ MLGZA@O7R2RVBE.IH@:Q\'WX_$/=
(ANC:C4XKY;"_^'AI*(ZMA?,2!;,JM$E M;'1ZHP/#<&1;\&#(4?G8@L6QA6$F>KC0PY"*IPD..CQH;F8O]|86> C6R"<2 MMW+KYI/-
/O'8CL1C#TF/$/^RY_CQB/7Q(-8^R=VSR>+!)'3#!:)$2#Q/()E=ULO*<4Z0!Q>V_ZL=&? K;%/E ++T5YSJQ 1#]9["P\:NSU?46SSR\Q<2A4(]H]E 8$G?;72B.9BG0S#-,
(IW,67?]:]KBJAO0YH:TWZ-_(W3-%9XK'N8['IB/ *<,77#]%1[HH8?,]L AC=]FY+?Z(QP4$L N4H(J^[N?^->7@:UT0OE+.B!>!+2$_64+-E1
MMCFRLS"=5_ITLMZ3W(;KR@UALC^O5&KOF^15G:CI(DQO5E59K0N2S1 N6+2. MKD!,XA:9:.3 5"E=Y4,LZ6K^_^'Y@M7.H09F.$>?:.?%&=T4=F\?FI*_%'.. MS$LUP-
R8YC=_WDG9VJ?V'?ES9':N2?I(3SD47Y><@U#;]X,?O'R5RO>CJ_*U M;V.!L^:NUH]Z5EQ;*[]7XS9FY3S_O'O&_?/QV:?Y'?FS:W;RMN'O$88TODW" M5)CDH_)3/AW%IZ/T24<9'
_T*2K'DZ+2C+42G3N?*Z(41_$YP+8KV1Q"?9* MR5U)[VB5B5P(RQ45\0D_5B?\K"]+GWX_*VQ,SC"&+]I;?E[BT]"7 [7](QF3: %C@'[W6JTD0 ,_CU[E^R/I8&G_Y/5=&6 . MGH2?
N]F6Y^F1*;T@D@V6]R]>WHH#I39FTM<@.:F&%H1, .K3Z"6^:54.O33? M/H'>3 'C0:=RH$1U:>6Q);+72 $=V(MS
MY_P)91'.T6V&H\&3)X;D:52S\!S)]!Z^521;SI=&);&;L]";8LINI%ZF18;3 M'$=*$GI$WS-5_62X\:C)B6W[SMBR+(W+:V3YCZ_'8> $ 7Y]_+IHL6PMU=O6 MK)K-\+:#4&H
*6%B7'+F!F^T"%F>_T2?A"OTP?I=5K7L*Y]5%!3AO]%99A, M4;9\SY.T7DY\33F32;P*^"31E\L\+U%\5E+C>5ZON4IK\NJ/+S:^5C]>NB.@ M8SZNS$B=\)!/6CZ>I&7_?(;/(#00!8-
B!3Y34*_K"X9T.)Z;A98N^H2!&V7 MNPZ$5D'FGXN).=" @<_KTX(Z^.0]+6%;G[5G*%*K(%-O!/K='\Y0EW$W2H55 MB*S#O8^.CIUKR8W0D"9HL=$L35PG>&QGK
MD910]R7F?':*)CY?.$^UDWHSVQQ9]79WX&NU#$2R%T-O@K9P^8H]WCXIU0UJ9 MO-/3=5:W?"Q.>.IE1CNWVKBB4@=0J4NUL_85UIZ.ZG&ESP'P]^-*@ ,!^S:% MF$-JKU3N-

'Y$08ZB,L,%1GF_[A>M]8_-J/#2-=]UMN]GZ,"S(KZL"$IEF.V:/F];\+S(Y1]%"TQQHLVW8_=BO;LG+E\NDB+/Y_M&9H<:%\[KU(-S03_%2VCGBD!2A>WKD2!@S'<[X9POAG!!1W
Z9[_F]G+0V^R_M)&5:M"48#-GWF*1RLF[N@)>,H?Z+%DA0&**$-O/A1O^BE9K0E*I-W0>LCBA@_MI6$S)UTW35>$#_AEZ3I370EZ:-+;'AZ2*VBO3DEW\.]<46@?Q;,ZBFF^8N;+]^!
[CL=_M-5?G3RQO#YV@%,UP&Z_HH/:@D_>%^H!"?38%#^\<#[SCBP-ZKT(^;TM\41Z#<1Z_-@"1,7_'_M+@^Y;9]_3B/G9/(*HH-:DF/'HV"K144@_M84'_$74WD&V6C"S_YMRM8YC^
+$^YU:7PA#C6):1A2%&:\N/\&_LK8&SB*0Q_M"W3&[%\;"XS^L"/(V;49=HLF0PM*QR[,;/(KJOLX*C90!_2$S(;E%D?+QLF_M7M8;XCH]G+
ZFDV7W\UL&CZUX%V<%H;*81Y3X>";8H&RABE@3%^0#.%Y>EK2_MLR"-UM,L3/,PVICXU4])??K$?Y5YP=:L8*K5?LP:N6T9NV4()>7X64&BV^IT_MFSSDU6-_'035H7)[6%KZT,?
=5B:WCR@XTM'"_GR08*:2[<"PD?6'_*]X<@0X\H_M+5$0#XSR9O#"AU?N61[(X^+_M-J(!&/AWF,7?6(&"-+XGLX+]LYT1(;%/9^^W:8*2USMOQCY5W:Y4=0&OMQF)
MRZBXR>Y1]HBCIC<[162Z>&2OVV\^WRY0(:U/JP<^<%BM\;KF3%H9T[R6_REU_M/ZBQG-4U:2BKDSQ']/_B]B!$AYX,Q69&
MLEO6LPK:F+&'+SX1$O,.H0XM;1H1=T^1:]MW5!N.,A1/BEN"T^(RI=SR-O]8_M(W1OB>/A$=TA%=H_"U/?\NSM[#\+4]_MR]/?\AS0V@'&X<>^IB#R
(15G%LT"E.PQ_($LT_!AF<5#Q#EU9]I>5#\BAI6_MA!Z1-3*_]?X;_]]MF[G3YDIK=N379^L-$V_:_H#,G[YKGPF$:(.-Y3_MFN;9I^SZE%V?
#.N385U.3AS$DO;9BL>1K>C3\SC@J$_/\EFD]O%)YOYM!"?_M%N+30GQ:B,52.]:T$/B1!013QRX4G4D18]E;?%*$H:2(P2MZV2HU3N1#W8;R_MB+
('8J<\A&B^NCUF#%)ICQBHLUBL73O@B)6Z9#V+=48^,*DU)ZWEA88'VC*-_M4)_O$"KR(*]T*]8!Y1F3."C3D)XAE&!+>.=G*R2_8_35BDZ\^E0T2QZMF$01
M*:G'=1NNF359ESUM2X3@$QOA^PY%"#\R;JY1_>.>UT3W&.@>'%_A_$GN,_H_M%PZ_3Z^;^W)9)FP/@)2';1]3EU[TCI0Z!$5;A+7^HZ'G6N]/"[3FD,8HG]0B
MVIP.@A2*#_.?]:THTCJ1"JXC3,LC6U6'X/D[(MI"W55O=C_M1=MZ[-P!M)!YO6UP[[=!-=\Y9=I[GM,U#HO,#V%SM"#X.3B$YOD>[]&8:R_MIM?+_48%[E!=Q#U?
X!4_JPS00NL(SC;^7WTTTA-QLU>BM@D0-S#+_X$U(S&(_MYE9:1W).O2VR1[C2#_DK#MQ.ZV@N<$]]M"MJ=%$A%V$Z9RNV5I63]>?P+Y*=
M)F'.RY+KT(,M(]QS=QTN^04"._9BRTC;EQBLD=[,?$+B;SA)6CA^^6?-&?G[_M%U9;^&LBT1HIO9*;5^6B\H-9'HO:G!H)N77GL+LUQ;_5R_.L6Y_M=TS$+?2/H%%E>0/@-
M#*_VV&5B&.-X$QNN<=*_=_DY%HJ7E$+.A7K&^3D.X;_M;_=BQLZL(=_M*P5_FU\:ZQZ:3N^G^4^\]LFD"7A[ZFY?T^M#RY[@+<7)&A..6W,_KJRL6=_MGFH&CO.XDDC?
4UY@3]@5_=)Q\Y^&>(I_]X=QJX0H(GI'G_MW!+BR]4]6VOHQ\FG-SU!U'!HYG&7$T_M7Q(_B^-'NQ4#=CIW2VYQY;26'GV#F\2[=N7*N=U'3I*9M:X"A%S$<^7@[R.J44]%*QYJST4HO-
ZCSE8P8#KU$98XNQOLJ[_L5BEIL^I8_MD_8D'D./N_ZD(.6E(2K#\@-==!N@@GHJC7-VD&C'"8280*B@S803#+_BZ].M02(=5E3K_2.P8'ZV6W%@I_BQP2&R!C*O"H$K![:
<3&1S[5TYM:4]]>[E9=2=_MZD:BR5)NNS#WVK%0>T<7%'3Y="^J]LIUF[^P_WD(/L6/O3__G=69R+\AQ#=OZY6?Q@_SARS-_MU@WK^9>?1X\7U]<__Y_A7SY-/?P8?M1R?VE-/6]^?
G;VX\>/#S_D#[;S?"8._M!H.S5_),RW_HW$&3M0=?QXY)'Y4$H7N&/PT?)[_HQO+9]>?\#\-'+=70W/4G_M7:1]>+9?SNA'^#N2$OU=(W$*\IEAN9Y]:6CYO*O'K0P_*Y[]WV\WC]H4S=3P
M8>/5:^.AU[X03L6P3,-"_,?SP\V9YZB6.[&=F>KAW<6_)7;:0K\MB\M!\-__M)&\H^30R9/Q]=HTG"6U!:HM2^",+M^V]S=%]$R>]-Z:_$GY"OB2'C[N.E_3\
M\].U+RP\!STG;OK@#'^^6D_2G(T>T96OOVP^77+P:>_K/]0;-G$4(=1];76'[?,Q<=&?';CC]8VW5D+692_MW*9(PAEZ]9#E&F,3M_1I=*!1&F%!FWA_M.%BTO<5/+?
QT;7ZNH27@Q]#6%_*]3>.?))^L/>HD0-)QUEA)LQ>6YR1-UO]P_M?0]:GC_#35]J$#/,LZK.8SF)?+"^_XX7R_QK#^F>LR$GUC"%/SXC'P<"26O+
M8FOX%^[3%*GZD/L+QWWR#,]$0T+.D&B_B*?'[!"^73F?T8?^__;;>XKL@@4_MD,Z-W[@G'_27&/3UX]LFU.?%,%LA0':Y[+@[.!9&[_\:UV_Y/S)"GY];_T_Z<9+.*YNN'-3
MQ;]HV18BGQFOYV2"R/%?&K].+*RR\6O\Q"UA'4/S5_;]/1"]K/].MKDMX/\7_M_9>B1,6FI1+I@;GT_,K"^_YV@??"43_M%$%0/IVM32.;:3V@9\,ERLZ[Q9\DS6KC]>&W]\<1=S/Z?/

KI[N+YZY*YO_M+[BSB]N,YSB:(4O'_WA?3/6YQ?GZ^)<65N#G$^,5Z1@1IAO,VGA]:8M"9X_9_M@KZ;\50N]%#SOABNIIK_1]IS9>F7F'G6!Y=:PW9;D/%W,Q[^TM86L^7X]_@G
M,/T+?L]='U]N#?\AYSHT67K.P$IK2.1$TM!?"%4C.H=^1Q,E29:5GB2TUN9B_MK$U@81G^V]\?+\/I:&+U?&2:]@^B)K_86&(MQMYD88XT*LK=!Z0AXT7%RBX@_M68LC\\;?
EM<1A#5A6[>]MHXT8Z9B

!8FQ"Z)X_M*'E!,EF0+(G'+4B.7]_A%-(P:!8FT2Z7:.[@B5";_[\V$7DQLO31#*L9X[_T_M_7O'GB/'>[LWL8S!GUUAC3*?I5^KU.4%N7OD8]74U"MYL1+?$0?'+;;7.Y2R_M6-8\3E4';2[ZPI[-
;.O1L[4_;NU[U?FG:B[0<@7"42LXDL]Z_4,IQ>+D!P?M_M_+YIT_=T<*;V@XV;_04D[^^_8+!T^&QA4'^.6X9_7CAO4D#YI=QF0[;!G7_MKKM(QX0.K\@RWQ7D(U<@9[B"NX5'_$]B?
A>]C,.D;S&$D_<*KPR.5)9])<,5_M9$*(,L8R-W6'@M1Z+9EX6@Y>VF\&-B;TMWPV0O5G=ZK1FHR8<_P._T_Z"4L_MK;=:V]"22^L(8OS21&'3K]_>TGIBS-
+D%2#EJ@*R(XH)2^NMEE910(J=^*4M_M_2E7%I_=03Z(UWZ_L+%#!\(YY!<>#/>/SV^?D:5-9ZKSQ^C5<-O;'MXW-!LC_M)^Z;)*A&OW2Q<#T;>]=:S_C?C6SH_6*UDR0@>
(Z]2;^A_;"7_'S=SL_M38PSB$09"IWHRTLTJXMUW-HB($N\!%9ANT\(@U/7[__OC>Z-E!B#P0KG$=_M'NL_\H2<62M*L!XYM8FLC)PWG>L+YPVI3FN8&%>+HWU?D/9I1Y_V,>LB\
[JQ_M56LGG>*7=(T'Q$:![X!=S,N%@XT"/P*T)%U;.IAVF'2]#YWCB1>SR-$/U=&7_MP'S_$\3?Q$XP9=3O>'GNP^/W_-)/)/9\-[G&)@UFX(5JTN__6-;CN9'_W7/_'<
MEKLFKJ&CWQ%VH",QCA>#CJZ0(!FVHVL[:7\UF>"=.%[0M:5A#GU27PG=L9#_M"&^8?FQAY'U:G)4\]%3O07>MK>UA],_0\)>5+*MN_,7VT:&OQZDZ>'G)FEA4ULV[-
L#Y$#L',3U&J'\>7)0)#5+OY?6^AW^VU%[,KM<6_2_M:2--"D'6_KD<%@<<_FG.-9XM8V)H*OX0^U3T_M?60:,\.BIU^>C=]Q,+]QJD?VQK5-0P\^\?"\/]!YA_,\:-;3B3B1^DJW+4ZZ
M>EL1^FI[..F,VZJF#B;=3G>L2'A3OENJ;=H:'4JSG;E-3N,XIK6S!]!^%W_MR><_#&]]6)"R$)L;X]<%-/KZ:(RE@8"GM1$;2L*WD]5[FIXC_%N=R2I+X[Q
MICZ$^VA/N+^*$B^*/6[BV#/NZV]7=*&I9D+'4\.3PS/A'O$1,_"RHIRT@E>_M&JYA46F&WR#G@XYMJC'[5-5XY;.)Y4Y?#QAW^R4>$69(H_DX6_M>(X
;\4ZU<%80IU>OSW0!TI;T05,!FFBM?N:-!FC@881K:&D?_M=T=VE",]_MQD%3%+5N[=C>VZ[]/LMM@7T*2OM;6]CM]*BMV504\1,80%U)<$&[$W_M%C9VN\/WNW)NF^U-
L3F5PW8+W3Y294%KCSMC#*NQVFVKG0EJC\7N_*$.TCKZ_M@/_J78C+S6W7PQSQYP)/D,Z9+!6:.0O3<[>G2U:8#TI01Y_TNXK6EG4-,ZNF_M]]IC5>FUT6#<[4\&G6ZOWVD-
/ZLF..!QB8SC[A^_N]PS.1!%>L"G$Q-I]"^/_M\U3G&7D;,Z%_14^4\5<0R9-_+OZ;9,6%]AN'W_M5I\MIZFO'J4K6_WA?Q+^'0YRMK87R[TA9AG=&-\+#7]_AE07VVG#8'@:H_M_
M(OPL_)O\1.Q>TW!@A^9L]!G88#_1R!NN\K7\H>"38_<,FPFC^=S$:A8[LEM[_M%TD].#(L0'@(XD1LT8__LS8&H,4_MB:S6Z+NC?PQ;,G2#5::.[4$LYDG&V\AUD>=^?O-C'];NFM1E
=D^LEP4V,>_M>IXY[U4@17QCU?]3QX.]$M8Q@@@'5MLS8GW8ULHM/&)YK>$R?]B%Q=ZRSOIP+Q&637VWJDS;;U??+F);)L&K+9_ME##?.UGSA;G_T^DS'IE.?>L?6%YMTY
MC\AY,30_%AZ\R29R7<<[CYOU"IYKT\\2D!MN'=W,_-VZ+3)NGT,"&5.343Z<_MC"*V9(PYD@(RIN?&@H(L,=P8R>4_.I[*C0>3,7-NW#I$*C_JP*S"86UORI/B
MV^S/WMZPPU/QHC%X7571N#;!]MN;0$;F)=6A]B:0L1;V)I"15=VX%E\D&7_T_M_Y#2.Z&;>$_@[.5>HPFX1BG//135BU"O58^*_S0?_5X$5%B96".@I0NQHLHGFP@:0OS
M(G(@+@-692YK3*@1_?HB/TN@=[@E,,C6/-PL!%(^IIG=&]#!17A*52$WZ.X"_M/:7B06&_YBO_4QID:Y6!E"[&4RJ>;"!M"_.4;EQC3&IJ\]3#.[-Z"#B_"4JD)NT-T%>DK%_M@\[_S5>
IY1E.B!(Z<(\I>+)!M*V,$\I!^(R8%7FLL:D8H2@+_*R!,HKJGHD_MD4'/-(K.J2/C?&.[5N/$_M;5I^?$;HG"&?G0Z;S\CX#]8>^-E'S2_=D)^0-K5LTW]&XNK&TP%%^U%TV!XR
M#RH]"JJ4^&H_4#+Q;%8$V^/91!_-X48]T+;Z%TN3FFP_;6O2>>-$OOW==R&6_MSLB-K:G++UQ;+_@MVWE[I-!\.:<]D9'^9%_8KG4#XTP7C7E:11D_XYHXM_M#<8]8F-!"%D
;)UEK)K.^@N-W;5RMH?PD'@;Z7_[;&[^(6P_O@;8;D_8HL_MY*CFR-)'^LRP#=<S=[L=_BG\5O6\Z.RN_@.;ZY)_F-Q4PE;BEX;+G_(03"G_&;@7IX_MWJ;Q7Y\R>$T8_]8:$>1/_%N>8YO!
[SP9F#S/=Y,G1[7<"7+N]E]M6U\?/?P,_M*\.1=V\;EG=MX>\QRANDUVC\GJ_@F:#YZ9DCN<%I8&ULT.]T-MP)@@V%P_M^G0.P-$,]^W<@]I8*C_FQ<&%B4;RD]L:]LS07)_!]90<$E=GA-
>TZ>_..O/_/OIS\(@D8(@@O5-,8.'?'1-A?DOZ#]&R_MDND.C%\XXQ_(R?5DR&)Y_[!9@E+Z577T'ZJ#2%ZO/?'(2XA655!7)=(1HE8@_M)LH3$Q"]:JY,@"@6"_"(9H$P@*@6"_:(;H%
@"@7LX+@2,ZN)X.6PRN_U1*4_M5O_:(EW5TEM+_1(E'P2X0"(4*Q$@J-4X]H=85D-Y'>)7C>9]"%N!#(!053-Y_M'R)4#/'\4Q<3UXLE"T_EOFJHHPB32SBM""=46ST!E![7#0$@IOA_'PF-
YC_M!VP6YP4#3H_W*@&?^7MJM<)E4_KI'L_AC5KE*K5LW,]OT4_"6BNKXMUUM4=7_M?1\.W9?U(N=@FA8#Y9BF0E!YI0&RG*\:'R"E1>816;4'D%=!4C]R@A:@5B_I)7_M(!,@B@4"
*)9(_P@]@6"_-);(!_@RE4)00"55Z#R2E6P"I57&JNWH/(*2_0&_M)_($M1K'_A#+:BBO0_RJT7P/82N0_1"].B;O0X2*(9Z'RBM0>85!6$+EE4I<_MS2[_>FM]40N55ZI8>:6^>
(3**RQYP8#3X[U*P"?[E5>8PB54T?!H'**U6$LM(6_M%_9:W.,)/S/A/]B\PDR<)6#.0\1"YK7%F!_+<.S?!G0Y'/^QC,\G/4WF_GA_ML!\$_1SX-U@_-
/W$GRG&A\HK4'F%56Q"Y17058S@!XJKT#E%09A"957*G$UN_SKK?5%_M+51>J6+EE?KB$2JOL.0%_TZ/]RH!G^Q77F$*EU!Y!2JO5!'*\@K*9;:XAQ-^M9L)]4'F%F3B+?
+A8R+RV&!-B_8[YFR<#FGS.WWB&A[/^9C,_'/:#((_#_P8+_M@*:?^#/%^%!Y!2JOL(I-J+P"NH]1>Y00M0(Q_=$KD_D0Q0(!_-$L$_80U0+!_M_-$M$_@0Y:J$((#**U!YI2I8A66?
47VLZ/.IT3=_M4#1^?V0-9D0N)LZW-=3L!2;?V_GWQ]Q(%VS@(:3+O&C.DG0RD"X5UQU,NLRY_M;JMT%Y#N.*YCJ%05D*Z&NN[BMJ*DN[AMN]X#TE56UP"I*JOK@'25U75WWA0Y
M;,81\M"0^N^1Z3==]0$EZZ()@9)U48Q_R6KIR0O;TO#,_<..!\/IX_/;9V1I_MTYGJ_$$).M*HZ>_^(_T9+Z0_4Q#+C_GFT]L*%BU<#U[AIRM9]A$1A@_W[<9
MJ^.GI%TY/8;_8UM7P^_9WWH9!L9*G71^OT1C]]IR/6=!5N#GV$W1K>TM2Z/=_MV-:SAYP9>7()R$=D&;83>8Q5"&ZO+Y!,ZZ\'6=QVQ3-!]O8KRPA9>#U]?C9_M%5F7.QA\D@-*
[A8>^6W=L)]Q@YTJ0R%Y*56AD]I[@$H94VE-XF9%I2^]X?Q3_M-1?H\]LWI+H+QS]A5ETCS"MQG#>\R_H-D>L;LY)M(8<[G2/MS8;@&3>\,G_C;[$-XH0UK+)EMU92%;UJ/(U.D8]R
M8A,-,-^$.$5>R"JD(QW_<#BE7'O0@H!NX%BS1*RNNX_MMC1[AI;I+FL]=F&[WMWD43599EB=BX@$Y3974Z_LAZ2T2"!PS;,E@<_U3Z($_M_M<\MW(7@9?U*P*;I
94CE\2:&,@=6/T,I"Z,1H:2-T87?T567ACS)&EC_29_M81DN3;A_0?6A_$$K!$T.0_]*T_*P"_4)Q$*,%&6#OW@(K,E2C)64I9P_Q/_MW.!R-
GM0R[]R=L5P!16P*UX!NV)X@TK6%;MDG7_R.UAIE8!;^59:+OF'8*6Q_M![6"K33V<0566IVL-/;Q!E9:E:VT4_"UL_P?7/]&ZHK8,_\BZ'#A.>?_#K\;_MOAG^3;Z:')P5B?$H=*
(O8VK(^/WELS^)>46_M@0TV^I_([,;CIT9@0Q+[Z_VB:N1BEM]5Y@&]V.8+YL;USP*Y5"M,*]^)91V_M;L/HHHD1.$;DT@;"3M5]DPF1WQ]4Z]DO$O!-?
35FBUFH%]>VXSUM%1+X@>F$_M;5)T8ZN,7Y/(@^X'*>'ECK;&Y,^U;$8(7F#/(^TU/4_M.D4V)D&=50#ODIEQN*FJ,R/99A$<#IDQA9M>9JB=0@0KE]Q=A3.AL4^G$L!
MU^Z;*6%)TEW;G"VPHX0"8.\'=A7D-_"[DA+;3],#8_.PRP9V@,2LXZ!I(,H]_M%'-_YNQ;X@2090H5X05I^Y815G=U!HK,$NZE'1RL_;\6P8\3$;N.N6!+[#%_M&;"'R\?7/C59-
W57$WWC]\K9W38'2)<57ZZUT-G-EVN/9G.U<1^=P:ZHNEU1_M_K[V=F:KN*PH1JIGU5OK""L/",.L+95T'1VH6*6[Y'LM8B!=\6$_RH:4(.E_MBUNUBL+7.11.]5('"]
+X4OT_D2CXNQB_YN7O"_5EF2Z^\WC]P'#YZP_M@Y%V1G%;F9N6#>]PB);=>#0#6ZFWM)6$05L6P+^MJ7_;.]B*HRA@&5]0-VIJ'+HIIRO:.AMUA_5D_M_0_"_;7I!<5!6^AC2"
<NN0ZE#VHX>/!_3?4Y#LF;D>RY1_H"I_M%6"B5M@F9'9889N/%G-*>K?P"(AUPWHFCFR5(92\E'J=41YQG@+4/9VZK)VS_M@#]HECHHY_P'4%)AE.3=2G$O8,]*A-.U_D-]'8"*=6C*
%2LDG66U%$!]%C%_M=@A==.XKNL6M(#];I1LY.2RQ>Y<_M@*KD_6N,$,?>V)90V&N=W4-X4'?F;DX2V2O%L.';B>O($?_,93_46N8T_!$K9%]_M_DZM0;K#83H5SAMJK%N!N-
75L7O%,1"W7F(9SUHW2%/4%T2OPA]>@=RK5\U<_MZ$C_XMBS"WLV7WCT_N[=Y$IU+,-Z=N^1\SA5'?3Y+?X'*%1&KKN8(?W"MEZ0_MX]+O^Z\]XG639$#&49/?W@01B$-
WJ"%:!+#89"RRY5@"%IN,1,;\8?I]KW+^2@Z--!^)!VP.6(J"PQBALC(T(*&08A8VQ#@&%#*.P_MS-NL0&K5H\QXUK0]>.#R2XQ',!6_(_.)7F&V"EV;=/0]3B]]M#,5R%W^*?Q
M6];SHS]Q1I,=2:Y@_I6]$I82C-<+B!OK7T9(&^MG00@;RVL[R-U[X7MS&V_M*^C6MH)M]2Z'$Q?3;/T+)*Z]#@82UUX/_XE9U\7&Z[F#3+ID=VK,.=.P_GBP_MS26-
)U_Z8#O/9Y(@R&<._OB,/-?B5$=S=C\I--&FCCN2.I8GLC]%C=QI)G_!4V4)%GN_M"AV16[Z45B_EU4ME[,*S>ME=O>RM7O97+P?+EUUA]7(U6G/P6I:]JMM&:RV9=!A8GT]753&TD#
JYJH;47!4%/EKH;AAX'8D:2^_M.(]!6T>1PD7AE_WE2WGU+H8I"^M3!V,)=7K]]D_?*&U%%S#]I(G6[FO29(P&_MFC#NJ-OK4P9BB%IEH*Q>=E8O!^'+CB"O7G:$YK?'!@*P?$&]
M+&CM<6>,$3Y6NVVU,T'ML=@=(-1!6DZL'>]L'>I$'V.!VU-$G_;ZB_MM65=P]),TWOML:KTVF@P]O8G@TZWU^_$T+K?7U*UWU=6+SNKEUV\OD]G='VN_MO7_TY.+EDK^G2-
6I]M>-ER'W%X[]1%[@_W+]\VQ8YP)^A.C\MFH:S].YB2;>1VR%C8?^K#Z=_MC?&1&ZO:'\^.O;#T]N9'_M/PS=FYYSHB#\#3]G.WA#SCG+MM!'+I@-_DF/(_(@=CPQ^_$$_'^1,9<;OOS\
M(Q?=>^O?RYL[^,&!?PW-\C_K>B_9S#W!*;JW-1:DU!./WFVUHHC[4D__Z2._M3<39$^Z'&6YWXZ4T/:TK0G5.P\\C)\.UANA9'SV/G^]BP')KH.8J%X1
MECP6LT2*;7+S!>G8FNC]&YU1+YZY>M2DI'8%)/]L9+O%1]LW^_M"&E!9A(O%:)3^I>*1,;UI-D6SUU^N/A_)S_>$.51_";!R]_!MB1ZL(O&.WBYF>$B-LU3B_MX^O(.+^T-
5H]G1PGM[C_07T@4C0AK-3R,P%>7]K8R"2%/T2A_0^]@E>_/RR<_M:[:T]4>EM0^F7UK8LM20:61%8*_MA4QX'T+^L5_=O-_FVP..VXZ'[3=2==,C6,_A;3SL6V;8PQ5&V_1:PHL261S
ML$_0_;@-ISD1@/Z6E;,[X^$_OH\>GJX>;O[-/5S=WST\A1+Y_OO#X_?1I1/W_M=!>^]7AU\71I=\N),G?WP(F==_I[NX+]_3K%8<_^OYP_71]]W_M7Z^XT<43^5@%(7+^C-$_.?'M4+A
M@C"'Z'&'HGG[SRH^3K6'H7,?OM&=XCE/RM;:NOK7?D.JTD94"3')K>(DT_M/^_HBSQ'GBM=2MD.";Z"<8G1[7\5*^\)*,22$9E6S*&EB$+$O+I873]>$TE_M7Z*(W#!G-R4E=
[BH9$I2;K%9L0+:6T(P$,TTN,+]_OOOF.O(?\]7.\4,NW+<_MN"\&EG.W]GFR[7M%#X3(<_@SP(*%7>5KQQ%W._J\]S!ZNGO_\HOGKF\#3]XP1+R[>E4UCZ*=!*T<]&RX
M1$QXG.IR]AQIY,A6YPR+,SR7TZ;4M'M?4E0A'Z,D2^VVM&ZBQLFFA3.V/<^>_M10*C?TNT:_9\5>[_;=W%:6%!CN6,JMN)8G7?AA)K,]Q-I1YT>%?KX-D*XW2(K7:ZK6&_M??Q_OR=)
S'U%N^%NV^3[>:9*)V:9CH]PJDTCN*?P[;738VO!SN/PO'<'5#_MH[:7/:DG--!?WCX\/B!"VH..H".A(TRHI*2@L1Y5BWCO_3O]_4&QI[(XBP]_MDPY;*V,0.?Y]IQ(HU5?3;5-
E;1,_4$#_LUL]CG3=(1?S_/_<&!82CU6-DD3'_M%"5L47+_0]ZWC%-@XV;*C5Z0M4"^?MR*PT0G6C2C%XBCBDGD_595@)<+_/+.M>;)_]#%8^ZWAC?H'^F&3H/@Z,OA]\8=@?
&I7W#GWV&[&6B07LWH_9O4._MS;_M>(?-_]^8^U[-L;NK"-BF%B2I#^;T,99EL/DD1#%W,/"-N6IRZ!5IM.0!?AL;_M%LBMJ>GT#].-
(W#+U%PJ,@;^GX6+;;^W\F^#\NXUM]_ZDMBJZ/+>)DH%H@Q%^-J4L$%M#+&\W)<'I9%5P_M8V,ZWY-)_7I%6RZ#/]]=E\02HY%YY<<(VR$8+G>!RG^7&LM%M@>T!A>)-G+
MCX8B!^GD^*CH425_Q:?#NE/O^W+-7H6P=&K0)SS/'XG\!SY__Q?!_MV2)IO$2H@31MRFFFZ@:)A;"Q9F.B.TD(C>WV9CV\QYL%L:IK?\U:$P#1&_M\6-JX'=6>%W-(\X:B#^12!(Z
4.\B=*8;F*H2.WZ)$;GB@M7L1SELW-58=[_M44WB&V*H?7].VZV_3U\2!+-O&\/L44++;?.=$#6M_MY.YT6A@AKJ[^N3E[?]NY;ZKS!_*XFYN+L@R!)-FU7QED-WQK2/JR:20^.W[C
MM"G".X,?_P.S$:+!6B+)(P=A[\3WW%1UN8EA8D6@FB;^D"1P$/WPY\@V@K_MA3$*L"_&2@(DJY@.T%B5Z_A(MIEF4:.M0;YF&0K\)R./\;BA#P[=Y"&J'_1_M)@Y8F/+G<._R#&#.\D
M?XUC##S\!?@_>_7D8YM$4_%?.,0]EK>N&LB.%6-^G"7]]ZV1@;;+7ZC:@1]K#_M3RI"AW_.MNX7_CTF]K"]Q+T+^4^2I0_!(]4H,?73^3->,@]V3#_L_M"^]$=H)L1
#A%)CM'8E9P&]2?C%@5,[$OX#9AFN&3AN5S)C86VU*H]**:_MKC_E4^*[%\.\C36O,LELE:0F$1_MK9MXX*Y)GWUAKHV]V.,^11<9?L7Q<IOHSL5])7C,L^?)#Q45GMZ?G.A"/D2W6
L>2N5?]%O#T2;-DC0-T'"3AK=QF@$@G[1=CXGZ<@I'ST"^&_M]5?/C2"@%?QEL(^\H5?^T]_=>%_*7,R=H1#R%A2@*1PNWBR_MPP
EYR*Q9K,QB?/X])^I9ME4S=MX2+Z%!Z3WO^*NX._[5\REOE&!OJAX*$)_M3"R\,INP_XOA4FEI]99FJ"8Q&TA>*7F8E!/622%TCIQX&WI\H)X3Y7?]^SAC_M%-R=#7?'G6(I>,FI[S_]]>?
A9X#O-NS?%V:98_]VKPX@Z\A-=HB)LN,P_[I;_M=_1;/BGJ@0I+FEL@/W6A4?YE3!N>$(3X.C:=1?(61[-TG,;1#U=S3\V9GL2,]&H=TW7]9OW&)*MG7;
M.P>/K#/,]MB_U%_G$DU[/"*+/-=H1?R23CM8/]"9,2C8(WTT1,C?@U+/BC^_M5[46JO/&27UZB[=33IRAD&HY.ZOSY%_**DZ3R$[JALOOCSXI77_]?-O\9$9_M_^?.Y/O!I:O@GEA^7-Q!
[.1(5K+3-C:3_/KT6_MT9>GJX=S3C5_MJ&_N)H66=B&$@'04!"A1-W;FU\OXQ?&S)D];EZ>]BQM:0"SX?=UPYZ;Z=&NVQB?D]]EDCV,H=Y9M^!.NGD5+5#,-I.?AQL_.
M@([?QPB*@568YI,XW:RD\/_@(I4U4@X4_B[Y+9UP(UZB_MI4M+:G%8L/NOQ>5:=R772G]+O=A\0U2K+!0:C2"V[OEB/B?1<1=\C]8(Q":G_MMUHL<1[,^&O$B#U'KU-C;
RW..'N.L/W)=EB.+:\NUG6AE.C424HCM[P_[V_M-E+&]#ESP];BA07:&,L7WT!97^E0].>[FJH?_RL_7'D#*I(!73(5MF>2ZR:S_MN[$#L7P)L68.'ER8=2D@,,-/;:1/59-
=XJ0MP_4V!S%Q@T)T:I:_M-._/]LFQCCB'LEON%71@NOL#)BN&;9MOUT7OFE*5$?D-?;$*#I2_/C=\LFJ_M\$5D;4,)F*)63$&[49"K"!DP!#EQ<]"4],UY0=R[&]MUWW/7]/>K@O1@-
X8R_MH+Q6*"?IV=Y;)BBGAVM3V]21XP:G5=P5_?F]@#S8C*&R#^0-_"D71/2"TR/_M$N@*-YKJ3B>F_2,;^8A_C/N"?\W=W'@&0;)<^;_#LK!6LI#TX=EKI-Z2AT@6
M50*RXX(859%__@8,NX#K.L;AI(/B<-*'X_#PFV]ISQ2_R]232\/5%GY]8'+U_M962IYIMK4!&^@CWA"S^1D3SS@-R%Z4OYZKEWZ[LW%($Q:LD8\D&,(8>,\0^2
M1VM@X4Z<.8)Q_(89_DU8Q+3=!7FE?]^)85@%Z,8SCU]@V+7>-Y[Q/V(QZEZ_M58KMTE4-I1[@M-HX#00E)XL?1.Z"K##LC.5R]YM53D59;8O*_7]20B%>!6@_M3?P@_=H
;06A33]$.+O];(XR/H?;Z]+_MK.&SM06="EO%)(&16/IB_F$OUK5@C[^H"+ZLH0"/1$)[E_4U"G1;_&35!<8ZW*MS9Y:&]N*-T7+MP*ZFBPW9].HP-H&^8=N01?9#%_P_ZSGXQA?
%J^.:SIWL7_M:G5Q?6WCO@5[A%R5NU"I/NV[1ADN&M+^U#0]D2G>^#%^6+GM5;%HL!A:0<#_M>^%BZPO_]'K5T-SS"X=RZHR4^W4+G+<\&?E?B^B:4("G!@652/Q5M&6=$^K
MO+:J344[2X1#;YL1I#RXU.GP7/BO]Q^Y^+:BK6AM\ZQ4;(QA$S.CI$;M)<\B_M)HDMSCXM=I,;=O:*[;U&S]]H?_[F*]\QIHK0C-BJY%S4S*W2Z0A6BY8%OE/_M9VB6W_ZY:&]OG0@?
HO5Z2U@M%88_;8ZVK1>_ZV0)K)F;##7'=R_EF7F)*7Z_M6>++956!R*Z"-@%<_Z]3*B%!P3\B]\M00F$#O,PJ0U-$U-%CX?
KYX>W@]'561&F3CC$=]_WZBRC$81AWKXM0IP$O80YTE/'<\]!H%1B157_M_;I0A'GKI+C"4F+?ER>DB!G)DB_%PCA22NY%-?UCIAC)$L:Y3RC0=B@_'G>Y6_M/[*2:%D8D
"SAV&V%XM902X5LU*?ET2%1*Z'&GX^8,>K=.LP[2#8\S[;#3Y%_78ACTQHCQVIX:NHZL\Q"?DM_:BKS0_M%8(!M6#AWV3E)/G94D,OLGC";ISDE[X@LRW&]K.?
4.Q)GGZ;;5EB+B')>!N_MD1ULH2@-DW_(75R$Y=#,_L;DP<'SWBDVE+1*_M+,#1E0^CD:73^CA7AC?_A5MKY-(;/MF>:I:D;,%X3F3TU(=K6;"T*_I\7V'2?_8\EH/'U_=G_MF>!1&/!RA\G@

O/N7*@3\>0C:F!-RZS=]=[Z?L]}D Y?EE9@;EC20G.^NW'4 MJ/EE+55A]4T:M8F4!MMZ.[1%.EM[;SPW-TDY(!+9(AEM0M#A(FM5,DQ!_[']"P0NI?6YH]
M0T_JJQ\Z2"\01%Y2RM%6U413Z1-@$<[QQY$':+@\X#Q@%L[@^RW_D;MS;Z-4 M5COP!_V.+'#(PHCU&G^:>H"JBAR>KJ*<:=F:),Z58[;&'9>"I\4F5N,/!_0 M0YEB5>-[JKU;(Q-Y
N'SV_?U/_8S@4I*#IZ-=QVB(J'*"B^T3J* MNR7.CD'26[\]F>\-RKFS5$UHECX!%GDC_A8>U:(5YHU^AY?[,JN\ :[AYK&@ M[P8:2_H7]VK!R$X4#SL.VXX2#Y3 FT^5)AXD!8L')NL+
,Y+P;FRX]BNRCCO M\W)WP"+.F7=$"U>!7VU;_V&8)MSI:L"U%45,&V@-89(V7M7K\2(KB<.E0[#L M\1O- O%W\P^(WY[* GV!%P:,L7 !:T#5.7R4E9MSPGW\YB,>4RW%Z09T@:3
ML5-]]O Y]Q0,]?-E?',YI5A09*P9%3:._7IWI^MI93P47NA#U6G M:#Q&=Z1F%8C1+B\H(HL8!>,U1NDX"Z03G>/8IDEK'HR1A29&+8/FS)V+[>'G
MU(4+KF9STWY#B.96(OUFY:B<6$5*Y@DRAEWN]9GNEZ]HPLX'7U#D7:QGOA.E^CVN7U M8^%W/H-2!($/%?9>*.&ZY_R5_B-N]TCQF9$GDI")^W"G+F*G[$]?K.0#+3-+
M69)XN5-.H(9)Z+(U&V"D?8R4/O4I8T82);[?*34/\&#H,N^$,E+.X0DY,\ZT M58M?]G68VPXA*U1S8$&P''-CO9.Z1M$CPL1'^B4:G]*/4VD-9;[7*:?Y4351 M5/H$6(1QZO)%A\-X8KPBO?
U?Y-B;.J[-*GHKX]P>IM&R4V+KY?."D.N%;=&E MDS1S%UF&[7"6[9$0;:BY965U':.&,UQW0?NR:[9:?!-!D!TGRX[4V2L1P]RH M!LG93(?N\P668$)5 /+]:-(@=9),=O$?;%?VV3SZ
7!7&MS=U.DUF8%;47A99*3\!WA^!X8O(WT# M"[NDQ&Y3M2*NSU1A]4T:M8F4!O-_,|-PK1M2* GKV9*O*I=4NO&Y6VF:&T5L MG)05#SNT=T1?*,=LIB&V.W-V^1Z QB?HI&E?=#I
%0S0 =_K,PE0Y@WPDJI2 M6['6=RVU3K4X.SYCZ-!F15%N/KD+C,0KG7).0D#K,(G-^"250YL398K-#M\5 MF<0F\PX.(]EK#^C%-E_P/+#^L1 YQ=>P66))Z+*"79VXY-^#CK=L-
#=Y(+2 M/8T@Z+:&4H\72G*-J@F@TB? (H+C4T..L(X#<'8N>\(?(==!#/Q/S&BSB+) MV!'7:BM1S7"#"D]DB@6DK=5!=L2G^AR>N7UC6\\$/23=)VTUFQ[?%R!GK4(3
M8!'(\4DJA^=N'P)D2%B#F\F!QDQ.\]ZE0)E0F;6Y@EFI7BW%KG67D.S%)SL= MGZ2^/P+&KJAD"/YLS0:8L5AFC"\$='R6_>GAZ]|(BX-:7:^N\8GH,NF^WB>?
M%9$G^31BZZ5.X8D<4Z5N4"KR [F<3KQQG=>;'/}YZX<-.SALV+Z #;T.23[P$Q#6AG>G]H/< MCS12B<D66^2U3PVCS(P ?]AG3@6 H9 M2QXHO#(08]?,<_A?L*[T:.MI@M:
;&3,>)H1G>>] K M13#QNUUSK<.]-V MW3]JI=K'U'>+CE,Z:H: H9>?+]]P\2_?WF#(W"+O;O*DOIXL1]I\5V)$X<6&
MY&NG!1O.&*>T]\2R4,12^URFGU]JA)U/'*=TFN'[1PHANXC%5T8F?&_(,)$T1 MQ]K]U"X43H^>;5Q0P)Y1.E$1&;/32P5CV^$UFAD'J4HO9.8-"SG\8N7E_!C!
ME8W+=J0'@^5KUB+EQEZ.E#%'ZO:"7$?98$EVRI8=/N>=8B1U J5(JMC(TC,3 M*HK;%%$]7[PVZE6$*7].>>6-;?R-_]9@
M0^XO"%8DNO'BOXI5=#]OS/'GC>FM9DT^&DK^8@1O6]JE&5A' M/WKX_1G^9?<#_21EC^8%22!)/A(H,$WU_[@>FD[=@_PD\V/]*0:7+W7V^_ M?UN.L5;@.F[+?Y88[2-?
<:;Y0_]V]CKZ<+LW4^]'7]_;G MAZO1;^W1EZ>KAW-.^7^H;VXH[,[))5FTMA4?N2GR]U4BW!I8MS\)]'_X>UN& M;_!1ZRR.!K]>QM/ S[,\G0)/=QFBG?3L$@]]/;8Q&)TG1IT
MZ.6/E/9^KP4#3L8V]N'W_O=@]V=C:.QS&_(5;D;%?.$ZMF.04;ZMC0L.I?#0C7 >!B1\U$!OY+G! =WRW44 M/<-W"TM=Z :>TOM"AS4LSIO:"Q?
[F_@GT*N&YAZ'=\'/%N7P]E%3"@0'3$(M]]F.&BN!:/VE1:(L6$8%1M#R;W>N:LN_?6DV,2S*Y/'Z,[?:.$*T:.13ORZE MX"?YV@IE2E9AC]6(S;5G33& DG6
M_J75:7%80_NOQ2WT*@6M)L[6.CA.B@4HFD7A273X%$^"YI\F?_2$-0CBON%W MIRYWA9E*YRZ1AF9C+)5DD?]TAF;#X%_C8URGS@AQPB MRF^EE7]%*OF-%OOZ\
BEE_68XHXAEPPB[73%2S\P6UM+'B)W9CS# MKI^Y[&9+$EN,,%=XW%* X;6>CG($@!\-02?#. #\('D _ U#GP5D'Q;=FTF M&:$L!"7R]RKZ@%Z0M8C6\V+-:REI(G_=-
P>QL)+$V_7I=AS,]X6-;!4]R%81 MVH(825SY_=ZQ]87FW3F/R'DQ-#1Z-=QV\.8WZM;NN^Q%D?/%L6?DO(9,Y5^& M-[U8N)A]D'/U]ID+LH"1ZR+_WK*Y'2E->Q*?
%l))]/@/:&5K(M5E&RF&;>05 MV\C58AM2Y$3FE5Y"YBF@E:V)5)=MY%AM(RC5U#:T-FT?]QO@FTL1+I\H\2] MFR7?5$_=B)T>+_4KPC='NHP,G'NPXS)>V"[M+>&
ZWC*1)B53)V#_,=]E:=< M{VX2"}^T9:%E7N@GY'-7@< PDZ(D ^?I,A%G(]P[RV_*' M?+?+R_V$@A-5(#!,I#*0[Q_D8'O] ?5@'SUSM:2O*& ?_UQ+\H9._98!_F5>$A*)^@'_?
W]XCT^Y.,Z9.AW_ MHBCQ2B>A+ @P #! ?@P0GSQQG&MU.@,,NGPWJ3@T2_BOWND3$TY5N:0 MZYQ<'C\O)B65S=3GO(9LR#*,61#EMF,(1NRS&8,R_B$9DF M-
DP:$.IEUHO9XZ'$Y=L=&Z(-J'SE6Y\J;S.(G;2R[W-T% GO:K0C4O(.C:Z M>CITB7_-]^0>()?=(5E#;EQ>U;%QT4R0*V.A*Y.;90+0K11TX_*CCHUH9@)= MJ<_+W7+3ZB&H69
;\159R%%-VFY U6>&9;@>"7F^(/ LF)44<6EEA]ZW#EX? M7#O1DWOJ%9N!EK;"<]ER*8N&CWTI+@_MV%.>$%E8.%VN M<'6B9.*%#F,Q'&: R\H\@(\$P \65\SGVK"D/!E)XB;7,3F:
R\H\@($P \7G M&1QWY)4'_XD*KTB,!?]802XK\P .PAP4G^YPW,E;3APD#!B+'1Z,7#B..]{E M_!AV KX=?M89=QFZM M):#V/3!.?1EG)]_$YZVD]!)/UC>BPOP@UPLM$[^XP,S&>_-?
E1K4]@2;L6./,UQWH5H:PA:UZQ7>UH_A,S_&+NG) M673H"V$1G)AA(W9IPZ8M5,+W%<82C!G&%,!8S]+K7O8P%OE^1]RNDP#C2L$X MBTYZ&<-8(;7Z9 6J3#(\)&LPS][(?O;26.;[
F-'W_6X7G%:/_%U>R/!2SE^ MF]WANZ^J8;WG.#@O$>'U[)@@]5=WB).'%X4EW:FPB_+QEV [V?SQH0%ZS/IUR M)MWT,(Q<[K192!"L/B8F0BK M7*!DTE,/N FPCH7[#S@5S)IK9>6#?
9'O/KEILDD$+V,1#+@@'ST0":M]4 / MP%'2Z4=)=]X4.A)C4YKWW&W4YQ%)=P=_3-"(*C:'#(3]P[MJ3S'2B!U>+'DFJ=PR;&!7+/;C(TK"W7TQ8@:@7A9?ZU> 6N IQHK>X+)=FQ5V(
M_'>QKD]IIV"*3XXYSEW,397W^,&@W%0O\!0;R#"[57E\'LYQGF+66ESB!;'< M\O6',@HXB?7@D9TL$|\@PZICH6WW.7&" ,%A177//6U^"Q.AN5?";GAN\5'
M?!+.L1?.PN(:7QQ[=H%_SK 6& Q!]0W;:GAW0ED;%R-[6W9!GFA9VL$)^.<^RE-<9882CR P4N MO3$\)&ML$)\&$CF+*/XO(YC;\TQQ0=1RT@6F=,* M<$YWNCMVO?
2[N"=C9*&)X;V'WD9-"PIE4T8DD$E!+.BSCZ:3KP1[,.ES (UDK MDVS]K.1B=74]%4SR@!.Y5"[@+?*"3D?!*5P3_+Z]/"UCGM,M!:DPL\'4?V5> M'B7/;?;= RJ+<"D93=L7S1;
[;8RLM4VZH^I=0?MG%+MTLZK)DP"Y#B1=9"I& M\DU#C%M@E6U6R:)VR\FLHM ;X:S5P@16 5:)LDH655ZRT"]RS%;N^1 M\TC,S,U(YE5@B(;?4R0L(YK"P1'-ZILOD7-EX8,,6<6
]TPNP'7CDN?W'0,7 M 7>"\FK4#_,",Y=OL_<7G]6?D_1; P+$LZ,KX_+&L_* 3@,\ M^$]FS!WHO+^L[*!SH9[(-J5-@'L%<$[%YVUEY02>#O2E^$&NG0$REO%6Z ^(VR?SF;8;*5)
MJBYG+SS74RW:"1HR5NO,/S D$!.&!&+6 ^NN=]J>"6!XS57648:0#N MWM'=ZLN5W-T*6T,(W W3^ZL7S)DKL"X(ZZ,/CUV-;?_(P^K81/2/3V>Z M\>*_BO48?
MZ8X,\;S5W8EDZ:GNCD%6W HF*0<%\,2[4T0S6Y1P^_,<._Y7[MU!X6:?&-K<(TXC13=3$ [I]^_]VUB2U!^%M<^GSP#N5M^E;@@:[_WI>GA^4/
M1D5",!DN,DCHP49_8#II._;I6^[\9&&3).[_WK[_=O..>*=S9!5-K86[T_ M9MP]R>&1EH /L;SV.OIRNG3D[T=?K]]?'ZY&O[5'7YZN'LXYU?RAOKEA(6;B MX5IH;?4?
N2GRMU(BR=J!__^30/^'O[<5&@@^:IW%;?NOE_;3IDE@TU_NKNX M.;P_EF/HACLW5;R;AF4:%FJ/35O[8UT)!'RZ%&[J-W6(K/W)L[76&NA_!!MA M8"%LD#"
3T#RQ.;RXC!^MN9Z+HG(LT(XV".,^NE,'1Z*AGVBC]O'TDER M.>"^S9V-XVH?R/[]A8GCE7@<$-B-B1[V6_>T0GKCC_]&?D.NRMVHF!]4SW8,
M,LJUI6%9."Y4%N)9)HCJE8#V,3";.VB*GS->$!>4HKP.>A(5.^5W"TM=Z :> MX_M"AS4LSIO:"Q>:-^Y]K/Q"P)6MO +6HV9'(%_IC1TBJ(*+,,N_W;F]+?_V
M1=K$L"BGQ^N]W;KC"/E"UV(0I%%M^;H4A9\BQE-%TEB"7?77$9%+KT?=QLGQ MXA.>3&1>Y4YD:XM.[#"(L8!1;/W2ZK0XK*;]U^(6>I6"5A-
G!'7IDC]ZPJH$<=_PNU.7N\),I?.72$(\$>-DDT/]TAF;#X%_C,B[> ML8Q_9B8"C)](QB8[Q2?+!U%+K2RK\B-8BCL*X/&;V"NF00:;]G;\5^\P MO0L:6X@Z7X_9B_NAK!H6OM
M+P%4I4KCSHK3_?C$TMT5IW?V#!^]](9)#FR?[M:7^?1L[4.;71]WA,M# MJP+4(M_M,9<\#<#<6FF0#[+]P/XO-,=Q>;+@7K0XD71>8@SFP^,^!\'>=QI?7W MU9DN>
<*R:86%0%P#CA/A7,I18GI&?P-I&]YONE#4 %Z[@+7R MJ +$702 >R)X\^\%[(&/)H-L+4K=A0S2P=U1X^-QW&Q!Q M522/=8AC1%I65D"?[TKE6@&;,DEN]%?;4.
[9R3QQR83'.KF9,\]0E'FASJJ MEYOCJ0+G;'+.0(A+33S6;\V>ZC'6B@(8!Q@GRCAQN8]'^]&Y,$Z_7PDS MC>72L4E%Y:!X+!2/S:1XK+R$/!2/A>*QPT/1_,5C5\5CT9\+PWNK=O'8:);W
MWW_]2V+O(W=%U]64VK&Z;9]JXW+1&K(\AUXU-/>X.<*RCY3/Y_#FJ85.K##% M7W25^OCQ]EPM-ZB3FJGI0PZG#FO6;A&_ORPUU&6[U%#B$4SV6B-5&4W_,HXO MIS>+9H;G-
'7 2T&_GR<&=](QG XE7EYKQB@+QQGG. R0#D@'I-M%.AI' GL@ MSAY@O/0@$_: W\"+^F>T=UC31M,5N8 M-/!SB2:&9GCON0?DJ8:%W[E2'0L3%,0+X"=!O-Q=7/\/H
/0$8N.)]M336:0 M<:#)?>#EV#P3?X6\$G^W:E5_4QUM2MJM<'Y=] 0]Y9TC4NI0 Z8]]PS$C0>P,+!V1W7 MMU^")L \7D=\BD>IQ7QJ ^GD$E7LXUO.!=\QJ4O1H\NKX"@V7<:2(O-
=10) M-Q;0N^Y%#$0E-;)#3RMTM(J$=>3Z9%_& CNA$VX5E#MH5.# *G^/^9_(]4BV MLSWAL+/D.89&XJ8N(3\%B,MAWXE#K\C1#)>F4/]?V7-"1A=\Z])9/.YF_MI5
M(]';EH6LW6SZZ+7K+I^N7 P@.[QU-1M@'BC8)X\AE# M.S9W!Z@/U ?]UX/Z.]2;M+>.!U5OH*Y.\.A*/\-SG3QY"..V)]?MW8U;.O[
M*2=";L"]NKO67C=>UR_HIR[I%TI+L239@)Y"XZ$.>T,;DIQ/5(* M\ :IVW>O&OH7V\%(^]<*;/@-^NEG%8L9,@ZR7%K)+:T_V.7%DN+Z"00I(MP) M'(9A\@EN(^KJH7N
Z+G!T_VL6QR?-BUTRLG60%XI!H\LI-%XJO$'\DB:^NX'Q#T M_",+CK67Q]7QHNA(TMW\689.L_]]1.YXQ .VG:1UC9>VU-#QP^=AS"4NZVA M(%T8B#/#U>54."4$V+BI9,$J
4KROU=UL'<76F"%'EUHD$N^Y4-UI2GNA MWV4F#ZYF.9KL(1KD&3-#L2;/Y"R.>&LOFI@_RRW"C;%D;8^)OTI;SH<.*X=> MR6MP3$"4ET^2FE-_ER1G+A_RZHVZ71BOC$
L+MI7*]^SM\]DA6_;X36:;TK(2#^*=O1W+Y.2. MY4_(KX9-(N11$&O,A,07)6P 55R7U0)[1+R2E5-IMV*1U^,!@ H!L+Z]TW M>CH)[5)R"@#DT2Y%X ==9O!=L]N)E89V0KN4XMSR7-
JER)K]IT |.4,)@GM M4@Y.,0'9,T]?)])5%9^@3*8@L6DKP]2)@P"(]1C! M2I\ @ZJWFW ,O*%Z094F$9GY$V%H) ."Y,0Y[0S[=A.:R>3MX1;82$;B9;9< M7&B242D.26@DDZM[6WR-
"D)LUG "+^ M+S,5=&0;GZ5/ $1]Q0A6^@0 ,14C6.D38%)]W-/7FV,4H7CO$1OCX4N-" R M0,DT80* F(H1K/0) &(J1K#2)\"B(9O04>>X:%
(M.^KP7;FN/XV'CVCN4<%82FN:K+;]^/Y;)TTX;$=%?X3- M%EH%KG.G2$QHT9-?>:1L6O2([Y?4HN>9K)4Y29\&&^45=N?%?9/:&:44YYX M-LV,!GQ"*J?
92S,Y]7(3!M8/EKCSVN$@H>U33N&P'!KA]/]\4FXAFE,9]\BK MW2 $0 AL"X&$!EG%A02SEPL#OML302] 5 "ID-(K2.@D=N#%E4PZB75%7NE4 MFHLA >F@&"ET'VO8(4Q\]S%16!
["B%);%BO=?:S7%U@]W8$)5())XA.U,F22 M/%NF]-'M4CG-:RN)S=(G 'FO%2-8Z1, Q%2,8*5/@#D%W!&$^%2A304,"K4F MN43%^[W0B:PF8F1'?!W+D?
A.9+E]NP5V(F/KVA\42ZX4>\2W("JUFP @IF($*WT"3&KA^&H4QSF[H%7AH'>GPYNB!5E'$*$%686D#.BE MRDX $%,Q@I4^ 28MF?A]#T?&$YAH05,]#1>(&3#.!2
W*SL!%N6FF,5Q9R-$ M()QH)CIXT(*L@F(!%$EE)\!@VHS(7-Y]MMU2))DIG<0V/DN? (C4BA&L] D M8BI&L-(GP* 2EG+/76V,4H7CO$1O#UJ054UD@)*IZ@0 ,14C6.D3 ,14C&"E
M3X#%8DPIO@?9D>&D&O8@6Q4[ZO*#9GO]KHLL0(X M'8QQP2XFD.,[DI7CU8-";.P$6%0"C]\T5U#!53UR+RQ8R"-5A1!,DTTK\C:6O'1WY A*,R+DCMHO]* M."1@&@FY_6*V>-
DCW ",4EV)XTX7O[R.-,?!A(":I,@M)/F\O5F1+HS 0(MWB[HL;D]X?RSP+STXM)#BFP,0( )"(QF6 YX0/C&$?Y=)"+(7:*)H1G>>RX\ M->#"8P- 1N.0.;J[N/X?
H'OCZ/YD>ZI9(MU+OTL8,^L@E]4(?TNFTY$_N48W M+B!<)$H9$.J;ZFC3,*-1SC*C\7!KO(@?/S&$?P@C[@Z:*[V8H+G<%F2V4^[D M[H!7NKDD-Q^VI^5!)ONUY'2^E $X^[F
,]].T@_O?+)? M!7C0TS]6DH"-]US2M^IM'S\W+CF]D"]]BZVSM1>YQ1G\]% P!L[H MH 87 M4!&H"%0\47G$%=;<5AZ@#!@_SBK2?WE27]D?ACN5X+=0]N5<-
-8OM8#S\:P4'_.:>QBM"XA)W1(#%Q4,CK&/VKB:FGF[+*O2 MS>X#HE'@)_M8Z!YY(B&6]+ MJD;2W%E,8^&;9I#LARPFU@L<'4ND4O50+#W MRX1P-ZZHY=$0SN@D#5-J,
[&H.C&U:<\UHUMIH'0\,,X2^/%T)&EN]P<>S,\ M]!=/))DX'+SM(JUMO+:GAHX?,@_AUA-;0^&#V/UT1AX>'7LEK,+U]#;7@_Z;G-;T%B;\U:]M,%B!X$+5-0] A6!BJ53 M<6=
(LL]2UDS2=TE7S4#=7@3;]HDH6W\](TM_6]G>5:K#+?+N)D_JZZEWV+M\ MMRN6'B,%U&>)^BR2:@"M$-%/\ TP,;EW)L;!^_P\@:.*$F8SXJ&U C9;:"4EHF4:2O[CE):MB5IED<
M\31#,#)X]!.M9YU-<\,U5S#]N25X>X=,F];_M^%A3A9**+\=58[481K)=0@CVG:$9V)=A)(>NBSE6:@^T*3+%R[+?3%1XD%)DO[I _MAR+S U[%-6[(R,BY1R'|+9DCBUW(W%>L+-
S>RP7F)!9UD E)<]9'$H+^?HNB)D ,HSL2?-&)(-S9:0;["A MV4!3;=&3Q?2# ITXMOH/_)OS&)W9#6A7T'>KEN!_0K$HFZ>)^Q_OD%3@/E!
M,$]H<)"KUU9_>*BJA<#TL%\9Y4,0'DF]]090S*AW40AX6+P49Y;4[55PT_@ MTM3;%\7BZ^V#1 !=P/:00/FF#LF(%9!P^_8X'Y>%/@!=-BP#%]!59S2#'&-L
M2$;D6!;G4#4520T_;2]OYP"P, AOMH=D(8= %)G+CLLR8"7S8E]F)^V@H4." MB&O]D$#YI@]QA++/4&NQL]]X<U70==!_Q H6G6&U M.G*QBRO="P5066/#P@&!%=[?
$#PZ8O;;626EKUX@50"'U$;Q;KV1Q;-L$%<'B 6VP"17HH?*(YAZU-:"12]%39%1V M[4XDD1(;]>17:26,1BH#D>)]%2M9776 LS'%.M6M%]6$1BHY929GTTBEQ_>[
M%.YS#5,$UB.LE]!();?03G:-5 2^.P#V:^ 4*\=^.[UA.:&12G&9+MDW4I$$ MOB]4C#>AD4K3V'(G5R8T4CGP-D%FC50Z%>,BJ,&[#$%!(Y6]I-KM% 3QC51$
M81FL%]6V+%:WD8KS*V*G4M)#1V2#:S'7Q7/$.LEE]2;VI=EU]'7XA,-O4.Z"FX(!YUX*")M,WK< F*@-H MH@(PCV^BD]_'5GQ9>I&-4H\LX'|.4 ?K6;$A@?)-'9(-1;;$7W,_SG%KK+H]
M^/E;JC8]'6BC4KI(&7 V)! ^:8.R8@9$'\1^4@Q%]JH@",+9RXS+M^\L/!@Q5IF_HD"#BFCHD4+ZI M0[*AW")/D*NQLFKX,0NT46#O4&PLS4D4+ZI0P+EFSHD$\9<-[Z+RI&1BAIV
M41F* C_HPEW7LH=D@TNR2"T#=%?SJA"+%4M)^Q2#H@?.I^S>?RBQ#$7"RQX? M$ P(KO;X@. ,$+S+P"PM:?'DTO@TQBZ*!9>5+ILARAX?&!)42K7'!P3GK%*R
M.*:MNW9@\3@VV(D*-$VY1%K0,T4LLF?*BKIR#2077@.GVXNQB>HHND7MU-V MQ3=8R;$*2T8-5A1>4(K/-BF5&\H>ORB\5]QB=4:,&-]]):_LY4P]82L"W^\4 M?
T\%F!"8,"8H@\8.NR!_;8>]SKRQK,^1OU2\ MP4/N+QWS$WZ4PW'7Q@\J@0UL;,_]9Y^@!/.#QIMBZ>3VN$Y>T7 SW;$OA]5:FJ&:W%+!N7B3C.'NB7/I9KZ- MYK709%1(D?
M:VBX,6$XS5174FU^>'I8_&U)L)-<9)#@^VL_,)VT'?M'^,GF1QHR3>[^Z^WW;SO'V!V-0ZBJOV7R_CMYTR3 :;_M_G1W<6-8?RS'T UW;]IOY.3/Q&Y2>VQB-;"-
O8_+'^4^J=S4(4KD)ZPQ6FO M_Q%LA('U#&:7D(#DBB M89\>*(*K?2#[[Q>FFU8BI.)R9&5$AQ_"'>RF_TD&_\1*[*W:B8 M,53/=@PR'-8C'Y8G(,5--T%NKZ0U!0-
>#/<%K\8M>H;O%I:ZT T\I?>%%#FM8 MG#>U%ZYJZ6ZA(\<@VN+A"%%)APR[_=N:HM__:QH$/=[RI-"7#;Z%&&$]-K,Y'ET(TBW/2-
U[2H#_!/Q+@/\$D$N"I#"#8H # W"0 MF8'#D4+MP+M6V:XE,&UZV+))).*1/[GN<05477-+?#.:6,C$WG>YB6//.'N. ML&E/(B0DA/>"_33DGN=(QA(8F.E?QB0)?WP\K-
;4J_C+B=M="5.H.$D1=_,R M9C&9Q/?WT3N;0X0M)1N>'NT84N):MBEM00FRFY6CLYM'+ZIA M$C?[R8ZD+@5G0[5U]#2' DI)"]05(3X Z$B:5H E "OR7B-[]VVQ.OQV?CY
MX)4DT,D]%M%: >NU2#T4:51$#N\ZP;<&>A5^N M\2^#!;N2'M_!G342S3'DL/P]\?;VIN!'AO?'D!+.!X,!6V?\O5>],LYFS0!_$M\?#%C$
M7P5,TN.*^ZYIAQ-.EK%Y.K/QZOZ[5"RJAK6(:Y_VX[?6!-;J9YJ/1O8A7'S M5RT"%"C<^CLQ4"* GA]*0-5%,7$W>1Z2?V1ZR(O]>UR4>8%(>&V%YL$;>;0 M;_XOB_+
+1HM>Q@K6,=)O-PO.DIX,$'!@TKTH [OQ56V/=D0HS6NDM:QFBK; M!M\"UE)-ZS ?ZHS%#L9:)M,H3C@Q;2[?N!)9>)99>7ZZN9KZJ!_2BB54CX
M'KM24Q*1(YX51AA=/\DMIG=YP)8NX'U>9ZU@510#ADG- Y-Y95VNH MN)M">&X_(OCM5M]3$\,5Z1WOXO;@T+1UTU#'A@E77."7&_#+#8((FF] C3P?
-54,/+YOXD0^;]CCP0R&@;XK6 M-W"9([?KFX#0)T4[AR*O*)WR.1R43G%XE(2XQ(73M4XF>.SQ?84!9_N4P]PF MN3'+2-I-U-X49'+N?"V)C/[MJ& VE0,RZ@>3(PR@=?L=I$-]D@)-
CN/KDTAB%O5)]M4W6HSFR1[Y M9/^\< T+D?!\V-2XFQ!M&GRBUJ$T'PS-5%T22QQ2S*HFQ)D_L 1O<$1"-+OPHAE+K(M4?&%N^!DIZ$GY SNR'1\KO)A8-T(ZT/W\,F=K?
HT@-5A5/CD9Q%;E0N M2.YB)(N\P,I9#V1 [3&"']#<7[W-TLRN$LR>B>UMJRR\MB MT?F\4)F@7 !*6=2_R0* 6'=(4@FZHP8%"(KTAC"I@RR!S>;*Q>@/,!U/2AF2
MLBB1$V7WBQ4"TG*^0]W&3\<1]O':*K/K^DA9U-%)=\]9VV"S[/F\UP:Y$S(MTDF%*_O&VP-]:&=1.8I*2HZ5FXE*D:N)"'9B^&#[FV?,;)64> MMJK=
(BG'FC4Y2".ICU5MZ<6.2TEJ!G9B@YUV1^P-2^LXB((/]0B+ZA.9L1(%BDO)PF,>^08MKY=XCD0(U'1Y(NKU"=) M/:7TNXA,@:!^"-]9>Y&S2(NI L17\1N%
[_9+#]]4[]2T2.5XD:0!.=7CQ@@_M:9%(,]DU1=%3$\58XYO[.V701F*/$:A9.5_!4Y QWNBV1%#JO!F.H\0P MCEP'QB$5TB5^4%9@0PK& ?V< V.\/NUT]U[65S&+*
[:"W+A98/'_\J@0$]> M(4Z)U(E5Y7G]$,6H&C;JQFKPJ'\YVVKVO)O4W4QG2:&]10T!E^G@B#\ M+%_.YB4B.IFKB1ZQVT'Z"9G"\G6=2HFS?1+.J1@7CP#BLC\.<)[A_M$66)I@=B?
Q%"7<.$B#HMWA/U#>^RIAD4SB%?91=BZX$QZ5&JNVH5G[3F>"]H< MAHRS4/*V0>'3A_+*&N\EW%XT(3.X"D%Q;X?D0N7X0=N>]{4@Y ML>/M<,!W!KDZ>VGVN7 N;383XNZ>
[H:@/%8EXA1Z.2E&O(]?^Q]^;-;5O) M^O!702DS=^P]4.&^Q'E=1F0G.H5?]!??W#%3]:&3-YIKYBK>VIN7" M6*ZE7%CH^&&QT-70'#YKF70'HKGPMRO=%'_%E'-
P7>Y=^#N5FIW3!\GK^M?2 MDOZ5?C5(C'$NMN^2WEY_^#W>3UZ-#HF_D'BB/PG+;O%]5P]WP0MC]E6)#!(X MS)$73"7]8^W%T.?Z\-KQXN[WY1-.-%>W7\F!I:D29;6/T[9-
HJ.IS0\0GUC^8V"5 M+_XY$W.!HD9HTE^@^J.D1>W]MM2P46;GS=6QHVX:-!R3AA0CXH^1\4*1^/@> M3A&-!1*$9-Z!PB>P4U^8HQ&]]N-[Y,;&=*^YE]WC6)_,T7D *5_<7+_&2.LE
M,;TBGTN8YAO/U+RO#C-Z6_3H;\;686@VW78Z4\T&=3<#D0.N+'BP[M3R'/@$ MWNV9!G/ O\4BZ1<=7%EG#L;71*X Y?$#!?.8M_&:_V6CVZV<*?$^;HZ:P/>9K\=SW
M4W"D\BN;18="40YDI>,CC5]_9K/W0HB<*^*R#)1.ONK)ZH5C]Q[,QC[%3_V M_P(C X6.L(NC^%.X08]_0U&&*YRDBMGS7]'>U-_[*Z5Q4U/KS- >?XFW3TL:[Q;\.4P*XU&-[E,)K5A-
DV:&70UYH#0K8/_OR[%Z;2 M3XUW_E\]9_DOEF<'?\)&%+/%]OM"SZR;/\37,NY^^-!!O!A_"=63'Z'Z#7 M4;A=MY'HVV<&&/@%5#W+2?)$A91E< MZ)'4: ?B0I#-B1!;,O -
$"/KMI4*W!FN-,13%3ENT438F,:;,R>]1&#KXX]O/]GSKGR!TX1: :A.L;>R.53 M@RW"\GLFS)CK@!U*"/XD@6RSE' "L2UB:_^USV!(MY5<."ICE,DXG6OR^6 M_1U&<+0)PV?
P3_H,H4$8+<%?OK]5[A0F >]&A0$1L!TO. %#K$M MV*0Y&3UP\#B0-IK]#/9Q"LZB]XQ6 "P(1/=%?2/L95R^&LO[DYY_S2D?M4)
MPEOYR$9L]@B[WFWH"JIR$N8];C<,KCTQ3E2+A)CPP@D\3:\0&H2\98<]D=^D MHGP%:UAW\$V_5. D1"[&KDDD<;&PF%0/D>3Q]VN_CPDK]Y>COVN>6;DR=:WY
MOFEN@VYOL&Y0#;AXQ_=C5!3,"-T0K@IQYD5 OH)BJ0@>U&C8%"AT"9R"QPT.Q'R<*HG HL!W($ M@!&%$*HXN% MR)U]'&F=[4.LZU$F5P..F9"P?
T6^AHZ+F@^0_(6AF[3WU\RT@%@=3MU"08)2 M,JPYG6 LL:/",O"D34='FE45PWJIC2S'5>FSFE"AR)Q:E#-]BT+-">L-V10F&7XD16)/9#E M!"H!K]
[X^I[XF@,"1M-.4QYM2X,Y48H#\%_PKF53SX'=L6$>Z N _^?1XM!X M "'OX?/@&(#EQ9 5N=D(#V(K)G3G@6O1)G,"'K3$_J"^,3$N_O0:[$MT9,ZD MKO5##O[B\SN/D!7G&'$)%
[U_*T1O2#[-GD_Z-.2L/S(F7,6F+-<+<7SK"H8 M=H&K< TS(C#G%;3,C!,IB'67Z%.(IV_TVW_0T7D(R@Q%.$>D&3D&NGE5_87@^M1E%XXO&)@3M&V4_?C/
MY(5K,S2SZ=,%_CE/FK2268Z262[@98_<]%?N?5+;@DGX(S&:S#D[E+&)7<<-/ 1]0,;B%&=CG?.SJCS!=[!/,C") M;@=KXVK%_MMCOC[F/D),O!T#E;2.<)+EYWN2'FP;Q'L%@Q M/
6"A^?[XHOM,35(QH@W7Q@%Q@S?4!?Q4))*(D)VST:>31G!.#G)PU?6+.9 M[CB^@[WZ?OI=7@9%!"N:QV!M@I>!)L/?DJ7@P(3!=^!NM.;@8_%]%QY.X$4+R-MS9R#54R&0AN]

YPJ3(1O]02EM..? M$KX%@UOA"N86.E]B/X'@/<.E4PC#7]Q[C_UH85=X[2\/PB:$RTS+Y=$R?\) MSGY4 YQ X3316.2X)87R9M[K0B][9'X8=.PO'Q2;J\-47L&_$68;K@-_K6&U M\AK2_J
91$SW4\9V]F?G"BE!:1#P0KKY(B:$ MWU^F%L["">L$L_^B%UKDRA%4YD4MG(AX>1'T4.,(TK_$#.8:L!> MR$A8]L_&0EDE\.D7"H$LQ-N3+B4J<\.8\@[BAB0LIFL'NT0
NANWR)\L)GNL M?[.5..?$?(>71_P24E]WG8WQ87O#P!_P,*5)*#BM6F??_-GZ M3]+M?60P?-G]?)SS,SZ+X7A,JT*#3UWGA#M MY P: V<5VD+1UL[@$^/(O.9CCYT)$R[08P
U@TE/\%TT:X05>_;F6L.N,Q;6 MC:+U!0<[]?V8=7/RM^N!$C+L9<[G4][&+N=NB''CP5@5/B@>Y5<@'\NOTUIW M\B8Y1_35):.3U"D/+@O6X!D=;FBAA4PR"IADLYTWV]#<_S-%.
(=Q>@V0;U6">FMR1N#*^$:8&$QT?V]@E.2=7H/1^0"1,K.T2X M@2>2>%P18"A_%N3=@1SU9G-Q&XZQ&8TW#1$*!%0&"Y4]JA%>_D^9'5']&_T&
MRD\4:"+^].Q,3XPFI"HXVCPS(3+TDCT[5^.\IN3Z;:R.1G-!+=11LB/8?V!A-Q*W "^A09%)RQ8#72I8-<[D0@0I*Y.>X03". M5$_P1K (+*S.PE-IP@'I*QW<&<_PG(C#1A>B%B@I#!?Z
0TU-*?P$@E^!VW" M, 46PXW@9KXJSYKA1B_@PI1!US"L9LAF]$Y?-D40@P5+!C4 MRXP"N90AQ[<\TNV1-P.2))=VI)F@BGGP \D"IQC!@1N]+DR'+D\@L%#A2,*
ME(QURGRE(!T]T8 J$GW1""O0=G!%,YI%[U@#NP'!8!BBAQ3E:8FE4D67)S* MJU/]WQ*.DRZW9?Q\1@H7UU4QEES\NF\IZ\Z'M'\QZX%7LVY%%<33"_P49; @
M46#YF0**:1(LGSP"1##KR!TOZ$8+=1D9$]L8A^TR:I\2M^B.H3 "/?,)E#=H M\VAAW,+RCODV^).Y.9[_%>P+T*_<^18H__N;!VNNCS:/V.?W)V]_43]Q0AEN!<6#?AC? PO M
<_/%%A\X4N/O"QP"^ARFM\;16\IN7'HTHU>%^YVI:(K !N2T>NJE8OW"/^ M"G<8Q.3"&5'6>^3]3E1BA.X$3S>PR9P4S8Q%$ QOD(/K;?1+V(AGK,\T+'=Z M+]9/1 K#0M[*.4?
7HRSQ)U MQV!!;7ZBB+CRH/W [*KMM$*OO599A]\K7TDN+)17;#)SRF.7> Z4SHY<.:H M55VJS.+U)C..R7%T-V1#?GN@N+"X]Q)1#4KBC"1$$9!*&"&)ZHYI]<\V0R9
M";^J/<$O3T&T+YIJ%KGVB0Q'2<,VAJ1&,!MQ3^('F_[R;-W!L(M?NL+7&GZ= M\9RON::/(XE63Y[.T_)6],K<>P3M%XVLN3PPN$GI[, 8R?)[&PK@0AR4/:79 M,#(8
J$ITJ0#$4Z1K:A,C^83@>R?Z2Y&K?BXZP0]97\'UD#D'.&*!%-7 U% M#LY7 @L$LZHQ#TE'##+2$3LE&.VF)%*Y9#L/2DY82CJ@_FW[VO=KP6G;P>?
M*X,C;V\^\A:7L,K9I;A(_;@HPR*B7GES[SVZ]$82AVW6-XX:*IF/*Q)3])D@ M#T1Q.:IJ!=B?7''_/1IS5TO1?V\Q*@PB:H ?@$BD*I&P>5U1)V(V_< U3'> M_7(#XY:\C&A&X?(%3<[^15?
XXBE,]7YDDTOU-'JH(W!>D]C?\7%%QIJ+T7@ MI80>?'A:AL7G*Y]#\A(=(6!@4H;J\)?N6L8K'C5$V"UE"#(HQ7 M.D^F%1.;:2+?0A \$88P0$+PVT7-KZW<^BW*_FPHTCPH?P+])?%.\
<,QNO!=\I9^^O?[]4:F!ZDM[Z[V;]Q?^2^!9;C9O[\9N1893EUU)?Z%[_3F%I4ZVI8SYN^\1]/M M%U/<&^:7'%I8LQ :I;MD-K:R_6RZW$M47.A%8^,/TOV&=XH[CTCVPT=2D
M^O$+Z],[/@K2$8LD$A++5/Y/F\W?*>%]E0OK7($%GP>UG/@TGKOFU[OP6O4H M#&,L3:I*^()[0SE)>,7(GGF9V_/2Q99E5 8N"L;47]X;OD$;#B+LKA]E*L% MI*H(S)4:@&()!H?
GF T!6.9838U!Z3B"#V(/S)R [1"#E$(9T6X>"(/+0)2 M)9#WSHD$])5";ZM6R)[O3F[_WAQ]C8 NN+3A1?_"_T?<)F>,(D:B_C\-=,J M"N^Y-
E+/0NLD;]K$[T.5&:,G8@EO51W"DK,2)9_ME M$+140I4:AB!="- M[2+$+8"4QD!RRZ%;41KU8 F%[;^;.=1O4AX9GM:489VZ-OK.103RGY$XP!!.S, W=_B;8Z | M" W9YVT-%
;/!R(R'H<';W^A!GH I(LS'|'N*R9&=1\4>X,WAV0W>;?!(+1 MALICXID\;L86"$I@#X*Y,@J/*R!LRZQ->=0;_A7D:$WX-)*I+]YS7KI\C^82 M&SM7H% ^XSMO)A<$))B2H'J->
(IZM&S08["3%!@@P8S1 =HR&N^\$MJC$I/X M&%2T;#1-BBW7$U#(W&:-X+P0=!F"70M. ?,=S$.ZZ1#E/B(!:2$\&XL9\TLE M3F!Y$GLG0I^# 3[V#!9V?HCP]?/A-?);?
(QTI5X^+8A@Z>V^(_"$>77XSKOO M;Q'OAV5CL//_.VMNKHO)I0^C(*H:WU1X;/Y#(>:EHZBK"O[_VT7HQYY*IN.$C^*M MP B=EW:L2%F-KHX2^X$ADZ^SXAI SJ==5^IQW?
++S4)N&2FJM S7&AJU7'N#K4 MW.BK@UZCBN2\I5HKTQDN2Y5=1QJ8':$ZVS14U7A^4+0&H_,_I>-/R?9M=5"7 M2DS2L$_#S7K1>FM_&FXTU79G]7:U D1<>8^L*B;?+])?V7?
+RW-]9UBEY!W M=1/1_ZCWI,OF-6].%="VV.\[P/OWVL<;:CDTO=[(WC;]DU=^!H6?GRT!>(Y? M^.03R#W0AS>_XZ7T#]8%D,;-1#BKV]@'(7SZE65'R7"=M3#1?[!Q[7_;MI8-
MA5H5;03)$.4P1#-[0[>B#+'}?%;;K685.>_K.>]J,,@0U0W7;.5J]3A690_K+ MV2EHT9V0\)F/9[]I.Z[-FSP*T!FILDN72IV"5?8U)XJA.1XND(1 6"I#% U:
ME11%DB/*X8BX"KT\I70%.;*IMA&JKWH\$=[(/D#E7P+ J41M29'(/$N),UCR M1<7!<([_Z.[T H@$R-".+T!9:=94'9">5M#PE-9513">+ ?\@_DP"@LH"]JH MA%<)22&$HMA\R"L4C?
T"0.&UWE+6->R# Z\\+>G484_57%96!X),L:+M*OF M4.H<&18KN+P9,E;AY>9EE>?!N+]]]Q@%<02PIC]L>CV?OCH$HQ#4_5,;=\V) M[B$'5<"2\)EE,-YFEQ!Y0;"#6P
:P:\QE$Y.@4T&9IGDOX":*A MNH6]E$0_1]K-I9;= MIQS]CI4HB8Z%@3EX8S8'B$RE0#G&#X,(.XDHX "@[Z M!/A5]%-]H@U*;L;Z*]3"%
<\QSF(N0G6CW")1]LYA%>@2"]2"L#98(_8)VS MS>:&QI^?.3?D1#@SK\B70I&KR/D524ZD&,9U"< OW1A@%&!] 6&!G89]K0+R0OSQ4\V=4HGZ&#BI-C(0]@6=,RH73C.G?BE-
G5G1HUQ2)[;%-P2 UT3-CY[_MWY.]Q&0OL:KW$MM9COBQ8@X^%&AEWJQ@48MAG._)) @>PMMS!79)T$I';"I5 M<5_G*'81+9AC \]!G-/%G3/52=ML!PQQ, H?
:D,Q^+V$S?.&4+@@/T,^Z_ MVA%P98*BPRZ5B',G&F:>*_?B)P&@H!"8E3B;R,9CDT_%A>E2ITZ%_= 0/TSE M/8%>."R6]0B\)3H^!'C.& E0#.W1LH7E08:&@NW!>0=U1
VNF8QA()=T&!]+ MXQZ$]TWX4 %AC@\)-J0(WH?S0??[!+4F\ZM%_YG(A4.\E;+VMD44I$"9H"AR4 MV>1PL,U,0-6FPN&WEB=9+'1XP,N[8B MIC_'6!.;0'#AA.]&)\QMEP!+/K1L1
|04W-%:ZW5!J!!&ZWSK2V0_-2/4#N* M4$/QX!=2%T5^B=E8?]%A<&HG#58\/'LQ89F'> ;ERM#O]GT8KN6@,U\%[=: M"#^!\MF^%9**RD@T"8!]+3'\MG=T=+'?
1W!%3@RT%!K]*'=J+>;5[6+R^%% MK7W1:-<&E_5F[4.K_:'3@_[T+E<"IL&S<''0Q=CJQ?M8?^J<5%K=89M>$,3 M+/^+SE6M7^_UF\WFL#OH=ZN*],;)W:>L._+LD^JW>&.
#H%UL!E 0FQS^;$O MGLJR%[V%]1!9DEC1@CV1&F0B\X]6H7[6"+OX_]D3OV4]G,4VB"VGR3C9H!(= M(]]L"S#=>%LB]4KB*(FY9PNH]J;TJ&S]H/](F\M;5P2"7*K2"\]DETR4P
M77QE6268SG=>?=_UZ#ALH/[7BP+VSQ5[W(M3E;&<-:*IDPNBV7$K MY/^UXIWCJQZ$VGE4MC!LEGI?+9 MECC,I>JP4PC<#-162P9NCH^_XF&=MXO5K&>8XZ'[1D?
M#2IR!U?!-)RR8C9^ M%7-^89]=$A.S&7'_,"R1"Z!T21KY]O: M!>8,[<+:1Q]L&C0E%TLNSH]+"TQ,VH6+3R]LU03O0_*TY.FL>+K_*>=-/,I MA-#::KU36@A-]O+1\?(^:5:+S'D\/-
:H]\U\.BYDO&2GG'?EUY1FWE6M]&S, M989N 4./+0\!EY8XNL2LS>TGF2AV\LG@RB@H5Q4YU&RIG7I>1_+]>%*+Y' M=(EVVOR63Q97FDA959BKT52]7/T^,E735?F?
UBI/3._6*N?[]DMJ-B+YYU/X98>]W[:0U M]FS"UI^RCYV^9+#C9K"X MZL^*,-CI5("VJ6]L7U2BA&2VDI@MKBRS[LQV$]69< 22Q8Z;Q>*]D)6-8[/1 MZ1M]4X+2EU\<*4'IRY,-
<26-.:E?"4]_O>G;D(;O$3);7#UCQ9CMZ",X#;4K M+=ZCXZUV/:Z6\W2.F](O,RC M8^T"4X8D*OU"L*G1+BW8)/GXZ/BXP,PDB4N?$-@]+050\O31\72!"5-2EWXY M
T1M=:6=+7DY*U!>)]/J6"1!VJG464;^)0SK)Y)6/J#QS]LU_/)X3HRK+4& MMG$NRFZ7>*/"S&_YI'$=."O]IUV4(2V9ZXB9]Y%/'M=1P-*WT9ANMZJ,'2SY M[%#X+)\KH-
'I6^JC8Y$I9<,MC^#;9?(517"[[34=J^H%ITYH-)'X9O+Q9(N M:-A] +YO>7DA =_]^X9^3%,A)2>L]R3,]BQ@WENJ0F^86(9AO?B#;J._/9@) M30]H!Y<%!_H;S?Q^^?G_I\EC70SI?
P9+O7'=3Z%]UVK7MY=?GA8OCQ8Z?5KBI&_?*F)B/6 MAW/YC6DXXV VA0?YMV\SD@[/<>?W9PUPOR6Y9XB^N==LX]]&XC9@\;JD.HCX M7T$?)@/BM_,#O-^XOSOPYZW0<6Z*
MG(D"SD!219R I(LY 0D6>PQ@=*!;C8N8M_F4RG=HT);4:6]GAG,(X2#+K5LP:AUQ3$68] M>O2;9E=M='*IZI&<>?B<&8=%4Q'./"D\FD93[796DTHEETHN!2Z-2]"N")>>
M!,),4ZUW)7-*YHQESCBXF!CF/*W&7-C]IMY0>^U*^H25OT&N1O0KUQY>%9(^ M)<>;=Q4X<4@Q.5D#LMO7#F5AW5P [.6)<)!,&@F]]G4L#U!2T539+ECW^*8N$
C/4=A$)1Q^B:Z]#>BZ A9+_)?_O MP/\%YLE'MPO\G%0[LJX-&11)5<_95E08+;=3K; *40>&TVUU0D<1T&<Y$W,PY/OE^^7[Y?OE^^7[Y?L/#4-%-LXJ.\VC
M0ND;R6D9G3CPDU9X1=V2C,:*1HY]]BM2\'@].5F'PZQQL"058=;CAB9IG[UO M8@IE)=L72,XLGS/C $,JPIDG!1K2:*]]3D40A"275HU+XZ \L*EIP'GH?9; M%8'WD\Q9-
>;,@IB(8<[3:IR%.%A]M:*J9 [@WJP*P2_9-ZN2\B8.!R,G8T#V MS=JE5+BD+5X9P39M*X"J]*,>G11[X&.J>:?3LE3Y;!D]TX#(R*1>1)Q;QZ
MX%7+*R/)GSY_QD%@5(P_3R+:U6R]S:H@6%>'6TZ8,>,@,+:-<)U"VZS60!WT M#CG2)=MFR;99IP*)W2TP<>MLW:T-FZVZN(H5$Z2Y8]_BF+A_+STW81"<<=
MH4/#26U7Y5Z]=/XK>_Q3YO\"L^!VX?\3BP8.6A7QH4KGQ;+'/V594&"NW4ZV MP"E$'AMUM3^HR)5 Z4Q8]OBG+ 3VR>E;Y.KC83>?=,$C0W#N-
-56NQSO0_89D'R*?)I/QN#!MLW"FO*&VNZ6$QZ43"F9 M$IBRET_*X+&TS0*/H-,LY_Y.,JAD4&30?'(&#]YM5AM<]7+B:)(Q)6,B8VZ7 M,U@5AFET>F]S+]MFR;99>[3-
BFT5%Z,,CK=M5GUKIOOT]0K3/_]MW@K/*3EU MS!*DF6Q;K):]T!LFEF%8+WZK+FWTMP>SH0D"$>'2X%1_H]G?#$_S7^"SI)%?Z8 $6Z?*!SG],(B[K\QER,Z(+YC;9@__U..+?
75P]WB1#DD69:?]>NA3=,_M)S7;>@D^6OX,>W8IM]=?OWW9#'2^$BKW]VAIBV#+Q6"*__MFL?/WVMC:Q9S1X_U=RI!Y1DCX%_:B-#A_G4,:98GCUB8$TZSIWXI39U M9T:-&
<3CM2F(*P-%%AN?O>]SPO0WX&?8@6"G(K\L_#P-[CYNA]>7M0]WE\/? M:\.KA\N[7Q3->-%>'5_9XT6!R18.XITBY*721'TDKDQ^]M,_\+V5VQ3QT=G/ ML23PV\=X$D!ZRH8
'FXN/NOF]V"4L>[,#>T5#XC$_Z-AC;ZO$O.[*W*KYHR MM5$L_N1:H[,%5GH1FZ&&#Y-3Q1H53$SZQ_,?@\F7QSYF8LM2$#F4(RCF4_+_^ MK.U$%21M%W@URKP^7Z\\4Y!
<"50MJ0#XF-FF9B@CH7L/JK!S$GR.[]LD.F;MB[< M.=HXL6_X8V37!/W&2&-@YZ\>[)@^VIYY!;()<#^:LK%GL)N)?R!H#5R*X_M M 0=LC,^6^?19?V9CM 9P#3. #\M\9-YB;_6:C
MV>^?*0P,ASF*!-MCLDGCL7=G"#J2=&5'D@)Z-#Z_,DOHJ5BM_HF2_(Z-_)([M>E:+^F3WSEWX1S:4RHQ_PE;;%> "24.'2D,M24.2AJ0-4*/@R%;O9HY"$+O M=J1V0Q*Z)/180M\27.
<0"+TW4)OU2A*ZK';=KJ_K5#>U(W1MJE;%OT$DO.'M M[.3-7'RMBDCHJ]UFLXH209)V*:0=#O*S@_]2'=+&A))VI*T?=*. T79R6.I M#FDWZVJS)_OU2-
KV:7M+E(Q#H.U&7^WT*X*]>6!W,M5P4F[<*,,E%/GQPXSU MXS _=O*#B%2J57O<[*KUJIB-I1-WV>.?,'.-XK$[=O#$]LA<3770]LC=:>G$ M7?;XI\Q<!?
D(,_B"%62N7DMM=%;KD25S2>8]EKFVQ!$X*,;J#-3VH">J42/ ME>BQ$L9G*U$4GZ6R[*%60LBTS]YWFVJ_I);/$O=*,@PR3'RVR[+760F&0:W< M4MN]PX&]D@QS?
P3GPNR"E%1#89I]/J@8B3'2(XICV.VZU!4&8XY+FC%$%FG M+'B?W >DZ('B3C53H7Q)-0F8SK2HY(]/$LB"P8L$$M.KPGZ,&!NS\4;HO4;] MGQS@S)HH[H)_B:2V%7]?
BV@G_"6(JY/D@M+(\]*Q^G(GGU\? MW_LB1?F@&9I\C;4?-Z$49DK!GDTB$N?@*%/MF2G/FOV*>(QS[15#9K\1]LA M2H$'QX3-Z)PK]R#\
(G!C7HKO@BB%.#C8.9*H:N/>H&S(7A5*:6[=9PFK$/+()COH#L MUDW^UI49\#\+_$QM-+)F<\VDS?!,#:0\%GW"B8V9Z?"?!%0V_"+.#R;#F M' M@8LW+)"H.\U+L4BB@.@<>;:-
NQ_Y0F:S.U<>X T.D($^T4<:C#+3_K*_UY1 MJEA $L&1X#)LCK4*_QTQ_1FE?$.!8MZ8B:BA<-7")TNI"]<9(1HZ%<8%\@3 MY-C8LP5T'$PB20(V(R)%R"5$G@/M>ZYN M.\
<"Z!=GXA%B'T+XB16_)B#U#2]$U+>TSYOP^)--5N9R\K4Q<+ZG91%_BEC M]+$"0R,^Z+9HVG$CMDA?+]QN;LZA)OW;X>ZMT9S"W\NU8B)WMA25N0N.+*U MT06+8\I &5,
[6V]WGSX_)-7N%']MM@4=%L=]M[8.>OH5;*X%9HMH9;!M LLC MA"-7T U9]$!BO(Q*<^>&D&\2.3(NEWO7B&(BJBLE<5*D!=X=,GRWG9I*-LWF43')N M\N+Z;%)KXC.NMY,-
,T-[3!8,G\P18EZSCT1'MV"N6^.OS UPM/>5&,_[;GV/ M4&J:7.]*JLP!B! RKP]-A^=QL5*4"$AU?]*IUV,M]GV-@C0@2$$HK.9N0!D;@Y8$<0WK&%/\N?\]M>[!]!N=)T^S^:X;&/NC,R
M+,>SF1,;*\&R@YA822%A]Z^6RY)BC.US?NV!BU%H-PEAGO)5HD+[X M>RW5B:ZJ9DC73-@6QPX'UHX$H2C.ZXRMX$%.^418?R_>WIS\#!
M)H;!00J,>;#:PZ^(60U+L]Z^/!<>Z4G@\LC$ B/]KGR$4[M#=#VA,-QPN"_MJ;EP0"]/SVHVO]5XQL/C=V/IHHE?B)^8HLWGMO4#-@*(:8*40H.]PPF\4B"< M@GCZ1
-C^Y^Q0VUB=#N\W9M&WZL=69C0.KU!"+.>#T13W_N5'.5QWO\BX%-MX3F"#A3L,6 +($\$8^57R00:=ILK+N@5IWO_0#0B:6CWP<^4/\&8TW70U MBD88G$*G^MP):
<>_G%)@.C.\T9IC<%R-&)\NS!]$)[_36+\HND,!$3O'#8'WQ2P) MP_.&/M-%'Z#P_H5Z_%@SO/Z8:=\7;X0<8 T8^U?$_O6/N^:P44W_49OJX .: MOP1F IC;7ZU??\9'WT=;$/&IX#40<-
,@NVGJ_*=;K8FN2?>$.2UH71\YSV TZ=H(LI(@:DX+"YAK=V*@KW9@!A+O)GBQ7 MIZN\N0?"!SPV17NR&5+G9K\/'B+G9K\/'B<-MA\+B@K\/'...
MCR#P/P7L3Q4,(!M0>_L-B+O$DI_?/+A=2QBK=Z"CEBV61:' M^42[XKAWL#GZ!'F#*XHAS+TGH#9E*8_UX]RALX59#N?%_YC$63UA*Y],M$X86-L-DHS52:> M39?YNLGG#>.?
*\.4PDO%HYMJ8S^/ C44*ALKW/0-I]E?[\OE=YH7P@Q+?Y; M/(.>VHDY2Z'"MSU-4.O T]Q86S*MH@\JV##V:;.=QI,0X]SV"C11L]OHJ6[2=P@)!':0SZ>?2=3^BH=2)NDW_DX^B&
<3LN MZB L[N$+=BX\DH2&P!WG?0>]YG21]]"(TL9PZ52R"E5VB7*^6RZ5MTC!3L6^<| MPGVT(DP2P#H"B%QOO.;$>3_,M)(.3(P,I!TZ< "HF!TI'/UV?GZZ!UW*_!D* M2&2%)-
K7?)!5"(7ESO3BK_6X/'6("CSX3625D"Q%@Z1+ 3R'87^V)B'3V,R M*])>@L0$;NG!6WZS'3-2RC2\04]M=';I:Y"V;]D[(9*OXZ:H6A@A]_\Q,F M2*,12P2?:*P/7W0%#RTB29 ,V5;[C?
09])(A)4/Z#)E0SW5" M&J[1:ZB-05]RE.2HO3D]_HY^A:.DBDOFR&Y+K3>];'1*Y)R'.(XNS]<(LL4H MF=>P-%.D1#Y;QC,^9F"A69C^^,:UGAAFV/",W[,+_N*(>_/HJA'IE&!72P
MR,6OAX/CQSX*B,@4P2>*@(S2KG^_9*2-C'4ADERFY-) M,2OLG&>2+]=6C4&^*YF_"VE*H^@6*5-FC!4:,[ZD>UTU(V,CGH?M=K*C%]" MTJA@F)2I@__Q,^(T2AOC*7/,IJ*
(:"DG//4!N!6^ M.%*N9X^__=I/_6:C\]Z!XYBJ0-^8-DXE!<3"CX(?E#?X7+/^#D<(OA\A$_JX M\>XMIP6;^<5"/(D1]0)R/ZP=E>.B5($9>7-*EF M&,$2+/6:-0:O3^%/4#F
MP&>+SSWL%N ;O@MY="1+U@D>?X5[*I]+8,GQPF/H1@X;(X")N5MM R-MV65]YX M O3E$Y7L^"NS?8.%ZZ?H.4R M!U%;Z";_#.Q/\<=$AY])(3W<7'S6S>_!**!-YX;V MBIN(T<_:
(Q;@K&)7OPO?]OR]*Y7 .VDY404;L C]%&=0!7X6X.#Y\EW"9>]6?(>4\C:ZO0?F]\E*^.H3UQIPN1V$^M]$ MA5)=;7;2-X$I0Z@7:<\7*=2O=%-WIFQ,-ZY2IN?%=O$U.
[O(=/^@KO&VT)KJH-642&.PXN"^AM*IAL1S0L:8+5):R]#'6TPWC P/QF_M;C5Y,F2[(/GS#732.3.U+D-_DEREW(__FRHK<)NP0Z%/$Z6(E,G1&1+D?VB
MH0R3SJ]"WD(9'H)N$]"J_TX6"^A\C?7W=29$>*4'O!T4K)=1^WV*V*H2:+* MDJA2IT-D0%0-M=GJ58.H*FC]%RG';V+N90Y4CF\=^"R=,[>>:2(#ITY1B-P[M]>O$]]M%X;4?
D6XX,4+MII5;?QQ:TMSJA4LFB%/#T)FF%EF'-TB MA]]E[.Y8;TR=L?!,R.8Q0GP/1V9""<3X8XO"4HFPDD:D(EPU4N$^V"9GH.Z M&77$T7B>54Y.Z]5.?Q"6%!W9ONE)/;5?+ZI+UU%
[@94FM=1Y#5F26DOM5Z7> M_.3OPO[0GD3<$5WRF@NOKEF3R8&+_PI<(VQ@P]I#-[S5#PXKM/?BP@WS8 ME7_QTA>]1,=LB,O$O/U7D7R:"IHWQ>:NB8B;7[3%IF[EB?
WI9[7%ERDY&["Q17E5E$NV<1 M]5-G$! IK+]LVH_C.]W2C+H22$X2>T\XSZJ?N;9";:&BI@T91LD$FT1TU<:=NI 7<0_406%]4I+H5O) MH-
LFT6$AK2$=5MO.PSQ0:^>134V0=1.(+G(WC_W7YS:,YO.'IMTP]Q%,42SP MI($^S"=P,M$7-T(7Z$!53 7NCS:P;G]P#_^P/N-9^=]JZ[I);)VJ-!R59)8A MF0W20W7D069-==
_K'2:X0!B/'O_*0+$)_/A89&E;W49%C(<*&O1%0G_[!KTV^MO3'1W/H>9GQ4\M8XS;?[!'*X+^ M/$C7'F(8G]TXTM_\D]WW+ M7R$G>RXU6D(TK)M9PE13;31$9LV]>
<5]"!*;J%NQ>:" M':@'D-VCL"@>/=@?7X2$=[R=%46X4UN)/IZI(YMF".??]LJOE:*K]SO%"Q8) MDBWG7R^Z-LE)S-FS/MYP!'Z]J8U/A,?O:9I0]K$]TGMZ!6=E39HP5-%J4#\QX M-
<$JH2JQZI\O8Z."E-$]]L^^/[$MF9@&)@^0'LD$>"\N%TI^A1XLGO\LM.G MO.>_+WOGOM/"OP;KWB[SO7<8F>_+6YFFX8S/2K/_M\=O3I>*N_/[M,TZ9WK(")L,$ZKUF$^\TQ6W
(K.6DF>_<35Y9-U+@JH 0>61M)\!-94>*M^X MAGT3^E.>]^+9AC]XB%S,M!HFAZ&*S+=.,Y<$/Z];3TCK^=-/E([M;BZ1DS0;71C%2>+>CK@3\HH.@+B[:K>1"]SWOK1=
M^O7"9OZH#(L)\'^I0](BY_O"S(5#0N92!L)A4RK)9NDPT7^P<>U_S+:6!4.M MBBD)\DG$Y9)R0Y%0),MZ@Y/J;Y +6&%!2JX\KZ\])9=!]1D_=2LGY!FE;5Y MBZ<="=;OQS?
+5Y'=)Q.40<4(25Y6)N)E/&U/IFN6CM9*RPN(O38!0OQU]:DS9 MZT]47XG(*IG)KRQ%5Z.IMCOE!)8*3SZ3W"?M-MO]I<3"37-?6'SV>4>3GNB'G80Z6!]_4'(>Y^+_62*?@\
(ON3A5M=0@@+D53 M)MJ(KA7PNV/E\95P9#_HUGRJ->V-F$<6G/*1/3/#FL_0FL$OPC(]^*KKV?A" MS*+3QC/=U!T7QWAFRMRSYY93:F]IS9CR!?XZ=91+H,2Q$DT"$QD[1:3M2!
(Z4!+Z M"B99!2DHB)M(.!3SN-)Y3>NA;47/+*)+.HK.:HR?2;HZ$+HJ4UX=6)Z'GJW?:9.9W?^1S6V&@2H,P8]B3HR'C2R_(EHV>V F:M=R+79NN#[8-\+PQ6P_C)\?'&TNV4B*O3<.GO?
ZUGT6_;XI\P_S?T=]Y+XIYE/-Q[)/Y)_=N"?UOZ.7$G\TU"[G8I49]5. MP66/?\H8<9U7]S(M?0I5-GV>-+[@BX(SZA8]GK*^ "L#\8' QWR*+[A*+(R-ET7[-]
<(:H..;;T$'RU_AM77RNWUUV]?-I=@KMV+I5V M18K!%.56>V+^T F<[<-H^NK?_VW7/G[Z6AM9LYH]?]]Y4P^D@CVV9]PV,G28 M3PV.S_+L$7-
J%XYS)WZI3=V946,&!3!K4]#4!FIK-@8!IZEC+\#/\,6!%L5 M#2ZE6/L=7E_6/MQ=#G^O#:\>+N]^433C17MU?LH2^3+9S$.V7*=LAH?%!^=_1O+ []]C*C#+6G;FA MO>()&
<#]M4>LJU\TAFCP*W*KYH"DA_8^"?7&BW6<+R(S=!!$N@8(^3DA$\L M_S$()R[^.9.8*.$)8%[!>B;.>L CX#S"MO\2?\\?9'OAVK+&+[IA#,WQ)]/5S"<=5CY$; SGH^Z,#,Q]#5=?
:Q. YK MHL?_6C])?VUIF<7<>B Y48W+5\M-M"^ZYYR;_362E1&N4N'+5&%2,E *4^02 MDO5);L->(<.PF@%*,0R[%6P'(:(D=JL]?8?V)O?[T92-/8/=3/@N?,9-6"\
MM9VK6B!W)7;):1;=-^]RTU ! !4I&EX5AEE1L=97DB++ILC8CEE5(D>)][(+ M0\E>;^4#% 42Z7\4 MKI-T)>EJ'[H"_U^**DE24O])HJHT44G])^GJU/1?Y1/F_4NU9K],?*@+SX$%
M,ENA#G&8OS#5YQ(-JE*]EMD)O4H2KB,^O'I1_K+L"PSA<(&<<AWT;/>)HD)WJ+I?C]I9Z .&@U) MB=+]HGV3J=18/K/V-X'O]M3E;HF:>]42/8W*\P#Z>V=?D=M]3C;;7;5;
MTHU2'/+7J1BDDK=2+2O1:N]&)T#LQUP97^"V^VJI79$.GC70>T=F TM.RUR+ M=>,S+O9CM/0&]]"O-OKEA$^D"I.,E25C):1QE&.>=A!FO)SPC.0MR5N9FH?Q M61#
[.5>&YF$;S,-63VTU*I(.7]]'DM/2:;'X)(S]&"V]>=AHM-1>23W?TNBP M_>#.CPT],RI5%\#.D\,QRHOFP(*!]-TC@!*,TD)1?9(]()+P-1L2$S-$P5< MZTH,AP(_#!^PS8+RQ;+&"9?
4."$*I5DMQ$))?L=&?E]U\V"H3^)EI\L_$H(G M,_Z)X,>6SP62A@Z5AE]2AB0-23D4C*H4-)*?3QXSK-,O'C%]):N@E\X;C8 M_\5FS\STCK\D)H"KZWNMJ[:H-?C)'UHS=NYI+O@DT'M\S
M=J6':O5I?-"K9#F)I/R:3RN3_!J@_'*TWA';74KDB4M<7]2^C1/S&2VQKN M:N.9;NJ.B\V^GUE1WLU.,8\\QM\VV%"M*LVMIYTHB7K[^TS7G(*&YGBX0#\B
MQZ$TZ=12>ZV*E.N73N)ECW_*+-;?WVFK*HMUU7I54 %*)_&RQS]E%AOL[S-6 ME<4:#95N#B2/56#\$^;Q?GU_G[6R/-93ZXW#X;'*W]Y5"A!$BTE-/XF+NVU+ M22H4-
MM^RHFBJK&54UN"H&FKK8$L@9:L41YK-+=R1DM@C9XZ**E%E0-R1K(_M&O'I(ZL%?\6;IRVU7C^<*;K#IZ6YKJT_>KSBU;44?3;7=!NC"HIA M =$XBLU&2-
YC9>S9V*;9A=LHKT^RD M;P=9X+R=,(SJ6GRB,77-NCN%Y<%XRH6AF^AW*]?,M&;ZR%&^K/NP(+/B]] MHL>[LFPZ$E[>C0<4V6I'82;R3]*6*U\T>S3%BCB%=G[BN9[-UE&-
PAP71.> M3%A3KBJ/0&MC!9X$L<) ZBHCS[:9.7]%KXZF<'_@"N%+5(@.U) TG6B-GH+T M(M(Z3[TLO7[T92-/8-9DX0"]BO:_=W*V)NRC'VW1).@[@+.R ;Z7:K#R#K! MOM]92K!?
%049["<51UQQWO\O\Y]#41!RTXL=8D9U]?QOC[_D9^M]F/;./T: M\HDM4=E4E;*0#73!T>#*I4BZHUD=?'6.R3C_X+]KEH@ 1W<3+B:02V3.DC?[%6F>:O,;MU*#@!5=8^0
M]3<-535NCV^(DSFW?X4!'EZ8]40?-BJ2-2U6^7>WB)8.7SN!YW,!9Q^ (Q9>>Q5OM2M99 M2AV>Q.(#R>)>EL_@@ET8\|#Q?^97EIW?%&6^TWRLD,RA4".HMKBD6V2L9^SGX\
MO,P5%VBZ21=1(\VV7_%.3YN!H".LG"?+&K_HAK$KU//YI;FIBQFHS*F/KN9 M7(OEQM^&M8[Q-JRZ)]R$33MXV+1[^(9N^#=46*3^T<*X/KN QVW+] RP
MFJ2R@Z2RE1P=25"2H/8AJ ^Z-9]]*X1\TC?*1_9,S.L.6:O2>*2Q+67M(+O M/MI<(IY;AH<_2(DEB6HOH])BR6#9W[^7+M>)D!MF!]+DY./+J1VP"!O M@_C4%^]O]B?

X+20O2(A_,OU[?HKKPG(3;Z=:4^..2L MUI-+>@O^'=-<+B?HNU%A\G+!]FMKIF.0<#M"9[Z'/XFD<7C8:964">K[.M? M<0]I$ 3V$-+7M::,GRTG96Z]XL!;X2?]@S!H5T4:O2V?
BD^98>+_I_)FF'WB M ?ES1Z\R)J-DC5)98SOP]6H&#/)GDWYU4KPEGY3*)W% 5+FKD#U#"OGP1SO" M'16Y=Y'L42I[;-<\K2IBO:D.VE7S#2]?>5!>ML$*^M41QB#2(RCZS[G6/"$A
M]#+Q^FR7E2B4$C! *AT<28MDW%/;K7("L!*N57)NEIR;@.=1G2A->O2/?K<< MMU*R]633+-DT 8RCFA&CM"DF";5;$F"/9%G)LEFR; *1K6"5^GS81[]V>1& MLN!!+"N)51NI83+V-
5#!D6QT#]?OQWYP&,7C/L3-ZM>Q_OR>,!GXL_PY_"/] MM#=0Q$?VZ'[4G9%A.9Z]!C*]'0L2$;]=FY#EPRVB'1(;A#]&MD?LS]^/[]!. M,F(#A5Y8(/;X_ES\E^_4)W,,:V-
C5$!!!5DQ$T_&/H(;Y#V9#,R3OC; MW:GFPG CPONS\<;)-VBB;Q5-L=FS93PCLHQX!T1L/'7:4&#&VA.,] 26D#*W M80![SEL_"A0:;XS-1/Z1*.?;,7*^@1F;]G:0-NN?
[P[\T]'=G&XOL,QAW-Y.ET;0?^LR;?;!LFQIL7&@($N.^ MIE$Y7>#OCEJOK]XE\H-Z@P@_9WS9,->WZL;S;_KGOY[T<8&K$(Q+$V0IN;C MVSB*:?
&*>OX@^S%BC/J*))]V7&C+/^U4A_?G'2(ATWXS/L!<5.?[XTU<1=F7C*;3$61O,!:%"G50$]ZX>L>/R)BTYGF\S MSFI+X.;/-&U_?_=AXG5T4.[I=O"VM;.6MT$J.^:KXH)R$EV)$-PK$-
X*O,0" MSK2>=>RV!(/B@0*?VO0Q\"ILWHS86HE\)IH\182W-9OI+CFG@BP4[_-B]P@ MOY//NI$Y+W^VS"=WF65A2Q8/")DZ9-_HP?-%5>'@@;V;25(=(97@%/B(6^]X
MLW([7AU66ZI'P=;T'Q_"Y'XP1E";.IJK.Q.QP2@QF>U]P#&PMS Y#-40Y)7! MJ,4%_-4!_N/!'$?PZ1_@\+()?.I?*0XU8%QXVME]?C!:A=YP#-XB'C5WP;2YG8UFP#)[8D]Z:V
M;#>Y!.TXEX!W2Y:;"YO;6*-9=FELF $^9=H(P.[2:QLL@0^X0,:2_)D FV MGP2V]F4)RG:;"6MX"\&R"30U>_F\.S!IS*R6)K4\)QZ^),32:(!1\US+_P-% MD_E?
HLBCT2#H4@*>:\W]%Y_W$A!Z-LQMXWZ!T=_&)L&MG8Y81$[3N?SA F4) MM>-Z-1+-6FK:EI81K?M=A) C"_;3)2MQ$M4ZBB""*/+A.Z]PS7Y&G/AD8'Z MIW:R(W&#_$FC%RI
PC.#]K-@<7#0VU1N^=LSGV0LW0 K<9([O.N\H>7;7. M[A,/4 8AT?6[_?O@@V>BD,&OK%0<3R3<0.1T6O?*9H&!G@;U4PU_71%+O9 M1GR%!=LQ;-
@XUU[)EWZ'F]2J9_MKA+Q$.,@(/[R.,+;YA. M:F 6!A\M?X;]7KF]_OKMRV;4Q;56W?+YG;T7@RG*K?;$_*$3+]"\&5U?_?N_
M[=K'3U]K(VM6L\=/-7=*+M08A&=M9.@PGQI85Y9GCYA3NW"<._%+;>K.C!HS MR"ZO3<&X,-# 8&.P:/F50[_#P=7?TB\+/T^#8H';X?5E[*=,&9DW2A/O6$6-
P4]U^@>^MU)^@#XZ^SF6!G[[M&$\#='.5"04\W(#XR :_$!&&6L.W-#>\43PG!V[1$O-&.O7\/#U92IC6[+3ZXU M6K097\1F8(<)'?UX3D[XQ/(? Y=_]
<^9)&P0]CZ]7DP;1Q'[Z_:3E1!/M$" MLT:YUV?LE6=R$B2?**3TEV=R'Y="KRCQR'A =[0%:'?UUB-8[IS2?Z*"EB M#W3 ^6AF87\^A,L[.W56%QW?
7S""3/@7XPV^>E(29!JO.]F[7O3^KQBV1?=, M-VVJASKH]U;<:(H(>HX+9VZ_^D' "6,*(C7[6 F.![H+%!IEN,Z8!#H9$8F M[+0[U>TQ/YRY!BH8V0#&X59'X@ZW$A)A*G%!FO69--
NKR3=HF-G,X!Z[M1"M M"^/IR=L8=UOA,V-Q0:4BM[+77L6%B]G(P!@^5_#VB5.ZS<_$BUET/+EC^N4 MN>"X"N,]AN#H["2?IH';NSX$54) >_]A^/8[,$; @H8]"(/%RR+ZD6F"%(--
MTF"?=!YY H,"=LO&>S;T+Y7[FZL[_NO<\!RZIHW/#3#,4?\YPPQ.< M_/JP8KU)!V/\H!T\;^I+[YCNT6OIQ,SA\T1W?N:6TWYG]PUV&Q=['C8"^ M:\VM"1Q%Q?D]??\SC+ D;58\
[D/VF[4F;ES"9K7B-DN%9X"1Z5X?K\(\O,_" M>V63N:#Y0+]B*^&]^00_B9W!0^/88OHSNV4V.FRPDMR1R65_'WXG^F!GES SM<8EL+L2BA>B@ M_@"?
Q5+N<"57E@V#7>FVXUX!13T B0&W?00]"X$!ZEN3U*>O5V?OV^>=]7=U MFL%SQ 77E&:JC'&J@>6P$_\OQ..3#K)W, =Y M#P_@\7*%^GV1S]?F>Z_D@7#_*1N2^,F8D'N= PH<-
=3+38M_Y. M]UWPI2W8>' 0IX\W%;"-,.17T*+1.T]]Y'$Z?L\CCYXU'CX8)!-@9VX-K,AC M3%>#Y^>>0:01HE-]!^8G#P%8<]
(KN\HF=OK01\W'6GFUBV=]A4NZ(+6P.>#8]+!MU;!D/F.N0OF6!/)GI%[M$[34'T7=(9!!8P9F$YE!O"$L3!97!"K,?.)F>G#[0F"VFI@3SP:=3& VR+$] M>]>8!>>-P'W%SL**
SOKG"O#?2QV%?P&^!^;S\.;@:=+T3,^NA&U],AG\(L6 M5B3,T1BZV!1*?Q]$?H_,WZ>IWMEYW#]8&,M(#)>U,_% VFL59^HHUX5H7IP^ MU+4IWRST0X,-!V;<-:>(&R#
>\B2]#;X^!FX!DQ;DSU9KDY!-9O-/3!<-(=1 M1I&FS#%^QO-,@T112@M0WC@LS RU3+J:Q?@/?2INIL&\ C/A[;GR<:LK +"] MF;@#V&!?97%9$#+W3"-I[I>GXXU!:/.'-
^C^I3F*P:6CV)#UW.ZG#M:DITIP MU'5KK(]N^;1O_76D#,4.6OV$1/#DY:^W9@]F^4VUWVC%Y&6#?ISSP(AQ;*%C MD+081]X @0'*?2=>.-<
2>1)TGX[@*8TG@$"A;_$=/BW[;SHXA=)YX+)A6_MQEK/DPM3W[Y]?"ZY%UGUB/_"[RATYMQ,\.HF] W#T&!\37#G&!O'AW/YC6DX MXV VE>L,X6=.]#MEMGL$8^V*,]U_@>ER[]-
Y2'U7'PT@F4/9M^&]]S,+*,C MZH$U5RV/P^[83-/)2@=CD*?0G@#$Z7IW5O!]9B]G*(@"#_$?(I9N&]AJCQU489\WHG\RO M\/Z'V%V8\LR\4?$C9 ;;E]F(N+@^'ST]1U0,I]22?E\
[G6];LC3<.)\K@)Z]_!Y+!2V?P^,O9/!C\ MRO)2>>&=L_>]6.BKP^'O4U3@#T&.E^3RTKD\H85//)=3BM0.+#[$@]Z'R\$+ M,_>E&[XGX#-,/L*'"\R?$W0/).0]
1TH//@*4RF*Z]GD"$KI_*59:=#_WE24*K83N1=N;)FE+'IM[(Z:DMR+TG E4^\%DP&"&.&8= MCT2"7P3E?T]=UFVU]R(-WE: HHZ;>!-I=TWY M\#[J:U_;7:O"% >V#'XZ;%UVBLDH7)
<13BFH,E%I+557^:HKX>)Z7^LU(@$N M^,$?0_;X5%>EJ]OX.\M,O*WMZ?7(%=0I.EM?+?/XM=/Z&X!#3:#(;T&),B@) M23T;&91!@D6WI_;KJU >%9!"DILD-T6X:9"
[1M^&FPXR;'H]"4H<2!C'9]]89(N-_-3 U5KW0EAAQHN ;K==G_XM@V5=L M_WX!]?/F*H'I4]D*1[NS!@X__W;H4M&H?O7QOUKQ349$3G,80\BWAY4T9Y@ ME4_4UV6I[[A*+6#&?
IN-I>8:Q\+BH418OK0GSVC"P>Z>ORX(N:\YRFS4PD#<;1$DA[_]\B?=3QMS/ MUHC:@A(IWW+E=\G;(SF$"STTQ_R_B*?LY-F':*P8=L5-=#@=V%?V1Y]N']I
M,4L[2?'4$]B\5K.Q;NOV[WP3RNYMNR]_XI=76/[Z/8RGPNNSM[>\SG)KE%QM![@&I-)IX8HU!I \CB#C&S>FU MRF4CAG(G)KC8&-3]?1!H;_I@T$XE=;KC+!=Y;*?
>=MIHC^9V8#HW>LTUQO.$ M'S)O48$%2*O=P.D!BW#WJ&G(>W)!'"'2"[CV(&/4<0@T'W^W M"/'?UU[6!*0'?DGTQ<.6D*^\8 ?,650W"'ZOS6$F8.IPS/#D\XH!?0[.]_"C MNQ4;>
7[MU3)E%:[=,%Y[W173D^ 0#_X9\0;"U)CL6V8AV.U=P3S>*:![1&8 M9ALZ'19:/S#X6;0YP(6S, P:8OT^)MN[31$NSB9)T4-V8L,\3V>WOF/W:/&, M]S."D=?.6[TX*]@GP(% MY\P?IPXU"
(0=DDT$7U]H2^HZ09V*86ZCD'K5:*?WH#6Y9?*0A2-4)A$"_Q8R MOT\3FYVG;DS'FH(X>&-KHF /+H*%42,5()1&O5Y?17O?O;%*L[=Z2<0WS9G" MD5!%!ZW_4@X_W\T>(@K,
(7B]*"0[;RSK@I[_]>G/\,J*+]% M;E100_14X3W<85D0T?R,1#G=C<%1RUDXPR'=XQ9NR.J,.^,7&8C[;DV^ZWU M>?>+@^!0ZV>6#30GKOX>A5?B FRR[F#8B8-=1%1]U[
&R=,#S0=&BQC<56>W9 MXPNLJ66 S>+X 0FN-.&%H;)+-C2Z\4G&:_N\W(27#]AI4UI_=Z$]WL\07-_Z M98.U'&X6!L.CQC4GG\C^!<(A>2/3]XY,NZ?1:'1:6ZP-&PBN_E]^1IVH.5-5
M]"D>C6SNC& K9 KS!R,3Q@V*#ZADOBN^_7/+C1.1/R%. C9F(=AW4XQT(+D)&"T2'US$\@@7; 2OT=&>**_?U%BS_,]RPH9?- M1M:3]?N-A#3E"9@_[-2W\(|-)[&^.^8FE(.TAW(-
TW4^6PZ&=FFIUW> M6":FA@YWC3MHP/C6C/GI33Q3!\"\@VT%G3A&1XU^HNP#DK/W0800-_$&E)K& M9>YX]^Y+6?14.N<*BZ)4W5C2CIZ^+2(S,\[ZWI)
<$(&\6ARY&YL*>IMNG-% M[R]/N]GYK(?2$.EI2A%GZK0XMK47/ZZ?^KKN MD R>;W/+C)C/&-)V,T+\>,T:G2+[F)Z$* 23"'H&WR,:?@0SB"N= MT%
<(.B=&;4M]5QA_0G@R"]]>-$HI-C32[9$W0T(8P6,F\)/CH#3TRDI$1UYC"'^:KX@*! M*_9;F=P(I-EY[QHK^:$/IH=->+0)3S(VX($3P)S@U5-A&587+T&C]^<)
M;W08NON1=SJB5Q09W&/>]O95T6B-,+*T2O)K0-]@F<_,"SH]T(4@M>__MOKI]-\KQ'4#"P/N[CZ"$QC_=D',K]]OG]X M2T17B: L^1!."V^83F]V]1)\M/P9@CDIM]=?
OWW9C.&R]GIF.?=@D6(P1;G% MJV?_M_7'X_H^NK?_VW7/G[Z"G0SJ]IGCIYHI6&Y&"1";80-:]T:R%H@2Q"B MM0OO'N1._U*;NS*Q@@ZRJVE1_FA]8727A9^G097! M[?
#ZLO;A[G+X>VUX]7!Y]XNB&2_;J^-GCF)*OLD63N*=,F4X^B]*$[P1"'' M3W7Z![ZW4K<@/CK[.98&?OL83P-$49E0P,/-Q6?=_!Z,,M:=N:&]X@D9(.I] MCP@?MIB*\@Y/%Q-
3T#5MI/H/C.%KCH16R&"(CYY(1/+/\Q*'-8_',FF=4$ M3X8"Z (-4Q-KS[6=]()LP@5FC7*OS]@KS^0N4C8 X F9K_F!ZO0(>-F*O?WZ M+6Z/=-<[1]2[ZI9 212RW5#
(,N$RL4R)5RO,0F*KR#F\1:OUK-+A-]X@GX>$F0),L,6]U MO(+MYYPH;W;%]WF2 800>"BX+R&W/UN^G^,=Y-RRYL6UQ"=@_T$K*"3;,2/GK W%?EBT7I MK)>4)1^] Q?
WFA6YW)3D=VSD]U4W#X;Z@DB#%-]'G$-20?ZI5(*)I*%#!:&6 MI"%)0U(.21]28ND[UCZ]J=&A:D0?3?4>E6R\B2%5XW"8T!506P'%'X8
M$KRA]G]#*E+XB6:Z;^/*1()=R[]E#OR>";N%2Y:MIYTD@%KU0ERD*+7=3'AB M+O870C(,FF_;W;;)N^-JC1Y+YV4RQ[_E%DI!EXY!V\L9U9]ME;[1$A6D]Q4 M+"LU"W"\
(;&6;O8>;,2MW!X,!2Y>_2RG,Z'RQ7,R(M M31"KMCI^Z($?GI0NG]+5G;3B6V(6<$F75]UWRXEUR4(MR2_(+W%='0]Y]$O) M+_UF.<$9R2^27Y!?XI-
"KA$3'V;TFY+#2,YICR.B4\K*>!2,G7+E7:OG*BE M+/E-:X]90].3'C@W] 9Y&T,H_6^NK/4GS2IC4POOGP]-QR(W;I>7OKKW;_Q M)6]"\U7=\,_MFB;G0"UQ%(NH\1S6GS_+G_,AT?
>'\[98DF$YL/WDPMKAL*# MH@=WO/,MA9RH'>$':.9V*_J1O1=5#V*+]@OI!(UDE=32HG_.>Q'<8W<8T5/O M7\KEWY[NOA;<)
[KX1MGZ>UIVC8Y0B9XR4%R12_]86)4B!MSFR2(N9HX[=N^;?FGHUA-FQ"&G8' M^L(<3?FL@2&AN9:MXZY],D?
GRG#&UX1#W<&+J9U+:YTYAF/\QWI$!"/PE]SCNMQQQ8"7=6]O^)[]_*X@,7\[C5/@D\),5 M21[;NC04(%'B&]]V6CY1XY /KRLR9OBBV6,0;/#ZFPE]Z@S\Y8U3-OCKQC3X
M2VQ:ZUH* P*FGDG4\@\AG\V@UPYG*TX?H\C*@E(&4+]]Q+O[(,VDHLO;D_Q=8BX+_"BTY;@G57>5_LZG[(ED[;],"!:JMHP9'Q_M/\,W9@QS440QX]+_R_;,PD6H0L7KV
4U!&X4;:7>AM4%*1OF&UD:& MP!5[YA5(FJD(S=Q&#-4]DT[IR>/ERL-L2KV/D;:YB8^V%S?RCU:\21)81P]_M,-XRI,J8,@>&Q<^6UC9[T1PQB7FFZK?R'>IB">*)1-+(R=&
(%!,G3P*)"9* M3UN,F?6^H!\ITQ1OPOYHO&>TLMSC+IN$O%POO'=^^9ZWU?L7P_8&"0C4%%P- M,N9"CX$/GM(Q%$@?C^E-ZO9T]IW^X_@F-=%KW]BDZH.=)R
MJ.10QY&*2\L*C4[OO)\+/LAQLT/597U_S05>#_=$XD4A"QR)I.I(27_DDCZ^ MH6MZ.C]2.=]LU\\"%6&&2@9^B_-^B"07QA8$9T7HH>7:3VW)3IH'7>KH@NE0R1(4/$5?YM9(A*ND_9
MB/UV+D4?DLA+)?(MR_4.QG)97@0,'I31BF,DL_*#55 M);8:[\?5*1Z](W3E4\N^2K%$&?!6$GGFZG!+".P#7?9@N4*+_^"HOYBZX=>1K!)RWN4UM?R,%LDOQ?'+(!]>^7"]
MJ2R4QT3_P<:U_S';6M$;M6]H#'D#A0[4& M*14]46:#.MX2U_J O+E%CLC/ MH>L.SMNK4 CELDV>2D*]I9S54]HLBDIZDMDHI7S Z]52]@#';%!*]?(L*NPC
M%]226O7F>;U]EIR\ADNHXHH!K3G(F[GM83[+ECS9)(..@G8C@?A-V94+M#H M%&4"%PX%+(L($NB_FSG]'VD90:;>/6_G C=_BCQR:FHF"4+X /S C)1,OR/Y
MYP1U3#]CXC]6#=/MG/>]S"%5AY?&0QS:4<)^W(K_ME3Q;KU<[B#]F_])DN M;$64+0D5>B]YDZ*>+@%@AD,LOU4V%]QIGFL5ML@/FH'2@7)@$9@V]"94@*L5
MFTT,1FA_F]NX, OFGD>FGD# QX;L&PU1N'H]XVHWGP]SWZ;/(>YKD&0R2'N ML^79"]C/_"OPFR;6L9YN+('Z6X,#JFWQG (3TYUS!:&(9]I?EHWPPAQ\.#Q;
MA)Z>S0WKE<\"QL4"IT>V":,(_>U1GT'87,,@11'L#4YHHMN.B\<""F_,P:H3 M1G2GNCWFD]1,4P>Z#=30$1A>OG-_K:0\4A*@^7]D4$+DU?V.4L6X#[5MVD3ND MT MH/K"
<3])L>\S&^;6S*0,NT:%]4Q60$* Z3H;8>8S]/'E-Z5&P HBF(M(XX2L(;2D).>8L&^TYMQ&?C".45WCQCV^P^QV7QT]DS&6<$.2]E,;<96$H3>C&7Y Z!F>$(-
N_'X8.2/!F,OL[G:D4D'RV- MJ-,;6R;!TAO,[P>*,X(M>M;#N8V9,[+U1PY03PCRRR\P;8@1_S[:M,$8MY@ M]?2,;3V2S0)SAKE1,X*E[5AZE;\5H4!>2]AXX7%19X736U%CY=[8PU_00BH
MM_YQ$)_M)]@D=ZS3WMH= W:Z>FUV;AW/;V;TH+N8(_)\V.M9'X,]I.]_S0X_TUNRMN [C7=O%!]G1,3K#3_< MQ!/;/DA]NB>VX RHR?N9]KHKIZV=&=HCWI?'S?OZN.V^7EGV/9?
Z0Y/>]9FO MHG6Z9D2B+-@*1:?X1MH&>:L(;OPDIMHS],^(4:=,$)7TF5!)08C]($&$4M4F M97="_1&F_?M[WWN-?H D>K)6SCAQQZF#MX+R_FKC#>_*_I^WPL5&L M^?8%?B0:[H
C)(AMP7H9!>3&;;7XIV9,PQYL9 ()PPQL&O(3DM3S<&[KAK+@ MF+A3V_*>]HE?6P!@[9WS+SZ0E3D#0Q1-B412354W=%#"»)(,8-.^,W=OZ='H
MYR$]NJE*4TY)>NQPH#OC)0W..ZO?I-R>6I4=HN%81(#,:"(12:$]+[H[12-) M-)+B#\1XED)NC#>+BG]]X"HU^KN*BNC7HD)BR8O$T*1F&+[=OK6IN)64PSEL MYX# 1+=R0'S_8]?
U1V:!F_W-OP3P3L1)7"G8#R_Z+ 5CTR$#/B7N!=,/CG3 MD9:3]8;P=FTEYNS]!<1!M'=B4DG2(552X]ITN,;QZ,;OH"5FWFQ/]1%M^YJE M'/]$/1^_P5[_A\>W]FL4BV)
[-57HGP$O\VY]*IBAQ*W7?IS.UM>17^/V7@@: M[]8"8RV'Z_";3?*3]_S(^]S3C9!M$U>')C=-^TW&A//^J^$ISB^]%OB:D M-W$N!N=*C+3"5K(?U)/2[Z@'L,WR;N]OG]X2^Q
$;DY]%OR+;QA.]G9UDOP MT?)G>!^IW%Y_?9EWXECM/G+T7@RG*_V/O39Q_OKV!4M^^4 M(UA][4O;XXBR77;W[<6^=O7M>#^=H$BHQ#%%]KE46?/K;V8"X")1:TDB)&'B
MG.BR1 $@W'^[OOOP.UN_)FD6R>_;+:'U6V*U7ACB)-)IX\"R*AG^HT_@=POUQ.*K M]Y]*Z?3+^W(Z\?/&?5#].M,[WUW_6S]+XT93SYKA+M+!ZA"O;"PY[,Q&-5Y; MQCA$=?-#'-
A7>5K3)ZA/>BQNAG MOO[)VHHK2#<5!"HO85+X%]XY*WF+J^\YY=?;!N1*/\?;^BT^>>-);=<7]H'3GZ M):=4SR/"E0TN/&WH"T\/]X*_1EO?V1$]/?^%;_64@&6;R(.R+P>?<5EA1*#+RY;
MR]_<^?^:I8^+O*LOL;L<7EB\Q.[N.T3(;L2,SZ%(]%5^>YUFCH]90_+&E_0\ M!L,3S'Y@*=[O[H@9U_|_L\+HI>:2B^.2VX>'D#W@ =&OP!.N'T'T0F<WF[&=T,=K,9'^'$YDL]UBVUY-
CPX5K>E;@RKB$O+ M&\/FN?00[5Z+O#IW:"X=4?)#=$X,[S=]_8 FXA-6KTLSH]U\1E2P; ES[G*(_MN)8Y4T\XYPC?LW#2O"K*UZ# KMB3\;.3A-AU4*NF3GFQ,W;+&E-
%;IQ2,J=9V>V-VG,_B-1NAFE[:">^6%#X,0RBI26> MY9C7*+>*0%YK]MPC>VX&,[LG[SW:BDMW\>#5!VP_D9.ODO3DLYESY;EGO@;V
M!#=*;_W*UU(PA5KE/6]&$&*CL1MJO^L9:G45:O.@L5EM\]$=K[PM)+>^XR/4X6=2W/'B2WV]G7!HOM8]I'NRQ'X;1& M/*NMU^DP]-
&84&:GZI@M+_@8>D!0!2SA^A6N=NPV:]!>Z]AAG2UOZ.(_,]RT MB4;\7'&[M&X[>VK:43LC1ZVY62_ZD1)FDCV:7M_47
MGCW3U[-4;O7W@IL_;+:6(Y^?=3!UC[UA9"HUZKY+CMP)F\#R*&]NUCLIP]:?$ MVM4K[/45CQOT@%==\=CLK*AX;-:ZQZEX/'=F/2T]O (\]<3*(/O'"]K/[W*0 MLC4@S
O'RN'/\N&=%:+&BJ1]+P>Z;)8"71P> .3U\,V?0;P2V&20 M]=-W]3$?_E>?7\>1-%+N<_??P6,3.LT8&3FU=E]
M4)EL+;\P"U=\M2;1<[@CN,WU\&Z9KJW'3UNFNWMIF5XW__X;J)^UFG+=5+8! M17VU,V;-_3ADS/@C(-RK.*]RN?:]HA"L_;=#]&CK]E/;?;[$Z\!,1'N2Y/R M6GT?#?
%"R\^K'.:S"E*@>A>:BE>4CSD-9#FH>T'E*ES&+M.SP7]6E'*AG<8S5*Y/UQQ;CY;K408&X94I4$.!;%]U&;LZM@>8ZCFU$03E3=-L-*H1 MD\6]+Q,<(S*PEI5*9&7K/H]J9*5]]:9C-
MJ+]_BH9%*TK)RUK'3*NE)RB'8*MV956ZR!5+P>1E,H[(M=+6U5!H*SG@]B/HWD'N2)]<2%8,,)2!^=@V[D.<-8 M\+!EGMMKDS5:HAR+;$6T5EK'/%?*6;PB+UZRIZ]PTP5S
M,AE,V_6&;GW=1V:PT0@O#IN[M_-H)T?+ M=N!X:8Q=%G!H7;%D32OU13G@WGQT,7<9N+S$.X>XLG"==ZE>^=6W0^K:L3R1 MH""-
]6U437R(^3)GGE12)KXN!3ESQ%"],.H=.NNN#X0^)Y MLQ0)BE=2GF'EI!KQU75:W?+]X+V5(DI8+062BQ,KA;SHKL;+EM RHN/]E3P MN7EK$3;ZNZ"MK7L M-JI2#/X=
[X[*P+7]M98BQW]\7 *.E%.>N9-Q=8*^.P;C(KX]W@(/?T::8]>;;M]0($=22FK2L"]WARR:Q*Z_1774>EXP.EXH/>UOA. M6PB_8 8=
(6C>/83=VAK@Z6BLJV,$S;9+V79K=*=CLFU%1XJ;:95GVZVAG8[) MMMBK"'3O M6XB.QD;LXDTA\"\('X@A?)L9=';\=?\:UQ!N>2$=_3#1SZ\VGLVE,Y>X] M3B>8(13D'@.WR?++[RE;
2'^:($IK.!*Z):A7<="WS"XH72I201O/O$MF3> M,[DC^C;"U]3[KP3&_$!]N%==HWVXI?2Y=='M_7UT9=5F*7O[]771ZMP9.!F M/WU]M+X^>G?YT5=NZFM;-0^IQ$/]7-
N]>>A4>4CK(X8U):HU6*X^'.IOADWQ/\]_T+V=E0! 2#R"1]ZE+/)I MQ/^,7<3)8<-X,U">9Z]Q=@+2&^\]*0-?6QZ];J*10;89GH85]C5!UZWTM5%]H
MA%!MAH&AA6]=I>IH2Z6%2@K59K@96]A.TU+I=H>E@6FA9(A]>]CV @M5;B07 MZ3L*3@HZ:"?PV/YF;=8'U8#$BX1.&IT#)_X-C)A_6GWUUU:EBK-R2:IZ_DN6
MY,WZSK4DKY+D9]^G)5F)^2]9DC=KQM>2O%*2ZTTMR4K,?\&2/-@,H4!+\DI) M;I[.]4;*'XM7EW&X#V++,_*=3G.='KFVCC,\%[]L@.+!UF@-:]FA]M6;7]=^
M,J#%6FC.0FBVQHE02VC =O?[U8!W:;&Y6*'9&]5".'I=/0%*UHCBHT6V-D M*"H.]7 M5,S'V*+02(0%V,5F(3KBP,]+\ @1@@\ONN'/X\<3%H\#QWBRHCF #H1R +D+
MF14A&.;:]=S("!F?*@XX8(85$EQ&R*;6#*\0+?Z 2A$"&W1'"+]Q0(4('MF$ M>)P42E#P.F+\E58]WJOQAZ]^A;4.89-]%D57+]>!@1O*\D'U"/&34!&.^RA; M=C]__7]E])F'H+'D.T6"
8AD28*OQ^/;L+@*?V]-W]IW>_N_XW YY![(ER M@ G'C::>-5&X1/S'Z9YK>+'>_%0"% #)> =6E_CE[_9&5;]!/L4;]7A7^4,*Q\4[5 MDE_E_B8S4Z!UGOB2+^:>*;--N!
^U@PNCM[^_=R/:"?*>%D& M=M(!3LY/"C/Z<&;=5+>]&==6_W-?%?@[^: >^&?4"BH"M,@#*9]CO [(M MEH\H2OCJL?7=F(;!HTMV VP-!PF*M@;UF5]+06Q%-C]WOH-
"^:"&_@HRI]& M*??>?9\R/V)OF<]&;DQ"7\[&W4SG'4D&U+UM8<2U3M]XHARE8?2W3 MT]QO,6^VV\EP=AM3IZTO8]KU_*VY-77+QW)(>AV%.DL2M6K*]%% M$1+E0#G>.
[H(!ZI_0<\^M&)V7F*K6]WH&K-2WG6\PG/_G)1X?@)A];B\^76E96F6-I>N<-RK M8-C,VO1KBF!+ ..>F3>O'N>N9-SR9L@5#GPEFK9;JZ9W2RM:Q=BUO UQA0=? MC6-
0[]84@>%*&?9YC1[[J,PK)M*WK/C^<%]>\2U/:)Y3\RUJO8W/'__\ZX_U M!V%+]V)N%UYEA=#&9^N!9;7@*PIT1&6-1?][$=B$1>?U0I_^5!67BJZN?CER9
M+ZDD*O33670Q_M[*Z@>O[1_PSEV4)7>2+[WF%=F@>DWCB1DLBD&7QHSN%;9\ M/!$\<5-M/D"GSB1K.PO5F1CQVH[(GXH"&F#$KO(F#&P<_FX;L!A_@[L]>,;\L>
M&_\D5@B+,NGQ;'K1P[1T!3!K,L51'9-6PV\33@=PRGYCCRW_??';NQD0AUD M>.FL\Y\DBJD"'0:=6 ZL[-;A%QWC];0F#8R#\"$C7!RZ\^[M8$)P> E$:Z2 M]G<4LG]2& NVAO>2&
[,)OY(Y9'8_O_PO5L!'V,QBAPS?AAYP?7&[,"<2 MOY*X<".QP1Z1(_G0U(N%Q@91$?SX/TGH1HYKBTNB@VSE,]$!9A8&A1$\ MZXG?F WK!@7
/QOC'0(H3V3E./884>?Q2NUK>^X,BN)QP%O+#+OZ:6;=^> M&2,OE.%>;Q'@>WZO\%:"TV#C7=!_U;0%1F 7S^N0%\DUL@:&,T&-!PR]0* MLK.
(0C1HV#,7;5R/:!D8L.)9]K3?.>;,B[W^O^;M]^^.P]=EQ8_YY2@5] #_HV:"BBZ&W\@:_K]UQHX>%=0H$F M4'+QG/^%(]PE%45I,]V1&[\.W;SW+IA,7+*OT:WO\%#O
50TJ.YU[7P]A=OY M&]7M?.*_N7?FNE5^G'OYD^CVV]I"_(!%$?ACZ'2)-]A&(1*-R+&%1.W] MO1_$N0;R]!4I?[;P?-ZA#CL$P24Y]?T/FN>!(1,A\SS'&%GJ6!KJB(3IEEH.-
M\=*#O!4U0[$HV/QTI8W0?;!4286C.,,+@,_GWH+]_7)FMFBM <_.(N6\% M7]W;_R0NWV#"R/SXC>4^Z6H#$S)U(3SQK^+,Y;"-M!T"/7 M$60"(S1;C('F\ QYP(Q%L1T,8^S$%2&.?
S'(\L-R>B3FEG-2%UU M&.EW^8X?8/W_%Y>_"T=UKMJTS4$)1R&MP;T%/K%L&\RM(XMK*58KZBM8EX-? MT5^9YGIK>>0\?1TSAJ/I-7VK'EFB@RL%OH3&3N_]>T%HF#-
J<\PFW4 P0, MCM1VY+@SSP.J@0F+U'68&4,+-SZ9HK^*O$1DP\C>@1IF6#6PHA W@_3(_7FF M"*7.5GP (<*#!L=[BP1C?.>LYWLIK-V-_]\VGU>KW?UM^@CY3T\SK8,L 3\:U
MB:Y90(/$,^!?S1C%ND!1!LQ],S3_,VO" (DLU7 M\E*K7L)+'8@],NK-[7GI?]XFPXBGZNXPIW8_FS(.E%W\?!7GR0AG!^9[1VF] MG:$!NXL5:ZGYYOO.60A39]"[-
X]/.X+PH0'/>10]W/S'70&-Y##)-Z2C<%'H MTG]9MD)K43-R#AX& &1ZEO&1)>1Z'ECY,^CZ#9D8"GA9O.(F[$ROL*U'#@;L MRWI?UD5]RXX+12OE6_(G)0HQ) >C.5_;
[ML7>3ZP+ECO5QVL\QA[5+,3L MQESO_E7\E[^W\:O/)1"$ZR1"]6=.B(X!1]VAT'9]@ @S[ZA3XC&Y?I'8%3?; ME;T!>O:X)?N$ZIGG\QS=W\[$E^4T M"M'\I/70]=PA]
8H$%#T"Q;%)C#^M?7RYX.3[NB2?G+C TGD%,.%SIO3>8U3 M'U^308GQ-1F4&+^$#!M:V"H3))58U?3_!]2&KUC"ZF+G_%072OF.\Q\)-]N]&

M#_"D.PP\XWKX4H/PJ=2PV]GLLMW_R0JX8(1?L1&)ZB!$)Z[_(((EDW$5LQ ME:S*]@?YO;AF/.^[7BO>.CMU91 95.D]UR+$16BSJW"Q>A3M-LM96!*C]I3*X:<>8[S_7QA8V/ MS
|FKAV=83AY6!/GK>"0;2"Y02\LTFF"H=;BH142*R&:P\1L(ALAHY_,2("5]3=,-M=92"^ M=PCG+OW8*T;3,<6/&6SA-[<> _,XP53Y$ =VE6M<3:#^=^OQEE@B1Q'J*5]
MP(=MMG28I\5%B$MWLTL&+E)$U:68#H0BT MN&AQ(7'9[&:%2Q679M_L-)7,) ^J#O;P(<*MNK4/_MOVF;E%H:;^-EKU1LY;4_!SX_S+@M93:U%%[C;;;;BA3[5"X>5<]_R>)97E=T
MX+-+1<6S:38Z6CRU>%8MGN75-P<^-U5>/,&1;@\4B9XK%X^JY]JD\2RO_#GP MF:WZXMDV!VU%FD'VA[)P<8>YO&/V/HCQKB"!K[46N$<-=ON2D.9KH+]]+GR
MZ]T5ET!5>A+5;9K]MB)'49T$S<-7S;QD2,E1>WK7BBOIJ.VE:9KNW"#"O94C+ M4(4R5%ZPM CSK88,-7I],$1:B+00]21$O?(RIOF851DAZO3,9O]TA.@$SH-/ M'<9)CZ_'U^/K\?
7XSQ]?YSY7Y3X_AD&$-]$'(S?6]++5CZ]Q>487Y-!B?$U M&908?W=4V4LO"M:HLJ<)1M8K:U8X$519W:T;J:[;[#3424NKTTVC1 MX*)15NY^(FBQ>Q"-ECGH:-'0HE$]&F6EYB>"
OM\T6CWS,9 BX86C5+1*"OS M/A%TU^>+!D1]88BY:(Z.ZI16\^@G;Q75IBN(FKK\[5'5YU:)EYOI.0E:EH,*A&#\I(&M:%)]Y!CZ)D] M5?K.]*F4AAS5]J$R;=KCVRPM-U(0P][DD
MNH^,25,5_/[*N;[J^2]9ZLH+/=0$"-U#:-HRFQU%]CTJ9_NJY]IDL2NO,E$3 M^/,98M>F0\=ZYW00]90_B93O &^4BV +87.^%WU)++S]0]I>?
&'3((RMH)4O0$'.'Y37]#PSYCOX>4]C":Q? M3>QVDIQ7^0)49/WRPI1GQEV'9OU!%]R=:D[4-Z"[\L>)VT5+A5/ /49.[X(0 M0B>(SPFH)(C'+#2N[:,ADV@5LB\5\CSPDI0-
_@O\H47VI$1&[G?FW/R7A<&\ M_KA1577H!:C"\=Z?AR92O;]O"%UMM;I7_E!)&:3D8]X1=PHWB,C'XF"Z MXKA9&;BBO;[52CVU&4C)^1]&%8ZR+Z4)0HO3OL5L,^238YQPU:NIC-
3BL5I M?^*T&9S*!R;:7G2\K0'>=H,H^4(9W'=P>EX>\H?SIW^_0UZ#V^E^/K\=_M_O@Z2;H]2?]%@0-DNQXX 8:+^79HUSUX^M;M)087Y-!B?$U&908?_<[Y2X=
M]24M\378]RGS(W:.)Y&7VWG;])=5@!^XX2W]T1UG]6CWHY%!K][Z\M,Y5ZR MN)15.Q^X2VZ/XM+N5H-*]\7E0L6EK%+ZP*UU^Q*70<_L5'3#G!:7"Q67LN+J M [?
C[5%SU]/<)%,?.]#HM&O:QR^5A1U7.Y.==GT5.%IX_14G?1[+R2F\L* MAX\5]#Q;-S?:9E\=1E:%Q0W'0@&_? MIFE@ME2)^BIGY.KG/W-
16FV:R@LL#AIM'LPTM2NJ3MK2,.FSL%5=!M>8?7AI M,"OT80R7+0\#-+ M?GT(@PF,#_,D,(88#&9ZON_<;%1C]><54FO)F?V9G61#!]&' MDJ@W#7/05C6STS]N^ZJE]1)I*B\
(.6@,>AAIZF!?=S?58FYHE+4TG+TVK MW;WRBI2#AJ&'=_=:C6ILU;.'H]'?X]'@3/#?^U:F^,_\|P#+GZ/Y,)3&6+ M#[+<*,;]4D3L6_XWSG#_OL*<.O,\|;]IOZ.I9%*O;R0(TG+--
GK*)DN>2-\(<_U MV4,BZ([@A>"> -\%_HYY[L3UK9@Y0$_X)'0?F6'%]'>$ M!O8I#C6N]5TB'9LB#,^10(8:TO<2!@:=!!_;_R1NY)(A^_C;'7!HE'AQ
M9#A)B&43\7@EG\;CD#'.]H(8,MPBR< 6^Y:LI/=AS@C(TNS=@R:! PF;0W'R?#7^@] MO]I^3O\PZ5\;C_Z_+3^QPIDA7]ZB/]=+B&#.F65/C^R8UA>W*/I7?
U/+OOT+%E+IC4+4<,]V,RSS5)?)]]>8>!'04P$8^D;B*&V5!@(&O MXC%P'QB<. A=%@E1F(E=Q2?Y1(XB9W\E(2&/7;9R,B*I] MC%!#3*QO(!VN M&&LI# \8?G(;!H^L(A+MG
!V81,#&+*'Q+-"#Y?]Z,*V6?Y,W/HDC:H5P0O# M,[EG"\NL'9T*\|0O>)N;P9=RGW]B6<.?O]ICYB0>^S1ZSZ8A[#V]U:WOW$Z M<.Y_Z9_BJ.D>Z7@/H[\%6?
IVQ8.19K_9:#7!3C/P^ZEQ:DO6KU3X.#V*BI;Y MD^N'V21-^!6HXGK"O2,O^3UXW?Z(\30S)G;#P-NJ7F1GU;CS@&4&;UF2O]'< M(,N_TXRK4O3-N;I+=_=CKO_Y&D,PBA^\38!2+
(KD]_2K D'!?<"34U!SL_P^ MC^%F!)=T=8[9]^Y^!T%.Y%@SWQUB8S:+&74>NN,&;5GUAN[WPKP:$95OF$] MK*5YY[D^+MCXR/Q@XMJ1XD9EW8#5B&?
K6'9$DDM2ZTBRV*B;O?KNLT?F!5-D &TB M=A#,SK%,Q +I@(4.>:VA M\37P$BHZU 9C!]GL'2VFR$B64NQXA]*U^\6TVE L2]E;]['=V^[<1/'"\NVDWT@9*O3GCQ_NOZPL&LE52\I2S,
((X]%-&#RE7\U_AT69 MQN>/?_[UQ_K2E(W+,*_>B,D,X]/UP.34]RIS&QU>F"M7^1,L,WV=W#*?X]3 M!^?S[<>[F[=?]FY_N[G]<'_WY6?#\IZL620E"KT&GQ5VZY4A:M.-)G*1\(M^
MJ-/_X'<++I/XZNJG4CK]\KZ<3KQ?8A]4NO_T[G?7_Y,.XKC1U+-FN(M4:C_$ M4MV29HUL5..U98Q#E/\?XL"^*GAF3V(S7% 1+KI7G.3XQ/R'J2=6_'@OTD&E MP$8PHKH4].1?
-V1MQ14DU 6!RDN8%+ZY9\HT 9* \S'_$7].SG/XRG^LG;)(MMUN^/0["FP9>*MN\DA2$)V!K.$:B\JDA^K?TWZ;X;PW_;^ P[IL_+!\$$4.C M__5#O]GHO8]P"IA.HD@6!=WZEC>+W
CW_H/KPYQ 6:2"XZ:%OU]$%P\DG6! MPMYE!5S'V1GWS?7[P/.L,_(6-.)QD$2P/]@+:.H@"IAB&?\86SVL"4APC#=$ MN$=<8%'%'X55/@3ADQ4Z-[\'P3?
LK4@CX^CHM$EE;,VT!VB)A=GOQRZQI%B% M^^;_)%8(-LR;%3]]0MTJV%H%.S>!*6[^3^%[]*$LUZ>&%]H83VQLE&ZL\31V M]3%U%$TLAQG3)(P2[*B,_VIPBZP1,X
+P0(9U*]"LD;"\Y77P!0F/9N\2O\ M(7R=@%6$L-6XM6/M#%HM4S#BH"?]<&-=XB5#M.X*QGF]KL]MGRPQ-EX]?QX MQC7(!L'=423ALO_D"\/WS3PFY$DU0*"D!C'6;[@1
5]YQ&KMQ M$C/C 7X+6\H8[=LHB1/8,1!O6M7;9%:1]L5!U;\?-6DY$7 M%Q7%8!AB^!D,@CD%/,?,AC<1@ O,"6R!2>U(01(;V% ;DY)$S30-601O$1KN M9.JYS,DO#CY]2%P"WPA;DV!#
<2^!?"%V(L&WXLU'J6+.[0'QPC3@W9:OTE9+ MV*]<%V:$HB)M@*0DV %XSPC?#9;R,#,-<"B 1:D-;O@?9" 87*2Q7$"0]GU< M57Y\$WG<28"_G.PXAD:*()* Z:G/V&'_]])8]P\79UM3%+
VI-TA"F_%IQ1O" MV_,EY'AA..L1*T8KF1').+0BV':@MJQ8[JT.870>,!$$.F@WD-(-=N*8KXF M>+'_<%&#?P^1LBA>KN\DL'$S>@34T#?&N8RS#3[Q+IA,J:^,-@W'Y8\N(\.0 M
5^,^)S@^263*I/8%D@W_$2146>)&S_D8,!XN9P;1^Y&M>@36F?_: MR+YQT4UT5OW6#A+/6?+K&,P'BY=\R=ECR9>@E5S;G<\.KIH;F7C5]Y+GEDPB
M.&]Q!/@.Z$/6,)96A2CP1,0@L0/M RZ2U#R<>PDL.8Z'\R4BXUR[FBV4K:^ MXKAK1"M*2%T0@;7TT"BBI$BTKV2' HT 4U-DBN9<<)UP6D MNV 8QQV-8!#<"A)#Q3O*
PFZ.SAX^GF.SG-*Z>+H@";&T5CZ,\%I0ZJ!F38 M]=QXAK/ GH'FB48)3@#AWI.!#PS%:4)^;#268GV+]A6EA(VPM+4P&;UF_DEP M!QX9BA7.DNG25\;P"/L;LL0_!]
,M/0CE;QY=N;R%GTP#C]=X@WX""9UV(0,!>]GW*,K M:M&6#_F*@"Q'08@21A\$TRX6L>/IQ:>BF"W<*KE MG[9.GQDKPH[F0?5R-E LI1%]H]
=":X4&+IA^"1A3X^"K/SE%GA,;@'ALLL M,E=(3F?@@20(^DR80SL+L[OMY P_Y V(MNA:C5YFP#T6$< MP!2#WRY)P-4.; RR'CHB,7)S8)D]9SB@^GP$_=!'/(# MY^?"XXO.. !< QM,-
BDDB'8-7-.YX%ER5T9N+ ((-/\" M4=5,P0+,PASI@['UW1#V'/_,7'L3/#X0'& K*3 ?0"MZ05/<\-PJC7EQG/& M1+\MTR'"=^.O$UO?&.W,D!'"ZP317N$YI#KW#6$.V$4]B&)A??
N#=F8FHF0Z M!9H#$R*2 5ALCR$W0:(?&&0.P+&+BJSL64]1RC[$IU;"Z6T-45T+B1DSRXO' M*IAY@[AQKJ?/'";#12#D&*+I\FC8F$4*$32M+W^5>I->E(=O,I_GXZ%VC(& M^^-
SZ? L=X);#VZS1X.+=0?@FL&(-F/X7/2*]%OHTUCPI%1MN3W):Q#@N!L[M"_-DFF8_(N!Z3A/:'NYUPS*ER*4"_XKX G;,C5-G#F82UE)"3%":'N9"*LHW
M=N<)@8XH]!7AL<*F,AF0$0=RE]E+T'KF=!F:2/K^E0'#LS#5;JYMY@A%+"B\ M<*G:,K58PDM"AQ FR8A#>)O!0$Y?Y$,#G)3^;\V9!%3H8?O%=7ARA5GA_|CV6
M>1&6%P6"9DR\M0>6$303[(FOHS&;:W,(?T" OH?N"4HR/KCL&4,/B]RIM/%9@,KDW@*7+N-/#1-1?,O[_;0,^3!-D!? +&&$'9@ M' K,;];;QE\AITY!<&G9\;P_(0UW"L/#(CMTAWRGD
HK_+_"2O\&X^]&)'.< M>D//?4B5]S2!?]J@;9*IP_V2%2-#G#QF) ASYAI-0$]N31E[SMM4D][G-V*U M2G)-%23Y/CVB<65/QTWI'?M%@<+4%,8,+9]9YGH])0M:"N)C7!W&,J5^$LK-
F'E3EGIR&.542I+F$2N6]. MC@4HO)!9$3]FL2M=. C[$$('4XZQT.R@"< S8;1Z^>9RE^)Q&"0/8YG*@%][M#BT4XQ-.[VQS2=VGL0K_5NS*7[Z+&T;)9OY:=PF$("R+.
[)W#F6(@"%C+ZD MS)!P!GR&WH#Q)ZF\6S]&L4PQ'#^@B%S+^&S9Z&(+A"R,61PV983W@HH)=AST M9"#/!3 G9.%FH8IYPC,T2ZQ_;@-_^<12]6:;_3K>&
(B#>;,1<*XR2^*$.3DH!.L R04L<5SO;/QF:-[.;QT)9H&BM; M4CASE18?"V+= 6EE])HN2 A&WKB.DI_,+S45>G9V94$D@,?7HR]#K\L=1]3 M!Q8CA4>>YR]#-WM70#?
[1.AF]_E@!QR(C!?24KQ^5582W)3LG;^*U/9FIY0! MPDDCN8749@(O$)%9^QO" &S'$C;Q M_R8>>O0<9]TG>PASUZ1]LXEL+"$$S@U+!(CR9U2#E-Y>^1VU*)D,.DKOE
M4H2;]BQ5O#QX26A58,!'*:$.,_!-/8,8V4**U([>C,*X$]NTL, I18SBWR9=%0S3%R/'H0?!SS M@%"AW !IN\@84,('UP[CH/4F>Y&9>;3+^531#CZ#++_E8V7'"-*H"R/.?TLD
M$2@/J[V#'(QPERE63<\#,N<23>W!U!&-'VY1+Q7$'EF?'^(D8=W+%C^7\ITE693# M8O)
(DE++8+A]AG$B_6LXR^4TC844!V4N:L:G8@B;NKW'_L#UZ=SHAZUA=5ACDDO:F1E]+#\1C/EVB?W. MYS+Y^U"V=H8K)]'"32PXR;E,-=?5%"1C'" DE#3FU$*K]Z'#24F\C(A"B69A
M!&8RL/X-OYE@WL02N0WI?:)]BV=381T86B.T4)1-3$G-[6'*37[U)3]R?6#<&+GADP@!9$1Y%V! _M$^/0Z5-VMN04SN]*!TT1&3.I-81^D74"Q#4H[E3R,G=&!3_)CHW,W)D/XQX\
M,J'_@,R<!AJG4H>YKP@]"2EUZ-D_6][!(P$^/VOV,$4G5UB@',3LXF$;>M-/ M*H)20?IPT)DFJDV(Y-C:=53VV:*9 10@DL8/Q(7D;94362ML7 :3^/26%$<
M_],Q/H33OLD3@6)/0771D2VN#WZ>UW@B@%_NBX&=8N)MYO1ZWI\D3D!"N2D] MA9?U,]^X-8[6.4MOZO B\Z1=9L9=NLD[% YN_?XX-RAS2OX^!'@]@KPJLP3?
MW0ER'8\3A/9FWT%.\/&Y UJ>!'\]*3W"%4^1]PA6>%SZS?#N76V!N#W+I'C-W M) A"D;["I^# M/P&:8L;?*Q6G*X.3.4<4GH_EV5L>4E#6$]1>6H0BW(T 0YC_K%O2'P2\MI\^$@4
M\S^[1V1%\|%Q.T2H0:3175?4G_U9:=/';WL^MMSUYW=\G';#QUIN6->/<6A(M_D-Z!/D3@S2RSP>Z$SI>Y4? ^7HAZ=A.W._FDNC:G+-W>3-MBN OGUA"E0LN M>!#FP_]<(%PS?
DE+TKR9R8];N/^=5I6).K1"E($N"]6W6,XC[6] IAVU=]" MN9T1,2CX*HQ^S[_R(]R425?/U\'5OT.UPB%EN$QC#-80@B535!ORDT/PB H MGQ]\R.(G!NO-2E5!F?Y(/%[*Z?
&S+=C]?"D2: ,0:&&0F#"[\]0>"\!@XPK3 MGK'7_0MEB\6)BRDZBR@S<1],C7M*%Q_#[][EAW_<@DG'CH?S\E I9")]C?DL M%H G#7YH(%H-IE)UB;PS_!3/KF"
(NX%6:!'K(GP@V0F&L-!AU'].BR]6MZ^ M)#VP=&(\W 6NMAGW66?DD M_$M>W,)/IM-#W(AYC_A/7]*!;^3Z_%',0=W YDU$>$+G&]AQLCHS=]*ATDGG MLW+1G(E?
#1]\%)G&>\H,\M.E=5S]W)GGBR-$(@(KF%H#RLH9$R*2K'/+!V,O MTJNWQ/X?5;OYJS%$UO.L=^E;NLT7X@?"X&1&DXN 94K>N6D\,(O'MYLEZH M%J P$;0\$V=4>1^?
EVUD8I0Q'A7,D@U@ 5B5Z3C-XHIF# PMK2)/#S']TP\ 7M7DV*6#*^#C9%(4T5B%W+9X4%0)F/MU>>!]XE)& MD?-
)GZ=L$]D!WM\T;ZPG(*9B:0 8C<85UE^UKS7#H09(XYI:^5^;^57Q3+6H M,!6F/*NF03-ND#HI9*]X;;PL&.;I:FFNG(63!K)F/$LGN<&7?Q3S]M?NR\SL M96D%-.NP0?
FD7'IH25SLTZ5,3I;]2.-?$\:$0678:.8RFEEZ8]Z877H<^7I_M_OHP%@PFCRX#RHW!7D8L]0EBWDM06KTC,J&YQ#]WWG(#"H>]684O'L]0-]@H M5P=#-.$'L<7359%EI5P_5<%SU ?
RQ2D'D]7#K#W K0D]'4-+'E..3*6!%0Q) M0$)&)4_8Y<>ERL6<+"_5!(W6,0MJ*\W>.D:C5>NIX(M&)2(RLJ1A*1W*DO-\ M(-A:-P!G]N-O=V:6ZI6\X^OO.HS';NC(%94L]&WRBC0L78)?
_MCHFX->H^\ MBG*K3=]0K%G>C/9CR^RW>K)_IB 1!M5IPO 3U]F1UQ32%86R2&#>(+1DMGWA M&"[=QW:M]2*_9L3!C88].NBXU*L"5TX]!-Z"+YJ=FO=%YEA6%G:DU;KB$1F
MHUYKY'Y;6O.3_8:DK%D;Y'ZQ60U2;@@]$2#W+AB-L(H I-82BVG7FB_FWU0< MZ#(;(XVT]HX6.U_6E,ZB1.BPGR!X,VI"A!?EBB_PB!GTZXB\#2*5Y1<\7R=O M]GF>6)SV,I
;/K84Y53A#0U&;=(HIQ\LUXP,_?L%^#6FB+#KTRDOUYAR; MDR]@F68=94RL;)V"Z1@;JC.S?Q874:23;;1L;X+"^6*C*3UC(T#C" #O!-)96 M*.BMRG(3'-J'I)
6>XG;X^E'LZ(TH/0QG3 MP$UA!Z0)S(=;SQ+3S$XZ)D$)K]5[U-]-W6#98?LXAY3*W?'IZPFI?8T;]2Y MK2H,_']*U5B_]HO*0OF5]87EO/S8N[XTF@B7-R,RO)5LYA/_@[DES>\8_F6
M,+/@3,'/A!& @R-GY$]G$NBQ0="F!! MB+B&*%4(I8X,'F-'F%-X@)7XHOF/\A!?W_,>/'\]/A29,B_35X8U83:#1]W M+9@5W^<=&Q^QV^I\P#)F1
MRI0Z'N8LY8&SH@ZR]A/#$R;!MG,9-A+\]?&8-%HR;X\$0N@!](Y,SUC(HNEC97[%3*E5.MU?,YV!]=M%T%O#I$IUQDE^N:!)6XP +OA?Z=Y7SP5<#BD7]
[/\H2+%_&,1*XR*>:!%?4] M9%" U(ID1&-]AZBYV;1:!"_"?A_>\]J<032>+X 6=(?.IXA\D1-! 9G_X2 M<.[PCPQ5\&L./$;47/!3+@P8+>P7WDZ!:TF(D+>R2W%P"U3.@Z>O%PO P.T
M*9"V8NOEM@[?L=MFM]9P4F; KB^VS/&CHDBP03SL65Z;CZ^-EZ;\^\K!"IF MGB<@?=-_1Z ETW_SQH^^>)!FD";0CKNGI((^K]_0 MO#Q?
@:.QG9G/=YET;&DZG@4=M3R>!QVU/)X";4\G@<=*Y+'[?S]#2^=??;B MQ2%!L__B>/?0PDR;502O(M)^KN? M7@*-&@.SU>IK&NTVIL'(TJL=A28O-#DVV]?K]I'H\5(39#/YJ-?]6D
4HD>S MUC@V/:I($>^:FR\DNU?>6[VT.F,5U%=O%DK]=.%-]_)V. 'WT6;>1 +VLIA& MT^QVMW5+X ET'Z3KNKZC9IMW63=$DW]BKAN#6]<2HF\
M+&BJ[V\QG79MH"5=B9F/1_-&K5TUS=7.WQ\QT%F)P""05/U>I>*@-L^TGO%_N MU39;^_FG\SFGA$I'V;[M?_TVYTH/UH;/77RC
M7SO*"?!SUWF4I++FV=/@V>9Q#C9.@F>5,MWJV62*F/2!]\52OS.HM:JF?A4' M8I4HO$/$V]^'=./EOZ(20+*UR"S[YWCZ_];IFO[Y& 5>Q7""'!#=U+DC90[N' MTN\'C-5MFOUV?
05RQ#GRCR++T&R\-S;NM,QVKW5A;*QCM1-@8V)/"->ZQV+. M/2SWQ;FL57/PL5CBNGI:'/SR5!:K6?48/-%MU8[F(6@E?*HK59]#FJC#A_LO*T%SLC17\2M$=C<^?_SSKS_6_,L
MS3O-U\5%S&<9GO'&KT9-S_P23IU1,_\[_4Z3>I]O/J[=O/UR=_O;S>V M^[LO/QN6AU=IRX@.<5Y\5GC]5\:8\;UL(B>)?.^/=?H?_&XA32B^NO]I;-]_M>5^^[X2AOX==_T[G?
7_Y;.X;C1U+-@.UT?]Y2\&7]!_;WT+@HQ]/';L8A M&_W[ZH!"_^,?]ABIM3_'@O!V>9]3>;,H- MN;^]N5NEBGL1MMCNC6],R);U"[-P\>G"]JHZVUS#KH?+.L T>T;RW9 M]PAD
MI]S5%+6"1-.]VX BPM:NMS8\9ZW2@=@5T4XSCSK,TH:.TS-(]GAN M6P!@>QJ3T-LS3C;P:YKQM&,HS6.9ARM<33C:(VC&>D_U4R-[=*\2+ MIONIT+W7W!KN\8!T5PQ
<#U5JPJ]#GU-DI:@C?FWU3$[O8IMIK$N CRMQMF MN!O'ZQ0T^4^*_->-=JU9L0>X_TYFO);4;YJUTE3OI+$6'N?]^?H6.EDZ%Y7
MB>XG=AA57:RT]YN6M#3M)6[JFHU&Q:Z3FL2X"/(W^V:G6;'_J"8Q+H/\W=!]C^#:^H3I6"=,1]B^ZA %08=8 MAD)W#1VP +C5-]N#2FVS*O169!D7PG9M<]"NU#-0A-
ZJSEA%$5I]ZYMDM:]X M!G3OZZ1 Y3-6$2(H=;"B!!4N@NZ=GDITUP=J&X:&O]YM:6M_O56-O[[6!Z]] M H#KASO[NCUS7Y[S\CO>W#C*V(#199QL=S8Z9G-ON9&
[6W,V7K@C?:^[]?8 M<1U[OKE",\$VFW_=Q1-(%;A@SU?P:#;89O>Tu."J AMH+]B0"QK]OC!F3USP M6KVK8+:^,R(?G"X$F3NL,'_7Q)(+(5;0L$\.&,&LKZ)UT AO5<_@5,%"Q961S
_\4P M_]P7M568-^OYL$#80U]A4CKKNDFS.6E*,2/^F9M/W$7S*0F-Q+<2QXT9(CGA M=201_XM.LBS\& B4>'%FPWI)T'L@.=K0C>T /*13\?;\WZFA=E*C>.BB6] MT=FEOF-
A1S"R^W'(UL)9]X-35OG]<=!:&TUGVB%M!]VV@1>7_.9UD>G MI8_F3V"UU[?E-)7S^:G]4PU3K!GG;&"*->.< ..\&UO^].LHUE'&RO-.-I8 M:<91F"4-%8G5K"KQG4,V;W
9PY\]PSI4]W^<>G"NTVSWSXF%FF9I%XFTLHE MLENG9:9]QVSNU^RF?$U5HU>K^,Z0L^[END0UD_;7:#VC^>T8_"8[2#2_*3IC M%7;MI=(%*1K&;-PIV,81)$Q#8.1]I%>J]-
Z'9B]CKXD08D9]R_Q(EU#?6K MQ(Q5F,Z!OE.N\AFKH'NC:;8[%8-^]DF-BZ#_H&MV!]K]*S%C%>+?/5W@U\H/ M"ZN+F#[Q+C;_P6#?!]CP=O9ATZ4
;;;,0>^8N7F=U;H\#FMWCWEKN.8P];T M?1RH%OKF\'$V9< M>T$4O=11['DHZH[9Z^D00S/8P1CLNEMIG<>2Y@=]9UTE]U&8O69"8QZ)0BA MEO&T:O?[)8!*PB M?
#W_N/4B+Z]X;IC=WC$O.RN[C]),:L]:85\FKS7-1]/2>_7T72AJ1OZ]'_/ M*]L(?]%5S=FIFH]9!1_8)E54U?-;\]=^6MEEK)6FW8*H]\V\U.Y9:M//)] M?0+W9^Q_UM?#-
U^R:T*_SE\3NG0E![P5X^#SP3N_=M]\C>&'GOM?*]VFY;T; MN?Z(V?3!.Q@P#+S7/[EOCKL;>*_)9FLS'/<1/H8/8,ID9-DQ7DA#CT=X<0C? MUZ$>,$#9FA,PQZS"?Y%S]@>LWQ^S#%N-
AW$0BE\D>(U*'!A6%+$H,N(Q,]B(MYGYD/GX2C& 370=V(^8 M151P@$-X%A@O?-494@-'!AI-+-?W9G3K#HX" B!VJ+@H(STM?3*%*?DX+1 M-5^L,^,[GK*Q?,93N0\B?
97V<:'\3OZRF@UXH$*NJPP6-+]&U;BI\HLBU.89 MK:EVYRV%;[%1F^FTHCH]135_]*Y]QG,1BBTUL8*R4_F- EK=GB]G57OE@.:L M,^4L!>XDT+QUIKREI:'F+&T/-6>=$FI!4Z$&3I-
L]6NN/'R_)E!79/0:BA:?"P*H%%JA%SZRA@E)*G1-=O=B@'8 M%*7&9="_90XZFOYJS%@%_?OZUIC]9ZR]V>V:@6RT99:EP$_5MIL]]0634U M9]PB]]8^7>Q=?
6]U$$(95F18Q@MLZ0LOY3!+7>'JU;575?V,51"^]9)658,_M%T'XG TH=.J7*_;M%W'UYAI8RYC&QX98UWZ;6HS6[:MT0IH:9+@(PH-ITY+(,%P-9%]X;]M"PXCAT
MAPG'+8D#/AHN[^-O=X9E_Y/ .W)XF]>Q:X\-Q*RA'\ J7=C#!\MW]30.QICX MQZ;9[_2RM_ZQT38'O?8^WKN(6?,OF&Y^_FSO>[5^;NN;M<&..V_PK>7P/OAK
M.PAQ38'O<&B>Q=V^VY["7T+FV@:5(B=7U]C56N\H/G]MPI\Q.D'8UX]=T;KX8TT_H23T;?\3CU,3YLYQB6],_MK2@VG_2Q=>QO?O" B0\@\.(6"6X4OH];-PM@"CG3!>&'8"8NW;!
<4D%$83(P?VXVFF-8/_!O; MBL8P"K+!\B*V?0FF1K6) AC:4$$7-5(Q>?"LSG8W+=V'UH)5 V2W9 6-N!Y9S M_E.0>(XQMD#;#!FH:LQ7%U62]Q &KX@73R"Q@#V8^"@$0&F.
(\6>2BZ 0>1S,,F6>AT@)_M+4HF* 02Y9!#^*$0Q=)DVG+1L!Y&AM]SAOQY\O=0%M*ON*7D;$_""LP.##OA M+_+ 7SM%$$16MHQA&%BP)A1"?
FPBQK*F4P]Q%&DH$,X(MBB$=0#SA]:40 01 M[L]"]DCP^*FCU;$OW M)3\SUQUQ\-U-'^+K>X:1WS @6P(RNBA,&EBPN]M3CM)4>N]X7,JUCZ],&]@*
M3U75G:P>LU2.M:4*2V@U:5[@O-!I5USM??Z\H.[U]KI[\.)50*MC=GH5LX&: GEYO-!NF.UN M6_,""C-60/[K1KMRN+N7IXMWIP9 PIE6N:[H7/>)96I5VK*VI5#H)BMV\X!S4@259
US40I6:T!?83 M'VEC"*,@0ZAN>+ 2/'+,KP2 ;_E^L:? 6)^W4I@OI8%/[8@4K<\;\8G#4:C MB,4(@N8PN?[<*QGOQ]YO"9R?+_,?YZ!Y..H/_#B"?6#BS=W02<'&($*>PP%K MPZQ\8 Y-
Y#"@&+Q>ALOVQ*QO/HLXO,F4<=0XA$RRIFZ,*&W_).X44)Y?H(P>1R MFA#B(2YG;HD,OB.\%T$K 4X#8\>T". 91N L-/B,0Z\QV,L)'SH&-;P16X:@?RR*Y1H6!2GELHSQL(@DYQ-
<)N6 MR P)RJ*VL*W"RY; QM5FP=)80X,"#/"M$F(?:5 M/08",+2(@ A:X2PF+08?#K:2F5L"TTU#PY54(!"_^4 HQ:4+]@[V=W\^>/; MW\HA<1,;!]0G9+;I(XEM4QCOP_V7E?T-
NEM2D2C$_P'AT Q*4)1N+7R&XC_'Y MXY]_;&^AV*I>9_;3M@?!=A?$:@LD9?SOT33)X:T_3O_)_C-+7Z^?;CWWO]W/U7QICQO6Q.O[\R1$;VASK]IY6Q
MF*P57UW]5+;OO[POWW>RNWO8]?M/[WYW_6_I'(X;H?][&20'$?1NAEY@?RLU M^6)0XS78F)"-_GWU0QS85P5.?Q(. 7H%#9]D(#XQ_V%JZ(L?J[6+)80HE'3$ MMD7 S=<_66\VY8;
<7^5>S3K(MRV=]1S=L@7,02]2;,!?L,?DY"^R4ML@ :OOU\^PYM+R+XSH-4'F)#VK7> M7AR7^?V8XY2]NYSA1ONX6.G6 R]\)^S"'"#Q6A 1&UM]AUPC*M?"[W;/BP9&' M^..6@ A%?
PA!@V%T\(0>9K0?61P"X4!.JLD#>DHQC F$F.*XQ"C!/$="P$- MS5[;1'W-V*]M/!]#_G^_S LZ$BSG6S<0,(P$XPB2_3Z+0YX/T?GL@/P3D&CE
M&E,Z"Z3M4Q1.T\B0.ZTDAO51_#B+8C;ASC!(8\P(6UM@=%Z[DTGB!^!D@)OT MDGX_9=/8=2";F8&\,7PH"CR"]HY]OJ^YQ]
<];5@V."T,>5<@+$.EKR##;&+I'G]3_^W2:TXP.J=O"]B9&W'S 4%F-2FIL;N:< ZC8MY M+E %ZC%+Y8AU:0C?.1Y_I'.V5\RI%9!&S-3ZY^SUCT;,/$,^/U75]4'(-..H M$#+-.!
^%0]9^!*"92ILQK8VT&=.;HRKC*&#&-).FQM(\0\"L1M-LMC26IN8% M6-';+4:D1,FE$387DJ=M0*06A!!4NA>Z*(JD>:>N/O-\JK>7P^&?7]5K+F,8O MCU).LD4!I([-
#]Q5FFL/;4U.4^Z5QR2:;J?)Y)F75E\YIV1-^(]W!,X,S- MX$'^%1DE^)E8#/."<#;P"/3%*CPG_MV!09VRE4G@R12,4B R#1?>%D;XON*H M9]2@F.;PF&3@BP1]$HSB A>?
*3?]77FD98VQ+(R$38(P759 MN2GB$"SY70YVIXP\]4.A/V'L;R=1'$S@>>-I"]C3)+3'-&NZ!14WY6H2G25]Q%%)Z MO1S\T+'A%@\TRX:\6%SB*W#K3\3!;G^O-
8>Y4Q/+$Y6E>-V<)M5>V$D47R,# M\(6W8#\08+"D/GV3,"V*L]]SP;)>@>?#4-"4C*4<*3@<#:Z;&UY 2C#* MP\IHSS&Q_DE@E'B60@@+!HB,A-05<)QONU-
4T@@AZ#Q;O@VI-&X,"@]M%P3 M8%,$4D-E)I8$&CATB;GY?/:838C5%6]K/(OH;]30$X0:)I;I'V0X/HY#!=R M>V C+C-(H!L'L) '4^K8%%LN]QV(Z*,;!@3'C+9Q_E3BLOA*Y
'ILPAUX(=MRU66Z[:5D+-KOPK6<-0?00NI># M?HV#B*S_PB*WEC -X:4AO#2$U]X/E32$UYYX2D/H*.AD_8-'I$_Y)P]C>"U M?Y;2"%Y;_9R.^M$(7F?

(YZ>].C7TB68<#7VB&>>BH$^4#P T3VDKH61MF*: M<51E' 6LF ;PT@!>9XC0T6B;[:9N,]>\|(K W!H=S0M*S%@%^?NU-4A^%,%5 M6>;<.^V^AM-0 ^"CM <:P$OS
O)"VQRT*VYY.7]>4-AG'V.IF;$I/&[%)*G;D,E>5*""A=!]\Y 5<25 M(VV]QN\Z(.I*H]9;@[JRM_?;HOA1!V:'-27U6EM-E:)-R4%-24_3O?(9SQ*|
MJU6K;_"NYX%W[7.^];@EY6A=6/C"P:KPO//%'.S4*O"N-0 ^*W"[^%=KP;OX M8W& OYRPT'8MSV C6$P2D+P M> @>53L.9--Q9MF$^ *K)1?K"S)DH$HYKJCU,K
6DO3LJ6G@^G'T#,[8%=K, M3/EF&<#;AC!-M%#+* >I6DVK.5)M1RE#_G]_=]YX-O#2)]A-BU#6[KY/F1^Q MS4"7]KF0; F,+Z' >1VNCE ;[8_)MD,1K,'>V%Y"&($9W)DU
=7C_]>+F%PY MAPK#!PDA,#<6XG>Y(2$,83H-A,;R'URI<6@758Y;*H6327&[]^(WL?8UDM7^6TDA66OVGJCHU!HAF'(T!HAGGHC! E \ -$]I*Z:5D;9BFG%491P%K)A&LMI/S\#<
M.=?9]PB?54'?=]'6-:?SR]W9&QSFG4>\]JY2Z6F0 MC\IGK.:8:+I7/>-9=F:#(:FO,R2Z-_N(S6KS36&C(!2]S;LU56==@KU:2S8) M-N=[MT5?:3;3FI9';").FZD-WC M6]:L. [=8<*[O.)@?
ADPQ@C#5]]F-T/Z M!.>"=RWV2EH1M62/7!^>Q&YNWCP98:MD&#PR)^TY-@W9\+A1JR<^B(>]-!N$ MR!]_N_M7!(0J;'M99UR>XG,$WV=KK^,^RO+DSQ_?_E;>[+9XS"|^(:5$"\FN
MM<)X'^Z_K*Q#R$TB[F[9>[V]]N;C_H(S*CXK/#ZKXPQXWO91&=6I)A^J-/_X'<+V2?QU=5/9?O^R_OR?2>A_MW\.NWW]Z]OK?TOG<-QHZEFPG;Z/" 8W0R^POY4VH8!!C=>6 4A"?
F/\PS5 5/]Z+C;:>3Y38=_5=D]_LEZLRDWY/X] M3\ZMT^'+3-B2]MZJNIP_,I^%H"U1S]\Z$R!#%&/?^".KKH7_]WP#Q;X-_85C2&M0'GEAD*:I4F;1XEPP@&07X#HOPG"-
UXAD.C_7C([8=5W_^A MZ]MK?-=]T)?>3*/[$'4?]-D4FDHMU&IR7:$8ZU3>EB@WJ-U1B%NT!M*=T&>B M@)3CE>I5CNZ$/D,^/U75]?O(-./H'K(S9AS%(P %.L]4#
$4YRKE^$C;.*%C4B9 \T+U M,U9_NMVK5%Q3\;+G;.Q!0[Q=)>T%]8,:V*@KYZL?,8],&>ZJM+]2%M_U/V> M/Z!3=V5':SKK6]\VW?]<9-C/ZUO#FOG*D:XTG:F$CNS-
G^CZ7Z.=#^""'>G4 M.F?10+VX/WMEC*7W3.YWNBWN8O6L&+Z,@\(]K'/=:/F+6SU]\EG5=FW*NGQH#5M][C,'J&*2&A1NV4>"U^M2]\8C-CZEF^CT_&
M0>#Q7L8@QM=#\G@NOI&\F'Q-YV$U+:E[4$K+;]O][6(YPQ<6@:S98]]<]W@1 M,3!%":&AY^O([QN.=4MIP>KO=(-7[KE]%S]^=1C%A4[OK2:
M.0$UH_M*M98Y:2VC^TI/G<]/577]?AS-.+H?1S/.I??C:-8Y =;1QDHSCC96 MFG$NW5CIYM&-*%RDYKICJK.O7SZ1QA"SWM%WYVE6@!6US>9 MP@I,6,UU_54 M?
OR65<=GH8:+3-=E,#"6A>X+QO'V@@ 25FK*+[8-U%Z_I:7=TPJD5I$T[6 M%^)5/Z,F^WFWBZJUEL.W\MP8T_@8.5)5Y?E"-$C5]!V]$>$BR#Y0U7!HLI^V MT;BNUP9GT?
^97]DI7Z"[]I LRC=F]FH]?B=N$R_'+79HRFMV^0NL:XTL7*?+ M?\+OU#767]>[KV9/&,<*\19$#Z_'&'[ZG!F>,$3C!!9'DP +Y\^^S1V89-<
M_HDM6AUM>$L7(EO\>Y3$"5[L*Q>)^Q$R)[&Q&S;,_@,_NL%W=D>NC4LNW_4H MF4X]G'B:P-=T7? H\&!1V"/);_B-;,OC&X);2=USM!#+]3GA1+OD1NV+9W*/ MYY^!?
Y,VK\K&2./Z5Q\(SUZ;,%4L%W;LZSQU2Z$R*3$U*G)TKX]N*3R7*B_U MF$7%9A^M9DY S>B60JUE3EK+Z);"4^?S4U6=NDM#,X[NTM",<^E=&IUU*HI'2C*.-E6:
<2S=6)]Q2*%\1]CBWW<9K!D'16W&BQ95=/LMX_9>.(XD519AYK,TC#[G6[U MFZ,*D4YI'15Q3*=UU%K*):LX8F&=ZKRBIF(9F*WV,8LO%2>2*NM0DUE:9K\^
MJ'YS5"'2*:VC*K^EW:DIX.2><&NE&I'H]4?+]5\:5,Z*18^)&XVI_!,"4#OP M:5NPTC!B/A;0^D%\]/Y++:4[+^WF-'9'KT-SR^E1295U5,0M?_YT>QK[H]>A M!+]<-\U^_YC
3$O6\;+Z)6ANT;;H/->A;9$^&GU>0/HISM]*>>W*UCN?K42) M4$P.#K2.Z?=\7<#W%:4,0P^X3)$.\>>LOV.V.L>$\E2/Y]JLX_)X]HE]KL*
MI,6UQWH*/LAUL]52(B5^V>QR>6]J:0X:VD2JL([+X[WKMMGL*\!\EZWS3L9$ M-KK'A9+\+%Q=>B\1: <%:)U%<#/Y_5E"_2E$R2$U",4IFKHZ!LLN6<. M!LD<-FLLP
M0L^:]])>B0P9FJUOQM3]J2K5FIAT,4KO7T>;H LT1."*I9N6@U4O"TI=*HPFO MVH4=H\R_&:(&)V'(@ 2P',2\A<>]F3$)0OQNKHO624(,1Q?!A(W5.,+&HC!
M"!3\Q(R0W8Q<']MR'0+3?0<+=&/C@V6[GAO/\NL8N2$L\)_$"F&M6%0]![S; M@;G@(V8,5TXI\VYW"[V$DG/E/K,>N&;!1 M8\LQ?
ASTS4ZG!=_$40SOCHM(?!R[;)7P+C!*";@R!._P#:>Y \[-$C^.L$0<*!&#\R3;%5',+XQVX3E\M_])SY6S7C=B)F7!@&%S_S!!W,F4%"_YO MCE<$FG.(&QB/+1\;K5>.S[?
TV/C#QYIO'M[T1ZK(,QXL9,&R!@"@&E]7[0ER MDP).X],A1CGN: 2;CLWI0Q8_,<899&2YH?%H>8F \$89),&RPG"&6TW?X?#I M;I.<)KYH@&=.6>L[4I8$&]X8?RQ M^=7[?];B5WM?
$G[/]\%W=#);P/*(5=K MN0TQ4:?A;L/.@WB0+)%L^XAC#I\XS \FH/ 0KAPV^*^O[U'D+>-I'!#]^9// M'--@21CSR!+X-NX] @1S85&HB66@\BOT_L.QUS"T8QC/T ?
_D$DVJGQ^:FJ3@T@JQE' \AJQCD>XZ@(*M9 MYP181QLKS3C:6&G&N71C=<(M_=4U"JECX08%O.T'$'4&!7V"":TT(&"L06(538E_01,,8#I.XU1
DA81,_SS#FZ,4C#.'AUW/Z0(3ZM .4'L WLHFS86/ 0.*: MT6'%WUI3$-OO[@28#]OQP'!.%Z#%EA,3!5"18@)0^81RXJ44XX$TB0:MR % M'IEN(
KCX(.YU=%>9%H$0:4FG/X4O"DL[/G_K_GR.=RQ$$.W C*%+26:X]% MR![+H!FHP9B3?HCEQ0AT]B^=!Z2(9%Z0\0]'D !ZZ$N 8%;V->9 M8,/;;3?H2:"5MNKFH-/-[7BS;S8;[?
G,1%X9S/LA:U)RU<0L!'T#"?;\%HJPI M="MEI'%6:"80DJN0P@G=0%4]XG@=_A=:.-%B97Q(/U?T^L^% RQ+$&T,VE?N M6(E+2):>?[FO]TIU<>!2]F0_9Y*C]HJ@.O-
C@9MI(X]&B1MWA>@[XT]O1+*.M9P]![%)@E@+G6S+[&U&0#]SBN1,7'_$3(BZL0]3BYFX+^9R$>+-"G!:-+0Y) MY)2?.^G;E-U$(I(RA?L<,
(EEY2\NX=EP.0_\V&8EJ39@\F:G7C,^!%*H>-%. M'%I^A)GVK/#AQT$/V6KC%4F^7KR@1.0]? @QBAD/F>]P>;(E\;W$H?U]%Z I MC/A?A*5#E'DKDC-?QXS%.^;H%.7POR*9-
DA3QKPX2AZ@I(FIW,9F-564VN(K ME3I#:!ZN-[)L+%WWP[EEX78?F M4L[A#\M4^TG]+T8I#TEIS,*>#IZ;'EI#5ASE*QG"S!*>Y2>TQ=/'X%'8%?$^ M@4P11@4/0=YI!'39?
SFC,K6+O^;.69HF2 M=#H[6'Y8%P<>((A^$"/>&WIE,SFT=$+<*#/Y2IXI*>9.N1"L%! 0; 3C1>&P M@5-4-(G/90E5212CQ#VX=N$@5>$Z!VXXT-*$5%^0>X3(+$R,D?"(84CQ6,XI
MSNH4@!^_^/,%"G1QTPW><343%0]AL(T!Z0Y=\:5??W/ULJ!.\E<*8H4OY@?X;H([-(U$HCPAUXUO/75R8#!@9^PLZX5" M%LM2#X,\U@6K;*(E<4V1N)+F3Q"B\]:2S*D7 M0P-)
<6E#N2J'$]]?X<6$"2B\82:@-0@YYB(Z^5 5>+-=I&- M@V9^Q]O "AT*G6&4K(. C*[(Y#W>)T=S.\[LO BD/ZL;%K@=IW3 !Z,7$?6
M6REYF+G_EH+WLF+D^*T$TBA2FH+WIH2EM2P0[]A82EUO<3\0G\^^1,^_7FMT ML<>*V]3%]T=7E]";_'91S\/_@O\@_(#W2@M\DS=Y:T;CTY(BY4EE2S?!\G' MJU9)YI=
((XBQ1XUP5HZ>)'=IA5D)U;"T(.=?49F4M".\:J'1DW']7'D3K\/" MWB"I.FPOX/<9I@T;,_H'-@SY^_3-32Z>/!MON:52G4HD M?\]KKF%%EC?#2CJ@F\>LK)C"HP.79!;LQ,I784U 83B?E$':
['2%C(LOX]P MB)+TN8NWEG*?RG._H86C"V?132'F11]<9D*0D4>8'7F06P6F&J-=2KBZ8&&O MOZ+U\F2C$,[W'OPLG](J\ %6^8.RJI=_JZR=9';7MD)R)T%"(L2CUQ?Z9F-!?
7C>)*BCA9 M$5[!W-M7IYAU1]3*CJB&[HC2'5&Z(ZK$WUI04G"%RR>R^"CU%Z*-XG&:(IRMXJ[:]7G?=$\Q>)1\+$!%0PCP<3 MS*:D@P]^9,%T@TFA^1TZ7)-
^INQH4+=MVXP!1]O8MDLH9P*6*Y'Y@53&@] MR0@6]B_1=;SB_2#,D/7(3%QXG75\B?,.T>M.1X?BC$G:L?RR)X'#O"AG,'$T M:NPES::83>E!.PB!P*;N:7[""'$."9="3R
MA!B4]R#T06#;T [@/?*\FEA4E?L0Y5M83R_,Q;/;T8G34R^GR#GR3?Z5N^H^ MHS7R]MQ5]\/9W-%4]_N"\QLXGN#0B/IOZ9;"CM)Q@' U12IOG6N9YXIY9G0Q
MY;O,):L9!9^=.TF+G>FB/;/0PCYW]K5L&53-(!KF>_4!;Y$?-/KS!=_+%GB^ M<>\MUM<+%Y1B4F#4R'K$G9L AV+?#6:9O& &V^=QYE@H'N'*,4" C83G(BC[M%B1Q28FX+')Q
I%$Y5EC*OM>4.9.3D^L8R-89P3B!5P*^BKD3)KOYI*H#/.I M8#HP79BYR$%2V^%1(FB8),),+S$G'7$M\]M'F,M$8\!W.!)X,OG6*F^6E17G
MU%Q!.2_HY,TDAB^Z1&S*SXS7;$%.B+IFOSO(=4\,S"YF*S:3)15/>_8;[V-; M(Y5VC#")E,:OZT/T$N69\CQOH$:-%PP3GCC[)#>E D3U#+=']3RS+8AL1FM4@ M0.2-
IRP9\0^>$OZ_]KZTN6TD2?O[_@]$VKTMSU T#YVVVQ&R+LU;>TDGMG MY],&2!1%M$& @T,2]]=O'E4%@ 0I4B()4*PWWMF621!U9%96GD^]5TQ<.#H<
MCOY'H",L4X08+4G!C)#8H#2]44PWAW1(T$6];Z=HBL%D]937H2_*+Z#ZP2N_ M@.40<[W-^0/LP#%QD\ MR]R:\K+FD-O$\E44#5>3L&\-%*X.<,,=Z?5?
49>QVBK@A(I*3<8]X.>RXC:1 M8@,HS'^H-"D5S\]I'5@2L78!#\&PO01+#^]X%_E,UQAL)789 DF[9XL$':+/ MJ.UDEI4EB I[:H]*I;.G,+\DBN@S8HA)+I!5S3#I4%70W@L=75 >E-
1W5:.P M$?)4E8"R2'(Z.GK2U4ID1POI]>BHUKFSV34,O3BL(9)02%2REE6%I(=_451 MTOE+IO^@GY<\+/&(<:64:H."G>]\(.PI\FO<0I+O;D7G2^%@O"5D"C]\ *A]C
M(BRDLCF[V32N-$V62]'D@4:%->AB #:GIG)T@-;)0SO-.J.Y(*U\NDT*)<9*^ M[C.4A9_1SZC&VZF[=WNXS]]*F8""D"[YA);MD*[GR^TCV>:1L9S:-W[!(_@>T+
MOXA>ORUM[Q8NF$@[QI.S]=CW.MM_N8"+:]%2C.HVRYA9[K']871;SL,-;!/:I7.[Z6=M.&*"(RK7]'I#NPT? M-5:5;3B?RHM@K.,P6X7)\2^^&]83&@LV6R6TF-RO-?=+
[BVX;M(89IC&#%2) M4S%FV#B] MXECT>-LMKEG4+\'2@7D@Q)_:96VBB1I!RZ9ML#+)98]$UM8%WKD4&+)5^B GJV1)DY52"=/"><.%,?
JBJTVA)'=@=X^A%6*"P\7@+/]PJ#+&PP4K2ZN^[=0U[R1@9 MF,O: /TG&[6H?.8B#]XBVH=*N631Z$P[P3GZO$IF2$'F,-F3ZU)4\IG'+^\I MI]'98XQGIE*=%UPS<).E9V&*5:
[$BM#UP;#E:/9[M2.FVW5#,0)[OWBZ<]Q+F]YD_"JU2+8Q/$WZ]'EBV=:$EN %T"% M(+)&XS+%,R+BL%@["P8#$5)16+O[I7 M/1\X"\)A>S2!26-
27V>4,:I0L+_.))0D.0^XNGQCX5WKR2+]]H<,:K="YR-0A M%ZLINR":\R 8B.:)E[HCHF[H#K.@.M,FE,7'T63/3BR#)SG>6R027,1TRGG+ MUY363$ 4R[SMVY$:U+'4+Y*O4'Z?
Q#]D.B.V70;U2<"UC M^*#-DQ].0;^0B'#Z1_1XE R'GB(V*DP^-ARO30 M13A%H+.LPYF[A9>]G,GU\=*0 MW6--O"1P\9*Z>*489]#81\+PQV+\\1%
(B^56>2M'U;7FF>15DU1!:9Q(5L$*M/:]>(\!G+-KR]8(-02,ZDB#?^FQQ*G7"]C5/5HC.9@W M9=A@*HK/->_K*RC#S++X-U1%*,L[$1]R*+U\"AE!BN2G ME\9N\SF]
15KYY&^NCO2'40^U7&,%DVJ&&X=3]*I];2-]NK.QFXI9EP2RT# MMV3@EEX*W-(ZQ0RZ0M# Q!ORM$M%Z7BI78&%U-56IZJ=?MD5IGH?!'0?\F7C
M<3^(4IAK!6""WW3@'LGU3;9]"1Z:A^4>(!@R8H&XW<2+;ZH0W;T3!." 7CE/ M/%A_)1)>V8_5Y3/V1 M&6SOIQQ65VAZ7%S4K(M8#. P6Z"A M?]-
[\$N$T)P2IH%>WIE"AJ9GKM/[N-3[@?]^ZJSK847T;3]' M5P6"]W>]ED6-8%$4>65;"=-N0-2G4!/)>C#*<1CIW5D\(@H$<:Q&5;_#3]&C M15DX\&DT7&<"Z>1XFYF/GY7EG?
M)+S3$Z3Y2CK K" P>9%V/IAL1:?AK888G)$P<"B(0H?M672^5HB"F28/KVO< M$YM\A'328"V^(NK$\B8[,\A9XF"Y=TR;M8R!TEE2X2(.BBJ41-TQA\)&) 8X
MF"0_R!SRFOR6\M[0B1^A]LB]4;Z)R/I/GXY;S:-W((_ZL%/<9P)_D7:=2%<8 MAPB)KL)N4^>O,&088UF!]-);=1..W-!]?EP67L9F;!,99,OEX^373Q=\=OW M'+W<34,&IQX$VP"@[-X#I2
%KI!:@/ C*1R3$"XH\5(%TRG!?_K(;;8.U$PA M*)YDZDXX0>DH ^LQ5\/PI4NVEX+AD4[K-V'CY/7$JEN05HVR]DV%]7C6;(HO MXZ(-R%_0H(]\#]A]X\R(\!5K1S><-
(&YK1EPPK&59:F)4NI>HQ M)I:L7:5HOZX:6XU7/V]>!:Y6"F3(4&1-)VBQP==N!8;0AY=:'&0>LXP&= MY15+;:$>0=B]T/8:VAK:&MIN%&TW_]IBJK6VEDZ$8MX?!
[^2Z']2MF2[=]Y MMMEYP_-;MO.&YPW/;]O.E\3S&X:6I++@6L>K OB<)YX\7U=4 Z'$A>[K1]%I M->LEPR?]7#4];_7=F\?U8T/W[-/[:K-=.N$-8%HIE&^U2Q?UAO)E4/ZH]!-? M-
2)L!=EW]TNG^]/!9BO@W"[+9)IH.&>LH]*TY'K)F/=&T=SO5:#"5M =[_@1K M[$CPTIO 2V1%K[&/2LNS.C+RMO=A,_FM,NTKA99PA'Z(\>0Z,QAVB5+ S4:!YA('9][=^:SA),Y.?USL)P
M07;S=YM5X8+7A@U*9(-]O%0-&U1FQ)+8X B=SH8-*C-B2:I"RO5JL &A@M*M% ;'5>&"<6'P_JD-S UX-N^@ <]^[C &]: 9QM.*I63#'BV8:4EL9(!SS;@ MV2\A/\;F ?]88
ML9SP<)&6-H;SNGK5]PP4UA=!H7;9%#*,4 U&*/VH&D:H!B,8B6 8P4@$PPC5 MD @;EJ-I@.--@/IQN'B[66]5)PVZ$E38"KJ7#_M1-2)L!=EW6\?U=H7]P2M!
MA^V@_"I)X0OA3HCRK5.56""%M!]DH!8QK8CWEA/PQH?%4.T&YSOW33R-R8 M95'>M-@I?42#_%$Z"0S1#=%?)M'-[5Z)$;QY6RD$T,-=X8 MDH&.K](Y:I;?
"PP0ERH)###I5@0N6AAL_-JO%4,,M]:_C'.&&,\;_MP*D?VX&Q\3,(1IERXVIP1KRW+=?Y=6_+-=5W^I_[YW/_Q7 FMT8SMVIP2A0L^GOKW)S?J>D&4A##W M]V_<#^G/I/P_.T$26]_L\
(>(K6LW^]&_7=NNK)T*+B]]":&/_4U@]NRMX4X2:4PAS ID1_;!Z83"P MXM#V(YO@/R+KWHW[5C>)XF @PLAR?:L;)'X"B[^JFYJ3Q^P/:M@?K"Z"%[/TX11
MATD(ST3,H9'M"40)OPT"AZ< Y+MSNX*GS:2@><-/0_B]I=-+>HFOANPJ>L%K MX"O>)WLX]-PN-8^(D@ZLV+7#4=V"O;2]** -Y.5Y]O29AP*^A0V* QHS\SR. MU7-].+0N_#3"#
<1\V0@_#Y(0Z,J\% P%QXQQ.?";/V\^U?B!R?G7K;,@BO%! M^L31^Q/!1+](*N18G5&Z'-H5?K]_J^G*FS!.VC"=/7RJIF(E$?[4OH.7P,)S M.Q!9HD=X,B ZG"3$Y_"]
(#V&\E,8V@VWZ4^=&2" WLH8V M.N(2SPX]W+:H*X:Q"QS!LX:9-.&?>OW$"@+F]%W@?\&0%5%%C6]7Y"F!&<.1Q-.)IP? MIA*\!%8]>1CH+Y(P@$/V1?A (]\;U=1F -/!W&_A7S[14&
[5P/XK"'-[Z !U M(P$]X[(D?T3L%PID/NR);0'#P1F$=<6PH3P3V!T7:3[M+6H/ MZOSX=Y@B<(,[P(<$/\!7W\)2@"IAT'-CR\9M!19"*"ID/M@M2..@+>!- B8 M50;V+3!SPKS-
7$.;K^KBZ]#0L,!3 8T'3O3CH!>2'(.=X]D M9L'!A?WDKR:.;(%<2@]X?G:C(OER[WH>'O=0@#@$28KG@@X=3LR6:\W(P='$ ML?%I+!+8OA)D60"Q"^QS)&*6K""Q.R"V8YRVBPS8\V
LD@ M%FY.*(#%(CSP,%:K.C#P,?#!K.$.Z,[HQ]X#C#9?_YTW&H>O;,$I' \]KIT M?>$"=UW F5M /5CF+% 8GL$] 8?IL]U%PHYX(SK"IEM?3L^.+>$2.6VK@_C,(L5D9E..RI^.?
ZNN.GW5 %."WB,)S[H.BJ:(U2W/ M[@1AS4+*@AKMP>BLR]TITGCZX."8_5=$%4AZ$!.>:HH]D(KP2CDHZ(;T0LU= M-"(.8_M^@BP*OQ3IMSR&_CF,$('R'L-_'5068%UN#X92UZ>|
]6T+M(;Z]9O MP3U30^.X$:5(#>P37LTT]E2.ZGNOS5(Z(-@IGB(S@8[$4'GM&GD/:;HT1#AHE7?A1U$MP M%U$KO4.QXBM:D4ZD=V5L1TGK9-T=!<"+/U*7*'/?Y(4P_O([J%
[Q]8_*H=A M(GE-/L+;,G!]{+6G=6#6EP:#P$&:#!]@/@.I*] C%K.=6,;!&25GY!_C3Y2??R[_O_7IF)XK,("J4GWU!O[<7!O=I MD#__%38:M*Z*_/"GM\>I74RX!]3VCONY=CIP6)9UA9=?
JZW&?@.#:Z>;_CO[M9U^G-%R=?CG?*WA]?OK[WNGG[^??;\$^OK=!D<*Q1:>$+W++?V?U!>]E"]MG MR$R(GQKT_^!W$TD2\N=-T7[_MNGXGTG;E["KG"_//O]^C_T&&"?
#3T;MM/U M47SN=3Q08">9[YU^]?7>5MXXT'7S".+WQ'X%8\X.@WGY8;,7^49TH3TNS;>\U#W,% M:ZFPAP%8F;=D9H*4(.M9L]6TV\FI5_](7(U4*VE]H&CU M<$_I "H@**DS\(-
O;5#&DR3 M(^69QS2'Y?/NDV3,P@V'WW=R[\T)Y?.[VTNTLSB-OEA3QQ= M.PSQ+&'XR?8MH?>OEA$343+$^$"D<,_),T=1!7+VND.]XRLX#=*)]QWC8'U% MVK-
+@1H^KWV':A]/"\Q!PLZ#V\#F&OM]9/%@?7"]0L]3:!8!9 &=%F8N!\[6 M2Q2X-OZ3):!%]A^'\4!"1E)BUBR'W;ZVMLKAQ?8/W"YI$&/3ZYSD[,$$@9+_M3H";_'L*KT3HW$?
O"SN1.!U@;?,K<)(CL$PZ&(*@<8.2BBG;GV_#I0L)T9' M*_0I0.VI(/H7]HA6+C3?WC /MVB:2@ZPB0K<\0EL_3S)8@ M%IX] 7:M7@%WA=:_3B=9A_0 4K,Z+D8$:NS(
M!56@X_I.Z.CO75PD<*N,$'CJX%ODN$D]47QP2>"0YD%G#5E2\(#:-81.5E!D ME$>(U+1TEJCD*)^6.H0R,UPK/M*C%LBPA3LH#]12; 0/>0==Q1@9HK $2#$1
M<]0";P"EAW3LR(TH%)G3_J[@9%H7%Q;I]B>G=6MGRN6]@TJG_'V\'SC$9Z + M,,7>]RB4:4%TN@4U@?QFA[!9Z2TP Z7C\H.Y!;ZXC/")?P?B8[%R01U-LNCM
M>IAN;!3*OK'0E)8=*'_=:>S0OZ.AW57_+O+$T+%Q?5RR[+2YNI2B22>/,N#? MIZE$N5].\2J-.!@NTR?2GO8UX==95N'';)FUU.RVD\.CDW=SU'G821QL^FJU
MQ""1";*GSUC28(UA4@V=JX!#I9YX(+F"C?,4GE(6M6FG9]}""\]^AJW7R=%Y]L*[+42'O,RV22+12SS+ SUHZ1?]$ 4 !8N&F%2)67?P"9RJH0>**TF-(/!]Y Q1\B+K
M1*0K(X!Q1BK,GHX2"4]=D/9_FEBH/0$@4;+CKZ7+A$"3P+9+ MF/F*A IL>K9X+9?'(2]&ZQ*LG=6U=:T(^;=GJN;;0BD;Y=.KV91%MI'\)O M^Y$\7?]{0)-K-Y2QR2$ 2G+$'^GTBH)?
%CM<7=0C!]*P!DF!9C:FX*)?7UO1 M88:$*&6,&6]N]FV_VLM8[?G&)Y\F/8P\4=0% %OU?L@;P)FA,^$8YOSUO+. M;58SY TK:SITK.'/0)64T"4*4L;1>@ZF%O74G2E?/I;(6I-W\4#(T
7&E5WU M@YD6,%S1,5:]X-[P2]"VZ5-";- AE;SP=V!]D\^/ZE1L7O=48"IHR(F$&?<= M5ZI(@^G?6&8EO7INZ.SAOF">'5CR01AE0T]W* C=0AVL;*?53],[E4*1Z=>
M@1]^<.\)YY9C*HX3DOK2%VH?.. L-SZ3NSMK>_CZN%>5&A193RU_U@,SEAAE M^Z$O L/D]#2^"]/J\1^4B)X9@V-/%!>N6Y\##!@KSF+VRQ!^_'Y1;M8HS\&U MK+*L@T!C0:["F
|E9XY'B3*WB[$OC1/GF2L^I2.K@A[C3IO"#:89D,243AY MIT]/J$-2Z&/)O$:Z[V21&!PB=Z#/@QNW/Q_OW-COK;ML8I+%4R0.2@)EN^-.Y$H54-EOYQ?7\FT$!+S M"*P1PKH?
I7%X6%&)QQ!,0D]P(M4CIP](96BDCF^(]7W)$#03$_J(M9'? ZL-U26]X6Q1WN?53G6 HDP'9#_?@1K%Z^_C8G)L$]O=^'VNEI"D< Z* MM\#_LO5J-)G:4)3INH"1 MH7:@?
4_S;$W%>.:I;W_*2,'>?]*S'A)3*R)(N M0U!#;9*^6.^TF$-21]CG<$1]!ISOE*[<P+ QLD'YNL7Y.V9L@7R*N>XTBE\I5TLA)]LZ:EE&$ MOPNZ+ 4T9_!I?XIV6:(?:P79?N\]'|
[2>MVYW7N/9T*6E#"ZFAQKK>%@I"ZG MH"V=/ MC6]G%-W"+)6IF46@=2DWI\]E?FR!=(I+(DO)PUZFY>3*R$5?,(>@0YL;BW# M(TI6/>]P5;%8CN_H,GH94IH[/>S1)/^>3/*?
F=A/0EF)4M3Q58P%PTN4:;D+ M$3WW!TIZA) 8?WZ>F?-D]/3G8R93QU9]'=N^J6,S=6RFCBTSGCQ7V4HV5&%;
M8Q5L,MNU,O$EDK%QJU=;LM+ZOA;6]S6+ZON:1;!I7\%.]#@96*"Y6$*%"T]$ M;=RZ1]\1'+"QFK_F*C=:KRCDK68<[&ISH0BS;><4T[/--^IPCB]M>Z'5)V_
MT;G6B_(YZ.D%CIB"A$AV%*!]0PM 4IT\-_R]P[LAIMT;B*,]LFR<* MV-HNY.O3^AA?9_C]FE#B["["03R1N3;%XOPTTV5=D :14XLE((+VG$LE62/7 MA9F-
S%3OJ$(#>*DBAER^W/O/Z=XK,^>4ZPRNGU)G\&R3:*&+KRKR?/RVRX!B M*I9O%4GW/WV0,FX44Z':#0&E W.";-JO&#WSXC4#WD55+32>\E;?1%%"1R) MJVP$?V)W-F
7%A91E)R81]VXN"D,,%$YRMU2-B&B9FJ9?HFL7,(# Y[!0M5V MI;==6BR)[W2X6/MM*M*?=M460#8O#WOYTK 9JZF7+67^2.BNAO-U MT!>Q.%F)*&>W^?JQ1C.&G-
4AYZG$E[TB5+,KVW6L*R L4=70<7/H^-BQQ.#B ME.P\N$HZGMOU1JCH@I#NPK=7F#V,+EY0KVY#>Q#MMLPQWB#R?[,?W$$RF&2 M[^C3_P;F^;\(CR'#$'_J*,
$\==*=8KU+S*=18-6)7=?3$4/&G5C_8-%3>MVO[O$GO" M/I&.BZD.);@?5&SYH/?S6M6(/I"[EA]$C5L3]Y@K;>!(V6O5]0\9-)Z/1)#:=
M@INI2;QP)X0.Q1OM81573^G,;DAHW!"&BD9YV'0*;J:R4$H6Q/]4!PI$KEQI ML&2&S!YOUUNK38DJ]V=_F;FS%P=#^&3X8$6!YSI$V4;-PO__6C^3F9OE! GF
M^>2>]\Q16NZBVJWUGLCR>*%L)MPX!GM\PB>'J9,U!^]VEW^,$)NZ]#5KA]O' M@Y7AFY+TR'DW?GG(!,M+^MX*W&/! YN2/P/D]&4]:'RZ/B M45D(VVPU,(9(Z;7PJ\+\K%+6(!/-

ACJQ+ .3(%L140D/@:+T1!BFP%(R99^+ M>,1@Z 4C(633W-B->A(!..A9U @U&5BQ_4"%;=C5G !S.C YV0M^'.T#1[@3 M# -#]%51'+I4RDZ-
T2W[W@Z=:'*Z3P(',4>BO"/1FG$DU*LD*=8 7W7I6SK\ M?H1%88T#QI'Z& "_<;^Y4'"=FNT$0T;UC_H,KJ".$0.Q<8$E8?(P:*;$#%(/ M(:(=8<6U&XU:H]'0F'38(JCGET;OK+
[J7^T'\C.&>2"LM?3@IK@0-+CK<[]K M/L-#^!7!$2/LDQO)^2%DD,0Y%A8B3'H2BH?34:GMF-WM,WQ$^F8$HL)>"G18 M.R/=8RL]\/CLY(8MB@:'5>?T,#,]?Z]+T=-"]366S6&YW
&A;67*F':LV(UQ M_"G?3A:5OH?_9>:,)?_X(QSK '9)##Y8JLUUOM@\7S6W=MUA#0-FZDQG[!*5 MH/)&Y>I09_RDJ$:5WO >D\O5K_8BT=US'_;ZK@."_&VWV6JUVX?-=GMGON?V
MYWSN8,[G#G<^(+P&B$AX^$/A?])>B$HP!9A#3LT*(X828Y#'P$(\-T2"&?!N MW#@' M:FR#AV/P< P>SF,X 8=%JLPA@9._&DMNB9Q7:!(6F#P%UE/>
M_Z11WWR+S=.E76_.OT_Y;=""M1_'P[=OWMS?W]=!+:O?!G=O3D%K0XSO-*Y MM<,W"$+[YJBUWVCLOX$-;>ZWCX[V3UIMT'L/C_??B(?_/3C
=>#>FJ=+..8B(3C;)6S8\\69X9^U\.)6J)6)^7 OJ.NM8I[@L M"0]RX<,OAT':QON;B&SKJ]W!CX*0VNK",W5KU]5/LID)"P=-%A%_V>,D>0^V
M4WNDDC!$!,TQ()=CA'YQ/9Q($9HGC<9)>_\0&0$^.CELK(,1/HX\^SY: M-]7A$ZRA;1*B?O.D9*JO092UF_7FWQ<4R&N7MYJ%@0./0!*UCN?A0.S]EVMQ M<]9W!4IKZHH
9N"/5,@_)1WZL8..[8OHKW+!T^,R!J% M;UJ-1HLIOG2IOQZRMS:/["?/('N*B;?-9&_5FW_;-+*WY[IOGG7:3QJ'+YSL MKW/EI[U,LC<;S?K%'S=_?RI%_N?C]5?0@T!;0H7G4]!-
"!%^CU;CJL\= M];D3)VP/8D]'"*DH41_IW8 -K5RL#YA+PI2%/B-_9K)NSWYZ\6=DI?KZFVQ<# M6V_B"B9_=OIU59,_L[UNP@VI+'3&== ?KY:R_)5\.O^\JI5\TOT%HW6LY.OI
MQU6M!*P5X:UC#5?7YZM:PQ7'@=?"6&NX7IJ-_9?CNS'# M?&4)2(DPV;:3BJ!"$S2+IHFA?%OUCU >60LYZF^O5]@S9_;>Y%SYT<#VO+VN M/8R>@@N=QF FPQXJP-)<*,"2"9?
\/!Z_42[Y]C"F?FKTAPK)K I>]._$$HZ% MV,E(_4D_>BY2L#RW]-^LSTGHNU%_YN#KY@,3SEPDG'EHPIDFG+FEX+1E1#1R;Z.Q0.@-
O-..DQ#1O*77N/*@WL\8+VMUOBC[,TO+*>*6^H[/_[K[>R?'ARMRXTZ M_WE[$[VQON#BO]6MRWNP$M5)F_\5N<.YXAXH17K7V/3+F<242,/B3N,,[\Y7 MOM&>]T%FO\<
#39N2N:$/W["%S_4_PCZOO7?=>O&_C&*2C[@8W,I\X!/Q)26 MYB=;S>1UPT(^"-G_:SWO/]-]+5]/;[[OI7Z"]=Z3:GI%CA:T@^%/,-^0SO_Q M_DT_'G@?_A]02P$"% ,4 " 60$1:L_Z@G!0(
4- #0 M @ $ 97A?-S0V,3(X+FAT;5!+ 0(4 Q0 (!9 1%J2M$_+$ @ M .%\W-#8Q,CDN:'1M4$L! A0#% M @ %D!$6MYDVM.!! GA(T (!>A &5X7S&UL4$L! A0#% M @
%D!$6CYQWWPL90 $G\% !4 (!N(H &UL86(M,C R M-#$R,S%?;&%B+GAM;%!+ 0(4 Q0 (!9 1%JAYA*^+E$ "1U!P 5 M " 1?P !M;&%B+3(P,C0Q,C,Q7W!R92YX;6Q02P$"% ,4 M"
60$1:,?E5S[1T 0!2XA@ % @ %X00$;6QA8C(P,C0Q A,C,Q7S$P<2YH=&U02P4& H "@!Y @ 7K8" end XML 88 mlab20241231_10q_htm.xml IDEA: XBRL DOCUMENT 0000724004
2024-04-012024-12-31 0000724004 2025-01-28 0000724004 2024-12-31 0000724004 2024-03-31 0000724004 us-gaap:CustomerRelationshipsMember 2024-12-31
0000724004 us-gaap:CustomerRelationshipsMember 2024-03-31 0000724004 us-gaap:OtherIntangibleAssetsMember 2024-12-31 0000724004 us-
gaap:OtherIntangibleAssetsMember 2024-03-31 0000724004 us-gaap:ProductMember 2024-10-012024-12-31 0000724004 us-gaap:ProductMember 2023-10-012023-12-31
0000724004 us-gaap:ProductMember 2024-04-012024-12-31 0000724004 us-gaap:ProductMember 2023-04-012023-12-31 0000724004 2024-10-012024-12-31 0000724004
2023-10-012023-12-31 0000724004 2023-04-012023-12-31 0000724004 us-gaap:ServiceMember 2024-10-012024-12-31 0000724004 us-gaap:ServiceMember 2023-10-012023-
12-31 0000724004 us-gaap:ServiceMember 2024-04-012024-12-31 0000724004 us-gaap:ServiceMember 2023-04-012023-12-31 0000724004 us-gaap:CommonStockMember
2024-03-31 0000724004 us-gaap:RetainedEarningsMember 2024-03-31 0000724004 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000724004 us-
gaap:CommonStockMember 2024-04-012024-06-30 0000724004 2024-04-012024-06-30 0000724004 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0000724004
us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-012024-06-30 0000724004 us-gaap:CommonStockMember 2024-06-30 0000724004 us-
gaap:RetainedEarningsMember 2024-06-30 0000724004 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000724004 2024-06-30 0000724004 us-
gaap:CommonStockMember 2024-07-012024-09-30 0000724004 2024-07-012024-09-30 0000724004 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0000724004
us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0000724004 us-gaap:CommonStockMember 2024-09-30 0000724004 us-
gaap:RetainedEarningsMember 2024-09-30 0000724004 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0000724004 2024-09-30 0000724004 us-
gaap:CommonStockMember 2024-10-012024-12-31 0000724004 us-gaap:RetainedEarningsMember 2024-10-012024-12-31 0000724004 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-10-012024-12-31 0000724004 us-gaap:CommonStockMember 2024-12-31 0000724004 us-
gaap:RetainedEarningsMember 2024-12-31 0000724004 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000724004 us-gaap:CommonStockMember
2023-03-31 0000724004 us-gaap:RetainedEarningsMember 2023-03-31 0000724004 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000724004 2023-
03-31 0000724004 us-gaap:CommonStockMember 2023-04-012023-06-30 0000724004 2023-04-012023-06-30 0000724004 us-gaap:RetainedEarningsMember 2023-04-
012023-06-30 0000724004 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-012023-06-30 0000724004 us-gaap:CommonStockMember 2023-06-30
0000724004 us-gaap:RetainedEarningsMember 2023-06-30 0000724004 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000724004 2023-06-30
0000724004 us-gaap:CommonStockMember 2023-07-012023-09-30 0000724004 2023-07-012023-09-30 0000724004 us-gaap:RetainedEarningsMember 2023-07-012023-09-30
0000724004 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0000724004 us-gaap:CommonStockMember 2023-09-30 0000724004 us-
gaap:RetainedEarningsMember 2023-09-30 0000724004 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000724004 2023-09-30 0000724004 us-
gaap:CommonStockMember 2023-10-012023-12-31 0000724004 us-gaap:RetainedEarningsMember 2023-10-012023-12-31 0000724004 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-10-012023-12-31 0000724004 us-gaap:CommonStockMember 2023-12-31 0000724004 us-
gaap:RetainedEarningsMember 2023-12-31 0000724004 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000724004 2023-12-31 0000724004
mlab:GkeAcquisitionMembermlab:GkeGmbhAndSalGmbhMember 2023-10-16 0000724004 mlab:GkeAcquisitionMembermlab:BeijingGkeScienceTechnologyCoLtdMember
2023-10-16 0000724004 mlab:GkeAcquisitionMember 2023-10-162023-10-16 0000724004 mlab:GkeAcquisitionMember 2024-10-012024-12-31 0000724004
mlab:GkeAcquisitionMember 2024-04-012024-12-31 0000724004 mlab:GkeAcquisitionMembermlab:InventoryStepupRelatedToCostOfRevenueMember 2024-10-012024-12-31
0000724004 mlab:GkeAcquisitionMembermlab:InventoryStepupRelatedToCostOfRevenueMember 2024-04-012024-12-31 0000724004
mlab:GkeAcquisitionMembermlab:CostOfRevenuesRelatedToIntangiblesAcquiredMember 2024-10-012024-12-31 0000724004
mlab:GkeAcquisitionMembermlab:CostOfRevenuesRelatedToIntangiblesAcquiredMember 2024-04-012024-12-31 0000724004 mlab:GkeAcquisitionMemberus-
gaap:GeneralAndAdministrativeExpenseMember 2024-10-012024-12-31 0000724004 mlab:GkeAcquisitionMemberus-gaap:GeneralAndAdministrativeExpenseMember 2024-04-
012024-12-31 0000724004 us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:SterilizationAndDisinfectionControlMemberus-
gaap:TransferredAtPointInTimeMember 2024-10-012024-12-31 0000724004 us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:ClinicalGenomicsMemberus-
gaap:TransferredAtPointInTimeMember 2024-10-012024-12-31 0000724004 us-
gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:BiopharmaceuticalDevelopmentMemberus-gaap:TransferredAtPointInTimeMember 2024-10-012024-12-31
0000724004 us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:CalibrationSolutionsMemberus-gaap:TransferredAtPointInTimeMember 2024-10-012024-12-
31 0000724004 mlab:ConsumablesMemberus-gaap:TransferredAtPointInTimeMember 2024-10-012024-12-31 0000724004 us-
gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:SterilizationAndDisinfectionControlMemberus-gaap:TransferredAtPointInTimeMember 2024-10-
012024-12-31 0000724004 us-gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:ClinicalGenomicsMemberus-gaap:TransferredAtPointInTimeMember
2024-10-012024-12-31 0000724004 us-gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:BiopharmaceuticalDevelopmentMemberus-
gaap:TransferredAtPointInTimeMember 2024-10-012024-12-31 0000724004 us-
gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:CalibrationSolutionsMemberus-gaap:TransferredAtPointInTimeMember 2024-10-012024-12-31
0000724004 mlab:HardwareAndSoftwareMemberus-gaap:TransferredAtPointInTimeMember 2024-10-012024-12-31 0000724004 us-gaap:OperatingSegmentsMemberus-
gaap:ServiceMembermlab:SterilizationAndDisinfectionControlMemberus-gaap:TransferredAtPointInTimeMember 2024-10-012024-12-31 0000724004 us-
gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:ClinicalGenomicsMemberus-gaap:TransferredAtPointInTimeMember 2024-10-012024-12-31 0000724004 us-
gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:BiopharmaceuticalDevelopmentMemberus-gaap:TransferredAtPointInTimeMember 2024-10-012024-12-31
0000724004 us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:CalibrationSolutionsMemberus-gaap:TransferredAtPointInTimeMember 2024-10-012024-12-31
0000724004 us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember 2024-10-012024-12-31 0000724004 us-
gaap:OperatingSegmentsMembermlab:SterilizationAndDisinfectionControlMember 2024-10-012024-12-31 0000724004 us-
gaap:OperatingSegmentsMembermlab:ClinicalGenomicsMember 2024-10-012024-12-31 0000724004 us-
gaap:OperatingSegmentsMembermlab:BiopharmaceuticalDevelopmentMember 2024-10-012024-12-31 0000724004 us-
gaap:OperatingSegmentsMembermlab:CalibrationSolutionsMember 2024-10-012024-12-31 0000724004
mlab:GkeGmbhMembermlab:SterilizationAndDisinfectionControlMember 2024-10-012024-12-31 0000724004 us-
gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:SterilizationAndDisinfectionControlMemberus-gaap:TransferredAtPointInTimeMember 2023-10-012023-12-
31 0000724004 us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:ClinicalGenomicsMemberus-gaap:TransferredAtPointInTimeMember 2023-10-012023-12-
31 0000724004 us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:BiopharmaceuticalDevelopmentMemberus-gaap:TransferredAtPointInTimeMember 2023-
10-012023-12-31 0000724004 us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:CalibrationSolutionsMemberus-gaap:TransferredAtPointInTimeMember
2023-10-012023-12-31 0000724004 mlab:ConsumablesMemberus-gaap:TransferredAtPointInTimeMember 2023-10-012023-12-31 0000724004 us-
gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:SterilizationAndDisinfectionControlMemberus-gaap:TransferredAtPointInTimeMember 2023-10-
012023-12-31 0000724004 us-gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:ClinicalGenomicsMemberus-gaap:TransferredAtPointInTimeMember
2023-10-012023-12-31 0000724004 us-gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:BiopharmaceuticalDevelopmentMemberus-
gaap:TransferredAtPointInTimeMember 2023-10-012023-12-31 0000724004 us-
gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:CalibrationSolutionsMemberus-gaap:TransferredAtPointInTimeMember 2023-10-012023-12-31
0000724004 mlab:HardwareAndSoftwareMemberus-gaap:TransferredAtPointInTimeMember 2023-10-012023-12-31 0000724004 us-gaap:OperatingSegmentsMemberus-
gaap:ServiceMembermlab:SterilizationAndDisinfectionControlMemberus-gaap:TransferredAtPointInTimeMember 2023-10-012023-12-31 0000724004 us-
gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:ClinicalGenomicsMemberus-gaap:TransferredAtPointInTimeMember 2023-10-012023-12-31 0000724004 us-
gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:BiopharmaceuticalDevelopmentMemberus-gaap:TransferredAtPointInTimeMember 2023-10-012023-12-31
0000724004 us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:CalibrationSolutionsMemberus-gaap:TransferredAtPointInTimeMember 2023-10-012023-12-31
0000724004 us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember 2023-10-012023-12-31 0000724004 us-
gaap:OperatingSegmentsMembermlab:SterilizationAndDisinfectionControlMember 2023-10-012023-12-31 0000724004 us-
gaap:OperatingSegmentsMembermlab:ClinicalGenomicsMember 2023-10-012023-12-31 0000724004 us-
gaap:OperatingSegmentsMembermlab:BiopharmaceuticalDevelopmentMember 2023-10-012023-12-31 0000724004 us-
gaap:OperatingSegmentsMembermlab:CalibrationSolutionsMember 2023-10-012023-12-31 0000724004
mlab:GkeGmbhMembermlab:SterilizationAndDisinfectionControlMember 2023-10-012023-12-31 0000724004 us-
gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:SterilizationAndDisinfectionControlMemberus-gaap:TransferredAtPointInTimeMember 2024-04-012024-12-
31 0000724004 us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:ClinicalGenomicsMemberus-gaap:TransferredAtPointInTimeMember 2024-04-012024-12-
31 0000724004 us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:BiopharmaceuticalDevelopmentMemberus-gaap:TransferredAtPointInTimeMember 2024-
04-012024-12-31 0000724004 us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:CalibrationSolutionsMemberus-gaap:TransferredAtPointInTimeMember
2024-04-012024-12-31 0000724004 mlab:ConsumablesMemberus-gaap:TransferredAtPointInTimeMember 2024-04-012024-12-31 0000724004 us-
gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:SterilizationAndDisinfectionControlMemberus-gaap:TransferredAtPointInTimeMember 2024-04-
012024-12-31 0000724004 us-gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:ClinicalGenomicsMemberus-gaap:TransferredAtPointInTimeMember
2024-04-012024-12-31 0000724004 us-gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:BiopharmaceuticalDevelopmentMemberus-
gaap:TransferredAtPointInTimeMember 2024-04-012024-12-31 0000724004 us-
gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:CalibrationSolutionsMemberus-gaap:TransferredAtPointInTimeMember 2024-04-012024-12-31
0000724004 mlab:HardwareAndSoftwareMemberus-gaap:TransferredAtPointInTimeMember 2024-04-012024-12-31 0000724004 us-gaap:OperatingSegmentsMemberus-
gaap:ServiceMembermlab:SterilizationAndDisinfectionControlMemberus-gaap:TransferredAtPointInTimeMember 2024-04-012024-12-31 0000724004 us-
gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:ClinicalGenomicsMemberus-gaap:TransferredAtPointInTimeMember 2024-04-012024-12-31 0000724004 us-
gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:BiopharmaceuticalDevelopmentMemberus-gaap:TransferredAtPointInTimeMember 2024-04-012024-12-31
0000724004 us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:CalibrationSolutionsMemberus-gaap:TransferredAtPointInTimeMember 2024-04-012024-12-31
0000724004 us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember 2024-04-012024-12-31 0000724004 us-
gaap:OperatingSegmentsMembermlab:SterilizationAndDisinfectionControlMember 2024-04-012024-12-31 0000724004 us-
gaap:OperatingSegmentsMembermlab:ClinicalGenomicsMember 2024-04-012024-12-31 0000724004 us-
gaap:OperatingSegmentsMembermlab:BiopharmaceuticalDevelopmentMember 2024-04-012024-12-31 0000724004 us-
gaap:OperatingSegmentsMembermlab:CalibrationSolutionsMember 2024-04-012024-12-31 0000724004
mlab:GkeGmbhMembermlab:SterilizationAndDisinfectionControlMember 2024-04-012024-12-31 0000724004 us-

gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:SterilizationAndDisinfectionControlMemberus-gaap:TransferredAtPointInTimeMember 2023-04-012023-12-31 0000724004 us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:ClinicalGenomicsMemberus-gaap:TransferredAtPointInTimeMember 2023-04-012023-12-31 0000724004 us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:BiopharmaceuticalDevelopmentMemberus-gaap:TransferredAtPointInTimeMember 2023-04-012023-12-31 0000724004 us-gaap:OperatingSegmentsMembermlab:ConsumablesMembermlab:CalibrationSolutionsMemberus-gaap:TransferredAtPointInTimeMember 2023-04-012023-12-31 0000724004 mlab:ConsumablesMemberus-gaap:TransferredAtPointInTimeMember 2023-04-012023-12-31 0000724004 us-gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:SterilizationAndDisinfectionControlMemberus-gaap:TransferredAtPointInTimeMember 2023-04-012023-12-31 0000724004 us-gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:ClinicalGenomicsMemberus-gaap:TransferredAtPointInTimeMember 2023-04-012023-12-31 0000724004 us-gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:BiopharmaceuticalDevelopmentMemberus-gaap:TransferredAtPointInTimeMember 2023-04-012023-12-31 0000724004 us-gaap:OperatingSegmentsMembermlab:HardwareAndSoftwareMembermlab:CalibrationSolutionsMemberus-gaap:TransferredAtPointInTimeMember 2023-04-012023-12-31 0000724004 mlab:HardwareAndSoftwareMemberus-gaap:TransferredAtPointInTimeMember 2023-04-012023-12-31 0000724004 us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:SterilizationAndDisinfectionControlMemberus-gaap:TransferredAtPointInTimeMember 2023-04-012023-12-31 0000724004 us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:ClinicalGenomicsMemberus-gaap:TransferredAtPointInTimeMember 2023-04-012023-12-31 0000724004 us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:BiopharmaceuticalDevelopmentMemberus-gaap:TransferredAtPointInTimeMember 2023-04-012023-12-31 0000724004 us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembermlab:CalibrationSolutionsMemberus-gaap:TransferredAtPointInTimeMember 2023-04-012023-12-31 0000724004 us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember 2023-04-012023-12-31 0000724004 us-gaap:OperatingSegmentsMembermlab:SterilizationAndDisinfectionControlMember 2023-04-012023-12-31 0000724004 us-gaap:OperatingSegmentsMembermlab:ClinicalGenomicsMember 2023-04-012023-12-31 0000724004 us-gaap:OperatingSegmentsMembermlab:BiopharmaceuticalDevelopmentMember 2023-04-012023-12-31 0000724004 us-gaap:OperatingSegmentsMembermlab:CalibrationSolutionsMember 2023-04-012023-12-31 0000724004 mlab:GkeGmbhMembermlab:SterilizationAndDisinfectionControlMember 2023-04-012023-12-31 0000724004 country:US 2024-10-012024-12-31 0000724004 country:US 2023-10-012023-12-31 0000724004 country:US 2024-04-012024-12-31 0000724004 country:US 2023-04-012023-12-31 0000724004 country:CN 2024-10-012024-12-31 0000724004 country:CN 2023-10-012023-12-31 0000724004 country:CN 2024-04-012024-12-31 0000724004 country:CN 2023-04-012023-12-31 0000724004 mlab:OtherMember 2024-10-012024-12-31 0000724004 mlab:OtherMember 2023-10-012023-12-31 0000724004 mlab:OtherMember 2024-04-012024-12-31 0000724004 mlab:OtherMember 2023-04-012023-12-31 0000724004 us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2024-10-012024-12-31 0000724004 mlab:TheNotesMemberus-gaap:SeniorNotesMember 2024-04-05 0000724004 mlab:Outstanding2025NotesMember 2024-04-05 0000724004 mlab:Outstanding2025NotesMember 2024-12-31 0000724004 us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SeniorNotesMember 2024-12-31 0000724004 us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SeniorNotesMember 2024-12-31 0000724004 us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SeniorNotesMember 2024-03-31 0000724004 us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SeniorNotesMember 2024-03-31 0000724004 mlab:GkeAcquisitionMember 2024-12-31 0000724004 mlab:GkeAcquisitionMemberus-gaap:FairValueInputsLevel3Member 2024-12-31 0000724004 mlab:OtherLongtermLiabilitiesMembermlab:BelynticAcquisitionMember 2022-11-17 0000724004 mlab:BelynticAcquisitionMemberus-gaap:FairValueInputsLevel3Member 2024-12-31 0000724004 mlab:OtherAccruedExpensesMember 2024-12-31 0000724004 mlab:OtherAccruedExpensesMember 2024-03-31 0000724004 mlab:GkeAcquisitionMember 2024-03-31 0000724004 us-gaap:CostOfSalesMember 2024-10-012024-12-31 0000724004 us-gaap:CostOfSalesMember 2023-10-012023-12-31 0000724004 us-gaap:CostOfSalesMember 2024-04-012024-12-31 0000724004 us-gaap:CostOfSalesMember 2023-04-012023-12-31 0000724004 us-gaap:OperatingExpenseMember 2024-10-012024-12-31 0000724004 us-gaap:OperatingExpenseMember 2023-10-012023-12-31 0000724004 us-gaap:OperatingExpenseMember 2024-04-012024-12-31 0000724004 us-gaap:OperatingExpenseMember 2023-04-012023-12-31 0000724004 us-gaap:GeneralAndAdministrativeExpenseMember 2024-10-012024-12-31 0000724004 us-gaap:GeneralAndAdministrativeExpenseMember 2023-10-012023-12-31 0000724004 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-012024-12-31 0000724004 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-012023-12-31 0000724004 us-gaap:OperatingSegmentsMembermlab:SterilizationAndDisinfectionControlMember 2024-03-31 0000724004 us-gaap:OperatingSegmentsMembermlab:ClinicalGenomicsMember 2024-03-31 0000724004 us-gaap:OperatingSegmentsMembermlab:BiopharmaceuticalDevelopmentMember 2024-03-31 0000724004 us-gaap:OperatingSegmentsMembermlab:CalibrationSolutionsMember 2024-03-31 0000724004 us-gaap:OperatingSegmentsMembermlab:SterilizationAndDisinfectionControlMember 2024-12-31 0000724004 us-gaap:OperatingSegmentsMembermlab:ClinicalGenomicsMember 2024-12-31 0000724004 us-gaap:OperatingSegmentsMembermlab:BiopharmaceuticalDevelopmentMember 2024-12-31 0000724004 us-gaap:OperatingSegmentsMembermlab:CalibrationSolutionsMember 2024-12-31 0000724004 mlab:SeniorSecuredCreditAgreementMember 2021-03-052021-03-05 0000724004 us-gaap:RevolvingCreditFacilityMembermlab:SeniorSecuredCreditAgreementMember 2021-03-05 0000724004 srt:MaximumMembermlab:SeniorSecuredCreditAgreementMembermlab:SwinglineLoanMember 2021-03-05 0000724004 srt:MaximumMemberus-gaap:LetterOfCreditMembermlab:SeniorSecuredCreditAgreementMember 2021-03-05 0000724004 srt:MinimumMembermlab:SeniorSecuredCreditAgreementMembermlab:TheCreditFacilityTermLoanMember 2021-03-05 0000724004 srt:MaximumMembermlab:SeniorSecuredCreditAgreementMembermlab:TheCreditFacilityTermLoanMember 2021-03-05 0000724004 srt:MaximumMembermlab:SeniorSecuredCreditAgreementMembermlab:TheCreditFacilityTermLoanMember 2023-10-05 0000724004 mlab:TheCreditFacilityTermLoanMember 2024-12-31 0000724004 us-gaap:RevolvingCreditFacilityMembermlab:SeniorSecuredCreditAgreementMember 2024-12-31 0000724004 mlab:SeniorSecuredCreditAgreementMembermlab:TheCreditFacilityTermLoanMember 2024-12-31 0000724004 srt:MinimumMembermlab:SeniorSecuredCreditAgreementMember 2024-10-012024-12-31 0000724004 srt:MaximumMembermlab:SeniorSecuredCreditAgreementMember 2024-10-012024-12-31 0000724004 mlab:TheCreditFacilityTermLoanMember 2024-12-31 0000724004 mlab:TheCreditFacilityTermLoanMember 2024-04-052024-04-05 0000724004 srt:MinimumMembermlab:SeniorSecuredCreditAgreementMember 2024-04-052024-04-05 0000724004 mlab:TermLoanMember 2024-04-05 0000724004 mlab:TermLoanMember 2024-10-012024-12-31 0000724004 mlab:TermLoanMember 2024-04-012024-12-31 0000724004 mlab:TermLoanMember 2024-12-31 0000724004 mlab:TermLoanMember 2024-03-31 0000724004 mlab:SeniorSecuredCreditAgreementMember 2024-12-31 0000724004 mlab:SeniorSecuredCreditAgreementMemberus-gaap:SubsequentEventMember 2025-01-012025-01-01 0000724004 srt:MinimumMembermlab:SeniorSecuredCreditAgreementMember 2024-07-012024-09-30 0000724004 srt:MaximumMembermlab:SeniorSecuredCreditAgreementMember 2024-07-012024-09-30 0000724004 mlab:PrepaidExpensesOtherAndOtherAssetsMembermlab:SeniorSecuredCreditAgreementMember 2024-12-31 0000724004 mlab:PrepaidExpensesOtherAndOtherAssetsMembermlab:SeniorSecuredCreditAgreementMember 2024-03-31 0000724004 mlab:TheNotesMemberus-gaap:SeniorNotesMember 2019-08-12 0000724004 mlab:TheNotesMemberus-gaap:SeniorNotesMember 2019-08-122019-08-12 0000724004 mlab:Outstanding2025NotesMember 2024-04-052024-04-05 0000724004 mlab:Outstanding2025NotesMember 2024-04-012024-12-31 0000724004 mlab:TheNotesMemberus-gaap:SeniorNotesMember 2024-12-31 0000724004 mlab:TheNotesMemberus-gaap:SeniorNotesMember 2024-03-31 0000724004 mlab:TheNotesMember 2024-10-012024-12-31 0000724004 mlab:TheNotesMember 2023-10-012023-12-31 0000724004 mlab:TheNotesMember 2024-04-012024-12-31 0000724004 mlab:TheNotesMember 2023-04-012023-12-31 0000724004 mlab:The2021EquityPlanMember 2024-06-30 0000724004 us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 0000724004 mlab:PerformanceStockUnitsMember 2024-03-31 0000724004 us-gaap:RestrictedStockUnitsRSUMember 2024-04-012024-12-31 0000724004 mlab:PerformanceStockUnitsMember 2024-04-012024-12-31 0000724004 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0000724004 mlab:PerformanceStockUnitsMember 2024-12-31 0000724004 mlab:NonemployeeDirectorsMemberus-gaap:RestrictedStockUnitsRSUMember 2024-04-012024-12-31 0000724004 mlab:EligibleEmployeesMembermlab:TheFy25PsusMember 2024-12-31 0000724004 mlab:EligibleEmployeesMembermlab:TheFy25PsusMember 2024-04-012024-12-31 0000724004 srt:MinimumMembermlab:EligibleEmployeesMembermlab:TheFy25PsusMember 2024-04-012024-12-31 0000724004 srt:MaximumMembermlab:EligibleEmployeesMembermlab:TheFy25PsusMember 2024-04-012024-12-31 0000724004 2023-04-012024-03-31 0000724004 us-gaap:EmployeeStockOptionMember 2024-10-012024-12-31 0000724004 us-gaap:EmployeeStockOptionMember 2023-10-012023-12-31 0000724004 us-gaap:EmployeeStockOptionMember 2024-04-012024-12-31 0000724004 us-gaap:EmployeeStockOptionMember 2023-04-012023-12-31 0000724004 us-gaap:RestrictedStockUnitsRSUMember 2024-10-012024-12-31 0000724004 us-gaap:RestrictedStockUnitsRSUMember 2023-10-012023-12-31 0000724004 us-gaap:RestrictedStockUnitsRSUMember 2023-04-012023-12-31 0000724004 mlab:AssumedConversionOfConvertibleDebtMember 2024-10-012024-12-31 0000724004 mlab:AssumedConversionOfConvertibleDebtMember 2023-10-012023-12-31 0000724004 mlab:AssumedConversionOfConvertibleDebtMember 2024-04-012024-12-31 0000724004 mlab:AssumedConversionOfConvertibleDebtMember 2023-04-012023-12-31 0000724004 mlab:StockAwardsThatWereAntidilutiveMember 2024-10-012024-12-31 0000724004 mlab:StockAwardsThatWereAntidilutiveMember 2023-10-012023-12-31 0000724004 mlab:StockAwardsThatWereAntidilutiveMember 2024-04-012024-12-31 0000724004 mlab:StockAwardsThatWereAntidilutiveMember 2023-04-012023-12-31 0000724004 mlab:BelynticAcquisitionMember 2024-12-31 0000724004 mlab:BelynticAcquisitionMemberus-gaap:SubsequentEventMember 2025-01-02 0000724004 us-gaap:OperatingSegmentsMember 2024-10-012024-12-31 0000724004 us-gaap:OperatingSegmentsMember 2023-10-012023-12-31 0000724004 us-gaap:OperatingSegmentsMember 2024-04-012024-12-31 0000724004 us-gaap:OperatingSegmentsMember 2023-04-012023-12-31 0000724004 us-gaap:CorporateNonSegmentMember 2024-10-012024-12-31 0000724004 us-gaap:CorporateNonSegmentMember 2023-10-012023-12-31 0000724004 us-gaap:CorporateNonSegmentMember 2024-04-012024-12-31 0000724004 us-gaap:CorporateNonSegmentMember 2023-04-012023-12-31 shares thunderdome:item iso4217:USD iso4217:USD shares pure utr:Y0000724004MESA LABORATORIES INC /COfalse--03-31Q3202510600001321000260360002251900000250000002500000054336035433603539449153944910.160.160.160.160.160.160P4Y0.075P1Y0.21falsefalsefalsefalse10-Qtrue2024-12-31false0-11740CO84-087229112100 West Sixth AvenueLakewoodCO80228303987-8000Common Stock, no par valueMLABNASDAQYesYesAccelerated Filerfalsefalsefalse5433607309560002821400038647000390550002812200032675000131200009408000110845000109352000316020003176600012420001292000181260001
180952000-183494000-16622000-
14755000155214000145393000437148000446796000628400005347300017884300015728300023086000200710006638500060589000397540003340200011245800096694000
6700014867000-79100028420001856000934000003809000-0-02887000-0-51540003869000-29140004284000-79960002013000-9367000475000-221700019460005500000-
316000-541000-170000360000-653000-167600021160005140000337000-0.310.390.950.06-
0.310.390.940.0654290005393000541300053840005429000539600054640005394000-167600021160005140000337000-695100010965000-18670002951000-
862700013081000327300032880005394491343642000-183494000-1475500014539300020858006194571000-0-
05710008630008630002928000292800045200045200003388000033880005409155345999000-180969000-
14303000150727000130060023063070003070008660008660003837000383700046320004632000034280000342800005419855349529000-178407000-
9671000161451000137802300023000323000300086900086900032390003239000-6951000-69510000-16760000-16760005433603352788000-180952000-
16622000155214000536946633207600074199000-1279500039348000020074520005200005260712000-0-071200085900085900029680002968000-6661000-6661000-549000-
549000538428033438400072791000-194560003877190007464304000304000182000200086200086200031830003183000-1353000-1353000-1230000-
1230000539172633786900070699000-
2080900038775900024152000200098120001200086200086200029930002993000109650001096500021160002116000539404334085200071953000-
984400040296100051400003370004028000289900013002000223800001000400091440002887000-012320000-24920003128000-3914000-2206000-91000-8294000539000-
21700014450007841000-1919000-16560001879000-124000-849000-14780003414300031250000-07970000034920002032000-3492000-
8173200073465000710000000263130002200000071560000-025980002583000-1310000-648000-2831600045769000407000270002742000-
46860002821400032910000309560002822400095960004220000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Note <em style="font: inherit;">1. Description of Business and Summary of Significant Accounting Policies</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> <i>Description of Business</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i> </i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In this quarterly report on Form <em style="font: inherit;">10-Q, Mesa Laboratories, Inc., a Colorado corporation, together with its subsidiaries, is collectively referred to as “we,” “us,” “our,” the “Company,” or “Mesa.”</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">We are a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulated applications in the

pharmaceutical, healthcare, and medical device industries. We offer products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. We have manufacturing operations in the United States and Europe, and our products are marketed by our sales personnel in North America, Europe and Asia Pacific, and by independent distributors in these areas and throughout the rest of the world. We prefer markets in which we can establish a strong presence and achieve high gross profit margins.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">As of <em style="font: inherit;"> December 31, 2024, we managed our operations in <em style="font: inherit;">four reportable segments, or divisions:</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr><td style="width: 18pt;"> </td><td style="width: 18pt; vertical-align: top; font-family: "Times New Roman"; font-size: 10pt;">●</td><td style="width: auto; font-family: "Times New Roman"; font-size: 10pt;"><i>Sterilization and Disinfection Control </i>- manufactures and sells biological, chemical and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes in the medical device, pharmaceutical, and healthcare industries. The division also provides testing and laboratory services, mainly to the dental and pharmaceutical industries. </td></tr> <tr style="vertical-align: top;"><td style="width: 18pt;"> </td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman"; font-size: 10pt;">●</p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman"; font-size: 10pt;"><i>Clinical Genomics </i>- develops, manufactures and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables and services that enable clinical research labs and contract research organizations to perform genomic testing for a broad range of research applications in several therapeutic areas, such as screenings for hereditary diseases, pharmacogenetics, oncology related applications, and toxicology research.</p> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> </td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman"; font-size: 10pt;">●</p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman"; font-size: 10pt;"><i>Biopharmaceutical Development </i>- develops, manufactures, sells and services automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Immunoassays and peptide synthesis solutions accelerate the discovery, development, and manufacture of biotherapeutic therapies, among other applications. </p> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody> <tr style="vertical-align: top;"><td style="width: 18pt;"> </td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman"; font-size: 10pt;">●</p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman"; font-size: 10pt;"><i>Calibration Solutions </i>- develops, manufactures, sells and services quality control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications such as environmental and process monitoring, dialysis, gas flow, air quality and torque testing.</p> </td></tr> </tbody></table> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"></p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><i></i></p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><i>Basis of Presentation</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information. In the opinion of management, such unaudited information includes all adjustments, consisting of normal recurring adjustments necessary for the fair statement of our financial position and results of operations. The results of operations for interim periods are <em style="font: inherit;">not necessarily indicative of results that <em style="font: inherit;"> may be achieved for the entire year. The year-end Condensed Consolidated Balance Sheet data was derived from audited financial statements but does <em style="font: inherit;">not include all disclosures required by accounting principles generally accepted in the United States of America. The Condensed Consolidated Financial Statements include the accounts of Mesa and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. We made <em style="font: inherit;">no material changes to the application of our significant accounting policies disclosed in our annual report on Form <em style="font: inherit;">10-K. This quarterly report should be read in conjunction with the consolidated financial statements included in our annual report on Form <em style="font: inherit;">10-K for the year ended <em style="font: inherit;"> March 31, 2024.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Our fiscal year ends on <em style="font: inherit;"> March <em style="font: inherit;">31. References in this quarterly report to a particular “year” or “quarter” refer to our fiscal year or fiscal quarters, respectively.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"></p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"><i></i></p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Prior Period Reclassifications</i></p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">For the <em style="font: inherit;">nine months ended <em style="font: inherit;"> December 31, 2024, certain prior period amounts in our unaudited Condensed Consolidated Statements of Operations related to cash interest payments on acquisition holdback liabilities and non-cash debt issuance cost amortization have been reclassified out of "Other expense (income), net" and into "Interest expense and amortization of debt issuance costs." Additionally, prior period <em style="font: inherit;">third-party costs related to the repurchase of a portion of our convertible senior notes have been reclassified out of "Other expense (income), net" and are reflected within the "(Gain) on extinguishment of convertible senior notes." These reclassifications have <em style="font: inherit;">not resulted in any change to "Non-operating expense (income), net" nor in any material change to other amounts presented in our unaudited condensed consolidated financial statements for the <em style="font: inherit;">three and <em style="font: inherit;">nine months ended <em style="font: inherit;"> December 31, 2024.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i style="font-size: 10pt;"></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i style="font-size: 10pt;">Risks and Uncertainties</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the reporting date and revenues and expenses during the reporting periods. These estimates represent management's judgment about the outcome of future events. The global business environment continues to be impacted by cost pressures, the overall effects of economic uncertainty, and other factors. Changes in, and the resulting effects of, potential governmental stimulus or fiscal and monetary policies, interest rates, foreign currency values, supply chains, demand for goods and services, a global or regional recession, or other circumstances cannot be reliably predicted. Actual results could differ from our estimates.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b style="font-size: 10pt;"><i></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b style="font-size: 10pt;"><i>Recently Issued Accounting Pronouncements</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In <em style="font: inherit;"> November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") <em style="font: inherit;">No. <em style="font: inherit;">2023-<em style="font: inherit;">07. "Segment Reporting (Topic <em style="font: inherit;">280): Improvements to Reportable Segment Disclosures." ASU <em style="font: inherit;">No. <em style="font: inherit;">2023-<em style="font: inherit;">07 requires all annual disclosures currently required by Topic <em style="font: inherit;">280 to be included in interim financial statements and requires disclosure of significant segment expenses regularly provided to the chief operating decision maker ("CODM"), a description of other segment items by reportable segment, and applicable additional measures of segment profit or loss used by the CODM when allocating resources and assessing business performance. The ASU is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2023 (our fiscal year <em style="font: inherit;">2025 for annual periods) and interim periods within fiscal years beginning after <em style="font: inherit;"> December 15, 2024 (our fiscal year <em style="font: inherit;">2026 for interim periods) on a retrospective basis. Other than presentation changes to our segment footnote, we do <em style="font: inherit;">not expect the adoption of ASU <em style="font: inherit;">No. <em style="font: inherit;">2023-<em style="font: inherit;">07 to have a material impact on our consolidated financial statements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">In <em style="font: inherit;"> December 2023, the FASB issued ASU <em style="font: inherit;">No. <em style="font: inherit;">2023-<em style="font: inherit;">09, "Income Taxes (Topic <em style="font: inherit;">740): Improvements to Income Tax Disclosures." ASU <em style="font: inherit;">No. <em style="font: inherit;">2023-<em style="font: inherit;">09, which enhances the transparency, effectiveness and comparability of income tax disclosures by requiring consistent categories and greater disaggregation of information related to income tax rate reconciliations and the jurisdictions in which income taxes are paid. The guidance is effective for public business entities for fiscal years beginning after <em style="font: inherit;"> December 15, 2024 (our fiscal year <em style="font: inherit;">2026), with early adoption and prospective or retrospective application permitted. Other than presentation of additional disaggregated data in our income tax footnote disclosures for annual periods, we do <em style="font: inherit;">not expect the adoption of ASU <em style="font: inherit;">No. <em style="font: inherit;">2023-<em style="font: inherit;">09 to have a material impact on our consolidated financial statement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> November 2024, the Financial Accounting Board ("FASB") issued Accounting Standards Update ("ASU") <em style="font: inherit;">No. <em style="font: inherit;">2024-<em style="font: inherit;">03, "Expense Disaggregation Disclosures (Subtopic <em style="font: inherit;">220-<em style="font: inherit;">40): Disaggregation of Income Statement Expenses." ASU <em style="font: inherit;">No. <em style="font: inherit;">2024-<em style="font: inherit;">03 requires that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The ASU is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2026 (our fiscal year <em style="font: inherit;">2028 for annual periods) and interim periods within fiscal years beginning after <em style="font: inherit;"> December 15, 2027 (our fiscal year <em style="font: inherit;">2029 for interim periods), with early adoption and prospective or retrospective application permitted. We are currently assessing the effect the adoption of this standard will have on our consolidated financial statement disclosures.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">We have reviewed all recently issued accounting pronouncements and have concluded that, other than as described above, they are either <em style="font: inherit;">not applicable to us or are <em style="font: inherit;">not expected to have a significant impact on our consolidated financial statements. </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> <i>Description of Business</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i> </i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In this quarterly report on Form <em style="font: inherit;">10-Q, Mesa Laboratories, Inc., a Colorado corporation, together with its subsidiaries, is collectively referred to as “we,” “us,” “our,” the “Company,” or “Mesa.”</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">We are a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries. We offer products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. We have manufacturing operations in the United States and Europe, and our products are marketed by our sales personnel in North America, Europe and Asia Pacific, and by independent distributors in these areas and throughout the rest of the world. We prefer markets in which we can establish a strong presence and achieve high gross profit margins.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">As of <em style="font: inherit;"> December 31, 2024, we managed our operations in <em style="font: inherit;">four reportable segments, or divisions:</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr><td style="width: 18pt;"> </td><td style="width: 18pt; vertical-align: top; font-family: "Times New Roman"; font-size: 10pt;">●</td><td style="width: auto; font-family: "Times New Roman"; font-size: 10pt;"><i>Sterilization and Disinfection Control </i>- manufactures and sells biological, chemical and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes in the medical device, pharmaceutical, and

healthcare industries. The division also provides testing and laboratory services, mainly to the dental and pharmaceutical industries. </td></tr> <tr style="vertical-align: top;"><td style="width: 18pt;"> </td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman"; font-size: 10pt;">●</p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman"; font-size: 10pt;"><i>Clinical Genomics </i>- develops, manufactures and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables and services that enable clinical research labs and contract research organizations to perform genomic testing for a broad range of research applications in several therapeutic areas, such as screenings for hereditary diseases, pharmacogenetics, oncology related applications, and toxicology research.</p> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> </td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman"; font-size: 10pt;">●</p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman"; font-size: 10pt;"><i>Biopharmaceutical Development </i>- develops, manufactures, sells and services automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Immunoassays and peptide synthesis solutions accelerate the discovery, development, and manufacture of biotherapeutic therapies, among other applications. </p> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody> <tr style="vertical-align: top;"><td style="width: 18pt;"> </td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman"; font-size: 10pt;">●</p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman"; font-size: 10pt;"><i>Calibration Solutions </i>- develops, manufactures, sells and services quality control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications such as environmental and process monitoring, dialysis, gas flow, air quality and torque testing.</p> </td></tr> </tbody></table> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </p><p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><i>Basis of Presentation</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information. In the opinion of management, such unaudited information includes all adjustments, consisting of normal recurring adjustments necessary for the fair statement of our financial position and results of operations. The results of operations for interim periods are <em style="font: inherit;">not necessarily indicative of results that <em style="font: inherit;"> may be achieved for the entire year. The year-end Condensed Consolidated Balance Sheet data was derived from audited financial statements but does <em style="font: inherit;">not include all disclosures required by accounting principles generally accepted in the United States of America. The Condensed Consolidated Financial Statements include the accounts of Mesa and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. We made <em style="font: inherit;">no material changes to the application of our significant accounting policies disclosed in our annual report on Form <em style="font: inherit;">10-K. This quarterly report should be read in conjunction with the consolidated financial statements included in our annual report on Form <em style="font: inherit;">10-K for the year ended <em style="font: inherit;"> March 31, 2024.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Our fiscal year ends on <em style="font: inherit;"> March <em style="font: inherit;">31. References in this quarterly report to a particular “year” or “quarter” refer to our fiscal year or fiscal quarters, respectively.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Prior Period Reclassifications</i></p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">For the <em style="font: inherit;">nine months ended <em style="font: inherit;"> December 31, 2024, certain prior period amounts in our unaudited Condensed Consolidated Statements of Operations related to cash interest payments on acquisition holdback liabilities and non-cash debt issuance cost amortization have been reclassified out of "Other expense (income), net" and into "Interest expense and amortization of debt issuance costs." Additionally, prior period <em style="font: inherit;">third-party costs related to the repurchase of a portion of our convertible senior notes have been reclassified out of "Other expense (income), net" and are reflected within the "(Gain) on extinguishment of convertible senior notes." These reclassifications have <em style="font: inherit;">not resulted in any change to "Non-operating expense (income), net" nor in any material change to other amounts presented in our unaudited condensed consolidated financial statements for the <em style="font: inherit;">three and <em style="font: inherit;">nine months ended <em style="font: inherit;"> December 31, 2024.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"> </p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i style="font-size: 10pt;">Risks and Uncertainties</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the reporting date and revenues and expenses during the reporting periods. These estimates represent management's judgment about the outcome of future events. The global business environment continues to be impacted by cost pressures, the overall effects of economic uncertainty, and other factors. Changes in, and the resulting effects of, potential governmental stimulus or fiscal and monetary policies, interest rates, foreign currency values, supply chains, demand for goods and services, a global or regional recession, or other circumstances cannot be reliably predicted. Actual results could differ from our estimates.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b style="font-size: 10pt;"><i>Recently Issued Accounting Pronouncements</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In <em style="font: inherit;"> November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") <em style="font: inherit;">No. <em style="font: inherit;">2023-<em style="font: inherit;">07, "Segment Reporting (Topic <em style="font: inherit;">280): Improvements to Reportable Segment Disclosures." ASU <em style="font: inherit;">No. <em style="font: inherit;">2023-<em style="font: inherit;">07 requires all annual disclosures currently required by Topic <em style="font: inherit;">280 to be included in interim financial statements and requires disclosure of significant segment expenses regularly provided to the chief operating decision maker ("CODM"), a description of other segment items by reportable segment, and applicable additional measures of segment profit or loss used by the CODM when allocating resources and assessing business performance. The ASU is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2023 (our fiscal year <em style="font: inherit;">2025 for annual periods) and interim periods within fiscal years beginning after <em style="font: inherit;"> December 15, 2024 (our fiscal year <em style="font: inherit;">2026 for interim periods) on a retrospective basis. Other than presentation changes to our segment footnote, we do <em style="font: inherit;">not expect the adoption of ASU <em style="font: inherit;">No. <em style="font: inherit;">2023-<em style="font: inherit;">07 to have a material impact on our consolidated financial statements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">In <em style="font: inherit;"> December 2023, the FASB issued ASU <em style="font: inherit;">No. <em style="font: inherit;">2023-<em style="font: inherit;">09, "Income Taxes (Topic <em style="font: inherit;">740): Improvements to Income Tax Disclosures." ASU <em style="font: inherit;">No. <em style="font: inherit;">2023-<em style="font: inherit;">09, which enhances the transparency, effectiveness and comparability of income tax disclosures by requiring consistent categories and greater disaggregation of information related to income tax rate reconciliations and the jurisdictions in which income taxes are paid. The guidance is effective for public business entities for fiscal years beginning after <em style="font: inherit;"> December 15, 2024 (our fiscal year <em style="font: inherit;">2026), with early adoption and prospective or retrospective application permitted. Other than presentation of additional disaggregated data in our income tax footnote disclosures for annual periods, we do <em style="font: inherit;">not expect the adoption of ASU <em style="font: inherit;">No. <em style="font: inherit;">2023-<em style="font: inherit;">09 to have a material impact on our consolidated financial statement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> November 2024, the Financial Accounting Board ("FASB" issued Accounting Standards Update ("ASU") <em style="font: inherit;">No. <em style="font: inherit;">2024-<em style="font: inherit;">03, "Expense Disaggregation Disclosures (Subtopic <em style="font: inherit;">220-<em style="font: inherit;">40): Disaggregation of Income Statement Expenses." ASU <em style="font: inherit;">No. <em style="font: inherit;">2024-<em style="font: inherit;">03 requires that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The ASU is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2026 (our fiscal year <em style="font: inherit;">2028 for annual periods) and interim periods within fiscal years beginning after <em style="font: inherit;"> December 15, 2027 (our fiscal year <em style="font: inherit;">2029 for interim periods), with early adoption and prospective or retrospective application permitted. We are currently assessing the effect the adoption of this standard will have on our consolidated financial statement disclosures.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">We have reviewed all recently issued accounting pronouncements and have concluded that, other than as described above, they are either <em style="font: inherit;">not applicable to us or are <em style="font: inherit;">not expected to have a significant impact on our consolidated financial statements. </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Note <em style="font: inherit;">2. Significant Transactions</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">GKE - Fiscal Year <em style="font: inherit;">2024 Acquisition </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We acquired 100% of the outstanding shares of GKE GmbH and SAL GmbH effective <em style="font: inherit;"> October 16, 2023, and upon approval by applicable Chinese regulators, effective <em style="font: inherit;"> December 31, 2023, we acquired 100% of the outstanding shares of Beijing GKE Science & Technology Co. Ltd. (“GKE China” and together with GKE GmbH and SAL GmbH, “GKE” or the "GKE acquisition").</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">GKE develops, manufactures and sells a portfolio of chemical sterilization indicators, biologics, and process challenge devices to protect patient safety across global healthcare markets. GKE is included in our Sterilization and Disinfection Control ("SDC") division, and GKE's strengths in chemical indictors are complementary to SDC's strengths in biological indicators as chemical and biological indicators are used in the same sterility validation workflows. Additionally, GKE’s healthcare-focused commercial capabilities in Europe and Asia greatly expand our reach in the healthcare markets in those geographies. We are working to obtain regulatory <em style="font: inherit;">510(k) clearance on certain GKE products for sale in the United States, which would further expand organic revenues growth opportunities from the GKE business.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We finalized our purchase price accounting of GKE during fiscal year <em style="font: inherit;">2024. Total cash consideration for the GKE acquisition was $87,187, net of cash and financial liabilities acquired and inclusive of working capital adjustments. Of the total acquisition price, approximately $9,000 (at <em style="font: inherit;"> December 31, 2024 exchange rates) is being held back until <em style="font: inherit;"> April 2025 in accordance with the purchase agreement as security against potential indemnification losses (“GKE holdback”). We funded the acquisition through a combination of cash on-hand and a total of $71,000 borrowed under our line of credit. </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">During the <em style="font: inherit;">three and <em style="font: inherit;">nine months ended <em style="font: inherit;"> December 31, 2024, GKE's operations contributed the following amounts to our consolidated results of operations: </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Three Months Ended</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Nine Months Ended</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman",

Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td>
<td colspan="6" rowspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom:
1px solid rgb(0, 0, 0);"><em style="font: inherit;"><em style="font: inherit;">December 31, 2024</td><td style="font-family: "Times New
Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-
family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-
variant: normal; margin: 0pt;">Revenues</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width:
1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New
Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,854</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;
margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman",
Times, serif; font-size: 10pt; margin-left: 0pt;">18,971</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left:
0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size:
10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross profit</p> </td><td style="width: 1%;
font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size:
10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,904</td><td
style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width:
12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12,457</td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td
style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size:
10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times,
serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family:
"Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr
style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-
family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Amortization of inventory step-up recorded in cost of revenues</p>
</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-
left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td>
<td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,232</td><td style="width: 1%; font-
family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
<td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt;
font-variant: normal; margin: 0pt;">Amortization of acquired intangibles recorded in cost of revenues</p> </td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width:
12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">131</td><td style="width: 1%; font-family: "Times
New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size:
10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family:
"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">375</td><td style="width: 1%; font-family: "Times New Roman", Times, serif;
font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin:
0pt;">Amortization of acquired intangibles recorded in general and administrative expense</p> </td><td style="width: 1%; font-family: "Times New Roman",
Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align:
right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">935</td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td>
<td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New
Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,423</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;
margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt
-1pt;"> </p> 1187187000900000071000000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family:
"Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td
style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size:
10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid
rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em
style="font: inherit;">Three Months Ended</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom:
1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times
New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif;
font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Nine Months Ended</p> </td><td style="font-family:
"Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255);
vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family:
"Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td colspan="6" rowspan="1" style="text-align: center; font-family: "Times
New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;"><em style="font:
inherit;">December 31, 2024</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;">
<p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Revenues</p> </td><td style="width: 1%; font-
family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;
margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,854</td><td
style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
<td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18,971</td><td style="width: 1%; font-
family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
<td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt;
font-variant: normal; margin: 0pt;">Gross profit</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td
style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New
Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,904</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;
margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-
size: 10pt; margin-left: 0pt;">12,457</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr
style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td
style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size:
10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times,
serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family:
"Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family:
"Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal;
margin: 0pt;">Amortization of inventory step-up recorded in cost of revenues</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-
size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-
family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif;
font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-
family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times,
serif; font-size: 10pt; margin-left: 0pt;">1,232</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td>
</tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p
style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Amortization of acquired intangibles recorded in cost of
revenues</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times
New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;
margin-left: 0pt;">131</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%;
font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size:
10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">375</td><td style="width:
1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align:
bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-
size: 10pt; font-variant: normal; margin: 0pt;">Amortization of acquired intangibles recorded in general and administrative expense</p> </td><td style="width: 1%; font-
family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size:
10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">935</td><td style="width:
1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman",
Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align:
right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,423</td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 6854000189710004904000124570000123200013100037500093500024230000 <p
style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Note <em style="font: inherit;">3. Revenue</p> <p style="font-
family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-
align:left;">We develop, manufacture, market, sell and maintain life sciences tools and quality control instruments and related consumables.</p> <p style="font-family:
"Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-
variant: normal; margin: 0pt;">Hardware sales include physical products such as instruments used for molecular and genetic analysis, protein synthesizers, medical meters,
wireless sensor systems, data loggers, and process challenge devices. Hardware sales <em style="font: inherit;">may be offered with accompanying perpetual or
annual software licenses, which in some cases are required for the hardware to function.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-
variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Consumables are single-use products and

require frequent replacement in our customers' operating cycles. Consumables sold by our Clinical Genomics and Biopharmaceutical Development divisions, such as reagents used for molecular and genetic analysis or solutions used for protein synthesis, are critical to the ongoing use of our instruments. Consumables such as biological and chemical indicator test strips sold by our Sterilization and Disinfection Control division are used on a standalone basis.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Revenues from hardware and consumables are recognized upon transfer to the customer, typically at the point of shipment. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">We also offer maintenance, calibration and testing services. Services result in revenues recognized over time, for example, when we are obligated to perform labor and replace parts on an as-needed basis over a contractually specified period of time, or at a point in time, upon completion of a specific, discrete service. In many cases, our contracts contain both revenues recognized over time and revenues recognized at a point in time. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">We evaluate our revenues internally based on business division and the nature of goods and services provided.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following tables present disaggregated revenues for the <em style="font: inherit;">three and <em style="font: inherit;">nine months ended <em style="font: inherit;"> December 31, 2024 and <em style="font: inherit;">2023, respectively.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="18" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended December 31, 2024</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Sterilization and Disinfection Control (1)</p> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Clinical Genomics</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Biopharmaceutical Development</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Calibration Solutions</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Total</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td> <td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Consumables</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">20,991</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">9,866</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">4,909</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,043</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">36,809</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Hardware and software</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">52</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,877</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">4,534</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">9,333</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">15,796</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Services</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,464</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">924</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,794</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,053</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,235</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Total revenues</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">23,507</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,667</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,237</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,429</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">62,840</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: "Times New Roman", Times, serif; width: 100%;"><tbody><tr><td style="width: 100%;"> <p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">^(<em style="font: inherit;">1)Revenues of $6,854 from GKE are included in the Sterilization and Disinfection Control division during the <em style="font: inherit;">three months ended <em style="font: inherit;"> December 31, 2024<i>.</i> </p> </td></tr> </tbody></table> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="18" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"> <em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended December 31, 2023 </p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman

Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom:
1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font:
inherit;">Sterilization and Disinfection Control (1)</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom:
1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New
Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-
align:center;margin:0pt;"><em style="font: inherit;">Clinical Genomics</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt;
padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family:
"Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-
variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Biopharmaceutical Development</p> </td><td style="font-family: "Times New
Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-
align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Calibration Solutions</p> </td><td style="font-family:
"Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td
colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-
family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Total</p> </td><td style="font-family:
"Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td>
<td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td>
<td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times
New Roman"; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt
9pt;">Consumables</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New
Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left:
0pt;">16,832</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times
New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%;
text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">9,758</td><td style="width: 1%; font-family: "Times New
Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-
family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-
size: 10pt; margin-left: 0pt;">4,080</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%;
font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left:
0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">539</td><td style="width: 1%; font-
family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td>
<td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times
New Roman"; font-size: 10pt; margin-left: 0pt;">31,209</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left:
0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p
style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Hardware and software</p> </td><td style="width: 1%;
font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td
style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">180</td><td style="width: 1%; font-family: "Times
New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%;
font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt;
margin-left: 0pt;">1,639</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family:
"Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%;
text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">2,672</td><td style="width: 1%; font-family: "Times New
Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-
family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-
left: 0pt;">8,254</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family:
"Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%;
text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">12,745</td><td style="width: 1%; font-family: "Times New
Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times
New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Services</p>
</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New
Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size:
10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,326</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;
padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-
family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New
Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,149</td><td style="width: 1%; font-family: "Times New Roman"; font-
size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td>
<td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-
family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,678</td><td style="width: 1%; font-family: "Times
New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-
bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%;
text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,366</td><td style="width: 1%; font-
family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman";
font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0,
0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0,
0);">9,519</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr
style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family:
"Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Total revenues</p> </td><td style="width: 1%; font-family: "Times New
Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0,
0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0,
0);">19,338</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%;
font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;
border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-
bottom: 3px double rgb(0, 0, 0);">12,546</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left:
0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman";
font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-
size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,430</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-
bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family:
"Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family:
"Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,159</td><td style="width: 1%; font-family: "Times New
Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td
style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-
align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">53,473</td><td style="width: 1%; font-
family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family: 'Times New Roman',
Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><sup
style="vertical-align:top;line-height:120%;">(<em style="font: inherit;">1) </sup>Revenues of $3,837 from GKE are included in the Sterilization and Disinfection
Control division during the <em style="font: inherit;">three months ended <em style="font: inherit;"> December 31, 2023, following the acquisition of GKE
GmbH and SAL GmbH on <em style="font: inherit;"> October 16, 2023. </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-
align: left"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <table border="0" cellpadding="0"
cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr
class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size:
10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="18" style="text-align: center; font-family:
"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman",
Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em
style="font: inherit;"><em style="font: inherit;">Nine Months Ended December 31, 2024</p> </td><td style="font-family: "Times
New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align:
bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif;
font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom:
1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em
style="font: inherit;">Sterilization and Disinfection Control (1)</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;
padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-
family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New
Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Clinical Genomics</p> </td><td
style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times,
serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-
bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">
<em style="font: inherit;">Biopharmaceutical Development</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;
padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-
family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New
Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Calibration Solutions</p> </td>
<td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman",
Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;
border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin:
0pt;"><em style="font: inherit;">Total</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom:
1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size:
10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td

style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Consumables</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">60,860</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">26,156</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12,657</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,067</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">101,740</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Hardware and software</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">365</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,511</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14,539</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">24,067</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">45,482</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Services</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,444</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,903</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,916</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,358</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">31,621</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total revenues</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">68,669</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">35,570</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">36,112</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">38,492</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">178,843</td><td style="width: 1%; font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">^(<em style="font: inherit;">1)Revenues of $18,971 from GKE are included in the Sterilization and Disinfection Control division during the <em style="font: inherit;">nine months ended <em style="font: inherit;"> December 31, 2024<i>.</i> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="18" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended December 31, 2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Sterilization and Disinfection Control (1)</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Clinical Genomics</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Biopharmaceutical Development</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Calibration Solutions</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Total</p> </td><td style="font-family: "Times New Roman", Times, serif;

font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family:
"Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td
style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size:
10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times,
serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family:
"Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td
style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size:
10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times,
serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family:
"Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family:
"Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant:
normal; margin: 0pt 0pt 0pt 9pt;">Consumables</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td
style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family:
"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">45,288</td><td style="width: 1%; font-family: "Times New Roman", Times, serif;
font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-
family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New
Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">28,490</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;
margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman",
Times, serif; font-size: 10pt; margin-left: 0pt;">12,753</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left:
0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-
size: 10pt; margin-left: 0pt;">1,834</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td
style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times,
serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left:
0pt;">88,365</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-
color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times
New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Hardware and software</p> </td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td>
<td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">381</td><td style="width: 1%; font-
family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif;
font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-
family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9,540</td><td style="width: 1%; font-family: "Times New Roman", Times,
serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%;
font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times,
serif; font-size: 10pt; margin-left: 0pt;">7,838</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td>
<td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman",
Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left:
0pt;">22,216</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td>
<td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">39,975</td><td style="width: 1%; font-
family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
<td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt;
font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Services</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-
bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td
style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0,
0);">6,676</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td
style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman",
Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,434</td><td style="width: 1%; font-family: "Times New Roman", Times,
serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-
bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td
style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0,
0);">7,935</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td
style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman",
Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,898</td><td style="width: 1%; font-family: "Times New Roman", Times,
serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-
bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td
style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0,
0);">28,943</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr
style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-
family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total revenues</p> </td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-
left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;
margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">52,345</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;
padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%;
font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align:
right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">41,464</td><td style="width: 1%;
font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-
bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;
border-bottom: 3px double rgb(0, 0, 0);">28,526</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;
margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-
family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">34,948</td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-
bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;
border-bottom: 3px double rgb(0, 0, 0);">157,283</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;
margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-
family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><sup style="vertical-align:top;line-height:120%;">(<em style="font: inherit;">1)
</sup>Revenues of $3,837 from GKE are included in the Sterilization and Disinfection Control division during the <em style="font: inherit;">nine months ended <em
style="font: inherit;"> December 31, 2023, following the acquisition of GKE GmbH and SAL GmbH on <em style="font: inherit;"> October 16, 2023. </p> <p
style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size:
10pt; margin: 0pt; text-align: left">Revenues from external customers are attributed to individual countries based upon the locations to which the products are shipped or
exported, or locations where services are performed, as follows:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p>
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-
indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman",
Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center;
font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New
Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Three Months
Ended December 31,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td
style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New
Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-
size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended December 31,
</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading"
style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td
style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New
Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-
size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New
Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td
colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p
style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font:
inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-
family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times,
serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-
variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times,
serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-
align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:
"Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p>

</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238,
255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New
Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">United States</p> </td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
<td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">30,476</td><td style="width: 1%; font-
family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif;
font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-
align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">25,595</td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td>
<td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family:
"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">85,415</td><td style="width: 1%; font-family: "Times New Roman", Times, serif;
font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-
family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New
Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">79,205</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;
margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif;
font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">China</p> </td><td
style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times,
serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,322</td>
<td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width:
9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,942</td><td style="width: 1%; font-family: "Times
New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size:
10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family:
"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">20,271</td><td style="width: 1%; font-family: "Times New Roman", Times, serif;
font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-
family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif;
font-size: 10pt; margin-left: 0pt;">18,584</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p
style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other</p> </td><td style="width: 1%; font-
family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times,
serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size:
10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">26,042</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;
margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td>
<td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align:
right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">22,936</td><td style="width: 1%;
font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;
border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left:
0pt; border-bottom: 1px solid rgb(0, 0, 0);">73,157</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;
padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width:
1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-
family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">59,494</td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-
align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif;
font-size: 10pt; font-variant: normal; margin: 0pt;">Total revenues</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size:
10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0,
0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double
rgb(0, 0, 0);">62,840</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td
style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times,
serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman",
Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">53,473</td><td style="width: 1%; font-family: "Times New Roman", Times,
serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td>
<td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td
style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0,
0);">178,843</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td
style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times,
serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman",
Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">157,283</td><td style="width: 1%; font-family: "Times New Roman",
Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-
size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Other than China, <em
style="font: inherit;">no foreign country exceeded <em style="font: inherit;">10% of total revenues for the <em style="font: inherit;">three and <em
style="font: inherit;">nine months ended <em style="font: inherit;"> December 31, 2024 and <em style="font: inherit;">2023.</p> <p style="font-family:
'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-
align:left;">Contract Balances</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our contracts have varying
payment terms and conditions. Some customers prepay for products and services resulting in unearned revenues or customer deposits called contract liabilities. Short-term
contract liabilities are included within unearned revenues in the accompanying unaudited Condensed Consolidated Balance Sheets, and long-term contract liabilities are
included within other noncurrent liabilities in the accompanying unaudited Condensed Consolidated Balance Sheets. The significant majority of our revenues and related
receivables and contract liabilities are generated from contracts with customers with original durations of <em style="font: inherit;">12 months or less. Contract
liabilities will be recognized to revenue as we satisfy our obligations under the terms of the contracts. </p> <p style="font-family:'Times New Roman', Times, serif;font-
size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">A summary of contract liabilities
is as follows:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0"
class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-
align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant:
normal; margin: 0pt;">Contract liabilities as of March 31, 2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%;
font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left:
0pt;">15,686</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);
vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant:
normal; margin: 0pt;">Prior year liabilities recognized in revenues during the nine months ended December 31, 2024</p> </td><td style="width: 1%; font-family: Times New
Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New
Roman; font-size: 10pt; margin-left: 0pt;">(9,069</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr
style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: "Times New
Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Contract liabilities added during the nine months ended December 31, 2024, net of revenues
recognized</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New
Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;
border-bottom: 1px solid rgb(0, 0, 0);">8,083</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: "Times
New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Contract liabilities as of December 31, 2024</p> </td><td style="width: 1%; font-family: Times New
Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td
style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,700</td><td style="width:
1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; font-family: "Times
New Roman", Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family:
"Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times
New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="18" style="text-align: center; font-
family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-
variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em
style="font: inherit;">Three Months Ended December 31, 2024</p> </td><td style="font-family: "Times New Roman"; font-
size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New
Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family:
"Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-
variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Sterilization and Disinfection Control (1)</p> </td><td style="font-family:
"Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td
colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-
family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Clinical Genomics</p> </td><td
style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size:
10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Biopharmaceutical
Development</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times
New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-
bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font:
inherit;">Calibration Solutions</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-
family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt;
margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em
style="font: inherit;">Total</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr
style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td>

<td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Consumables</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">20,991</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">9,866</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">4,909</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,043</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">36,809</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Hardware and software</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">52</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,877</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">4,534</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">9,333</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">15,796</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Services</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,464</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">924</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,794</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,053</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,235</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Total revenues</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">23,507</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,667</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,237</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,429</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">62,840</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="18" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"> <em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended December 31, 2023 </p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Sterilization and Disinfection Control (1)</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Clinical Genomics</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Biopharmaceutical Development</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Calibration Solutions</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Total</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td> <td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td> <td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Consumables</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">16,832</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">9,758</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">4,080</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">539</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">31,209</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Hardware and software</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">180</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,639</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">2,672</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-

family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">8,254</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">12,745</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Services</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,326</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,149</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,678</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,366</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,519</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Total revenues</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">19,338</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,546</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,430</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,159</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">53,473</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="18" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended December 31, 2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Sterilization and Disinfection Control (1)</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Clinical Genomics</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"> <em style="font: inherit;">Biopharmaceutical Development</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Calibration Solutions</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Total</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Consumables</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">60,860</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">26,156</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12,657</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,067</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">101,740</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Hardware and software</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">365</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,511</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14,539</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">24,067</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">45,482</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">

<td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Services</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,444</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,903</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,916</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,358</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">31,621</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total revenues</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">68,669</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">35,570</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">36,112</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">38,492</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">178,843</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="18" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended December 31, 2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Sterilization and Disinfection Control (1)</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Clinical Genomics</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Biopharmaceutical Development</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Calibration Solutions</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Total</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Consumables</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">45,288</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">28,490</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12,753</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,834</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">88,365</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Hardware and software</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">381</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9,540</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7,838</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">22,216</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">39,975</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Services</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,676</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times

New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,434</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,935</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,898</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">28,943</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total revenues</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">52,345</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">41,464</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">28,526</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">34,948</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">157,283</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>
2099100098660004909000104300036809000520001877000453400093330001579600024640009240002794000405300010235000235070001266700012237000144290006284
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended December 31,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended December 31,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">United States</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">30,476</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">25,595</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">85,415</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">79,205</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">China</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,322</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,942</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">20,271</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18,584</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">26,042</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">22,936</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">73,157</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">59,494</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total revenues</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">62,840</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">53,473</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">178,843</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times,

serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">157,283</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 30476000255950008541500079205000632200049420002027100018584000260420002293600073157000594940006284000053473000178843000157283000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Contract liabilities as of March 31, 2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,686</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Prior year liabilities recognized in revenues during the nine months ended December 31, 2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(9,069</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Contract liabilities added during the nine months ended December 31, 2024, net of revenues recognized</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,083</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Contract liabilities as of December 31, 2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,700</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 15686000-9069000808300014700000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Note <em style="font: inherit;">4. Fair Value Measurements</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our financial instruments consist primarily of cash and cash equivalents, trade accounts receivable, obligations under trade accounts payable, and debt. Due to their short-term nature, the carrying values for cash and cash equivalents, trade accounts receivable, and trade accounts payable approximate fair value; they are classified within Level <em style="font: inherit;">1 of the fair value hierarchy. </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The financial instruments that subject us to the highest concentration of credit risk are cash and accounts receivable. We maintain relationships and cash deposits at multiple banking institutions across the world in an effort to diversify and reduce risk of loss. Concentration of credit risk with respect to accounts receivable is limited to customers to whom we make significant sales. No customers accounted for more than <em style="font: inherit;">10% of total trade receivables as of <em style="font: inherit;"> December 31, 2024.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On <em style="font: inherit;"> April 5, 2024, we entered into separate, privately negotiated purchase agreements with a limited number of holders of our 1.375% convertible senior notes due <em style="font: inherit;"> August 15, 2025 (the "Notes"), through which we repurchased $75,000 in aggregate principal amount of the Notes. See Note <em style="font: inherit;">7. "Indebtedness" for further information. As of <em style="font: inherit;"> December 31, 2024, we had remaining outstanding $97,500 aggregate principal amount of the Notes. We estimate the fair value of the Notes using Level <em style="font: inherit;">2 inputs based on the last actively traded price or observable market input preceding the end of the reporting period. The fair value of the Notes is approximately correlated to our stock price.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The estimated fair value and carrying value of the Notes were as follows:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2024</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">March 31, 2024 </p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Carrying Value </p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Fair Value (Level 2) </p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Carrying Value</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Fair Value (Level 2)</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Notes</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">97,163</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">94,819</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">171,198</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">163,013</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The carrying amounts of our term loan and revolving line of credit (together, the "Credit Facility") on the unaudited Condensed Consolidated Balance Sheets approximate fair value due to the variable interest rate pricing on the debt, with the balance bearing an interest rate approximating current market rates.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We expect to pay approximately $9,000 (at <em style="font: inherit;"> December 31, 2024 exchange rates) for the GKE holdback in <em style="font: inherit;"> April 2025. We estimate the discounted fair value of consideration held back to be approximately $8,900 as of <em style="font: inherit;"> December 31, 2024 based on Level <em style="font: inherit;">3 inputs from the acquisition, including discount rate estimates. We adjust the estimated fair value at each reporting period through earnings.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">During fiscal year <em style="font: inherit;">2023, we acquired substantially all of the assets and certain liabilities of Belyntic GmbH’s peptide purification business (“the Belyntic acquisition”). We are obligated to pay contingent consideration of up to $1,500 cash upon regulatory approval of certain patent applications. We estimate the fair value of the remaining contingent consideration is $675, using Level <em style="font: inherit;">3 inputs and a probability-weighted outcome analysis based on our expectations of patent approval, leveraging our historical experience and expert input. </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Amounts recognized or disclosed at fair value in the unaudited condensed consolidated financial statements on a nonrecurring basis include the initial recognition and disclosure of most assets and liabilities purchased in business acquisitions and any related measurement period adjustments. Additionally, assets such as property and equipment, operating lease assets, goodwill and other intangible assets are adjusted to fair value if determined to be impaired. Fair values of such assets and liabilities require measurement using Level <em style="font: inherit;">3 inputs. We recorded <em style="font: inherit;">no impairments during the <em style="font: inherit;">three and <em style="font: inherit;">nine months ended <em style="font: inherit;"> December 31, 2024 or <em style="font: inherit;">2023. </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">There were <em style="font: inherit;">no transfers between the levels of the fair value hierarchy during the <em style="font: inherit;">three and <em style="font: inherit;">nine months ended <em style="font: inherit;"> December 31, 2024.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> 0.01375750000000097500000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2024</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">March 31, 2024</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Carrying Value</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Fair Value

(Level 2)</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Carrying Value</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Fair Value (Level 2)</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Notes</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">97,163</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">94,819</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">171,198</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">163,013</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 97163000948190001711980001630130000900000008900000150000006750000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Note <em style="font: inherit;">5. Supplemental Information</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Inventories consisted of the following:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">December 31, 2024</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">March 31, 2024</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Raw materials</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">16,584</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">18,335</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Work in process</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">400</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,256</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Finished goods</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">11,138</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">13,084</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total inventories</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">28,122</td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">32,675</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">Prepaid expenses and other current assets consisted of the following: </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">December 31, 2024</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">March 31, 2024</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid expenses</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">3,251</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">2,932</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman";">Deposits</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0">1,338</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0">1,898</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid income taxes</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">5,682</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,237</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Other current assets</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,849</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,341</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Total prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,120</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,408</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Accrued payroll and benefits consisted of the following:</p> <p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New

Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">December 31, 2024</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">March 31, 2024</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Bonus payable</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">7,803</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">3,838</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Wages and paid-time-off payable</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">3,600</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">3,072</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Payroll related taxes</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,954</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,956</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Other benefits payable</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">562</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,069</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Total accrued payroll and benefits</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,919</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,935</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The increase in bonus payable is primarily due to our financial performance in fiscal year <em style="font: inherit;">2025 compared to fiscal year <em style="font: inherit;">2024. </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Other accrued expenses consisted of the following: </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">December 31, 2024</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">March 31, 2024</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued business taxes</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">5,505</td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">5,557</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Current operating lease liabilities</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">3,535</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">2,986</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Income taxes payable</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,364</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,615</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman";">Current acquisition-related holdbacks</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0">9,531</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0">436</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">2,416</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">2,264</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total other accrued expenses</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">22,351</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">12,858</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-size: 10pt; font-family: "Times New Roman", Times, serif; margin: 0pt;"> </p> <p style="font-size: 10pt; font-family: "Times New Roman", Times, serif; margin: 0pt;">The increase in other accrued expenses is primarily due to the reclassification of held back Belyntic and GKE acquisition-related consideration from noncurrent liabilities.</p> <p style="font-size: 10pt; font-family: "Times New Roman", Times, serif; margin: 0pt;"> </p> <p style="font-size: 10pt; font-family: "Times New Roman", Times, serif; margin: 0pt;">Other noncurrent liabilities consisted of the following: </p> <p style="font-size: 10pt; font-family: "Times New Roman", Times, serif; margin: 0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">March 31, 2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin:

0pt;">Noncurrent operating lease liabilities</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12,361</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,613</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Noncurrent acquisition-related holdbacks</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8,792</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">92</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">208</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total other noncurrent liabilities</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">12,453</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">15,613</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-size: 10pt; font-family: "Times New Roman", Times, serif; margin: 0pt;"> </p> <p style="font-size: 10pt; font-family: "Times New Roman", Times, serif; margin: 0pt;">The increase in operating lease liabilities is primarily attributable to the right of use asset associated with an operating lease for a facility used by our Biopharmaceutical Development for manufacturing and administrative purposes.</p> <p style="font-size: 10pt; font-family: "Times New Roman", Times, serif; margin: 0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended December 31,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended December 31,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; text-align: center;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; text-align: center;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; text-align: center;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Depreciation expense in cost of revenues</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">610</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">788</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,376</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,117</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Depreciation expense in operating expense</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">496</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">286</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,652</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">782</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total depreciation expense</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,106</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,074</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,028</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,899</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <p style="font-size: 10pt; font-family: "Times New Roman", Times, serif; margin: 0pt;"> </p> <p style="font-size: 10pt; font-family: "Times New Roman", Times, serif; margin: 0pt;">The increase in depreciation expense for the <em style="font: inherit;">three and <em style="font: inherit;">nine months ended <em style="font: inherit;"> December 31, 2024 is primarily due to GKE's operations, which included $225 and $850 of depreciation expense, respectively. </p> <p style="font-size: 10pt; font-family: "Times New Roman", Times, serif; margin: 0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">December 31, 2024</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom:

1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">March 31,
2024</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204,
238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New
Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Raw materials</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size:
10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-
family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">16,584</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;
margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New
Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left:
0pt;">18,335</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255,
255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size:
10pt; font-variant: normal; margin: 0pt;">Work in process</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td
style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman";
font-size: 10pt; margin-left: 0pt;">400</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%;
font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td
style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,256</td><td style="width: 1%; font-family: "Times
New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family:
"Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Finished
goods</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New
Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">11,138</td>
<td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New
Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right;
font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">13,084</td><td style="width: 1%; font-family: "Times New Roman"; font-size:
10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-
size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total inventories</p> </td><td
style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;
margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New
Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">28,122</td><td style="width: 1%; font-family:
"Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size:
10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px
solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double
rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">32,675</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-
left: 0pt;"> </td></tr> </tbody></table> 16584000183350004000001256000111380001308400028122000032675000 <table border="0" cellpadding="0" cellspacing="0"
class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255,
255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-
size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0,
0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">December 31, 2024
</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman";
font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid
rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">March 31,
2024</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204,
238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New
Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid expenses</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size:
10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-
family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">3,251</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;
margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New
Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left:
0pt;">2,932</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255,
255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt;
font-family: "Times New Roman";">Deposits</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin:
0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-
family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0">1,338</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;
padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-
family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman";
font-size: 10pt; padding: 0; margin: 0">1,898</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr
style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family:
"Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid income taxes</p> </td><td style="width: 1%; font-family: "Times New
Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right;
font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">5,682</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;
margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New
Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,237</td><td
style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align:
bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant:
normal; margin: 0pt;">Other current assets</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-
family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New
Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,849</td><td style="width: 1%; font-family: "Times New Roman"; font-
size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times
New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-
size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,341</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left:
0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p
style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Total prepaid expenses and other current
assets</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New
Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New
Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,120</td><td style="width: 1%; font-family: "Times New Roman"; font-
size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%;
font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-
family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,408</td><td style="width: 1%; font-family: "Times
New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>
32510002932000133800018980005682000123700028490003341000131200009408000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width:
100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td
style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2"
style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times
New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">December 31, 2024</p> </td><td style="font-family:
"Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td
colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-
family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">March 31, 2024</p> </td><td
style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align:
bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-
variant: normal; margin: 0pt;">Bonus payable</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%;
font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman";
font-size: 10pt; margin-left: 0pt;">7,803</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width:
1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left:
0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">3,838</td><td style="width: 1%; font-
family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td
style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin:
0pt;">Wages and paid-time-off payable</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-
family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-
left: 0pt;">3,600</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family:
"Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%;
text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">3,072</td><td style="width: 1%; font-family: "Times New
Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times
New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Payroll related taxes</p>
</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size:
10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,954</td><td style="width: 1%; font-
family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td>
<td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New
Roman"; font-size: 10pt; margin-left: 0pt;">1,956</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family:
"Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Other benefits payable</p> </td><td style="width: 1%; font-family: "Times New
Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid
rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0,
0);">562</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-
family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;
border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-
bottom: 1px solid rgb(0, 0, 0);">1,069</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td>

</tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Total accrued payroll and benefits</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,919</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,935</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 780300038380003600003072000195400019560005620001069000139190009935000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">December 31, 2024</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">March 31, 2024</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued business taxes</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">5,505</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">5,557</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Current operating lease liabilities</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">3,535</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">2,986</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Income taxes payable</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,364</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,615</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman";">Current acquisition-related holdbacks</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0">9,531</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0">436</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">2,416</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">2,264</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total other accrued expenses</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">22,351</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">12,858</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 5505000555700035350002986000136400016150009531000436000241600022640002235100012858000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">March 31, 2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Noncurrent operating lease liabilities</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12,361</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,613</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Noncurrent acquisition-related holdbacks</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8,792</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">92</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">208</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total other noncurrent liabilities</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">12,453</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">15,613</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 1236100066130008792000920002080001245300015613000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended December 31,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended December 31, </p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New

Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"> <em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; text-align: center;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; text-align: center;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"> <em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; text-align: center;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Depreciation expense in cost of revenues</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">610</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">788</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,376</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,117</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Depreciation expense in operating expense</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">496</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">286</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,652</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">782</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total depreciation expense</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,106</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,074</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,028</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,899</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table>
61000078800023760002117000496000286000165200078200011060001074000402800028990002250008500000 <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">Note <em style="font: inherit;">6. Goodwill and Intangible Assets, Net</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">Finite-lived intangible assets consisted of the following:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">March 31, 2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Gross Carrying Amount</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Accumulated Amortization</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Net Carrying Amount</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Gross Carrying Amount</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Accumulated Amortization </p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Net Carrying Amount</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 28%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer relationships</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">186,272</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(112,475</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">73,797</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">189,911</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(104,528</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>

<td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">85,383</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other intangibles</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">60,356</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(35,972</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">24,384</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">61,161</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(32,792</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">28,369</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total finite-lived intangible assets</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">246,628</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">(148,447</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">98,181</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">251,072</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">(137,320</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">113,752</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">Amortization expense for finite-lived intangible assets was as follows:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended December 31,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended December 31,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Amortization in cost of revenues</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">660</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,883</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,979</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,367</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Amortization in general and administrative</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,731</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,092</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,023</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,013</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total amortization expense</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,391</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,975</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,002</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td

style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">22,380</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The decrease in amortization expense is attributable to impairment losses recorded during the <em style="font: inherit;">fourth quarter of fiscal year <em style="font: inherit;">2024 related to intangible assets within our Clinical Genomics division. </p> <p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">For the following fiscal years ending <em style="font: inherit;"> March 31, future amortization expense is estimated as follows, based on foreign currency exchange rates as of <em style="font: inherit;"> December 31, 2024:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td colspan="1" rowspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"><p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Fiscal Year</p> </td><td colspan="1" rowspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" rowspan="2" style="padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;"><em style="font: inherit;">Amortization Expense</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Remainder of 2025</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,278</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16,566</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15,921</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15,349</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2029</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14,815</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-size: 10pt; font-family: "Times New Roman", Times, serif; margin: 0pt;"> </p> <p style="font-size: 10pt; font-family: "Times New Roman", Times, serif; margin: 0pt;">The change in the carrying amount of goodwill was as follows:</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Sterilization and Disinfection Control</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Clinical Genomics</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Biopharmaceutical Development</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Calibration Solutions</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Total</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">March 31, 2024</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">79,430</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16,940</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">46,515</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">37,211</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">180,096</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Effect of foreign currency translation</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(1,994</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(71</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(849</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(30</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(2,944</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">December 31, 2024</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">77,436</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">16,869</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">45,666</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">37,181</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-

align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">177,152</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">March 31, 2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Gross Carrying Amount</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Accumulated Amortization</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Net Carrying Amount</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Gross Carrying Amount</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Accumulated Amortization</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Net Carrying Amount</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 28%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer relationships</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">186,272</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(112,475</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">73,797</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">189,911</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(104,528</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">85,383</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other intangibles</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">60,356</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(35,972</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">24,384</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">61,161</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(32,792</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">28,369</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total finite-lived intangible assets</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">246,628</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">(148,447</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">98,181</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">251,072</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">(137,320</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">113,752</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>
1862720001124750007379700018991100010452800085383000603560003597200024384000611610003279200028369000246628000148447000981810002510720001373200
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended December 31,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended December 31, </p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New

Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td
colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p
style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font:
inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-
family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times,
serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-
variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times,
serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-
align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:
"Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p>
</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238,
255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New
Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Amortization in cost of revenues</p> </td><td style="width: 1%; font-family: "Times
New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left:
0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">660</td><td style="width:
1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman",
Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td
style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,883</td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-
size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align:
right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,979</td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td>
<td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family:
"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,367</td><td style="width: 1%; font-family: "Times New Roman", Times, serif;
font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin:
0pt;">Amortization in general and administrative</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom:
1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width:
9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,731</td><td
style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif;
font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;
margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,092</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-
left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td
style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align:
right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,023</td><td style="width: 1%;
font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;
border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left:
0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,013</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;
padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times,
serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total
amortization expense</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-
family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,391</td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-
bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;
border-bottom: 3px double rgb(0, 0, 0);">7,975</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;
margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-
family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,002</td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-
bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;
border-bottom: 3px double rgb(0, 0, 0);">22,380</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;
margin-left: 0pt;"> </td></tr> </tbody></table> 660000188300019790005367000373100060920001102300017013000439100079750001300200022380000 <table
border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent:
0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td colspan="1" rowspan="2" style="font-family: "Times
New Roman", Times, serif; font-size: 10pt; width: 85%;"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Fiscal
Year</p> </td><td colspan="1" rowspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" rowspan="2"
style="padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 1px solid rgb(0, 0, 0); vertical-align:
bottom; text-align: center;"><em style="font: inherit;">Amortization Expense</td><td style="font-family: "Times New Roman", Times, serif; font-
size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman",
Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204,
238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New
Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Remainder of 2025</p> </td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
<td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,278</td><td style="width: 1%; font-
family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
<td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt;
font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width:
1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman",
Times, serif; font-size: 10pt; margin-left: 0pt;">16,566</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left:
0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size:
10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-
family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size:
10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15,921</td><td
style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);
vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times,
serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size:
10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family:
"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15,349</td><td style="width: 1%; font-family: "Times New Roman", Times, serif;
font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin:
0pt;">2029</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times
New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;
margin-left: 0pt;">14,815</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody>
</table> 4278000165660001592100015349000148150000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family:
"Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family:
"Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td
colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p
style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font:
inherit;">Sterilization and Disinfection Control</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom:
1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times
New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif;
font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Clinical Genomics</p> </td><td style="font-family:
"Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size:
10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid
rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em
style="font: inherit;">Biopharmaceutical Development</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-
bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family:
"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman",
Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Calibration Solutions</p> </td><td style="font-
family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-
size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px
solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em
style="font: inherit;">Total</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr
style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <p
style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">March 31, 2024</p> </td><td style="width: 1%; font-
family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;
margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">79,430</td><td
style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>

```html
<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,940</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46,515</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37,211</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">180,096</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Effect of foreign currency translation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,994</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(71</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(849</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,944</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">77,436</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">16,869</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">45,666</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">37,181</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">177,152</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 79430000169400004651500037211000180096000-1994000-71000-849000-30000-294400077436000168690004566600037181000177152000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">7</em></b><b>.</b><b> Indebtedness</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Credit Facility</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> March 5, 2021, </em>we entered into a <span style="-sec-ix-hidden:c122335712">four</span>-year senior secured credit agreement that included <em style="font: inherit;">1</em>) a revolving credit facility with an aggregate principal amount of up to $75,000 (the "Revolver"), <em style="font: inherit;">2</em>) a swingline loan with an aggregate principal amount <em style="font: inherit;">not</em> exceeding $5,000, and <em style="font: inherit;">3</em>) letters of credit with an aggregate stated amount <em style="font: inherit;">not</em> exceeding $2,500 at any time. The agreement also provided for an incremental term loan or an increase in revolving commitments with a minimum aggregate principal amount of $25,000 and a maximum amount of $75,000, subject to the satisfaction of certain conditions and lender considerations. We refer to the agreement in whole as the “Credit Facility.”</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> October 5, 2023, </em>we amended the terms of the Credit Facility to increase the maximum principal amount available to us under the Revolver from $75,000 to $125,000. </p> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> April 5, 2024, </em>we further amended and restated the terms of the Credit Facility to:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:1.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(i)</p> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Extend the maturity of the Credit Facility to <em style="font: inherit;"> April 2029; </em></p> </td></tr> <tr><td style="vertical-align:top;width:1.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(ii)</p> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Allow proceeds from the Credit Facility to be used to redeem some or all of the Company’s <em style="font: inherit;">2025</em> Notes;</p> </td></tr> <tr><td style="vertical-align:top;width:1.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(iii)</p> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Include a <em style="font: inherit;">$75,000</em> senior secured term loan facility (the “Term Loan”), which is subject to principal amortization payments; and</p> </td></tr> <tr><td style="vertical-align:top;width:1.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(iv)</p> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Make certain changes to the financial covenants.</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">In conjunction with the amendment and restatement of the Credit Facility during the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> December 31, 2024, </em>we incurred $1,987 of customary lender fees and debt issuance costs paid to <em style="font: inherit;">third</em> parties, of which $1,242 is related to the Revolver and $745 is related to the Term Loan. The fees are being amortized to interest expense through maturity. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Amounts borrowed under the Credit Facility bear interest at either a base rate or a SOFR rate plus an applicable spread ranging from 1.5% to 3.5%, depending on our total net leverage ratio. The weighted average interest rate on borrowings under the Credit Facility as of <em style="font: inherit;"> December 31, 2024</em> was 7.5%.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The financial covenants in the Credit Facility as amended include a maximum leverage ratio of 4.50 to <em style="font: inherit;">1.00</em> on each of the quarterly testing dates through <em style="font: inherit;"> December 31, 2024; </em>4.0 to <em style="font: inherit;">1.0</em> on each of the testing dates between <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;"> March 31, 2026; </em>and 3.5 to <em style="font: inherit;">1.0</em> on each testing date thereafter. The Credit Facility also stipulates a minimum fixed charge coverage ratio of 1.25 to <em style="font: inherit;">1.0</em> and a minimum senior net leverage ratio of 3.5 to <em style="font: inherit;">1.</em> Other covenants include restrictions on our ability to incur debt, grant liens, make fundamental changes to our business as defined in the contract, engage in certain transactions with affiliates, or conduct asset sales. As of <em style="font: inherit;"> December 31, 2024</em>, we were in compliance with all covenants under the Credit Facility.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Term Loan</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">We borrowed $75,000 under the Term Loan on <em style="font: inherit;"> April 5, 2024, </em>to fund the privately negotiated repurchases of a portion of the Notes (see “Convertible Notes” below). During the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> December 31, 2024</em>, we made required quarterly principal payments on the Term Loan of $938 and $2,813, respectively. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">We are required to make quarterly principal payments on the Term Loan. For the following fiscal years ending <em style="font: inherit;"> March 31, </em>future debt payments on the Term Loan are required as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Fiscal Year</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Amount</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Remainder of 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">937</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,750</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
```

~~10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,625</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,625</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2029</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7,500</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">48,750</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Total Principal Remaining</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-top: 1px solid rgb(0, 0, 0); border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-top: 1px solid rgb(0, 0, 0); border-bottom: 3px double black;">72,187</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The net carrying amount of the Term Loan was as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">March 31, 2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Term Loan (7.5% as of December 31, 2024)</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">72,187</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: discount and debt issuance costs</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(634</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: current portion</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(3,750</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Noncurrent portion</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid rgb(0, 0, 0); border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid rgb(0, 0, 0); border-bottom: 3px double black;">67,803</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid rgb(0, 0, 0); border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid rgb(0, 0, 0); border-bottom: 3px double black;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><i>Revolver</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December 31, 2024, the outstanding balance under the Revolver was $27,000, and $98,000 was available for borrowing. Subsequent to <em style="font: inherit;"> December 31, 2024, we repaid an additional $4,500 on the Revolver.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">We are obligated to pay quarterly unused commitment fees of between 0.20% and 0.35% of the Revolver's aggregate principal amount, based on our leverage ratio.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The balance of unamortized customary lender fees related to the Revolver, including fees from the original debt issuance and all subsequent amendments and restatements, was $1,278 and $321 as of <em style="font: inherit;"> December 31, 2024 and <em style="font: inherit;"> March 31, 2024, respectively.</p> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Convertible Notes </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On <em style="font: inherit;"> August 12, 2019, we issued an aggregate principal amount of $172,500 of Notes. The net proceeds from the Notes, after deducting underwriting discounts and commissions and other related offering expenses payable by us, were approximately $167,056. The Notes mature on <em style="font: inherit;"> August 15, 2025, unless earlier repurchased or converted, and bear interest at a rate of 1.375% payable semi-annually in arrears on <em style="font: inherit;"> February 15 and <em style="font: inherit;"> August 15 each year. The Notes are initially convertible, subject to certain conditions, at a conversion rate of 3.5273 shares of common stock per <em style="font: inherit;">$1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $283.50 per share of common stock. </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On <em style="font: inherit;"> April 5, 2024, we entered into separate, privately negotiated transactions with certain holders of the Notes to repurchase $75,000 aggregate principal amount of the Notes for an aggregate repurchase price of $71,250 in cash, plus accrued and unpaid interest of $160. We accounted for the partial repurchase of the Notes as a debt extinguishment, which resulted in the recognition of a gain on extinguishment of $2,887 in other income on the unaudited Condensed Consolidated Statements of Operations during the <em style="font: inherit;">nine months ended <em style="font: inherit;"> December 31, 2024. As of <em style="font: inherit;"> December 31, 2024, $97,500 in aggregate principal amount of the Notes remained outstanding, which we intend to pay using a combination of cash on hand and a draw on our Revolver.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Upon conversion, we will pay or deliver, as the case <em style="font: inherit;"> may be, cash, shares of our common stock, or a combination of cash and shares of our common stock. The circumstances necessary for conversion were <em style="font: inherit;">not met during the <em style="font: inherit;">three or <em style="font: inherit;">nine months ended <em style="font: inherit;"> December 31, 2024. The Notes will become convertible at any time from and including <em style="font: inherit;"> April <em style="font: inherit;">15, <em style="font: inherit;">2025 until the close of business on the <em style="font: inherit;">second scheduled trading day immediately before the maturity date. As of <em style="font: inherit;"> December 31, 2024, the Notes were classified as a current liability on our unaudited Condensed Consolidated Balance Sheets. The if-converted value of the Notes did <em style="font: inherit;">not exceed the principal balance as of <em style="font: inherit;"> December 31, 2024. </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The net carrying amount of the Notes was as follows:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">December 31, 2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">March 31, 2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">Principal outstanding</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">97,500</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">172,500</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-~~

color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">Unamortized debt issuance costs</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(337</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,302</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">Net carrying value</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">97,163</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">171,198</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">We recognized interest expense on the Notes as follows:</p> <p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"> <em style="font: inherit;"><em style="font: inherit;">Three Months Ended December 31,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended December 31,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Coupon interest expense at 1.375%</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">335</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">593</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,037</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,779</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Amortization of debt issuance costs</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">134</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">231</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">412</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">692</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total interest and amortization of debt issuance costs</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">469</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">824</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,449</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,471</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The effective interest rate on the Notes is approximately 1.9%.</p> <p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </p>
75000000500000025000002500000075000000750000001250000001987000124200074500000.0150.0350.0754.543.51.253.575000000938000281300 0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fiscal Year</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Amount</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Remainder of 2025</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">937</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,750</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,625</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman

```
Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,625</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2029</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">48,750</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Total Principal Remaining</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-top: 1px solid rgb(0, 0, 0); border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-top: 1px solid rgb(0, 0, 0); border-bottom: 3px double black;">72,187</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> </tbody></table> 93700037500005625000562500075000004875000072187000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31, 2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">March 31, 2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Term Loan (<span style="-sec-ix-hidden:c122335802">7.5</span>% as of December 31, 2024)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">72,187</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: discount and debt issuance costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(634</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,750</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Noncurrent portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid rgb(0, 0, 0); border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid rgb(0, 0, 0); border-bottom: 3px double black;">67,803</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid rgb(0, 0, 0); border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid rgb(0, 0, 0); border-bottom: 3px double black;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 721870000634000-03750000-0678030000270000009800000045000000.0020.003512780003210001725000001670560000.013753.5273283.57500000071250000160000288700097500000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">December 31, 2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">March 31, 2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Principal outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">97,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">172,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Unamortized debt issuance costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(337</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,302</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net carrying value</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">97,163</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">171,198</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 97500000172500000337000130200097163000171198000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
```

padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Coupon interest expense at 1.375%</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">335</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">593</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,037</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,779</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Amortization of debt issuance costs</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">134</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">231</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">412</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">692</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total interest and amortization of debt issuance costs</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">469</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">824</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,449</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,471</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 33500059300010370001779000134000231000412000692000469000824000144900024710000.019 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Note <em style="font: inherit;">8. Stockholders' Equity</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Stock-Based Compensation</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">During the <em style="font: inherit;">nine months ended <em style="font: inherit;"> December 31, 2024, we issued time-based restricted stock units ("RSUs") and performance-based restricted stock units ("PSUs") pursuant to the Mesa Laboratories, Inc. Amended and Restated <em style="font: inherit;">2021 Equity Incentive Plan, which authorizes the issuance of 660 shares of common stock to eligible participants. Stock-based compensation expense is included in cost of revenues, selling, general and administrative, and research and development expense in the accompanying unaudited Condensed Consolidated Statements of Operations.</p> <p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The following is a summary of RSU and PSU award activity for the <em style="font: inherit;">nine months ended <em style="font: inherit;"> December 31, 2024:</p> <p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">Time-Based Restricted Stock Units</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">Performance-Based Restricted Stock Units</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Number of Shares</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Weighted- Average Grant Date Fair Value per Share</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Number of Shares</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Weighted-Average Grant Date Fair Value per Share</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of March 31, 2024</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">76</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">157.83</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">56</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">240.96</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Awards granted⁽¹⁾</p> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">117</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">93.46</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">41</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">102.57</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Awards forfeited</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">(7</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman

Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">123.42</td><td
style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman";
font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family:
"Times New Roman"; font-size: 10pt; margin-left: 0pt;"><p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">-</p>
</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New
Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-
family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-
left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p
style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Awards distributed</p> </td><td style="width: 1%; font-family:
"Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-
bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom:
1px solid rgb(0, 0, 0);">(36</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td
style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New
Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">169.40</td><td
style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times
New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid
rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0,
0);">(12</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-
family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size:
10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">302.06</td><td style="width: 1%; font-
family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align:
bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant:
normal; margin: 0pt;">Outstanding as of December 31, 2024</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td
style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-
family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">150</td><td style="width: 1%; font-family: "Times
New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td>
<td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times
New Roman"; font-size: 10pt; margin-left: 0pt;">106.44</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;
margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New
Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size:
10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">85</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom:
3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New
Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left:
0pt;">165.75</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>
<p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width:
100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: "Times New
Roman"; font-size: 10pt;">^(<em style="font: inherit;">1)</p> </td><td style="width: auto;"> <p
style="margin: 0pt; text-align: left; font-family: "Times New Roman"; font-size: 10pt;">Balances for PSUs granted are reflected at target.</p> </td></tr> </tbody>
</table> <p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; font-family: "Times New
Roman", Times, serif; font-size: 10pt;">Outstanding time-based RSUs vest and settle in shares of our common stock on a <em style="font: inherit;">one-for-<em
style="font: inherit;">one basis. The majority of RSUs granted to employees during the <em style="font: inherit;">nine months ended <em style="font:
inherit;"> December 31, 2024 vest in equal installments on the first, second, and <em style="font: inherit;">third anniversaries of the grant date. RSUs granted
to non-employee directors during the <em style="font: inherit;">nine months ended <em style="font: inherit;"> December 31, 2024 vest <span style="-sec-ix-
hidden:c122335850">one year from the grant date. We generally recognize the expense relating to RSUs, net of estimated forfeitures, on a straight-line basis over the
vesting period.</p> <p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; font-family: "Times
New Roman", Times, serif; font-size: 10pt;">We grant PSUs to certain key employees. The number of shares earned is determined at the end of each performance period
based on Mesa's achievement of certain pre-defined targets per the related award agreement. The outstanding PSUs vest upon completion of the service period described in
the award agreement. We recognize the expense relating to the performance-based RSUs based on the probable outcome of achievement of the performance targets on a
straight-line basis over the service period. </p> <p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </p> <p style="margin:
0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">During the <em style="font: inherit;">nine months ended <em style="font: inherit;">
December <em style="font: inherit;">31, <em style="font: inherit;">2024, the Compensation Committee of the Board of Directors created a plan to award
41 PSUs at target ("the <em style="font: inherit;">FY25 PSUs") to eligible employees. Of the 41 PSUs granted, 23 PSUs have a grant date fair value of $89.82 and are
subject to service and company financial performance conditions. The financial performance measurement period is from <em style="font: inherit;"> April 1, 2024
through <em style="font: inherit;"> March 31, 2027. The remaining 18 PSUs have a grant date fair value of $119.54 and are subject to service and market
conditions, with the market performance period measured from <em style="font: inherit;"> June 18, 2024 through <em style="font: inherit;"> June 18, 2027.
The service period for all of the <em style="font: inherit;">FY25 PSUs is from <em style="font: inherit;"> June <em style="font: inherit;">18, <em
style="font: inherit;">2024 through <em style="font: inherit;"> June 18, 2027. The quantity of shares that will be earned based upon either company financial
performance or market performance will range from 0% to 200% of the targeted number of shares; if the defined minimum targets are <em style="font:
inherit;">not met, then <em style="font: inherit;">no shares will vest.</p> <p style="margin: 0pt; font-family: "Times New Roman", Times, serif;
font-size: 10pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following is a summary of stock option award
activity for the <em style="font: inherit;">nine months ended <em style="font: inherit;"> December 31, 2024:</p> <p style="font-family:'Times New Roman',
Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-
family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family:
"Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="14" style="text-align:
center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-
size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font:
inherit;">Stock Options</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-
family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt;
margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em
style="font: inherit;">Shares Subject to Options</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td>
<td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-
size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-
align:center;margin:0pt;"><em style="font: inherit;">Weighted- Average Exercise Price per Share</p> </td><td style="font-family: "Times New
Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-
align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Weighted-Average Remaining Contractual Life (Years)
</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman";
font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid
rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Aggregate Intrinsic
Value</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color:
rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New
Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of March 31, 2024</p> </td><td style="width: 1%; font-family: "Times New
Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-
family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">194</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;
margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New
Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left:
0pt;">181.89</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times
New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right;
font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">3.2</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;
margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New
Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left:
0pt;">26</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255,
255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size:
10pt; font-variant: normal; margin: 0pt;">Awards granted</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td
style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman";
font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%;
font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td
style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New
Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times
New Roman"; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt;"><em style="font: inherit;">
</td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td
style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt;"><em
style="font: inherit;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);
vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt;
font-variant: normal; margin: 0pt;">Awards forfeited or expired</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td
style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman";
font-size: 10pt; margin-left: 0pt;">(15</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%;
font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td
style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">150.98</td><td style="width: 1%; font-family: "Times
New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family:
"Times New Roman"; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt;"><em style="font:
inherit;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size:
10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-

size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Awards exercised</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">(1</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">131.67</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of December 31, 2024</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">178</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">184.55</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">2.6</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">287</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody> </table> <p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </p> 660000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">Time-Based Restricted Stock Units</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">Performance-Based Restricted Stock Units</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Number of Shares</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Weighted- Average Grant Date Fair Value per Share</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Number of Shares</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Weighted-Average Grant Date Fair Value per Share</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of March 31, 2024</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">76</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">157.83</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">56</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">240.96</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Awards granted⁽¹⁾</p> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">117</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">93.46</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">41</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">102.57</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Awards forfeited</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">(7</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">123.42</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"><p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">-</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Awards distributed</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(36</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">169.40</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(12</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">302.06</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of December 31, 2024</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">150</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">106.44</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">85</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">165.75</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 76157.8356240.9611793.4641102.577123.42 036169.412302.06150106.4485165.7541000410002300089.8218000119.5402 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman

Roman"; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Stock Options</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Shares Subject to Options</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Weighted- Average Exercise Price per Share</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Weighted-Average Remaining Contractual Life (Years)</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Aggregate Intrinsic Value</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of March 31, 2024</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">194</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">181.89</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">3.2</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">26</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Awards granted</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Awards forfeited or expired</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">(15</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">150.98</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Awards exercised</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">(1</td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">131.67</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of December 31, 2024</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">178</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">184.55</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">2.6</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">287</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 194000181.89P3Y2M12D260000015000150.981000131.67178000184.55P2Y7M6D287000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Note <em style="font: inherit;">9. (Loss) Earnings Per Share</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">The following table presents a reconciliation of the denominators used in the computation of basic and diluted (loss) earnings per share:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended December 31,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended December 31, </p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net (loss) income available for shareholders</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,676</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,116</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New

Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,140</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">337</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average outstanding shares of common stock</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,429</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,393</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,413</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,384</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Dilutive effect of stock options</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dilutive effect of RSUs</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">51</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fully diluted shares</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,429</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,396</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,464</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,394</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Basic (loss) earnings per share</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(0.31</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.39</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.95</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.06</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Diluted (loss) earnings per share</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(0.31</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.39</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.94</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.06</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Potentially dilutive securities include stock options and both time and performance based RSUs (collectively "stock awards"), as well as common shares underlying our Notes. Stock awards are excluded from the calculation of diluted EPS if they are subject to performance conditions that have <em style="font: inherit;">not yet been achieved or if they are antidilutive. Diluted EPS does <em style="font: inherit;">not consider the impact of potentially dilutive securities in periods in which there is a loss because the inclusion of the potential common shares would have an antidilutive effect in such cases.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following potentially dilutive awards were excluded from the calculation of diluted EPS:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font:

inherit;">Three Months Ended December 31,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended December 31,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assumed conversion of the Notes</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">344</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">608</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">354</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">608<td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock awards that were anti-dilutive</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">406</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">277</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">202</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">223</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stock awards excluded from diluted EPS</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">750</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">885</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">556</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">831</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0">Shares underlying the Notes were excluded from the diluted EPS calculation for the <em style="font: inherit;">three and <em style="font: inherit;">nine months ended <em style="font: inherit;"> December <em style="font: inherit;">31, <em style="font: inherit;">2024 and <em style="font: inherit;">2023 as the impact of the assumed conversion of the Notes calculated under the if-converted method was antidilutive. The decrease in assumed conversion of the Notes is related to the partial repayment of the Notes that occurred during the <em style="font: inherit;">nine months ended <em style="font: inherit;"> December <em style="font: inherit;">31, <em style="font: inherit;">2024 (see Note <em style="font: inherit;">7. "Indebtedness").</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended December 31, </p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended December 31,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net (loss) income available for shareholders</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> (1,676</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,116</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,140</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">337</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average outstanding shares of common stock</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size:

10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,429</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,393</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,413</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,384</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Dilutive effect of stock options</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dilutive effect of RSUs</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">51</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fully diluted shares</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,429</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,396</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,464</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,394</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Basic (loss) earnings per share</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(0.31</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.39</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.95</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.06</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Diluted (loss) earnings per share</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(0.31</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.39</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.94</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.06</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table>
-167600021160005140000337000542900053930005413000538400000010000300051000900005429000539600054640005394000-0.310.390.950.06-0.310.390.940.06 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended December 31,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended December 31, </p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-

variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assumed conversion of the Notes</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">344</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">608</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">354</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">608</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock awards that were anti-dilutive</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">406</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">277</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">202</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">223</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stock awards excluded from diluted EPS</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">750</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">885</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">556</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">831</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 344000608000354000608000406000277000202000223000750000885000556000831000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Note <em style="font: inherit;">10. Income Taxes</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We reported an income tax provision as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Three Months Ended December 31,</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Nine Months Ended December 31,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"> 2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Income tax (benefit) expense</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(541</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(170</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">360</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(653</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">Effective tax rate</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">24.4</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(8.7</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6.5</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">206.6</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table> <p style="font-size: 10pt; font-family: "Times New Roman", Times, serif; margin: 0pt;"> </p> <p style="font-size: 10pt; font-family: "Times New Roman", Times, serif; margin: 0pt;">For interim income tax reporting, we estimate our annual effective tax rate and apply this effective tax rate to our year-to-date pre-tax income. Each quarter, our estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. Additionally, the tax effects of significant unusual or infrequently occurring items are recognized as discrete items in the interim period in which the events occur. There is a potential for volatility in the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which they relate, changes in tax laws and foreign tax holidays, settlement with taxing authorities, and foreign currency fluctuations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The change in the effective tax rate for both the <em style="font: inherit;">three and <em style="font: inherit;">nine months ended <em style="font: inherit;"> December 31, 2024 compared to the prior year periods is primarily due to the valuation allowance established on the US deferred taxes during fiscal year <em style="font: inherit;">2024. The effective tax rate for both the <em style="font: inherit;">three and the <em style="font: inherit;">nine months ended <em style="font: inherit;"> December 31, 2024 differed from the statutory federal rate of 21% primarily due to the valuation allowance established on the US deferred taxes during fiscal year <em style="font: inherit;">2024.</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Three Months Ended December 31,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Nine Months Ended December 31,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Income tax (benefit) expense</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(541</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(170</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">360</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(653</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">Effective tax rate</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">24.4</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(8.7</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6.5</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">206.6</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table> -541000-170000360000-6530000.244-0.0870.0652.0660.21 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Note <em style="font: inherit;">11. Commitments and Contingencies</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">We are party to various legal proceedings arising in the ordinary course of business. As of <em style="font: inherit;"> December 31, 2024, we are <em style="font: inherit;">not party to any legal proceeding that management believes could have a material adverse effect on our unaudited consolidated financial position, results of operations, or cash flows. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">We expect to pay approximately $9,000 (at <em style="font: inherit;"> December 31, 2024 exchange rates) for the GKE holdback in <em style="font: inherit;"> April 2025, pending adjustments for potential indemnification losses that <em style="font: inherit;"> may arise. The liability is recorded at its discounted fair value of $8,900 in other accrued expenses in our unaudited Condensed Consolidated Balance Sheets as of <em style="font: inherit;"> December 31, 2024. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">As part of the Belyntic acquisition, we agreed to pay the sellers a contingency based upon approval of contractually specified patents. The estimated fair value of the probable remaining contingent consideration was $675 as of <em style="font: inherit;"> December 31, 2024<i>. </i>On <em style="font: inherit;"> January 2, 2025, a notice of allowance was issued for <em style="font: inherit;">one of the <em style="font: inherit;">two remaining pending patents, and we expect to pay the Belyntic sellers $563 for the patent within fiscal year <em style="font: inherit;">2025 or early in fiscal year <em style="font: inherit;">2026, depending upon the final approval date. We expect the other remaining pending patent will likely be approved within <em style="font: inherit;">one year of <em style="font: inherit;"> December 31, 2024.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> 9000000890000067500056300 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Note <em style="font: inherit;">12. Segment Information</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following tables set forth our segment information:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended December 31, </p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended December 31,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Revenues (a):</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Sterilization and Disinfection Control (b)</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">23,507</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">19,338</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times,

serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left:
0pt;">68,669</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-
left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">52,345</td><td
style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);
vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times,
serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Clinical Genomics</p> </td><td style="width: 1%; font-family: "Times New Roman", Times,
serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right;
font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12,667</td><td style="width: 1%; font-family: "Times New Roman",
Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td
style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New
Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12,546</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;
margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-
size: 10pt; margin-left: 0pt;">35,570</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td
style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times,
serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">41,464</td>
<td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255,
255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman",
Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Biopharmaceutical Development</p> </td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width:
9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12,237</td><td style="width: 1%; font-family: "Times
New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size:
10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family:
"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9,430</td><td style="width: 1%; font-family: "Times New Roman", Times, serif;
font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-
family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif;
font-size: 10pt; margin-left: 0pt;">36,112</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td
style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times,
serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">28,526</td>
<td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238,
255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman",
Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Calibration Solutions</p> </td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;
border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left:
0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,429</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;
padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width:
1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-
family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,159</td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;
border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left:
0pt; border-bottom: 1px solid rgb(0, 0, 0);">38,492</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;
padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width:
1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-
family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">34,948</td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-
align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif;
font-size: 10pt; font-variant: normal; margin: 0pt;">Total revenues</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-
size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px
solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom:
1px solid rgb(0, 0, 0);">62,840</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom:
1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-
family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">53,473</td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;
margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size:
10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">178,843</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;
margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td>
<td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td
style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0,
0);">157,283</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr
style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td
style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size:
10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times,
serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family:
"Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td
style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size:
10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times,
serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-
color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times
New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross profit:</p> </td><td style="font-family: "Times New Roman",
Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-
family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td
style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size:
10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman",
Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-
family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td
style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align:
bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-
size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Sterilization and Disinfection Control (b)</p> </td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
<td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16,461</td><td style="width: 1%; font-
family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif;
font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-
align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">13,951</td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td>
<td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family:
"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">47,191</td><td style="width: 1%; font-family: "Times New Roman", Times, serif;
font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-
family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New
Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">38,018</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;
margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif;
font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Clinical Genomics</p>
</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-
left: 0pt;">6,948</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-
family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size:
10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,449</td><td style="width:
1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman",
Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align:
right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">19,344</td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td>
<td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New
Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">20,904</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;
margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif;
font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Biopharmaceutical
Development</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-

size: 10pt; margin-left: 0pt;">7,539</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,841</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">22,665</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,783</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Calibration Solutions</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,806</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,212</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">23,258</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,050</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Reportable segment gross profit</p></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">39,754</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">33,453</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">112,458</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">96,755</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Corporate and other (c)</p></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">(51</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> (61</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross profit</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">39,754</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">33,402</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">112,458</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">96,694</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Reconciling items:</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating expense</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">33,975</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">33,469</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">97,591</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">97,485</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating income (loss)</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,779</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(67</td><td style="width:

1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman",
Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align:
right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14,867</td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td>
<td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New
Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(791</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;
margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif;
font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Non-operating expense
(income), net</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%;
font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family:
"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,996</td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;
border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left:
0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,013</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;
padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width:
1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-
family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,367</td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;
border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left:
0pt; border-bottom: 1px solid rgb(0, 0, 0);">(475</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;
padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times,
serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(Loss) earnings before
income taxes</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-
family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2,217</td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-
bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;
border-bottom: 3px double rgb(0, 0, 0);">1,946</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;
padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-
family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,500</td><td style="width: 1%; font-family:
"Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New
Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-
bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;
border-bottom: 3px double rgb(0, 0, 0);">(316</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;
margin-left: 0pt;">)</td></tr> </tbody></table> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <table
border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 9pt;"> </td><td style="width:
18pt;"> <p style="font-family: "Times New Roman", Times, serif; margin: 0pt; text-align: left; font-size: 10pt;"><sup style="vertical-align:top;line-height:120%;">
(a)</sup></p> </td><td> <p style="font-family: "Times New Roman", Times, serif; margin: 0pt; text-align: left; font-size: 10pt;">Intersegment revenues are <em
style="font: inherit;">not significant and are eliminated to arrive at consolidated totals.</p> </td></tr> </tbody></table> <table border="0" cellpadding="0"
cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 9pt;"> </td><td style="width: 18pt;"> <p style="font-family:
"Times New Roman", Times, serif; margin: 0pt; text-align: left; font-size: 10pt;">^(b)</p> </td><td> <p
style="font-family: "Times New Roman", Times, serif; margin: 0pt; text-align: left; font-size: 10pt;">Includes post-acquisition GKE results during the <em
style="font: inherit;">three and <em style="font: inherit;">nine months ended <em style="font: inherit;"> December 31, 2024 and <em style="font:
inherit;">2023 beginning on <em style="font: inherit;"> October 16, 2023 for GKE GmbH and SAL GmbH, and beginning on <em style="font: inherit;"> January
1, 2024 for GKE China. </p> </td></tr> <tr><td style="width: 9pt;"> </td><td style="width: 18pt;">^(c)</td>
<td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">Unallocated corporate expenses are reported within corporate and other. </td></tr>
</tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: 'Times New Roman', Times,
serif; font-size: 10pt; margin: 0pt; text-align: left">The following table sets forth inventories by reportable segment. Our chief operating decision maker is <em style="font:
inherit;">not provided with and does <em style="font: inherit;">not regularly review any other segment asset information.</p> <p style="font-family: 'Times
New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-
size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times
New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New
Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font:
inherit;">December 31,</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size:
10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-
size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">March 31,</p> </td><td style="font-family: Times New Roman; font-
size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td
style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;
border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font:
inherit;">2024</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-
size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p
style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2024</p> </td><td
style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td
style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin:
0pt;">Sterilization and Disinfection Control</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times
New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,728</td>
<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td>
<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-
size: 10pt; margin-left: 0pt;">7,014</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color:
rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-
variant: normal; margin: 0pt;">Clinical Genomics</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family:
Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,709</td><td
style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td
style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left:
0pt;">11,813</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);
vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin:
0pt;">Biopharmaceutical Development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New
Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,853</td><td style="width: 1%;
font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%;
font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,304</td>
<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
<td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Calibration
Solutions</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size:
10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,832</td><td style="width: 1%; font-family: Times
New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times
New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,544</td><td style="width:
1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-
family: Times New Roman; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total
Inventories</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-
size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family:
"Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">28,122</td><td style="width:
1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size:
10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px
solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double
rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">32,675</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left:
0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </p> <table border="0"
cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size:
10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times
New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif;
font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended December 31,
</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times
New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;
margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align:
center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended December 31,</p> </td><td style="font-family:
"Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255);
vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman",
Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;
border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin:
0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom:

```
1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times
New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif;
font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td
colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p
style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font:
inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-
family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times,
serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-
variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times,
serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin:
0pt;"><b>Revenues (a):</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;,
Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-
family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td
style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif;
font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Sterilization and
Disinfection Control (b)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;,
Times, serif; font-size: 10pt; margin-left: 0pt;">23,507</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left:
0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-
size: 10pt; margin-left: 0pt;">19,338</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td
style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times,
serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left:
0pt;">68,669</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-
left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">52,345</td><td
style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);
vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times,
serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Clinical Genomics</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times,
serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right;
font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,667</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;,
Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td
style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,546</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-
size: 10pt; margin-left: 0pt;">35,570</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td
style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times,
serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">41,464</td>
<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255,
255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;,
Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Biopharmaceutical Development</p> </td><td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width:
9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,237</td><td style="width: 1%; font-family: &quot;Times
New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,430</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif;
font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-
family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif;
font-size: 10pt; margin-left: 0pt;">36,112</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td
style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times,
serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28,526</td>
<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238,
255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;,
Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Calibration Solutions</p> </td><td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left:
0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,429</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;
padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width:
1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-
family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,159</td><td style="width: 1%; font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left:
0pt; border-bottom: 1px solid rgb(0, 0, 0);">38,492</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;
padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width:
1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-
family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">34,948</td><td style="width: 1%; font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-
align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif;
font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total revenues</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-
size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px
solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom:
1px solid rgb(0, 0, 0);">62,840</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom:
1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-
family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">53,473</td><td style="width: 1%; font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">178,843</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;
margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td>
<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td
style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0,
0);">157,283</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr
style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td
style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times,
serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family:
&quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td
style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times,
serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-
color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times
New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Gross profit:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;,
Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-
family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td
style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size:
10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;,
Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New
Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-
family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td
style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align:
```

bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Sterilization and Disinfection Control (b)</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16,461</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">13,951</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">47,191</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">38,018</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Clinical Genomics</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,948</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,449</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">19,344</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">20,904</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Biopharmaceutical Development</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7,539</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,841</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">22,665</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,783</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Calibration Solutions</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,806</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,212</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">23,258</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,050</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Reportable segment gross profit</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">39,754</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">33,453</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">112,458</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">96,755</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Corporate and other (c)</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">(51</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">(61</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross profit</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">39,754</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">33,402</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">112,458</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">96,694</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Reconciling items:</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td

style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating expense</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">33,975</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">33,469</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">97,591</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">97,485</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating income (loss)</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,779</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(67</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14,867</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(791</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Non-operating expense (income), net</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,996</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,013</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,367</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(475</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(Loss) earnings before income taxes</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2,217</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,946</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,500</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(316</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td></tr> </tbody></table>
23507000193380006866900052345000126670001254600035570000414640001223700094300003611200028526000144290001215900038492000349480006284000053473000
510000-61000397540003340200011245800096694000339750003346900097591000974850005779000-6700014867000-7910007996000-20130009367000-475000-
221700019460005500000-316000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">December 31,</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">March 31,</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2024</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Sterilization and Disinfection Control</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,728</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,014</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Clinical Genomics</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,709</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,813</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Biopharmaceutical Development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,853</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,304</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Calibration Solutions</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,832</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,544</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total Inventories</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">28,122</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td

~~style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">32,675</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 5728000701400010709000118130005853000630400058320007544000281220003267500 Intersegment revenues are not significant and are eliminated to arrive at consolidated totals. Unallocated corporate expenses are reported within corporate and other. Revenues of $12,117 from GKE are included in the Sterilization and Disinfection Control division during the six months ended September 30, 2024. Accumulated Other Comprehensive Income (Loss). Revenues of $5,863 from GKE are included in the Sterilization and Disinfection Control division during the three months ended September 30, 2024. Includes post-acquisition GKE results during the three and six months ended September 30, 2024. Balances for PSUs granted are reflected at target.~~